Clustering O 0 0.0001315671397605911
of O 0 1.898748564599373e-06
missense O 0 0.19384902715682983
mutations O 0 0.0002093885705107823
in O 0 7.351217163886758e-07
the O 0 6.654707249253988e-06
ataxia B-Disease 1 0.9999768733978271
- I-Disease 1 0.9997872710227966
telangiectasia I-Disease 1 0.999967098236084
gene O 0 1.5358939435827779e-06
in O 0 2.490289574552662e-08
a O 0 1.0466726507729618e-07
sporadic B-Disease 0 0.00017414918693248183
T I-Disease 1 0.928134560585022
- I-Disease 1 0.6119645237922668
cell I-Disease 0 0.3785969614982605
leukaemia I-Disease 1 0.9718450903892517
. O 0 9.476241757511161e-06

Ataxia B-Disease 1 0.9999068975448608
- I-Disease 1 0.9997126460075378
telangiectasia I-Disease 1 0.9999641180038452
( O 0 5.74349905946292e-06
A B-Disease 0 0.0002251289552077651
- I-Disease 1 0.9983507394790649
T I-Disease 1 0.9999109506607056
) O 0 2.7967587357125012e-08
is O 0 5.710904638078773e-09
a O 0 4.6103370010541767e-08
recessive B-Disease 0 3.643827585619874e-05
multi I-Disease 0 0.06534348428249359
- I-Disease 1 0.997884213924408
system I-Disease 0 0.1205969974398613
disorder I-Disease 0 0.23607991635799408
caused O 0 1.452255037293071e-05
by O 0 1.3643480656355678e-07
mutations O 0 6.106556611484848e-07
in O 0 5.689692716970285e-09
the O 0 6.03470251547833e-09
ATM O 0 6.3416227931156754e-06
gene O 0 5.642909428615894e-08
at O 0 1.606052535407798e-08
11q22 O 0 5.35197978024371e-06
- O 0 0.00016028364188969135
q23 O 0 7.137080683605745e-05
( O 0 5.2113581006096865e-08
ref O 0 0.0001395131112076342
. O 0 1.2807864990804774e-08
3 O 0 2.842611657172256e-08
) O 0 6.698692089912583e-08
. O 0 7.017457619440393e-07

The O 0 6.950964689167449e-06
risk O 0 3.816507523879409e-05
of O 0 1.069033487510751e-06
cancer B-Disease 0 0.05509514361619949
, O 0 2.2007313305039133e-07
especially O 0 9.293754601458204e-07
lymphoid B-Disease 0 0.01471958588808775
neoplasias I-Disease 0 0.019374828785657883
, O 0 1.391460386912513e-07
is O 0 2.8315833233705234e-08
substantially O 0 1.3523991810870939e-06
elevated O 0 1.3399514500633813e-05
in O 0 7.987811301291003e-08
A B-Disease 0 0.0005106671596877277
- I-Disease 1 0.9998512268066406
T I-Disease 1 0.9999929666519165
patients O 0 7.379282124020392e-06
and O 0 7.109209576583453e-08
has O 0 6.585474210396569e-08
long O 0 4.146722858422436e-07
been O 0 1.079201652487427e-07
associated O 0 2.2069807528168894e-06
with O 0 8.42209283291595e-06
chromosomal O 1 0.9999493360519409
instability O 1 0.9967708587646484
. O 0 7.449297845596448e-05

By O 0 3.3903761504916474e-06
analysing O 0 0.0005190771771594882
tumour B-Disease 1 0.9992986917495728
DNA O 0 5.2193005103617907e-05
from O 0 3.52745985310321e-07
patients O 0 8.406497045143624e-07
with O 0 1.1114561715430682e-07
sporadic B-Disease 0 0.00014363889931701124
T I-Disease 1 0.9326396584510803
- I-Disease 0 0.08831889182329178
cell I-Disease 0 0.034229788929224014
prolymphocytic I-Disease 1 0.9408806562423706
leukaemia I-Disease 1 0.8835508227348328
( O 0 2.590327028428874e-07
T B-Disease 0 0.0010586376301944256
- I-Disease 0 0.0002080651029245928
PLL I-Disease 0 0.0014837980270385742
) O 0 1.4072807807963272e-08
, O 0 3.836329476314404e-09
a O 0 3.9859358480498486e-08
rare O 0 1.1483717571536545e-05
clonal B-Disease 0 0.12799465656280518
malignancy I-Disease 1 0.679535448551178
with O 0 9.603067496755102e-08
similarities O 0 8.542072578165971e-07
to O 0 5.918680656691322e-09
a O 0 1.53551312109812e-07
mature B-Disease 0 1.4441866369452327e-05
T I-Disease 0 0.04687415435910225
- I-Disease 0 0.02394396811723709
cell I-Disease 0 0.04927114397287369
leukaemia I-Disease 1 0.7757564187049866
seen O 0 1.4676528508061892e-06
in O 0 5.524348622998332e-08
A B-Disease 0 5.268954555504024e-05
- I-Disease 1 0.9822591543197632
T I-Disease 1 0.9993638396263123
, O 0 2.4922520935888315e-08
we O 0 2.10712047810091e-09
demonstrate O 0 2.1538427930067883e-08
a O 0 7.821469694135885e-09
high O 0 6.743997715830119e-08
frequency O 0 3.8987220563058145e-08
of O 0 3.1530009714231255e-09
ATM O 0 8.587273623561487e-05
mutations O 0 5.483770110004116e-06
in O 0 4.3749690803451813e-07
T B-Disease 0 0.06645233929157257
- I-Disease 0 0.01812811754643917
PLL I-Disease 0 0.04621764272451401
. O 0 6.021440640324727e-06

In O 0 1.0487634654055e-06
marked O 0 2.3788438738847617e-06
contrast O 0 6.342054916785855e-07
to O 0 5.437225780724475e-09
the O 0 1.3052385838818736e-08
ATM O 0 0.00013705712626688182
mutation O 0 1.0519164789002389e-05
pattern O 0 7.739068337286881e-07
in O 0 2.983375679832534e-08
A B-Disease 0 2.0879557268926874e-05
- I-Disease 1 0.9803987145423889
T I-Disease 1 0.9991963505744934
, O 0 1.126704152198954e-08
the O 0 1.6520819157150868e-09
most O 0 1.3629526396385927e-09
frequent O 0 8.309162069508602e-08
nucleotide O 0 9.634804882807657e-07
changes O 0 4.009046250530446e-08
in O 0 3.3046525516056136e-08
this O 0 3.482708450519567e-07
leukaemia B-Disease 1 0.7943328022956848
were O 0 2.4868020318535855e-06
missense O 0 0.007974290288984776
mutations O 0 0.00014916155487298965
. O 0 6.02557702222839e-06

These O 0 3.6413288739822747e-07
clustered O 0 1.423005414835643e-06
in O 0 2.8981354205370735e-08
the O 0 7.4062644905836805e-09
region O 0 5.6899015277167564e-08
corresponding O 0 4.5028169637362225e-08
to O 0 2.861748393812036e-09
the O 0 4.31387681132378e-09
kinase O 0 4.596227825004462e-07
domain O 0 2.4273138166108765e-08
, O 0 2.5680451098963886e-09
which O 0 1.1424837742524119e-09
is O 0 1.1202836436297048e-09
highly O 0 6.254986306686305e-09
conserved O 0 2.3220199096840588e-08
in O 0 5.60834534368837e-09
ATM O 0 5.048362254456151e-06
- O 0 5.460885222419165e-05
related O 0 1.359133960932013e-07
proteins O 0 6.536491792275001e-09
in O 0 7.590204020857527e-09
mouse O 0 8.911817985790549e-07
, O 0 1.6514148271085105e-08
yeast O 0 4.4567204326995125e-07
and O 0 1.4933645786641137e-07
Drosophila O 0 3.524141675370629e-06
. O 0 1.2128022035540198e-06

The O 0 7.036348392830405e-07
resulting O 0 9.458557315156213e-07
amino O 0 1.691326048103292e-07
- O 0 4.428635747899534e-06
acid O 0 1.20206763654096e-07
substitutions O 0 3.600979070483845e-08
are O 0 1.297575158432096e-09
predicted O 0 1.0194530375429167e-07
to O 0 2.5200659337087927e-09
interfere O 0 4.5100200907199905e-08
with O 0 3.849186924753667e-08
ATP O 0 8.914466161513701e-05
binding O 0 6.444686846407421e-07
or O 0 8.587488764533191e-08
substrate O 0 1.2523604709713254e-05
recognition O 0 4.850899586017476e-06
. O 0 5.286107807478402e-06

Two O 0 2.510741126116045e-07
of O 0 1.1862346127600176e-07
seventeen O 0 3.075988388445694e-06
mutated O 0 0.00010248429316561669
T B-Disease 0 0.001402051537297666
- I-Disease 0 0.00010621928959153593
PLL I-Disease 0 0.00032734047272242606
samples O 0 2.7872167152054317e-07
had O 0 9.096491560001141e-09
a O 0 3.3029824209052094e-08
previously O 0 8.216264859584044e-07
reported O 0 8.438147233391646e-06
A B-Disease 0 0.00022809005167800933
- I-Disease 1 0.9942242503166199
T I-Disease 1 0.9997454285621643
allele O 0 0.00011948185419896618
. O 0 1.933277189891669e-06

In O 0 2.6537531994108576e-06
contrast O 0 1.18353491416201e-05
, O 0 1.0150291984700743e-07
no O 0 1.7747660763234308e-07
mutations O 0 1.0525319567022962e-06
were O 0 1.3097698925434997e-08
detected O 0 1.96062524082663e-06
in O 0 5.823209026090126e-09
the O 0 1.0384398230200986e-08
p53 O 0 4.0020714209276775e-07
gene O 0 6.724602030772076e-08
, O 0 4.598189384807938e-09
suggesting O 0 6.926916995553256e-08
that O 0 7.752880115674543e-09
this O 0 1.250867143198775e-07
tumour B-Disease 1 0.9996150732040405
suppressor O 0 0.00018440860731061548
is O 0 8.987753652434094e-09
not O 0 2.685371036648121e-09
frequently O 0 4.496311589718971e-08
altered O 0 5.299198733155208e-07
in O 0 1.1681733980140052e-07
this O 0 1.3130861589161213e-06
leukaemia B-Disease 1 0.9729577302932739
. O 0 1.0222651326330379e-05

Occasional O 0 0.00010120229126187041
missense O 0 0.018596500158309937
mutations O 0 0.00012496125418692827
in O 0 2.6189971435996995e-07
ATM O 0 8.208024155464955e-06
were O 0 1.9761001723850313e-08
also O 0 2.3147766370357203e-08
found O 0 7.78898936459882e-08
in O 0 8.214940407924587e-07
tumour B-Disease 1 0.999523401260376
DNA O 0 1.0310416655556764e-05
from O 0 7.181659356092496e-08
patients O 0 1.4349059540563758e-07
with O 0 5.139466807690951e-08
B B-Disease 0 9.753959602676332e-06
- I-Disease 0 0.0010051674908027053
cell I-Disease 0 0.0005361519288271666
non I-Disease 0 1.1949440704484005e-05
- I-Disease 1 0.9988037347793579
Hodgkins I-Disease 1 0.9999889135360718
lymphomas I-Disease 1 0.9988282322883606
( O 0 7.23632993526735e-08
B B-Disease 0 4.472900627661147e-07
- I-Disease 0 4.145935599808581e-05
NHL I-Disease 0 6.681573836431198e-07
) O 0 1.6935906010928647e-09
and O 0 1.5667036556976655e-09
a O 0 3.451442154300821e-08
B B-Disease 0 9.595466963219224e-07
- I-Disease 0 9.027746273204684e-05
NHL I-Disease 0 4.035986876260722e-06
cell O 0 7.279573765117675e-06
line O 0 2.4421451598755084e-06
. O 0 1.1997533420071704e-06

The O 0 5.197872496864875e-07
evidence O 0 2.4432767986581894e-07
of O 0 8.878892288066709e-09
a O 0 1.9593089817249165e-08
significant O 0 4.480978077481268e-08
proportion O 0 1.3757937722402858e-07
of O 0 7.1994041839218426e-09
loss O 0 7.868959983170498e-06
- O 0 3.946311608160613e-06
of O 0 7.398216705922778e-09
- O 0 0.002128424821421504
function O 0 4.648251490380062e-07
mutations O 0 2.14165424949897e-07
and O 0 2.353121253406698e-09
a O 0 7.703059523578304e-09
complete O 0 1.1912818109749423e-07
absence O 0 6.438101962658038e-08
of O 0 1.00270558522908e-09
the O 0 3.3579017344465e-09
normal O 0 2.044560609704149e-08
copy O 0 8.481903179813344e-09
of O 0 5.704914318727106e-10
ATM O 0 3.9592501366314536e-07
in O 0 3.2712752506824927e-09
the O 0 2.1858201915136988e-09
majority O 0 2.2350503670054422e-08
of O 0 3.538294635063721e-08
mutated O 0 0.041231248527765274
tumours B-Disease 1 0.9976320266723633
establishes O 0 4.372288913145894e-06
somatic O 0 5.2105806389590725e-06
inactivation O 0 2.878016857721377e-05
of O 0 1.7210811664725156e-09
this O 0 1.992509934822806e-09
gene O 0 1.3191363557041313e-08
in O 0 3.9435787968500335e-09
the O 0 1.4428891859097348e-08
pathogenesis O 0 1.4672912584501319e-05
of O 0 1.1240619102181881e-08
sporadic B-Disease 0 4.469671330298297e-05
T I-Disease 0 0.2928678095340729
- I-Disease 0 0.0007798686856403947
PLL I-Disease 0 0.00043289794120937586
and O 0 2.588888925458832e-08
suggests O 0 5.254315382785535e-08
that O 0 2.6931266106089424e-09
ATM O 0 4.731241176614276e-07
acts O 0 8.963293396391236e-08
as O 0 1.9494901692951316e-08
a O 0 3.6535284380079247e-06
tumour B-Disease 1 0.9997603297233582
suppressor O 0 0.006440555211156607
. O 0 3.714263584697619e-06

As O 0 3.4688792993620154e-07
constitutional O 0 5.840776111654122e-07
DNA O 0 2.4907658371375874e-06
was O 0 3.290412919909613e-08
not O 0 4.9513775302045815e-09
available O 0 8.208720814195658e-09
, O 0 3.544642579456081e-09
a O 0 5.2255217042329605e-08
putative O 0 0.002976769581437111
hereditary O 0 0.11380667984485626
predisposition O 0 0.00804052408784628
to O 0 2.068898794505003e-07
T B-Disease 0 0.025375403463840485
- I-Disease 0 0.00033167775836773217
PLL I-Disease 0 0.0007685492746531963
will O 0 3.606822218671368e-08
require O 0 2.0449897775165482e-08
further O 0 1.7777551875042263e-08
investigation O 0 1.047604882842279e-06
. O 0 4.876503680861788e-07
. O 0 1.1706631539709633e-06

Myotonic B-Disease 1 0.9999415874481201
dystrophy I-Disease 1 0.9999239444732666
protein O 0 0.00028147452394478023
kinase O 0 4.349795199232176e-05
is O 0 2.8300338072995146e-08
involved O 0 1.0666078686938363e-08
in O 0 3.819915495029136e-09
the O 0 3.626418054736291e-09
modulation O 0 9.729933481139597e-08
of O 0 2.4394868347599186e-09
the O 0 3.735730302878437e-08
Ca2 O 0 0.0002699023752938956
+ O 0 1.8410382836009376e-05
homeostasis O 0 1.2401569620124064e-05
in O 0 3.8808278191027057e-07
skeletal O 0 0.08089441061019897
muscle O 0 0.002555016428232193
cells O 0 0.00014974783698562533
. O 0 6.483941433543805e-06

Myotonic B-Disease 1 0.9999842643737793
dystrophy I-Disease 1 0.9999756813049316
( O 0 0.000234666615142487
DM B-Disease 1 0.9998076558113098
) O 0 1.6899458898933517e-07
, O 0 1.4283575211493371e-08
the O 0 6.9528587332001734e-09
most O 0 1.0760383872820967e-07
prevalent O 0 0.00014475233911070973
muscular B-Disease 1 0.999627947807312
disorder I-Disease 1 0.8185517191886902
in O 0 1.090295427275123e-05
adults O 0 1.936614171427209e-05
, O 0 2.3410292726566695e-07
is O 0 6.806867958175644e-08
caused O 0 1.5069973642312107e-06
by O 0 4.370961192989853e-08
( O 0 6.677643682451162e-08
CTG O 0 7.603116682730615e-05
) O 0 3.844108142914138e-09
n O 0 3.953530267608585e-07
- O 0 2.110662990162382e-06
repeat O 0 4.84874931316881e-07
expansion O 0 2.632809881220055e-08
in O 0 1.6618032505633096e-09
a O 0 1.8235539744893003e-09
gene O 0 5.1150927937726465e-09
encoding O 0 5.184705109684273e-09
a O 0 6.000361540969834e-09
protein O 0 5.9281511255449004e-08
kinase O 0 9.535478397992847e-07
( O 0 4.433709221984827e-08
DM B-Disease 1 0.9726760387420654
protein O 0 3.466055034095916e-07
kinase O 0 3.648903884823085e-06
; O 0 8.106283644337964e-08
DMPK O 0 2.042351297859568e-05
) O 0 1.0629069846501693e-09
and O 0 1.3814777100051856e-09
involves O 0 2.0086861951540413e-08
changes O 0 2.2340657324093627e-08
in O 0 2.8345825242581668e-08
cytoarchitecture O 0 6.57827258692123e-05
and O 0 4.2999795368814375e-07
ion O 0 0.0013720968272536993
homeostasis O 0 0.001606888952665031
. O 0 3.222866780561162e-06

To O 0 3.439777458424942e-07
obtain O 0 5.092987294119666e-07
clues O 0 2.288604491695878e-06
to O 0 7.158435177956335e-09
the O 0 9.468673844992281e-09
normal O 0 1.0579727671711225e-07
biological O 0 2.7258516865913407e-07
role O 0 5.411536108113069e-09
of O 0 3.951944549385189e-09
DMPK O 0 9.768949530553073e-05
in O 0 4.210846427099568e-08
cellular O 0 1.581881588208489e-05
ion O 0 6.885000766487792e-05
homeostasis O 0 5.571645306190476e-05
, O 0 6.715806577517469e-09
we O 0 1.492377998957295e-09
have O 0 1.1741904115680768e-09
compared O 0 2.186142289417603e-08
the O 0 4.494114413944317e-09
resting O 0 3.6465942230279325e-06
[ O 0 4.65776565761189e-07
Ca2 O 0 4.407993401400745e-06
+ O 0 5.022963591727603e-07
] O 0 6.120239248730286e-08
i O 0 1.8432907422649691e-09
, O 0 3.1428942781630553e-10
the O 0 2.8601426782515205e-10
amplitude O 0 1.640824542903374e-08
and O 0 2.861541004151036e-09
shape O 0 8.224051839533786e-08
of O 0 2.816677335815143e-09
depolarization O 0 1.0941534128505737e-05
- O 0 0.001109389471821487
induced O 0 0.00011528308095876127
Ca2 O 0 6.594025035155937e-05
+ O 0 1.732760665618116e-06
transients O 0 1.5331866052292753e-06
, O 0 1.5956428400798472e-09
and O 0 5.985658635410118e-10
the O 0 6.848129840975048e-10
content O 0 1.4209006193866003e-09
of O 0 7.371422361401869e-10
ATP O 0 1.3418761000139057e-06
- O 0 1.279216348848422e-06
driven O 0 1.137658429684052e-07
ion O 0 9.071662816495518e-07
pumps O 0 4.972788474333356e-07
in O 0 1.4847581830679246e-08
cultured O 0 9.771379154699389e-06
skeletal O 0 0.001998250838369131
muscle O 0 2.1397432647063397e-05
cells O 0 1.6707480199329439e-07
of O 0 1.7024971432633151e-09
wild O 0 1.480649700624781e-07
- O 0 2.0251227397238836e-05
type O 0 5.313895030667481e-07
and O 0 3.043047414053035e-08
DMPK O 0 0.0002448292216286063
[ O 0 8.144965590872744e-07
- O 0 2.567759293015115e-05
/ O 0 3.360883783898316e-05
- O 0 0.00030185701325535774
] O 0 2.051823503279593e-05
knockout O 0 0.0028881439939141273
mice O 0 0.0003877285053022206
. O 0 7.2070920396072324e-06

In O 0 2.3353438791673398e-06
vitro O 0 2.0073122868780047e-05
- O 0 0.0002556727558840066
differentiated O 0 3.0438533940468915e-05
DMPK O 0 0.002600304316729307
[ O 0 1.3766249367108685e-06
- O 0 1.8091182937496342e-05
/ O 0 4.859979981119977e-06
- O 0 1.6420335668954067e-05
] O 0 6.915800554452289e-07
myotubes O 0 2.2194506072992226e-06
exhibit O 0 2.0542829304304178e-07
a O 0 1.6552178294659825e-08
higher O 0 1.0659411486813042e-07
resting O 0 2.597842694740393e-06
[ O 0 3.208461123449524e-07
Ca2 O 0 5.107177912577754e-06
+ O 0 4.635656978280167e-07
] O 0 6.448843237194524e-08
i O 0 2.6902000627160305e-09
than O 0 5.931843904960488e-10
do O 0 1.6978469741246727e-09
wild O 0 2.3366011348002758e-08
- O 0 1.0875454790948424e-05
type O 0 1.5335798480009544e-06
myotubes O 0 3.258096330682747e-05
because O 0 4.569503442297673e-09
of O 0 3.8658701240201765e-10
an O 0 1.1047573966749269e-09
altered O 0 8.478268398448563e-08
open O 0 2.856481984281345e-08
probability O 0 7.639848753626666e-09
of O 0 9.709162362980805e-10
voltage O 0 6.429468726310006e-07
- O 0 4.81270944874268e-06
dependent O 0 6.924248907580477e-08
l O 0 5.163853074918734e-06
- O 0 3.2505392937309807e-06
type O 0 4.759462228776101e-07
Ca2 O 0 4.96575466968352e-06
+ O 0 2.2063569815600204e-07
and O 0 2.495615092357184e-08
Na O 0 3.737028964678757e-05
+ O 0 3.072373374379822e-06
channels O 0 1.2284718877708656e-06
. O 0 1.3868107089365367e-06

The O 0 3.2287518934026593e-06
mutant O 0 9.850059723248705e-05
myotubes O 0 0.00020782877982128412
exhibit O 0 5.522932951862458e-06
smaller O 0 1.2881454836133344e-07
and O 0 1.9014050778309866e-08
slower O 0 3.4346442134847166e-07
Ca2 O 0 8.179236829164438e-06
+ O 0 2.6733735580819484e-07
responses O 0 4.8798906249203355e-08
upon O 0 1.2356594858431436e-08
triggering O 0 2.9042396931799885e-07
by O 0 1.6697693894229815e-08
acetylcholine O 0 5.322102424543118e-06
or O 0 4.018692578711125e-08
high O 0 2.8512354788290395e-07
external O 0 9.997375855164137e-06
K O 0 0.0002002781693590805
+ O 0 1.9925048036384396e-05
. O 0 1.3193977110859123e-06

In O 0 1.131903786699695e-06
addition O 0 2.560891232405993e-07
, O 0 1.6385259371531902e-08
we O 0 4.025817901265327e-09
observed O 0 1.3685175659361448e-08
that O 0 8.015488828228001e-10
these O 0 3.1575326797650405e-09
Ca2 O 0 7.752580131636932e-06
+ O 0 2.5686988465167815e-06
transients O 0 3.893791017617332e-06
partially O 0 2.2229302487630775e-07
result O 0 1.0900330416063753e-08
from O 0 6.603995683640562e-10
an O 0 3.439438733821021e-10
influx O 0 1.967165275118532e-08
of O 0 2.4632529349588594e-09
extracellular O 0 4.594527354129241e-07
Ca2 O 0 3.3919413908733986e-06
+ O 0 9.159904124089735e-08
through O 0 1.3598522308200245e-09
the O 0 3.8374268207519435e-09
l O 0 1.1227054528717417e-05
- O 0 1.3601621503767092e-05
type O 0 3.297366674814839e-06
Ca2 O 0 3.215392280253582e-05
+ O 0 2.594312263681786e-06
channel O 0 1.0373084933235077e-06
. O 0 8.475274739794258e-07

Neither O 0 7.318854841287248e-06
the O 0 7.831713588757339e-08
content O 0 6.025870646908515e-08
nor O 0 5.221009047318148e-08
the O 0 3.9736218759856e-09
activity O 0 1.3511144203448566e-08
of O 0 3.7948830744483075e-09
Na O 0 2.3533220883109607e-05
+ O 0 1.1878687473654281e-06
/ O 0 5.424590199254453e-07
K O 0 4.005053142464021e-07
+ O 0 1.2294383111566276e-07
ATPase O 0 7.417215783789288e-07
and O 0 1.9248531657467538e-08
sarcoplasmic O 0 2.711361230467446e-05
reticulum O 0 7.352168177021667e-05
Ca2 O 0 2.6262998289894313e-05
+ O 0 8.45538181692973e-07
- O 0 2.1650930648320355e-06
ATPase O 0 5.497163783729775e-06
are O 0 4.7101686995176806e-09
affected O 0 3.170098139548827e-08
by O 0 5.723895668552359e-08
DMPK O 0 0.004127183463424444
absence O 0 9.603737453289796e-06
. O 0 4.343537966633448e-06

In O 0 2.7197595500183525e-06
conclusion O 0 8.956172337093449e-07
, O 0 2.92137833923789e-08
our O 0 1.9946783780255828e-08
data O 0 5.228283228575492e-08
suggest O 0 3.583945229479468e-08
that O 0 3.5982998802808197e-09
DMPK O 0 7.41899129934609e-05
is O 0 7.326292461584671e-09
involved O 0 4.170146006288178e-09
in O 0 7.2805317330448815e-09
modulating O 0 1.4359644637806923e-06
the O 0 3.839945694750213e-09
initial O 0 2.4887416572028087e-08
events O 0 7.299873594490691e-09
of O 0 2.339802129824875e-09
excitation O 0 6.72316673444584e-06
- O 0 0.00013800790475215763
contraction O 0 4.09569802286569e-05
coupling O 0 2.4555245090596145e-06
in O 0 4.517630713962717e-07
skeletal O 0 0.017477020621299744
muscle O 0 0.00026599023840390146
. O 0 8.633190873297281e-07
. O 0 2.4127293727360666e-06

Constitutional O 0 0.00043212450691498816
RB1 O 1 0.592067301273346
- O 0 0.0031651200260967016
gene O 0 3.093608029303141e-05
mutations O 0 6.164425576571375e-05
in O 0 6.727135541950702e-07
patients O 0 2.2375897970050573e-06
with O 0 5.210533231547743e-07
isolated O 0 7.395357533823699e-05
unilateral B-Disease 0 0.0018778961384668946
retinoblastoma I-Disease 1 0.9354462027549744
. O 0 2.7726518965209834e-05

In O 0 5.317059731169138e-06
most O 0 7.277868689925526e-07
patients O 0 2.2834419723949395e-06
with O 0 1.110350140720584e-07
isolated O 0 4.12376857639174e-06
unilateral B-Disease 0 9.422923176316544e-05
retinoblastoma I-Disease 1 0.6017258167266846
, O 0 2.9796874514431693e-06
tumor B-Disease 0 0.0007582776015624404
development O 0 4.952948273739821e-08
is O 0 3.973303464022138e-09
initiated O 0 2.528772924392797e-08
by O 0 7.825170733610776e-09
somatic O 0 2.5815893422986846e-06
inactivation O 0 1.5648756743757986e-05
of O 0 2.6037090261610274e-09
both O 0 6.333584767759248e-09
alleles O 0 9.472037731939054e-08
of O 0 1.6221724408183036e-08
the O 0 1.3913571592638618e-06
RB1 O 0 0.08687254041433334
gene O 0 5.895456524740439e-06
. O 0 3.6001254102302482e-06

However O 0 3.6793328490603017e-06
, O 0 5.317904694379649e-08
some O 0 2.406802090959559e-09
of O 0 5.38760147605899e-09
these O 0 5.127041546870714e-08
patients O 0 2.5468239073234145e-06
can O 0 3.758357820515812e-07
transmit O 0 0.005018882919102907
retinoblastoma B-Disease 0 0.30490151047706604
predisposition O 0 0.00027239107294008136
to O 0 5.6905527401340805e-08
their O 0 3.211611101505696e-07
offspring O 0 0.00010057790495920926
. O 0 5.058009719505208e-06

To O 0 5.85210557346727e-07
determine O 0 8.042669037422456e-07
the O 0 3.522269054201388e-08
frequency O 0 3.982919452028e-07
and O 0 1.2029398810398106e-08
nature O 0 1.1708569047641504e-07
of O 0 7.279407299165541e-09
constitutional O 0 6.1801160882168915e-06
RB1 O 0 0.1397557407617569
- O 0 0.000244674040004611
gene O 0 9.475612046117021e-07
mutations O 0 2.0040326944581466e-06
in O 0 8.96982683684655e-08
patients O 0 4.825145083486859e-07
with O 0 4.9207820040919614e-08
isolated O 0 2.5608721898606746e-06
unilateral B-Disease 0 2.6884456019615754e-05
retinoblastoma I-Disease 0 0.004601224325597286
, O 0 1.7747602498729975e-08
we O 0 3.2747586864445566e-09
analyzed O 0 1.2822023620628897e-07
DNA O 0 1.2069402544057084e-07
from O 0 1.2559036477455265e-08
peripheral O 0 8.562326911487617e-06
blood O 0 4.6669747462146915e-06
and O 0 1.3865762582554453e-07
from O 0 1.0728246024882537e-06
tumor B-Disease 0 0.2326131910085678
tissue O 0 0.002942988881841302
. O 0 1.3038699762546457e-05

The O 0 5.406431569099368e-07
analysis O 0 4.5505800017053843e-07
of O 0 1.2608857957729924e-07
tumors B-Disease 1 0.9599925875663757
from O 0 6.704777177901633e-08
54 O 0 3.3455816605965083e-07
( O 0 1.624472822925327e-08
71 O 0 5.5205141791248025e-08
% O 0 4.482874071953802e-09
) O 0 9.039962112211697e-10
of O 0 1.359717449744835e-09
76 O 0 1.0037069841928314e-06
informative O 0 9.401484021509532e-06
patients O 0 1.157417045760667e-05
showed O 0 7.370631647063419e-05
loss O 0 3.338523310958408e-05
of O 0 1.0388720994569667e-07
constitutional O 0 6.460231088567525e-05
heterozygosity O 1 0.9044128060340881
( O 0 3.021140400960576e-06
LOH O 1 0.9998230338096619
) O 0 9.387611044076039e-08
at O 0 1.381497298780232e-07
intragenic O 0 0.00022438705491367728
loci O 0 1.4511390872939955e-05
. O 0 3.8420398595917504e-06

Three O 0 7.269953243849159e-07
of O 0 1.8444845295562118e-07
13 O 0 1.7020716995830298e-06
uninformative O 0 0.15002046525478363
patients O 0 3.5731201933231205e-05
had O 0 7.512990123359486e-07
constitutional O 0 7.649994586245157e-06
deletions O 0 0.0007640575058758259
. O 0 1.4525292499456555e-05

For O 0 3.1817353374208324e-07
39 O 0 5.216539875618764e-07
randomly O 0 2.960719029942993e-07
selected O 0 3.3452161005698144e-06
tumors B-Disease 1 0.9950770735740662
, O 0 1.5157088739670144e-07
SSCP O 0 0.000255587394349277
, O 0 3.240574031337928e-08
hetero O 0 2.238028173451312e-05
- O 0 1.3809054507873952e-05
duplex O 0 7.398283923976123e-05
analysis O 0 5.123112245541961e-08
, O 0 2.0112116416726167e-09
sequencing O 0 4.42432401825954e-08
, O 0 1.4744173659764215e-09
and O 0 2.0482677776101355e-09
Southern O 0 3.821345728738379e-08
blot O 0 1.5417217582580633e-05
analysis O 0 2.452387448670379e-08
were O 0 1.745139255326933e-09
used O 0 1.115929304518204e-08
to O 0 2.247588781756349e-08
identify O 0 3.5096597912342986e-06
mutations O 0 3.2869542337721214e-05
. O 0 3.5919977108278545e-06

Mutations O 0 0.0007994452607817948
were O 0 4.923392111777503e-07
detected O 0 1.0180293429584708e-05
in O 0 4.2056775839682814e-08
21 O 0 6.436505373130785e-08
( O 0 8.539366547211102e-09
91 O 0 4.7614232556725256e-08
% O 0 4.713745838103023e-09
) O 0 3.3097349305677426e-09
of O 0 3.8820857639620954e-08
23 O 0 0.0012664509704336524
tumors B-Disease 1 0.9999409914016724
with O 0 0.0001576010399730876
LOH O 1 0.9999749660491943
. O 0 0.00010396766447229311

In O 0 2.3953646177687915e-06
6 O 0 4.2674204792092496e-07
( O 0 2.7701185345563317e-08
38 O 0 2.6287253263035382e-08
% O 0 6.800468188572495e-09
) O 0 2.6450446277692663e-09
of O 0 5.451878060114268e-09
16 O 0 1.8420269043417647e-05
tumors B-Disease 1 0.9999597072601318
without O 0 5.8169339354208205e-06
LOH O 1 0.9999599456787109
, O 0 5.934203883839473e-08
one O 0 2.5358293243016305e-08
mutation O 0 1.9570477434172062e-06
was O 0 3.570633211325003e-08
detected O 0 1.6769622561696451e-06
, O 0 4.1748888790493766e-09
and O 0 3.348353150300909e-09
in O 0 1.5144353326945748e-08
9 O 0 5.263985158876494e-08
( O 0 3.547936389125539e-09
56 O 0 2.3537687354746595e-08
% O 0 6.909140815025694e-09
) O 0 1.2604867150045607e-09
of O 0 2.5481188270504163e-09
the O 0 4.714971510111354e-06
tumors B-Disease 1 0.999985933303833
without O 0 1.2194722330605146e-05
LOH O 1 0.9999690055847168
, O 0 1.2831992535211612e-07
both O 0 4.8031079558086276e-08
mutations O 0 1.3570723922384786e-06
were O 0 6.786333983654913e-08
found O 0 9.252614745491883e-07
. O 0 3.1999859402276343e-06

Thus O 0 2.387355152677628e-06
, O 0 2.649337638160887e-08
a O 0 6.311756894916698e-09
total O 0 5.147243076208952e-09
of O 0 3.512258262006185e-09
45 O 0 6.354012072051773e-08
mutations O 0 8.657208354634349e-07
were O 0 1.4776528445281656e-08
identified O 0 2.324939487152733e-06
in O 0 4.608684776030714e-06
tumors B-Disease 1 0.9973366856575012
of O 0 3.7820379361619416e-07
36 O 0 2.5206614736816846e-05
patients O 0 0.00011898352386197075
. O 0 1.557859286549501e-05

Thirty O 0 8.319616426888388e-06
- O 0 6.406011380022392e-06
nine O 0 6.268412988674754e-08
of O 0 6.6320477998260685e-09
the O 0 3.0294035724409696e-08
mutations O 0 6.96127358423837e-07
- O 0 4.086437002115417e-06
including O 0 2.0735122063797462e-08
34 O 0 6.621433357167916e-08
small O 0 6.533340268788379e-08
mutations O 0 1.7079725012081326e-06
, O 0 1.1918722897519274e-08
2 O 0 1.3437231771717961e-08
large O 0 1.6122992008149595e-07
structural O 0 0.0009453402599319816
alterations O 0 1.7204480172949843e-05
, O 0 2.370302887300113e-08
and O 0 3.350162813831048e-08
hypermethylation O 0 0.0031993768643587828
in O 0 4.1147745832859073e-07
3 O 0 4.850862751482055e-06
tumors O 1 0.9995700716972351
- O 0 0.00025192552129738033
were O 0 1.5870178060595208e-08
not O 0 1.4298784378752316e-08
detected O 0 6.82005122598639e-07
in O 0 6.385147077736519e-09
the O 0 1.1519941445214954e-08
corresponding O 0 2.2377221284841653e-06
peripheral O 0 9.235716424882412e-05
blood O 0 3.227834531571716e-05
DNA O 0 4.0975617594085634e-05
. O 0 4.7089229155972134e-06

In O 0 2.4084029064397328e-06
6 O 0 3.976725508891832e-07
( O 0 2.0430286795658503e-08
17 O 0 2.2169889035694723e-08
% O 0 4.266970332622577e-09
) O 0 4.888511817568997e-10
of O 0 4.4247583375067734e-10
the O 0 1.3249612962340507e-08
36 O 0 5.907506874791579e-07
patients O 0 3.584851242521836e-07
, O 0 2.8832049636662305e-08
a O 0 2.0410642775914312e-07
mutation O 0 1.3355564078665338e-05
was O 0 8.873885803950543e-08
detected O 0 1.9016862324860995e-06
in O 0 4.8301704858033645e-09
constitutional O 0 5.243493106377173e-08
DNA O 0 6.474829774560931e-07
, O 0 2.650154984351616e-09
and O 0 8.123627881495565e-10
1 O 0 1.0779952486217326e-09
of O 0 6.009750475044484e-10
these O 0 6.230612470403685e-09
mutations O 0 3.218638937596552e-07
is O 0 2.6139543862768733e-09
known O 0 4.7271431213857795e-09
to O 0 1.557895257242592e-09
be O 0 8.067073231643462e-09
associated O 0 1.4569549477982946e-07
with O 0 1.4167991935210011e-07
reduced O 0 1.8891536456067115e-05
expressivity O 1 0.5963782072067261
. O 0 9.416548891749699e-06

The O 0 4.819295895686082e-07
presence O 0 1.8710416327394341e-07
of O 0 7.3767290054149726e-09
a O 0 5.14708879961745e-08
constitutional O 0 1.300360281675239e-06
mutation O 0 7.773080142214894e-06
was O 0 3.2779222891576865e-08
not O 0 4.809596276800221e-09
associated O 0 3.382103486160304e-08
with O 0 4.785894791581313e-09
an O 0 4.61719906752478e-09
early O 0 4.53502252639737e-07
age O 0 1.1850445389427477e-06
at O 0 4.116191689718107e-07
treatment O 0 1.8013901353697293e-05
. O 0 8.050434189499356e-06

In O 0 3.7069737572892336e-06
1 O 0 8.344928232872917e-07
patient O 0 5.178500032343436e-06
, O 0 1.069888639904093e-07
somatic O 0 2.15671825571917e-05
mosaicism O 0 0.003444392466917634
was O 0 1.394690087863637e-07
demonstrated O 0 2.770840410448727e-07
by O 0 6.642225880426622e-09
molecular O 0 1.8060146658172016e-06
analysis O 0 1.7213086067613403e-08
of O 0 1.838115659680284e-09
DNA O 0 1.8761340925266268e-07
and O 0 1.9106609627783655e-08
RNA O 0 1.230976351962454e-07
from O 0 3.756866462367725e-08
peripheral O 0 2.0818575649173e-05
blood O 0 3.48477806255687e-05
. O 0 5.827166660310468e-06

In O 0 6.421425496228039e-06
2 O 0 1.5655357401556103e-06
patients O 0 1.9898654954886297e-06
without O 0 3.579251739438405e-08
a O 0 2.0784585785804666e-07
detectable O 0 0.004170379135757685
mutation O 0 5.933517968514934e-06
in O 0 3.781453017381864e-08
peripheral O 0 2.537312320782803e-05
blood O 0 5.919798059039749e-05
, O 0 3.298211197488854e-07
mosaicism O 0 0.0004987093852832913
was O 0 1.9610737922448607e-08
suggested O 0 1.4757771005236009e-08
because O 0 1.9242942794761575e-09
1 O 0 7.726746464875589e-10
of O 0 5.983900597250624e-10
the O 0 1.0718576248791578e-07
patients O 0 2.130919529008679e-05
showed O 0 0.16696962714195251
multifocal O 1 0.9999808073043823
tumors B-Disease 1 0.9999908208847046
and O 0 5.572552552735033e-08
the O 0 1.0633010028016088e-08
other O 0 5.594637642047928e-09
later O 0 8.669049833542886e-08
developed O 0 1.1429036703702877e-06
bilateral B-Disease 0 3.9914277294883505e-05
retinoblastoma I-Disease 0 0.23816819489002228
. O 0 1.8596685549709946e-05

In O 0 1.7388791775374557e-06
conclusion O 0 1.4103015928412788e-06
, O 0 4.2084941753728344e-08
our O 0 3.42590240620666e-08
results O 0 6.935682250741593e-08
emphasize O 0 5.969303629171918e-08
that O 0 2.0668620148711625e-09
the O 0 3.178779017787292e-09
manifestation O 0 1.5972627807059325e-06
and O 0 2.8125503703790855e-08
transmissibility O 0 7.485821697628126e-05
of O 0 1.0489906721034004e-08
retinoblastoma B-Disease 0 0.00010371863027103245
depend O 0 5.794836610562015e-08
on O 0 3.304518436664239e-09
the O 0 1.949325589833961e-09
nature O 0 3.4079409516607484e-08
of O 0 3.5145347743181787e-10
the O 0 1.996176779428538e-09
first O 0 2.8017188569151585e-08
mutation O 0 4.328211673509941e-07
, O 0 7.517183542304906e-10
its O 0 8.61525517592554e-10
time O 0 1.1747280925789028e-09
in O 0 2.6949866782643994e-09
development O 0 8.330104606102395e-09
, O 0 2.217757533173881e-09
and O 0 1.3126727482770661e-09
the O 0 1.2544379979217979e-09
number O 0 2.433454771022525e-09
and O 0 2.5325361807659874e-09
types O 0 1.6113117951022105e-08
of O 0 4.9603667839903665e-09
cells O 0 6.34064008409041e-07
that O 0 9.861725658311116e-09
are O 0 7.351993236426324e-09
affected O 0 1.9161174691362248e-07
. O 0 1.1976335656527226e-07
. O 0 2.4278247110487428e-06

Hereditary B-Disease 1 0.9996153116226196
deficiency I-Disease 1 0.9978575110435486
of I-Disease 0 1.8205840035534493e-07
the I-Disease 0 6.623680803841125e-08
fifth I-Disease 0 3.5686218780028867e-07
component I-Disease 0 7.692755588095679e-08
of I-Disease 0 6.426358112321395e-09
complement I-Disease 0 5.398301254899707e-07
in O 0 3.0547045071216417e-07
man O 0 2.2830694433650933e-05
. O 0 3.297174771432765e-06

I O 0 0.00045276686432771385
. O 0 5.955935921519995e-05

Clinical O 0 0.0038129447493702173
, O 0 2.8391657451720675e-06
immunochemical O 0 0.001068232348188758
, O 0 2.0215395579725737e-07
and O 0 1.9993564137621433e-07
family O 0 2.0032509837619727e-06
studies O 0 4.607054506777786e-06
. O 0 4.706068466475699e-06

The O 0 7.168391107370553e-07
first O 0 2.479540910371725e-07
recognized O 0 3.599967044465302e-07
human O 0 7.45929469303519e-07
kindred O 0 0.00034199104993604124
with O 0 7.845610525691882e-06
hereditary B-Disease 1 0.997054934501648
deficiency I-Disease 1 0.9460917711257935
of I-Disease 0 8.136828100191451e-09
the I-Disease 0 1.774299995815909e-08
fifth I-Disease 0 3.50916025126935e-07
component I-Disease 0 1.4894204980464565e-07
of I-Disease 0 4.407207487844289e-09
complement I-Disease 0 9.260842261937796e-07
( O 0 5.3296329127761055e-08
C5 O 0 1.412901565345237e-05
) O 0 1.0145063455979653e-08
is O 0 1.4910101597820358e-08
described O 0 2.9064335649309214e-06
. O 0 4.511290171649307e-06

The O 0 1.915638449645485e-06
proband O 0 8.974751835921779e-05
, O 0 2.6140655862150197e-08
a O 0 9.692921132398169e-09
20 O 0 1.4399996750569244e-08
- O 0 5.762306045653531e-06
year O 0 9.669086864505516e-08
- O 0 3.905240373569541e-05
old O 0 9.899636097543407e-06
black O 0 2.8473561542341486e-05
female O 0 0.00012536931899376214
with O 0 0.019182056188583374
systemic B-Disease 1 0.9999996423721313
lupus I-Disease 1 0.9999986886978149
erythematosus I-Disease 1 0.9999923706054688
since O 0 0.00010044985538115725
age O 0 5.71400732951588e-06
11 O 0 3.144121194509353e-07
, O 0 1.569696195247161e-07
lacked O 0 0.0006419640267267823
serum O 1 0.9751503467559814
hemolytic O 1 0.9919106364250183
complement O 0 1.9412307210586732e-06
activity O 0 1.6256453250207414e-07
, O 0 1.2487426204188523e-08
even O 0 5.810984760046267e-08
during O 0 2.391972429904854e-06
remission O 0 0.0013914599549025297
. O 0 6.643585038546007e-06

C5 O 0 0.0029989357572048903
was O 0 1.858232621998468e-06
undetectable O 0 4.087445995537564e-05
in O 0 8.773982074217201e-08
her O 0 4.668945905450528e-07
serum O 0 0.0001176253063022159
by O 0 2.9672701629124276e-08
both O 0 3.9075217728168354e-08
immunodiffusion O 0 0.0018753544427454472
and O 0 9.08918991626706e-06
hemolytic O 1 0.9972032308578491
assays O 0 0.0017066247528418899
. O 0 9.847791261563543e-06

Other O 0 5.095382675790461e-07
complement O 0 9.909506388794398e-07
components O 0 3.082223543060536e-07
were O 0 9.955350321888545e-09
normal O 0 6.369640459524817e-08
during O 0 1.3620210381759534e-07
remission O 0 3.234422911191359e-05
of O 0 1.8147041203064873e-07
lupus O 1 0.7927075624465942
, O 0 8.485774571909133e-08
but O 0 4.3397179183557455e-08
C1 O 0 0.0006490666419267654
, O 0 2.082187577912009e-08
C4 O 0 1.762873216648586e-05
, O 0 3.849936192068526e-08
C2 O 0 4.449402695172466e-05
, O 0 2.0759340912945845e-08
and O 0 1.1016147993814229e-07
C3 O 0 0.0049552032724022865
levels O 0 6.012329777149716e-06
fell O 0 8.311622877954505e-06
during O 0 5.590859927906422e-06
exacerbations O 1 0.501595675945282
. O 0 1.4686786926176865e-05

A O 0 5.063483058620477e-06
younger O 0 2.141996446880512e-06
half O 0 1.3296059364620305e-07
- O 0 2.6620331482263282e-05
sister O 0 6.562679573107744e-06
, O 0 2.2869622640087073e-08
who O 0 4.5452537733581266e-08
had O 0 1.7036518329405226e-07
no O 0 7.680192538828123e-06
underlying O 1 0.7932407259941101
disease O 0 0.0037115211598575115
, O 0 2.5604949271951227e-08
was O 0 1.547624961517613e-08
also O 0 6.585383349744234e-09
found O 0 1.919471159794739e-08
to O 0 3.924237290675592e-08
lack O 0 4.226701094012242e-06
immunochemically O 0 0.42528921365737915
detectable O 0 0.026650503277778625
C5 O 0 0.0007472606375813484
. O 0 2.9774064387311228e-06

By O 0 2.4352670152438805e-05
hemolytic O 1 0.9965376853942871
assay O 0 0.0008305766968987882
, O 0 1.9311512744479842e-07
she O 0 5.39663425058734e-08
exhibited O 0 2.0925597254972672e-07
1 O 0 6.327631751901208e-09
- O 0 7.51466700421588e-07
2 O 0 8.349209323910145e-09
% O 0 1.840964714006077e-09
of O 0 5.936178215648624e-10
the O 0 9.136659429032079e-09
normal O 0 8.396833663937286e-07
serum O 0 0.001903003896586597
C5 O 0 1.6074391169240698e-05
level O 0 1.7888913461661105e-08
and O 0 5.706136008143403e-09
normal O 0 5.692832871773135e-08
concentrations O 0 4.3616381617539446e-07
of O 0 3.2676708006107447e-09
other O 0 1.6782914613600042e-08
complement O 0 1.0585616792013752e-06
components O 0 6.117851626186166e-06
. O 0 2.9164348234189674e-06

C5 O 0 0.009710768237709999
levels O 0 8.204596269933973e-06
of O 0 1.785986647462323e-08
other O 0 4.69660488278123e-09
family O 0 2.606130244942051e-08
members O 0 3.15254400362619e-09
were O 0 3.2233240521151174e-09
either O 0 1.0024403529484971e-08
normal O 0 1.9708306098209505e-08
or O 0 1.4230920886149079e-09
approximately O 0 9.171923776030155e-10
half O 0 3.0467337541750794e-09
- O 0 1.9289425836177543e-05
normal O 0 1.8806537127602496e-07
, O 0 8.999572642665044e-09
consistent O 0 9.110698329095612e-08
with O 0 6.541096553291936e-08
autosomal O 0 9.50967296375893e-05
codominant O 0 0.0018990518292412162
inheritance O 0 4.063244887220208e-06
of O 0 1.8985529592896455e-08
the O 0 1.9372771475900663e-07
gene O 0 1.1802301742136478e-05
determining O 0 0.0002522348368074745
C5 B-Disease 1 0.9997853636741638
deficiency I-Disease 1 0.999901533126831
. O 0 2.7614370992523618e-05

Normal O 0 0.012776948511600494
hemolytic O 1 0.9991600513458252
titers O 0 0.2184760719537735
were O 0 3.1294658242586593e-07
restored O 0 4.518841478784452e-07
to O 0 1.793065784738701e-08
both O 0 6.660953744130893e-08
homozygous O 0 0.008443474769592285
C5 B-Disease 1 0.9998103976249695
- I-Disease 1 0.9997259974479675
deficient I-Disease 1 0.9998942613601685
( O 0 1.183183485409245e-06
C5D B-Disease 1 0.993361234664917
) O 0 2.5757726618280685e-08
sera O 0 7.852412977626955e-07
by O 0 5.563225435878394e-09
addition O 0 1.4742831844216653e-08
of O 0 9.448918980581311e-09
highly O 0 4.454255986274802e-07
purified O 0 1.875400084827561e-05
human O 0 5.3215439947962295e-06
C5 O 0 0.0005768942646682262
. O 0 3.39215489475464e-06

In O 0 3.292809878985281e-06
specific O 0 1.7754208556652884e-06
C5 O 0 0.00023852808226365596
titrations O 0 0.0020165424793958664
, O 0 6.831059806700068e-08
however O 0 1.657005732624839e-08
, O 0 3.410696391981105e-09
it O 0 6.442480993129607e-10
was O 0 1.7400605401007851e-09
noted O 0 6.4205019079111025e-09
that O 0 5.223772525653203e-10
when O 0 1.601704768816603e-09
limited O 0 1.3272978272027558e-09
amounts O 0 4.100391137740189e-09
of O 0 1.4755652255615814e-09
C5 O 0 9.654874020270654e-07
were O 0 1.2129891535650472e-09
assayed O 0 1.9234629178299656e-07
in O 0 2.2277715228113948e-09
the O 0 1.1709341274368512e-09
presence O 0 8.443229226884341e-09
of O 0 2.096085305325346e-09
low O 0 2.0248485554930085e-07
dilutions O 0 2.3595234779349994e-06
of O 0 6.145257636092083e-09
either O 0 2.4671479081916914e-07
C5D B-Disease 1 0.9993849992752075
serum O 0 0.0005456522922031581
, O 0 5.39932898391271e-09
curving O 0 6.15452648844439e-08
rather O 0 1.9162877951117707e-09
than O 0 1.2706927732253348e-09
linear O 0 5.0577696697473584e-08
dose O 0 2.562895133451093e-06
- O 0 1.4223827747628093e-05
response O 0 3.3004104693645786e-07
plots O 0 4.045718640099949e-07
were O 0 1.1424233115064908e-08
consistently O 0 9.618833018976147e-08
obtained O 0 4.579059620368753e-08
, O 0 6.250466810797661e-09
suggesting O 0 8.117687144704178e-08
some O 0 1.1161549018368078e-08
inhibitory O 0 3.0215953756851377e-06
effect O 0 1.411359221492603e-06
. O 0 2.1349319467844907e-06

Further O 0 1.5755513231852092e-06
studies O 0 8.039364161049889e-07
suggested O 0 2.8706233479169896e-07
that O 0 1.8892945874426914e-08
low O 0 3.1133967581808975e-07
dilutions O 0 1.95042957784608e-05
of O 0 1.6921536882819055e-07
C5D B-Disease 1 0.9999126195907593
serum O 0 0.06740971654653549
contain O 0 4.828238502341264e-07
a O 0 4.371744921627396e-08
factor O 0 5.1162182046482485e-08
( O 0 6.655820783407762e-09
or O 0 9.382059573681545e-09
factors O 0 1.8534379364609777e-08
) O 0 2.2816544209547374e-09
interfering O 0 1.42599745345251e-08
at O 0 2.813149935221304e-09
some O 0 5.013678361365237e-10
step O 0 2.075340255203173e-08
in O 0 1.2356665024526592e-08
the O 0 1.0546242634745795e-07
hemolytic O 1 0.7544912695884705
assay O 0 1.1308547982480377e-05
of O 0 3.270652726428125e-08
C5 O 0 5.451078322948888e-05
, O 0 5.3323550019968025e-09
rather O 0 4.725971169960985e-09
than O 0 4.179478541033177e-09
a O 0 4.130898290100049e-08
true O 0 3.1455326734430855e-06
C5 O 0 0.00011090923362644389
inhibitor O 0 2.2040762814867776e-06
or O 0 2.4896158379306144e-07
inactivator O 0 0.0003553205169737339
. O 0 2.4313185349456035e-06

Of O 0 3.1368122108688112e-06
clinical O 0 9.894965478451923e-05
interest O 0 5.24292318004882e-07
are O 0 2.4635875561784815e-08
( O 0 1.4890519928201229e-08
a O 0 1.3069922921715715e-08
) O 0 4.017602250883101e-09
the O 0 5.101656874728633e-09
documentation O 0 3.4836884310607275e-07
of O 0 2.808892247685435e-07
membranous O 1 0.9996521472930908
glomerulonephritis B-Disease 1 0.9999982118606567
, O 0 0.0005030909669585526
vasculitis B-Disease 1 0.9999047517776489
, O 0 2.0008758383482927e-06
and O 0 4.776952846441418e-05
arthritis B-Disease 1 0.9999442100524902
in O 0 1.763894488249207e-07
an O 0 1.2747667810231178e-08
individual O 0 4.5902177703283087e-07
lacking O 0 8.33936283015646e-05
C5 O 0 0.0003741783439181745
( O 0 4.941291820159677e-09
and O 0 2.3623760725399734e-09
its O 0 6.329575530372722e-09
biologic O 0 2.7879452318302356e-05
functions O 0 1.795272908111656e-08
) O 0 2.8936268936519127e-09
, O 0 2.6132167540993123e-09
and O 0 5.731550789533912e-09
( O 0 1.0875763400974847e-08
b O 0 1.1112696540749312e-07
) O 0 1.0930951699350544e-09
a O 0 5.253130375137971e-09
remarkable O 0 4.870786597166443e-06
propensity O 0 0.0005554749513976276
to O 0 1.0754596587503329e-05
bacterial B-Disease 1 0.9999798536300659
infections I-Disease 1 0.9993731379508972
in O 0 1.6074585573733202e-07
the O 0 6.017510401079562e-08
proband O 0 0.0011459974339231849
, O 0 8.872357959432975e-09
even O 0 3.8536072111128306e-09
during O 0 1.1461292359626896e-08
periods O 0 3.981764606919569e-08
of O 0 2.783283381546653e-09
low O 0 2.1825037777034595e-07
- O 0 1.625927870918531e-05
dose O 0 4.41497286374215e-06
or O 0 1.2283865480355871e-08
alternate O 0 6.624615878081386e-08
- O 0 1.563442128826864e-05
day O 0 1.7758085277819191e-06
corticosteroid O 0 0.40503349900245667
therapy O 0 0.00016562480595894158
. O 0 3.648591018645675e-06

Other O 0 2.527073945657321e-07
observations O 0 1.9680674085975625e-06
indicate O 0 6.647036911999749e-07
that O 0 8.157401865105385e-09
the O 0 4.048203194884081e-08
C5D B-Disease 1 0.9856443405151367
state O 0 8.454014022163392e-08
is O 0 2.630710316253726e-09
compatible O 0 1.103652191858373e-08
with O 0 8.684138741443803e-09
normal O 0 1.3853602354174654e-07
coagulation O 0 2.1452613054862013e-06
function O 0 1.5194059344025845e-08
and O 0 1.4221097632827195e-09
the O 0 3.4893017364368006e-09
capacity O 0 6.373200989173711e-08
to O 0 4.878361714588664e-09
mount O 0 3.8475027395179495e-06
a O 0 2.5761419237824157e-06
neutrophilic O 1 0.9861844182014465
leukocytosis O 1 0.9430726766586304
during O 0 0.00021395750809460878
pyogenic B-Disease 1 0.9980413913726807
infection I-Disease 0 0.07084767520427704
. O 0 1.4326951713883318e-06
. O 0 3.7760119084850885e-06

Susceptibility O 1 0.9925058484077454
to O 0 0.002716608578339219
ankylosing B-Disease 1 0.9999967813491821
spondylitis I-Disease 1 0.9999991655349731
in O 0 9.95591763057746e-05
twins O 0 0.004638040438294411
: O 0 7.150332237415569e-08
the O 0 2.5289548233331516e-09
role O 0 8.539643658878049e-09
of O 0 3.073447718549005e-09
genes O 0 4.599901970436804e-08
, O 0 1.1121767506949709e-08
HLA O 0 2.7216872695134953e-05
, O 0 7.576665517206038e-09
and O 0 1.196932064573275e-08
the O 0 1.0655143256599331e-07
environment O 0 2.360140933888033e-05
. O 0 1.651432739890879e-06

OBJECTIVE O 0 7.327130788326031e-06
To O 0 2.1064913369173155e-07
determine O 0 2.474414770858857e-07
the O 0 3.09580059365544e-08
relative O 0 8.685200327818166e-07
effects O 0 5.224534902481537e-07
of O 0 2.9237641641088885e-08
genetic O 0 3.166289388900623e-05
and O 0 6.841594881734636e-07
environmental O 0 4.1305916965939105e-05
factors O 0 1.871480748150134e-07
in O 0 9.220771062246058e-07
susceptibility O 1 0.6019846796989441
to O 0 0.003098228247836232
ankylosing B-Disease 1 0.9999995231628418
spondylitis I-Disease 1 0.9999997615814209
( O 0 1.3369377484195866e-05
AS B-Disease 0 2.518143446650356e-05
) O 0 7.822098950782674e-07
. O 0 1.952977527253097e-06

METHODS O 0 0.00015336234355345368
Twins O 0 0.00032179683330468833
with O 0 1.0864240351793342e-07
AS B-Disease 0 5.202380748414726e-07
were O 0 9.085410646036962e-09
identified O 0 8.176986909802508e-08
from O 0 7.88833443010617e-09
the O 0 3.665354597615078e-08
Royal O 0 0.0001499114150647074
National O 0 3.849015411105938e-05
Hospital O 0 0.0009489620570093393
for O 0 9.2872760433238e-05
Rheumatic B-Disease 1 0.9999873638153076
Diseases I-Disease 1 0.9937007427215576
database O 0 0.0002136726980097592
. O 0 1.8865108359022997e-05

Clinical O 0 0.0006718566874042153
and O 0 2.268854814246879e-06
radiographic O 0 0.10815628618001938
examinations O 0 2.679405406524893e-05
were O 0 4.5726359587661136e-08
performed O 0 9.669750511420716e-08
to O 0 1.6102456257272024e-08
establish O 0 1.724233698041644e-06
diagnoses O 0 0.18919320404529572
, O 0 2.886511992983287e-06
and O 0 0.0002536770480219275
disease O 1 0.5146619081497192
severity O 0 0.05661512911319733
was O 0 1.547209507180014e-07
assessed O 0 1.1466217131328449e-07
using O 0 6.467107294128027e-09
a O 0 1.826318651865222e-08
combination O 0 2.336530542379478e-07
of O 0 1.383741032867647e-08
validated O 0 6.798447429900989e-06
scoring O 0 7.13945041752595e-07
systems O 0 1.297908693231875e-05
. O 0 1.8624090216690092e-06

HLA O 0 0.001411715755239129
typing O 0 2.6453682949068025e-05
for O 0 2.1511357317649527e-07
HLA O 0 0.00010736030526459217
- O 0 4.1388724639546126e-05
B27 O 0 8.635723133920692e-06
, O 0 2.6772100980565483e-08
HLA O 0 4.166247435932746e-06
- O 0 6.216730071173515e-06
B60 O 0 2.308002194695291e-06
, O 0 5.223894650185912e-09
and O 0 7.889704001229347e-09
HLA O 0 0.00011429422738729045
- O 0 0.00440490897744894
DR1 O 0 0.4167231023311615
was O 0 3.006613980005568e-08
performed O 0 8.383182148463675e-09
by O 0 1.340890842804754e-09
polymerase O 0 8.15001897080947e-08
chain O 0 1.936763709409206e-07
reaction O 0 1.7698788212783256e-08
with O 0 1.5241246043018464e-09
sequence O 0 3.035974316389911e-08
- O 0 5.672957854585547e-07
specific O 0 7.613272678952399e-09
primers O 0 1.676412239248748e-06
, O 0 8.054465538975819e-09
and O 0 1.3668427278901163e-08
zygosity O 0 5.094290099805221e-05
was O 0 5.7174904810608496e-08
assessed O 0 2.8953104447282385e-07
using O 0 2.3724112452327972e-07
microsatellite O 0 0.00034744860022328794
markers O 0 0.00010554112668614835
. O 0 7.844300853321329e-06

Genetic O 0 0.0014048691373318434
and O 0 1.8591525758893113e-06
environmental O 0 6.201357791724149e-06
variance O 0 4.715475085959042e-07
components O 0 4.831333626498235e-07
were O 0 9.179873750042589e-09
assessed O 0 8.321914179987289e-08
with O 0 4.733052616501254e-09
the O 0 6.150088882606042e-09
program O 0 1.1965011026404682e-07
Mx O 0 5.088509624329163e-06
, O 0 8.952436569842348e-10
using O 0 8.210376822859189e-10
data O 0 5.8224314258836785e-09
from O 0 5.930700930356636e-10
this O 0 7.923026679179657e-10
and O 0 2.3975421648003703e-09
previous O 0 1.0573070596819889e-07
studies O 0 3.060539199850609e-08
of O 0 9.501872177963833e-09
twins O 0 0.0006370293558575213
with O 0 1.3918571539761615e-07
AS B-Disease 0 1.4477498552878387e-05
. O 0 3.6223318602424115e-06

RESULTS O 0 2.7865153242601082e-05
Six O 0 3.828324111054826e-07
of O 0 6.591380241616207e-08
8 O 0 1.4217044963515946e-06
monozygotic O 0 0.018857745453715324
( O 0 5.927217898715753e-07
MZ O 1 0.8794686794281006
) O 0 9.667721911910121e-08
twin O 0 0.0005690530524589121
pairs O 0 1.3099870557198301e-05
were O 0 8.027925559872529e-07
disease O 0 0.0003260724770370871
concordant O 0 0.00027982762549072504
, O 0 6.973247934638493e-08
compared O 0 1.0065426891969764e-07
with O 0 4.36114877544469e-09
4 O 0 7.3696830860114915e-09
of O 0 2.146353317300509e-09
15 O 0 4.108872175834222e-08
B27 O 0 1.4071099940338172e-05
- O 0 8.894681377569214e-05
positive O 0 2.60183469436015e-07
dizygotic O 0 0.002461461117491126
( O 0 4.327658231773057e-08
DZ O 0 0.0018144886707887053
) O 0 1.3180422975267447e-08
twin O 0 4.882741268374957e-05
pairs O 0 7.192982707238116e-07
( O 0 8.411483065629e-09
27 O 0 2.4462069703190537e-08
% O 0 3.826229999503994e-09
) O 0 8.987423028017361e-10
and O 0 1.1015359735466745e-09
4 O 0 3.5069160908562935e-09
of O 0 1.809708161104595e-09
32 O 0 3.9254280181921786e-07
DZ O 0 0.3608923554420471
twin O 0 0.007310161832720041
pairs O 0 1.2232869721628958e-06
overall O 0 3.907361758592742e-07
( O 0 6.365957538889688e-09
12 O 0 7.491066433829019e-09
. O 0 7.09252034880592e-09
5 O 0 3.1248159615415716e-08
% O 0 5.944308512084717e-08
) O 0 9.772059428314606e-08
. O 0 1.2003863503196044e-06

Nonsignificant O 0 0.008263864554464817
increases O 0 2.204819793405477e-05
in O 0 1.3383395014443522e-07
similarity O 0 9.399326472703251e-07
with O 0 1.8740593077382073e-08
regard O 0 7.651766509297886e-08
to O 0 3.163345496659531e-08
age O 0 3.0867379336996237e-06
at O 0 3.3801934478105977e-06
disease O 0 0.00500911520794034
onset O 0 0.00014874993939884007
and O 0 1.7454231837632506e-08
all O 0 1.2848965225131792e-09
of O 0 1.4137536474834178e-08
the O 0 1.2412656360538676e-05
disease O 0 0.23064808547496796
severity O 0 0.028406905010342598
scores O 0 1.6210145759032457e-06
assessed O 0 8.537072062608786e-07
were O 0 3.522497493690935e-08
noted O 0 9.58593659561302e-07
in O 0 4.0820823414833285e-06
disease O 0 0.002073196228593588
- O 0 0.2913281321525574
concordant O 1 0.9705314636230469
MZ O 1 0.9999068975448608
twins O 0 0.06381907314062119
compared O 0 2.910605417127954e-06
with O 0 7.824068575246201e-07
concordant O 1 0.6666356921195984
DZ O 1 0.9993504881858826
twins O 0 0.12344595789909363
. O 0 6.575121460627997e-06

HLA O 0 0.010898631066083908
- O 0 0.0003690715238917619
B27 O 0 4.4984841224504635e-05
and O 0 1.391561283980991e-07
B60 O 0 1.06000179584953e-05
were O 0 1.5543758280500697e-08
associated O 0 8.569834619720496e-08
with O 0 1.9056312083876037e-08
the O 0 5.668259177582513e-07
disease O 0 0.00015996056026779115
in O 0 6.16953528265185e-08
probands O 0 0.0004925394896417856
, O 0 9.858115213035035e-09
and O 0 2.7001216817978957e-09
the O 0 7.832666959473045e-09
rate O 0 1.0904327751859455e-07
of O 0 4.246658491524613e-08
disease O 0 0.0006099873571656644
concordance O 0 0.00013852711708750576
was O 0 2.0065768069343903e-07
significantly O 0 3.9235041526808345e-07
increased O 0 8.829617570427217e-08
among O 0 3.138117321555001e-08
DZ O 0 0.1358736753463745
twin O 0 0.007338228635489941
pairs O 0 6.533490477522719e-07
in O 0 4.468881709129846e-09
which O 0 2.4983952684465294e-09
the O 0 6.004300168171994e-09
co O 0 1.6005829820642248e-05
- O 0 0.008282428607344627
twin O 0 0.009677113965153694
was O 0 2.8916751659835427e-08
positive O 0 5.050749152246681e-09
for O 0 2.0522683552570697e-09
both O 0 3.159112793582608e-08
B27 O 0 0.00013279503036756068
and O 0 3.3454232379881432e-06
DR1 O 1 0.5834944248199463
. O 0 1.4650052435172256e-05

Additive O 0 0.00019389064982533455
genetic O 0 0.00021538556029554456
effects O 0 4.16128386859782e-06
were O 0 2.0472375794611253e-08
estimated O 0 6.0341520224938e-08
to O 0 2.431570944594341e-09
contribute O 0 3.085955313508748e-08
97 O 0 2.9587758021420996e-08
% O 0 3.877081322656295e-09
of O 0 2.261749010301628e-09
the O 0 4.114087204243333e-08
population O 0 1.301823999710905e-07
variance O 0 9.374716682941653e-07
. O 0 2.862216661014827e-06

CONCLUSION O 0 0.00013782591850031167
Susceptibility O 0 0.0035575730726122856
to O 0 1.7150173903246468e-07
AS B-Disease 0 8.251309964180109e-07
is O 0 2.2907517660541998e-08
largely O 0 3.906776058215655e-08
genetically O 0 1.236652593661347e-07
determined O 0 1.1832506885411931e-07
, O 0 7.121067735482711e-09
and O 0 4.210587434272384e-09
the O 0 9.767564534968187e-09
environmental O 0 1.6638313127259607e-06
trigger O 0 1.6280979480143287e-06
for O 0 2.6624324078738937e-08
the O 0 1.2720510085273418e-06
disease O 0 0.0024512491654604673
is O 0 2.2998936799467629e-07
probably O 0 1.647830004003481e-06
ubiquitous O 0 5.401376256486401e-05
. O 0 3.037306441910914e-06

HLA O 0 0.006061751861125231
- O 0 0.0002739537740126252
B27 O 0 1.3165133168513421e-05
accounts O 0 7.871459928310287e-08
for O 0 2.6845363709782077e-09
a O 0 8.794284411806075e-09
minority O 0 4.424028432481464e-08
of O 0 3.8859062634344355e-09
the O 0 5.9272920793773665e-08
overall O 0 4.2946008761646226e-05
genetic O 0 0.00011858470679726452
susceptibility O 0 0.0009909364162012935
to O 0 1.5585624169034418e-07
AS B-Disease 0 3.07878726744093e-05
. O 0 5.69308258491219e-06

Cell O 0 0.00020720530301332474
cycle O 0 1.2911545127280988e-05
- O 0 1.5399729818454944e-05
dependent O 0 2.3204044907743082e-07
colocalization O 0 4.724013706436381e-06
of O 0 1.4892565403101798e-08
BARD1 O 0 0.00024389005557168275
and O 0 1.0966400054712722e-07
BRCA1 O 0 1.4498996279144194e-05
proteins O 0 8.171592469352618e-08
in O 0 5.681366843646174e-08
discrete O 0 2.680291800061241e-06
nuclear O 0 0.0005297493189573288
domains O 0 1.811633956094738e-05
. O 0 4.764662207890069e-06

Germ O 0 0.08849211782217026
- O 0 0.0003455202386248857
line O 0 3.7735314890596783e-06
mutations O 0 4.191483355953096e-07
of O 0 3.6210405784942168e-09
the O 0 3.049915520136892e-08
BRCA1 O 0 4.2718620534287766e-05
gene O 0 7.209657724160934e-07
predispose O 0 1.9834596969303675e-06
women O 0 3.805648773891335e-08
to O 0 7.702412929688762e-09
early O 0 6.549772706421209e-07
- O 1 0.9268730282783508
onset O 1 0.9965729713439941
breast B-Disease 1 0.9993438124656677
and I-Disease 1 0.9906856417655945
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999755620956421
by O 0 3.5350032590031333e-07
compromising O 0 1.8311468011233956e-05
the O 0 8.371169712972915e-08
genes O 0 4.710944097041647e-07
presumptive O 0 0.016578540205955505
function O 0 1.642660265588347e-07
as O 0 3.099156486996435e-08
a O 0 2.0697507352451794e-06
tumor B-Disease 0 0.1293560117483139
suppressor O 0 0.0022553533781319857
. O 0 7.57396082917694e-06

Although O 0 2.1020973690610845e-06
the O 0 2.4745799009906477e-07
biochemical O 0 6.760159158147871e-05
properties O 0 3.475253436135972e-07
of O 0 2.850418923117104e-08
BRCA1 O 0 9.45493156905286e-05
polypeptides O 0 7.654934961465187e-06
are O 0 5.725803831069243e-09
not O 0 3.1504159281325883e-09
understood O 0 3.6036521322557746e-08
, O 0 2.101116836072947e-09
their O 0 3.294945427612106e-09
expression O 0 7.604480600775787e-08
pattern O 0 4.4412084321265866e-07
and O 0 1.8856727734828382e-08
subcellular O 0 1.8800197722157463e-05
localization O 0 2.919169901360874e-06
suggest O 0 4.3163726815009795e-08
a O 0 4.283818189065869e-09
role O 0 2.495105810851328e-08
in O 0 4.559806754400597e-08
cell O 0 4.318597711971961e-05
- O 0 0.00044132841867394745
cycle O 0 4.616154183167964e-05
regulation O 0 4.586428985930979e-06
. O 0 2.365927457503858e-06

When O 0 6.225261586223496e-06
resting O 0 6.859109998913482e-05
cells O 0 3.1259958177543012e-06
are O 0 1.1407423450293663e-08
induced O 0 1.8195283928434947e-06
to O 0 1.1098372887374808e-08
proliferate O 0 1.1780710337916389e-05
, O 0 2.394681342110516e-09
the O 0 9.087364749582605e-10
steady O 0 4.3862780074732655e-08
- O 0 2.1603575532935793e-06
state O 0 2.7918925837866482e-08
levels O 0 2.9704185777745806e-08
of O 0 1.823769690822985e-09
BRCA1 O 0 3.4321335533604724e-06
increase O 0 6.442437694431646e-08
in O 0 1.3215742278305243e-08
late O 0 3.4571419860185415e-07
G1 O 0 0.0005018813535571098
and O 0 8.373530313576794e-09
reach O 0 6.9423502502274914e-09
a O 0 1.1394440946332907e-08
maximum O 0 1.444109329895582e-07
during O 0 6.052803200873313e-07
S O 0 0.0007244349108077586
phase O 0 1.765435627021361e-05
. O 0 2.574115796960541e-06

Moreover O 0 4.196725058136508e-05
, O 0 1.6065084196270618e-07
in O 0 6.126394680450176e-08
S O 0 0.00010838577145477757
phase O 0 8.720118785277009e-06
cells O 0 8.826239650261414e-07
, O 0 1.509624780737795e-08
BRCA1 O 0 1.4787688087380957e-06
polypeptides O 0 3.53577235046032e-07
are O 0 5.901996669166465e-09
hyperphosphorylated O 0 9.123476047534496e-06
and O 0 2.2778115393862208e-08
accumulate O 0 2.1025175556133036e-07
into O 0 1.2986627773159398e-08
discrete O 0 9.358146257909539e-07
subnuclear O 0 0.0002470116305630654
foci O 0 7.400450704153627e-05
termed O 0 7.517551239288878e-06
" O 0 1.7877099480756442e-06
BRCA1 O 0 0.0001485221873736009
nuclear O 0 0.000599284190684557
dots O 0 0.0009583232458680868
. O 0 4.266828455001814e-06

" O 0 4.459418778424151e-05
BRCA1 O 0 0.007677061948925257
associates O 0 0.0001385272480547428
in O 0 3.4764931911013264e-07
vivo O 0 5.7245320931542665e-05
with O 0 4.936584474535266e-08
a O 0 7.033302722447843e-07
structurally O 0 0.0001744187466101721
related O 0 4.657215413317317e-06
protein O 0 3.0261692245403538e-06
termed O 0 3.0415669243666343e-05
BARD1 O 0 0.026103083044290543
. O 0 6.835713520558784e-06

Here O 0 1.5712973890913418e-06
we O 0 2.375154295464199e-08
show O 0 1.4336197118325344e-08
that O 0 8.957508623730348e-10
the O 0 1.0415019957576988e-09
steady O 0 6.281602793478669e-08
- O 0 3.010303544215276e-06
state O 0 1.5877443360068355e-08
levels O 0 2.2344622152559168e-08
of O 0 1.5965745392421127e-09
BARD1 O 0 0.00015717122005298734
, O 0 6.058714863144132e-09
unlike O 0 8.529844386373497e-09
those O 0 1.1972990376918347e-09
of O 0 5.929855717567989e-09
BRCA1 O 0 5.87164904573001e-05
, O 0 3.4042766827724336e-08
remain O 0 2.497472273432777e-08
relatively O 0 2.55815173488827e-08
constant O 0 1.3675160914772277e-07
during O 0 6.228618190107227e-07
cell O 0 0.00023537268862128258
cycle O 0 4.971562520950101e-05
progression O 0 6.915994890732691e-05
. O 0 8.641526960673218e-07

However O 0 5.658997451973846e-06
, O 0 2.9589011774078244e-07
immunostaining O 0 0.00016718611004762352
revealed O 0 7.845729669497814e-06
that O 0 1.0293494057123098e-07
BARD1 O 0 0.001717005972750485
resides O 0 4.199211161903804e-06
within O 0 4.054880164972019e-08
BRCA1 O 0 1.3334641153051052e-05
nuclear O 0 1.4250955246097874e-05
dots O 0 7.910968633950688e-06
during O 0 1.1537746047451947e-07
S O 0 8.55021698953351e-06
phase O 0 5.1272277090674834e-08
of O 0 1.192649312642402e-09
the O 0 8.54497184121783e-09
cell O 0 8.941486157709733e-06
cycle O 0 1.3357259831536794e-06
, O 0 4.4522914244282674e-09
but O 0 1.7244921046710715e-09
not O 0 1.1836344127047482e-09
during O 0 1.9528023642578773e-08
the O 0 5.914056444566995e-08
G1 O 0 0.05044827610254288
phase O 0 2.627577487146482e-05
. O 0 4.73897216579644e-06

Nevertheless O 0 4.6086282964097336e-05
, O 0 4.2389706322865095e-07
BARD1 O 0 6.936820864211768e-05
polypeptides O 0 1.568722041156434e-06
are O 0 3.1380920084700392e-09
found O 0 4.488084126563763e-09
exclusively O 0 3.619245125818793e-09
in O 0 2.4863822112308753e-09
the O 0 1.5757360971591083e-09
nuclear O 0 2.510015804091381e-07
fractions O 0 1.0365123870315074e-08
of O 0 5.613747244836986e-10
both O 0 2.5622814980863495e-09
G1 O 0 0.00022092481958679855
- O 0 9.191594472213183e-06
and O 0 7.839994253799887e-08
S O 0 0.0002747052058111876
- O 0 0.00034980810596607625
phase O 0 3.34559845214244e-05
cells O 0 1.7022150132106617e-05
. O 0 2.350958993702079e-06

Therefore O 0 9.278751349484082e-06
, O 0 3.4571419860185415e-07
progression O 0 1.8802103340931353e-06
to O 0 1.379277225765918e-08
S O 0 2.871234573831316e-05
phase O 0 5.854204232491611e-07
is O 0 3.6920366763837364e-09
accompanied O 0 2.0700348102309363e-08
by O 0 1.3669151366357823e-09
the O 0 1.6474375197361724e-09
aggregation O 0 3.427078709705711e-08
of O 0 5.906388267362672e-09
nuclear O 0 1.7125152226071805e-05
BARD1 O 0 7.722567534074187e-05
polypeptides O 0 1.7048463405444636e-06
into O 0 1.127818336499331e-07
BRCA1 O 0 7.618989911861718e-05
nuclear O 0 0.0003434556710999459
dots O 0 0.00034602783853188157
. O 0 4.1320163290947676e-06

This O 0 1.7501355387139483e-06
cell O 0 2.3307904484681785e-05
cycle O 0 4.738434199680341e-06
- O 0 2.195189881604165e-05
dependent O 0 1.9427129416271782e-07
colocalization O 0 3.892038421327015e-06
of O 0 9.185479044049316e-09
BARD1 O 0 0.0001484131789766252
and O 0 1.821160537929245e-07
BRCA1 O 0 4.423173231771216e-05
indicates O 0 5.164859544493083e-07
a O 0 8.45096259638467e-09
role O 0 1.5707376732621015e-08
for O 0 1.0689479523762202e-08
BARD1 O 0 0.00035759189631789923
in O 0 3.708147744418966e-07
BRCA1 O 0 0.00025713659124448895
- O 0 0.006814905442297459
mediated O 0 0.007026694715023041
tumor B-Disease 0 0.3352372944355011
suppression O 0 0.0005199346342124045
. O 0 9.464934009884018e-06

Ethnic O 0 1.388523742207326e-05
differences O 0 8.586982403357979e-06
in O 0 2.441914261908096e-07
the O 0 2.288045095610869e-07
HFE O 0 0.0022480995394289494
codon O 0 8.681045983394142e-06
282 O 0 3.995438419224229e-06
( O 0 4.471761769764271e-07
Cys O 1 0.5791706442832947
/ O 0 0.0014558155089616776
Tyr O 0 0.002272405195981264
) O 0 5.612719178316183e-07
polymorphism O 0 9.482541645411402e-05
. O 0 4.3610325519694015e-06

Recent O 0 4.2660361941671e-05
studies O 0 2.0887125629087677e-06
have O 0 1.3501127682502556e-07
shown O 0 2.313639470230555e-06
that O 0 2.2145764887682162e-05
hereditary B-Disease 1 0.9999949932098389
hemochromatosis I-Disease 1 0.9999998807907104
( O 0 0.0003606264654081315
HH B-Disease 1 0.9998098015785217
) O 0 6.817067088604745e-08
is O 0 7.274632451981233e-09
likely O 0 2.6350504001015906e-08
to O 0 2.716849190065318e-09
be O 0 9.512771015351973e-09
caused O 0 1.821528741174916e-07
by O 0 1.0449328513573164e-08
homozygosity O 0 0.00022990420984569937
for O 0 3.090418587703425e-09
a O 0 4.1002682138469027e-08
Cys282Tyr O 0 0.0018472211668267846
mutation O 0 1.164366835837427e-06
in O 0 1.0388241378223029e-08
the O 0 3.0732444145087356e-08
HFE O 0 0.002202008618041873
gene O 0 6.094228979236505e-07
located O 0 2.690643725600239e-07
4 O 0 5.384475230130192e-07
. O 0 2.0032739485031925e-06

5 O 0 1.0764797480078414e-05
Mb O 0 0.00046071369433775544
telomeric O 0 0.0012263088719919324
to O 0 1.0039940434580785e-06
HLA O 0 0.0009227620321325958
- O 0 0.00025522580835968256
A O 0 4.240351245243801e-06
. O 0 9.436183063371573e-06

Population O 0 5.132862042955821e-06
studies O 0 2.543410744237917e-07
of O 0 1.2209002697716187e-08
this O 0 1.1141938038861099e-08
polymorphism O 0 4.023458131996449e-06
are O 0 2.1790891313600014e-09
facilitated O 0 3.940671078339619e-08
by O 0 2.9046640648289213e-09
the O 0 2.9105313714694603e-09
fact O 0 8.018382402497082e-09
that O 0 2.379052510548263e-09
the O 0 1.810433936100253e-08
Cys282Tyr O 0 0.0007937627378851175
mutation O 0 4.31701710112975e-06
creates O 0 1.6210070441502467e-07
a O 0 8.133913809160731e-08
Rsal O 0 4.557085412670858e-05
restriction O 0 5.792962838313542e-07
site O 0 2.2182423435879173e-06
. O 0 1.150957245954487e-06

We O 0 9.695963854028378e-07
have O 0 5.734560915016118e-08
studied O 0 5.974121108920372e-08
the O 0 1.410989813876995e-08
codon O 0 5.141574774825131e-07
282 O 0 7.867081990298175e-07
( O 0 1.265117219872991e-07
Cys O 0 0.0570150725543499
/ O 0 6.558655150001869e-05
Tyr O 0 0.0001285369653487578
) O 0 1.0617729806483567e-08
polymorphism O 0 1.231147052749293e-06
in O 0 1.2212217015417082e-08
different O 0 1.1723381376782527e-08
ethnic O 0 1.8913863186753588e-07
groups O 0 1.2312926855884143e-06
. O 0 4.037326561956434e-06

In O 0 2.0939301066391636e-06
agreement O 0 2.2941016197819408e-07
with O 0 1.6043044226421443e-08
previous O 0 9.177182391795213e-08
observations O 0 5.463695629259746e-07
the O 0 3.268170800652115e-08
Tyr O 0 0.0002127891348209232
allele O 0 8.082066642600694e-07
appeared O 0 1.706008667667902e-08
to O 0 1.6146243231318635e-09
be O 0 3.636773326931575e-09
rare O 0 2.2105966479557537e-07
or O 0 3.512112201065065e-08
absent O 0 1.2425864497345174e-06
in O 0 1.2453656950128789e-07
Asiatic O 0 1.917152440000791e-05
( O 0 7.553780712044045e-09
Indian O 0 2.5829015370959496e-08
, O 0 9.13882036712721e-09
Chinese O 0 5.363121147183847e-08
) O 0 1.4752612287338707e-07
populations O 0 2.8049298634869047e-06
. O 0 1.6924600458878558e-06

The O 0 1.6195713214983698e-06
highest O 0 1.1726302545866929e-05
allele O 0 1.2367636372800916e-05
frequency O 0 7.035040425762418e-07
( O 0 8.40274338997915e-09
7 O 0 1.0509292103222379e-08
. O 0 1.3235158524693702e-09
5 O 0 3.562291572833942e-09
% O 0 4.231084371753013e-09
) O 0 2.5307498319193655e-09
was O 0 5.904586153349101e-09
found O 0 4.2086387708195616e-08
in O 0 2.0084607399439847e-07
Swedes O 0 0.0004907235270366073
. O 0 8.466892722935881e-06

Saamis O 0 0.002048763446509838
( O 0 2.506955922854104e-07
2 O 0 6.647792361036409e-08
% O 0 1.3310531343790899e-08
) O 0 3.2465361510247703e-09
and O 0 4.077042703443112e-09
Mordvinians O 0 1.28025922094821e-05
( O 0 1.6033675498405842e-09
1 O 0 1.2774727942144182e-09
. O 0 9.225472052953876e-10
8 O 0 3.5972156364749708e-09
% O 0 3.3496370122065855e-09
) O 0 2.2151194212227665e-09
had O 0 1.4161042116711542e-08
significantly O 0 1.4151085281355336e-07
lower O 0 6.006673203273749e-08
frequencies O 0 3.322513109083047e-08
of O 0 3.688587657535436e-09
the O 0 1.1911534869568641e-07
Tyr O 0 0.0021396749652922153
allele O 0 4.161328251939267e-05
. O 0 2.489659209459205e-06

Comparisons O 0 1.8432165234116837e-05
with O 0 7.510296882173861e-07
allele O 0 1.1625709703366738e-05
frequencies O 0 7.261991754603514e-07
based O 0 4.374363982151408e-08
on O 0 1.1280743450470254e-07
prevalence O 0 0.0002738093608058989
estimates O 0 6.448769340750005e-07
of O 0 3.154572425501101e-08
HH B-Disease 1 0.9937900900840759
showed O 0 2.2146721221361076e-06
some O 0 1.1001501931673374e-09
disagreements O 0 1.0560373198131856e-07
with O 0 4.935480468759579e-09
the O 0 2.1440714093046154e-08
RFLP O 0 1.7086769730667584e-05
data O 0 3.692989878345543e-07
, O 0 1.394338422500141e-08
particularly O 0 4.573028178356253e-08
in O 0 1.465599410721552e-07
Finns O 0 0.0003275106137152761
. O 0 3.327245849504834e-06

The O 0 1.4313213796413038e-06
newly O 0 4.889472620561719e-06
described O 0 6.521290742966812e-06
HFE O 0 0.0031596438493579626
marker O 0 3.3025341963366373e-06
provides O 0 2.6954454668270955e-08
a O 0 4.147254095698827e-09
new O 0 6.775867866792851e-09
approach O 0 6.039423627868246e-09
to O 0 8.565004261384956e-10
the O 0 1.4341988707755604e-09
screening O 0 4.042339440957221e-08
of O 0 1.9017967645140743e-08
HH B-Disease 1 0.9618955254554749
as O 0 7.068104324048363e-09
well O 0 2.8162261411779355e-09
as O 0 1.8022607850554095e-09
studies O 0 2.554673805832408e-09
of O 0 5.377281397933587e-10
the O 0 5.3286646206629484e-09
relationship O 0 2.3436540175225673e-07
between O 0 3.4749842114933926e-08
the O 0 2.0080929630239552e-07
HFE O 0 0.48692166805267334
Tyr O 0 0.0021684770472347736
allele O 0 4.977916887582978e-06
and O 0 1.2595613441135356e-07
different O 0 1.7014938293868909e-06
disorders O 0 0.33472928404808044
including O 0 0.0012851775391027331
cancer B-Disease 1 0.9968530535697937

Autosomal B-Disease 1 0.9934297204017639
dominant I-Disease 0 0.46119555830955505
neurohypophyseal I-Disease 1 0.9996343851089478
diabetes I-Disease 1 0.9997695088386536
insipidus I-Disease 1 0.9893634915351868
associated O 0 1.8538410586188547e-05
with O 0 1.0832189190068675e-07
a O 0 3.3048863201656786e-07
missense O 0 0.00046372649376280606
mutation O 0 4.972929673385806e-06
encoding O 0 2.175415687588611e-07
Gly23 O 0 2.3596772734890692e-05
- O 0 7.035356247797608e-05
- O 0 0.003184400498867035
> O 0 0.00014277655282057822
Val O 0 0.0017264112830162048
in O 0 6.132029852778942e-07
neurophysin O 0 0.0018044086173176765
II O 0 0.0006250342121347785
. O 0 7.002061465755105e-06

Autosomal B-Disease 1 0.9924524426460266
dominant I-Disease 0 0.4663790762424469
neurohypophyseal I-Disease 1 0.9995909333229065
diabetes I-Disease 1 0.9996951818466187
insipidus I-Disease 1 0.9910719990730286
( O 0 6.805154953326564e-06
ADNDI B-Disease 0 0.07220874726772308
) O 0 1.6231015820267203e-07
is O 0 9.95592444041904e-08
an O 0 7.297993761312682e-06
inherited B-Disease 1 0.9999991655349731
disease I-Disease 1 0.9999904632568359
caused O 0 0.0007682903669774532
by O 0 9.527770430395321e-07
progressive O 0 0.0017215465195477009
degeneration O 0 0.0013889748370274901
of O 0 9.556781144226534e-09
the O 0 6.220474091378492e-08
magnocellular O 0 0.0026424042880535126
neurons O 0 1.5467876437469386e-06
of O 0 2.335860171953641e-09
the O 0 8.756390279529569e-09
hypothalamus O 0 3.228388550269301e-06
leading O 0 5.0210335444944576e-08
to O 0 8.760883574154832e-09
decreased O 0 1.8982000256073661e-06
ability O 0 2.60840788968153e-08
to O 0 1.8613656171950765e-09
produce O 0 2.060572690254503e-08
the O 0 3.300217699120367e-08
hormone O 0 2.438535602777847e-06
arginine O 0 4.851899120694725e-06
vasopressin O 0 9.565749678586144e-06
( O 0 9.854283433696764e-08
AVP O 0 1.5901461665634997e-05
) O 0 3.4536654425210145e-07
. O 0 1.8035035509456065e-06

Affected O 0 5.955004598945379e-05
individuals O 0 7.750376198600861e-07
are O 0 2.6211452563984494e-08
not O 0 2.3791535852524248e-08
symptomatic O 0 9.872333066596184e-06
at O 0 2.4225596462201793e-07
birth O 0 1.57696249516448e-05
, O 0 5.513285117331179e-08
but O 0 4.466378555889605e-08
usually O 0 5.665848448188626e-07
develop O 0 9.991450497182086e-05
diabetes B-Disease 0 0.06429721415042877
insipidus I-Disease 0 0.0004750079242512584
at O 0 4.1020751240239406e-08
1 O 0 3.017063221477656e-08
- O 0 3.768414171645418e-05
6 O 0 1.8392041738479747e-06
yr O 0 0.007686384487897158
of O 0 6.36904502471225e-08
age O 0 4.38992856288678e-06
. O 0 2.0686279640358407e-06

The O 0 3.867186933348421e-06
genetic O 0 4.543788963928819e-05
locus O 0 1.4813554116699379e-05
of O 0 1.2650954772652767e-07
the O 0 5.022933692089282e-06
disease O 0 0.0021240259520709515
is O 0 2.0071047046599233e-08
the O 0 1.4804260040079953e-08
AVP O 0 1.6260502889053896e-05
- O 0 0.0008616876439191401
neurophysin O 0 0.007572319358587265
II O 0 3.2431886211270466e-05
( O 0 2.0728242233758465e-08
NPII O 0 4.474021261557937e-05
) O 0 4.8958579412783365e-09
gene O 0 1.9487169211629407e-08
, O 0 3.949397253677489e-09
and O 0 1.9266749973212427e-08
mutations O 0 1.39916778607585e-06
that O 0 3.7315857071007486e-08
cause O 0 2.530829078750685e-06
ADNDI B-Disease 0 0.002771185478195548
have O 0 2.270580878871442e-08
been O 0 6.587367984423054e-09
found O 0 9.373420262193122e-09
in O 0 3.602193654472785e-09
both O 0 1.238627311828111e-09
the O 0 4.377900708618654e-09
signal O 0 5.2800338323777396e-08
peptide O 0 2.182268055150871e-08
of O 0 4.4693229672709833e-10
the O 0 3.959828909216867e-09
prepro O 0 2.1752219254267402e-05
- O 0 2.682959529920481e-05
AVP O 0 8.600439286965411e-06
- O 0 4.157900912105106e-05
NPII O 0 0.0001064517127815634
precursor O 0 5.933586066930729e-07
and O 0 2.6678614872821527e-08
within O 0 1.160899074648114e-07
NPII O 0 0.0001807137014111504
itself O 0 3.20984599966323e-06
. O 0 1.4740631968379603e-06

An O 0 8.685001944286341e-07
affected O 0 2.146243559764116e-06
girl O 0 1.732776036078576e-05
who O 0 7.05025371416923e-08
presented O 0 8.165313403196706e-08
at O 0 2.0463163608042123e-08
9 O 0 4.431063160836857e-08
months O 0 2.9512627008898562e-08
of O 0 3.0324138755588592e-09
age O 0 1.8422394987283042e-07
and O 0 8.80146622250777e-09
her O 0 3.576325013909809e-07
similarly O 0 2.17748402064899e-06
affected O 0 2.6258746288476686e-07
younger O 0 2.7796249923994765e-07
brother O 0 4.3540950400711154e-07
and O 0 1.2999291421067483e-08
father O 0 1.8238772270251502e-07
were O 0 2.2515909137155177e-09
all O 0 7.453309081029147e-10
found O 0 9.759892449778818e-09
to O 0 2.236712370873306e-09
have O 0 5.529099400547466e-09
a O 0 3.8069050134481586e-08
novel O 0 1.1261433883191785e-06
missense O 0 0.0003548286622390151
mutation O 0 2.729633933995501e-06
( O 0 7.750720953936252e-09
G1758 O 0 1.3219115544416127e-06
- O 0 1.7493530322099105e-05
- O 0 0.00023954840435180813
> O 0 2.2152271412778646e-05
T O 0 8.817078196443617e-06
) O 0 7.281430458583316e-10
encoding O 0 3.200412601600533e-09
the O 0 1.343573807766063e-09
amino O 0 8.5544789030223e-09
acid O 0 1.4368747081050515e-08
substitution O 0 2.1639065650447264e-08
Gly23 O 0 7.77936202212004e-06
- O 0 4.154033013037406e-05
- O 0 0.0012555198045447469
> O 0 0.00021667829423677176
Val O 0 0.0012504546903073788
within O 0 5.393844730861019e-07
NPII O 0 0.0013854053104296327
. O 0 3.199796992703341e-06

The O 0 3.2142143027158454e-06
mutation O 0 4.163059202255681e-05
was O 0 3.2657911219757807e-07
confirmed O 0 3.8121805800983566e-07
by O 0 6.518652639897482e-08
restriction O 0 5.549175625674252e-07
endonuclease O 0 4.072182855452411e-05
analysis O 0 2.544313701946521e-06
. O 0 2.4667579054948874e-06

A O 0 1.08444573925226e-05
T1 O 0 0.0032099063973873854
- O 0 1.7383372323820367e-05
weighted O 0 4.6373369855245983e-07
magnetic O 0 2.7393871278036386e-06
resonance O 0 7.9538604040863e-06
imaging O 0 7.974983418534975e-06
of O 0 5.341384223811474e-09
the O 0 4.384554941339047e-08
fathers O 0 7.509547231165925e-06
pituitary O 0 0.00025805909535847604
gland O 0 6.72644455335103e-05
demonstrates O 0 2.4645710254844744e-06
an O 0 7.7254277641714e-08
attenuated O 0 0.0007004212820902467
posterior O 0 0.0028528717812150717
pituitary O 0 0.09211087226867676
bright O 0 0.0010694661177694798
spot O 0 4.680320489569567e-05
. O 0 7.288395408977522e-06

This O 0 4.472517503018025e-06
mutation O 0 0.00017764230142347515
may O 0 3.573832714209857e-07
be O 0 4.465380065710178e-09
valuable O 0 1.2505112501060012e-08
for O 0 2.6159794330737896e-09
developing O 0 6.230211369029348e-08
models O 0 8.839795384574245e-08
of O 0 3.423492245246962e-08
dominantly B-Disease 1 0.9314757585525513
inherited I-Disease 1 0.9989292025566101
neurodegeneration I-Disease 1 0.9999953508377075
, O 0 4.097735128993918e-08
as O 0 1.5264811636939157e-09
the O 0 3.174585927467888e-09
early O 0 4.9130072454772744e-08
age O 0 3.09816350352321e-08
of O 0 6.691359466515223e-09
onset O 0 0.0003338098176755011
of O 0 5.067000756753259e-07
symptoms O 0 0.00825725868344307
suggests O 0 1.1490906217659358e-06
that O 0 1.3373411711370409e-08
this O 0 5.991672225036382e-08
mutation O 0 2.077371573250275e-05
may O 0 1.1153317558409981e-07
be O 0 2.298304213610436e-09
particularly O 0 2.7888164666478588e-08
deleterious O 0 9.76004230324179e-07
to O 0 1.733456045371895e-08
the O 0 1.6640281330637663e-07
magnocellular O 0 0.04881332814693451
neuron O 0 0.01172615122050047
. O 0 6.136101546871942e-07
. O 0 1.727774360915646e-06

Frequent O 0 0.00020715041318908334
inactivation O 0 0.00391443120315671
of O 0 2.4978780857054517e-06
PTEN O 0 0.33957698941230774
/ O 0 0.0011413029860705137
MMAC1 O 0 0.012132873758673668
in O 0 2.792263876472134e-05
primary O 1 0.9665300250053406
prostate B-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9999758005142212
. O 0 0.00024661465431563556

Sporadic B-Disease 1 0.9832932949066162
prostate I-Disease 1 0.9999821186065674
carcinoma I-Disease 1 0.9999972581863403
is O 0 1.2273793572603608e-06
the O 0 7.550701042191577e-08
most O 0 5.0577696697473584e-08
common O 0 1.6533332427570713e-06
male B-Disease 0 0.0020120209082961082
cancer I-Disease 0 0.0031887232325971127
in O 0 2.0737772388201847e-08
the O 0 9.97713556216695e-09
Western O 0 9.052255478536608e-08
world O 0 2.588869847386377e-07
, O 0 8.541615414969783e-09
yet O 0 8.64911164910609e-09
many O 0 2.6917898465761425e-10
of O 0 6.394687002142518e-10
the O 0 3.7369258798491956e-09
major O 0 1.2094072587842675e-07
genetic O 0 6.228452207324153e-07
events O 0 3.415059524058961e-08
involved O 0 7.966460380259832e-09
in O 0 8.020554886911668e-09
the O 0 1.1554027068427786e-08
progression O 0 2.2373358206095872e-06
of O 0 3.5744402993032054e-09
this O 0 5.669286196052781e-08
often O 0 9.207492439600173e-06
fatal O 1 0.9984619617462158
cancer B-Disease 1 0.5841047167778015
remain O 0 5.093123149890744e-07
to O 0 4.485364968331851e-08
be O 0 3.389304765732959e-07
elucidated O 0 0.0006575934821739793
. O 0 3.6574956538970582e-06

Numerous O 0 2.4017601390369236e-05
cytogenetic O 0 0.30612123012542725
and O 0 2.9625366551044863e-06
allelotype O 0 0.027193427085876465
studies O 0 1.5150454828471993e-06
have O 0 6.156405163437739e-08
reported O 0 1.873993255685491e-06
frequent O 0 5.022957793698879e-06
loss O 0 8.500552212353796e-05
of O 0 1.4029342310095672e-07
heterozygosity O 0 0.034771133214235306
on O 0 1.7211252725246595e-06
chromosomal O 0 0.08544580638408661
arm O 0 0.00046465304330922663
10q O 0 0.001210609683766961
in O 0 1.1792074474215042e-05
sporadic B-Disease 1 0.9790621995925903
prostate I-Disease 1 0.9999985694885254
cancer I-Disease 1 0.9999721050262451
. O 0 0.00012952531687915325

Deletion O 0 0.010318681597709656
mapping O 0 0.0013601375976577401
studies O 0 4.021548193122726e-06
have O 0 1.1631730956196407e-07
unambiguously O 0 1.0171878784603905e-05
identified O 0 3.8102979260656866e-07
a O 0 2.361088924374144e-08
region O 0 6.624527770782151e-08
of O 0 9.17850861981151e-09
chromosome O 0 2.7808555387309752e-05
10q23 O 0 8.080031875579152e-06
to O 0 2.7737863117494044e-09
be O 0 1.495221502167965e-09
the O 0 5.665738100901763e-09
minimal O 0 4.2981184833479347e-07
area O 0 4.58364688427082e-08
of O 0 7.141786539932582e-08
loss O 0 0.0004092178132850677
. O 0 7.354032277362421e-06

A O 0 1.0225557161902543e-05
new O 0 1.178437378257513e-05
tumor B-Disease 0 0.005058599170297384
suppressor O 0 0.0004294073150958866
gene O 0 3.1010363272798713e-06
, O 0 1.7536530094730551e-07
PTEN O 0 0.001758922473527491
/ O 0 6.607306568184868e-05
MMAC1 O 0 0.0014282300835475326
, O 0 5.2518704052317844e-08
was O 0 3.9000308760250846e-08
isolated O 0 1.941925518167409e-07
recently O 0 9.036315162802566e-08
at O 0 4.16332701647093e-09
this O 0 1.4242379497986235e-09
region O 0 9.053926497415432e-09
of O 0 2.8700077869814322e-09
chromosome O 0 6.25893608230399e-06
10q23 O 0 5.968181540083606e-06
and O 0 1.015549866423271e-08
found O 0 5.719450690833128e-09
to O 0 2.2123287646280687e-09
be O 0 6.492827608894913e-09
inactivated O 0 7.44479734748893e-07
by O 0 1.6836455785096405e-08
mutation O 0 2.0027162008773303e-06
in O 0 2.2668015731142077e-07
three O 0 0.00021341614774428308
prostate B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999940395355225
cell O 1 0.5179094076156616
lines O 0 0.0008596415282227099
. O 0 9.133853382081725e-06

We O 0 5.411308848124463e-06
screened O 0 3.65712221537251e-05
80 O 0 4.0542116039432585e-05
prostate B-Disease 1 0.9993079900741577
tumors I-Disease 1 0.9997276663780212
by O 0 1.911764258011317e-07
microsatellite O 0 0.0002859341911971569
analysis O 0 4.22039107661476e-07
and O 0 3.0482350865668195e-08
found O 0 7.571497206981803e-08
chromosome O 0 1.1927786545129493e-05
10q23 O 0 5.452584900922375e-06
to O 0 2.8382383110425735e-09
be O 0 2.756513683976891e-09
deleted O 0 2.411808281976846e-07
in O 0 6.140057706716107e-08
23 O 0 7.903215077931236e-07
cases O 0 1.3146562878318946e-06
. O 0 4.020501364720985e-06

We O 0 3.023080523689714e-07
then O 0 2.613721505895228e-08
proceeded O 0 1.745789290907851e-08
with O 0 1.6007640768478382e-09
sequence O 0 1.944862759728494e-08
analysis O 0 2.470880389182639e-09
of O 0 6.331648538804302e-10
the O 0 4.95923169196999e-09
entire O 0 2.1619453605126182e-07
PTEN O 0 0.0012843986041843891
/ O 0 1.8692880985327065e-05
MMAC1 O 0 0.0002989962522406131
coding O 0 5.39304483027081e-06
region O 0 1.2206911037537793e-07
and O 0 1.3591632708198631e-08
tested O 0 2.7448504624771886e-07
for O 0 4.7090820132211775e-09
homozygous O 0 8.122679901134688e-06
deletion O 0 6.075408236938529e-06
with O 0 2.2227174767408542e-08
new O 0 2.2225019336019614e-07
intragenic O 0 0.0008974795928224921
markers O 0 3.467725719019654e-06
in O 0 9.774385745231484e-09
these O 0 2.3935169402022893e-09
23 O 0 5.445676976023606e-08
cases O 0 2.1383373294270314e-08
with O 0 7.492941023201638e-08
10q23 O 0 0.002279505832120776
loss O 0 3.703262336784974e-05
of O 0 6.965537409087119e-07
heterozygosity O 0 0.11447926610708237
. O 0 1.1277198609604966e-05

The O 0 3.70584274378416e-07
identification O 0 1.6016514337025e-07
of O 0 5.4632454116188e-09
the O 0 7.06367053737722e-09
second O 0 5.767523347799397e-08
mutational O 0 0.0003187726251780987
event O 0 9.424476843378216e-07
in O 0 1.3757197159236512e-08
10 O 0 6.186088530313327e-09
( O 0 6.762221005374158e-09
43 O 0 1.1281271383722924e-07
% O 0 1.876905457720568e-07
) O 0 1.981253490157542e-06
tumors B-Disease 1 0.9997296929359436
establishes O 0 0.0002455173816997558
PTEN O 0 0.16188719868659973
/ O 0 4.316802369430661e-05
MMAC1 O 0 7.138415094232187e-05
as O 0 2.8218178904637625e-09
a O 0 3.6626484067880938e-09
main O 0 4.584958546161033e-08
inactivation O 0 8.114178854157217e-06
target O 0 2.1330173183287116e-08
of O 0 2.755183858837995e-09
10q O 0 8.584783790865913e-05
loss O 0 5.993780359858647e-05
in O 0 6.0226470850466285e-06
sporadic B-Disease 1 0.9584764838218689
prostate I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999897480010986
. O 0 1.2677500308200251e-05
. O 0 1.3581257917394396e-05

Risk O 0 0.0003604226221796125
reversals O 0 8.566122414777055e-05
in O 0 1.738345304147515e-06
predictive O 0 7.967452984303236e-05
testing O 0 5.710176264983602e-05
for O 0 9.412793588126078e-05
Huntington B-Disease 1 0.9999551773071289
disease I-Disease 1 0.999677300453186
. O 0 0.0001396954758092761

The O 0 9.352070833301696e-07
first O 0 3.7097217386872217e-07
predictive O 0 1.8818891476257704e-05
testing O 0 8.618905667390209e-06
for O 0 4.0103524952428415e-05
Huntington B-Disease 1 0.9999966621398926
disease I-Disease 1 0.9997952580451965
( O 0 5.520287231775001e-07
HD B-Disease 0 0.0002708123065531254
) O 0 4.662527253174176e-09
was O 0 3.132601955613268e-09
based O 0 3.865296971383714e-09
on O 0 3.5130620634760135e-09
analysis O 0 1.1193400872855364e-08
of O 0 1.92604954207809e-09
linked O 0 2.649984935487737e-06
polymorphic O 0 1.8007684047915973e-05
DNA O 0 1.4231668501452077e-06
markers O 0 6.234763532120269e-07
to O 0 3.7424321419621265e-09
estimate O 0 1.002658649440491e-07
the O 0 2.5286652771683293e-09
likelihood O 0 1.2867482723777357e-07
of O 0 5.959517324072294e-09
inheriting O 0 4.443790203367826e-06
the O 0 7.131020396400345e-08
mutation O 0 2.7481032702780794e-06
for O 0 1.1344526029688495e-07
HD B-Disease 0 0.0002481477567926049
. O 0 2.916045332312933e-06

Limits O 0 3.4621377835719613e-06
to O 0 8.613143620550545e-08
accuracy O 0 2.229154461019789e-07
included O 0 1.8103131438351738e-08
recombination O 0 3.38258843157746e-07
between O 0 7.79861863975384e-09
the O 0 6.882887149117778e-09
DNA O 0 1.2689841923929635e-06
markers O 0 1.6717488051654072e-06
and O 0 9.366717179659645e-09
the O 0 2.979611046782793e-08
mutation O 0 4.887556315225083e-06
, O 0 4.2343479833562014e-08
pedigree O 0 2.7066978873335756e-05
structure O 0 6.639656362494861e-07
, O 0 2.6293556221190784e-09
and O 0 2.3825035277980078e-09
whether O 0 8.383469918271658e-09
DNA O 0 2.5448690621487913e-07
samples O 0 6.838202892822665e-08
were O 0 2.39721753558797e-09
available O 0 1.0138815120797062e-08
from O 0 1.52589390012281e-08
family O 0 1.5884522497344733e-07
members O 0 4.6521941499122477e-07
. O 0 4.8972328841045965e-06

With O 0 3.547766596057045e-07
direct O 0 1.7754788927959453e-07
tests O 0 1.8856158590097039e-07
for O 0 4.3102743596534765e-09
the O 0 3.53055575885719e-08
HD B-Disease 0 0.0017787995748221874
mutation O 0 1.9251820049248636e-06
, O 0 3.232263567909399e-09
we O 0 9.031827508110268e-10
have O 0 7.536162804910873e-10
assessed O 0 9.285143320880707e-09
the O 0 1.5263881270044521e-09
accuracy O 0 6.437524291413865e-08
of O 0 2.6094013616528855e-09
results O 0 5.953055506324745e-07
obtained O 0 3.7674652730856906e-08
by O 0 4.483463822424483e-09
linkage O 0 5.508281333277409e-07
approaches O 0 2.98797147024743e-08
when O 0 3.0266815720381146e-09
requested O 0 4.51335635531791e-09
to O 0 5.080457166073415e-10
do O 0 1.6113815837215384e-09
so O 0 5.464597663262794e-10
by O 0 9.547247437069473e-10
the O 0 1.0573127262603066e-08
test O 0 5.544118266698206e-07
individuals O 0 6.142781785456464e-07
. O 0 3.2757466215116438e-06

For O 0 3.6355552879285824e-07
six O 0 1.156121740564231e-07
such O 0 4.1051826826787874e-08
individuals O 0 5.980894002277637e-08
, O 0 2.441973911970763e-08
there O 0 8.942797613542552e-09
was O 0 3.1381294007815086e-08
significant O 0 1.2126143644763943e-07
disparity O 0 4.114246621611528e-06
between O 0 3.6524927082837166e-08
the O 0 1.5545603559985466e-07
tests O 0 1.010093455988681e-05
. O 0 3.191866198903881e-06

Three O 0 5.150374136064784e-07
went O 0 1.1858658410801581e-07
from O 0 9.342630669095797e-09
a O 0 7.357972009458535e-08
decreased O 0 6.127151573309675e-05
risk O 0 2.627066919558274e-07
to O 0 2.4906967599491736e-09
an O 0 1.1074647865427778e-08
increased O 0 3.988585831393721e-06
risk O 0 1.3523231245926581e-06
, O 0 6.095899784952508e-09
while O 0 2.7049977813220494e-09
in O 0 4.408401199640366e-09
another O 0 3.861200248422847e-09
three O 0 5.050594609201653e-09
the O 0 6.125401341705583e-08
risk O 0 4.263964456185931e-06
was O 0 6.975461701586028e-07
decreased O 0 4.198831084067933e-05
. O 0 4.279510449123336e-06

Knowledge O 0 3.783541842494742e-06
of O 0 5.427706284422129e-08
the O 0 2.4013649735366016e-08
potential O 0 2.5395669922545494e-07
reasons O 0 1.6855285167594047e-08
for O 0 1.0313766507508149e-09
these O 0 1.5949035425677494e-09
changes O 0 1.3299998435911675e-08
in O 0 1.3393118614146715e-08
results O 0 3.65846858585428e-07
and O 0 1.2393345016903368e-08
impact O 0 7.461537165909249e-08
of O 0 2.931792808524847e-09
these O 0 1.4390852953738431e-08
risk O 0 3.580710199457826e-07
reversals O 0 1.2646216873690719e-06
on O 0 4.0622264663170427e-08
both O 0 3.896090561283927e-08
patients O 0 5.101241526972444e-07
and O 0 2.2677546951399563e-08
the O 0 2.2806112554007996e-08
counseling O 0 3.2520168247174297e-07
team O 0 5.261535562794961e-08
can O 0 4.490053218120238e-09
assist O 0 1.0387449123072656e-08
in O 0 3.676710047528786e-09
the O 0 1.2779918234784304e-09
development O 0 3.1591171900657855e-09
of O 0 1.2648554426064607e-09
strategies O 0 9.360952191173055e-08
for O 0 3.792502756283511e-09
the O 0 3.49668525245761e-08
prevention O 0 7.321850262087537e-06
and O 0 3.744225907098553e-08
, O 0 1.5988028678748378e-08
where O 0 2.369959339887373e-08
necessary O 0 3.8131254598283704e-08
, O 0 2.891609085509117e-08
management O 0 2.387116992963456e-08
of O 0 1.943274652305149e-09
a O 0 2.2969740598455246e-07
risk O 0 1.8396602854409139e-06
reversal O 0 3.3442081530665746e-06
in O 0 9.351080798580824e-09
any O 0 9.982008108977425e-09
predictive O 0 2.024199147854233e-06
testing O 0 3.964350696605834e-07
program O 0 2.3030629847653472e-07
. O 0 1.2891420908545115e-07
. O 0 7.475068741769064e-07

A O 0 3.998117790615652e-06
novel O 0 2.5981055387092056e-06
common O 0 1.058028828992974e-06
missense O 0 0.00027648801915347576
mutation O 0 1.2346637049631681e-05
G301C O 0 4.728895419248147e-06
in O 0 1.2137396865341543e-08
the O 0 1.1673934707800981e-08
N O 0 9.398409019922838e-06
- O 0 1.539795266580768e-05
acetylgalactosamine O 0 6.303744885371998e-05
- O 0 1.7162758013000712e-05
6 O 0 2.400101948296651e-07
- O 0 0.00018833483045455068
sulfate O 0 0.0017623754683881998
sulfatase O 0 0.0008808785350993276
gene O 0 7.36011941171455e-07
in O 0 3.0723600730198086e-07
mucopolysaccharidosis B-Disease 0 0.0008148335618898273
IVA I-Disease 0 0.01330562587827444
. O 0 9.938667062669992e-06

Mucopolysaccharidosis B-Disease 1 0.679474413394928
IVA I-Disease 1 0.8184581398963928
( O 0 1.545903978694696e-05
MPS B-Disease 1 0.6985223293304443
IVA I-Disease 1 0.9996801614761353
) O 0 3.4222719591525674e-07
is O 0 5.09323037078957e-08
an O 0 2.239262641978712e-07
autosomal B-Disease 1 0.722946286201477
recessive I-Disease 1 0.9888308644294739
lysosomal I-Disease 1 0.9999845027923584
storage I-Disease 1 0.9999802112579346
disorder I-Disease 1 0.9975132942199707
caused O 0 3.514433410600759e-05
by O 0 2.5193639885401353e-07
a O 0 2.843831134669017e-05
genetic B-Disease 1 0.9970700740814209
defect I-Disease 1 0.9681404829025269
in O 0 2.885931849050394e-07
N O 0 5.3504489187616855e-05
- O 0 7.574619667138904e-05
acetylgalactosamine O 0 0.00033468767651356757
- O 0 0.0003061152237933129
6 O 0 1.7153262206193176e-06
- O 0 0.006443637423217297
sulfate O 0 0.05146897956728935
sulfatase O 0 0.0946740210056305
( O 0 3.9657422234995465e-07
GALNS O 0 0.0002989404310937971
) O 0 4.908399091618776e-07
. O 0 1.999239430006128e-06

In O 0 1.9970118501078105e-06
previous O 0 1.2290836366446456e-06
studies O 0 4.2065602201546426e-07
, O 0 2.0837330083622874e-08
we O 0 3.42464634428552e-09
have O 0 2.51871101752954e-09
found O 0 9.713427395752205e-09
two O 0 3.6908398559631905e-09
common O 0 3.1102482012101973e-07
mutations O 0 1.0918141697402461e-06
in O 0 1.3770480755681547e-08
Caucasians O 0 7.20903869932954e-07
and O 0 2.1658099313981438e-08
Japanese O 0 7.088026450219331e-07
, O 0 1.1142750366843757e-07
respectively O 0 2.830525090757874e-06
. O 0 1.4930753877706593e-06

To O 0 1.0604300086924923e-06
characterize O 0 1.8102797184837982e-05
the O 0 3.3989897474384634e-07
mutational O 0 0.0015061335870996118
spectrum O 0 1.7136044334620237e-06
in O 0 1.4231851253043715e-08
various O 0 2.650827335415329e-09
ethnic O 0 2.0280152668306073e-08
groups O 0 3.0565313835495544e-08
, O 0 3.341043708360303e-08
mutations O 0 9.614009144343072e-08
in O 0 2.8114655048483428e-09
the O 0 5.303042893700649e-09
GALNS O 0 0.00011266655928920954
gene O 0 1.1124615184598952e-07
in O 0 2.0894162844342645e-08
Colombian O 0 1.8735658159130253e-05
MPS B-Disease 1 0.9884030222892761
IVA I-Disease 1 0.9999608993530273
patients O 0 2.1411678972071968e-05
were O 0 6.44381472625355e-08
investigated O 0 1.0935274985968135e-05
, O 0 7.433567361658788e-08
and O 0 7.629483889104449e-08
genetic O 0 7.0399460128101055e-06
backgrounds O 0 7.621353006470599e-07
were O 0 9.724216099016303e-09
extensively O 0 1.1922263354335882e-07
analyzed O 0 3.4348573763054446e-07
to O 0 3.3999534299056222e-09
identify O 0 3.975769047315225e-08
racial O 0 4.715034052082956e-08
origin O 0 7.848088756645666e-08
, O 0 4.792115593232893e-09
based O 0 6.805009444832422e-09
on O 0 1.947836203441966e-08
mitochondrial O 0 2.2334868845064193e-05
DNA O 0 7.6004580478183925e-06
( O 0 1.2964062534592813e-07
mtDNA O 0 1.876282226476178e-06
) O 0 9.955905255765174e-08
lineages O 0 2.971313733723946e-06
. O 0 1.6873706272235722e-06

Three O 0 3.0418516416830244e-06
novel O 0 9.78911884885747e-06
missense O 0 0.0049474784173071384
mutations O 0 0.00011481354158604518
never O 0 8.559343882552639e-07
identified O 0 2.783211243695405e-07
previously O 0 5.179726514370486e-08
in O 0 1.3298629752966917e-08
other O 0 4.669451048044948e-09
populations O 0 6.780201289302568e-08
and O 0 5.2162776320585635e-09
found O 0 1.2487379130732279e-08
in O 0 5.113240053589152e-09
16 O 0 4.302520562049494e-09
out O 0 1.1547609535256242e-09
of O 0 2.2790924703031123e-09
19 O 0 4.3780244141089497e-07
Colombian O 0 1.4072133126319386e-05
MPS B-Disease 0 0.4634053111076355
IVA I-Disease 1 0.9984753727912903
unrelated O 0 5.5600747145945206e-05
alleles O 0 8.769612804826465e-07
account O 0 2.717141569519299e-07
for O 0 1.033973546782363e-07
84 O 0 6.3083143686526455e-06
. O 0 4.690332843892975e-06

2 O 0 9.518760748505883e-07
% O 0 4.621782778713168e-08
of O 0 4.16137391212601e-09
the O 0 1.3910869789413027e-08
alleles O 0 4.2883860373876814e-07
in O 0 6.630848048416738e-08
this O 0 8.515575444789647e-08
study O 0 1.920447402881109e-06
. O 0 3.6937437926098937e-06

The O 0 1.963411250471836e-06
G301C O 0 4.2258689063601196e-05
and O 0 3.2379423942074936e-07
S162F O 0 0.00010116870544152334
mutations O 0 4.244004685460823e-06
account O 0 2.246991499532669e-07
for O 0 4.8692818666040694e-08
68 O 0 2.381324748057523e-06
. O 0 3.3916437587322434e-06

4 O 0 7.993066901690327e-06
% O 0 1.069900463335216e-06
and O 0 2.3542364147033368e-07
10 O 0 8.416348009632202e-07
. O 0 3.78633922082372e-06

5 O 0 1.453137883800082e-06
% O 0 1.144985901646578e-07
of O 0 3.589630281908285e-08
mutations O 0 5.361374405765673e-06
, O 0 1.92158839951162e-08
respectively O 0 1.3099901252644486e-07
, O 0 8.35967828294315e-09
whereas O 0 1.5562832800242177e-08
the O 0 1.4892216348982856e-09
remaining O 0 7.853550698655454e-09
F69V O 0 2.591473821667023e-05
is O 0 3.2261413540624062e-09
limited O 0 2.9610440765992507e-09
to O 0 3.283095129091862e-09
a O 0 5.8691188797865834e-08
single O 0 2.434404450468719e-06
allele O 0 3.5632318031275645e-05
. O 0 2.031199301200104e-06

The O 0 2.629373057061457e-06
skewed O 0 3.893114626407623e-05
prevalence O 0 7.670874038012698e-05
of O 0 2.5554452776077596e-08
G301C O 0 1.2324474482738879e-05
in O 0 3.026140404926991e-08
only O 0 6.720599188270171e-09
Colombian O 0 1.990552618735819e-06
patients O 0 8.176096457646054e-07
and O 0 1.1179302106256728e-07
haplotype O 0 0.00046300276881083846
analysis O 0 7.733830642564499e-08
by O 0 7.531308909847212e-09
restriction O 0 2.721949243777999e-08
fragment O 0 5.483636869030306e-07
length O 0 1.0076893630639461e-07
polymorphisms O 0 6.101294616200903e-07
in O 0 4.137859388464449e-09
the O 0 7.678268687527634e-09
GALNS O 0 0.000483676849398762
gene O 0 2.4408967647104873e-07
suggest O 0 5.278140946529675e-08
that O 0 5.682328829692551e-09
G301C O 0 2.649345788086066e-06
originated O 0 4.192190772300819e-08
from O 0 6.173712208124016e-09
a O 0 6.30140277735336e-08
common O 0 1.7327838577330112e-06
ancestor O 0 5.5126005463534966e-05
. O 0 8.084224646154325e-06

Investigation O 0 6.5613221522653475e-06
of O 0 1.3012505917231465e-07
the O 0 1.9927756511606276e-07
genetic O 0 7.3328269536432344e-06
background O 0 6.426446930163365e-07
by O 0 5.214357834404382e-09
means O 0 5.37113375997933e-09
of O 0 1.0940275352311346e-09
mtDNA O 0 2.5391454983036965e-07
lineages O 0 9.241752962907412e-08
indicate O 0 5.380456968850922e-08
that O 0 9.271052814341374e-10
all O 0 1.123546811143683e-09
our O 0 7.497029486103202e-08
patients O 0 1.5184954804681183e-07
are O 0 4.5550931915272486e-09
probably O 0 2.4086450167715157e-08
of O 0 9.344091722596204e-09
native O 0 9.283195936404809e-07
American O 0 5.836438049300341e-06
descent O 0 0.00019544403767213225

Low O 0 1.6463112842757255e-05
frequency O 0 3.4445843084540684e-06
of O 0 3.444655476414482e-07
BRCA1 O 0 0.0007083797245286405
germline O 0 0.005497537087649107
mutations O 0 7.138733963074628e-06
in O 0 1.1547995626415286e-07
45 O 0 3.961357606385718e-07
German O 1 0.606264054775238
breast B-Disease 1 0.9999468326568604
/ I-Disease 1 0.9999933242797852
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999897480010986
families O 0 0.00015862970030866563
. O 0 2.429819869576022e-05

In O 0 1.4780440551476204e-06
this O 0 5.525570756503839e-08
study O 0 1.099878446098046e-07
we O 0 1.373863334208636e-08
investigated O 0 5.984214794807485e-07
45 O 0 3.1356796625914285e-07
German O 1 0.5381265878677368
breast B-Disease 1 0.9999160766601562
/ I-Disease 1 0.9999938011169434
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.999983549118042
families O 0 1.3877341871193494e-06
for O 0 3.2531056604057085e-07
germline O 0 0.33180004358291626
mutations O 0 1.1423640899010934e-05
in O 0 6.840564026333595e-08
the O 0 2.955122226921958e-07
BRCA1 O 0 0.00021245786047074944
gene O 0 1.3479449989972636e-05
. O 0 6.494431090686703e-06

We O 0 2.345076381971012e-06
identified O 0 2.4241689970949665e-06
four O 0 2.4789733288343996e-07
germline O 0 0.008572523482143879
mutations O 0 1.0803052646224387e-05
in O 0 8.44345819928094e-08
three O 0 9.69379016169114e-07
breast B-Disease 1 0.9511898756027222
cancer I-Disease 0 0.35730117559432983
families O 0 3.288230345788179e-07
and O 0 9.629314234871345e-08
in O 0 3.2685207429494767e-07
one O 0 6.270700851018773e-06
breast B-Disease 1 0.9998012185096741
- I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999947547912598
family O 0 2.0666363980126334e-06
. O 0 2.331316828474428e-08
among O 0 3.072891274769063e-09
these O 0 1.4472680831545404e-09
were O 0 4.654210794541314e-09
one O 0 1.1096175711600154e-07
frameshift O 1 0.5102972388267517
mutation O 0 4.663077106670244e-06
, O 0 7.918317557198407e-09
one O 0 7.729079598561839e-09
nonsense O 0 6.212889275047928e-05
mutation O 0 1.8733213664745563e-06
, O 0 3.098303613668918e-09
one O 0 2.340489579921723e-09
novel O 0 4.049006463446858e-08
splice O 0 7.045385700621409e-06
site O 0 2.5616293441999005e-06
mutation O 0 1.5099623169589904e-06
, O 0 7.4069426148071216e-09
and O 0 1.5971357569810607e-08
one O 0 2.0070285700057866e-07
missense O 0 0.004839531611651182
mutation O 0 0.00011122653813799843
. O 0 4.266600171831669e-06

The O 0 9.194602171191946e-06
missense O 0 0.004883676767349243
mutation O 0 0.00014125113375484943
was O 0 2.037584891922961e-07
also O 0 4.459959868086116e-08
found O 0 5.347941467448436e-08
in O 0 7.105359145498369e-08
2 O 0 7.91297395608126e-07
. O 0 3.173164031977649e-06

8 O 0 1.250084096682258e-06
% O 0 4.553358579073574e-08
of O 0 2.6305246869640087e-09
the O 0 6.2076708218228305e-09
general O 0 4.712246948201937e-08
population O 0 1.2390153791841385e-08
, O 0 7.688146119733119e-09
suggesting O 0 9.205792395050594e-08
that O 0 3.817155036500708e-09
it O 0 3.1753006890511415e-09
is O 0 3.082072908000555e-08
not O 0 5.855935114595923e-07
disease O 0 0.0015862310538068414
associated O 0 2.5132827431662008e-05
. O 0 9.727882570587099e-06

The O 0 1.651820298320672e-06
average O 0 1.1514290235936642e-05
age O 0 3.119640268778312e-06
of O 0 1.4183270877765608e-06
disease O 1 0.5281795859336853
onset O 0 0.011832814663648605
in O 0 2.4959325628515217e-07
those O 0 1.257589303804707e-07
families O 0 9.496998814029212e-07
harbouring O 1 0.7359147071838379
causative O 0 0.05268433690071106
mutations O 0 1.982345747819636e-05
was O 0 5.202965880357624e-08
between O 0 1.2030871232582285e-07
32 O 0 2.1070509319542907e-06
. O 0 2.762500116659794e-06

3 O 0 1.0030515113612637e-05
and O 0 2.0972297534171958e-06
37 O 0 8.050188625929877e-06
. O 0 6.82508243698976e-06

4 O 0 3.70081352230045e-06
years O 0 4.3019321083193063e-07
, O 0 2.578422098054034e-08
whereas O 0 4.2677783085309784e-08
the O 0 7.250805733605148e-09
family O 0 1.151731012782875e-07
harbouring O 0 0.00021435182134155184
the O 0 1.8573312843273015e-07
missense O 0 0.000485357508296147
mutation O 0 4.47593129138113e-06
had O 0 1.788676406988543e-08
an O 0 1.839729257824274e-09
average O 0 1.0471160294400761e-07
age O 0 6.140526664921708e-08
of O 0 1.3420172528810781e-08
onset O 0 8.573739614803344e-05
of O 0 1.1075665895532438e-07
51 O 0 8.60779982758686e-06
. O 0 5.815558324684389e-06

2 O 0 3.864315658574924e-05
years O 0 4.369201633380726e-05
. O 0 2.0480816601775587e-05

These O 0 6.235988507796719e-07
findings O 0 1.2252461374373524e-06
show O 0 2.3376226465643413e-07
that O 0 5.663720159532204e-08
BRCA1 O 0 1.6238729585893452e-05
is O 0 1.2835990048642998e-08
implicated O 0 6.259750762183103e-07
in O 0 1.2508714064551896e-08
a O 0 7.921731715043734e-09
small O 0 1.6058413265795934e-08
fraction O 0 5.785724965789996e-07
of O 0 1.4569314998880145e-06
breast B-Disease 1 0.9999005794525146
/ I-Disease 1 0.9999947547912598
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999735355377197
families O 0 6.897220146129257e-07
suggesting O 0 1.0662212162060314e-06
the O 0 1.40973082096707e-08
involvement O 0 2.937031240435317e-07
of O 0 1.6342873720986972e-08
another O 0 1.5734026419522706e-06
susceptibility O 0 0.14574918150901794
gene O 0 1.2364440408418886e-05
( O 0 5.641284133162117e-07
s O 0 0.00114875053986907
) O 0 5.687563316314481e-06

Paternal O 0 0.20949804782867432
transmission O 0 0.06741023808717728
of O 0 0.0014209439978003502
congenital B-Disease 1 0.9999771118164062
myotonic I-Disease 1 0.9999897480010986
dystrophy I-Disease 1 0.9999752044677734
. O 0 0.00536287622526288

We O 0 3.01984982797876e-06
report O 0 9.664998970038141e-07
a O 0 1.1635393093456514e-07
rare O 0 1.426761286893452e-06
case O 0 7.6574741569857e-07
of O 0 1.2058857237207121e-06
paternally O 1 0.9885959029197693
transmitted O 1 0.999566376209259
congenital B-Disease 1 0.999996542930603
myotonic I-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999978542327881
( O 0 0.0035527434665709734
DM B-Disease 1 0.9999336004257202
) O 0 4.327152964833658e-06
. O 0 4.488956619752571e-06

The O 0 1.5683705214541988e-06
proband O 0 9.704968397272751e-05
is O 0 4.4973582191687456e-08
a O 0 2.0244096177179927e-08
23 O 0 1.0538079209254647e-07
year O 0 2.2857963699607353e-07
old O 0 2.3701510144746862e-05
, O 0 8.103816071525216e-06
mentally B-Disease 1 0.9976937174797058
retarded I-Disease 1 0.9975219368934631
male O 0 0.003247395157814026
who O 0 0.0006022269371896982
suffers O 1 0.999419093132019
severe O 1 0.9984766840934753
muscular B-Disease 1 0.9997238516807556
weakness I-Disease 1 0.9917508959770203
. O 0 8.4728017100133e-05

He O 0 5.777768819825724e-06
presented O 0 1.0745186045824084e-05
with O 0 1.1642940080491826e-05
respiratory O 1 0.9665935039520264
and O 0 2.4735611532378243e-06
feeding O 0 3.04810018860735e-05
difficulties O 0 5.040034375269897e-05
at O 0 2.3872823931014864e-06
birth O 0 0.00022474311117548496
. O 0 6.008065156493103e-06

His O 0 1.2990565664949827e-05
two O 0 5.1415731832094025e-06
sibs O 1 0.9178169369697571
suffer O 0 0.0028714844956994057
from O 0 4.605530193657614e-06
childhood O 0 0.3589058816432953
onset O 1 0.9985185265541077
DM B-Disease 1 0.9999489784240723
. O 0 9.913581016007811e-05

Their O 0 5.67576648791146e-07
late O 0 6.819160489612841e-07
father O 0 2.868054025384481e-07
had O 0 1.2399611115654352e-08
the O 0 5.930794966246822e-09
adult O 0 5.994210283688517e-08
type O 0 1.7308468613919104e-07
of O 0 4.5481332477947944e-08
DM B-Disease 1 0.9997358918190002
, O 0 5.9382681882880206e-08
with O 0 6.112318118312032e-08
onset O 0 9.132237028097734e-05
around O 0 7.234122278987343e-08
30 O 0 1.326613130459009e-07
years O 0 7.081938520059339e-07
. O 0 2.019617568294052e-06

Only O 0 3.644128980795358e-07
six O 0 8.586080468830914e-08
other O 0 1.0660953009278273e-08
cases O 0 2.5074193388263666e-08
of O 0 2.722348924066864e-08
paternal O 0 0.006739094853401184
transmission O 0 0.005087788682430983
of O 0 1.348859314020956e-05
congenital B-Disease 1 0.9999945163726807
DM I-Disease 1 0.9999969005584717
have O 0 2.7625501388683915e-06
been O 0 6.289095040301618e-07
reported O 0 1.938579953275621e-05
recently O 0 1.4799179552937858e-05
. O 0 3.2126697533385595e-06

We O 0 6.344704956973146e-07
review O 0 4.0148165680875536e-07
the O 0 4.9522487444164653e-08
sex O 0 1.1345406392138102e-06
related O 0 2.641696482896805e-06
effects O 0 1.0582816685200669e-05
on O 0 1.2126403134971042e-06
transmission O 0 0.0012235053582116961
of O 0 3.328119419165887e-05
congenital B-Disease 1 0.9999765157699585
DM I-Disease 1 0.999970555305481
. O 0 0.00027019024128094316

Decreased O 0 0.0009992355480790138
fertility O 0 0.0001093994069378823
of O 0 1.1058567395139107e-07
males O 0 1.3030565924054827e-06
with O 0 1.0119826754362293e-07
adult O 0 1.1776261999330018e-05
onset O 0 0.1599704772233963
DM B-Disease 1 0.9998816251754761
and O 0 1.6519999235242722e-07
contraction O 0 2.6831150989892194e-06
of O 0 2.0568808878351774e-09
the O 0 1.3451643354756015e-08
repeat O 0 2.041696234300616e-06
upon O 0 4.6577383727708366e-08
male O 0 1.2161935956100933e-06
transmission O 0 1.715542111924151e-06
contribute O 0 1.1574297964500602e-08
to O 0 1.5482265469657364e-09
the O 0 2.8135307417187505e-09
almost O 0 1.2143371641570866e-08
absent O 0 3.062635585138196e-07
occurrence O 0 1.7143220247817226e-06
of O 0 4.2154834289931387e-08
paternal O 0 0.0035372506827116013
transmission O 0 0.001033347798511386
of O 0 1.9910079572582617e-05
congenital B-Disease 1 0.9999821186065674
DM I-Disease 1 0.9999717473983765
. O 0 0.0001588585728313774

Also O 0 5.293889557833609e-07
the O 0 4.148252585878254e-08
fathers O 0 9.02052477158577e-08
of O 0 4.2677275047253715e-09
the O 0 4.923635898990142e-08
reported O 0 2.9063863621558994e-05
congenitally O 0 0.010014322586357594
affected O 0 3.3551540923326684e-07
children O 0 9.11779096668397e-08
showed O 0 2.590151780168526e-06
, O 0 7.768926835183265e-09
on O 0 1.3538565823978388e-08
average O 0 1.4303699913398304e-07
, O 0 8.644081006536908e-09
shorter O 0 4.12099922186826e-07
CTG O 0 3.298698356957175e-05
repeat O 0 2.2519802769238595e-06
lengths O 0 4.349681148596574e-06
and O 0 2.810694965660332e-08
hence O 0 5.869230221833277e-07
less O 0 3.458315802618017e-07
severe O 0 0.3146628737449646
clinical O 1 0.6692789196968079
symptoms O 0 0.04265793040394783
than O 0 2.8334039114952247e-08
the O 0 3.482156429868155e-08
mothers O 0 1.3881524409953272e-06
of O 0 2.3160311002357048e-08
children O 0 5.36026482222951e-06
with O 0 0.0022727728355675936
congenital B-Disease 1 0.9999934434890747
DM I-Disease 1 0.9999818801879883
. O 0 0.0002482547133695334

We O 0 2.439931449771393e-06
conclude O 0 4.607973096426576e-06
that O 0 1.2082658429335424e-07
paternal O 0 9.123011113842949e-05
transmission O 0 0.00018088384240400046
of O 0 1.1645150152617134e-05
congenital B-Disease 1 0.9999966621398926
DM I-Disease 1 0.9999971389770508
is O 0 1.1590290114327217e-06
rare O 0 1.8020575680566253e-06
and O 0 1.154594713170809e-07
preferentially O 0 6.944199867575662e-06
occurs O 0 1.4071243015223445e-07
with O 0 9.535787270920082e-09
onset O 0 8.73059434525203e-06
of O 0 3.533681436351799e-08
DM B-Disease 1 0.991456925868988
past O 0 2.3500348333982402e-07
30 O 0 2.002248500332371e-08
years O 0 1.4785804580697004e-08
in O 0 8.379792859614099e-09
the O 0 2.1883952427970144e-08
father O 0 3.315270078019239e-06
. O 0 2.6809436803887365e-07
. O 0 1.4352675634654588e-06

The O 0 1.2250346117070876e-05
RB1 O 0 0.08662255853414536
gene O 0 1.6083284208434634e-05
mutation O 0 1.3614690033136867e-05
in O 0 1.277821155554193e-07
a O 0 3.4770533829941996e-07
child O 0 6.143446080386639e-05
with O 0 7.193740020738915e-05
ectopic B-Disease 1 0.9995653033256531
intracranial I-Disease 1 0.9999706745147705
retinoblastoma I-Disease 1 0.9982574582099915
. O 0 9.788933675736189e-05

The O 0 1.5360772522399202e-05
RB1 O 0 0.170322984457016
gene O 0 5.7776967878453434e-05
mutation O 0 3.105528958258219e-05
was O 0 1.1903210861419211e-07
investigated O 0 9.517916055301612e-07
in O 0 3.0628573455260266e-08
a O 0 9.699638070514993e-08
child O 0 1.4607139746658504e-05
with O 0 3.038013346667867e-06
ectopic B-Disease 1 0.9965835213661194
intracranial I-Disease 1 0.9999597072601318
retinoblastoma I-Disease 0 0.07890622317790985
using O 0 1.1398032739862174e-07
DNA O 0 1.0981276545862784e-06
obtained O 0 4.211489113004063e-08
from O 0 1.7830417142761235e-09
both O 0 1.5208432291302643e-09
the O 0 2.553744593569718e-08
pineal B-Disease 0 0.0004537956847343594
and I-Disease 0 4.621157586370828e-06
retinal I-Disease 1 0.9900879263877869
tumours I-Disease 1 0.9989916682243347
of O 0 8.822731700774966e-08
the O 0 6.355556934067863e-07
patient O 0 9.939791925717145e-05
. O 0 7.747502422716934e-06

A O 0 7.30543115423643e-06
nonsense O 0 0.0004466407117433846
mutation O 0 6.333982310025021e-05
in O 0 2.0212657148022117e-07
exon O 0 8.272592822322622e-05
17 O 0 2.2225188445190724e-07
( O 0 5.631530797245432e-09
codon O 0 4.0687787361548544e-08
556 O 0 4.8437716060334424e-08
) O 0 4.5612638666092664e-10
of O 0 4.370256656560656e-10
the O 0 3.005966320301923e-08
RB1 O 0 0.008211794309318066
gene O 0 6.36189412261956e-08
was O 0 3.2423652651658585e-09
found O 0 3.898928291334869e-09
to O 0 7.145063984914657e-10
be O 0 1.4369478940068348e-09
present O 0 3.350450228367663e-08
homozygously O 0 5.522661376744509e-05
in O 0 7.367996435192481e-09
both O 0 3.4571789875315062e-09
the O 0 5.8418013537675506e-08
retinal B-Disease 0 0.010263905860483646
and I-Disease 0 3.208696739420702e-07
the I-Disease 0 2.8384238248690963e-06
pineal I-Disease 1 0.7643308043479919
tumours I-Disease 1 0.9994704127311707
. O 0 1.4683312656416092e-05

The O 0 5.301478154251527e-07
same O 0 4.5931341219329624e-07
mutation O 0 4.266075393388746e-06
was O 0 2.5222409050229544e-08
present O 0 1.9158209241254553e-08
heterozygously O 0 6.2850394897395745e-06
in O 0 3.4799834125465168e-09
the O 0 2.2218813455765485e-09
DNA O 0 7.675959068365046e-08
from O 0 1.7981611755146787e-09
the O 0 1.5708687683968492e-09
constitutional O 0 8.930528849759867e-08
cells O 0 5.1071701534510794e-08
of O 0 1.0150128515462598e-09
the O 0 1.9805035833542206e-08
patient O 0 1.9944859559473116e-06
, O 0 1.8256987033282712e-08
proving O 0 2.1515768366953125e-07
it O 0 8.064914847061289e-10
to O 0 8.471114920638456e-10
be O 0 2.54850762715364e-09
of O 0 1.59969655300074e-08
germline O 0 0.0022385220509022474
origin O 0 4.223256382829277e-06
. O 0 2.758366917987587e-06

The O 0 1.9764147509704344e-06
initial O 0 2.582695560704451e-05
mutation O 0 2.3879016225691885e-05
was O 0 6.41358894881705e-08
shown O 0 5.440683281676684e-08
to O 0 4.840268630346145e-09
have O 0 1.600197130358083e-08
occurred O 0 3.7835604871361284e-07
in O 0 1.6933329405333097e-08
the O 0 8.71872956054176e-08
paternally O 0 0.00010600477980915457
derived O 0 5.396610504249111e-06
RB1 O 0 0.0008610713412053883
allele O 0 1.1318302313156892e-05
. O 0 1.222808691636601e-06

The O 0 4.122125119465636e-06
mutation O 0 3.068741716560908e-05
is O 0 4.3393622917164976e-08
in O 0 5.248713463856802e-09
an O 0 8.569384091217103e-10
area O 0 4.189982139024551e-09
of O 0 5.466453401048454e-10
the O 0 3.041949137028155e-09
gene O 0 1.2666233395464133e-08
that O 0 6.509427996626016e-10
encodes O 0 5.563926208651537e-09
the O 0 1.2686487416146974e-09
protein O 0 1.8142952029620574e-08
- O 0 2.8278377612878103e-06
binding O 0 1.2548291294933733e-07
region O 0 4.4367208573703465e-08
known O 0 4.666183439638871e-09
as O 0 6.696412313544897e-10
the O 0 3.42452866064491e-09
pocket O 0 8.377813355764374e-05
region O 0 1.2973536911431438e-07
and O 0 1.2095474843931697e-08
has O 0 1.6989103457376586e-08
been O 0 2.5074767151522792e-08
detected O 0 2.05123205887503e-06
in O 0 7.092602061220532e-09
other O 0 3.7044727285717727e-09
cases O 0 2.6975801148410028e-08
of O 0 4.6853159574311576e-08
retinoblastoma B-Disease 0 0.04092211276292801
. O 0 1.306147055402107e-06
. O 0 3.4685988339333562e-06

Low O 0 0.00013623377890326083
levels O 0 2.2490635274152737e-06
of O 0 2.877513338717108e-08
beta O 0 3.8916536482247466e-07
hexosaminidase O 0 4.3949308746960014e-05
A O 0 1.1240323516403805e-07
in O 0 7.592741013695559e-08
healthy O 0 5.676394607689872e-07
individuals O 0 4.720802593283224e-08
with O 0 6.441737809836923e-07
apparent O 1 0.8716520071029663
deficiency O 1 0.9567112922668457
of O 0 4.15004137721553e-08
this O 0 4.13683636679707e-07
enzyme O 0 8.774993148108479e-06
. O 0 2.0504537587839877e-06

Appreciable O 0 0.0011067853774875402
beta O 0 4.153731788392179e-05
hexosaminidase O 0 0.0003933299158234149
A O 0 6.686998403893085e-07
( O 0 4.084648708158056e-08
hex O 0 2.954120873255306e-06
A O 0 3.109186152983057e-08
) O 0 3.733100051306337e-09
activity O 0 1.6860559171050227e-08
has O 0 5.524187329797314e-09
been O 0 1.1933371624195388e-08
detected O 0 1.3666286804436822e-06
in O 0 5.9342490033031936e-08
cultured O 0 0.00045203889021649957
skin O 0 0.0036576022394001484
fibroblasts O 0 4.862296555074863e-05
and O 0 1.9246981537435204e-05
melanoma B-Disease 1 0.9997389912605286
tissue O 0 0.0014069691533222795
from O 0 2.616001495425735e-07
healthy O 0 3.2208236007136293e-06
individuals O 0 5.845167194706846e-08
previously O 0 5.893966772418935e-07
reported O 0 2.3511854578828206e-06
as O 0 9.653589216895853e-08
having O 0 1.9071230781264603e-05
deficiency B-Disease 0 0.2085152566432953
of I-Disease 0 6.027478072212489e-09
hex I-Disease 0 1.6675257938914e-05
A I-Disease 0 2.9963437953028915e-08
activity O 0 2.1769883673528057e-08
indistinguishable O 0 4.494785343922558e-08
from O 0 1.8519457078980395e-09
that O 0 1.7465212609479863e-09
of O 0 1.2231331503187448e-08
patients O 0 6.367299647536129e-06
with O 0 0.00019254593644291162
Tay B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999948740005493
Sachs I-Disease 1 0.9999929666519165
disease I-Disease 1 0.7842518091201782
( O 0 1.4512570487568155e-06
TSD B-Disease 0 0.054412540048360825
) O 0 5.751363119088637e-07
. O 0 1.7506162066638353e-06

Identification O 0 1.5612667993991636e-05
and O 0 3.1975375236470427e-07
quantitation O 0 9.438796405447647e-05
of O 0 4.352691362896621e-08
hex O 0 6.372961252054665e-06
A O 0 6.999351853664848e-08
, O 0 1.3629066764053732e-08
amounting O 0 2.7205175001654425e-07
to O 0 4.2921296738995807e-08
3 O 0 4.94521714244911e-07
. O 0 1.6863956489032716e-06

5 O 0 7.800534149282612e-06
% O 0 3.3817702842497965e-06
- O 0 9.086597856367007e-05
6 O 0 5.068666268925881e-06
. O 0 2.18784384742321e-06

9 O 0 2.2266397081693867e-06
% O 0 4.993450986034986e-08
of O 0 2.762603479311565e-09
total O 0 3.154313787945284e-08
beta O 0 2.2306430480512063e-07
hexosaminidase O 0 3.561353150871582e-05
activity O 0 7.937373425193073e-08
, O 0 3.5234231088310253e-09
has O 0 2.4952757637919376e-09
been O 0 2.5496111888401174e-09
obtained O 0 2.149951860985766e-08
by O 0 7.4294677077091364e-09
cellulose O 0 2.7911744382436154e-06
acetate O 0 1.2571591696541873e-06
gel O 0 1.71929677890148e-05
electrophoresis O 0 4.269490545993904e-06
, O 0 1.1975234137651114e-08
DEAE O 0 7.541059858340304e-06
- O 0 4.5048714127915446e-06
cellulose O 0 1.1782009323724196e-06
ion O 0 1.000256361294305e-06
- O 0 2.729170546444948e-06
exchange O 0 1.029549636655247e-07
chromatography O 0 2.587050857982831e-06
, O 0 1.1699435198408992e-08
radial O 0 1.1173689244969864e-06
immunodiffusion O 0 4.612435805029236e-05
, O 0 3.8007236469184136e-08
and O 0 1.8037529514458583e-07
radioimmunoassay O 0 0.001202664221636951
. O 0 4.481868018046953e-06

Previous O 0 2.475090695952531e-05
family O 0 7.6125943451188505e-06
studies O 0 7.289371524166199e-07
suggested O 0 2.47778473294602e-07
that O 0 1.0021421026351618e-08
these O 0 6.2729674787931344e-09
individuals O 0 2.9605766727058835e-08
may O 0 1.163108862556328e-07
be O 0 3.4494396228268442e-09
compound O 0 4.4245771846362913e-07
heterozygotes O 0 6.023485639161663e-06
for O 0 3.670046933024196e-09
the O 0 1.769359059267117e-08
common O 0 3.244569768412475e-07
mutant O 0 8.095466182567179e-05
TSD B-Disease 0 0.0024546582717448473
gene O 0 2.3697700157754298e-07
and O 0 1.564566254330657e-08
a O 0 1.115180765509649e-07
rare O 0 1.5894849639153108e-05
( O 0 2.0211905393807683e-07
allelic O 0 0.0001985182025237009
) O 0 2.3449061359315237e-07
mutant O 0 3.0444920412264764e-05
gene O 0 3.952251063310541e-06
. O 0 1.846576992647897e-06

Thus O 0 5.1499841902113985e-06
, O 0 9.589358995754083e-08
the O 0 2.594504699970912e-08
postulated O 0 4.859465661866125e-06
rate O 0 3.6233711853128625e-07
mutant O 0 1.1526960861374391e-06
gene O 0 8.274258078699859e-08
appears O 0 2.8311944788583787e-08
to O 0 6.783248407415954e-10
code O 0 3.2866476207260575e-09
for O 0 4.436284672948432e-10
the O 0 1.4701097006408759e-09
expression O 0 1.494173140770272e-08
of O 0 3.0372762083175076e-09
low O 0 1.467840178293045e-07
amounts O 0 3.6783319501410006e-08
of O 0 1.0213268453185265e-08
hex O 0 3.69755580322817e-05
A O 0 1.473745555813366e-06
. O 0 2.1768507849628804e-06

Heterozygotes O 0 0.0009015789837576449
for O 0 2.675168957466667e-07
the O 0 2.8114729389017157e-07
rare O 0 6.0656243476842064e-06
mutant O 0 0.00022490581613965333
may O 0 7.887884976298665e-07
be O 0 5.475492947937255e-09
indistinguishable O 0 2.4242191898338206e-07
from O 0 1.43634579785612e-08
heterozygotes O 0 4.3275363168504555e-06
for O 0 8.577859311742486e-09
the O 0 1.0776363978948211e-07
common O 0 5.1619922487589065e-06
TSD B-Disease 0 0.34684887528419495
mutant O 0 0.0007904024096205831
. O 0 4.624340817827033e-06

However O 0 9.85562337518786e-07
, O 0 4.1203850997817426e-08
direct O 0 3.104954870991605e-08
visualization O 0 1.7150138091892586e-06
and O 0 2.607940174925716e-08
quantitation O 0 3.7848225474590436e-05
of O 0 8.727411682230013e-09
hex O 0 2.7056989893026184e-06
A O 0 8.073753221538027e-09
by O 0 1.7507704175301342e-09
the O 0 5.562143634563199e-09
methods O 0 1.192038681097074e-07
described O 0 1.5241712389979511e-06
may O 0 2.1146593098819721e-07
prevent O 0 6.632492954850022e-08
false O 0 8.074478046182776e-07
- O 0 0.00035418893094174564
positive O 0 1.5399492667711456e-06
prenatal O 1 0.8186718821525574
diagnosis O 0 0.0029520047828555107
of O 0 7.163969684143012e-08
TSD B-Disease 0 0.0711529478430748
in O 0 9.385353223478887e-07
fetuses O 0 0.00014940640539862216
having O 0 3.045346730345955e-08
the O 0 1.0982136089410233e-08
incomplete O 0 1.6980701502689044e-06
hex B-Disease 0 0.00012745657295454293
A I-Disease 0 3.1798256259207847e-06
deficiency I-Disease 0 0.0031960434280335903
of O 0 1.6873740182887786e-09
the O 0 1.5213778681300028e-08
type O 0 4.3957097659586e-06
described O 0 4.873630814472563e-07
in O 0 1.3443153257242102e-08
the O 0 3.002316262268323e-08
four O 0 6.333435749183991e-07
healthy O 0 2.3492566469940357e-05
individuals O 0 1.2699691069428809e-05

The O 0 1.0337904313928448e-05
tumor B-Disease 0 0.0025794217362999916
suppressor O 0 0.00024035257229115814
gene O 0 3.624038754423964e-06
Smad4 O 0 0.0002516064851079136
/ O 0 1.722519846225623e-05
Dpc4 O 0 3.53534851456061e-05
is O 0 3.715844743013008e-09
required O 0 3.0979609988435186e-09
for O 0 3.308800788914823e-09
gastrulation O 0 1.135391357820481e-05
and O 0 8.998302547524872e-09
later O 0 1.0301955732927581e-08
for O 0 2.5490132227190543e-09
anterior O 0 7.594314411107916e-06
development O 0 5.422491256013018e-08
of O 0 5.5090043638017505e-09
the O 0 1.0376126624578319e-07
mouse O 0 3.918188303941861e-05
embryo O 0 1.7565918824402615e-05
. O 0 2.8604513317986857e-06

Mutations O 0 0.0005359273636713624
in O 0 1.0446060514368583e-06
the O 0 3.6740485143127444e-07
SMAD4 O 0 0.08081527799367905
/ O 0 0.002354089403524995
DPC4 O 0 0.18749016523361206
tumor B-Disease 0 0.02395624667406082
suppressor O 0 0.00014568341430276632
gene O 0 2.0986691140478797e-07
, O 0 3.4128306847236445e-09
a O 0 6.630453519562707e-09
key O 0 3.0723651178732325e-08
signal O 0 1.9487472968648945e-07
transducer O 0 5.250030426395824e-06
in O 0 8.253842054273264e-09
most O 0 3.87721499350846e-09
TGFbeta O 0 6.275776104303077e-05
- O 0 0.00046674261102452874
related O 0 5.731619694415713e-06
pathways O 0 3.5281032069178764e-06
, O 0 6.408878316932487e-09
are O 0 5.139451642044435e-10
involved O 0 3.8760314957642095e-09
in O 0 7.2288361963046555e-09
50 O 0 1.7564238063982884e-08
% O 0 5.3867104554683465e-08
of O 0 1.3783931080979528e-06
pancreatic B-Disease 1 0.9987737536430359
cancers I-Disease 1 0.9847840070724487
. O 0 6.8457200541161e-05

Homozygous O 0 0.004881732631474733
Smad4 O 0 0.06471429765224457
mutant O 0 0.040579475462436676
mice O 0 0.035366807132959366
die O 0 0.0005453546182252467
before O 0 4.112126816835371e-07
day O 0 4.989867079530086e-07
7 O 0 2.0785269043699373e-06
. O 0 1.5990704014257062e-06

5 O 0 7.124484909581952e-06
of O 0 1.9148073988617398e-06
embryogenesis O 0 0.0005099518457427621
. O 0 1.609856917639263e-05

Mutant O 0 0.00015674020687583834
embryos O 0 8.764998710830696e-06
have O 0 1.6624800025510922e-07
reduced O 0 3.7756015558443323e-07
size O 0 1.5647148075004225e-06
, O 0 8.099421933138728e-08
fail O 0 6.295996399785508e-07
to O 0 5.683401749223549e-09
gastrulate O 0 1.2980288374819793e-05
or O 0 1.0824996898861627e-08
express O 0 4.22300772129347e-08
a O 0 1.1302859093120787e-08
mesodermal O 0 2.0182091247988865e-05
marker O 0 2.2751535198040074e-06
, O 0 1.367077473446443e-08
and O 0 1.751005029859698e-08
show O 0 8.795929602456454e-07
abnormal O 0 4.656054079532623e-05
visceral O 0 0.0004395047144498676
endoderm O 0 0.08604124933481216
development O 0 3.4490910820750287e-06
. O 0 3.3914657251443714e-06

Growth B-Disease 1 0.9502241015434265
retardation I-Disease 1 0.9764971137046814
of O 0 2.662306144429749e-07
the O 0 4.959632065038022e-07
Smad4 O 0 0.00647095637395978
- O 0 0.03703944385051727
deficient O 0 0.0006291124736890197
embryos O 0 6.610920308958157e-07
results O 0 1.8950045443943964e-07
from O 0 2.0168210213000748e-08
reduced O 0 2.487318795374449e-07
cell O 0 9.693443644209765e-06
proliferation O 0 3.3749686281225877e-06
rather O 0 2.078953365014513e-08
than O 0 3.418213623263e-08
increased O 0 1.8677949356060708e-06
apoptosis O 0 5.210890594753437e-05
. O 0 2.8438212211767677e-06

Aggregation O 0 5.2274190238676965e-05
of O 0 1.051995013767737e-06
mutant O 0 0.0001642162969801575
Smad4 O 0 0.0017492022598162293
ES O 0 8.341493958141655e-05
cells O 0 1.2284800732231815e-06
with O 0 2.2442431912850225e-08
wild O 0 8.674051059642807e-07
- O 0 5.045142097515054e-05
type O 0 5.462380158860469e-06
tetraploid O 0 9.324074926553294e-05
morulae O 0 0.00029411527793854475
rescues O 0 4.734666435979307e-05
the O 0 8.032512255340407e-07
gastrulation B-Disease 0 0.006015157327055931
defect I-Disease 0 0.002035329584032297
. O 0 7.16473323336686e-06

These O 0 9.097975635086186e-07
results O 0 2.4339492483704817e-06
indicate O 0 7.340617571571784e-07
that O 0 1.3458315351044803e-08
Smad4 O 0 1.6959589629550464e-05
is O 0 5.302354999514591e-09
initially O 0 4.750027926547773e-09
required O 0 8.52543202700673e-10
for O 0 2.3438745389015025e-10
the O 0 7.173452942765834e-10
differentiation O 0 4.088302585358861e-09
of O 0 5.790554702400641e-10
the O 0 5.037606776170378e-09
visceral O 0 3.727028160938062e-05
endoderm O 0 0.001919997506774962
and O 0 8.75244943188136e-09
that O 0 3.3858391645935626e-09
the O 0 1.3600398141022652e-08
gastrulation B-Disease 0 7.704304152866825e-05
defect I-Disease 0 1.0574060070211999e-05
in O 0 1.6838063388036062e-08
the O 0 3.606347220852513e-08
epiblast O 0 0.022769151255488396
is O 0 3.469897436048086e-08
secondary O 0 7.414860903054432e-08
and O 0 2.7657261369995467e-08
non O 0 2.981598470341851e-07
- O 0 0.0003578036557883024
cell O 0 0.00023134713410399854
autonomous O 0 7.879171789682005e-06
. O 0 2.947178700196673e-06

Rescued O 0 0.0006549630779772997
embryos O 0 9.845721069723368e-05
show O 0 3.391832797206007e-05
severe O 0 0.013478904962539673
anterior O 0 0.036949701607227325
truncations O 0 0.006561699789017439
, O 0 5.192219418859167e-07
indicating O 0 7.139225317587261e-07
a O 0 1.1539315281083873e-08
second O 0 2.2575308733507882e-08
important O 0 5.556057391942204e-09
role O 0 2.3071820010045485e-08
for O 0 1.942905036855791e-08
Smad4 O 0 0.0001312089734710753
in O 0 4.1035235653907876e-07
anterior O 0 0.0003893207758665085
patterning O 0 0.00298966933041811
during O 0 8.102656465780456e-06
embryogenesis O 0 0.0006321586552076042
. O 0 8.103274922177661e-06

Prevalence O 0 0.002265617251396179
of O 0 9.005540277939872e-07
p16 O 0 6.405609747162089e-05
and O 0 6.819577151873091e-07
CDK4 O 0 0.01315391343086958
germline O 0 0.027452096343040466
mutations O 0 1.0480072887730785e-05
in O 0 2.540274124385178e-07
48 O 0 1.3594968550023623e-05
melanoma B-Disease 1 0.9996163845062256
- O 1 0.9007639288902283
prone O 0 0.07114154100418091
families O 0 1.2434589962140308e-06
in O 0 1.9985129711130867e-06
France O 0 0.0001109741788241081
. O 0 1.3531870536098722e-05

The O 0 1.4295928849605843e-05
French O 0 0.000497048778925091
Familial B-Disease 1 0.9980489015579224
Melanoma I-Disease 1 0.9999432563781738
Study O 0 0.00011888973676832393
Group O 0 1.809230525395833e-05
. O 0 1.065517426468432e-05

Germline O 1 0.8351469039916992
mutations O 0 0.00042777188355103135
in O 0 1.989211568798055e-07
the O 0 6.896215154483798e-08
p16 O 0 6.4369933170382865e-06
and O 0 7.745197194708453e-08
CDK4 O 0 0.0018912761006504297
genes O 0 1.473530346629559e-07
have O 0 6.5872174381809145e-09
been O 0 6.637679295096177e-09
reported O 0 1.270381204676596e-07
in O 0 5.464037222679963e-09
a O 0 1.7322662415608647e-08
subset O 0 5.924697461523465e-07
of O 0 1.5225992910927744e-06
melanoma B-Disease 1 0.9999176263809204
pedigrees O 0 0.012996815145015717
, O 0 3.582482577257906e-08
but O 0 1.0553563356552331e-08
their O 0 5.0037101573252585e-08
prevalence O 0 7.222581916721538e-05
is O 0 1.2834863838406818e-08
not O 0 6.944919750395684e-09
well O 0 5.585950546560525e-08
known O 0 1.3439969279716024e-06
. O 0 2.0125189621467143e-06

We O 0 8.528023158760334e-07
searched O 0 1.3810247310175328e-06
for O 0 2.3570304819031662e-08
such O 0 9.053395189084767e-08
germline O 0 0.006350955925881863
mutations O 0 4.5833639887860045e-06
in O 0 4.1669991901471803e-08
48 O 0 3.9463654388782743e-07
French O 0 0.0001388725795550272
melanoma B-Disease 1 0.999681830406189
- O 1 0.7485356330871582
prone O 0 0.0011421536328271031
families O 0 3.719008745406427e-08
selected O 0 1.760089141100707e-08
according O 0 1.390206438856012e-08
to O 0 7.789606182306841e-10
two O 0 1.3831386036500248e-09
major O 0 9.344879714490162e-08
criteria O 0 1.2314319519646233e-07
families O 0 1.0822747142924527e-08
with O 0 7.024720805048901e-09
at O 0 2.7532573554367445e-08
least O 0 4.109677487207364e-09
three O 0 4.343740478418567e-09
affected O 0 3.03687777147843e-08
members O 0 6.3004144124079176e-09
( O 0 8.483488578292508e-09
n O 0 5.825383595947642e-06
= O 0 7.3793166848190594e-06
20 O 0 2.846044511173318e-09
) O 0 6.343858216517617e-10
or O 0 9.828858837934717e-10
families O 0 2.2023631807144284e-09
with O 0 3.738322984503384e-09
two O 0 9.579045112673157e-09
affected O 0 4.2476788308931646e-08
members O 0 2.2659807363822893e-09
, O 0 2.242248386963297e-09
one O 0 2.9411559299141743e-10
of O 0 2.552592859306202e-10
them O 0 1.0762386537521706e-09
affected O 0 7.378445854300253e-09
before O 0 1.8115660083140028e-09
the O 0 1.3732652792697309e-09
age O 0 1.1277728084735372e-08
of O 0 8.210454538470913e-10
50 O 0 5.099672684139023e-09
( O 0 5.275551551164881e-09
n O 0 4.627985163097037e-06
= O 0 9.828632755670696e-06
28 O 0 1.4733583242332315e-08
) O 0 9.286785784823337e-10
, O 0 9.227829611546667e-10
and O 0 2.726504799710483e-09
one O 0 9.305904491441197e-09
additional O 0 8.549589836093219e-08
minor O 0 1.0278823538101278e-05
criterion O 0 2.5326080503873527e-05
. O 0 6.657379799435148e-06

Sixteen O 0 1.527468702988699e-05
different O 0 9.0758601345442e-07
p16 O 0 0.00010191350156674162
germline O 0 0.013123814016580582
mutations O 0 1.8705042748479173e-05
were O 0 2.6173983869171025e-08
found O 0 6.545214858988402e-08
in O 0 2.5517287838283664e-08
21 O 0 7.918200140011322e-08
families O 0 1.957658035678378e-08
, O 0 7.10646830270889e-09
while O 0 6.4986882541973046e-09
one O 0 1.4200721487611645e-08
germline O 0 0.002265334827825427
mutation O 0 3.897049282386433e-06
, O 0 2.1181747911214188e-08
Arg24His O 0 3.839989221887663e-05
, O 0 7.926991507645198e-09
was O 0 2.0506377040874213e-08
detected O 0 8.406336746702436e-07
in O 0 1.6107431832779184e-08
the O 0 9.405606249401899e-08
CDK4 O 0 0.003750954521819949
gene O 0 4.281429028196726e-06
. O 0 1.9183314634574344e-06

The O 0 7.805614927747229e-07
frequency O 0 1.0020982017522329e-06
of O 0 2.8803796681131644e-08
p16 O 0 5.57244766241638e-06
gene O 0 5.086483270133613e-07
mutation O 0 5.339945801097201e-07
in O 0 6.455190604270911e-09
our O 0 5.5077959970617485e-09
sample O 0 2.0652944243693128e-08
( O 0 3.1927303023593367e-09
44 O 0 1.8260053025187517e-08
% O 0 6.210833181086173e-09
) O 0 1.7489381054502928e-09
is O 0 1.1642219410745724e-09
among O 0 1.1739440530789125e-09
the O 0 1.0268272454538874e-08
highest O 0 8.91082345333416e-06
rates O 0 4.322708662130026e-07
yet O 0 5.86481085917967e-08
reported O 0 5.9284676723336815e-08
and O 0 4.704979073011373e-09
the O 0 1.390994253114286e-08
CDK4 O 0 0.013240315951406956
mutation O 0 5.906537694500003e-07
is O 0 1.0448326648315742e-09
the O 0 7.811685742709074e-10
second O 0 1.031017689001601e-07
mutation O 0 1.3547806702263188e-05
detected O 0 1.6624560430500424e-06
in O 0 1.3256336472977637e-08
this O 0 2.839782808905511e-08
gene O 0 7.532446488767164e-07
worldwide O 0 2.3047314243740402e-06
. O 0 2.5660544906713767e-06

In O 0 1.5802582993273973e-06
summary O 0 2.200210019509541e-06
, O 0 3.63858596585942e-08
our O 0 3.693602224075221e-08
results O 0 1.2627161538603104e-07
show O 0 3.36176775306285e-08
frequent O 0 4.137269371540242e-08
involvement O 0 1.079526938951858e-07
of O 0 6.3129608207646015e-09
the O 0 3.5113888685600614e-08
p16 O 0 5.035385129303904e-06
gene O 0 3.5189930258638924e-07
in O 0 2.6780151074490277e-07
familial B-Disease 1 0.8268435597419739
melanoma I-Disease 1 0.9999020099639893
and O 0 4.5615556132361235e-07
confirm O 0 1.3918374861532357e-06
the O 0 4.092312710923807e-09
role O 0 9.061563055468014e-09
of O 0 1.1657107501505948e-09
the O 0 1.9088906455522192e-08
CDK4 O 0 0.0008258404559455812
gene O 0 1.2517108416432166e-07
as O 0 5.6525584213318325e-09
a O 0 7.76720185058366e-07
melanoma B-Disease 1 0.9979429841041565
- O 0 0.1241467222571373
predisposing O 0 0.0001269856293220073
gene O 0 1.847734324655903e-06
. O 0 3.024842669674399e-07
. O 0 1.1779548003687523e-06

Progression O 0 0.00025324642774648964
of O 0 6.641644745286612e-07
somatic O 0 9.765569848241284e-05
CTG O 0 0.002485341392457485
repeat O 0 2.802606650220696e-05
length O 0 2.184922550441115e-06
heterogeneity O 0 9.065661288332194e-06
in O 0 3.6199512720713756e-08
the O 0 8.653569949501616e-08
blood O 0 3.819715493591502e-05
cells O 0 2.2167443603393622e-05
of O 0 8.840181180858053e-06
myotonic B-Disease 1 0.9999932050704956
dystrophy I-Disease 1 0.9999924898147583
patients O 0 0.048139628022909164
. O 0 4.704475213657133e-05

The O 0 3.1445276817976264e-06
genetic O 0 1.8218992408947088e-05
basis O 0 5.326594418875175e-07
of O 0 1.2075270205968991e-05
myotonic B-Disease 1 0.9999984502792358
dystrophy I-Disease 1 0.9999971389770508
( O 0 0.00020632900123018771
DM B-Disease 1 0.9999408721923828
) O 0 2.8542816110643798e-08
is O 0 1.6401761060436115e-09
the O 0 1.3653308483796422e-09
expansion O 0 2.4014473964939498e-08
of O 0 1.9344510437946383e-09
an O 0 2.194255088738828e-08
unstable O 0 0.0002491812047082931
CTG O 0 0.0004212555068079382
repeat O 0 1.068986534846772e-06
in O 0 3.2843292530060353e-09
the O 0 4.046441404170764e-09
34 O 0 4.5250988733869235e-08
UTR O 0 2.040160779870348e-06
of O 0 2.8111437622158064e-09
the O 0 5.4647074421154684e-08
DM B-Disease 1 0.9847027659416199
protein O 0 7.624187787769188e-07
kinase O 0 2.6589414119371213e-06
gene O 0 1.3569994905537897e-07
on O 0 7.496143439311709e-08
chromosome O 0 3.903167089447379e-05
19 O 0 3.2126451969816117e-06
. O 0 2.416646339042927e-06

One O 0 2.881517957575852e-07
of O 0 1.8589325634366105e-08
the O 0 2.588977920936486e-08
principal O 0 9.26681735791135e-08
features O 0 4.477501036603826e-08
of O 0 5.717128104265612e-09
the O 0 5.172431087885343e-07
DM B-Disease 1 0.9999676942825317
mutation O 0 1.5584730135742575e-05
is O 0 6.663264606743269e-09
an O 0 6.2781384535526286e-09
extraordinarily O 0 1.8030297724180855e-05
high O 0 2.891482893119246e-07
level O 0 2.1086895785060733e-08
of O 0 5.084133114507949e-09
somatic O 0 3.062003088416532e-05
mosaicism O 0 0.024412104859948158
, O 0 6.864810586648673e-08
due O 0 5.547429893226763e-08
to O 0 4.220960025946852e-09
an O 0 1.0511215897679449e-08
extremely O 0 8.093567203104612e-07
high O 0 6.699854679936834e-07
degree O 0 3.2783668757474516e-07
of O 0 8.470053103337705e-09
somatic O 0 2.748031147348229e-05
instability O 0 7.163318969105603e-06
both O 0 1.1928456444820768e-08
within O 0 6.732505219986251e-09
and O 0 1.2553050154906487e-08
between O 0 5.970931482579545e-08
different O 0 3.0849142262923124e-07
tissues O 0 0.0002213558036601171
. O 0 3.886415470333304e-06

This O 0 2.3484783469029935e-06
instability O 0 2.5725630621309392e-05
appears O 0 8.202743515539623e-07
to O 0 4.62170124393424e-09
be O 0 2.2185020487341944e-09
biased O 0 8.16496648070597e-09
towards O 0 2.310452940079699e-09
further O 0 2.014060029864595e-09
expansion O 0 1.0881510803528727e-08
and O 0 1.4177223839340058e-09
continuous O 0 1.5978761425117227e-08
throughout O 0 4.702072509132904e-09
the O 0 1.898468715566537e-09
life O 0 9.757918917330244e-09
of O 0 6.236863248076929e-10
an O 0 1.4653143143306124e-09
individual O 0 1.0526344240702201e-08
, O 0 3.6508609468910436e-09
features O 0 4.938891962069647e-08
that O 0 8.213890012598313e-09
could O 0 1.9575384868630863e-08
be O 0 2.339007876273058e-09
associated O 0 2.3421161898795617e-08
with O 0 4.164725009303538e-09
the O 0 2.3102600721358613e-08
progressive O 0 7.247169378388207e-06
nature O 0 1.1374266932762112e-06
of O 0 4.6843236845006686e-08
the O 0 4.641005943994969e-06
disease O 0 0.005328931380063295
. O 0 4.14041005569743e-06

Although O 0 2.997684077854501e-06
increasing O 0 1.0132639545190614e-06
measured O 0 3.0733785933989566e-06
allele O 0 1.5817765870451694e-06
size O 0 9.014150350594718e-07
between O 0 1.1808415933955985e-07
patients O 0 7.126001833057671e-07
clearly O 0 7.57963221076352e-08
correlates O 0 8.242784588219365e-07
with O 0 6.703035015931391e-09
an O 0 8.162117204335573e-09
increased O 0 3.4993793178728083e-06
severity O 0 0.0014519928954541683
of O 0 4.5206218146631727e-07
symptoms O 0 0.0036656339652836323
and O 0 3.8046039207983995e-08
an O 0 4.989278767908445e-09
earlier O 0 7.28549991890759e-07
age O 0 1.2718044217763236e-07
of O 0 7.866113094223692e-09
onset O 0 9.963229967979714e-05
, O 0 1.0314381349019186e-08
this O 0 3.42331407665597e-09
correlation O 0 1.4443655516060971e-07
is O 0 2.261692833016582e-09
not O 0 1.194652932134943e-09
precise O 0 2.30658415034668e-07
and O 0 1.839519470081541e-08
measured O 0 2.0093873445148347e-06
allele O 0 3.9256076433957787e-07
length O 0 1.4270916892655805e-07
cannot O 0 3.418448102365801e-08
be O 0 5.158937166349631e-10
used O 0 1.4446893681352435e-09
as O 0 6.524095153004339e-10
an O 0 1.2273765337411646e-09
accurate O 0 7.504833661187149e-07
predictor O 0 7.211205956991762e-05
of O 0 1.6075084374733706e-08
age O 0 5.316707643032714e-07
of O 0 1.7806047480917186e-07
onset O 0 0.009094704873859882
. O 0 1.6669946489855647e-05

In O 0 1.5940822777338326e-06
order O 0 8.720409994111833e-08
to O 0 1.3716245028660978e-08
further O 0 1.3658471686994744e-08
characterize O 0 5.869420647286461e-07
the O 0 2.1415536011204495e-08
dynamics O 0 4.3936561269219965e-06
of O 0 6.693877452335073e-08
DM B-Disease 1 0.9995430707931519
CTG O 0 0.0011874421034008265
repeat O 0 3.836715677607572e-06
somatic O 0 4.233332674630219e-06
instability O 0 4.79438540423871e-06
, O 0 1.1686811518529794e-08
we O 0 2.7080746534124955e-09
have O 0 3.0308640042164825e-09
studied O 0 2.295063872281844e-08
repeat O 0 5.30587897173973e-07
length O 0 1.1011966449814281e-07
changes O 0 6.509841110613479e-09
over O 0 2.147102495797526e-09
time O 0 6.2517782062343485e-09
in O 0 2.36487551319442e-07
111 O 0 0.013224010355770588
myotonic B-Disease 1 0.9999992847442627
dystrophy I-Disease 1 0.9999988079071045
patients O 0 0.000267524883383885
with O 0 1.0602914244373096e-06
varying O 0 0.0007332578534260392
clinical O 0 0.010677555575966835
severity O 0 0.0375325046479702
and O 0 3.7608245406772767e-07
CTG O 0 0.0024090984370559454
repeat O 0 2.119275677614496e-06
size O 0 6.811218611346703e-08
over O 0 1.5167326283815896e-09
time O 0 1.1983271042126376e-09
intervals O 0 1.029517893158527e-08
of O 0 7.628865317244049e-10
1 O 0 1.4510666446199139e-08
- O 0 1.0451068192196544e-05
7 O 0 3.424779606575612e-07
years O 0 3.760731317470345e-07
. O 0 1.0211729204456788e-06

We O 0 1.0790993201226229e-06
have O 0 4.734770442382796e-08
found O 0 1.172496943979695e-08
a O 0 4.106919249124985e-09
direct O 0 1.3962067058059802e-08
progression O 0 9.045944580066134e-07
of O 0 1.3456820102675238e-09
the O 0 4.335852121784001e-09
size O 0 1.0505483487577294e-06
heterogeneity O 0 1.6553715340705821e-06
over O 0 8.459332789811924e-09
time O 0 4.795745578434207e-09
related O 0 2.2239600383500147e-08
to O 0 5.669445801714801e-09
initial O 0 1.2720836366497679e-06
CTG O 0 0.000312024203594774
repeat O 0 1.4296759900389588e-06
size O 0 6.025928911412848e-08
and O 0 9.505529696696158e-10
the O 0 1.2000745952533975e-09
time O 0 2.237779295199971e-09
interval O 0 1.4072834453315863e-08
and O 0 2.531420628670844e-09
always O 0 2.9243425458957972e-09
biased O 0 7.886364450371275e-09
towards O 0 6.306197342098585e-09
further O 0 1.7883523995010364e-08
expansion O 0 9.86680561254616e-07
. O 0 9.832670002651867e-07

Attempts O 0 5.4381271183956414e-06
to O 0 1.7669805174591602e-07
mathematically O 0 2.2506619643536396e-06
model O 0 2.1215474532709777e-07
the O 0 2.2505016517015974e-08
dynamics O 0 9.736068022903055e-06
have O 0 1.057827070383155e-08
proved O 0 4.030421862921685e-08
only O 0 8.464622336390448e-10
partially O 0 1.3738979021127307e-07
successful O 0 3.536972315032472e-08
suggesting O 0 2.3208207267089165e-07
that O 0 4.251567098378928e-09
individual O 0 1.4059017061640589e-08
specific O 0 2.855839120741166e-08
genetic O 0 1.4320559102998232e-06
and O 0 1.9278665774891124e-07
/ O 0 0.00010444990766700357
or O 0 2.8405582952473196e-07
environmental O 0 2.1424300939543173e-05
factors O 0 6.047148559673587e-08
also O 0 3.6746630183159823e-09
play O 0 1.9510328908012298e-09
a O 0 6.810683572666676e-09
role O 0 2.7277025083094486e-08
in O 0 9.497545505610105e-08
somatic O 0 0.00018917967099696398
mosaicism O 0 0.05077987536787987
. O 0 4.16404873249121e-07
. O 0 1.2671169997702236e-06

Aspartylglucosaminuria B-Disease 1 0.9249906539916992
among O 0 1.2523903023975436e-05
Palestinian O 0 4.091560185770504e-05
Arabs O 0 3.152793942717835e-05
. O 0 7.617830760864308e-06

Aspartylglucosaminuria B-Disease 1 0.9993886947631836
( O 0 4.884250301984139e-05
AGU B-Disease 1 0.9979522228240967
) O 0 1.8751252639503946e-07
is O 0 1.8877312157883352e-08
a O 0 1.875198591960725e-07
rare O 0 0.0003573795547708869
disorder B-Disease 0 0.00022225161956157535
of I-Disease 0 1.1131024990618243e-07
glycoprotein I-Disease 1 0.9760544300079346
metabolism I-Disease 0 0.001245958381332457
caused O 0 9.542592351863277e-07
by O 0 2.676577004478986e-08
the O 0 6.332958832899749e-07
deficiency B-Disease 0 0.02364944852888584
of I-Disease 0 7.230090748322482e-09
the I-Disease 0 2.465901332016074e-07
lysosomal I-Disease 1 0.5109427571296692
enzyme I-Disease 0 8.720485311641824e-06
aspartylglucosaminidase I-Disease 0 0.0006175180897116661
( O 0 1.466716526010714e-07
AGA O 0 0.0003565237275324762
) O 0 3.111850332970789e-07
. O 0 9.061408263733028e-07

AGU B-Disease 1 0.9996858835220337
is O 0 1.6778592907940038e-05
inherited O 0 0.0026219021528959274
as O 0 1.421290676262288e-07
an O 0 6.91383604589646e-07
autosomal O 1 0.9100291728973389
recessive O 1 0.8507079482078552
trait O 0 0.005105267278850079
and O 0 8.07857645668264e-07
occurs O 0 6.283831339715107e-07
with O 0 8.012481345076594e-09
a O 0 1.100396787023783e-07
high O 0 5.602248052127834e-07
frequency O 0 4.309894450216234e-07
in O 0 2.6962323929069498e-08
Finland O 0 1.785276936061564e-06
because O 0 1.2105168423204304e-08
of O 0 4.1119827542956955e-09
a O 0 2.2407708399896364e-07
founder O 0 1.973982944036834e-05
effect O 0 2.7845594559039455e-06
. O 0 1.7513676766611752e-06

While O 0 2.300012738487567e-06
very O 0 2.831740744113631e-07
few O 0 2.201745274987843e-07
patients O 0 7.352325042120356e-07
with O 0 6.184216090332484e-07
AGU B-Disease 1 0.9997683167457581
have O 0 1.3133626453054603e-07
been O 0 1.3674217314019188e-08
reported O 0 8.855253241790706e-08
from O 0 4.331793590495181e-09
non O 0 3.529060776941151e-08
- O 0 3.179254417773336e-05
Finnish O 0 6.418425618903711e-05
origin O 0 2.0967365799151594e-07
, O 0 2.6862021940132763e-08
we O 0 1.5666871888697642e-07
diagnosed O 0 0.0021686782129108906
the O 0 1.4197737527865684e-06
disorder O 0 0.00401898380368948
in O 0 7.408513056361699e-07
8 O 0 5.6521794249420054e-06
patients O 0 7.273789037753886e-07
originating O 0 6.591883305873125e-08
from O 0 1.866792054272537e-08
3 O 0 7.773153498646934e-08
unrelated O 0 1.0967734169753385e-06
families O 0 2.148754774111694e-08
, O 0 5.110967649102349e-09
all O 0 9.922436206011298e-10
Palestinian O 0 5.06226740526472e-08
Arabs O 0 2.175062441267528e-08
from O 0 3.838195539174194e-09
the O 0 5.707159189682898e-09
region O 0 6.609811720181824e-08
of O 0 2.2803154919870394e-08
Jerusalem O 0 9.919151125359349e-06
. O 0 3.8297112041618675e-06

The O 0 2.7148355002282187e-05
clinical O 0 0.028263308107852936
diagnosis O 1 0.8063732385635376
of O 0 5.503175088961143e-06
AGU B-Disease 1 0.9999325275421143
is O 0 3.1210996098707255e-07
often O 0 5.840519889943607e-08
difficult O 0 1.0316195897530633e-07
, O 0 7.451692596305293e-09
in O 0 3.5802334430456995e-09
particular O 0 5.88376547483449e-09
early O 0 7.477162888847033e-09
in O 0 3.1967153368839263e-09
the O 0 2.1037391828571117e-09
course O 0 1.4369404333081093e-08
of O 0 2.2393762399985917e-09
the O 0 9.467410109209595e-07
disease O 0 0.0002747188264038414
, O 0 1.1258964427440787e-08
and O 0 3.698725548062498e-09
most O 0 1.0320693188958785e-09
of O 0 3.22743365366307e-09
the O 0 4.50270107421602e-07
patients O 0 1.0473608199390583e-05
are O 0 2.2242447528242337e-07
diagnosed O 0 0.00304323248565197
after O 0 7.901604703874909e-08
the O 0 5.192397622977296e-08
age O 0 2.5072716880458756e-07
of O 0 2.5397161707019222e-08
5 O 0 6.535765351145528e-07
years O 0 2.37317453866126e-06
. O 0 4.048847586091142e-06

However O 0 4.361726951174205e-06
, O 0 1.9569866083202214e-07
since O 0 2.2825528844805376e-07
these O 0 1.5512364726077976e-08
patients O 0 1.6021462556636834e-07
excrete O 0 7.297746265066962e-07
early O 0 1.4817029381219982e-08
large O 0 5.730905527912e-09
amounts O 0 2.296736667517507e-08
of O 0 4.574561174308656e-09
aspartylglucosamine O 0 2.5605258997529745e-05
in O 0 4.223378269330169e-08
urine O 0 1.7592186623005546e-06
, O 0 1.6187572171588727e-08
biochemical O 0 7.81377821112983e-06
screening O 0 1.3927228792454116e-07
is O 0 6.515567640974496e-09
easy O 0 4.803941422437674e-08
by O 0 5.3809493749668036e-08
urine O 0 1.7080594261642545e-05
chromatography O 0 0.0002876090875361115
. O 0 3.2857695941856946e-07
. O 0 1.3700789622816956e-06

Detection O 0 0.00030004451400600374
of O 0 4.714058832178125e-07
heterozygous O 0 6.896977083670208e-06
carriers O 0 1.1157781045767479e-06
of O 0 4.993317759272031e-08
the O 0 7.046393420750974e-06
ataxia B-Disease 1 0.9999877214431763
- I-Disease 1 0.9999101161956787
telangiectasia I-Disease 1 0.9999791383743286
( O 0 1.440924535245358e-07
ATM O 0 3.6593585264199646e-06
) O 0 8.208908219842215e-09
gene O 0 3.2714329023519895e-08
by O 0 1.8207328977837278e-08
G2 O 0 0.00043501387699507177
phase O 0 5.737252649851143e-06
chromosomal O 0 0.0008261324255727232
radiosensitivity O 0 0.000329317495925352
of O 0 1.4969192818625743e-07
peripheral O 0 0.0008397435303777456
blood O 0 0.0035956623032689095
lymphocytes O 0 0.35505884885787964
. O 0 8.973948752100114e-06

In O 0 0.0013646918814629316
ataxia B-Disease 1 0.9999490976333618
- I-Disease 1 0.9995253086090088
telangiectasia I-Disease 1 0.9999676942825317
( O 0 2.2746914964955067e-06
A B-Disease 0 0.00015195751620922238
- I-Disease 1 0.9996117949485779
T I-Disease 1 0.9999873638153076
) O 0 7.283707645910908e-07
patients O 0 9.201840498462843e-07
, O 0 9.510851128879949e-08
mutations O 0 7.215944606286939e-07
in O 0 6.081371406452263e-09
a O 0 1.0091354418761966e-08
single O 0 9.361773578575594e-08
gene O 0 2.2646730712949648e-07
, O 0 1.843523733668917e-08
ATM O 0 5.020338448957773e-06
, O 0 3.860738218008919e-08
result O 0 1.9914932636311278e-07
in O 0 7.76200351992884e-07
an O 0 0.000895368168130517
autosomal B-Disease 1 0.9999988079071045
recessive I-Disease 1 0.999997615814209
syndrome I-Disease 1 0.9999994039535522
that O 0 3.542515969456872e-07
embraces O 0 7.0239848355413415e-06
a O 0 9.528463351671235e-08
variety O 0 4.755832350156197e-08
of O 0 1.4188755059763025e-08
clinical O 0 7.874980838096235e-06
features O 0 4.8079982661874965e-06
and O 0 9.82856477094174e-07
manifests O 0 0.00018738102517090738
extreme O 0 4.184296994935721e-05
radiosensitivity O 0 0.0003606182290241122
and O 0 1.2437650909191689e-08
a O 0 2.286133593543127e-08
strong O 0 2.2747667571820784e-07
pre O 0 8.640129817649722e-05
- O 0 0.0017142570577561855
disposition O 0 0.00011180916771991178
to O 0 8.384751026824233e-07
malignancy B-Disease 1 0.5208901762962341
. O 0 9.948813385562971e-06

Heterozygotes O 0 0.0004645354929380119
for O 0 2.0359436803119024e-07
the O 0 8.071724266756064e-08
ATM O 0 2.0450874217203818e-05
gene O 0 3.8166479043866275e-07
have O 0 1.1811498445979396e-08
no O 0 3.257255443145368e-08
clinical O 0 7.900773653091164e-07
expression O 0 8.26093327077615e-08
of O 0 5.970929528587021e-09
A B-Disease 0 7.310976070584729e-05
- I-Disease 1 0.9937406182289124
T I-Disease 1 0.9997522234916687
but O 0 4.41024553765601e-07
may O 0 1.0574195812296239e-06
be O 0 3.2239165648206836e-07
cancer B-Disease 0 0.06087358668446541
prone O 0 0.0001891013962449506
with O 0 3.792193226104246e-08
a O 0 2.777926226826821e-07
moderate O 0 1.61223051691195e-05
increase O 0 1.7304785160376923e-06
in O 0 1.0748220802270225e-07
in O 0 4.3676945438164694e-07
vitro O 0 0.00024545605992898345
radiosensitivity O 0 0.05062932148575783
. O 0 8.840233022056054e-06

We O 0 1.7449525557822199e-06
performed O 0 7.528252581323613e-07
a O 0 2.779534611363488e-07
blind O 0 8.75231944519328e-06
chromosomal O 0 0.0003391931240912527
analysis O 0 4.6458981728392246e-07
on O 0 2.0689383006811113e-07
G2 O 0 0.03184900060296059
- O 0 0.0005199604202061892
phase O 0 2.711412889766507e-05
lymphocytes O 0 6.698739889543504e-05
from O 0 2.0999479488637007e-08
7 O 0 1.1189498394514885e-07
unrelated O 0 1.3503899936040398e-06
A B-Disease 0 0.00014333869330585003
- I-Disease 1 0.9998897314071655
T I-Disease 1 0.9999936819076538
patients O 0 6.7623013819684274e-06
, O 0 3.61394256742642e-08
13 O 0 5.466104369133973e-08
obligate O 0 1.134265858127037e-06
A B-Disease 0 0.00019909028196707368
- I-Disease 1 0.9980916380882263
T I-Disease 1 0.9999734163284302
heterozygotes O 0 0.0010210415348410606
( O 0 2.8685700925734636e-08
parents O 0 1.550100670044685e-08
of O 0 1.9043875365554186e-09
the O 0 1.3511032648239052e-07
patients O 0 1.4638311540693394e-06
) O 0 1.293493756548969e-08
, O 0 5.360919708152778e-09
and O 0 8.112714944275012e-09
14 O 0 3.419511429569866e-08
normal O 0 3.314727692327324e-08
controls O 0 9.665413358561636e-09
following O 0 9.347514762225728e-09
X O 0 1.0856761036848184e-05
- O 0 5.364504431781825e-06
irradiation O 0 4.36799041381164e-07
with O 0 5.775865119517221e-09
1 O 0 1.7816011776972118e-08
Gy O 0 0.0003332571650389582
in O 0 4.645731799257646e-09
order O 0 2.223272010937194e-09
to O 0 2.215043481967882e-09
evaluate O 0 1.1554869416841029e-07
this O 0 8.15338907500518e-09
cytogenetic O 0 0.00012185905507067218
method O 0 1.4452055552283127e-08
as O 0 9.50130529808746e-10
a O 0 3.3970235513436364e-09
tool O 0 1.0805733552388119e-07
for O 0 2.8348567937541702e-09
detection O 0 1.0792289231176255e-06
of O 0 4.456524749230084e-08
ATM O 0 0.0004908859264105558
carriers O 0 3.21203660860192e-05
. O 0 2.9034249564574566e-06

Both O 0 1.9811363927146886e-06
A B-Disease 0 6.093193223932758e-05
- I-Disease 1 0.8112844824790955
T I-Disease 1 0.9994348883628845
homozygotes O 0 0.00047762683243490756
and O 0 1.0406986916677852e-07
heterozygotes O 0 3.8569520256714895e-05
showed O 0 1.251761113962857e-05
significantly O 0 7.643137678314815e-07
increased O 0 1.8379698474291217e-07
levels O 0 2.8443750466067286e-07
of O 0 6.296104260172797e-08
radiation O 1 0.9878118634223938
- O 0 0.49433276057243347
induced O 0 0.03748999908566475
chromatid O 1 0.8811235427856445
damage O 0 0.000579927465878427
relative O 0 7.582855232612928e-07
to O 0 9.057259831024567e-09
that O 0 6.428994225871065e-09
of O 0 2.656872588602255e-08
normal O 0 2.1484449916897574e-06
controls O 0 3.616091589719872e-06
. O 0 2.6843026716960594e-06

These O 0 8.45136753468978e-07
results O 0 7.032544999674428e-07
show O 0 4.663045416464229e-08
that O 0 4.337060044434793e-09
the O 0 9.539752987564043e-09
G2 O 0 0.00016858972958289087
- O 0 3.4028162190224975e-05
phase O 0 5.574897841142956e-06
chromosomal O 0 0.0004112366586923599
radiosensitivity O 0 0.0005533721996471286
assay O 0 1.4059444765734952e-05
can O 0 6.326509982557127e-09
be O 0 5.312961737224953e-10
used O 0 1.4359780031725222e-09
for O 0 5.628392196754817e-10
the O 0 6.56469101301127e-09
detection O 0 3.0146300105116097e-06
of O 0 2.7320240292283415e-08
A B-Disease 0 0.0005602990859188139
- I-Disease 1 0.9989705085754395
T I-Disease 1 0.9999006986618042
heterozygotes O 0 0.016658900305628777
. O 0 6.323022716969717e-06

In O 0 5.464828973344993e-06
combination O 0 1.5805650036782026e-05
with O 0 6.584675702470122e-07
molecular O 0 0.004547928925603628
genetic O 0 4.914788587484509e-05
analyses O 0 2.4299879441969097e-06
, O 0 1.1378956443763855e-08
this O 0 4.65419258688371e-09
test O 0 2.7005819447367685e-07
may O 0 2.3832502193954497e-08
be O 0 2.831645196099686e-10
of O 0 4.095340178089657e-10
value O 0 8.106249893558015e-09
in O 0 9.605611417384807e-09
studies O 0 1.6422179172081997e-08
of O 0 1.0576011177931832e-08
familial B-Disease 0 0.0030081160366535187
and I-Disease 0 1.979347871383652e-06
sporadic I-Disease 0 0.0018694797763600945
cancers I-Disease 0 0.007681386545300484
aimed O 0 1.4553593530308717e-07
at O 0 1.5196262026506702e-08
determination O 0 1.1580949177414368e-07
of O 0 1.615542366550926e-09
the O 0 3.7202627645172015e-09
potential O 0 5.2620173107698065e-08
involvement O 0 5.5426390588309005e-08
of O 0 1.1311376724165711e-08
ATM O 0 0.0017694327980279922
mutations O 0 2.534726809244603e-05
in O 0 3.979050234192982e-06
tumor B-Disease 0 0.48762527108192444
risk O 0 1.0678152648324613e-05
or O 0 1.6174276140645816e-07
development O 0 9.622198149372707e-07
. O 0 5.962265845482762e-07
. O 0 3.5740138173423475e-06

Ataxia B-Disease 1 0.9999071359634399
- I-Disease 1 0.9987817406654358
telangiectasia I-Disease 1 0.9998925924301147
: O 0 3.9840283534431364e-06
identification O 0 8.759967045079975e-07
and O 0 4.781627183092496e-08
detection O 0 2.207216539318324e-06
of O 0 7.47960182678753e-09
founder O 0 1.0011057383962907e-05
- O 0 0.0011589030036702752
effect O 0 7.285646574928251e-07
mutations O 0 1.2924215297971386e-07
in O 0 3.0863775979383945e-09
the O 0 6.2776113196605365e-09
ATM O 0 3.821502559731016e-06
gene O 0 1.1416309320111395e-07
in O 0 2.333372250973298e-08
ethnic O 0 1.7475092306540319e-07
populations O 0 4.14154374084319e-06
. O 0 2.609162265798659e-06

To O 0 2.8314627797954017e-07
facilitate O 0 3.159474601943657e-07
the O 0 2.386634534445875e-08
evaluation O 0 4.8507612149251145e-08
of O 0 4.059846236970088e-09
ATM O 0 6.774779194529401e-06
heterozygotes O 0 1.9247127056587487e-05
for O 0 2.7937305802083756e-08
susceptibility O 0 0.0004656391975004226
to O 0 5.8301470318156134e-08
other O 0 5.431392082755337e-07
diseases O 0 0.2374897301197052
, O 0 3.522148261936309e-08
such O 0 4.849521673122581e-08
as O 0 5.1079964578093495e-06
breast B-Disease 1 0.9910781979560852
cancer I-Disease 1 0.8008944988250732
, O 0 9.060616434908297e-08
we O 0 8.070797363757265e-09
have O 0 2.2516684072826365e-09
attempted O 0 3.029559536571469e-08
to O 0 2.9299538351068577e-09
define O 0 5.007872516671341e-08
the O 0 6.301988708656836e-09
most O 0 8.57897219930237e-09
common O 0 2.852448517387529e-07
mutations O 0 8.812638725430588e-07
and O 0 9.68963043135318e-09
their O 0 2.5525466185172263e-08
frequencies O 0 4.149505912209861e-06
in O 0 6.095529442973202e-06
ataxia B-Disease 1 0.9999775886535645
- I-Disease 1 0.999941349029541
telangiectasia I-Disease 1 0.9999927282333374
( O 0 9.61143996391911e-07
A B-Disease 0 0.00010491078137420118
- I-Disease 1 0.9915306568145752
T I-Disease 1 0.9996973276138306
) O 0 6.925120743517255e-08
homozygotes O 0 6.599181688216049e-06
from O 0 1.1194254412316695e-08
10 O 0 2.196105874929799e-08
ethnic O 0 2.918430368481495e-07
populations O 0 7.714677849435247e-06
. O 0 5.7022057262656745e-06

Both O 0 3.208958560207975e-06
genomic O 0 0.00057775410823524
mutations O 0 9.904546459438279e-05
and O 0 7.808773716533324e-08
their O 0 3.391832947841067e-08
effects O 0 3.713183502895845e-07
on O 0 3.401680359615966e-08
cDNA O 0 7.319966925933841e-07
were O 0 6.244034267410825e-08
characterized O 0 1.2514649824879598e-05
. O 0 3.6780697882932145e-06

Protein O 0 2.4718523491173983e-05
- O 0 2.031107032962609e-05
truncation O 0 7.377748261205852e-06
testing O 0 1.5433161593136902e-07
of O 0 3.198715736729696e-09
the O 0 5.256056923030883e-09
entire O 0 2.746464922154246e-08
ATM O 0 5.297586653796316e-07
cDNA O 0 4.317278694543347e-07
detected O 0 7.146357461351727e-07
92 O 0 4.078833271137228e-08
( O 0 3.2189253484915525e-09
66 O 0 4.8846864331153483e-08
% O 0 2.386907560492091e-08
) O 0 1.2984473052313206e-08
truncating O 0 2.5848836230579764e-05
mutations O 0 8.989297839434585e-07
in O 0 3.7368991456787626e-08
140 O 0 2.5546415827193414e-07
mutant O 0 3.312158150947653e-05
alleles O 0 7.331841061386513e-06
screened O 0 3.7264093407429755e-05
. O 0 4.804684522241587e-06

The O 0 1.08591802927549e-06
haplotyping O 0 0.00011172380618518218
of O 0 1.6210611875067116e-07
patients O 0 1.6455985587526811e-06
with O 0 1.4618095178775548e-07
identical O 0 0.0029269615188241005
mutations O 0 4.5286997192306444e-05
indicates O 0 1.0868815252251807e-06
that O 0 1.172896668677481e-09
almost O 0 7.56714413352455e-10
all O 0 1.2225348511307743e-10
of O 0 6.637346783300302e-10
these O 0 1.9636330339523056e-09
represent O 0 1.5900900152132635e-08
common O 0 7.770886156777124e-08
ancestry O 0 1.526008190921857e-06
and O 0 3.140272752943929e-08
that O 0 1.5272100029051217e-08
very O 0 1.4532825609592237e-08
few O 0 4.4123570575038684e-08
spontaneously O 0 3.5066018426732626e-06
recurring O 0 2.783439776976593e-05
ATM O 0 0.0014074937207624316
mutations O 0 5.058573151472956e-05
exist O 0 4.842321231990354e-06
. O 0 3.791430572164245e-06

Assays O 0 0.00021395526709966362
requiring O 0 6.052709522919031e-06
minimal O 0 2.40332292378298e-06
amounts O 0 1.3892091033085308e-07
of O 0 8.254581906896874e-09
genomic O 0 5.3046769608045e-06
DNA O 0 1.1297037190161063e-06
were O 0 5.787399892653866e-09
designed O 0 1.3408971710759943e-07
to O 0 4.059474534301444e-09
allow O 0 1.433286200835937e-08
rapid O 0 8.479300390717981e-07
screening O 0 2.7980641448266397e-07
for O 0 6.5884111499769915e-09
common O 0 1.9107963566966646e-07
ethnic O 0 8.311807846439478e-07
mutations O 0 3.2172261853702366e-05
. O 0 3.921307325072121e-06

These O 0 1.1524158480824553e-06
rapid O 0 5.9437061281641945e-06
assays O 0 5.544846135308035e-05
detected O 0 7.734042446827516e-05
mutations O 0 9.696694860394928e-07
in O 0 1.8374857191361116e-08
76 O 0 1.5963050259415468e-07
% O 0 5.292301707982006e-09
of O 0 4.531591546452773e-09
Costa O 0 8.436280040768906e-06
Rican O 0 2.9883709430578165e-05
patients O 0 8.674853120282933e-07
( O 0 7.058121642700144e-09
3 O 0 5.599356089902585e-09
) O 0 6.789189210820723e-10
, O 0 1.1274516875658946e-09
50 O 0 1.7128743978744865e-09
% O 0 1.993273990308353e-09
of O 0 3.370921985990094e-09
Norwegian O 0 0.06971719861030579
patients O 0 2.3771135602146387e-06
( O 0 6.9349126441409226e-09
1 O 0 2.6442676936966336e-09
) O 0 7.016468517306862e-10
, O 0 1.0990596210902481e-09
25 O 0 2.3379196356643206e-09
% O 0 1.5520998930540486e-09
of O 0 6.044448053188489e-09
Polish O 0 0.03486020863056183
patients O 0 2.6392615382064832e-06
( O 0 5.3527560162081045e-09
4 O 0 6.9047407791344995e-09
) O 0 1.247539738180592e-09
, O 0 1.0125088545365202e-09
and O 0 1.966871554515137e-09
14 O 0 8.632811798747753e-09
% O 0 3.5087495131591595e-09
of O 0 2.2995056969676853e-09
Italian O 0 3.0242130378610454e-05
patients O 0 2.7010298708773917e-06
( O 0 1.28184476366755e-08
1 O 0 7.520815969996875e-09
) O 0 1.8528432121911464e-09
, O 0 8.834241116417729e-10
as O 0 7.014969161112106e-10
well O 0 2.5209170306794704e-09
as O 0 2.2812716160558466e-09
in O 0 4.1489727209409466e-08
patients O 0 9.152255131539277e-08
of O 0 1.2890162714995768e-08
Amish O 0 0.0002808472781907767
/ O 0 0.00012576155131682754
Mennonite O 0 1.343350868410198e-05
and O 0 7.244229038860794e-08
Irish O 0 1.269648805646284e-06
English O 0 8.048277777561452e-07
backgrounds O 0 1.5584344509989023e-05
. O 0 3.4796814816218102e-06

Additional O 0 6.266121545195347e-06
mutations O 0 2.1218731490080245e-05
were O 0 2.9173580884389594e-08
observed O 0 8.957755426308722e-08
in O 0 5.693622462388248e-09
Japanese O 0 6.417039344341902e-08
, O 0 1.3032658507938777e-08
Utah O 0 4.779994924319908e-07
Mormon O 0 5.6687888161377487e-08
, O 0 4.445248613649255e-09
and O 0 4.312971757514106e-09
African O 0 6.05252594709782e-08
American O 0 1.047940600074071e-06
patients O 0 7.361575626418926e-06
. O 0 4.956670181854861e-06

These O 0 6.816683253418887e-07
assays O 0 3.7707577575929463e-06
should O 0 2.6502929628691163e-08
facilitate O 0 2.9024944225852778e-08
screening O 0 1.7190930634569668e-07
for O 0 1.920057002280373e-08
A B-Disease 0 6.913910328876227e-05
- I-Disease 1 0.9835302233695984
T I-Disease 1 0.9994823932647705
heterozygotes O 0 5.8198507758788764e-05
in O 0 2.8439133714641684e-08
the O 0 4.2467636518495055e-08
populations O 0 4.6847483758938324e-07
studied O 0 6.410024298020289e-07
. O 0 1.8384116629022174e-07
. O 0 1.040075176206301e-06

The O 0 2.9104472559993155e-05
von B-Disease 1 0.8620662689208984
Hippel I-Disease 1 0.9938547015190125
- I-Disease 1 0.8077278733253479
Lindau I-Disease 1 0.9988669157028198
tumor I-Disease 0 0.30731767416000366
suppressor O 0 0.00030887415050528944
gene O 0 7.521980478486512e-07
is O 0 1.0674952477529587e-08
required O 0 6.3517311410521415e-09
for O 0 9.554028679303883e-09
cell O 0 6.952999683562666e-06
cycle O 0 1.2848306596424663e-06
exit O 0 8.652281167087494e-07
upon O 0 3.5218295124650467e-07
serum O 0 0.0004383469349704683
withdrawal O 0 3.6537268897518516e-05
. O 0 4.297931809560396e-06

The O 0 3.4016659355984302e-06
inactivation O 0 0.00010446745000081137
of O 0 7.915904376432081e-08
the O 0 4.6542353970835393e-07
von B-Disease 1 0.9384433627128601
Hippel I-Disease 1 0.9963688850402832
- I-Disease 1 0.7892830967903137
Lindau I-Disease 1 0.9771966934204102
( I-Disease 0 1.0939768344542244e-06
VHL I-Disease 0 0.005968690849840641
) I-Disease 0 9.915444820762787e-08
tumor I-Disease 0 2.871250944735948e-05
suppressor O 0 3.1333645893028006e-05
gene O 0 1.0402080761195975e-06
predisposes O 0 5.2084214985370636e-05
affected O 0 1.9958055474944558e-07
individuals O 0 1.5626694604975455e-08
to O 0 1.892168732808841e-08
the O 0 2.548206111896434e-06
human O 0 0.48511555790901184
VHL B-Disease 1 0.999998927116394
cancer I-Disease 1 0.999994158744812
syndrome I-Disease 1 0.9999815225601196
and O 0 1.4959488225940731e-06
is O 0 2.3701453244484583e-07
associated O 0 1.3150287259122706e-06
with O 0 1.0743419807113241e-06
sporadic B-Disease 1 0.813127875328064
renal I-Disease 1 0.9999938011169434
cell I-Disease 1 0.9999611377716064
carcinomas I-Disease 1 0.9999983310699463
( O 0 8.421041275141761e-05
RCC B-Disease 1 0.9980906844139099
) O 0 4.0419661218038527e-07
and O 0 1.69645966252574e-06
brain B-Disease 0 0.054213523864746094
hemangioblastomas I-Disease 0 0.2461562603712082
. O 0 1.1530861229402944e-05

VHL O 0 0.21765628457069397
- O 0 0.00018991036631632596
negative O 0 4.538078428595327e-06
786 O 0 5.549786510528065e-05
- O 0 0.0003709091688506305
0 O 0 5.975175099592889e-06
RCC B-Disease 1 0.505435049533844
cells O 0 8.259324886239483e-07
are O 0 6.664052421001543e-09
tumorigenic O 0 1.1349258784321137e-05
in O 0 8.690472697026053e-08
nude O 0 0.00437799422070384
mice O 0 3.1489871616940945e-05
which O 0 1.2631250712047404e-08
is O 0 5.062148478174322e-09
suppressed O 0 8.46506651441814e-08
by O 0 7.991221018244232e-09
the O 0 1.8719406469358546e-08
reintroduction O 0 1.5188492398010567e-05
of O 0 6.660324629592651e-07
VHL B-Disease 0 0.20946229994297028
. O 0 7.0418122959381435e-06

Remarkably O 0 0.0006641769432462752
, O 0 3.070994694098772e-07
this O 0 3.5527531139223356e-08
occurs O 0 9.258054944893956e-08
without O 0 7.476805841122314e-09
affecting O 0 3.4689577432800434e-08
the O 0 9.417593815896907e-09
growth O 0 6.848605949016928e-07
rate O 0 9.044333637575619e-08
and O 0 1.2600210652635724e-08
cell O 0 3.6562262266670587e-06
cycle O 0 2.5750560439519177e-07
profile O 0 1.9042981591610442e-07
of O 0 3.501515744019912e-09
these O 0 2.2467188998120946e-08
cells O 0 9.610761253497913e-07
in O 0 9.424138625035994e-08
culture O 0 1.7101957610066165e-06
. O 0 1.459348482057976e-06

The O 0 1.381956167278986e-06
786 O 0 6.332725752145052e-05
- O 0 4.700067802332342e-05
0 O 0 4.757211229389213e-07
cell O 0 1.744050791785412e-06
line O 0 2.2062810955958412e-07
, O 0 4.622882521232441e-09
like O 0 1.7822026521230327e-08
many O 0 2.6051859336462257e-08
cancer B-Disease 0 0.0011848858557641506
cells O 0 1.3250063375380705e-06
, O 0 1.2593482701106495e-08
fails O 0 1.8344378815982054e-07
to O 0 1.072684940872648e-09
exit O 0 7.550081448925994e-08
the O 0 1.5715318824049973e-08
cell O 0 5.340691132005304e-06
cycle O 0 1.0514003179196152e-06
upon O 0 2.734112740654382e-07
serum O 0 0.00023075079661794007
withdrawal O 0 1.8042303054244258e-05
. O 0 2.1272373942338163e-06

Here O 0 2.9416580673569115e-06
, O 0 5.280728743173313e-08
it O 0 3.7834131383363e-09
is O 0 1.6521386481116451e-09
shown O 0 7.708585769705678e-09
that O 0 1.0985063969570774e-09
reintroduction O 0 1.6585052264872502e-07
of O 0 1.3466987525134755e-09
the O 0 8.216193059240595e-09
wild O 0 5.548010904021794e-07
- O 0 9.875396790448576e-05
type O 0 2.1735153495683335e-05
VHL B-Disease 0 0.002751272404566407
gene O 0 1.604259409759834e-07
restores O 0 5.005332468499546e-07
the O 0 6.023203269478472e-09
ability O 0 4.289764632403603e-08
of O 0 1.5414208576203237e-08
VHL O 0 0.10347068309783936
- O 0 0.009477718733251095
negative O 0 0.00015182366769295186
RCC B-Disease 1 0.9998824596405029
cancer I-Disease 0 0.01125900074839592
cells O 0 3.140213777896861e-07
to O 0 2.3353703415551763e-09
exit O 0 1.5844035772261122e-07
the O 0 1.7742932456599192e-08
cell O 0 4.150416316406336e-06
cycle O 0 3.6780309642381326e-07
and O 0 1.994221854317857e-08
enter O 0 8.294244935314055e-07
G0 O 0 0.0028978646732866764
/ O 0 2.075539669021964e-05
quiescence O 0 8.778439951129258e-05
in O 0 5.795449737888703e-07
low O 0 4.1143324779113755e-05
serum O 0 0.010158173739910126
. O 0 7.087667199812131e-06

Both O 0 7.294222541531781e-06
VHL O 0 0.014005964621901512
- O 0 4.641460327547975e-05
positive O 0 1.9339896084602515e-07
and O 0 2.3435869422883115e-07
VHL O 0 0.014773257076740265
- O 0 0.0001251722133019939
negative O 0 3.1856141049502185e-06
RCC B-Disease 0 0.17381387948989868
cells O 0 2.359986552846749e-07
exit O 0 6.62186181443758e-08
the O 0 1.2821455896983025e-08
cell O 0 1.1567365163500654e-06
cycle O 0 2.493110855539271e-07
by O 0 3.7554908516312935e-08
contact O 0 1.4530962744174758e-06
inhibition O 0 1.4345888303068932e-05
. O 0 4.072267984156497e-06

The O 0 4.026759597763885e-06
cyclin O 0 0.0010012300917878747
- O 0 7.24549827282317e-05
dependent O 0 1.4501973737424123e-06
kinase O 0 4.527993041847367e-06
inhibitor O 0 1.2686974741882295e-06
, O 0 4.550432564087714e-08
p27 O 0 7.964494216139428e-06
, O 0 1.4699646833093993e-08
accumulates O 0 4.885888529315707e-07
upon O 0 1.767713087019729e-08
serum O 0 2.3627711925655603e-05
withdrawal O 0 3.91913630437557e-07
, O 0 1.8722541295090878e-09
only O 0 3.120256553135192e-10
in O 0 5.284088722135039e-10
the O 0 1.1865933791099792e-09
presence O 0 1.4174527329657849e-08
of O 0 1.1444472036714615e-08
VHL B-Disease 0 0.009660585783421993
, O 0 2.6368487393568785e-09
as O 0 5.215419762727436e-10
a O 0 2.3997064335645746e-09
result O 0 6.698702481600094e-09
of O 0 5.449588003081374e-10
the O 0 3.216507060699314e-09
stabilization O 0 1.3635688844715332e-07
of O 0 3.8432941273924826e-09
the O 0 3.3955611655756e-08
protein O 0 1.3283363387017744e-06
. O 0 1.4605041087634163e-06

We O 0 1.1995485920124338e-06
propose O 0 1.5307408602893702e-06
that O 0 1.520582948444371e-08
the O 0 1.1054577697677814e-08
loss O 0 2.382746231432975e-07
of O 0 3.0247482296630324e-09
wild O 0 6.410030550796364e-07
- O 0 0.0006910002557560802
type O 0 1.9539073036867194e-05
VHL B-Disease 0 0.0058682807721197605
gene O 0 1.4190871411301487e-07
results O 0 6.548835784769835e-08
in O 0 4.005207276946976e-09
a O 0 9.560627844962255e-09
specific O 0 1.272478868941107e-07
cellular O 0 0.00019834980776067823
defect O 0 5.012990004615858e-05
in O 0 1.1225517937418772e-07
serum O 0 0.011789842508733273
- O 0 0.000548662559594959
dependent O 0 3.5042307899857406e-07
growth O 0 3.19423691053089e-07
control O 0 9.257065869405778e-08
, O 0 1.749692835062433e-08
which O 0 2.791472120122762e-08
may O 0 5.606892727882951e-07
initiate O 0 1.6749525457271375e-05
tumor B-Disease 0 0.15972362458705902
formation O 0 6.535629654536024e-05
. O 0 7.167473540903302e-06

This O 0 1.3263743312563747e-06
is O 0 2.1134133021405432e-07
corrected O 0 2.5184899641317315e-06
by O 0 5.373869793601216e-09
the O 0 3.332857323457006e-09
reintroduction O 0 3.157914250095928e-07
of O 0 4.542131559759355e-09
wild O 0 5.317564841789135e-07
- O 0 0.0002966228930745274
type O 0 3.7516187148867175e-05
VHL B-Disease 0 0.09371594339609146
, O 0 6.671825758530758e-08
implicating O 0 4.264949893695302e-05
VHL B-Disease 0 0.003579620271921158
as O 0 4.282902921204368e-09
the O 0 2.6165485333962124e-09
first O 0 6.464076562906484e-08
tumor B-Disease 0 0.00014088416355662048
suppressor O 0 3.561951189112733e-06
involved O 0 6.755298098681806e-09
in O 0 2.635380802473719e-09
the O 0 3.408875404176115e-09
regulation O 0 1.040612840341737e-08
of O 0 3.392659264633835e-09
cell O 0 8.897611223801505e-06
cycle O 0 1.21714731449174e-06
exit O 0 5.068122277407383e-07
, O 0 8.025818232226811e-09
which O 0 1.4741783349592197e-09
is O 0 1.7652592720907023e-09
consistent O 0 8.935704620682827e-09
with O 0 2.269787247044519e-09
its O 0 1.4906262890690414e-08
gatekeeper O 0 1.4308491699921433e-05
function O 0 3.9697376053027256e-08
in O 0 1.386306003325899e-08
the O 0 2.0588528570897324e-07
kidney O 0 0.0016345161711797118
. O 0 7.212524906208273e-07
. O 0 3.653291514638113e-06

Piebaldism B-Disease 1 0.9981251358985901
with O 0 0.0003394894301891327
deafness B-Disease 1 0.9999831914901733
: O 0 5.068887912784703e-05
molecular O 0 0.00037721049739047885
evidence O 0 9.98858013190329e-07
for O 0 5.537862435289753e-08
an O 0 5.948747912043473e-07
expanded O 0 0.004245300777256489
syndrome O 1 0.9996756315231323
. O 0 3.636038672993891e-05

In O 0 8.987959745354601e-07
a O 0 1.2143745209414192e-07
South O 0 1.2747757693887252e-07
African O 0 9.798506539482332e-08
girl O 0 9.155342581834702e-07
of O 0 1.6724754914321238e-08
Xhosa O 0 0.0002371407172176987
stock O 0 7.495999625461991e-07
with O 0 2.786791526432353e-07
severe O 0 0.012077675200998783
piebaldism B-Disease 1 0.9108607769012451
and O 0 0.000779571128077805
profound O 1 0.9995079040527344
congenital O 1 0.9999994039535522
sensorineural B-Disease 1 0.9999991655349731
deafness I-Disease 1 0.9999994039535522
we O 0 2.672298023753683e-06
identified O 0 4.1652998561403365e-07
a O 0 2.6944947606466485e-08
novel O 0 1.5780506146256812e-07
missense O 0 1.7495115116616944e-06
substitution O 0 2.3020696460207546e-08
at O 0 2.2114681197393793e-09
a O 0 4.5870902631861554e-09
highly O 0 2.4727960123982484e-08
conserved O 0 6.354824222398747e-08
residue O 0 5.238235090132548e-08
in O 0 2.670538012949919e-09
the O 0 4.479908000121213e-09
intracellular O 0 2.4087289602903184e-06
kinase O 0 2.918820030117786e-07
domain O 0 8.306432874860548e-09
of O 0 1.7948648123322641e-09
the O 0 1.9744350154837775e-08
KIT O 0 0.00029392351279966533
proto O 0 0.0024607705418020487
- O 0 0.0069484100677073
oncogene O 0 0.0013263019500300288
, O 0 2.3280115613033558e-07
R796G O 0 2.640730599523522e-05
. O 0 1.445044972570031e-06

Though O 0 3.4639240766409785e-05
auditory B-Disease 0 0.06917062401771545
anomalies I-Disease 0 0.08379555493593216
have O 0 2.0585208915235853e-07
been O 0 5.764531962881847e-08
observed O 0 3.3167833635161514e-07
in O 0 6.908959448992391e-08
mice O 0 3.1771733119967394e-06
with O 0 4.861356828200769e-08
dominant O 0 4.91363516630372e-06
white O 0 5.4778043704573065e-05
spotting O 0 0.002061517909169197
( O 0 2.82784924365842e-07
W O 0 0.35388097167015076
) O 0 1.4765343614442372e-08
due O 0 5.536595182320525e-08
to O 0 5.3810623512617894e-08
KIT O 1 0.9351624250411987
mutations O 0 0.0018302726093679667
, O 0 1.2128936759836506e-05
deafness B-Disease 1 0.9999576807022095
is O 0 7.548108982291524e-08
not O 0 1.6925968182590623e-08
typical O 0 6.325347499114287e-07
in O 0 3.208972430002177e-07
human O 0 2.4026767277973704e-06
piebaldism B-Disease 0 0.023868490010499954
. O 0 9.151309313892853e-06

Thus O 0 4.383862687973306e-06
, O 0 1.5560792121505074e-07
the O 0 6.751745473820847e-08
occurrence O 0 2.2052678104955703e-05
of O 0 2.0157231119810604e-06
sensorineural B-Disease 1 0.999988317489624
deafness I-Disease 1 0.9999970197677612
in O 0 1.5160181874307455e-06
this O 0 7.850019301258726e-08
patient O 0 1.8582716165838065e-06
extends O 0 4.4347837047098437e-07
considerably O 0 1.3575315449543268e-07
the O 0 5.1182649229986055e-09
phenotypic O 0 4.0651104882272193e-07
range O 0 2.7909610622600667e-08
of O 0 5.452855944554358e-09
piebaldism B-Disease 0 0.00021648644178640097
due O 0 1.995927192410818e-07
to O 0 9.340777040733883e-09
KIT O 0 0.00018878142873290926
gene O 0 9.22886442822346e-07
mutation O 0 7.594246085318446e-07
in O 0 1.623726397781411e-08
humans O 0 4.5699589890091374e-08
and O 0 2.1000280625571577e-08
tightens O 0 9.789867181098089e-05
the O 0 3.936711934215964e-08
clinical O 0 3.189614744769642e-06
similarity O 0 2.2847727905173087e-06
between O 0 8.23265153826469e-08
piebaldism B-Disease 0 9.085983037948608e-05
and O 0 9.614317342254708e-09
the O 0 3.466535503093837e-09
various O 0 1.1759526685750643e-08
forms O 0 2.0650425085477764e-06
of O 0 4.147754953010008e-05
Waardenburg B-Disease 1 0.9999929666519165
syndrome I-Disease 1 0.9999402761459351
. O 0 3.555462399162934e-06
. O 0 6.486588063125964e-06

Cycloheximide O 0 0.0004893017467111349
facilitates O 0 7.01766384736402e-06
the O 0 1.0265829075706279e-07
identification O 0 2.4832090161908127e-07
of O 0 1.483954203962412e-08
aberrant O 0 1.1413599168008659e-05
transcripts O 0 1.7603061905901995e-06
resulting O 0 1.7557849218974297e-07
from O 0 3.862172359703209e-09
a O 0 1.1541846589580018e-08
novel O 0 1.1013206346888182e-07
splice O 0 4.134306436753832e-06
- O 0 7.634997746208683e-05
site O 0 1.1175309282407397e-06
mutation O 0 3.95908415384838e-07
in O 0 1.5631165695140226e-08
COL17A1 O 0 6.180800119182095e-05
in O 0 3.3004383226398204e-08
a O 0 2.600554864784499e-07
patient O 0 1.5976747818058357e-05
with O 0 5.127930307935458e-06
generalized O 0 0.13981235027313232
atrophic B-Disease 1 0.9997979998588562
benign I-Disease 1 0.998422384262085
epidermolysis I-Disease 1 0.999056875705719
bullosa I-Disease 1 0.9956644177436829
. O 0 6.658615893684328e-05

Patients O 0 0.001087120152078569
with O 0 1.2529601917776745e-05
generalized O 0 0.0056170206516981125
atrophic B-Disease 1 0.9993808269500732
benign I-Disease 1 0.9957471489906311
epidermolysis I-Disease 1 0.9991061091423035
bullosa I-Disease 1 0.9766560196876526
often O 0 8.61275566421682e-07
show O 0 7.323542376980186e-07
decreased O 0 7.063335374368762e-07
expression O 0 5.455886054051007e-08
of O 0 9.042553372751172e-09
type O 0 5.798899564979365e-06
XVII O 0 0.009038395248353481
collagen O 0 8.283168426714838e-06
, O 0 7.58939400213876e-09
a O 0 1.0816246565070742e-08
transmembrane O 0 7.393666237476282e-06
hemidesmosomal O 0 1.3143568139639683e-05
protein O 0 4.9212886210625584e-08
encoded O 0 4.685235310830649e-08
by O 0 8.797291428663812e-08
COL17A1 O 0 0.0006874572718515992
. O 0 3.6233820992492838e-06

This O 0 1.6591268376942025e-06
report O 0 3.5154710076312767e-07
documents O 0 8.582200194950929e-08
a O 0 2.8234774518409722e-08
novel O 0 7.763345166722502e-08
splice O 0 3.1938820939103607e-06
- O 0 2.2444961359724402e-05
site O 0 9.769372582013602e-07
mutation O 0 3.9181048805403407e-07
in O 0 2.020039602257384e-08
COL17A1 O 0 0.00013047995162196457
in O 0 3.025747830065484e-08
a O 0 2.542373067626613e-07
patient O 0 1.492986484663561e-05
with O 0 1.2637874533538707e-06
generalized O 0 0.027498945593833923
atrophic B-Disease 1 0.9997857213020325
benign I-Disease 1 0.9608920812606812
epidermolysis I-Disease 1 0.9990705847740173
bullosa I-Disease 1 0.9611235857009888
, O 0 1.9797849404312728e-07
and O 0 2.454235925597459e-08
applies O 0 3.450283614370164e-08
a O 0 8.764878600686643e-09
new O 0 2.6771592942509415e-08
methodology O 0 7.883480179771141e-08
to O 0 1.879918887226495e-09
define O 0 7.00154174637646e-08
and O 0 1.4408072956939577e-08
characterize O 0 1.1302231541776564e-06
the O 0 1.8795971001850376e-08
resulting O 0 1.8969301152083062e-07
mRNA O 0 6.666901981589035e-07
splice O 0 5.216333647695137e-06
variants O 0 3.1469216992263682e-06
. O 0 2.822303940774873e-06

Mutational O 0 0.005162326153367758
analysis O 0 2.417971927570761e-06
of O 0 8.049922683994737e-08
COL17A1 O 0 0.0014286728110164404
identified O 0 9.441172892366012e-07
a O 0 1.0512082582181392e-07
maternally O 0 0.000161361662321724
inherited O 0 0.000864904373884201
G O 0 8.749957487452775e-05
- O 0 8.84326800587587e-06
to O 0 1.7898676318850448e-08
- O 0 0.00036261044442653656
T O 0 0.0005084862350486219
transversion O 0 3.2073796774056973e-06
at O 0 2.299799461980001e-09
the O 0 1.2322672882092434e-09
- O 0 5.18287890827196e-07
1 O 0 4.834935563025056e-09
position O 0 6.619536474516963e-09
of O 0 1.0269134875784403e-08
exon O 0 9.140669862972572e-05
32 O 0 3.830551577266306e-06
. O 0 3.251602947784704e-06

This O 0 7.811855198269768e-07
acceptor O 0 4.911348696623463e-06
splice O 0 2.853137812053319e-05
- O 0 9.991659317165613e-05
site O 0 1.3121974689056515e-06
mutation O 0 6.923251589796564e-07
led O 0 1.4783746671298559e-08
to O 0 1.9809223150701882e-09
the O 0 2.530479381590567e-09
formation O 0 1.0789587889803443e-07
of O 0 6.275265196364899e-09
aberrant O 0 6.820631369919283e-06
transcripts O 0 1.05451920262567e-06
present O 0 5.182562290428905e-08
at O 0 1.2888777689568087e-07
extremely O 0 1.9812912341876654e-06
low O 0 9.5520299510099e-06
levels O 0 6.503069471364142e-06
. O 0 2.059376356555731e-06

Based O 0 1.8828714019036852e-06
on O 0 9.864155714467415e-08
our O 0 4.607743520068652e-08
recent O 0 6.314095202242243e-08
finding O 0 3.277197180295843e-08
that O 0 1.4857327812478616e-08
cycloheximide O 0 0.00013465927622746676
stabilized O 0 3.2469579309690744e-05
mutant O 0 5.349642833607504e-06
COL17A1 O 0 2.8694443244603463e-05
transcripts O 0 4.3387831283325795e-07
in O 0 4.3377152536550057e-08
keratinocytes O 0 9.354156645713374e-06
homozygous O 0 8.1592236256256e-07
for O 0 7.643055077721783e-09
a O 0 4.4711006808029197e-07
frameshift O 1 0.7675115466117859
mutation O 0 1.528587927168701e-05
, O 0 4.307151524329811e-09
the O 0 4.269925746314129e-09
effects O 0 8.462628642291747e-08
of O 0 1.0571549191595864e-09
the O 0 3.0753655178017425e-09
splice O 0 2.541294634283986e-06
- O 0 2.0896230125799775e-05
site O 0 3.289237042736204e-07
mutation O 0 8.09140772162209e-08
on O 0 1.732364585116386e-09
splicing O 0 1.6640939293210977e-08
of O 0 2.0156394331394267e-09
COL17A1 O 0 1.977672400244046e-05
transcripts O 0 2.184721523690314e-07
were O 0 2.9580804472573163e-09
determined O 0 9.976488080098989e-09
using O 0 3.746403187676606e-09
reverse O 0 1.991375597754086e-07
transcriptase O 0 3.3821109468590294e-07
polymerase O 0 9.094499375805754e-08
chain O 0 5.109041012474336e-08
reaction O 0 9.186144289685672e-09
of O 0 5.660021340503363e-10
total O 0 5.7670805908571765e-09
RNA O 0 2.7559210025174252e-08
from O 0 8.552994756882981e-09
keratinocytes O 0 3.5826101338898297e-06
incubated O 0 1.1343307733113761e-06
for O 0 3.2540764749455775e-08
2 O 0 3.994308315213857e-07
. O 0 1.96746327674191e-06

5 O 0 3.7375411920947954e-06
h O 0 2.5370170988026075e-05
in O 0 2.991700753796067e-08
the O 0 1.26576837899961e-08
presence O 0 9.297977499045373e-08
or O 0 1.2060965559612669e-08
absence O 0 3.552149863139675e-08
of O 0 6.089624360328116e-09
10 O 0 3.587446784081294e-08
microg O 0 4.5305834646569565e-05
cycloheximide O 0 0.00022637759684585035
per O 0 1.3249899666334386e-06
ml O 0 5.6115834013326094e-05
. O 0 2.4513806238246616e-06

Using O 0 7.166135560510156e-07
this O 0 8.177735821846e-08
approach O 0 9.100260456307296e-08
, O 0 1.2553313943897138e-08
an O 0 4.798051289611749e-09
abnormally O 0 4.0608701965538785e-06
spliced O 0 3.297901230325806e-06
transcript O 0 7.803756489010993e-06
was O 0 2.3600625453923385e-08
identified O 0 2.1755560908331972e-08
that O 0 4.169825873479027e-10
contains O 0 7.324486017701304e-10
an O 0 2.0602328176799745e-10
extra O 0 4.25866897302285e-09
264 O 0 2.9127097178616168e-08
bases O 0 1.5553041521343403e-08
upstream O 0 1.902769142247962e-08
from O 0 2.107446217536335e-09
exon O 0 1.485939037593198e-06
32 O 0 2.7449777562083e-08
, O 0 4.687592536356533e-09
resulting O 0 2.5676840209598595e-08
in O 0 1.1473366257064299e-08
a O 0 9.540338652413993e-08
premature O 0 3.0505370887112804e-05
termination O 0 8.582577720517293e-06
codon O 0 7.654772389287245e-07
27 O 0 1.2778235713994945e-07
bp O 0 1.1160600479342975e-06
downstream O 0 5.583564188782475e-08
from O 0 7.067443963393316e-09
the O 0 4.662902952645709e-08
cryptic O 0 5.110346683068201e-05
splice O 0 5.222108666202985e-05
site O 0 1.1495748367451597e-05
. O 0 2.2765252651879564e-06

Three O 0 5.707144623556815e-07
other O 0 6.012094644347599e-08
splice O 0 5.196576694288524e-06
variants O 0 5.107394258629938e-07
, O 0 1.3870968373908e-08
including O 0 2.942049492915544e-09
one O 0 1.93634108747176e-09
derived O 0 6.272201868995353e-09
from O 0 9.286733049229667e-10
the O 0 1.0638218084224604e-09
skipping O 0 3.6491641708380484e-08
of O 0 3.796338354788986e-09
exon O 0 2.4157838197425008e-05
32 O 0 1.2255739534339227e-07
, O 0 7.94647370128132e-09
were O 0 1.2068444021906544e-08
also O 0 1.3465560755321349e-07
identified O 0 3.85264320357237e-06
. O 0 3.441021817707224e-06

These O 0 1.1146443057441502e-06
results O 0 2.4311470951943193e-06
indicate O 0 2.612844980376394e-07
the O 0 8.816168239889066e-09
usefulness O 0 1.3429729506242438e-07
of O 0 8.219500635675558e-09
cycloheximide O 0 0.0003787567256949842
treatment O 0 7.527857519562531e-07
in O 0 1.4020455907370888e-08
evaluating O 0 1.3397250597790844e-07
the O 0 7.167398230478739e-09
abnormal O 0 4.3822643647217774e-07
processing O 0 6.717574496661882e-09
of O 0 6.549217279605557e-10
mRNA O 0 1.8340612584211158e-08
due O 0 5.993841867280025e-09
to O 0 7.830720516466272e-10
splice O 0 5.830846703247516e-07
- O 0 4.482015719986521e-05
site O 0 3.0177134249242954e-06
mutations O 0 1.165375579148531e-06
, O 0 1.2576343522141542e-08
because O 0 1.3069548998601022e-08
( O 0 8.450141031346448e-09
i O 0 1.7484586223304177e-08
) O 0 2.8288396070053068e-09
aberrant O 0 1.9257902295066742e-07
splicing O 0 1.2688315109699033e-07
often O 0 7.711143723554414e-09
generates O 0 4.821962207302022e-08
a O 0 4.924218188762097e-08
premature O 0 8.451806024822872e-06
termination O 0 6.298029347817646e-06
codon O 0 5.352329708330217e-07
, O 0 7.480272401494403e-09
( O 0 2.8938145213430744e-09
ii O 0 2.480723537701124e-07
) O 0 4.786040896931354e-09
transcripts O 0 8.34139726180183e-08
with O 0 2.4369905204935094e-08
premature O 0 1.6416204744018614e-05
termination O 0 2.278004103573039e-06
codons O 0 3.002476773872331e-07
can O 0 1.8923744349308436e-08
occur O 0 2.8280101815880698e-08
at O 0 9.329524708334702e-09
low O 0 8.342111641468364e-07
or O 0 2.544934432080481e-07
undetectable O 0 0.0016280945856124163
levels O 0 8.124608825710311e-07
due O 0 2.178151170539877e-08
to O 0 2.4892958805367016e-09
nonsense O 0 4.6608980142082146e-07
- O 0 2.0802881408599205e-06
mediated O 0 7.378856139439449e-07
mRNA O 0 2.4117761654451897e-07
decay O 0 7.85032398198382e-07
, O 0 2.4469335446752893e-09
and O 0 3.5800560294063644e-09
( O 0 6.7001462156213165e-09
iii O 0 1.4592524166801013e-06
) O 0 1.5152377130789318e-09
the O 0 2.003202492772971e-09
levels O 0 3.118367786214549e-08
of O 0 5.35205879614864e-10
these O 0 1.6266301638978575e-09
transcripts O 0 1.0257784310852003e-07
can O 0 6.026938059733311e-09
be O 0 2.2394530674318958e-09
increased O 0 4.9771248455954265e-08
by O 0 1.8732646367425332e-07
cycloheximide O 0 0.0031061882618814707
. O 0 3.6070330224902136e-06

A O 0 1.3612288057629485e-05
deletion O 0 0.001353836734779179
mutation O 0 6.685224070679396e-05
in O 0 2.8304287980063236e-07
COL17A1 O 0 0.0005532991490326822
in O 0 6.542818198340683e-08
five O 0 5.6799908776383745e-08
Austrian O 0 8.976053504738957e-05
families O 0 5.486084546646453e-07
with O 0 1.3775323850495624e-06
generalized O 0 0.0027264172676950693
atrophic B-Disease 1 0.9996547698974609
benign I-Disease 1 0.9918547868728638
epidermolysis I-Disease 1 0.9992519021034241
bullosa I-Disease 1 0.9725439548492432
represents O 0 2.9771313165838365e-06
propagation O 0 6.950209012757114e-07
of O 0 2.1507064573711432e-08
an O 0 5.558741733580064e-08
ancestral O 0 0.0003550719702616334
allele O 0 8.901180990505964e-05
. O 0 2.6024079033959424e-06

Patients O 0 0.0007731086225248873
with O 0 1.048797093972098e-05
generalized O 0 0.008345505222678185
atrophic B-Disease 1 0.9993342757225037
benign I-Disease 1 0.9919369220733643
epidermolysis I-Disease 1 0.9994820952415466
bullosa I-Disease 1 0.994831383228302
, O 0 6.446248335123528e-07
a O 0 1.1574158520488709e-07
usually O 0 5.48468328531726e-08
nonlethal O 0 3.827185082627693e-06
form O 0 2.1520160942145594e-07
of O 0 2.0290450208904076e-07
junctional B-Disease 1 0.9818429350852966
epidermolysis I-Disease 1 0.9988387227058411
bullosa I-Disease 1 0.9902462959289551
, O 0 3.381033764071617e-07
have O 0 4.4946396826617274e-08
generalized O 0 1.8882408312492771e-06
blistering B-Disease 0 0.003534117713570595
, O 0 6.400979600584833e-06
nail B-Disease 1 0.9998257756233215
dystrophy I-Disease 1 0.9998397827148438
, O 0 8.945207082433626e-05
patchy B-Disease 1 0.9972071051597595
alopecia I-Disease 1 0.9999202489852905
, O 0 8.986495231511071e-06
and O 0 0.00012443793821148574
dental B-Disease 1 0.9997126460075378
abnormalities I-Disease 1 0.9990932941436768
. O 0 9.350154141429812e-05

Skin B-Disease 1 0.8961641192436218
fragility I-Disease 0 0.44004833698272705
in O 0 9.83486529548827e-07
most O 0 1.1166493862901916e-07
cases O 0 2.2940842825391883e-07
is O 0 4.7347434417588374e-08
due O 0 1.584287332434542e-07
to O 0 3.031455619861845e-08
mutations O 0 1.0968989272441831e-06
in O 0 7.586527850378388e-09
the O 0 4.572982437167639e-09
gene O 0 5.324329066525024e-08
encoding O 0 1.9669030848490365e-07
type O 0 7.884839760663453e-06
XVII O 0 0.04088268056511879
collagen O 0 0.00010006982483901083
( O 0 3.915908450835559e-07
COL17A1 O 0 0.001173520926386118
) O 0 3.245993411837844e-07
. O 0 1.088367866941553e-06

Recently O 0 3.7424495531013235e-05
, O 0 2.214519270182791e-07
we O 0 3.85696239391109e-08
reported O 0 1.7597845669570233e-07
five O 0 1.6441640937614466e-08
Austrian O 0 4.0558741602580994e-05
families O 0 2.682470494619338e-07
with O 0 5.981179356240318e-07
generalized O 0 0.0027204547077417374
atrophic B-Disease 1 0.9996838569641113
benign I-Disease 1 0.9719638824462891
epidermolysis I-Disease 1 0.9982074499130249
bullosa I-Disease 1 0.8444508910179138
who O 0 4.2977126213372685e-07
share O 0 1.7318789957698755e-07
the O 0 6.684460629458044e-08
same O 0 1.283091933146352e-06
COL17A1 O 0 0.04095660150051117
mutation O 0 0.00012422916188370436
. O 0 4.964192157785874e-06

Affected O 0 4.662612991523929e-05
individuals O 0 4.833522666558565e-07
in O 0 5.1570829384672834e-08
three O 0 2.054231451609212e-08
families O 0 6.166664689999379e-08
are O 0 8.20753065511326e-09
homozygous O 0 6.62503282455873e-07
for O 0 1.668126792253588e-08
4003delTC O 0 7.519534119637683e-05
, O 0 1.7991567347053206e-08
whereas O 0 3.615080146346372e-08
those O 0 2.1383035342381618e-09
in O 0 3.918430913074644e-09
two O 0 6.6240835039366175e-09
others O 0 9.443300541533972e-08
are O 0 7.934996659741955e-08
compound O 0 1.9399227312533185e-05
heterozygotes O 0 0.0011006660060957074
. O 0 7.111146715033101e-06

To O 0 5.803131557513552e-07
determine O 0 5.645611054205801e-07
if O 0 2.2704076840796006e-08
the O 0 6.215679970722476e-09
occurrence O 0 6.022700063113007e-07
of O 0 3.902499656760483e-09
4003delTC O 0 9.554609277984127e-06
in O 0 1.472071708974454e-08
these O 0 5.063751640221881e-09
unrelated O 0 4.36799041381164e-07
families O 0 7.305838067850345e-08
signifies O 0 1.922686578836874e-06
propagation O 0 4.3580246966712366e-08
of O 0 8.274519402995395e-10
an O 0 4.309000267710417e-09
ancestral O 0 3.228370405850001e-05
allele O 0 1.9686681298480835e-06
or O 0 1.2056364795398622e-08
a O 0 3.657023839309659e-08
mutational O 0 0.0001986590796150267
hot O 0 1.8639317431734526e-06
spot O 0 1.124741629610071e-06
, O 0 4.7932331881384016e-08
haplotypes O 0 6.070103609090438e-06
were O 0 8.793445971377878e-09
determined O 0 6.139308794672615e-08
for O 0 3.587766750356991e-09
polymorphisms O 0 5.19721606906387e-06
both O 0 8.114448668550267e-09
within O 0 1.9071947576776438e-08
and O 0 2.3342410315763118e-07
flanking O 0 0.04230289161205292
COL17A1 O 1 0.8138213753700256
. O 0 8.565226380596869e-06

Five O 0 5.150239758222597e-06
intragenic O 0 0.0005205631605349481
polymorphisms O 0 3.2803029171191156e-05
were O 0 3.2286667561720606e-08
chosen O 0 7.071748342468709e-08
based O 0 3.8309785566070786e-08
on O 0 2.9679211976940678e-08
their O 0 3.445871641361009e-07
informativeness O 0 0.0023875045590102673
. O 0 4.620972504199017e-06

One O 0 3.7196585367382795e-07
of O 0 3.091965083967807e-08
these O 0 1.7904138616131604e-08
, O 0 7.755246222984624e-09
not O 0 3.1925659893516922e-09
previously O 0 1.0830412833229275e-07
reported O 0 5.683805284206755e-07
, O 0 1.1765853180634167e-08
was O 0 1.1269921884604628e-08
2988 O 0 4.051362338941544e-06
A O 0 2.6675154529698375e-08
or O 0 2.502163987117001e-08
C O 0 2.41233749420644e-07
that O 0 1.4783372304094655e-09
introduces O 0 2.975681034911304e-08
a O 0 6.866313295716964e-09
new O 0 2.2269015076403775e-08
restriction O 0 2.186642866774946e-08
site O 0 3.189530417557762e-08
for O 0 1.6031727056997624e-08
Eco0109 O 0 1.786655957403127e-05
I O 0 2.6280092697561486e-06
. O 0 1.32664251850656e-06

All O 0 2.4683623678356525e-07
the O 0 1.516871463991265e-07
4003delTC O 0 1.5839179468457587e-05
alleles O 0 1.2235902886459371e-06
showed O 0 5.890213401471556e-07
the O 0 1.4290496785918094e-08
same O 0 7.834956505803348e-08
haplotype O 0 6.907650094944984e-05
for O 0 6.9217502840501766e-09
these O 0 1.5668359054643588e-08
five O 0 1.6931980439949257e-07
polymorphic O 0 0.00017576634127181023
markers O 0 0.000265478971414268
. O 0 1.3184895578888245e-05

Fourteen O 0 7.726110925432295e-05
microsatellite O 0 0.009772444143891335
polymorphisms O 0 0.000677361385896802
were O 0 1.650518015594571e-07
selected O 0 9.670728218225122e-08
based O 0 2.753640693242687e-08
on O 0 8.662566663986127e-09
their O 0 1.559549112073455e-08
high O 0 1.3460776244755834e-06
heterozygosity O 0 0.0002941477869171649
and O 0 1.3995554937196175e-08
their O 0 6.001505958863618e-09
location O 0 6.206631297800413e-08
within O 0 8.003469886830317e-09
10q23 O 0 5.604970283457078e-06
- O 0 4.6586304961238056e-05
q25 O 0 4.533120591077022e-05
near O 0 4.685683052230161e-06
COL17A1 O 0 0.0006507222424261272
. O 0 2.7136452445120085e-06

Three O 0 1.0197967412750586e-06
families O 0 5.628231178889109e-07
shared O 0 6.862322265988041e-07
microsatellite O 0 0.0012041052104905248
polymorphisms O 0 0.00013038591714575887
covering O 0 7.104640644683968e-07
at O 0 2.040594715424504e-08
most O 0 5.159234817142533e-09
19 O 0 3.005398809818871e-07
cM O 0 2.0792227587662637e-05
, O 0 1.6183188122909087e-08
whereas O 0 2.4615726346155498e-08
the O 0 1.4088402666700972e-09
others O 0 3.4185378972040326e-09
shared O 0 1.677465633065367e-08
smaller O 0 5.228333321838363e-08
regions O 0 6.169241117959245e-08
consistent O 0 4.696992661479271e-08
with O 0 2.20960028052275e-09
cross O 0 4.3425913531791593e-08
- O 0 1.8209311747341417e-06
over O 0 2.1567894137319854e-09
events O 0 1.0963133512120748e-08
during O 0 9.82865699938884e-09
passage O 0 1.9958884323045822e-08
of O 0 1.114214498443289e-09
this O 0 5.932559776766766e-09
mutation O 0 1.1975136260389263e-07
through O 0 6.267681040839079e-09
several O 0 5.139633074691119e-08
generations O 0 2.3338832306762924e-06
. O 0 1.9485814846120775e-06

These O 0 8.46127875320235e-07
results O 0 1.5492959164475906e-06
indicate O 0 5.280135155771859e-07
that O 0 1.8377800614644002e-08
4003delTC O 0 2.4525741537217982e-05
occurs O 0 8.039641841151024e-08
on O 0 5.578611794732069e-09
a O 0 1.3607091453593512e-08
single O 0 1.3475234084125987e-07
ancestral O 0 6.125924119260162e-05
allele O 0 8.588464879721869e-06
. O 0 2.3470225585242588e-07
. O 0 1.0436220918563777e-06

The O 0 4.904187335341703e-06
haptoglobin O 0 0.0010720365680754185
- O 0 0.00013019473408348858
gene O 0 2.2876422463014023e-06
deletion O 0 1.1628770153038204e-05
responsible O 0 8.733407526051451e-07
for O 0 3.772527747969434e-07
anhaptoglobinemia B-Disease 0 0.01135720033198595
. O 0 1.1312527931295335e-05

We O 0 8.323643214680487e-07
have O 0 5.097691158084672e-08
found O 0 2.1857255561030797e-08
an O 0 6.541742703092268e-09
allelic O 0 1.312569384026574e-05
deletion O 0 8.305473784275819e-06
of O 0 1.095773960457791e-08
the O 0 1.2953508132795832e-07
haptoglobin O 0 0.0016882801428437233
( O 0 3.496498734989473e-08
Hp O 0 2.833834571447369e-07
) O 0 5.217004162005878e-09
gene O 0 1.1852480774621199e-08
from O 0 2.0385240162568152e-09
an O 0 3.639931023258214e-09
individual O 0 1.339776218856059e-07
with O 0 7.604153324791696e-07
anhaptoglobinemia B-Disease 0 0.11618012934923172
. O 0 9.053185749507975e-06

The O 0 1.3692587117475341e-06
Hp O 0 6.984041192481527e-06
gene O 0 1.2203738606331171e-06
cluster O 0 1.0173692999160266e-06
consists O 0 2.715436231426338e-08
of O 0 7.370667187700519e-09
coding O 0 1.7916286196850706e-06
regions O 0 3.7539297892408285e-08
of O 0 1.7748067460132688e-09
the O 0 1.065717114556719e-08
alpha O 0 1.8265700418851338e-07
chain O 0 2.3754992639624106e-07
and O 0 3.951559968129459e-09
beta O 0 2.5797010749784022e-08
chain O 0 5.808480452174081e-08
of O 0 1.1553029644062462e-09
the O 0 1.3722657676851213e-08
haptoglobin O 0 9.075427078641951e-05
gene O 0 1.3016787647757155e-07
( O 0 2.529335629830598e-09
Hp O 0 3.122039871072957e-08
) O 0 7.811820079695053e-10
and O 0 3.1857330662354855e-10
of O 0 2.8126226347957584e-10
the O 0 4.080823234886566e-09
alpha O 0 1.1770639218866563e-07
chain O 0 1.4823409344444372e-07
and O 0 3.807897996921383e-09
beta O 0 1.404047367259409e-08
chain O 0 2.8518545747147073e-08
of O 0 9.142023249530951e-10
the O 0 2.7474291286466723e-08
haptoglobin O 0 0.00045162587775848806
- O 0 6.219361966941506e-05
related O 0 1.5296508308892953e-06
gene O 0 3.9990268874134927e-07
( O 0 1.649481973231559e-08
Hpr O 0 7.750092481728643e-05
) O 0 4.502179073995194e-09
, O 0 1.6824570625573187e-09
in O 0 8.955941765975695e-09
tandem O 0 3.149468057017657e-06
from O 0 7.195615214783402e-09
the O 0 1.770520441368717e-08
5 O 0 9.486971208616524e-08
side O 0 7.580368333037768e-07
. O 0 2.234898374808836e-06

Southern O 0 2.5307441319455393e-05
blot O 0 0.0003570294938981533
and O 0 3.2982677566906204e-07
PCR O 0 8.85437384567922e-06
analyses O 0 3.886489594151499e-06
have O 0 2.412088306869009e-08
indicated O 0 1.2102309199235606e-07
that O 0 1.2448752029214916e-09
the O 0 9.55601042740284e-10
individual O 0 3.417025551399888e-09
with O 0 6.669545804527388e-09
anhaptoglobinemia B-Disease 0 8.583065209677443e-05
was O 0 3.28633618096319e-08
homozygous O 0 1.6088281995507714e-07
for O 0 9.044757720566565e-10
the O 0 2.2165946855778884e-09
gene O 0 3.41199957176741e-08
deletion O 0 6.633042630710406e-07
and O 0 5.473205888506527e-09
that O 0 1.2845290386920283e-09
the O 0 4.61168925269817e-09
gene O 0 1.2006641725292866e-07
deletion O 0 3.505200993458857e-06
was O 0 6.895514825799864e-09
included O 0 5.353113508022034e-09
at O 0 5.047840812011373e-09
least O 0 1.0268620398434791e-09
from O 0 1.2076796229720799e-09
the O 0 4.443315937407988e-09
promoter O 0 2.1461248707055347e-06
region O 0 3.2990723042303216e-08
of O 0 4.187010294032234e-09
Hp O 0 4.5730675424238143e-07
to O 0 1.7040800770473652e-08
Hpr O 0 5.071373379905708e-05
alpha O 0 1.3214385319315625e-07
but O 0 3.829851547010321e-09
not O 0 1.3864878134484115e-09
to O 0 1.0678413708831158e-08
Hpr O 0 0.00021475418179761618
beta O 0 6.742974960616266e-07
( O 0 8.590273381514635e-08
Hpdel O 0 8.435467316303402e-05
) O 0 3.127222214516223e-07
. O 0 7.792866085765127e-07

In O 0 1.0436320962980972e-06
addition O 0 1.6658158585869387e-07
, O 0 1.530878890321219e-08
we O 0 2.8877604751897934e-09
found O 0 6.333753521658991e-09
seven O 0 4.955156285291196e-09
individuals O 0 3.0600002531855353e-09
with O 0 1.345154032605933e-08
hypohaptoglobinemia B-Disease 0 0.0005599049618467689
in O 0 9.94159332634581e-09
three O 0 4.193708047495193e-09
families O 0 1.3648524976872523e-08
, O 0 2.8100073379278e-09
and O 0 3.902618672668723e-09
the O 0 7.328304185705292e-09
genotypes O 0 2.757996071522939e-06
of O 0 9.56899670612188e-10
six O 0 3.3249585307260077e-09
of O 0 1.0014727935825363e-09
the O 0 7.127889389835218e-09
seven O 0 2.9842919246902966e-08
individuals O 0 5.9392846196715254e-09
were O 0 4.91278928649308e-09
found O 0 2.1343197431633598e-08
to O 0 5.8973150807162256e-09
be O 0 6.458851231627705e-08
Hp2 O 0 0.013310686685144901
/ O 0 0.0005482733249664307
Hpdel O 0 0.001040762523189187
. O 0 4.581602752296021e-06

The O 0 7.507578175136587e-06
phenotypes O 0 0.001138998894020915
and O 0 6.222171009540034e-07
genotypes O 0 9.481430606683716e-05
in O 0 3.480575827552457e-08
one O 0 2.593622427937703e-09
of O 0 1.3104187734924722e-09
these O 0 1.5368991634900908e-09
three O 0 4.418705401576517e-09
families O 0 1.9305964826799027e-08
showed O 0 3.380247335371678e-07
the O 0 4.875896575384786e-09
father O 0 1.9978581633495196e-07
to O 0 2.344707317192274e-09
be O 0 7.297173088005593e-09
hypohaptoglobinemic B-Disease 0 0.00016782083548605442
( O 0 2.5106542622665984e-08
Hp2 O 0 9.024402970680967e-06
) O 0 3.057071928935784e-09
and O 0 7.523786038632352e-09
Hp2 O 0 7.412351260427386e-05
/ O 0 4.300366981624393e-06
Hpdel O 0 2.1281735826050863e-05
, O 0 2.474908500360584e-09
the O 0 2.5692796778997717e-09
mother O 0 1.169217824781299e-07
to O 0 1.7104518912347544e-09
be O 0 1.7826097264972418e-09
Hp2 O 0 4.867197731073247e-06
- O 0 2.505096972527099e-06
1 O 0 6.927112661259116e-09
and O 0 8.198252743341072e-09
Hp1 O 0 5.270678593660705e-05
/ O 0 3.798738134719315e-06
Hp2 O 0 7.4931358540197834e-06
, O 0 1.356670886742961e-09
one O 0 2.9895588782302696e-10
of O 0 3.3974234536771064e-10
the O 0 9.123941047128881e-10
two O 0 2.0964892044617045e-09
children O 0 1.5395933417039487e-08
to O 0 3.6617402443539504e-09
be O 0 1.8088567088625496e-08
hypohaptoglobinemic B-Disease 0 0.0003053116670344025
( O 0 2.9126210776553307e-08
Hp2 O 0 1.851932938734535e-05
) O 0 2.7971307492435926e-09
and O 0 3.7927772034151985e-09
Hp2 O 0 5.657918154611252e-05
/ O 0 1.060244449035963e-05
Hpdel O 0 6.623278750339523e-05
, O 0 2.797355014294567e-09
and O 0 8.017460584319736e-10
the O 0 1.0566770791697877e-09
other O 0 2.2305350899642917e-09
child O 0 2.9857497452212556e-07
to O 0 2.876853200106666e-09
be O 0 5.460661700595892e-09
Hp1 O 0 1.4948571333661675e-05
and O 0 3.751638999460738e-08
Hp1 O 0 0.00014897932123858482
/ O 0 1.619568865862675e-05
Hpdel O 0 0.00011941510456381366
, O 0 1.1701443369815934e-08
showing O 0 2.2214128136965883e-07
an O 0 6.805632501993841e-09
anomalous O 0 3.9152226236183196e-05
inheritance O 0 2.2901785996509716e-06
of O 0 4.975056100420261e-08
Hp O 0 2.8333037334959954e-05
phenotypes O 0 0.00021561507310252637
in O 0 4.960170585377455e-08
the O 0 6.25618170602138e-08
child O 0 5.928229256824125e-06
with O 0 1.1780515478676534e-06
Hp1 O 0 0.03574752062559128
. O 0 7.83249743108172e-06

The O 0 3.704231403389713e-06
Hp2 O 0 0.0023489068262279034
/ O 0 0.00016764778411015868
Hpdel O 0 0.0001625882723601535
individuals O 0 5.9181868294899687e-08
had O 0 2.4892068850590476e-08
an O 0 8.504744464232772e-09
extremely O 0 2.7448948003439e-07
low O 0 2.486514745214663e-07
level O 0 2.3480472677306352e-08
of O 0 4.196757164010023e-09
Hp O 0 9.979781907532015e-07
( O 0 1.143482908361193e-08
mean O 0 1.0692276219970154e-07
+ O 0 2.7706846594810486e-07
/ O 0 2.5463378960921546e-07
- O 0 2.021428826992633e-06
SD O 0 4.280335269868374e-05
= O 0 2.2857338990434073e-06
0 O 0 1.288514805963814e-08
. O 0 2.952145417012275e-09
049 O 0 4.598069608618971e-06
+ O 0 4.688346280090627e-07
/ O 0 2.6811278530658456e-07
- O 0 4.4719791958414135e-07
0 O 0 1.714159658661174e-08
. O 0 6.7589587260386e-09
043 O 0 4.215658918838017e-06
mg O 0 4.9759373723645695e-06
/ O 0 1.4515103430312593e-06
ml O 0 1.5562128510282491e-06
; O 0 1.6056880269843532e-08
n O 0 1.4456005601459765e-06
= O 0 1.682851575424138e-06
6 O 0 7.065166229835995e-09
) O 0 4.458883817726189e-10
, O 0 7.374432176021628e-10
compared O 0 1.1463566984559748e-08
with O 0 1.2611888200453336e-09
the O 0 7.421791625716878e-09
level O 0 5.235847666540394e-08
( O 0 9.526947009064202e-10
1 O 0 6.575414657206125e-10
. O 0 7.655978628839932e-10
64 O 0 5.4104938307375505e-09
+ O 0 8.372255422273156e-08
/ O 0 5.670443670169334e-08
- O 0 9.164797631910915e-08
1 O 0 1.7338784852327649e-09
. O 0 1.5589177726482717e-09
07 O 0 4.3522189230316144e-07
mg O 0 3.634942004282493e-06
/ O 0 1.3220881101005943e-06
ml O 0 6.563278134308348e-07
) O 0 1.3183358849033766e-09
obtained O 0 5.8513327516607205e-09
from O 0 2.863572046152285e-09
52 O 0 8.635565507120191e-08
healthy O 0 1.2519137726485496e-07
volunteers O 0 1.5370530093150592e-07
having O 0 1.682766850308326e-07
phenotype O 0 0.0004187232116237283
Hp2 O 0 3.321552139823325e-05
, O 0 8.304152032678758e-09
whereas O 0 2.7031990867953937e-08
the O 0 8.764243553116557e-09
serum O 0 5.933616921538487e-05
Hp O 0 2.8662140039159567e-07
level O 0 7.437110038921446e-09
of O 0 5.365120570033355e-10
an O 0 1.160054718951642e-09
individual O 0 1.2217202360886859e-08
with O 0 1.0994463650604303e-07
Hp1 O 0 0.020852703601121902
/ O 0 7.630616892129183e-05
Hpdel O 0 0.00010042132635135204
was O 0 2.034819743812477e-07
0 O 0 1.0535261480981717e-06
. O 0 1.3315478781805723e-06

50 O 0 4.266807991371024e-06
mg O 0 4.6508714149240404e-05
/ O 0 1.1277736120973714e-05
ml O 0 1.0712302355386782e-05
, O 0 8.819430519224625e-09
which O 0 1.4524946800875682e-09
was O 0 1.1474367012098696e-09
approximately O 0 8.431187414892349e-10
half O 0 1.253251724619986e-09
the O 0 1.0061981248199459e-09
level O 0 4.586644397619466e-09
of O 0 1.5458483382246868e-09
Hp O 0 4.4836588131147437e-07
in O 0 1.1864921489745939e-08
control O 0 1.3882780081075907e-07
sera O 0 3.3618816814851016e-06
from O 0 7.204115970438352e-09
the O 0 5.644911738045266e-08
Hp1 O 0 0.029091889038681984
phenotype O 0 0.0002253112761536613
( O 0 5.4540207905517946e-09
1 O 0 2.380509567245781e-09
. O 0 1.6832467641947346e-09
26 O 0 3.9019358410996574e-08
+ O 0 2.089397099780399e-07
/ O 0 2.7727571705327136e-07
- O 0 8.231228889599151e-07
0 O 0 1.3229310091844582e-08
. O 0 1.4928676073111546e-09
33 O 0 2.4005039733765443e-08
mg O 0 1.8327065163248335e-06
/ O 0 1.8156525811718893e-06
ml O 0 4.193841050437186e-06
; O 0 2.392614639745716e-08
n O 0 1.8664914023247547e-06
= O 0 1.7143613604275743e-06
9 O 0 1.0697086771926934e-08
) O 0 1.151844175595329e-09
, O 0 1.4645039625449385e-09
showing O 0 1.0887453072427888e-07
a O 0 3.410789162217043e-08
gene O 0 5.076481102150865e-07
- O 0 0.00025536309112794697
dosage O 0 0.0001597273803781718
effect O 0 3.881544671457959e-06
. O 0 2.600400875962805e-06

The O 0 8.088258596217202e-07
other O 0 1.3693482969756587e-07
allele O 0 5.028757641412085e-06
( O 0 5.069862041295892e-08
Hp2 O 0 7.910599379101768e-06
) O 0 3.583293883835381e-09
of O 0 1.0056474541997318e-09
individuals O 0 7.079329567005743e-09
with O 0 2.102147966809298e-08
Hp2 O 0 0.027007469907402992
/ O 0 0.00015086100029293448
Hpdel O 0 0.0002802005910780281
was O 0 2.049405978254981e-08
found O 0 8.232804660224247e-09
to O 0 1.1797082200004638e-09
have O 0 2.3000761295577377e-09
, O 0 2.307805946344388e-09
in O 0 2.8371718308051186e-09
all O 0 1.043685471380229e-09
exons O 0 3.259987977344281e-07
, O 0 6.331785318280936e-09
no O 0 2.679468202870794e-08
mutation O 0 2.979751343445969e-07
, O 0 5.476161302198079e-09
by O 0 1.9697557362974294e-08
DNA O 0 1.5275035138984094e-06
sequencing O 0 6.854525963717606e-06
. O 0 1.1034891258532298e-06

On O 0 3.756902628992975e-07
the O 0 2.971359158721043e-08
basis O 0 5.473216990736773e-09
of O 0 1.2001524218874238e-09
the O 0 4.5426684636140635e-09
present O 0 4.019366883767361e-08
study O 0 5.961122440112376e-08
, O 0 5.611319853215946e-09
the O 0 1.8585807337601068e-09
mechanism O 0 9.952122681511355e-09
of O 0 2.5135182823987634e-09
anhaptoglobinemia B-Disease 0 2.1291052689775825e-05
and O 0 5.77646019905842e-09
the O 0 2.9723892236432903e-09
mechanism O 0 1.5916981510599726e-08
of O 0 3.703822581968552e-09
anomalous O 0 1.2649626114580315e-05
inheritance O 0 1.4821883951299242e-06
of O 0 2.97884401589954e-08
Hp O 0 3.136845043627545e-05
phenotypes O 0 0.0001587825536262244
were O 0 3.407791382414871e-08
well O 0 2.0860781546616636e-07
explained O 0 4.5831238821847364e-06
. O 0 1.917994723044103e-06

However O 0 2.0117727217439096e-06
, O 0 1.082256559925554e-07
the O 0 3.012664606671933e-08
mechanism O 0 2.3323116238316288e-07
of O 0 8.717699273574908e-08
hypohaptoglobinemia B-Disease 0 0.004048354458063841
remains O 0 2.13173043448478e-05
unknown O 0 6.082644540583715e-05

ATM O 0 0.004717614501714706
mutations O 0 0.0010623701382428408
and O 0 5.46002593182493e-06
phenotypes O 0 0.04711819067597389
in O 0 3.051776729989797e-05
ataxia B-Disease 1 0.999957799911499
- I-Disease 1 0.9994933605194092
telangiectasia I-Disease 1 0.9999746084213257
families O 0 5.71798068449425e-07
in O 0 2.2993447146291146e-08
the O 0 1.1226798157792928e-08
British O 0 4.02435375690402e-07
Isles O 0 1.729417704154912e-06
: O 0 1.4381304147548235e-08
expression O 0 8.25651902403024e-09
of O 0 9.584047999666723e-10
mutant O 0 6.845020834589377e-07
ATM O 0 1.2830148534703767e-06
and O 0 1.0645551107302254e-08
the O 0 3.379369672984467e-08
risk O 0 1.2421942301443778e-06
of O 0 2.2240421913011232e-06
leukemia B-Disease 1 0.9999885559082031
, O 0 0.14838387072086334
lymphoma B-Disease 1 0.9999995231628418
, O 0 1.819173303374555e-05
and O 0 0.0002442572731524706
breast B-Disease 1 0.9991958737373352
cancer I-Disease 1 0.9820797443389893
. O 0 2.7383779524825513e-05

We O 0 1.4135805486148456e-06
report O 0 4.7173102757369634e-07
the O 0 1.603224575319473e-08
spectrum O 0 1.2092860401935468e-07
of O 0 1.1235688823774126e-08
59 O 0 7.760567655168416e-07
ATM O 0 0.0001719218271318823
mutations O 0 2.6597745090839453e-05
observed O 0 4.828496003028704e-06
in O 0 1.7980020857066847e-05
ataxia B-Disease 1 0.9999897480010986
- I-Disease 1 0.9999604225158691
telangiectasia I-Disease 1 0.9999942779541016
( O 0 1.226612766913604e-06
A B-Disease 0 0.00043265247950330377
- I-Disease 1 0.9953725934028625
T I-Disease 1 0.9999619722366333
) O 0 4.926087626699882e-07
patients O 0 3.0127625905151945e-07
in O 0 5.8342848774373124e-08
the O 0 1.507683151658057e-07
British O 0 3.12582342303358e-05
Isles O 0 0.00022505770903080702
. O 0 9.804152796277776e-06

Of O 0 5.385235226640361e-07
51 O 0 2.8064257548976457e-06
ATM O 0 0.000642233295366168
mutations O 0 0.00010075415048049763
identified O 0 1.2042492016917095e-06
in O 0 3.5760308492172044e-08
families O 0 4.960889654626044e-08
native O 0 4.820748245037976e-08
to O 0 2.6729332081032453e-09
the O 0 5.780780298891841e-09
British O 0 5.38537449301657e-07
Isles O 0 1.9547385363694048e-06
, O 0 1.4122013780593079e-08
11 O 0 1.4967058703518887e-08
were O 0 6.555907372529646e-09
founder O 0 6.9774109761056025e-06
mutations O 0 5.432386842585402e-07
, O 0 3.813821702891573e-09
and O 0 1.256214576805803e-09
2 O 0 2.4223407724122126e-09
of O 0 5.796831348270359e-10
these O 0 3.758032995904159e-09
11 O 0 1.2149075701017864e-07
conferred O 0 3.6347273635328747e-06
a O 0 1.172930637949321e-06
milder O 0 0.09663652628660202
clinical O 0 0.003920703660696745
phenotype O 0 0.003342763753607869
with O 0 2.0953548229840635e-08
respect O 0 3.092401357207564e-08
to O 0 1.6480887765624175e-08
both O 0 5.010366521673859e-07
cerebellar B-Disease 1 0.9997005462646484
degeneration I-Disease 1 0.8657420873641968
and O 0 4.0836162042978685e-06
cellular O 0 0.00032042499515227973
features O 0 2.2438842279370874e-05
. O 0 4.78936317449552e-06

We O 0 2.6390753191662952e-06
report O 0 1.0092741149492213e-06
, O 0 1.5930071484149266e-08
in O 0 7.143486691063572e-09
two O 0 6.59229559829555e-09
A B-Disease 0 2.9712386094615795e-05
- I-Disease 1 0.9764515161514282
T I-Disease 1 0.9971351623535156
families O 0 1.1609046879357265e-07
, O 0 5.865154584228094e-09
an O 0 1.4292833583340325e-09
ATM O 0 1.2094597877876367e-05
mutation O 0 1.1638283012871398e-06
( O 0 6.219736281565247e-09
7271T O 0 4.4793119968744577e-07
- O 0 1.055738357536029e-05
- O 0 0.00046679956722073257
> O 0 4.06950457545463e-05
G O 0 0.00013774982653558254
) O 0 2.691575629043541e-09
that O 0 1.7565302545818895e-09
may O 0 4.98669336934654e-08
be O 0 2.7853437334357523e-09
associated O 0 3.802268011554588e-08
with O 0 4.948318643727134e-09
an O 0 1.5793929719620792e-08
increased O 0 5.427247742773034e-06
risk O 0 4.8046936171886045e-06
of O 0 1.4010987570145517e-06
breast B-Disease 1 0.998963475227356
cancer I-Disease 0 0.36350592970848083
in O 0 1.4650696300577692e-07
both O 0 1.2584411024363362e-07
homozygotes O 0 0.010567775927484035
and O 0 3.9759137848704995e-07
heterozygotes O 0 0.0002709791297093034
( O 0 5.984168893746755e-08
relative O 0 5.448426236398518e-06
risk O 0 3.6157564409222687e-07
12 O 0 1.5495508876028907e-08
. O 0 7.14375936183842e-09
7 O 0 9.164482861478973e-08
; O 0 1.7655354156431713e-07
P O 0 0.0017234274419024587
= O 0 1.2263343705853913e-05
. O 0 9.554757873786457e-09
0025 O 0 5.901852091483306e-06
) O 0 2.1598396404698406e-09
, O 0 1.5116468077280842e-09
although O 0 3.1081053286641236e-09
there O 0 2.3923849568063815e-09
is O 0 2.4793118669208525e-09
a O 0 3.482866972603915e-08
less O 0 3.7632855764968554e-07
severe O 0 0.035205163061618805
A B-Disease 0 0.06369198113679886
- I-Disease 1 0.9999788999557495
T I-Disease 1 0.999996542930603
phenotype O 0 0.04112662002444267
in O 0 1.3589144032266631e-08
terms O 0 1.6560232296569666e-08
of O 0 2.253705000399009e-09
the O 0 3.540191428896833e-08
degree O 0 5.25965697306674e-06
of O 0 2.7906635295948945e-06
cerebellar B-Disease 1 0.9996713399887085
degeneration I-Disease 1 0.9905903339385986
. O 0 3.195433964719996e-05

This O 0 1.908595777422306e-06
mutation O 0 1.2411022908054292e-05
( O 0 5.853300066860356e-08
7271T O 0 2.3877923922555055e-06
- O 0 3.458148057688959e-05
- O 0 0.0009985360084101558
> O 0 7.588412699988112e-05
G O 0 2.4027403924264945e-05
) O 0 1.2181385899978636e-09
also O 0 4.072315262781956e-10
allows O 0 7.079785091512747e-10
expression O 0 2.3470920762491687e-09
of O 0 2.2113696984682463e-10
full O 0 7.592115380816722e-09
- O 0 1.2787845662387554e-06
length O 0 3.296267081509541e-08
ATM O 0 3.5421106758803944e-07
protein O 0 8.978415344529367e-09
at O 0 2.2616024608623775e-09
a O 0 8.156623820809727e-09
level O 0 8.87987923192668e-08
comparable O 0 5.595493917098793e-07
with O 0 6.737592261885084e-09
that O 0 2.420947176062782e-08
in O 0 3.2466931543240207e-07
unaffected O 0 0.0001488990819780156
individuals O 0 8.449578103864042e-07
. O 0 2.6576740310702007e-06

In O 0 1.6912966884774505e-06
addition O 0 1.7354352621623548e-07
, O 0 2.0734173489245222e-08
we O 0 7.686328018507993e-09
have O 0 6.759139026257799e-09
studied O 0 8.424652975236313e-08
18 O 0 4.51888872987638e-08
A B-Disease 0 2.5025108698173426e-05
- I-Disease 1 0.99964439868927
T I-Disease 1 0.9999954700469971
patients O 0 8.047279152378906e-06
, O 0 7.005079183386442e-09
in O 0 7.394943768446183e-09
15 O 0 1.5427385591237908e-08
families O 0 2.3587572783867472e-08
, O 0 7.072530650020781e-08
who O 0 4.991031801182544e-06
developed O 0 0.15376907587051392
leukemia B-Disease 1 0.9999887943267822
, O 0 0.04812353104352951
lymphoma B-Disease 1 0.9999996423721313
, O 0 2.4323435354745016e-06
preleukemic O 0 0.30843690037727356
T O 0 0.1316038817167282
- O 0 0.002646876499056816
cell O 0 0.00022152512974571437
proliferation O 0 0.00011082486162194982
, O 0 8.359695584658766e-07
or O 0 0.0009334076894447207
Hodgkin B-Disease 1 0.9999991655349731
lymphoma I-Disease 1 0.9999995231628418
, O 0 1.044223495227925e-06
mostly O 0 1.3549174582294654e-07
in O 0 1.1935259180972935e-06
childhood O 0 0.002145718550309539
. O 0 1.836503724916838e-05

A O 0 1.7181454268211382e-06
wide O 0 5.704048362531466e-07
variety O 0 1.2224386125581077e-07
of O 0 2.3574980190232964e-08
ATM O 0 0.00021169977844692767
mutation O 0 1.8404220099910162e-05
types O 0 2.0826828972531075e-07
, O 0 1.5913521167476574e-08
including O 0 1.3909867391248554e-07
missense O 0 0.04048258438706398
mutations O 0 6.71684165354236e-06
and O 0 2.6041028888812434e-08
in O 0 3.179605201353297e-08
- O 0 9.028736531035975e-05
frame O 0 0.00018338403606321663
deletions O 0 1.660505404288415e-05
, O 0 2.756993566777055e-08
were O 0 7.211277797125604e-09
seen O 0 3.211954435755615e-07
in O 0 9.386089772078776e-08
these O 0 1.508490043988786e-07
patients O 0 1.0547150850470643e-05
. O 0 6.547008979396196e-06

We O 0 4.390069534565555e-07
also O 0 2.8656060635512404e-08
show O 0 2.2589221160274064e-08
that O 0 2.5486242005712256e-09
25 O 0 4.080403126494048e-09
% O 0 1.254359061064747e-09
of O 0 7.652883327047277e-10
all O 0 4.408140519274184e-09
A B-Disease 0 0.00014126689347904176
- I-Disease 1 0.9986794590950012
T I-Disease 1 0.9999724626541138
patients O 0 1.50379594288097e-06
carried O 0 1.2526733428330772e-07
in O 0 1.962615492345776e-08
- O 0 1.667284050199669e-05
frame O 0 1.4697771803184878e-05
deletions O 0 5.609093022940215e-06
or O 0 1.38538794658416e-07
missense O 0 0.00032917215139605105
mutations O 0 1.5413994560731226e-06
, O 0 2.3395609893839264e-09
many O 0 2.6477434134086764e-10
of O 0 7.259381984425772e-10
which O 0 6.151543274768301e-09
were O 0 6.727909340753513e-09
also O 0 1.6414601233805115e-08
associated O 0 2.3927970715931224e-08
with O 0 3.5138325582551033e-09
expression O 0 5.4479315281241725e-08
of O 0 1.3903469486820086e-08
mutant O 0 1.8711481970967725e-05
ATM O 0 3.573556386982091e-05
protein O 0 3.620656798375421e-06
. O 0 1.4219973536455655e-06

The O 0 3.741902901310823e-06
DMPK O 0 0.00043964083306491375
gene O 0 5.420099569164449e-06
of O 0 6.758515382898622e-07
severely O 0 0.0767211988568306
affected O 0 0.05273435637354851
myotonic B-Disease 1 0.9999984502792358
dystrophy I-Disease 1 0.9999984502792358
patients O 0 0.0033117742277681828
is O 0 4.136532538723259e-07
hypermethylated O 0 0.0004913207958452404
proximal O 0 1.0282431503583211e-05
to O 0 1.9179378085709686e-08
the O 0 2.4613191484945673e-08
largely O 0 1.6239160061104485e-07
expanded O 0 1.5392445220641093e-06
CTG O 0 0.0006816770182922482
repeat O 0 3.1008861697046086e-05
. O 0 1.8332973468204727e-06

Using O 0 1.632888938729593e-06
methylation O 0 1.2467524356907234e-05
- O 0 2.232754195574671e-05
sensitive O 0 1.4732227100466844e-06
restriction O 0 1.8616475472299499e-07
enzymes O 0 7.464156936975996e-08
, O 0 5.029973770831475e-09
we O 0 1.905597457607655e-09
characterized O 0 4.684618559736009e-08
the O 0 5.248823597980845e-09
methylation O 0 5.758904535468901e-07
pattern O 0 1.1297010615862746e-07
on O 0 1.648405523191343e-09
the O 0 8.917550586851064e-10
5 O 0 3.5969618394915415e-09
side O 0 3.373366030956504e-09
of O 0 1.1244793984843682e-09
the O 0 1.819032036110002e-08
CTG O 0 7.422260387102142e-05
repeat O 0 7.203465202110237e-07
in O 0 3.5209173354644463e-09
the O 0 3.649399005212217e-09
DMPK O 0 1.942984999914188e-05
gene O 0 1.2585343434068363e-08
of O 0 1.3255065933748256e-09
normal O 0 3.861732622567615e-08
individuals O 0 6.1636522552532824e-09
and O 0 7.67727392769757e-09
of O 0 9.74910463469314e-08
patients O 0 0.00014161552826408297
affected O 0 7.39191091270186e-06
with O 0 0.00046781764831393957
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999964237213135
, O 0 5.74759667415492e-07
showing O 0 1.7024256067088572e-06
expansions O 0 2.354003527216264e-06
of O 0 9.652186605535462e-09
the O 0 1.175829709154641e-07
repetitive O 0 0.0002480963885318488
sequence O 0 6.321642104012426e-06
. O 0 1.7471488718001638e-06

The O 0 7.08430263784976e-07
gene O 0 1.4072237490836415e-06
segment O 0 9.464404229220236e-07
analyzed O 0 8.603471428614284e-07
corresponds O 0 1.4551415006280877e-07
to O 0 4.033365197386729e-09
the O 0 1.2738674115553295e-08
genomic O 0 3.4439899536664598e-06
SacI O 0 8.059502579271793e-05
- O 0 1.0752259186119772e-05
HindIII O 0 1.0308805030945223e-05
fragment O 0 7.461408131348435e-07
carrying O 0 1.635123680898687e-07
exons O 0 7.916582376310544e-07
11 O 0 2.0766022146290197e-07
- O 0 1.931020597112365e-05
15 O 0 1.020619833980163e-06
. O 0 1.7020439599946258e-06

There O 0 1.6064241208368912e-06
is O 0 1.2328220577728644e-07
constitutive O 0 4.522330527834129e-06
methylation O 0 2.5698798253870336e-06
in O 0 4.085256577468499e-08
intron O 0 2.609584953461308e-05
12 O 0 3.189968467154358e-08
at O 0 3.6505825029564676e-09
restriction O 0 6.399033747328531e-09
sites O 0 5.378279155365817e-09
of O 0 1.5446752765768679e-09
SacII O 0 2.24177711061202e-05
and O 0 1.674598237855207e-08
HhaI O 0 1.2166877240815666e-05
, O 0 3.863307007634376e-09
localized O 0 6.371997329779333e-08
1 O 0 3.0128122219252873e-09
, O 0 1.2372742830280004e-09
159 O 0 7.768129250962374e-08
- O 0 3.2643201848259196e-06
1 O 0 8.221726410795327e-09
, O 0 3.026381589776861e-09
232 O 0 6.771955440854072e-08
bp O 0 1.1729340485544526e-06
upstream O 0 2.8244954819456325e-08
of O 0 7.431377180289189e-10
the O 0 6.3066787348020625e-09
CTG O 0 3.226711123716086e-05
repeat O 0 8.718361641513184e-07
, O 0 7.64439711531395e-09
whereas O 0 1.6087353671423443e-08
most O 0 1.2039170771416252e-09
, O 0 1.9792869565549154e-09
if O 0 2.036060431365172e-09
not O 0 2.7857938178499353e-10
all O 0 1.7155317444395024e-10
, O 0 6.266435148560845e-10
of O 0 2.978653435015133e-10
the O 0 1.1098917340746084e-09
other O 0 6.45753950312411e-10
sites O 0 6.330094226569827e-09
of O 0 2.0574968395692395e-09
SacII O 0 4.052912481711246e-05
, O 0 1.9987609789495764e-08
HhaI O 0 1.2551116924441885e-05
, O 0 2.7622029108442803e-09
and O 0 4.6303476608500205e-09
HpaII O 0 9.962531294149812e-06
in O 0 1.133208638037786e-08
this O 0 4.032042255630586e-09
region O 0 4.5402458681564895e-08
are O 0 6.329418766881645e-09
unmethylated O 0 3.3946093026315793e-05
, O 0 1.7044344602368255e-08
in O 0 1.1914494280063082e-08
normal O 0 6.807854902035615e-08
individuals O 0 4.966520528171259e-09
and O 0 6.468809932158592e-09
most O 0 4.061333047644666e-09
of O 0 8.299243070553075e-09
the O 0 1.4073822285354254e-06
patients O 0 3.0408360544242896e-05
. O 0 7.18216460882104e-06

In O 0 9.673694876255468e-07
a O 0 1.0223348567706125e-07
number O 0 2.7620254527960242e-08
of O 0 1.4510805890211032e-08
young O 0 9.82706524155219e-07
and O 0 1.4230894294087193e-06
severely O 0 0.00442478246986866
affected O 0 8.31513443699805e-06
patients O 0 1.8328131545786164e-06
, O 0 4.900307715161034e-08
however O 0 1.4811857518282068e-08
, O 0 4.604991055146002e-09
complete O 0 2.2640548991148535e-08
methylation O 0 1.2409766725340887e-07
of O 0 6.627112747459307e-10
these O 0 9.544407486572482e-10
restriction O 0 8.000860418633238e-09
sites O 0 1.599294030540932e-08
was O 0 4.8143871111960834e-09
found O 0 1.097618973489034e-08
in O 0 1.269588700836266e-08
the O 0 8.604851586824225e-08
mutated O 0 7.708653720328584e-05
allele O 0 2.4183907953556627e-05
. O 0 1.5774186294947867e-06

In O 0 5.756652967647824e-07
most O 0 2.5404235159953714e-08
of O 0 7.418125669289566e-09
these O 0 3.9923421013554616e-08
patients O 0 4.986408725926594e-07
, O 0 1.8917321042977164e-08
the O 0 3.0168159526056115e-08
onset O 0 7.327998901018873e-05
of O 0 1.568639760307633e-07
the O 0 6.492060492746532e-05
disease O 1 0.80186927318573
was O 0 0.0004033686709590256
congenital O 1 0.9997889399528503
. O 0 0.00017822167137637734

Preliminary O 0 4.5348453568294644e-05
in O 0 2.145357484550914e-06
vivo O 0 0.0009318228112533689
footprinting O 0 0.21698372066020966
data O 0 6.615499046347395e-07
gave O 0 2.3174184349272764e-08
evidence O 0 1.5184847157456716e-08
for O 0 1.6969597949056947e-09
protein O 0 6.644407335443248e-08
- O 0 7.860993719077669e-06
DNA O 0 6.704028123749595e-07
contact O 0 7.50072004507274e-08
in O 0 1.9286311214727903e-08
normal O 0 6.436420108002494e-08
genes O 0 1.3087110062315332e-08
at O 0 2.47835685307507e-09
an O 0 2.314007430115339e-09
Sp1 O 0 1.0455248684593244e-06
consensus O 0 2.010552790920883e-08
binding O 0 5.887809706450753e-08
site O 0 2.9955437241824256e-08
upstream O 0 1.1771824404149811e-08
of O 0 4.822913735047507e-10
the O 0 5.911550360337969e-09
CTG O 0 4.155518763582222e-05
repeat O 0 5.687948032573331e-07
and O 0 2.716185720785802e-09
for O 0 7.126825796177627e-10
a O 0 9.627181718485645e-09
significant O 0 5.0792991146408895e-08
reduction O 0 1.9424757624619815e-07
of O 0 1.6940492342243374e-09
this O 0 3.299322592908993e-09
interaction O 0 2.184062708465717e-08
in O 0 3.699694417491628e-08
cells O 0 1.469753669880447e-07
with O 0 7.267199286786763e-09
a O 0 1.0829751317942282e-07
hypermethylated O 0 0.003288772189989686
DMPK O 0 0.0028265102300792933
gene O 0 1.0740510560935945e-06
. O 0 9.018442881369992e-08
. O 0 8.500513786202646e-07

The O 0 4.933868331136182e-05
hemochromatosis B-Disease 1 0.9992092251777649
gene O 0 1.2929437616548967e-05
product O 0 1.1128004189231433e-06
complexes O 0 1.8223573761133594e-06
with O 0 2.286936329198852e-08
the O 0 3.3283676259543427e-08
transferrin O 0 0.00011482548143249005
receptor O 0 5.752581273554824e-07
and O 0 2.6724400470357068e-08
lowers O 0 3.781053237617016e-06
its O 0 9.847252790962102e-09
affinity O 0 2.2512321606882324e-07
for O 0 4.8274099384570945e-08
ligand O 0 1.8454467863193713e-05
binding O 0 1.0030610610556323e-05
. O 0 2.9118434667907422e-06

We O 0 1.961216185009107e-06
recently O 0 2.177164105887641e-06
reported O 0 1.6790973234037665e-07
the O 0 8.156623820809727e-09
positional O 0 6.484735877165804e-07
cloning O 0 2.5173031303893367e-07
of O 0 2.9773146170697373e-09
a O 0 4.316726887054756e-08
candidate O 0 2.772066864054068e-06
gene O 0 2.5978874873544555e-06
for O 0 4.6124264372338075e-06
hereditary B-Disease 1 0.9999809265136719
hemochromatosis I-Disease 1 0.9999995231628418
called O 0 0.04345233738422394
HFE O 1 0.9943477511405945
. O 0 4.997420546715148e-05

The O 0 9.209496170115017e-07
gene O 0 7.655780223103648e-07
product O 0 1.4380911750322412e-07
, O 0 9.50489997819659e-09
a O 0 7.745711627649143e-09
member O 0 7.062498141863216e-09
of O 0 1.0758384183517933e-09
the O 0 1.0084389323594678e-08
major O 0 2.836827661667485e-07
histocompatibility O 0 0.004611094947904348
complex O 0 8.755339990784705e-07
class O 0 1.3101301021833933e-07
I O 0 6.939228569535771e-08
- O 0 9.023929123941343e-07
like O 0 2.4732628389756428e-08
family O 0 2.7748406239425094e-08
, O 0 6.492641979605196e-09
was O 0 7.88140130936199e-09
found O 0 8.795559836016764e-09
to O 0 1.5490565496989461e-09
have O 0 4.934538999634697e-09
a O 0 1.1374197583791101e-07
mutation O 0 2.466880232532276e-06
, O 0 3.2881793288197514e-08
Cys O 0 0.00013367889914661646
- O 0 3.4117570066882763e-06
282 O 0 3.8002309565854375e-07
- O 0 7.96812164480798e-05
- O 0 0.0031409957446157932
> O 0 0.00010285015014233068
Tyr O 0 6.303239933913574e-05
( O 0 6.5766467827188535e-09
C282Y O 0 3.9269815488296445e-07
) O 0 1.849164488199051e-09
, O 0 5.940154479411319e-10
in O 0 2.5201620790227253e-09
85 O 0 3.0611342793918084e-08
% O 0 1.646970204660647e-08
of O 0 2.5810397374925742e-08
patient O 0 9.132950799539685e-05
chromosomes O 0 0.0002324544475413859
. O 0 6.1889395510661416e-06

This O 0 2.516861968615558e-06
mutation O 0 2.7956686608376913e-05
eliminates O 0 2.8420697617548285e-06
the O 0 3.106968904376117e-08
ability O 0 5.3855700343774515e-08
of O 0 1.625266499161171e-08
HFE O 0 0.0010563050163909793
to O 0 1.2000614724172465e-08
associate O 0 4.515149498729443e-08
with O 0 2.1109432424282204e-08
beta2 O 0 0.0024099235888570547
- O 0 0.0023880067747086287
microglobulin O 0 0.0023148530162870884
( O 0 5.679427417248917e-08
beta2m O 0 2.4449707780149765e-05
) O 0 7.436982141229009e-09
and O 0 1.7092267157181595e-08
prevents O 0 2.1386375692600268e-07
cell O 0 9.636214599595405e-06
- O 0 0.00026086578145623207
surface O 0 9.226342081092298e-05
expression O 0 8.768894986133091e-06
. O 0 2.490485485395766e-06

A O 0 1.9317219539516373e-06
second O 0 1.2819739367841976e-06
mutation O 0 1.2797357157978695e-05
that O 0 1.3270200049930736e-08
has O 0 8.494676961845471e-09
no O 0 7.1649375321669595e-09
effect O 0 2.212114402766474e-08
on O 0 2.8316534894656797e-08
beta2m O 0 0.00020645376935135573
association O 0 4.5899987810571474e-08
, O 0 8.970798326402019e-09
H63D O 0 2.0964493160136044e-05
, O 0 4.058143154850313e-09
was O 0 3.1363445174292792e-09
found O 0 2.9966049641672043e-09
in O 0 1.5223408089681811e-09
eight O 0 1.8499335396882088e-09
out O 0 1.4622849597856202e-09
of O 0 3.036581208704092e-09
nine O 0 6.850225986454461e-07
patients O 0 2.0303239125496475e-06
heterozygous O 0 4.893806817563018e-07
for O 0 2.4452830871268816e-08
the O 0 3.293248482805211e-07
C282Y O 0 0.000512349943164736
mutant O 0 0.00024068258062470704
. O 0 7.130609446903691e-06

In O 0 1.6037330397011829e-06
this O 0 1.2660406412123848e-07
report O 0 1.908596232169657e-07
, O 0 8.0347941633363e-09
we O 0 2.714062530273509e-09
demonstrate O 0 3.558938388437127e-08
in O 0 1.1368803676248262e-08
cultured O 0 4.91913942823885e-06
293 O 0 7.76370052335551e-06
cells O 0 3.258391870986088e-06
overexpressing O 0 3.427793853916228e-05
wild O 0 2.6810127451426524e-07
- O 0 5.344981673260918e-06
type O 0 4.643067939014145e-07
or O 0 3.7122475760043017e-08
mutant O 0 1.9398765289224684e-05
HFE O 0 0.0007177267107181251
proteins O 0 1.5729742841585903e-08
that O 0 1.343276601062371e-09
both O 0 6.05434424816309e-10
the O 0 1.9375159254764185e-09
wild O 0 8.115627991855945e-08
- O 0 9.430065802007448e-06
type O 0 3.7501087035707314e-07
and O 0 5.2387846949386585e-08
H63D O 0 0.002211368642747402
HFE O 0 0.0008926452719606459
proteins O 0 6.242569838832424e-08
form O 0 7.072180352452051e-08
stable O 0 5.224634946898732e-07
complexes O 0 6.863081694064022e-07
with O 0 9.438579695597582e-09
the O 0 1.1583334469378315e-07
transferrin O 0 0.023420419543981552
receptor O 0 1.982907451747451e-05
( O 0 4.471885404200293e-07
TfR O 0 0.0017048093723133206
) O 0 2.7345168973624823e-07
. O 0 1.1737351996998768e-06

The O 0 2.6081995656568324e-06
C282Y O 0 0.0001874768058769405
mutation O 0 1.930035614350345e-05
nearly O 0 1.6361624943783681e-07
completely O 0 7.03231037846308e-08
prevents O 0 4.889524163331771e-08
the O 0 3.851843288771306e-09
association O 0 5.236484135195951e-09
of O 0 9.822298530082207e-10
the O 0 1.8706844073790307e-08
mutant O 0 1.6002426491468213e-05
HFE O 0 0.0005688520614057779
protein O 0 1.1808090505383007e-07
with O 0 3.0936757156041494e-08
the O 0 6.913704169164703e-07
TfR O 0 0.05047407001256943
. O 0 5.207043614063878e-06

Studies O 0 8.667362635605969e-06
on O 0 3.621436519551935e-07
cell O 0 2.325386776647065e-05
- O 0 0.00025428461958654225
associated O 0 1.3831810292685986e-06
transferrin O 0 3.9329232095042244e-05
at O 0 2.7101428656806092e-08
37 O 0 6.675020358670736e-08
degrees O 0 2.114078654358309e-07
C O 0 1.0210832215307164e-06
suggest O 0 6.52920419952352e-08
that O 0 1.7776187188900394e-09
the O 0 1.0139163286737585e-08
overexpressed O 0 1.5582263586111367e-05
wild O 0 3.0089609026617836e-07
- O 0 1.088033059204463e-05
type O 0 3.2607918001303915e-06
HFE O 0 0.0005819205543957651
protein O 0 1.1628914364791854e-07
decreases O 0 9.220536156817616e-08
the O 0 2.134037613288342e-09
affinity O 0 7.359796683203967e-08
of O 0 5.797895941128672e-09
the O 0 1.473890165470948e-07
TfR O 0 0.0008734509465284646
for O 0 3.0099883474576927e-07
transferrin O 0 0.019877485930919647
. O 0 4.320353127695853e-06

The O 0 4.506555796979228e-06
overexpressed O 0 0.0005849458975717425
H63D O 0 0.000679443241097033
protein O 0 6.836820602984517e-07
does O 0 2.2400692856194837e-08
not O 0 1.5116957685634702e-09
have O 0 1.3518509645038534e-09
this O 0 2.374088925449769e-09
effect O 0 2.184833469698333e-08
, O 0 1.5440978495817603e-09
providing O 0 1.3811404242503045e-09
the O 0 5.664600455368429e-10
first O 0 1.139041638786864e-09
direct O 0 2.165821300081916e-09
evidence O 0 1.488239931290991e-08
for O 0 1.1492196083651152e-09
a O 0 1.3010155619497255e-08
functional O 0 1.7838256383129192e-07
consequence O 0 2.3422060735356354e-07
of O 0 7.611079766434159e-09
the O 0 3.5681898680195445e-07
H63D O 0 0.29921165108680725
mutation O 0 9.688609861768782e-05
. O 0 4.143017122260062e-06

Addition O 0 2.0182890239084372e-06
of O 0 2.749841598870262e-07
soluble O 0 6.620658678002656e-05
wild O 0 1.6000802816051873e-06
- O 0 0.0001463351072743535
type O 0 4.954566975357011e-05
HFE O 0 0.04243944212794304
/ O 0 2.4875489543774165e-05
beta2m O 0 4.45532969024498e-05
heterodimers O 0 1.5431734937010333e-05
to O 0 1.8124516998341278e-08
cultured O 0 1.39154217322357e-05
cells O 0 5.402163765211299e-07
also O 0 1.3758456596235646e-08
decreased O 0 1.267501090751466e-07
the O 0 2.7394531088020813e-09
apparent O 0 2.8273262842049007e-07
affinity O 0 1.0711975306776367e-07
of O 0 2.0992021454446785e-09
the O 0 1.920430747759383e-08
TfR O 0 0.00013380323071032763
for O 0 7.194622675399387e-10
its O 0 2.3492734424479522e-09
ligand O 0 1.9656673089230026e-07
under O 0 1.0700189179146946e-08
steady O 0 3.3093834872488515e-07
- O 0 1.6855108697200194e-05
state O 0 1.5985611412361322e-07
conditions O 0 5.245063334768929e-07
, O 0 1.6989450957183294e-09
both O 0 1.4092622624417572e-09
in O 0 1.3218135919146334e-08
293 O 0 4.455039288586704e-06
cells O 0 6.76855847814295e-07
and O 0 5.223120425057459e-08
in O 0 9.110331120609771e-07
HeLa O 0 0.04305310547351837
cells O 0 4.1187482565874234e-05
. O 0 2.344727590752882e-06

Furthermore O 0 1.4154828022583388e-05
, O 0 6.388475526364346e-08
at O 0 2.2408043420796275e-08
4 O 0 2.3240138702362856e-08
degrees O 0 1.7546767594467383e-07
C O 0 4.838476002078096e-07
, O 0 1.985946074256617e-09
the O 0 3.2128038007783744e-09
added O 0 5.246424095162183e-08
soluble O 0 2.8912204470543656e-06
complex O 0 1.3135993981450156e-07
of O 0 1.7809929531154012e-08
HFE O 0 0.04847421869635582
/ O 0 1.6119060092023574e-05
beta2m O 0 2.0004021280328743e-05
inhibited O 0 3.007354507644777e-07
binding O 0 5.6100386558455284e-08
of O 0 9.184287108610079e-09
transferrin O 0 6.316489452729002e-05
to O 0 6.699522714370687e-08
HeLa O 0 0.0005361115327104926
cell O 0 5.3141928219702095e-05
TfR O 0 0.00019159582734573632
in O 0 1.28815349498268e-08
a O 0 5.250388213084989e-08
concentration O 0 4.404576975503005e-05
- O 0 0.0005609844229184091
dependent O 0 9.607791753296624e-07
manner O 0 6.147714429971529e-06
. O 0 2.609378725537681e-06

Scatchard O 0 7.820084283594042e-05
plots O 0 2.9461134545272216e-06
of O 0 3.8353654474576615e-08
these O 0 1.2311331509806678e-08
data O 0 7.000032553605706e-08
indicate O 0 6.576649980161164e-08
that O 0 1.2133478666243036e-09
the O 0 2.200968962640104e-09
added O 0 1.259583726209712e-08
heterodimer O 0 1.0701131031964906e-05
substantially O 0 5.743229394283844e-07
reduced O 0 1.3998331382936158e-08
the O 0 2.963942424827337e-09
affinity O 0 2.1049389431482268e-07
of O 0 8.098510306808748e-08
TfR O 0 0.000924810185097158
for O 0 4.218419462631573e-07
transferrin O 0 0.015722006559371948
. O 0 1.2222933037264738e-05

These O 0 1.3212007843321771e-06
results O 0 3.322043085063342e-06
establish O 0 2.495149544756714e-07
a O 0 1.193232890273066e-07
molecular O 0 3.527754233800806e-05
link O 0 4.040461590193445e-06
between O 0 1.3304634194355458e-07
HFE O 0 0.0014087408781051636
and O 0 8.77166872470525e-09
a O 0 7.2300356812604605e-09
key O 0 2.396533282933433e-08
protein O 0 1.495256363170938e-08
involved O 0 4.725881019851386e-09
in O 0 1.488444301145364e-08
iron O 0 0.0018508073408156633
transport O 0 1.3835887102686684e-06
, O 0 5.791640500518724e-09
the O 0 1.5212183512858246e-08
TfR O 0 0.00039841284160502255
, O 0 4.028529065891462e-09
and O 0 1.867147325640417e-09
raise O 0 1.5988181445436567e-08
the O 0 1.1595061577551746e-09
possibility O 0 1.9558290986765314e-08
that O 0 3.1585447590742888e-09
alterations O 0 4.064164329520281e-07
in O 0 1.3690135247657054e-08
this O 0 7.633730980671771e-09
regulatory O 0 2.286505832671537e-06
mechanism O 0 2.063076749436732e-07
may O 0 1.9578932253239145e-08
play O 0 6.676899033664085e-10
a O 0 1.9846511101206943e-09
role O 0 1.712960262523211e-08
in O 0 1.6087291498934064e-08
the O 0 1.680252381675018e-07
pathogenesis O 0 0.005462024826556444
of O 0 2.3554683139082044e-05
hereditary B-Disease 1 0.9999922513961792
hemochromatosis I-Disease 1 0.9999995231628418
. O 0 0.00011514135985635221
. O 0 1.0377079888712615e-05

Genomic O 0 0.0003227600536774844
organization O 0 1.974634415091714e-06
of O 0 5.985972251210114e-08
the O 0 2.3706020613190049e-07
UBE3A O 0 0.004095134790986776
/ O 0 5.233230331214145e-05
E6 O 0 4.5926193706691265e-05
- O 0 0.0003557458985596895
AP O 0 6.966897490201518e-05
gene O 0 4.311320935812546e-07
and O 0 8.058218270434736e-08
related O 0 2.9660959626198746e-06
pseudogenes O 0 0.0002719772164709866
. O 0 9.154486178886145e-06

The O 0 2.7724661322281463e-06
UBE3A O 0 0.00028776348335668445
gene O 0 1.0109349659614963e-06
encodes O 0 3.870759428536985e-07
the O 0 4.807360554082152e-08
E6 O 0 9.682476047601085e-06
- O 0 2.7226529709878378e-05
AP O 0 2.685244908207096e-06
ubiquitin O 0 9.480293670094397e-07
- O 0 5.094113021186786e-06
protein O 0 6.524685858266821e-08
ligase O 0 5.619381795440859e-07
and O 0 4.5614227950352415e-09
has O 0 4.081804227951125e-09
recently O 0 3.463390996216731e-08
been O 0 5.01529751062435e-09
shown O 0 2.4648283414308025e-08
to O 0 4.195564340392366e-09
be O 0 9.322696570279732e-08
mutated O 0 0.0032727583311498165
in O 0 0.1473911702632904
Angelman B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
patients O 0 0.0006323381094262004
who O 0 8.560012929592631e-07
lack O 0 2.1589653442788403e-06
15q11 O 0 0.0001690533390501514
- O 0 0.00025820103473961353
q13 O 0 3.6101355362916365e-05
deletions O 0 7.302087851712713e-06
or O 0 3.2283409723277146e-07
chromosome O 0 5.638963557430543e-05
15 O 0 1.0162792705159518e-06
paternal O 0 0.00035733290133066475
uniparental B-Disease 1 0.6132829189300537
disomy I-Disease 0 0.12745410203933716
. O 0 1.4988768270995934e-05

Previous O 0 1.996738683374133e-05
UBE3A O 0 0.00039148645009845495
cDNA O 0 9.528420378046576e-06
analysis O 0 1.6691473092578235e-06
has O 0 4.603219494470068e-08
shown O 0 5.204464414987342e-08
a O 0 3.333564535523692e-08
coding O 0 2.176026782763074e-06
region O 0 5.428358562653557e-08
of O 0 7.376602439990165e-09
approximately O 0 4.415000631752264e-08
2 O 0 1.641407436636655e-07
. O 0 8.278329346467217e-07

6 O 0 6.25043094260036e-06
kb O 0 8.019927918212488e-05
and O 0 5.0405699170141816e-08
a O 0 3.9512528360319266e-08
3 O 0 8.737941925573978e-08
- O 0 0.0002964510058518499
untranslated O 0 0.002142376499250531
region O 0 5.422913886832248e-07
( O 0 1.9539536211254926e-08
UTR O 0 1.4103707144386135e-05
) O 0 1.0725295096492005e-09
of O 0 6.992006418293784e-10
< O 0 3.2985855114020524e-07
50 O 0 8.657941030776328e-09
bp O 0 2.3979839625098975e-06
, O 0 3.0671700734785645e-09
whereas O 0 1.3673642662581642e-08
Northern O 0 9.100534548167616e-09
analysis O 0 4.5078847321633475e-09
has O 0 2.434169532605779e-09
indicated O 0 2.8053497302948927e-08
mRNA O 0 1.7543380081974647e-08
sizes O 0 3.4615819544114856e-08
of O 0 1.608697619559507e-09
5 O 0 2.4092560835242693e-08
- O 0 6.1890400502306875e-06
8 O 0 1.0546619932938484e-06
kb O 0 0.000772606348618865
. O 0 5.961127953924006e-06

We O 0 6.270176982070552e-07
have O 0 2.249119823716228e-08
analyzed O 0 4.078833271137228e-08
additional O 0 4.1648515747283454e-09
cDNA O 0 8.005014962009227e-08
clones O 0 9.898684538711677e-08
and O 0 4.163374534016384e-09
provide O 0 5.0909836346590964e-09
evidence O 0 1.7801710328058107e-08
for O 0 1.5348835535888838e-09
an O 0 5.356555643487582e-09
additional O 0 1.2248074199305847e-07
0 O 0 1.1984498087258544e-06
. O 0 9.330414627584105e-07

5 O 0 1.783212951522728e-06
kb O 0 9.566936569171958e-06
of O 0 6.215422132527237e-08
5 O 0 1.7826080522809207e-07
- O 0 3.969502722611651e-05
UTR O 0 0.00016313488595187664
and O 0 1.674882454949511e-08
> O 0 3.412983176076523e-07
2 O 0 9.312225657254203e-09
kb O 0 1.7658597926129005e-06
of O 0 3.315808783099783e-08
3 O 0 7.910830959190207e-07
- O 0 0.00399179058149457
UTR O 0 0.009773140773177147
. O 0 4.460855052457191e-06

We O 0 8.574581329412467e-07
have O 0 2.574687307799195e-08
established O 0 1.253962533809272e-08
the O 0 4.787182206200669e-09
genomic O 0 1.0534989769439562e-06
organization O 0 1.2936910209759844e-08
of O 0 2.7649544875885113e-09
UBE3A O 0 2.677231896086596e-05
and O 0 3.746031485007961e-09
the O 0 1.8932542200644775e-09
sequence O 0 1.4996091479702045e-08
of O 0 4.129856456813741e-09
intron O 0 8.866751886671409e-05
- O 0 0.00042976808617822826
exon O 0 0.00022311025531962514
borders O 0 7.039408501441358e-06
. O 0 2.6163709208049113e-06

We O 0 1.16576234177046e-06
have O 0 5.590245777398195e-08
also O 0 1.7992597634020058e-08
mapped O 0 7.551160479124519e-07
two O 0 6.955577891432085e-09
highly O 0 3.478963250813649e-08
homologous O 0 2.797816023303312e-07
processed O 0 2.0710623971353925e-07
pseudogenes O 0 4.2562778617138974e-06
, O 0 2.516546437902889e-08
UBE3AP1 O 0 3.640854265540838e-05
and O 0 1.966714968659744e-08
UBE3AP2 O 0 3.2645930332364514e-05
, O 0 2.1869086541670413e-09
to O 0 3.842764439987434e-10
chromosomes O 0 4.316133939141764e-08
2 O 0 1.8304536775204383e-09
and O 0 3.374479362605598e-09
21 O 0 1.9838269693650545e-08
, O 0 4.80722972540093e-09
respectively O 0 1.2642705371490592e-07
, O 0 3.493364042483904e-09
and O 0 9.396206479550528e-09
determined O 0 2.2683411771140527e-07
their O 0 1.0572566822020235e-07
genomic O 0 3.7361987779149786e-05
organization O 0 2.8268780170037644e-06
. O 0 1.639009383325174e-06

These O 0 8.155303703460959e-07
results O 0 1.480481842008885e-06
will O 0 1.9037857512671508e-08
form O 0 9.555996882681939e-09
the O 0 2.309677338274696e-09
basis O 0 3.773251933125721e-09
for O 0 1.9988017907479616e-09
studies O 0 1.807549487864435e-08
of O 0 5.972113914509691e-09
mutation O 0 2.164771103707608e-06
and O 0 8.283400632080884e-08
imprinting O 0 3.152571298414841e-05
of O 0 3.5866193570655014e-07
UBE3A O 0 0.05793493613600731
. O 0 8.640788109914865e-06

Mutation O 0 0.004644489847123623
spectrum O 0 0.00010784512414829805
and O 0 2.7189089450985193e-06
genotype O 1 0.5535430312156677
- O 1 0.6211757063865662
phenotype O 0 0.38262486457824707
analyses O 0 6.342685810523108e-05
in O 0 2.054764627246186e-05
Cowden B-Disease 1 0.9994127750396729
disease I-Disease 0 0.0976564809679985
and O 0 3.6219655612512724e-06
Bannayan B-Disease 1 0.996951699256897
- I-Disease 1 0.9999644756317139
Zonana I-Disease 1 0.9999899864196777
syndrome I-Disease 1 0.9999071359634399
, O 0 5.713205837309943e-07
two O 0 2.9099778657837305e-06
hamartoma B-Disease 1 0.9993891716003418
syndromes I-Disease 1 0.9856575131416321
with O 0 5.153688107384369e-05
germline O 1 0.9931199550628662
PTEN O 1 0.9749548435211182
mutation O 0 0.0005035896319895983
. O 0 1.285918551729992e-05

The O 0 4.1299150325357914e-05
tumour B-Disease 1 0.9989941716194153
suppressor O 0 0.008017240092158318
gene O 0 1.818020064092707e-05
PTEN O 0 0.0007986766868270934
, O 0 3.783963720138672e-08
which O 0 2.59303032379421e-08
maps O 0 3.7374729799921624e-07
to O 0 8.705901421990347e-08
10q23 O 0 0.00012339458044152707
. O 0 2.62115122495743e-06

3 O 0 9.507620006843354e-07
and O 0 3.411088300708798e-08
encodes O 0 5.54750414494265e-08
a O 0 1.6036100447536228e-08
403 O 0 1.601463424094618e-07
amino O 0 6.775004379733218e-08
acid O 0 8.477248769622747e-08
dual O 0 7.419119469886937e-07
specificity O 0 1.0647535418684129e-05
phosphatase O 0 0.011428548023104668
( O 0 3.7962607279951044e-08
protein O 0 1.930252864212889e-07
tyrosine O 0 6.21511162535171e-06
phosphatase O 0 0.08749697357416153
; O 0 6.137763648439432e-07
PTPase O 0 0.00013329209468793124
) O 0 9.15993503269874e-09
, O 0 5.1037400972120395e-09
was O 0 8.285830688237183e-09
shown O 0 3.097690637332562e-08
recently O 0 4.909616535542227e-08
to O 0 2.0111732279559646e-09
play O 0 2.846082258756155e-09
a O 0 1.1942708155743276e-08
broad O 0 2.7341570785210934e-07
role O 0 2.0137387934937578e-07
in O 0 7.895109206401685e-07
human O 0 4.0221337258117273e-05
malignancy B-Disease 1 0.8871107697486877
. O 0 1.4982595530455e-05

Somatic O 0 0.0015675191534683108
PTEN O 0 0.01763448305428028
deletions O 0 0.00020660675363615155
and O 0 1.664473984419601e-06
mutations O 0 6.950049737497466e-06
were O 0 2.878287119756351e-08
observed O 0 2.8397784035405493e-07
in O 0 1.0563515928652123e-07
sporadic B-Disease 0 0.00010513320739846677
breast I-Disease 1 0.8485013246536255
, I-Disease 0 2.8871319955214858e-05
brain I-Disease 1 0.5130453109741211
, I-Disease 0 2.1084031686768867e-05
prostate I-Disease 1 0.9931182861328125
and I-Disease 0 0.01680767349898815
kidney I-Disease 1 0.9999397993087769
cancer I-Disease 1 0.9892237782478333
cell O 0 0.0006510677631013095
lines O 0 3.6150499909126665e-06
and O 0 1.9162740727551864e-08
in O 0 1.8536217893938556e-08
several O 0 4.009948639804861e-08
primary O 0 0.001503703068010509
tumours B-Disease 1 0.9995043277740479
such O 0 5.948992338744574e-07
as O 0 1.2452564988052472e-05
endometrial B-Disease 1 0.999930739402771
carcinomas I-Disease 1 0.999998927116394
, O 1 0.9858468174934387
malignant B-Disease 1 0.9999997615814209
melanoma I-Disease 1 0.9999998807907104
and O 1 0.9932399988174438
thyroid B-Disease 1 0.9999847412109375
tumours I-Disease 1 0.9999468326568604
. O 0 0.0002730517880991101

In O 0 1.9658846213133074e-06
addition O 0 5.325954361978802e-07
, O 0 1.7003601726628403e-07
PTEN O 0 0.0003082222829107195
was O 0 5.1376531473579234e-08
identified O 0 7.219868791707995e-08
as O 0 2.9750097940706155e-09
the O 0 1.846571429098276e-08
susceptibility O 0 0.00021103813196532428
gene O 0 1.7510025429601228e-07
for O 0 2.7330038676609547e-08
two O 0 6.031216798874084e-06
hamartoma B-Disease 1 0.9999816417694092
syndromes I-Disease 1 0.9999949932098389
Cowden B-Disease 1 0.9999887943267822
disease I-Disease 1 0.906981348991394
( O 0 1.4514463941850408e-07
CD B-Disease 0 1.661449459788855e-05
; O 0 1.339357481811021e-06
MIM O 0 0.007732658181339502
158350 O 0 5.8478672144701704e-05
) O 0 7.612996455463872e-09
and O 0 2.066137660960976e-08
Bannayan B-Disease 0 0.0011816403130069375
- I-Disease 0 0.21032507717609406
Zonana I-Disease 1 0.6913431286811829
( I-Disease 0 5.033767536133382e-08
BZS I-Disease 0 9.930205123964697e-05
) I-Disease 0 9.147015589405783e-09
or I-Disease 0 2.4832981893041506e-08
Ruvalcaba I-Disease 0 0.0009775826474651694
- I-Disease 0 0.0026722268667072058
Riley I-Disease 0 0.0001386576914228499
- I-Disease 1 0.9241073131561279
Smith I-Disease 0 0.05582953616976738
syndrome I-Disease 1 0.9992486834526062
( O 0 1.0799877827594173e-06
MIM O 0 0.06759368628263474
153480 O 0 0.00042798518552444875
) O 0 1.1033449709429988e-06
. O 0 2.28843873628648e-06

Constitutive O 0 0.00029204809106886387
DNA O 0 1.6022248018998653e-05
from O 0 1.424940307970246e-07
37 O 0 1.1399511379295291e-07
CD B-Disease 0 2.7894611775991507e-07
families O 0 3.202160314685898e-08
and O 0 1.413548833539835e-08
seven O 0 1.2928036596804304e-07
BZS B-Disease 0 0.0015211243880912662
families O 0 1.2068896637629223e-07
was O 0 4.277876186620233e-08
screened O 0 1.4090339846006827e-06
for O 0 6.413258688553469e-07
germline O 0 0.18470676243305206
PTEN O 1 0.6202347278594971
mutations O 0 8.282522321678698e-05
. O 0 4.810617156181252e-06

PTEN O 1 0.8656429052352905
mutations O 0 0.0002689883403945714
were O 0 8.693655217939522e-08
identified O 0 1.187056213325377e-07
in O 0 8.299465115158e-09
30 O 0 3.979074847393349e-09
of O 0 2.272204202569128e-09
37 O 0 8.032055376361313e-08
( O 0 9.595539474105408e-09
81 O 0 2.3226915857321728e-07
% O 0 8.074739099583894e-09
) O 0 1.9034724907385225e-09
CD B-Disease 0 1.5858201152241236e-07
families O 0 1.6306444194924552e-08
, O 0 7.391051770611057e-09
including O 0 4.822035393203805e-08
missense O 0 3.9732822187943384e-05
and O 0 4.007127074601158e-08
nonsense O 0 1.403226542606717e-05
point O 0 6.185654655155304e-08
mutations O 0 3.265071768510097e-07
, O 0 5.554298354581988e-09
deletions O 0 6.387372764038446e-07
, O 0 1.6889977416667534e-08
insertions O 0 2.731503627728671e-06
, O 0 7.621248521161306e-09
a O 0 2.9287313907389034e-08
deletion O 0 2.3995897208806127e-05
/ O 0 2.632975701999385e-05
insertion O 0 2.2232829905988183e-06
and O 0 2.0216339180478826e-07
splice O 0 0.00010339216532884166
site O 0 3.7413112295325845e-05
mutations O 0 4.883122892351821e-05
. O 0 4.389811692817602e-06

These O 0 1.9408421394473407e-06
mutations O 0 3.882388682541205e-06
were O 0 1.1423361812035182e-08
scattered O 0 4.2778921738317877e-08
over O 0 4.541386822154436e-09
the O 0 4.043139600895529e-09
entire O 0 1.5320706481247726e-08
length O 0 3.864724007485165e-08
of O 0 5.847383022228314e-09
PTEN O 0 0.0004205342847853899
, O 0 1.740807498151753e-09
with O 0 7.832872128687995e-10
the O 0 1.2336759391828878e-09
exception O 0 2.9846718430093233e-09
of O 0 2.9721497485368786e-10
the O 0 1.7195684876014639e-09
first O 0 6.687302267494033e-09
, O 0 5.949125636561803e-09
fourth O 0 9.408979195768552e-08
and O 0 4.987892410213135e-08
last O 0 1.7516399566375185e-06
exons O 0 1.3641307305078954e-05
. O 0 1.7026479781634407e-06

A O 0 1.8529466387917637e-06
hot O 0 3.077129804296419e-06
spot O 0 1.5006728517619194e-06
for O 0 7.150959646651245e-08
PTEN O 0 0.009465510956943035
mutation O 0 4.2641840991564095e-06
in O 0 1.4782504997867818e-08
CD B-Disease 0 3.9968878695617605e-07
was O 0 1.726454534889399e-08
identified O 0 6.693136356261675e-08
in O 0 9.740830364535213e-09
exon O 0 1.820084435166791e-05
5 O 0 1.4694376382351493e-08
that O 0 8.378462368341388e-10
contains O 0 1.413062777899654e-09
the O 0 2.4128417042135197e-09
PTPase O 0 8.967916983237956e-06
core O 0 1.800731439516312e-07
motif O 0 1.7631913351578987e-07
, O 0 5.921319545798553e-10
with O 0 5.425692672922366e-10
13 O 0 2.311510760577562e-09
of O 0 1.100024293876345e-09
30 O 0 1.2693853079781547e-08
( O 0 5.467050367968795e-09
43 O 0 3.978310303409671e-08
% O 0 1.4867873154855715e-08
) O 0 8.559848829747807e-09
CD B-Disease 0 2.2760846150049474e-06
mutations O 0 1.9114938822895056e-06
identified O 0 2.52207570383689e-07
in O 0 9.027977654341157e-08
this O 0 2.523747753002681e-07
exon O 0 0.001871687825769186
. O 0 1.0994524018315133e-05

Seven O 0 5.914812959417759e-07
of O 0 4.0371613607703694e-08
30 O 0 8.354676594990451e-08
( O 0 2.07228652016056e-08
23 O 0 3.6884912901768985e-08
% O 0 1.2132767679418066e-08
) O 0 1.2066757593132138e-09
were O 0 5.910949507637042e-10
within O 0 7.71214037076362e-10
the O 0 2.3299644436036715e-09
core O 0 7.931817549433617e-07
motif O 0 1.5204285546133178e-06
, O 0 3.005316884241438e-09
the O 0 1.1442393699212516e-09
majority O 0 8.518998839690539e-09
( O 0 7.061133899810557e-10
five O 0 4.3458847631683284e-10
of O 0 3.731439601750708e-10
seven O 0 3.771136736219205e-09
) O 0 6.091851467715514e-10
of O 0 3.736880804794396e-10
which O 0 4.749085569244471e-09
were O 0 5.942970915384649e-08
missense O 0 0.010289885103702545
mutations O 0 7.496782018279191e-06
, O 0 2.2861685877728632e-08
possibly O 0 7.565304116496918e-08
pointing O 0 1.4242378654216736e-07
to O 0 9.76197234159315e-10
the O 0 2.449534575177381e-09
functional O 0 1.2435722851478204e-07
significance O 0 7.866596973826745e-08
of O 0 1.0555898377617723e-08
this O 0 1.2795479165106372e-07
region O 0 3.2570371786277974e-06
. O 0 3.5226162253820803e-06

Germline O 1 0.9809834361076355
PTEN O 1 0.9725339412689209
mutations O 0 0.000615634664427489
were O 0 1.718991313737206e-07
identified O 0 2.7499515908857575e-07
in O 0 9.59411217138495e-09
four O 0 3.09712788748584e-09
of O 0 2.384294761625938e-09
seven O 0 2.9248237609635908e-08
( O 0 1.6059024332548688e-08
57 O 0 8.71134915314542e-08
% O 0 3.465809683689258e-08
) O 0 6.140971464674294e-08
BZS B-Disease 0 0.0008064248249866068
families O 0 4.756539908612467e-07
studied O 0 4.742145847558277e-06
. O 0 4.292279299988877e-06

Interestingly O 0 0.00022311067732516676
, O 0 4.028796922739275e-07
none O 0 1.3743512283781456e-07
of O 0 8.3563937991471e-09
these O 0 3.470837484087497e-08
mutations O 0 1.3724799146075384e-06
was O 0 3.0412774520982566e-08
observed O 0 1.131900049244905e-07
in O 0 1.1586225312498755e-08
the O 0 4.671092312946712e-08
PTPase O 0 0.0001803941559046507
core O 0 5.336343292583479e-06
motif O 0 2.095591844408773e-05
. O 0 1.5800005712662823e-06

It O 0 5.018142132939829e-07
is O 0 3.375839341401843e-08
also O 0 7.615465591470638e-09
worthy O 0 5.178076989409419e-08
of O 0 4.686082188953833e-09
note O 0 2.355520933861044e-07
that O 0 1.2944209037968335e-09
a O 0 3.6166232231238382e-09
single O 0 3.16412993583981e-08
nonsense O 0 1.950931846295134e-06
point O 0 1.8151155245504924e-08
mutation O 0 2.427018159778527e-07
, O 0 3.677684823344407e-09
R233X O 0 1.1778886346291984e-06
, O 0 3.6486196286489303e-09
was O 0 3.3278138023007386e-09
observed O 0 1.790553838532105e-08
in O 0 3.006463300536666e-09
the O 0 7.92817100858656e-09
germline O 0 5.57771090825554e-05
DNA O 0 4.826848112315929e-07
from O 0 3.825996408579613e-09
two O 0 3.941623472059064e-09
unrelated O 0 1.1799157846326125e-06
CD B-Disease 0 2.4187468170566717e-06
families O 0 7.639444277174334e-08
and O 0 7.482344699383248e-08
one O 0 3.651309157248761e-07
BZS B-Disease 0 0.03101968765258789
family O 0 7.5139673754165415e-06
. O 0 5.239442089077784e-06

Genotype O 1 0.9909783601760864
- O 1 0.8943701386451721
phenotype O 1 0.9093338251113892
studies O 0 8.845881893648766e-07
were O 0 8.164250608899692e-09
not O 0 2.310338365063558e-09
performed O 0 1.8840191629010405e-08
on O 0 5.956733328815744e-09
this O 0 3.954138350081848e-09
small O 0 2.6370816641474448e-08
group O 0 9.046679849689099e-08
of O 0 9.831229874635028e-08
BZS B-Disease 0 0.05919964239001274
families O 0 4.8704569053370506e-06
. O 0 3.915462912118528e-06

However O 0 7.87633234722307e-06
, O 0 1.5047054375827429e-06
genotype O 0 0.002734523266553879
- O 0 0.03604535385966301
phenotype O 0 0.011918345466256142
analysis O 0 5.816878001496661e-07
inthe O 0 2.7620479158940725e-05
group O 0 2.220171246847258e-08
of O 0 2.045979607956383e-09
CD B-Disease 0 7.718945767010155e-07
families O 0 6.135866925660594e-08
revealed O 0 6.409247816918651e-07
two O 0 3.1865370342387678e-09
possible O 0 3.4816515892543975e-08
associations O 0 7.469393992209916e-09
worthy O 0 2.5165991957010192e-08
of O 0 1.3413461452671527e-09
follow O 0 1.4642449919222145e-08
- O 0 2.228118319180794e-06
up O 0 2.0269865785849106e-08
in O 0 1.3284179978256816e-08
independent O 0 1.3341900739760604e-07
analyses O 0 9.710717677080538e-06
. O 0 3.6117728541285032e-06

The O 0 5.327219128048455e-07
first O 0 8.406755114265252e-08
was O 0 3.147780702761338e-08
an O 0 9.630707786811854e-09
association O 0 1.1086719098329922e-07
noted O 0 4.540540388120462e-08
in O 0 5.761121801839408e-09
the O 0 4.397383346343986e-09
group O 0 1.864159138165178e-08
of O 0 3.3532230325761248e-09
CD B-Disease 0 2.1285241018631496e-06
families O 0 3.0809891882199736e-07
with O 0 1.4861664567433763e-05
breast B-Disease 1 0.9986183643341064
disease I-Disease 1 0.9444422721862793
. O 0 1.5223091395455413e-05

A O 0 4.310011263441993e-06
correlation O 0 1.4330000340123661e-05
was O 0 1.9293969444333925e-07
observed O 0 1.2784890657258074e-07
between O 0 4.522758167979646e-09
the O 0 5.038740535923125e-09
presence O 0 1.1817102318900652e-07
/ O 0 3.903621745848795e-06
absence O 0 2.165525003761104e-08
of O 0 1.1709563318973437e-09
a O 0 2.0640447928599315e-07
PTEN O 0 0.321847140789032
mutation O 0 1.060222643900488e-06
and O 0 5.029043403936839e-09
the O 0 5.681071613139466e-09
type O 0 7.227914693430648e-07
of O 0 6.483041659066657e-08
breast O 0 0.0064590913243591785
involvement O 0 3.359653419465758e-05
( O 0 1.225189976139518e-06
unaffected O 0 0.0005123271839693189
versus O 0 0.0011456126812845469
benign O 0 0.1836199313402176
versus O 0 0.04322133958339691
malignant O 1 0.9859588742256165
) O 0 2.6610421173245413e-06
. O 0 6.080996172386222e-06

Specifically O 0 2.6869149678532267e-06
and O 0 4.878475934333437e-08
more O 0 3.897537848018828e-09
directly O 0 7.959382486433242e-09
, O 0 4.740578596340583e-09
an O 0 1.8477259722260442e-09
association O 0 2.4733431303047837e-08
was O 0 5.599890329222035e-09
also O 0 3.555788330444898e-09
observed O 0 2.4590526948031766e-08
between O 0 2.2979360636554702e-09
the O 0 1.4790930702446303e-09
presence O 0 9.301309056297669e-09
of O 0 2.641097340827514e-09
a O 0 6.128639142843895e-07
PTEN O 1 0.7542814016342163
mutation O 0 8.25025126687251e-05
and O 0 6.996071169851348e-05
malignant B-Disease 1 0.9999569654464722
breast I-Disease 1 0.9998379945755005
disease I-Disease 1 0.9467020034790039
. O 0 2.9528129743994214e-05

Secondly O 0 0.0013691396452486515
, O 0 3.746802121895598e-07
there O 0 2.9356328923313413e-08
appeared O 0 5.492304211429655e-08
to O 0 2.5687407756436187e-09
be O 0 2.265124976474908e-09
an O 0 7.008714053569065e-09
interdependent O 0 0.0005266756052151322
association O 0 3.359758693477488e-07
between O 0 6.405703345535585e-08
mutations O 0 8.467227985420323e-07
upstream O 0 5.0263416540019534e-08
and O 0 2.531488352275346e-09
within O 0 1.9461938727260986e-09
the O 0 7.015053427039675e-09
PTPase O 0 1.845867336669471e-05
core O 0 6.24378401425929e-07
motif O 0 5.423534616966208e-07
, O 0 1.6974455174789682e-09
the O 0 7.302488058691381e-10
core O 0 5.656994517266867e-08
motif O 0 7.072827656884328e-08
containing O 0 4.850666091016365e-09
the O 0 1.4997427744134484e-09
majority O 0 1.0099055813839186e-08
of O 0 1.2875566390846416e-08
missense O 0 0.0020657845307141542
mutations O 0 4.118337074032752e-06
, O 0 5.647299516908788e-09
and O 0 1.9643597859442252e-09
the O 0 4.126793129444195e-09
involvement O 0 6.685748843437977e-08
of O 0 3.5536187326101754e-09
all O 0 1.1359830409674032e-08
major O 0 1.2477496511564823e-06
organ O 0 0.0012125050416216254
systems O 0 1.1960648407693952e-05
( O 0 2.0272070244686802e-08
central O 0 9.437161452297005e-08
nervous O 0 7.434739927703049e-06
system O 0 1.5698474271630403e-06
, O 0 1.7116364006142248e-06
thyroid O 1 0.7125431895256042
, O 0 4.1446651266596746e-06
breast O 0 0.08052556961774826
, O 0 3.5846147511620075e-05
skin O 1 0.896851658821106
and O 0 0.003706397023051977
gastrointestinal O 1 0.9999016523361206
tract O 1 0.9717478156089783
) O 0 3.1222505185724003e-06
. O 0 5.117192358738976e-06

However O 0 2.499622496543452e-06
, O 0 7.051706063521124e-08
these O 0 5.895470778227718e-09
observations O 0 1.8970405335494434e-07
would O 0 6.0005675983632045e-09
need O 0 5.38324629317799e-09
to O 0 1.3840358858985269e-09
be O 0 3.4151226291356807e-09
confirmed O 0 5.411188297443914e-08
by O 0 3.817249627502406e-09
studying O 0 2.2807244093314694e-08
a O 0 5.543206782476773e-09
larger O 0 1.7288401821247135e-08
number O 0 5.088683252552073e-09
of O 0 9.062237182888566e-09
CD B-Disease 0 1.0306484909961e-05
families O 0 1.7430248817618121e-06
. O 0 2.3501497707911767e-06

Molecular O 1 0.9928338527679443
defects O 1 0.941413938999176
leading O 0 2.2049591734685237e-06
to O 0 8.159101838600691e-08
human O 0 5.888718987989705e-07
complement B-Disease 0 2.379302168264985e-05
component I-Disease 0 0.08469392359256744
C6 I-Disease 1 0.9999979734420776
deficiency I-Disease 1 0.9999641180038452
in O 0 2.958871903047111e-08
an O 0 4.492434868552664e-09
African O 0 8.098047032945033e-08
- O 0 6.42710438114591e-05
American O 0 6.819336135777121e-07
family O 0 1.4075150147618842e-06
. O 0 1.960924237209838e-06

Complement B-Disease 0 0.0012632914585992694
component I-Disease 1 0.6572998762130737
C6 I-Disease 1 0.9999949932098389
deficiency I-Disease 1 0.9999903440475464
( O 0 9.30499084006442e-07
C6D B-Disease 0 0.004207212943583727
) O 0 9.71476481481659e-08
was O 0 3.939694579457864e-07
diagnosed O 0 0.0004313453973736614
in O 0 1.400030757991999e-08
a O 0 1.9798465089593265e-08
16 O 0 5.133167135795702e-08
- O 0 1.7260783351957798e-05
year O 0 1.067477271021744e-07
- O 0 6.384299922501668e-06
old O 0 3.613019430304121e-07
African O 0 3.7015436049614436e-08
- O 0 7.331261713261483e-06
American O 0 4.7559046834066976e-07
male O 0 5.78889876123867e-06
with O 0 2.4215203666244633e-05
meningococcal B-Disease 1 0.9999473094940186
meningitis I-Disease 1 0.9997223019599915
. O 0 2.964137638628017e-05

The O 0 1.0057353392767254e-05
patients O 0 1.5675848771934398e-05
father O 0 1.5840621472307248e-06
and O 0 1.9690270747219074e-08
two O 0 6.029087895598195e-09
brothers O 0 4.171636476257845e-07
also O 0 1.1032144087153029e-08
had O 0 2.0672176859193314e-08
C6D B-Disease 0 0.0002057816309388727
, O 0 7.774529464654734e-09
but O 0 2.0569750347476656e-09
gave O 0 3.4830911488370475e-09
no O 0 6.061303459148348e-09
history O 0 3.984119345545878e-08
of O 0 4.989110280462228e-08
meningitis B-Disease 1 0.9876240491867065
or O 0 3.6401416991793667e-07
other O 0 2.6606994651956484e-07
neisserial B-Disease 1 0.9403160214424133
infection I-Disease 0 0.18546950817108154
. O 0 1.3199715795053635e-05

By O 0 4.95658639465546e-07
using O 0 1.0212376366780518e-07
exon O 0 1.2309837984503247e-05
- O 0 5.4538118092750665e-06
specific O 0 3.532630188374242e-08
polymerase O 0 3.198236129264842e-07
chain O 0 6.836780812591314e-07
reaction O 0 1.475971913578178e-07
( O 0 6.333101598698931e-09
PCR O 0 2.422920033495757e-07
) O 0 7.311466987403037e-09
/ O 0 1.0148492890493799e-07
single O 0 1.3391432851506124e-08
- O 0 4.307968993089162e-06
strand O 0 3.7870215692237252e-06
conformation O 0 9.237757694791071e-06
polymorphism O 0 1.5448107433257974e-06
as O 0 1.5939516373464357e-09
a O 0 2.6639854766585813e-09
screening O 0 4.220205696015e-08
step O 0 1.308611174977159e-08
and O 0 1.7558769993542e-09
nucleotide O 0 2.231668183583224e-08
sequencing O 0 6.664484963891937e-09
of O 0 3.2450858666877025e-10
target O 0 1.7005961083782495e-08
exons O 0 1.344414499726554e-07
, O 0 2.838038026808931e-09
we O 0 1.895118506567428e-09
determined O 0 7.824991321569996e-09
that O 0 8.670298368151919e-10
the O 0 3.3812894706386487e-09
proband O 0 2.0500179743976332e-05
was O 0 5.836106709011801e-09
a O 0 5.246241663314777e-09
compound O 0 2.739074034252553e-07
heterozygote O 0 4.409258508530911e-06
for O 0 9.167887782268735e-09
two O 0 7.753223485451599e-08
C6 O 0 0.0073550245724618435
gene O 0 5.2259729272918776e-06
mutations O 0 1.1726280717994086e-05
. O 0 2.2901851934875594e-06

The O 0 5.021425977247418e-07
first O 0 1.1049458947809399e-07
, O 0 4.549989540691968e-08
1195delC O 0 2.5372187337779906e-06
located O 0 4.674746634236726e-08
in O 0 3.342114496263093e-08
exon O 0 4.372227704152465e-05
7 O 0 3.318988888167951e-07
, O 0 5.442818196144117e-09
is O 0 1.2982731556476779e-09
a O 0 7.226134357551928e-09
novel O 0 6.383554023159377e-07
mutation O 0 1.2810525049644639e-06
, O 0 1.0456600030295249e-09
while O 0 6.194657564684292e-10
the O 0 5.553681403647204e-10
second O 0 1.1881521544410134e-08
, O 0 8.728742173502724e-09
1936delG O 0 1.8356206510361517e-06
in O 0 1.256260695470246e-08
exon O 0 1.933785097207874e-05
12 O 0 6.742878611021297e-08
, O 0 6.115592920963309e-09
has O 0 7.17029724484064e-09
been O 0 4.559804533954548e-09
described O 0 1.2392285952955717e-07
before O 0 1.4352941946071951e-08
to O 0 8.909972315507275e-09
cause O 0 2.713168896661955e-06
C6D B-Disease 0 0.0008025897550396621
in O 0 1.4988485119715733e-08
an O 0 4.117790552982115e-09
unrelated O 0 1.2356144907244015e-06
African O 0 8.185568844965019e-08
- O 0 2.3840562789700925e-05
American O 0 6.890132908665692e-07
individual O 0 7.892323878877505e-07
. O 0 1.6123989325933508e-06

Both O 0 6.4286127781088e-06
mutations O 0 0.00012125192006351426
result O 0 1.774799443410302e-06
in O 0 5.253784820524743e-07
premature O 0 0.0001183170170406811
termination O 0 4.248355617164634e-05
codons O 0 3.142710966130835e-06
and O 0 4.731935803192755e-07
C6 O 0 0.0017616926925256848
null O 0 3.0154984415275976e-05
alleles O 0 1.7089198081521317e-05
. O 0 6.799718448746717e-06

Allele O 0 0.00021580942848231643
- O 0 2.6221807274851017e-05
specific O 0 3.692679797495657e-07
PCR O 0 7.535229542554589e-06
indicated O 0 8.756809393162257e-07
that O 0 4.352805671459237e-09
the O 0 4.988174762132758e-09
probands O 0 1.4056508007342927e-05
two O 0 8.741971591064157e-09
brothers O 0 3.5435530776339874e-07
also O 0 1.3155382561080842e-08
inherited O 0 1.3451228824123973e-06
the O 0 1.2454126618877126e-08
1195delC O 0 8.893129415810108e-05
mutation O 0 8.711272698747052e-07
from O 0 3.912635548886101e-09
their O 0 8.526916062123746e-09
heterozygous O 0 8.288440653814177e-07
mother O 0 1.2434068139555166e-06
and O 0 1.0821529450311118e-08
the O 0 3.1449243209635824e-08
1936delG O 0 0.00014446924615185708
mutation O 0 8.003883067431161e-07
from O 0 6.931593077297293e-09
their O 0 1.9198154177502147e-08
homozygous O 0 3.649854625109583e-05
father O 0 6.657709946011892e-06
. O 0 7.172521350184979e-07
. O 0 2.4070434392342577e-06

PAX6 O 1 0.9034957885742188
mutations O 0 0.021431859582662582
reviewed O 0 0.0006237205234356225
. O 0 6.535529246320948e-05

Mutations O 0 0.001274234033189714
in O 0 3.30565967487928e-06
PAX6 O 0 0.002493566134944558
are O 0 4.63196663247345e-08
responsible O 0 9.709392401191508e-08
for O 0 1.9739077927738435e-08
human O 0 1.7333425148535753e-06
aniridia B-Disease 1 0.9983276724815369
and O 0 1.384286605343732e-07
have O 0 1.0451840282144076e-08
also O 0 5.731747965143086e-09
been O 0 9.391458277718812e-09
found O 0 3.8160870019510185e-08
in O 0 3.570674778075045e-07
patients O 0 3.894348083122168e-06
with O 0 7.917988114058971e-06
Peters B-Disease 1 0.9999743700027466
anomaly I-Disease 1 0.9999772310256958
, O 0 2.2203728804015554e-05
with O 0 0.06682445853948593
congenital B-Disease 1 0.9999994039535522
cataracts I-Disease 1 0.9999666213989258
, O 0 7.176433882705169e-06
with O 0 2.555442370066885e-05
autosomal B-Disease 1 0.5391730666160583
dominant I-Disease 0 0.010702847503125668
keratitis I-Disease 1 0.9790937304496765
, O 0 1.0931101996902726e-06
and O 0 2.8122292405896587e-07
with O 0 4.172879926045425e-06
isolated B-Disease 0 0.008631781674921513
foveal I-Disease 1 0.9999381303787231
hypoplasia I-Disease 1 0.9999395608901978
. O 0 0.00013536657206714153

No O 0 2.609796865726821e-06
locus O 0 7.632490451214835e-06
other O 0 2.1903664659816968e-08
than O 0 2.1517815085303482e-08
chromosome O 0 1.336912282567937e-05
11p13 O 0 4.5577016862807795e-05
has O 0 5.71036302687844e-08
been O 0 2.2105412611495012e-08
implicated O 0 2.7045612114307005e-06
in O 0 3.2001858585317677e-07
aniridia B-Disease 1 0.996239185333252
, O 0 4.678386034129289e-08
and O 0 4.332341063673084e-08
PAX6 O 0 0.0008018202497623861
is O 0 1.3667959208873981e-08
clearly O 0 1.4014521099170452e-08
the O 0 1.2106362579089591e-09
major O 0 1.1817514966594445e-08
, O 0 4.819192156446661e-09
if O 0 4.079998561223874e-09
not O 0 9.930919420142459e-10
only O 0 1.701961571676236e-09
, O 0 2.060380310808796e-08
gene O 0 2.721202463362715e-07
responsible O 0 9.467428299103631e-07
. O 0 1.5822774912521709e-06

Twenty O 0 6.059016413928475e-06
- O 0 1.7591430150787346e-05
eight O 0 1.567343304031965e-07
percent O 0 1.0649068116208582e-07
of O 0 1.5335734460109052e-08
identified O 0 8.326760507770814e-06
PAX6 O 0 0.2044088989496231
mutations O 0 1.2681310181505978e-05
are O 0 1.3279973565261116e-08
C O 0 3.6333478874439606e-06
- O 0 0.0011974381050094962
T O 0 0.0014597580302506685
changes O 0 3.779787505209242e-08
at O 0 7.978427696286872e-09
CpG O 0 6.630533334828215e-06
dinucleotides O 0 1.2695479199464899e-05
, O 0 2.7752522502311194e-09
20 O 0 2.699205081668765e-09
% O 0 2.2826991408209096e-09
are O 0 6.707738253730611e-10
splicing O 0 1.6306140082633647e-07
errors O 0 1.373197022758177e-07
, O 0 1.636457525044932e-09
and O 0 7.108714727976917e-10
more O 0 2.6523180873816443e-10
than O 0 1.6244350309335687e-09
30 O 0 8.910448379140234e-09
% O 0 9.606234030457017e-09
are O 0 5.672496250497261e-09
deletion O 0 5.137612333783181e-06
or O 0 1.052018561154e-07
insertion O 0 5.027434326621005e-06
events O 0 4.601649379765149e-06
. O 0 5.703804617951391e-06

There O 0 8.741973260839586e-07
is O 0 5.113252399269186e-08
a O 0 5.170802808152075e-08
noticeably O 0 6.310192020464456e-06
elevated O 0 8.030842764128465e-06
level O 0 3.104883816718029e-08
of O 0 3.2753519896289163e-09
mutation O 0 3.673578987672954e-07
in O 0 3.08621284084154e-09
the O 0 1.0609019218676963e-09
paired O 0 2.1051116050330165e-07
domain O 0 3.951832994175675e-08
compared O 0 3.5992695046616063e-08
with O 0 1.4326787534102436e-09
the O 0 3.6444880446850902e-09
rest O 0 9.175392889915202e-09
of O 0 2.9637166054641284e-09
the O 0 6.136850316806886e-08
gene O 0 1.920176373459981e-06
. O 0 1.8002471051659086e-06

Increased O 0 4.88785226480104e-05
mutation O 0 2.008557021326851e-05
in O 0 7.500948839833654e-08
the O 0 4.170673051362428e-08
homeodomain O 0 2.4946763005573303e-05
is O 0 1.8867089224272604e-08
accounted O 0 4.18498444787474e-08
for O 0 1.866178767073734e-09
by O 0 8.354513525432594e-09
the O 0 2.441182189727442e-08
hypermutable O 0 0.0006362651474773884
CpG O 0 4.547967546386644e-05
dinucleotide O 0 9.632245564716868e-06
in O 0 1.0365326374994766e-07
codon O 0 2.935425982286688e-06
240 O 0 1.4941408608137863e-06
. O 0 1.290038881052169e-06

Very O 0 1.3367454130275291e-06
nearly O 0 1.7415149500266125e-07
all O 0 2.304793689233975e-08
mutations O 0 1.530809527139354e-06
appear O 0 9.590383598379049e-08
to O 0 1.7763655435487635e-08
cause O 0 1.9012256871064892e-06
loss O 0 4.294211521482794e-06
of O 0 5.205910813543824e-09
function O 0 1.3786932484549652e-08
of O 0 1.2517276104517805e-09
the O 0 7.1955601477213804e-09
mutant O 0 1.017184058582643e-05
allele O 0 3.1264380595530383e-07
, O 0 9.959751912091974e-10
and O 0 4.291241251230815e-10
more O 0 1.944920058338795e-10
than O 0 8.360758751990716e-10
80 O 0 2.22534213278891e-09
% O 0 1.5494791005821185e-09
of O 0 3.0243330062518226e-09
exonic O 0 3.753980854526162e-05
substitutions O 0 3.6342240150588623e-07
result O 0 1.9598404321641283e-07
in O 0 1.903419359905456e-07
nonsense O 0 0.00015079240256454796
codons O 0 4.803365663974546e-05
. O 0 4.2752108129207045e-06

In O 0 1.2758074490193394e-06
a O 0 1.1108733843911978e-07
gene O 0 1.5024842525690474e-07
with O 0 9.638609022033506e-09
such O 0 3.9636244508756135e-08
extraordinarily O 0 0.00011293029820080847
high O 0 2.016324742726283e-06
sequence O 0 2.598511628093547e-07
conservation O 0 5.9353130410499944e-08
throughout O 0 4.707223055788745e-09
evolution O 0 2.0431338398907428e-08
, O 0 1.9172601284367374e-09
there O 0 3.0741924561539236e-09
are O 0 6.8346666104446285e-09
presumed O 0 0.0004089919966645539
undiscovered O 0 0.17910274863243103
missense O 0 0.013528247363865376
mutations O 0 1.167012032965431e-05
, O 0 1.1843351188645102e-08
these O 0 1.4304233353357176e-09
are O 0 2.9456375116865274e-09
hypothesized O 0 2.1955199258627545e-07
to O 0 4.973468747948573e-09
exist O 0 3.604394649414644e-08
in O 0 4.854784574348514e-09
as O 0 1.1461860793815504e-08
- O 0 0.00014991727948654443
yet O 0 6.543244580825558e-06
unidentified O 0 0.0004972426104359329
phenotypes O 0 0.0006620206986553967
. O 0 5.638868856294721e-07
. O 0 2.749757413766929e-06

Genetic O 0 0.01177345309406519
heterogeneity O 0 0.0027131387032568455
and O 0 3.2391610602644505e-06
penetrance O 0 0.001621124567463994
analysis O 0 3.661721734715684e-07
of O 0 1.2444936636768489e-08
the O 0 7.96860675222888e-08
BRCA1 O 0 0.00013091265282128006
and O 0 1.1943707249884028e-06
BRCA2 O 0 0.0006708240834996104
genes O 0 5.233369392954046e-06
in O 0 1.4019170521351043e-05
breast B-Disease 1 0.9978526830673218
cancer I-Disease 1 0.953553318977356
families O 0 2.4959994334494695e-05
. O 0 1.9212027837056667e-05

The O 0 0.0026525501161813736
Breast B-Disease 1 0.9998365640640259
Cancer I-Disease 1 0.9996168613433838
Linkage O 0 0.011920761317014694
Consortium O 0 0.0010183074045926332
. O 0 1.817548763938248e-05

The O 0 3.625320630362694e-07
contribution O 0 6.834890200480004e-07
of O 0 4.606372883131371e-08
BRCA1 O 0 3.9922808355186135e-05
and O 0 1.1493974625409464e-06
BRCA2 O 0 0.009320062585175037
to O 0 4.450412598089315e-05
inherited B-Disease 1 0.9999971389770508
breast I-Disease 1 0.9999929666519165
cancer I-Disease 1 0.999982476234436
was O 0 1.866345542111958e-06
assessed O 0 7.730172342235164e-07
by O 0 2.150845901383036e-08
linkage O 0 1.7970951375900768e-05
and O 0 9.479121843014582e-08
mutation O 0 1.6213996332226088e-06
analysis O 0 1.7193562129591555e-08
in O 0 4.829654454141519e-09
237 O 0 1.328192951177698e-07
families O 0 1.7511752048449125e-08
, O 0 3.5758385141804183e-09
each O 0 5.447987616591377e-10
with O 0 4.740994707930213e-09
at O 0 1.0895134572308507e-08
least O 0 2.974635204822107e-09
four O 0 5.939081226813414e-09
cases O 0 7.376309696383032e-08
of O 0 1.123128527069639e-06
breast B-Disease 1 0.9995139837265015
cancer I-Disease 1 0.6503252387046814
, O 0 4.059631564246047e-08
collected O 0 9.911020981689944e-08
by O 0 1.700569356444248e-07
the O 0 9.763408888829872e-05
Breast B-Disease 1 0.9999911785125732
Cancer I-Disease 1 0.999925971031189
Linkage O 0 0.012139413505792618
Consortium O 0 0.00013644112914334983
. O 0 4.587986495607765e-06

Families O 0 6.162212685012491e-06
were O 0 5.9418375997211115e-08
included O 0 4.246350826520029e-08
without O 0 2.1689684714942814e-08
regard O 0 2.0735756223189128e-08
to O 0 2.205734483951005e-09
the O 0 9.30950871946834e-09
occurrence O 0 9.328865417046472e-06
of O 0 5.373728413360368e-07
ovarian B-Disease 1 0.995987594127655
or I-Disease 0 5.225858785706805e-06
other I-Disease 0 2.806934389809612e-06
cancers I-Disease 0 0.4780008792877197
. O 0 2.033894088526722e-05

Overall O 0 0.003215717151761055
, O 0 4.514870670391247e-05
disease O 0 0.0013118977658450603
was O 0 1.6028279503643716e-07
linked O 0 1.5191283182502957e-06
to O 0 2.2276960720546413e-08
BRCA1 O 0 1.094884100893978e-05
in O 0 8.824697417253446e-09
an O 0 2.8458324585756145e-09
estimated O 0 3.3354790929251976e-08
52 O 0 3.512782598136255e-08
% O 0 4.010512810737055e-09
of O 0 1.1094685170576213e-09
families O 0 3.0819258256542525e-08
, O 0 7.092466614011528e-09
to O 0 5.458766327848252e-09
BRCA2 O 0 1.6623831697870628e-06
in O 0 6.036913191564963e-09
32 O 0 1.1934214505515683e-08
% O 0 1.5058797542266689e-09
of O 0 1.6042486228329267e-09
families O 0 2.761614403823387e-08
, O 0 9.181344573505612e-09
and O 0 3.213980415139872e-09
to O 0 2.1017501072861933e-09
neither O 0 7.864076678743004e-08
gene O 0 1.2985562847234178e-08
in O 0 3.0906306403011286e-09
16 O 0 7.59185514453975e-09
% O 0 5.7031761535597525e-09
( O 0 1.8576451488172552e-09
95 O 0 6.998721602258229e-09
% O 0 8.820388863739481e-09
confidence O 0 5.601639259111835e-07
interval O 0 5.443962436402217e-07
[ O 0 1.176753471554548e-06
CI O 0 6.34916068520397e-05
] O 0 7.253547806840288e-08
6 O 0 4.779964868362185e-09
% O 0 2.3824309192121973e-09
- O 0 1.8848477338906378e-06
28 O 0 1.0921895210458388e-07
% O 0 1.1428003432456535e-08
) O 0 3.874826681737886e-09
, O 0 9.860032790243167e-09
suggesting O 0 3.4837148632504977e-07
other O 0 9.204212858548999e-08
predisposition O 0 0.0016942007932811975
genes O 0 6.464584657805972e-06
. O 0 3.684607008835883e-06

The O 0 9.050923495124152e-07
majority O 0 7.8695057936784e-07
( O 0 5.007586523220198e-08
81 O 0 1.39103590868217e-07
% O 0 8.556045649754651e-09
) O 0 1.2192800102894807e-09
of O 0 1.860900544770061e-09
the O 0 1.4545936437571072e-06
breast B-Disease 1 0.9995405673980713
- I-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999809265136719
families O 0 3.9365511383948615e-07
were O 0 2.3481414146431234e-08
due O 0 2.0216842244735744e-07
to O 0 4.8957392806414646e-08
BRCA1 O 0 0.00015739962691441178
, O 0 1.1803660271425542e-08
with O 0 7.3370318709464755e-09
most O 0 4.069770298542608e-09
others O 0 1.680652239599567e-08
( O 0 1.07332613907829e-08
14 O 0 3.050421781836121e-08
% O 0 1.908006019846198e-08
) O 0 1.2789460157591748e-08
due O 0 1.1080144446395934e-07
to O 0 3.4661346148823213e-07
BRCA2 O 0 0.0014384626410901546
. O 0 5.510758455784526e-06

Conversely O 0 8.925046131480485e-05
, O 0 1.3692844902379875e-07
the O 0 1.7602303614694392e-08
majority O 0 2.4522192276776877e-08
of O 0 2.5367856704150427e-09
families O 0 2.312420299688256e-08
with O 0 4.41944898454949e-08
male B-Disease 0 9.44575367611833e-06
and I-Disease 0 2.426040055070189e-06
female I-Disease 0 0.3502010703086853
breast I-Disease 1 0.994021475315094
cancer I-Disease 1 0.5622098445892334
were O 0 7.786108113805312e-08
due O 0 7.276175324477663e-07
to O 0 6.641747063440562e-08
BRCA2 O 0 0.00016966566909104586
( O 0 5.6993076924527486e-08
76 O 0 1.0337079174860264e-06
% O 0 2.94698025982143e-07
) O 0 3.955657064125262e-07
. O 0 1.9312465155962855e-06

The O 0 5.910966365263448e-07
largest O 0 1.8817189584297012e-06
proportion O 0 2.6036366307380376e-06
( O 0 3.9785458483265757e-08
67 O 0 1.1759901497043757e-07
% O 0 1.4332560915875092e-08
) O 0 1.7157583132032528e-09
of O 0 1.0908957071009695e-09
families O 0 3.250106672680886e-08
due O 0 9.045093207760146e-08
to O 0 4.065596304059227e-09
other O 0 4.703884393109092e-09
genes O 0 4.3267831983939686e-08
was O 0 7.722094075290897e-09
found O 0 1.1557927948047109e-08
in O 0 8.435727671951554e-09
families O 0 3.3275595612280995e-09
with O 0 3.14700487891173e-09
four O 0 7.28879889777545e-09
or O 0 5.27673904571202e-09
five O 0 5.681179970906669e-09
cases O 0 2.4191976422116568e-08
of O 0 8.470961887496742e-08
female O 1 0.7432156801223755
breast B-Disease 1 0.9997326731681824
cancer I-Disease 1 0.7992883324623108
only O 0 1.1831406254714238e-06
. O 0 7.281601028807927e-06

These O 0 6.410654123101267e-07
estimates O 0 1.1797267234214814e-06
were O 0 1.4421434713085546e-08
not O 0 1.2584598252374235e-08
substantially O 0 4.843138299293059e-07
affected O 0 2.8691719222706524e-08
either O 0 6.066508184687791e-09
by O 0 3.976798446103658e-09
changing O 0 3.541630277936747e-08
the O 0 4.85088813562129e-09
assumed O 0 4.5224331302051723e-07
penetrance O 0 1.231415899383137e-05
model O 0 6.155876519642334e-08
for O 0 5.092955390750831e-09
BRCA1 O 0 3.4440652143530315e-06
or O 0 7.507901855774435e-09
by O 0 5.116137291594214e-09
including O 0 3.667081927005711e-08
or O 0 1.4948406601433817e-07
excluding O 0 1.1961002201132942e-05
BRCA1 O 0 0.001412973739206791
mutation O 0 1.720694126561284e-05
data O 0 4.733105015475303e-06
. O 0 3.209298029105412e-06

Among O 0 1.683072923697182e-06
those O 0 1.1556510770560635e-07
families O 0 4.325554243678198e-07
with O 0 5.5852055993455e-06
disease O 0 0.04339425638318062
due O 0 1.3518963442038512e-06
to O 0 7.442235983035062e-08
BRCA1 O 0 6.0666210629278794e-05
that O 0 1.4299220474356389e-08
were O 0 1.0709172215683793e-08
tested O 0 2.5482859200565144e-07
by O 0 1.033560570462555e-09
one O 0 5.204637831823788e-10
of O 0 3.926906022577725e-10
the O 0 3.2294718010916768e-09
standard O 0 4.501923811517372e-08
screening O 0 1.3276381594096165e-07
methods O 0 1.2892208189896337e-07
, O 0 2.0833676117604227e-08
mutations O 0 3.101744141531526e-07
were O 0 6.585433975914157e-09
detected O 0 8.526283181709005e-07
in O 0 2.894852357826494e-09
the O 0 2.7627033993837813e-09
coding O 0 3.3952898093048134e-07
sequence O 0 1.1313772141363643e-08
or O 0 1.1520419063160148e-09
splice O 0 1.0322906973669888e-07
sites O 0 8.842236276507265e-09
in O 0 8.545847363095049e-10
an O 0 6.235340577198656e-10
estimated O 0 2.550103950227367e-08
63 O 0 2.3201517151960616e-08
% O 0 3.5486065197432026e-09
( O 0 9.199887518462901e-10
95 O 0 4.952416254866421e-09
% O 0 7.348235797621783e-09
CI O 0 3.480214945739135e-05
51 O 0 5.231325772570017e-08
% O 0 1.789416970154889e-08
- O 0 1.745924964779988e-05
77 O 0 6.28189013696101e-07
% O 0 1.0834131813908243e-07
) O 0 2.559152676440135e-07
. O 0 9.958067721527186e-07

The O 0 1.9943033748859307e-06
estimated O 0 1.722217120914138e-06
sensitivity O 0 2.9489387998182792e-06
was O 0 4.763685268471818e-08
identical O 0 1.0798358829333665e-07
for O 0 1.466362697932766e-09
direct O 0 8.217086566730814e-09
sequencing O 0 1.678682650663177e-07
and O 0 7.969469528745776e-09
other O 0 2.0399097522272314e-08
techniques O 0 1.611716470506508e-06
. O 0 2.8873600967926905e-06

The O 0 1.7300741319559165e-06
penetrance O 0 0.00024027352628763765
of O 0 1.9578881449433538e-07
BRCA2 O 0 7.660398841835558e-05
was O 0 8.492186509556632e-08
estimated O 0 5.4301807494994137e-08
by O 0 5.9137832408850954e-09
maximizing O 0 2.482531726855086e-07
the O 0 1.5244626894173052e-08
LOD O 0 5.629576844512485e-05
score O 0 1.9860681987893258e-08
in O 0 3.543427595786852e-08
BRCA2 O 0 1.9765619072131813e-05
- O 0 0.0007694319938309491
mutation O 0 3.4108916224795394e-06
families O 0 1.566029261823587e-08
, O 0 2.266568488451526e-09
over O 0 5.342168485356069e-09
all O 0 6.01337690753212e-09
possible O 0 7.837718953851436e-07
penetrance O 0 0.0012457933044061065
functions O 0 6.320867100839678e-07
. O 0 1.472135750191228e-06

The O 0 1.600805262569338e-06
estimated O 0 1.765716660884209e-06
cumulative O 0 3.26691624650266e-05
risk O 0 4.11103110309341e-06
of O 0 4.6684652943440597e-07
breast B-Disease 1 0.9602300524711609
cancer I-Disease 0 0.10312965512275696
reached O 0 9.614199143470614e-07
28 O 0 2.0530001165752765e-07
% O 0 8.202007073521145e-09
( O 0 2.7012188041908303e-09
95 O 0 1.3182208213891045e-08
% O 0 1.79511889797368e-08
CI O 0 0.00014039347297511995
9 O 0 2.8517568750885403e-08
% O 0 4.327722180619276e-09
- O 0 1.3984448514747783e-06
44 O 0 3.4295769779646434e-08
% O 0 7.162109572078634e-09
) O 0 7.896986953248586e-10
by O 0 1.253538606249549e-09
age O 0 1.3869805748356612e-08
50 O 0 1.964644447127739e-09
years O 0 5.813265424592373e-09
and O 0 6.366625449061303e-09
84 O 0 7.221824205316807e-08
% O 0 8.145073060461527e-09
( O 0 1.180442077419741e-09
95 O 0 5.081690179764564e-09
% O 0 7.87947751490492e-09
CI O 0 3.113764978479594e-05
43 O 0 3.1779865850012357e-08
% O 0 5.8636895339247985e-09
- O 0 7.686315370847296e-07
95 O 0 1.7697304954822357e-08
% O 0 6.379364592135062e-09
) O 0 1.2637509927415636e-09
by O 0 3.680898919000697e-09
age O 0 3.274813877851557e-07
70 O 0 1.0165191355326897e-07
years O 0 8.26395705644245e-07
. O 0 2.400130142632406e-06

The O 0 8.417805656790733e-05
corresponding O 1 0.9903890490531921
ovarian B-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999929666519165
risks O 0 0.006170380860567093
were O 0 1.4767027778361808e-06
0 O 0 6.5064937189163174e-06
. O 0 2.8861734335805522e-06

4 O 0 1.8067330529447645e-06
% O 0 2.2517539832733746e-07
( O 0 1.0943244532768404e-08
95 O 0 1.3228503625839494e-08
% O 0 6.297543375666237e-09
CI O 0 2.5117733457591385e-05
0 O 0 1.3317971614412727e-08
% O 0 2.6976609834861165e-09
- O 0 2.5777688961170497e-07
1 O 0 2.9291153946786608e-09
% O 0 1.4461644104457605e-09
) O 0 2.9006319568480876e-10
by O 0 6.851017531062098e-10
age O 0 1.7782028294277552e-08
50 O 0 1.1419827306013985e-09
years O 0 3.2631242152802997e-09
and O 0 5.5500199991342924e-09
27 O 0 7.269891710848242e-08
% O 0 3.964136574552413e-09
( O 0 1.8453027994524973e-09
95 O 0 9.229682795819372e-09
% O 0 9.251590604719695e-09
CI O 0 1.7782604118110612e-05
0 O 0 1.0806637362748006e-08
% O 0 2.3787076752768144e-09
- O 0 1.554831783323607e-06
47 O 0 6.079692838056872e-08
% O 0 3.7111698159009165e-09
) O 0 1.16393328308817e-09
by O 0 4.3390455672920325e-09
age O 0 3.486450452783174e-07
70 O 0 8.799707984508132e-08
years O 0 9.020762945510796e-07
. O 0 3.240060095777153e-06

The O 0 6.02758291279315e-06
lifetime O 0 0.000385020743124187
risk O 0 1.4885308701195754e-05
of O 0 1.9136864466418047e-06
breast B-Disease 1 0.9980321526527405
cancer I-Disease 1 0.9372725486755371
appears O 0 3.272268259024713e-06
similar O 0 3.261644820895526e-08
to O 0 5.041105310965577e-09
the O 0 2.210482286102433e-08
risk O 0 5.753228720095649e-07
in O 0 9.945257772869809e-08
BRCA1 O 0 4.8978043196257204e-05
carriers O 0 7.117933478184568e-07
, O 0 1.1252438092412831e-08
but O 0 3.2885163481211066e-09
there O 0 7.454588057953515e-10
was O 0 5.197316466087898e-10
some O 0 1.3597011017107974e-10
suggestion O 0 2.8581061073396086e-08
of O 0 1.9282988539259804e-09
a O 0 1.150475128497419e-07
lower O 0 8.71048541739583e-06
risk O 0 2.088708697556285e-06
in O 0 1.3632268291985383e-07
BRCA2 O 0 4.411251939018257e-05
carriers O 0 1.1507465842441889e-06
< O 0 1.1727628361768438e-06
50 O 0 1.3819052568919687e-08
years O 0 3.3062161008956537e-08
of O 0 7.608355190313887e-08
age O 0 1.3931859939475544e-05
. O 0 4.956925749866059e-06

Eye B-Disease 1 0.7840640544891357
movement I-Disease 0 0.0016000157920643687
abnormalities I-Disease 1 0.9299607872962952
correlate O 0 0.00040572418947704136
with O 0 4.839721896132687e-06
genotype O 1 0.6807268261909485
in O 0 4.5543780288426206e-05
autosomal O 1 0.6666878461837769
dominant O 0 0.2531895935535431
cerebellar B-Disease 1 0.9998071789741516
ataxia I-Disease 1 0.9995287656784058
type I-Disease 0 0.005944996606558561
I I-Disease 0 6.705584382871166e-05
. O 0 1.2214579328428954e-05

We O 0 2.63545348389016e-06
compared O 0 5.618365776172141e-06
horizontal O 0 5.073326610727236e-05
eye O 0 0.00037804062594659626
movements O 0 1.95730353880208e-06
( O 0 4.560485677984616e-08
visually O 0 6.994640102675476e-07
guided O 0 8.649327014609298e-07
saccades O 0 0.005032946355640888
, O 0 5.149386694824898e-08
antisaccades O 0 2.2975635147304274e-05
, O 0 5.396775915045282e-09
and O 0 2.6437583233729356e-09
smooth O 0 1.0019741836231333e-07
pursuit O 0 3.2158698104467476e-06
) O 0 5.355452081801104e-09
in O 0 6.254377904468811e-09
control O 0 5.272566738767637e-08
subjects O 0 2.511196157684026e-07
( O 0 1.3932059950150233e-08
n O 0 2.536552528908942e-05
= O 0 1.8857695977203548e-05
14 O 0 7.821141956299016e-09
) O 0 2.300062806881442e-09
and O 0 1.6436780825301867e-08
patients O 0 6.969816723767508e-08
with O 0 6.355875381558462e-09
three O 0 1.3071992377433617e-08
forms O 0 3.6154460758552887e-07
of O 0 3.041930654035241e-07
autosomal O 0 0.025246530771255493
dominant O 0 0.00031129710259847343
cerebellar B-Disease 1 0.8930437564849854
ataxias I-Disease 0 0.15731683373451233
type I-Disease 0 4.6823028242215514e-05
I I-Disease 0 5.155576218385249e-06
spinocerebellar B-Disease 0 0.010239037685096264
ataxias I-Disease 0 5.974321538815275e-05
1 I-Disease 0 1.193851684178071e-08
and I-Disease 0 6.774795391351063e-09
2 I-Disease 0 1.669148375071927e-08
( O 0 9.647732390760666e-09
SCA1 B-Disease 0 6.36821350781247e-05
, O 0 1.8625810227490547e-08
n O 0 4.1228563532058615e-06
= O 0 3.6093420021643396e-06
11 O 0 1.6209940056910455e-08
; O 0 2.3609629806742305e-08
SCA2 B-Disease 0 3.2167110475711524e-05
, O 0 7.264233659043384e-09
n O 0 1.227168581863225e-06
= O 0 8.031440188460692e-07
10 O 0 1.524293247179287e-09
) O 0 1.5428995858712824e-09
and O 0 1.922974490753404e-08
SCA3 B-Disease 1 0.9931144118309021
/ O 0 9.875415707938373e-05
Machado B-Disease 0 0.00010842958727153018
- I-Disease 0 0.06829793751239777
Joseph I-Disease 0 0.02006572112441063
disease I-Disease 0 0.0017915299395099282
( O 0 1.979037307364706e-07
MJD B-Disease 1 0.9946660995483398
) O 0 2.2566052138017767e-08
( O 0 1.3477735372191546e-08
n O 0 1.161917043646099e-05
= O 0 2.2517788238474168e-05
16 O 0 1.9266609285750746e-07
) O 0 7.359516018823342e-08
. O 0 6.639516527684464e-07

In O 0 4.072124283993617e-06
SCA1 B-Disease 0 0.0002847279829438776
, O 0 1.2704030893928575e-07
saccade O 0 1.9822362446575426e-05
amplitude O 0 2.272497113153804e-06
was O 0 6.782750006095739e-08
significantly O 0 2.8873330393253127e-07
increased O 0 4.344902748698587e-08
, O 0 1.7451666778356412e-08
resulting O 0 2.0799834032914077e-07
in O 0 2.8603702162399713e-07
hypermetria B-Disease 0 0.0014635594561696053
. O 0 5.047947979619494e-06

The O 0 1.8711680240812711e-06
smooth O 0 3.27774023389793e-06
pursuit O 0 1.3791892342851497e-05
gain O 0 4.790016191691393e-06
was O 0 1.6338718751285342e-06
decreased O 0 3.0119203074718826e-05
. O 0 1.9075023374170996e-06

In O 0 4.154241196374642e-06
SCA2 B-Disease 0 0.0003296007926110178
, O 0 3.6031028116667585e-07
saccade O 0 6.073491385905072e-05
velocity O 0 5.698139375454048e-06
was O 0 7.953503313729016e-07
markedly O 0 5.328351107891649e-05
decreased O 0 2.469258106430061e-05
. O 0 2.7309201868774835e-06

The O 0 6.52633502795652e-07
percentage O 0 5.325009624357335e-07
of O 0 1.0130348115922061e-08
errors O 0 2.191229668824235e-07
in O 0 4.612131121461971e-08
antisaccades O 0 8.673148840898648e-05
was O 0 3.254362113125353e-08
greatly O 0 4.686084409399882e-08
increased O 0 1.194580612207119e-08
and O 0 4.64169280789406e-09
was O 0 2.0046407200879912e-08
significantly O 0 2.5442091100558173e-07
correlated O 0 7.592943234158156e-07
with O 0 9.559683178395062e-08
age O 0 9.535509889246896e-06
at O 0 1.8264450773131102e-05
disease O 0 0.0531097836792469
onset O 0 0.10804668813943863
. O 0 3.5547607694752514e-05

In O 0 1.48098456520529e-06
addition O 0 1.3052812164460192e-07
, O 0 1.0671409533813403e-08
a O 0 8.187782896129647e-09
correlation O 0 1.547699355342047e-07
between O 0 1.1755647122413393e-08
smooth O 0 3.061672089188505e-07
pursuit O 0 3.3078483738790965e-06
gain O 0 1.516942376156294e-07
and O 0 2.0484005602838806e-09
the O 0 9.60606372224504e-10
number O 0 2.9196889350657784e-09
of O 0 6.3107217229685375e-09
trinucleotide O 0 0.0007980965892784297
repeats O 0 4.583032023219857e-06
was O 0 7.667808432643142e-08
found O 0 2.889159134156216e-07
. O 0 1.0510874517422053e-06

In O 0 1.7140184354502708e-05
SCA3 B-Disease 1 0.9543465375900269
, O 0 5.070224915471044e-07
gaze B-Disease 0 6.45014806650579e-05
- I-Disease 0 0.0001739680883474648
evoked I-Disease 0 0.000458840950159356
nystagmus I-Disease 0 9.61900659603998e-05
was O 0 4.0222509767318115e-08
often O 0 1.0464047406344434e-08
present O 0 8.677946361501654e-09
as O 0 2.156760547933345e-09
was O 0 1.2544960625859858e-08
saccade O 0 1.6549500287510455e-05
hypometria O 0 1.6195210264413618e-05
and O 0 5.391178614644332e-09
smooth O 0 1.2301244112222776e-07
pursuit O 0 3.518560333759524e-06
gain O 0 1.4487500266113784e-06
was O 0 3.5857883062817564e-07
markedly O 0 3.0261804567999206e-05
decreased O 0 2.090677480737213e-05
. O 0 1.981276227525086e-06

Three O 0 7.729671551715001e-07
major O 0 7.177687848525238e-07
criteria O 0 4.7300949290729477e-07
, O 0 2.2687755674155596e-08
saccade O 0 9.381412382936105e-06
amplitude O 0 6.276273438743374e-07
, O 0 9.14530673412628e-09
saccade O 0 6.523188403662061e-06
velocity O 0 4.380571851925197e-07
, O 0 2.022729761463893e-09
and O 0 8.908744297819737e-10
presence O 0 4.179135260073963e-09
of O 0 2.0212873597103e-09
gaze B-Disease 0 3.563439167919569e-05
- I-Disease 0 0.00044522309326566756
evoked I-Disease 0 0.0005538661498576403
nystagmus I-Disease 0 2.143787241948303e-05
, O 0 2.2365334029217365e-09
permitted O 0 1.457434395391033e-09
the O 0 1.0569634056878385e-09
correct O 0 1.7056605017273796e-08
assignment O 0 1.1656179133012756e-08
of O 0 2.809769916733984e-10
90 O 0 1.8182887417950155e-09
% O 0 1.1306928726639853e-09
of O 0 4.4622441852659733e-10
the O 0 6.056819490396492e-09
SCA1 B-Disease 0 5.468764356919564e-05
, O 0 2.4718513902399764e-09
90 O 0 1.129039861602621e-09
% O 0 6.822081788371293e-10
of O 0 2.76996786618966e-10
the O 0 5.173838690808452e-09
SCA2 B-Disease 0 9.855358803179115e-05
, O 0 2.3663175863219976e-09
and O 0 2.8137294716401584e-09
93 O 0 2.7830084903257557e-08
% O 0 2.543884214389891e-09
of O 0 1.1870846527983758e-09
the O 0 8.218719216301906e-08
patients O 0 5.027027327741962e-07
with O 0 1.991212172924861e-07
SCA3 B-Disease 1 0.9995946288108826
to O 0 1.7100321159091436e-08
their O 0 1.9747965041005955e-08
genetically O 0 9.890566161629977e-07
confirmed O 0 5.771523774456e-06
patient O 0 4.160196567681851e-06
group O 0 1.228664672225932e-07
and O 0 1.821653405897905e-08
, O 0 2.4099545470335215e-08
therefore O 0 2.1334201960598875e-08
, O 0 1.8701278747812466e-08
may O 0 6.477183944753051e-08
help O 0 3.5096348938168376e-08
orient O 0 1.3328183285921114e-06
diagnoses O 0 1.7690723325358704e-05
of O 0 1.5480441817317114e-08
SCA1 B-Disease 0 0.06856413185596466
, O 0 9.627991914840095e-08
SCA2 B-Disease 0 0.0002853443438652903
, O 0 1.0793453242285977e-08
and O 0 1.985454645136997e-08
SCA3 B-Disease 1 0.9657196402549744
at O 0 3.3003818344923275e-08
early O 0 7.059632167738528e-08
clinical O 0 1.2391806194500532e-06
stages O 0 5.501908049154736e-07
of O 0 5.553644299993721e-08
the O 0 1.023654385789996e-05
diseases O 0 0.4836992025375366
. O 0 1.2426432931533782e-06
. O 0 4.576244919007877e-06

Genetic O 0 0.0006000431021675467
basis O 0 1.3984914630782441e-06
and O 0 1.1694413615259691e-06
molecular O 0 0.0011989715276286006
mechanism O 0 1.4891982573317364e-05
for O 0 4.169785461272113e-05
idiopathic B-Disease 1 0.9999909400939941
ventricular I-Disease 1 0.9998027682304382
fibrillation I-Disease 1 0.9998661279678345
. O 0 0.00032399260089732707

Ventricular B-Disease 1 0.9023200869560242
fibrillation I-Disease 1 0.8880132436752319
causes O 0 5.2119790780125186e-05
more O 0 4.552125076884295e-08
than O 0 1.4847299389941782e-08
300 O 0 2.5772715517291545e-08
, O 0 8.287632802250755e-09
000 O 0 1.0339972078554638e-07
sudden O 0 5.512061761692166e-06
deaths O 0 5.410598760136054e-07
each O 0 2.8248605676850502e-09
year O 0 3.8275167923984554e-08
in O 0 1.2531711668373191e-08
the O 0 1.1153977652611502e-07
USA O 0 2.895166471716948e-05
alone O 0 5.011574558011489e-06
. O 0 1.0285206144544645e-06

In O 0 5.261244950816035e-07
approximately O 0 8.52605737122758e-08
5 O 0 2.5667535652473816e-08
- O 0 1.1241785387028358e-06
12 O 0 1.0881842094079275e-08
% O 0 1.4329820663405712e-09
of O 0 7.343440855400729e-10
these O 0 5.2916862003371534e-09
cases O 0 6.450196821106147e-08
, O 0 1.8738841589538424e-08
there O 0 7.03035052396217e-09
are O 0 5.74293146371474e-09
no O 0 3.038402098809456e-07
demonstrable O 1 0.8847482800483704
cardiac O 1 0.8537968397140503
or O 0 9.405827086084173e-07
non O 0 8.741725650907028e-06
- O 1 0.9967164397239685
cardiac O 1 0.9917944073677063
causes O 0 4.211584382574074e-06
to O 0 7.509392219162692e-09
account O 0 1.6826374960032808e-08
for O 0 1.118788728327047e-09
the O 0 4.262772801411074e-09
episode O 0 1.9406333251481556e-07
, O 0 2.146027000549111e-08
which O 0 9.039105464125896e-09
is O 0 1.3249056962649775e-08
therefore O 0 4.93410858837251e-08
classified O 0 6.480911906692199e-06
as O 0 2.118589691235684e-05
idiopathic B-Disease 1 0.9999967813491821
ventricular I-Disease 1 0.9999189376831055
fibrillation I-Disease 1 0.999976396560669
( O 0 8.112165960483253e-05
IVF B-Disease 1 0.972394585609436
) O 0 1.0924100024567451e-06
. O 0 3.2553541586821666e-06

A O 0 3.888606443069875e-06
distinct O 0 6.9667459001721e-07
group O 0 2.492160149358824e-07
of O 0 1.2514530567386828e-07
IVF B-Disease 1 0.9969325065612793
patients O 0 2.160174335585907e-05
has O 0 9.968047010033843e-08
been O 0 1.821517692235375e-08
found O 0 1.3236554075035656e-08
to O 0 4.466819358839302e-09
present O 0 1.685965678177581e-08
with O 0 1.8683238067751518e-08
a O 0 5.686467261512007e-07
characteristic O 0 0.0002685171493794769
electrocardiographic O 0 0.10612820833921432
pattern O 0 0.00012999153113923967
. O 0 1.730778762976115e-06

Because O 0 7.949370797177835e-07
of O 0 1.3411933785789643e-08
the O 0 7.463356155312795e-09
small O 0 9.431668779313895e-09
size O 0 5.2349491852510255e-08
of O 0 1.371689428708578e-09
most O 0 3.09955661137451e-09
pedigrees O 0 3.48246680914599e-06
and O 0 8.174753318712646e-09
the O 0 1.5773757411352562e-08
high O 0 5.218059413891751e-06
incidence O 0 0.000186063363798894
of O 0 2.7809498703845748e-08
sudden B-Disease 0 0.0018334690248593688
death I-Disease 0 1.9996487026219256e-05
, O 0 2.2640808339247087e-08
however O 0 1.6193563823208024e-08
, O 0 4.20901606901225e-08
molecular O 0 8.226996578741819e-05
genetic O 0 2.3219020022224868e-06
studies O 0 3.628841227509838e-08
of O 0 9.360253017121067e-09
IVF B-Disease 0 0.2233361452817917
have O 0 5.003137459880236e-08
not O 0 5.883013631802214e-09
yet O 0 9.234175735173267e-08
been O 0 3.4276805394029e-08
done O 0 5.106040816826862e-07
. O 0 2.3689030967943836e-06

Because O 0 0.000643692968878895
IVF B-Disease 1 0.9985883831977844
causes O 0 0.1257382184267044
cardiac O 1 0.9959731698036194
rhythm O 0 0.022894149646162987
disturbance O 0 0.00020938956004101783
, O 0 4.121941898915793e-08
we O 0 1.3054551217805965e-08
investigated O 0 2.781926866646245e-07
whether O 0 5.6769042799942326e-08
malfunction O 0 1.4210322660801467e-05
of O 0 6.62973320686433e-09
ion O 0 4.1091800085268915e-05
channels O 0 6.337332933981088e-07
could O 0 2.911147305439954e-07
cause O 0 9.923644483933458e-07
the O 0 1.7622197390210204e-07
disorder O 0 6.239167851163074e-05
by O 0 4.1337198553037524e-08
studying O 0 1.005190824798774e-06
mutations O 0 6.921911221979826e-07
in O 0 2.591072423285823e-08
the O 0 2.7331532237440115e-07
cardiac O 0 0.02020268328487873
sodium O 0 2.7353087716619484e-05
channel O 0 2.6240475108352257e-06
gene O 0 2.530773826947552e-06
SCN5A O 0 0.0003144412476103753
. O 0 3.681593170767883e-06

We O 0 1.088551698558149e-06
have O 0 1.1115240283743333e-07
now O 0 3.2355529810956796e-08
identified O 0 6.784767947465298e-08
a O 0 1.0044617226867558e-07
missense O 0 0.001384573639370501
mutation O 0 2.8222232231200906e-06
, O 0 4.161564426397035e-09
a O 0 7.362911169650488e-09
splice O 0 6.65847846903489e-06
- O 0 0.0015173733700066805
donor O 0 0.00013945484533905983
mutation O 0 2.0953479179297574e-05
, O 0 1.701900487205421e-08
and O 0 9.215082918956341e-09
a O 0 5.890494207960728e-07
frameshift O 1 0.526347815990448
mutation O 0 1.4470681435341248e-06
in O 0 4.634774786183016e-09
the O 0 7.070045882073828e-09
coding O 0 1.3166072676540352e-06
region O 0 2.6124904906055235e-08
of O 0 3.997384645515467e-09
SCN5A O 0 0.0005517008830793202
in O 0 4.631525030163175e-08
three O 0 2.12291155321509e-07
IVF B-Disease 0 0.249806210398674
families O 0 7.137188731576316e-06
. O 0 7.715501851635054e-06

We O 0 5.273929559734825e-07
show O 0 1.8866374773551797e-07
that O 0 7.338487595376364e-09
sodium O 0 6.41473860696351e-08
channels O 0 9.454597105218454e-09
with O 0 3.0373918935566735e-09
the O 0 2.786025454781793e-08
missense O 0 0.0003404004673939198
mutation O 0 4.365551831142511e-06
recover O 0 3.101896936641424e-06
from O 0 1.449274300568959e-08
inactivation O 0 1.8467371774022467e-05
more O 0 2.8085660463972317e-09
rapidly O 0 8.071815926768977e-08
than O 0 2.7633624277711988e-09
normal O 0 1.5663280450439743e-08
and O 0 2.584102265501542e-09
that O 0 4.291652366816834e-09
the O 0 4.8109928485473574e-08
frameshift O 0 0.13048824667930603
mutation O 0 7.00202826919849e-06
causes O 0 9.596055150495886e-08
the O 0 5.99800475953316e-09
sodium O 0 1.8246983302105946e-07
channel O 0 2.6602801739272763e-08
to O 0 3.068439724529526e-09
be O 0 5.607040165500621e-09
non O 0 1.3693562550542993e-07
- O 0 8.079525287030265e-05
functional O 0 1.762666397553403e-05
. O 0 3.6598612496163696e-06

Our O 0 4.580366294248961e-06
results O 0 3.8842554204165936e-06
indicate O 0 1.185385826829588e-06
that O 0 3.457543584772793e-08
mutations O 0 9.645459613238927e-07
in O 0 6.474515856780272e-08
cardiac O 0 0.001357634668238461
ion O 0 0.00011109869956271723
- O 0 0.00033785990672186017
channel O 0 1.298839151786524e-07
genes O 0 1.0614448875401195e-08
contribute O 0 3.7278984343913635e-09
to O 0 1.1972625113543245e-09
the O 0 6.6911809426528635e-09
risk O 0 1.4181037499838567e-07
of O 0 1.5855471602321813e-08
developing O 0 1.5740084563731216e-05
IVF B-Disease 1 0.8895596265792847
. O 0 1.5006886542323628e-06
. O 0 2.9382431421254296e-06

Molecular O 0 0.005641622003167868
heterogeneity O 0 0.000834797858260572
in O 0 3.484958597255172e-06
mucopolysaccharidosis B-Disease 0 0.02039068564772606
IVA I-Disease 0 0.025850921869277954
in O 0 1.9634734371720697e-07
Australia O 0 7.27302591485568e-08
and O 0 1.6166929128758056e-08
Northern O 0 5.1403389988990966e-08
Ireland O 0 1.1558362444930026e-07
: O 0 2.7829237581045163e-08
nine O 0 2.4319618319168512e-08
novel O 0 1.81259579790094e-07
mutations O 0 3.123165868146316e-07
including O 0 2.464913073652042e-08
T312S O 0 3.922203541151248e-05
, O 0 9.99576421634174e-09
a O 0 1.932678017624312e-08
common O 0 2.250620383392743e-07
allele O 0 2.034217686741613e-06
that O 0 3.68522812266292e-08
confers O 0 1.866023194452282e-05
a O 0 7.3947171586041804e-06
mild O 1 0.5568768978118896
phenotype O 1 0.8077667951583862
. O 0 1.7007758287945762e-05

Mucopolysaccharidosis B-Disease 0 0.4875156879425049
IVA I-Disease 1 0.5918130278587341
( O 0 1.0447740351082757e-05
MPS B-Disease 1 0.6882714629173279
IVA I-Disease 1 0.9994644522666931
) O 0 3.455711237165815e-07
is O 0 3.741520515632146e-08
an O 0 2.744450000591314e-07
autosomal B-Disease 1 0.9771978259086609
recessive I-Disease 1 0.9985950589179993
lysosomal I-Disease 1 0.9999852180480957
storage I-Disease 1 0.9999760389328003
disorder I-Disease 1 0.970147430896759
caused O 0 7.128660945454612e-05
by O 0 2.802895551212714e-07
a O 0 7.546889537479728e-05
genetic B-Disease 1 0.9986578226089478
defect I-Disease 1 0.9659436345100403
in O 0 2.0426378455340455e-07
N O 0 3.739509702427313e-05
- O 0 0.0001298177521675825
acetylgalactosamine O 0 0.000504267169162631
- O 0 0.0001070087164407596
6 O 0 9.514422458778427e-07
- O 0 0.00455519650131464
sulfate O 0 0.11962710320949554
sulfatase O 0 0.2865961492061615
( O 0 3.2817200690260506e-07
GALNS O 0 0.0001801679318305105
) O 0 2.1774580716282799e-07
. O 0 1.7153278122350457e-06

Previous O 0 9.201295142702293e-06
studies O 0 1.5275267060133046e-06
of O 0 7.164270243720239e-08
patients O 0 6.833535053374362e-07
from O 0 1.5536556929873768e-08
a O 0 2.7556477988355255e-08
British O 0 1.3386193131736945e-06
- O 0 0.000583810149691999
Irish O 0 2.1431776531244395e-06
population O 0 2.691351141947962e-08
showed O 0 1.52197927150155e-07
that O 0 2.6658102392218552e-09
the O 0 7.98989496786362e-09
I113F O 0 0.00015040066500660032
mutation O 0 1.02292926840164e-06
is O 0 1.395745297116946e-09
the O 0 1.3395973219587631e-09
most O 0 2.922814656969308e-09
common O 0 3.389000369224959e-08
single O 0 4.4678699850919656e-07
mutation O 0 1.3434968423098326e-05
among O 0 5.385579129324469e-07
MPS B-Disease 1 0.9945804476737976
IVA I-Disease 1 0.9999822378158569
patients O 0 0.00013413526176009327
and O 0 9.509968208476494e-07
produces O 0 7.651614396309014e-06
a O 0 1.112232894229237e-05
severe O 1 0.8130913376808167
clinical O 0 0.49930933117866516
phenotype O 1 0.9882785081863403
. O 0 3.286634455434978e-05

We O 0 2.2120675566839054e-06
studied O 0 2.4177459181373706e-06
mutations O 0 1.1813513083325233e-06
in O 0 1.7833961862834258e-08
the O 0 1.2241297753234903e-08
GALNS O 0 7.489355630241334e-05
gene O 0 7.471164309436062e-08
from O 0 3.1089235630332723e-09
23 O 0 3.675456738960747e-08
additional O 0 6.313528899681842e-08
MPS B-Disease 1 0.9371521472930908
IVA I-Disease 1 0.999976634979248
patients O 0 2.594762554508634e-05
( O 0 1.664747983909365e-08
15 O 0 4.811779863445054e-09
from O 0 2.3759416656332633e-09
Australia O 0 2.35277237692344e-08
, O 0 3.874109921753188e-09
8 O 0 6.602815183498478e-09
from O 0 2.969952506148843e-09
Northern O 0 4.978283385526083e-08
Ireland O 0 9.848195503536772e-08
) O 0 3.0781119875200602e-09
, O 0 1.1239862374168297e-09
with O 0 4.320414692671193e-09
various O 0 1.1068316752016472e-07
clinical O 0 0.04164835065603256
phenotypes O 1 0.9658329486846924
( O 0 4.120026460441295e-06
severe O 0 0.0026248465292155743
, O 0 2.3163937612480368e-07
16 O 0 1.6189122220566787e-07
cases O 0 1.0895595892179699e-07
; O 0 6.108700176810089e-07
intermediate O 0 2.671278707566671e-06
, O 0 2.30951116009237e-08
4 O 0 1.2678371774654806e-07
cases O 0 2.0046832105435897e-07
; O 0 3.936992925446248e-06
mild O 0 0.00015028240159153938
, O 0 2.425373111236695e-07
3 O 0 3.434919619849097e-07
cases O 0 9.911472034218605e-07
) O 0 5.197193218009488e-07
. O 0 2.131861947418656e-06

We O 0 8.687942454344011e-07
found O 0 1.4245706836391037e-07
two O 0 1.3329993109323368e-08
common O 0 2.5409767090422974e-07
mutations O 0 4.06831389909712e-07
that O 0 2.3955903927230793e-09
together O 0 3.5334100090267384e-09
accounted O 0 3.1055943594537894e-08
for O 0 9.287919877642992e-10
32 O 0 8.28172286304607e-09
% O 0 1.7288656062319774e-09
of O 0 7.630350240539485e-10
the O 0 1.8050206662678647e-08
44 O 0 2.287235645326291e-07
unrelated O 0 2.065326043521054e-06
alleles O 0 9.845930435403716e-07
in O 0 1.0135338612826672e-07
these O 0 3.3316263170490856e-07
patients O 0 2.4122686227201484e-05
. O 0 6.910500815138221e-06

One O 0 7.510167847613047e-07
is O 0 3.530858450062624e-08
the O 0 3.3078308092626685e-08
T312S O 0 3.150401607854292e-05
mutation O 0 1.4321951766760321e-06
, O 0 4.678464282648065e-09
a O 0 1.494167278792702e-08
novel O 0 6.059052566342871e-07
mutation O 0 1.117643932957435e-06
found O 0 2.8898774928620696e-08
exclusively O 0 8.218609792720599e-08
in O 0 6.939400236660731e-07
milder O 0 0.01208721473813057
patients O 0 7.136713247746229e-05
. O 0 1.2776369658240583e-05

The O 0 8.16713395579427e-07
other O 0 3.987646834957559e-08
is O 0 1.2995672094007205e-08
the O 0 6.99916258284361e-09
previously O 0 1.577453190293454e-07
described O 0 1.1250709803789505e-06
I113F O 0 1.2240326213941444e-05
that O 0 5.2609539835657415e-08
produces O 0 1.0386258963990258e-06
a O 0 3.091943881372572e-06
severe O 1 0.7516533732414246
phenotype O 1 0.9443238377571106
. O 0 4.168286614003591e-05

The O 0 1.5302751990020624e-06
I113F O 0 2.5125207685050555e-05
and O 0 1.6330993446445063e-07
T312S O 0 6.449649663409218e-05
mutations O 0 2.1923513031651964e-06
accounted O 0 1.0051478938066793e-07
for O 0 4.5395682768401e-09
8 O 0 2.9687987179727315e-08
( O 0 6.963063903242528e-09
18 O 0 1.5318953217047238e-08
% O 0 4.816076870639563e-09
) O 0 1.0817974294141663e-09
and O 0 2.912563745738339e-09
6 O 0 1.9254517980016317e-08
( O 0 1.607838751027657e-09
14 O 0 4.253384311425634e-09
% O 0 3.0924884875105363e-09
) O 0 5.269544800512449e-10
of O 0 1.190958220931293e-09
44 O 0 1.3662061348895804e-07
unrelated O 0 4.8074252845253795e-06
alleles O 0 1.5555065147054847e-06
, O 0 1.4767182676678203e-07
respectively O 0 8.484198588121217e-06
. O 0 3.837615622614976e-06

The O 0 1.4750110040040454e-06
relatively O 0 5.100404791846813e-07
high O 0 3.0873923151375493e-07
residual O 0 1.8164881112170406e-05
GALNS O 0 0.00018307009304407984
activity O 0 1.4822956018178957e-07
seen O 0 3.237219559082405e-08
when O 0 3.776074564143528e-09
the O 0 3.234372769611582e-09
T312S O 0 4.232515209423582e-07
mutant O 0 2.2382036490853352e-07
cDNA O 0 9.006788559418055e-08
is O 0 1.3854205782592999e-08
overexpressed O 0 1.4538683217324433e-06
in O 0 3.456172237292776e-08
mutant O 0 1.2565919860207941e-05
cells O 0 2.8903139082103735e-07
provides O 0 7.793206968642608e-09
an O 0 8.592068168056244e-10
explanation O 0 3.338750431680637e-08
for O 0 3.191853448214488e-09
the O 0 1.1050196491169118e-07
mild O 0 0.06468506902456284
phenotype O 0 0.2314259558916092
in O 0 5.123767436998605e-07
patients O 0 1.2478911912694457e-06
with O 0 1.608068771474791e-07
this O 0 1.37430311042408e-06
mutation O 0 6.644731911364943e-05
. O 0 2.6498335046198918e-06

The O 0 5.326340328792867e-07
distribution O 0 1.8815040903064073e-07
and O 0 2.070311211355147e-08
relative O 0 2.0487226493060007e-07
frequencies O 0 4.661978181275117e-08
of O 0 1.1282218492780771e-09
the O 0 5.5427098466509506e-09
I113F O 0 2.53034181696421e-06
and O 0 3.1417105361697395e-08
T312S O 0 2.169716935895849e-05
mutations O 0 2.7600856356002623e-07
in O 0 5.256317159307855e-09
Australia O 0 1.6149302339840688e-08
corresponded O 0 9.520470456436669e-08
to O 0 3.492218070277886e-09
those O 0 5.912869749380434e-09
observed O 0 3.794197311890457e-08
in O 0 6.478268588239189e-09
Northern O 0 4.0251212141129145e-08
Ireland O 0 1.1144280875896584e-07
and O 0 6.7740586473519215e-09
are O 0 6.636966531914368e-10
unique O 0 7.1870833728837624e-09
to O 0 1.0968292940560787e-09
these O 0 8.844340260161232e-10
two O 0 2.7979845107495294e-09
populations O 0 1.4472611553628667e-07
, O 0 8.59108872930392e-09
suggesting O 0 7.466463358696274e-08
that O 0 2.6180562162636534e-09
both O 0 4.636295347637542e-09
mutations O 0 2.0339506079380953e-07
were O 0 5.1147908131099484e-09
probably O 0 2.127747222857579e-08
introduced O 0 1.928057358213664e-08
to O 0 1.3857422986873758e-09
Australia O 0 5.267236424799648e-09
by O 0 1.9695067798863874e-09
Irish O 0 1.1272452837829405e-07
migrants O 0 2.1395775817723006e-08
during O 0 1.0291899776859736e-08
the O 0 1.3057515069192505e-08
19th O 0 6.755995514140523e-07
century O 0 1.5563359738735016e-06
. O 0 2.019382691287319e-06

Haplotype O 0 0.038080111145973206
analysis O 0 4.986417025065748e-06
using O 0 2.9070776008666144e-07
6 O 0 2.3324496112309134e-07
RFLPs O 0 8.36631988931913e-06
provides O 0 2.2457633974681812e-08
additional O 0 5.689573256972835e-09
data O 0 1.967108786971039e-08
that O 0 1.0870220279457499e-09
the O 0 4.84987960902572e-09
I113F O 0 2.1495685359695926e-05
mutation O 0 8.976721233011631e-07
originated O 0 4.402672715286826e-08
from O 0 5.371389999453413e-09
a O 0 5.2846484521751336e-08
common O 0 1.3868530004401691e-06
ancestor O 0 6.226199184311554e-05
. O 0 7.622881184943253e-06

The O 0 3.378413566679228e-07
other O 0 3.617018151658158e-08
9 O 0 1.8500603005122684e-07
novel O 0 4.999645852876711e-07
mutations O 0 1.8467547988620936e-06
identified O 0 1.9295883646464063e-07
in O 0 9.882248797055126e-09
these O 0 9.046210891483497e-09
23 O 0 8.762539778217615e-07
patients O 0 1.5675958309202542e-07
were O 0 2.3722916964175056e-09
each O 0 1.986544706511495e-09
limited O 0 5.94377258522627e-09
to O 0 2.0687076496272994e-09
a O 0 4.786353713370772e-08
single O 0 1.1722015642590122e-06
family O 0 2.295003923791228e-06
. O 0 4.604581135936314e-06

These O 0 7.520875442423858e-07
data O 0 7.240616355375096e-07
provide O 0 2.9504409582159496e-08
further O 0 1.153372686246712e-08
evidence O 0 3.0156193986385915e-08
for O 0 6.340788782921436e-09
extensive O 0 1.009131665341556e-06
allelic O 0 0.0027308096177875996
heterogeneity O 0 0.001098332810215652
in O 0 2.058037352981046e-06
MPS B-Disease 0 0.3424934446811676
IVA I-Disease 1 0.9929996728897095
in O 0 3.2855655263119843e-07
British O 0 1.9030179601031705e-06
- O 0 0.01575143076479435
Irish O 0 8.225866622524336e-05
patients O 0 6.425215133276652e-07
and O 0 1.3486273431340123e-08
provide O 0 1.3495974116040088e-08
evidence O 0 1.805206473193266e-08
for O 0 1.4764942601885878e-09
their O 0 1.5606053338501624e-08
transmission O 0 9.264366553907166e-07
to O 0 1.8949668501022643e-09
Australia O 0 1.0053200938386908e-08
by O 0 2.4917374830124572e-09
British O 0 1.9184945188044367e-07
- O 0 2.2753880330128595e-05
Irish O 0 1.7286607771893614e-06
migrants O 0 2.977515691782173e-07
. O 0 1.1945468259000336e-07
. O 0 1.2497944226197433e-06

Identification O 0 1.3171186765248422e-05
of O 0 4.6603156533819856e-07
constitutional O 0 1.9907743990188465e-05
WT1 O 1 0.8999853730201721
mutations O 0 0.00023134889488574117
, O 0 1.3345896832106519e-07
in O 0 2.9031431836301635e-07
patients O 0 1.5112863138710964e-06
with O 0 1.1706018767654314e-06
isolated O 0 0.05163348466157913
diffuse B-Disease 1 0.999923586845398
mesangial I-Disease 1 0.9999992847442627
sclerosis I-Disease 1 0.9999966621398926
, O 0 5.52052426883165e-07
and O 0 3.353583011289629e-08
analysis O 0 7.53691651311783e-08
of O 0 4.996042690663671e-08
genotype O 1 0.7483127117156982
/ O 0 0.07463599741458893
phenotype O 0 0.011315545998513699
correlations O 0 2.3271311420103302e-06
by O 0 2.7271702673914433e-09
use O 0 6.095528082283863e-09
of O 0 6.6544245669319935e-09
a O 0 5.314811915013706e-07
computerized O 0 0.42664408683776855
mutation O 0 0.00023693505499977618
database O 0 1.8809631001204252e-05
. O 0 4.008303676528158e-06

Constitutional O 0 4.246063326718286e-05
mutations O 0 1.8099724911735393e-05
of O 0 3.617501320718475e-08
the O 0 7.455491157770666e-08
WT1 O 0 0.000496506632771343
gene O 0 1.7083914372051368e-07
, O 0 3.2006324257594088e-09
encoding O 0 1.6482994524835703e-08
a O 0 1.8802818857466264e-08
zinc O 0 0.00016780899022705853
- O 0 7.2552675192127936e-06
finger O 0 6.26938174264069e-07
transcription O 0 4.265833197791835e-08
factor O 0 1.1659025744847895e-08
involved O 0 1.1991050818949134e-08
in O 0 2.399811194209178e-07
renal O 1 0.6170603632926941
and O 0 3.4508414046285907e-06
gonadal O 1 0.9477639198303223
development O 0 6.899634854562464e-07
, O 0 2.7880826536375025e-08
are O 0 1.9943919848941505e-09
found O 0 2.0101465381117123e-08
in O 0 2.4055916370002706e-08
most O 0 3.8703745985912974e-08
patients O 0 2.0444963411136996e-06
with O 0 6.571661288035102e-06
Denys B-Disease 1 0.9999431371688843
- I-Disease 1 0.9999933242797852
Drash I-Disease 1 0.9999959468841553
syndrome I-Disease 1 0.999990701675415
( O 0 9.490764568909071e-06
DDS B-Disease 1 0.9999428987503052
) O 0 1.3145606203579518e-07
, O 0 7.834822213226289e-08
or O 0 3.5097064028377645e-06
diffuse B-Disease 1 0.9989944100379944
mesangial I-Disease 1 0.9999995231628418
sclerosis I-Disease 1 0.9999986886978149
( O 0 4.152314431848936e-05
DMS B-Disease 1 0.9837653040885925
) O 0 7.185550998656254e-08
associated O 0 2.512666981147049e-07
with O 0 9.166335956933835e-08
pseudohermaphroditism B-Disease 1 0.9992573857307434
and O 0 6.640918400080409e-06
/ O 0 0.003930979408323765
or O 0 7.598754018545151e-05
Wilms B-Disease 1 0.999830961227417
tumor I-Disease 1 0.6455605626106262
( O 0 9.101498108066153e-06
WT B-Disease 1 0.9997209906578064
) O 0 8.809597034087346e-07
. O 0 3.3266971968259895e-06

Most O 0 1.4467520486505236e-05
mutations O 0 0.00034489165409468114
in O 0 3.232899325666949e-05
DDS B-Disease 1 0.9999731779098511
patients O 0 0.00017523806309327483
lie O 0 6.012442827341147e-05
in O 0 2.507027829778963e-07
exon O 0 0.00010234121873509139
8 O 0 1.5247383089445066e-07
or O 0 1.1923270371028138e-08
exon O 0 4.724694008473307e-06
9 O 0 5.689749471571304e-08
, O 0 2.6042452638819213e-09
encoding O 0 4.264450481628046e-08
zinc O 0 5.3151961765252054e-05
finger O 0 2.6259147034579655e-07
2 O 0 6.4424967582965564e-09
or O 0 7.56860529804726e-09
zinc O 0 0.00012102642358513549
finger O 0 1.293916511713178e-06
3 O 0 2.6300892130848297e-08
, O 0 9.834320024992849e-09
respectively O 0 6.358619231150442e-08
, O 0 2.112194641412657e-09
with O 0 1.404716343245127e-09
a O 0 2.922559971807459e-08
hot O 0 2.1555520106630865e-06
spot O 0 2.093686589432764e-06
( O 0 1.623528156358134e-08
R394W O 0 2.381047806920833e-06
) O 0 7.953767422463898e-09
in O 0 2.4885137506203137e-08
exon O 0 5.7737535826163366e-05
9 O 0 5.434565537143499e-06
. O 0 1.8062592062051408e-06

We O 0 1.3181262374928338e-06
analyzed O 0 9.094115398511349e-07
a O 0 2.3100133361708686e-08
series O 0 2.1629325885896833e-08
of O 0 1.102366820049383e-08
24 O 0 1.6397503941334435e-06
patients O 0 8.933670301303209e-07
, O 0 1.8276045565812638e-08
10 O 0 8.426866315858206e-09
with O 0 9.460661942739534e-08
isolated B-Disease 0 9.486648923484609e-05
DMS I-Disease 1 0.9966211318969727
( O 0 5.462559897750907e-07
IDMS B-Disease 0 0.14795130491256714
) O 0 2.0797068955857867e-08
, O 0 5.256648449858403e-09
10 O 0 3.672119497366566e-09
with O 0 9.36393433903504e-08
DDS B-Disease 1 0.9999414682388306
, O 0 6.436432187229002e-08
and O 0 2.238715346436493e-08
4 O 0 8.462321687829899e-08
with O 0 1.1508672059790115e-06
urogenital B-Disease 1 0.9998565912246704
abnormalities I-Disease 1 0.9964699745178223
and O 0 9.683583812147845e-06
/ O 0 0.010958775877952576
or O 0 3.116111474810168e-05
WT B-Disease 1 0.9998739957809448
. O 0 1.9162072931067087e-05

We O 0 6.712077265547123e-06
report O 0 6.3842148847470526e-06
WT1 O 0 0.0017257105791941285
heterozygous O 0 2.338271042390261e-05
mutations O 0 1.2784512364305556e-05
in O 0 1.1495077956169553e-07
16 O 0 8.026371460800874e-07
patients O 0 2.0560009943437763e-06
, O 0 2.4277257537619334e-08
4 O 0 2.9185546424059794e-08
of O 0 1.359598833516884e-08
whom O 0 2.554213324401644e-06
presented O 0 1.0117072633875068e-05
with O 0 1.746344605635386e-05
IDMS B-Disease 1 0.9924352765083313
. O 0 1.4819474017713219e-05

One O 0 1.8740487348622992e-06
male O 0 3.933877906092675e-06
and O 0 1.2785891101430025e-07
two O 0 1.5430997279963776e-07
female O 0 0.004014268051832914
IDMS B-Disease 1 0.9995648264884949
patients O 0 7.088414713507518e-05
with O 0 7.230145456560422e-06
WT1 O 1 0.9831455945968628
mutations O 0 0.0006839917041361332
underwent O 0 0.003125961171463132
normal O 0 6.114356801845133e-05
puberty O 0 0.0005968909244984388
. O 0 9.01067687664181e-06

Two O 0 6.924632089067018e-06
mutations O 0 0.00034166910336352885
associated O 0 3.706263441927149e-06
with O 0 6.10511847298767e-07
IDMS B-Disease 0 0.35399600863456726
are O 0 1.9010860441426303e-08
different O 0 6.8265633146324944e-09
from O 0 1.059846699291711e-08
those O 0 6.109532790787853e-08
described O 0 9.277874596591573e-06
in O 0 4.0809070924296975e-05
DDS B-Disease 1 0.9999682903289795
patients O 0 0.0007324247271753848
. O 0 2.5513074433547445e-05

No O 0 4.79701193398796e-05
WT1 O 1 0.5285924077033997
mutations O 0 0.00018850334163289517
were O 0 1.3611224858323112e-07
detected O 0 4.114858711545821e-06
in O 0 9.998127659116562e-09
the O 0 1.3216320482456467e-08
six O 0 1.1672313604549345e-07
other O 0 4.172289038706367e-07
IDMS B-Disease 1 0.9980698227882385
patients O 0 2.6442787202540785e-05
, O 0 1.829081952564593e-07
suggesting O 0 7.737437954347115e-06
genetic O 0 7.781520253047347e-06
heterogeneity O 0 3.437630948610604e-05
of O 0 1.2660731840696826e-07
this O 0 8.127019100356847e-06
disease O 0 0.003529366571456194
. O 0 7.997215107025113e-06

We O 0 7.27563156033284e-06
analyzed O 0 0.00018101514433510602
genotype O 0 0.41785600781440735
/ O 0 0.04796302318572998
phenotype O 0 0.2521504759788513
correlations O 0 3.073219340876676e-05
, O 0 1.7284905950987195e-08
on O 0 4.42349490370475e-09
the O 0 2.016654621073144e-09
basis O 0 8.219213643023693e-10
of O 0 3.6252681412385357e-10
the O 0 2.0709027825915882e-09
constitution O 0 6.7913945578368384e-09
of O 0 1.2899303847291321e-09
a O 0 8.424428443731813e-08
WT1 O 0 0.004177980590611696
mutation O 0 5.189323815102398e-07
database O 0 2.3960668116274064e-08
of O 0 1.7827661569214115e-09
84 O 0 1.211136151368919e-07
germ O 0 0.003112431848421693
- O 0 0.0005086816381663084
line O 0 9.388249964104034e-06
mutations O 0 6.987119718360191e-07
, O 0 1.8225942977068144e-09
to O 0 6.752512438090719e-10
compare O 0 3.591123132196117e-08
the O 0 1.1728116255937948e-09
distribution O 0 2.396678189242607e-09
and O 0 5.3385122988913736e-09
type O 0 2.0108966225507174e-07
of O 0 9.911111042981702e-09
mutations O 0 2.6910131509794155e-06
, O 0 8.759847958117462e-09
according O 0 1.7405659136215945e-08
to O 0 2.749325433981653e-09
the O 0 3.055196273749061e-08
different O 0 5.824705908707983e-07
symptoms O 0 0.0015033335657790303
. O 0 5.115923613630002e-06

This O 0 2.3332179353019455e-06
demonstrated O 0 4.12376857639174e-06
( O 0 2.840671342596579e-08
1 O 0 5.780460998749959e-09
) O 0 2.1021671070542425e-09
the O 0 4.052002289256507e-09
association O 0 2.78879532800147e-08
between O 0 1.116915182564071e-08
mutations O 0 2.653085289239243e-07
in O 0 1.2970612139895366e-08
exons O 0 4.7319585405602993e-07
8 O 0 1.1300573810046899e-08
and O 0 4.624073124404049e-09
9 O 0 9.349425766913555e-08
and O 0 2.2775537900088239e-07
DMS B-Disease 0 0.4362330436706543
; O 0 1.1720725012764888e-07
( O 0 2.4739361670356175e-09
2 O 0 6.499084825861701e-09
) O 0 4.097045369633179e-09
among O 0 1.966208706960515e-08
patients O 0 2.376600747311386e-07
with O 0 3.1317617299464473e-07
DMS B-Disease 1 0.9792750477790833
, O 0 1.9263884709630474e-08
a O 0 1.0954145146513383e-08
higher O 0 9.446868176610224e-08
frequency O 0 2.6223652582757495e-08
of O 0 3.105343981957276e-09
exon O 0 3.74117553292308e-05
8 O 0 4.211023281186499e-07
mutations O 0 3.740867953183624e-07
among O 0 1.1290748780368176e-08
46 O 0 1.2949988104082877e-07
, O 0 3.752892325792345e-07
XY O 0 0.14865514636039734
patients O 0 7.535535928582249e-07
with O 0 1.0155521579235938e-07
female O 0 0.00017357525939587504
phenotype O 0 0.0062664952129125595
than O 0 1.113870862212707e-08
among O 0 1.6821754655893528e-08
46 O 0 4.819093533114938e-07
, O 0 8.386605827581661e-07
XY O 0 0.1539827585220337
patients O 0 5.210289941715018e-07
with O 0 3.2699166041538774e-08
sexual O 0 1.0542698873905465e-06
ambiguity O 0 5.0099260988645256e-06
or O 0 1.0494547950656852e-06
male O 0 0.0007183740381151438
phenotype O 0 0.10721445083618164
; O 0 1.0823845286722644e-07
and O 0 1.818567163525131e-08
( O 0 6.173111799512299e-09
3 O 0 1.0941407779796464e-08
) O 0 2.6464777036494525e-09
statistically O 0 2.2258271670239083e-08
significant O 0 9.060232564195303e-09
evidence O 0 8.416975560976425e-08
that O 0 2.646837415909431e-08
mutations O 0 2.385374671121099e-07
in O 0 1.0329717525792148e-08
exons O 0 4.0323524785890186e-07
8 O 0 1.522576731360914e-08
and O 0 3.339837961746639e-09
9 O 0 2.658332398652874e-08
preferentially O 0 2.1061940458366735e-07
affect O 0 5.783904910572346e-08
amino O 0 2.0413109425021503e-08
acids O 0 5.725257601341127e-09
with O 0 1.3622873940022373e-09
different O 0 5.4838644736321385e-09
functions O 0 3.898513867284237e-08
. O 0 2.2696850976444694e-07
. O 0 1.1464767339930404e-06

The O 0 3.956814452976687e-06
185delAG O 0 0.0006232614396139979
BRCA1 O 0 0.000578413309995085
mutation O 0 1.4322677088784985e-05
originated O 0 3.1168104897005833e-07
before O 0 6.865894075502865e-09
the O 0 1.9207373469498634e-09
dispersion O 0 1.207195907682035e-07
of O 0 1.5256196306268066e-09
Jews O 0 1.3997343728533451e-08
in O 0 5.2495243707539885e-09
the O 0 4.323745361745068e-09
diaspora O 0 1.9891831470886245e-07
and O 0 1.2713673669395575e-08
is O 0 2.926100028943779e-09
not O 0 4.062480574162919e-09
limited O 0 3.1825418744801937e-08
to O 0 4.533219311042558e-08
Ashkenazim O 0 3.889497020281851e-05
. O 0 1.6898537751330878e-06

The O 0 3.400932655495126e-06
185delAG O 0 0.001242873608134687
mutation O 0 8.830097794998437e-05
in O 0 1.0354137884860393e-06
BRCA1 O 0 0.0001439966872567311
is O 0 1.619310694422893e-07
detected O 0 6.218295311555266e-06
in O 0 6.18279969444302e-08
Ashkenazi O 0 1.2791358585673152e-06
Jews O 0 3.294538686304804e-08
both O 0 8.094692915960877e-09
in O 0 5.584772679867456e-07
familial B-Disease 1 0.9774847626686096
breast I-Disease 1 0.9998984336853027
and I-Disease 1 0.9991604089736938
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999868869781494
and O 0 2.2811732947047858e-07
in O 0 2.598689619048855e-08
the O 0 2.5517580937162165e-08
general O 0 5.014974817640905e-07
population O 0 8.037761176638014e-07
. O 0 1.5460310578419012e-06

All O 0 1.697739890005323e-06
tested O 0 2.9349830583669245e-05
Ashkenazi O 0 6.26724140602164e-05
mutation O 0 1.424308902642224e-05
carriers O 0 4.791349965671543e-07
share O 0 4.914966211799765e-08
the O 0 8.033415710428926e-09
same O 0 3.565719097764486e-08
allelic O 0 2.7888547265320085e-05
pattern O 0 2.361560973440646e-06
at O 0 5.0569017417956275e-08
the O 0 2.1476245137819205e-07
BRCA1 O 0 0.0003444500616751611
locus O 0 0.0002251360274385661
. O 0 9.161683010461275e-06

Our O 0 2.2506685581902275e-06
previous O 0 9.012714485834294e-07
study O 0 3.6914863699166744e-07
showed O 0 5.965035825283849e-07
that O 0 6.48247056034279e-09
this O 0 1.1516711140302505e-08
Ashkenazi O 0 1.1718768291757442e-05
mutation O 0 3.4833037716452964e-06
also O 0 1.7330792800862582e-08
occurs O 0 2.356868655795097e-08
in O 0 1.985483999433768e-09
Iraqi O 0 5.493865629091488e-08
Jews O 0 6.3596838906221365e-09
with O 0 5.009054504512278e-09
a O 0 6.352848203050598e-08
similar O 0 2.7367473194317427e-06
allelic O 0 0.0014175517717376351
pattern O 0 0.00011209923832211643
. O 0 2.7142921226186445e-06

We O 0 6.211943173184409e-07
extended O 0 1.460299046129876e-07
our O 0 5.05416295482064e-08
analysis O 0 1.8582094085672907e-08
to O 0 1.6351408005377266e-09
other O 0 9.890579466542704e-10
non O 0 1.4311827278845612e-08
- O 0 3.49876199834398e-06
Ashkenazi O 0 2.730884034463088e-07
subsets O 0 1.5266762432020187e-07
354 O 0 9.97961251414381e-08
of O 0 2.5754520738274778e-09
Moroccan O 0 1.1129681070087827e-06
origin O 0 4.4809528532141485e-08
, O 0 4.746948167877463e-09
200 O 0 1.4485115329421205e-08
Yemenites O 0 2.1850664779776707e-06
and O 0 1.743499922213232e-08
150 O 0 5.50594982939856e-08
Iranian O 0 1.0853175353986444e-06
Jews O 0 1.0386100939285825e-06
. O 0 1.3722705034524552e-06

Heteroduplex O 0 0.0007249230984598398
analysis O 0 2.599999106678297e-06
complemented O 0 8.869433258951176e-07
by O 0 1.6428884919150732e-08
direct O 0 2.59237253885658e-08
DNA O 0 2.6914725026472297e-07
sequencing O 0 2.590154224435537e-07
of O 0 2.704824098032077e-08
abnormally O 0 2.392054011579603e-05
migrating O 0 6.221974899744964e-07
bands O 0 3.2620496881463623e-07
were O 0 4.7510180678500546e-08
employed O 0 1.4581048617401393e-06
. O 0 1.999883807002334e-06

Four O 0 2.817627944295964e-07
of O 0 2.6973845379529848e-08
Moroccan O 0 4.317255843488965e-06
origin O 0 1.545585774920255e-07
( O 0 3.530055581180136e-09
1 O 0 9.809605350241668e-10
. O 0 8.260295225603898e-10
1 O 0 2.360286410763024e-09
% O 0 3.076456644990344e-09
) O 0 9.642502352136262e-10
and O 0 1.3046329572219406e-09
none O 0 8.293800313197153e-09
of O 0 8.937115492102521e-10
the O 0 1.5656647534001422e-08
Yemenites O 0 1.8850054402719252e-05
or O 0 8.425821818036638e-09
Iranians O 0 2.830346801374617e-08
was O 0 3.2855571596712707e-09
a O 0 5.0621293823382985e-09
carrier O 0 2.019701099698068e-07
of O 0 5.545036430021355e-09
the O 0 1.5946174869441165e-07
185delAG O 0 0.000467814999865368
mutation O 0 3.0644074286101386e-05
. O 0 1.7186978311656276e-06

BRCA1 O 0 0.16877800226211548
allelic O 0 0.031155474483966827
patterns O 0 0.00029141869163140655
were O 0 6.753599990361181e-08
determined O 0 5.6443951734763687e-08
for O 0 1.1284542189571312e-09
four O 0 2.085676520380275e-09
of O 0 1.031225216330256e-09
these O 0 3.1182831872200723e-09
individuals O 0 3.649002211503216e-09
and O 0 2.954370081909019e-09
for O 0 2.8782254357651027e-09
12 O 0 8.491712222280512e-09
additional O 0 8.676126483919688e-09
non O 0 6.913229810834309e-08
- O 0 8.68131683091633e-05
Ashkenazi O 0 7.176153303589672e-06
185delAG O 0 3.7790447095176205e-05
mutation O 0 2.216225084339385e-06
carriers O 0 5.605246542472742e-07
who O 0 2.6089807647622365e-07
had O 0 4.972463648300618e-05
breast B-Disease 1 0.999755322933197
/ I-Disease 1 0.999988317489624
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999828338623047
. O 0 0.00015424743469338864

Six O 0 7.838564670237247e-06
non O 0 8.098917533061467e-06
- O 0 0.001038996153511107
Ashkenazi O 0 2.173635584767908e-05
individuals O 0 4.208454029708264e-08
shared O 0 6.6316957259005e-08
the O 0 4.7900254429578126e-08
common O 0 1.1448901204857975e-06
Ashkenazi O 0 5.555823736358434e-05
haplotype O 0 0.0030609420500695705
, O 0 2.1081829615354764e-08
four O 0 7.254125744537987e-09
had O 0 1.2798879289732668e-08
a O 0 4.7026937011196424e-08
closely O 0 4.4284698219598795e-07
related O 0 1.4114440318735433e-06
pattern O 0 9.324702659796458e-06
, O 0 9.220340047022546e-09
and O 0 1.7714720801365047e-09
the O 0 3.789667690767828e-09
rest O 0 2.2441577485210473e-08
( O 0 4.958162769241881e-09
n O 0 4.50414563601953e-06
= O 0 4.546781383396592e-06
6 O 0 1.7110238559325808e-08
) O 0 2.239256557956537e-09
displayed O 0 1.0013629037075589e-07
a O 0 8.876627788367841e-08
distinct O 0 1.4308654954220401e-06
BRCA1 O 0 0.00018928396457340568
allelic O 0 0.0004661187995225191
pattern O 0 0.00012400369450915605
. O 0 9.461324225412682e-06

We O 0 8.544956813238969e-07
conclude O 0 5.019481932322378e-07
that O 0 1.1331222182775491e-08
the O 0 1.7321209355714018e-08
185delAG O 0 0.0002550348872318864
BRCA1 O 0 0.001143227331340313
mutation O 0 1.719477222650312e-05
occurs O 0 1.1994029591733124e-07
in O 0 4.1096930303297086e-09
some O 0 1.5784855644795925e-09
non O 0 8.715222321598048e-08
- O 0 0.004576422274112701
Ashkenazi O 0 2.9487835490726866e-05
populations O 0 2.5864613917292445e-07
at O 0 2.370972218557199e-08
rates O 0 5.99461031924875e-08
comparable O 0 8.056281330937054e-08
with O 0 4.3047858611089396e-09
that O 0 1.1515965070429957e-08
of O 0 9.248806520645303e-08
Ashkenazim O 0 7.641065894858912e-05
. O 0 3.4413042158121243e-06

The O 0 8.651422263028508e-07
majority O 0 3.498884382224787e-07
of O 0 2.8634753235223798e-08
Jewish O 0 5.157033911018516e-07
185delAG O 0 0.00024335439957212657
mutation O 0 1.4217602256394457e-05
carriers O 0 3.749061079361127e-07
have O 0 7.5585937509004e-09
a O 0 3.441962448391678e-08
common O 0 3.5950642995885573e-07
allelic O 0 0.0001821627520257607
pattern O 0 1.9232429622206837e-05
, O 0 1.321518716679293e-08
supporting O 0 4.296814992699183e-08
the O 0 8.540539830903526e-09
founder O 0 4.289883008823381e-07
effect O 0 3.6148456672435714e-08
notion O 0 1.4375078905004557e-08
, O 0 2.922390995863111e-09
but O 0 2.081658401209552e-09
dating O 0 1.5124210506201052e-07
the O 0 6.036336763770578e-09
mutations O 0 1.5179206513948884e-07
origin O 0 5.0310005050846485e-09
to O 0 5.663919888654334e-10
an O 0 1.0038403441825494e-09
earlier O 0 8.684838803674211e-08
date O 0 1.9013221219665866e-07
than O 0 1.7412034480912553e-08
currently O 0 8.06484550253117e-08
estimated O 0 1.6115811831696192e-06
. O 0 2.7446174044598592e-06

However O 0 2.0192458123347024e-06
, O 0 4.00598878513847e-08
the O 0 8.870276957395618e-09
different O 0 8.769661441476728e-09
allelic O 0 1.2557078662212007e-05
pattern O 0 1.3794608548778342e-06
at O 0 1.2374425040206916e-08
the O 0 1.939261906613865e-08
BRCA1 O 0 1.2833395885536447e-05
locus O 0 2.373860297666397e-06
even O 0 1.9677242946158913e-08
in O 0 2.593800507710853e-09
some O 0 1.303777308336862e-09
Jewish O 0 9.176691406764803e-08
mutation O 0 2.587796188890934e-06
carriers O 0 3.5525198427421856e-07
, O 0 1.2486616185469757e-08
might O 0 3.498019651715367e-08
suggest O 0 4.309158541104807e-08
that O 0 2.597890347288967e-09
the O 0 1.701089225036867e-08
mutation O 0 2.7078283437731443e-06
arose O 0 8.654376983940892e-07
independently O 0 3.7594978152810654e-07
. O 0 1.0997987232030937e-07
. O 0 1.2833365872211289e-06

Crystal O 0 0.002059920458123088
structure O 0 2.4404107534792274e-06
of O 0 3.830876238453129e-08
the O 0 9.440110488867504e-07
hemochromatosis B-Disease 1 0.9999532699584961
protein O 0 1.0874914551095571e-05
HFE O 0 0.0005078744143247604
and O 0 2.12158326462486e-08
characterization O 0 5.59881925710215e-07
of O 0 3.0011124696471825e-09
its O 0 1.4108874069052035e-08
interaction O 0 1.0635893943344854e-07
with O 0 3.41630453704056e-07
transferrin O 0 0.012630489654839039
receptor O 0 5.3893367294222116e-05
. O 0 3.8687512642354704e-06

HFE O 0 0.0981764867901802
is O 0 4.254173973095021e-07
an O 0 2.5750408028102356e-08
MHC O 0 7.976879714988172e-05
- O 0 4.754207475343719e-05
related O 0 4.971252565155737e-07
protein O 0 4.740508785516795e-08
that O 0 1.3680210297906115e-09
is O 0 2.9173343740751534e-09
mutated O 0 2.1042065156962053e-07
in O 0 7.812285929276186e-09
the O 0 1.2513885394582758e-07
iron B-Disease 1 0.9714031219482422
- I-Disease 1 0.9998807907104492
overload I-Disease 1 0.9999604225158691
disease I-Disease 1 0.9995620846748352
hereditary B-Disease 1 0.9999783039093018
hemochromatosis I-Disease 1 0.9999980926513672
. O 0 0.0007152679027058184

HFE O 0 0.005482503212988377
binds O 0 1.1779136912082322e-05
to O 0 4.628050191968214e-07
transferrin O 0 0.000544019800145179
receptor O 0 1.4668282346974593e-05
( O 0 1.487626093421568e-07
TfR O 0 0.00026277315919287503
) O 0 6.279072817250153e-09
and O 0 3.2118356863009012e-09
reduces O 0 8.561305975263167e-08
its O 0 1.978165853344649e-09
affinity O 0 9.451229487922319e-08
for O 0 6.99027680184372e-09
iron O 0 0.00012197833711979911
- O 0 2.8557291443576105e-05
loaded O 0 2.945026608358603e-06
transferrin O 0 0.00020680544548667967
, O 0 4.916166318480464e-08
implicating O 0 2.1765081328339875e-05
HFE O 0 0.00310921692289412
in O 0 5.245518650554004e-07
iron O 0 0.1155189722776413
metabolism O 0 0.00037108248216100037
. O 0 3.35661502504081e-06

The O 0 1.0982787898683455e-05
2 O 0 1.2778489690390415e-05
. O 0 1.4399315659829881e-05

6 O 0 1.265142418560572e-05
A O 0 1.7739956774676102e-06
crystal O 0 0.0007347128703258932
structure O 0 2.16883768189291e-06
of O 0 6.205068814324477e-08
HFE O 0 0.011092656292021275
reveals O 0 4.129640274186386e-06
the O 0 1.311166997197688e-08
locations O 0 9.537154710415052e-08
of O 0 3.023510259936302e-07
hemochromatosis B-Disease 1 0.999997615814209
mutations O 0 6.085289714974351e-05
and O 0 1.705517327366124e-08
a O 0 3.941151760500361e-08
patch O 0 6.79755539749749e-05
of O 0 1.1194169147188404e-08
histidines O 0 0.000917808327358216
that O 0 1.763752344174918e-08
could O 0 8.631888981369684e-09
be O 0 1.7573245081337063e-09
involved O 0 1.2203461352555678e-08
in O 0 1.5974090672443708e-07
pH O 0 0.000906876812223345
- O 0 0.0005247989320196211
dependent O 0 1.8325947621633532e-06
interactions O 0 2.7634698653855594e-06
. O 0 2.829958248184994e-06

We O 0 1.7125900058090338e-06
also O 0 2.0436841907667258e-07
demonstrate O 0 8.715211379239918e-07
that O 0 1.243459735178476e-07
soluble O 0 0.00029995362274348736
TfR O 0 0.0005279003526084125
and O 0 3.68307802034451e-08
HFE O 0 0.00020784701337106526
bind O 0 1.9799283279553492e-07
tightly O 0 4.9224524900637334e-08
at O 0 3.4847058572040623e-09
the O 0 3.402113479822333e-09
basic O 0 1.0043277143267915e-07
pH O 0 8.871522823028499e-07
of O 0 7.101613741511414e-10
the O 0 3.982552509995685e-09
cell O 0 1.0819034287123941e-05
surface O 0 6.203990324138431e-06
, O 0 2.461782777629651e-09
but O 0 1.1056660031982801e-09
not O 0 4.0190104022563844e-10
at O 0 2.0988697446711058e-09
the O 0 1.8323758510518928e-08
acidic O 0 1.8046537661575712e-05
pH O 0 1.2947746654390357e-05
of O 0 9.356043761954425e-08
intracellular O 0 0.0005934026557952166
vesicles O 0 0.001008892199024558
. O 0 3.820037818513811e-06

TfR O 1 0.968761682510376
HFE O 0 0.14737117290496826
stoichiometry O 0 0.0007973462343215942
( O 0 2.647625763074757e-07
2 O 0 5.543633108118229e-08
1 O 0 1.8889126707222204e-08
) O 0 3.562318662275743e-09
differs O 0 3.3888579054064394e-08
from O 0 1.971966234748379e-08
TfR O 0 0.001139659434556961
transferrin O 0 0.000276370468782261
stoichiometry O 0 1.2766455256496556e-05
( O 0 5.891626297938046e-09
2 O 0 2.862343473353235e-09
2 O 0 3.744488719092942e-09
) O 0 1.3857053282606557e-09
, O 0 1.2727204845575102e-09
implying O 0 4.344380855059171e-08
a O 0 2.6334008307316026e-09
different O 0 7.266197643573946e-10
mode O 0 1.1201175098562999e-08
of O 0 1.1689749168652952e-09
binding O 0 4.152662214096381e-08
for O 0 7.328039064447012e-09
HFE O 0 0.0017749613616615534
and O 0 7.987140548948446e-08
transferrin O 0 0.0007695652893744409
to O 0 9.363792230487888e-08
TfR O 0 0.01933278702199459
, O 0 1.533784121932058e-08
consistent O 0 1.4833259065483162e-08
with O 0 2.7021307413832574e-09
our O 0 1.0561014285315196e-08
demonstration O 0 3.23123629186739e-07
that O 0 2.1838753028191604e-08
HFE O 0 0.0007259546546265483
, O 0 5.6359073852263464e-08
transferrin O 0 0.0001578788214828819
, O 0 2.4484382521450243e-08
and O 0 1.105949536395201e-07
TfR O 0 0.001516042510047555
form O 0 1.4276172066729487e-07
a O 0 3.6172670547784946e-07
ternary O 0 0.0008855487685650587
complex O 0 2.1775960703962483e-05
. O 0 3.830672085314291e-06

Identification O 0 6.5010726757464e-06
of O 0 3.652625224503936e-08
three O 0 5.484191589744114e-08
novel O 0 2.0074546682735672e-06
mutations O 0 3.985271177953109e-06
and O 0 1.824229833857771e-08
a O 0 1.7847471056597897e-08
high O 0 1.5133356612295756e-07
frequency O 0 3.612129972907496e-08
of O 0 8.192481137925256e-10
the O 0 1.5897533955921972e-08
Arg778Leu O 0 0.0005088357720524073
mutation O 0 2.3888810574135277e-06
in O 0 7.535982149420306e-08
Korean O 0 8.892741789168213e-06
patients O 0 4.575118964567082e-06
with O 0 5.461046384880319e-06
Wilson B-Disease 1 0.743811845779419
disease I-Disease 0 0.08820714056491852
. O 0 8.335134225490037e-06

Four O 0 3.5870273222826654e-06
mutations O 0 2.0775698430952616e-05
- O 0 4.627314046956599e-05
- O 0 8.525230805389583e-05
R778L O 0 1.9574397811084054e-05
, O 0 1.219285206133236e-08
A874V O 0 7.04061790202104e-07
, O 0 3.1770575059653083e-09
L1083F O 0 3.668513386401173e-07
, O 0 1.299318541647665e-09
and O 0 2.167606760750118e-09
2304delC O 0 7.704677500441903e-07
- O 0 2.1245571133476915e-06
- O 0 1.955719426405267e-06
in O 0 4.414644649841648e-09
the O 0 2.5247084423085653e-09
copper O 0 6.697594471916091e-06
- O 0 7.844815854696208e-07
transporting O 0 9.605247441868414e-08
enzyme O 0 4.2849155335034084e-08
, O 0 3.4930307535319116e-09
P O 0 2.3451325432688463e-06
- O 0 5.3088510867382865e-06
type O 0 1.8258122054248815e-06
ATPase O 0 4.042467480758205e-05
( O 0 2.913521157665855e-08
ATP7B O 0 4.2287396354367957e-05
) O 0 4.731238512079017e-09
, O 0 1.1825468382298254e-09
were O 0 2.424152434343796e-09
identified O 0 1.6620805354250479e-07
in O 0 9.799085631811977e-08
Korean O 0 7.067862316034734e-05
Patients O 0 8.036489816731773e-06
with O 0 2.354149273742223e-06
Wilson B-Disease 0 0.19472777843475342
disease I-Disease 0 0.013043832965195179
. O 0 7.412177183141466e-06

Arg778Leu O 0 0.0016560432268306613
, O 0 2.649692021350347e-07
the O 0 2.6956152865409422e-08
most O 0 9.423667179930817e-09
frequently O 0 1.1961417101247207e-07
reported O 0 6.541532684423146e-07
mutation O 0 1.1536184274518746e-07
of O 0 1.2118513970094114e-09
this O 0 4.701821154640129e-09
enzyme O 0 5.772277944515736e-08
, O 0 2.7993403151072016e-09
was O 0 2.2048767256421797e-09
found O 0 4.147902910034418e-09
in O 0 2.056802284045034e-09
six O 0 4.15980228041235e-09
of O 0 3.072902821088519e-09
eight O 0 2.692645750812517e-07
unrelated O 0 0.00016418607265222818
patients O 0 7.974634172569495e-06
studied O 0 4.478423534237663e-07
, O 0 1.2979521457623378e-08
an O 0 3.580561180882569e-09
allele O 0 4.330374849814689e-07
frequency O 0 7.715473060443401e-08
of O 0 1.3147857025330723e-08
37 O 0 1.3008998394070659e-06
. O 0 1.236313437402714e-06

5 O 0 5.232610874372767e-06
% O 0 3.7128009466869116e-07
, O 0 1.6310051975665374e-08
which O 0 6.187457657347295e-09
is O 0 7.324448159096164e-09
considerably O 0 1.582258022381211e-07
higher O 0 1.4021953376186502e-08
than O 0 1.4545185056391574e-09
those O 0 3.4439766594118737e-09
in O 0 1.0245988946167017e-08
other O 0 1.725894804849304e-08
Asian O 0 9.47234127579577e-07
populations O 0 4.396456461108755e-06
. O 0 4.061989784531761e-06

The O 0 7.121545309018984e-07
novel O 0 6.468010838034388e-07
single O 0 1.3949188826245518e-07
nucleotide O 0 1.816795816012018e-06
deletion O 0 5.553523806156591e-06
, O 0 3.380607438430161e-08
2304delC O 0 6.117752491263673e-06
, O 0 1.4325673980408737e-08
was O 0 1.0187547694329169e-08
found O 0 2.4851081192878155e-08
in O 0 3.322810826489331e-08
one O 0 1.4228707811980712e-07
patient O 0 4.860006083617918e-05
. O 0 6.50783385935938e-06

Since O 0 1.2782389603671618e-05
a O 0 4.349741402620566e-07
mutation O 0 1.8298965187568683e-06
at O 0 4.6436703371455224e-08
cDNA O 0 7.472345942005632e-07
nucleotide O 0 2.9879995508963475e-06
2302 O 0 0.00013695914822164923
( O 0 1.8127837009274117e-08
2302insC O 0 1.1214020787519985e-06
) O 0 5.805332214947612e-09
had O 0 5.434902750067749e-09
been O 0 9.027079528323156e-09
previously O 0 6.837786514779509e-08
described O 0 1.9212573931781662e-07
, O 0 4.587020541180209e-09
this O 0 1.6538538316623885e-09
region O 0 1.1288423529265401e-08
of O 0 1.3508328899902722e-09
the O 0 1.765263490938196e-08
ATP7B O 0 0.00871623307466507
gene O 0 6.020782166160643e-07
may O 0 1.3598159398497955e-07
be O 0 1.1819859757622453e-08
susceptible O 0 4.1053813220059965e-06
to O 0 8.469862677884521e-08
gene O 0 6.963186478969874e-06
rearrangements O 0 0.03555917739868164
causing O 0 0.0045806472189724445
Wilson B-Disease 0 0.4807933270931244
disease I-Disease 0 0.07439382374286652
. O 0 1.8909740902017802e-05

Disruption O 0 5.6806191423675045e-05
of O 0 1.80854158315924e-07
splicing O 0 3.129700417048298e-06
regulated O 0 6.490211603704665e-07
by O 0 1.4790994207203312e-08
a O 0 4.0783511678910145e-08
CUG O 0 0.00013783774920739233
- O 0 2.8424678021110594e-05
binding O 0 1.3842090993421152e-06
protein O 0 2.5068413833650993e-06
in O 0 9.920863703882787e-06
myotonic B-Disease 1 0.9999644756317139
dystrophy I-Disease 1 0.9999558925628662
. O 0 9.830467024585232e-05

Myotonic B-Disease 1 0.9999693632125854
dystrophy I-Disease 1 0.9999771118164062
( O 0 0.002176441252231598
DM B-Disease 1 0.9999312162399292
) O 0 9.254891324417258e-07
is O 0 9.1625778964044e-08
caused O 0 2.2725309634097357e-07
by O 0 8.282260210989989e-09
a O 0 5.236147515574885e-08
CTG O 0 8.268491365015507e-05
expansion O 0 9.954025159686353e-08
in O 0 4.594129965340699e-09
the O 0 2.9798370437816857e-09
3 O 0 5.0972243315072774e-08
untranslated O 0 1.3678392861038446e-05
region O 0 6.651178097172306e-08
of O 0 1.595926768516165e-08
the O 0 6.477171154983807e-07
DM B-Disease 1 0.999370276927948
gene O 0 1.5614914445905015e-05
. O 0 2.605400368338451e-06

One O 0 1.5275574014594895e-06
model O 0 1.8988610008818796e-06
of O 0 6.670348966508755e-07
DM B-Disease 1 0.9999611377716064
pathogenesis O 0 0.09367965906858444
suggests O 0 1.3459697356665856e-06
that O 0 7.708041316334402e-09
RNAs O 0 3.3876244742714334e-07
from O 0 1.7337263846783912e-09
the O 0 1.4640264556220473e-09
expanded O 0 2.7439726935085673e-08
allele O 0 8.994462064038089e-08
create O 0 3.4482097177601645e-09
a O 0 3.415989047184098e-09
gain O 0 3.670573534009236e-08
- O 0 4.7135236513895507e-07
of O 0 2.6568003352878122e-09
- O 0 7.365627971012145e-05
function O 0 8.750583901928621e-08
mutation O 0 7.713516225749117e-08
by O 0 1.0762817304055261e-09
the O 0 2.9256035372071665e-09
inappropriate O 0 3.797020653451e-08
binding O 0 1.853211628599638e-08
of O 0 1.2611167665710354e-09
proteins O 0 8.51177084371102e-09
to O 0 3.867671516388782e-09
the O 0 6.677822028677838e-08
CUG O 0 0.002570557640865445
repeats O 0 5.048568345955573e-05
. O 0 1.5507208672715933e-06

Data O 0 2.150124237232376e-05
presented O 0 4.390762114780955e-06
here O 0 2.714106130952132e-07
indicate O 0 2.9113056143614813e-07
that O 0 3.3818698952359227e-09
the O 0 6.88234891299544e-09
conserved O 0 7.162008728300862e-07
heterogeneous O 0 2.1235109670669772e-05
nuclear O 0 0.00037169925053603947
ribonucleoprotein O 0 0.0010265401797369123
, O 0 1.502925073282313e-08
CUG O 0 1.1307674867566675e-05
- O 0 9.467263225815259e-06
binding O 0 3.172554272623529e-07
protein O 0 8.623220537629095e-08
( O 0 1.0036532493984396e-08
CUG O 0 2.2347290723701008e-05
- O 0 6.0868391301482916e-05
BP O 0 0.00018752992036752403
) O 0 1.0524737525940964e-08
, O 0 5.903144639773927e-09
may O 0 9.89041382126743e-09
mediate O 0 3.4951252558812484e-08
the O 0 1.0008374573544643e-08
trans O 0 1.4651775472884765e-06
- O 0 3.1506297091254964e-05
dominant O 0 2.81909564137095e-07
effect O 0 1.7562999943265822e-08
of O 0 3.7176453027143452e-09
the O 0 4.2513100595442666e-08
RNA O 0 1.460986140955356e-06
. O 0 1.3481485439115204e-06

CUG O 0 0.009599409997463226
- O 0 0.0007815761491656303
BP O 0 0.0002484348660800606
was O 0 8.35633429119298e-08
found O 0 1.7614796732345894e-08
to O 0 3.001157988791192e-09
bind O 0 1.9336484058385395e-07
to O 0 6.450341150099348e-09
the O 0 3.785602586958703e-08
human O 0 9.118683919950854e-06
cardiac O 1 0.9963443875312805
troponin O 1 0.9999253749847412
T O 0 0.036230869591236115
( O 0 2.3692090067584104e-08
cTNT O 0 1.357121618639212e-06
) O 0 4.2640251329828516e-09
pre O 0 3.521597875533189e-07
- O 0 3.4530467019067146e-06
messenger O 0 4.571140550524433e-07
RNA O 0 2.8143212205122836e-08
and O 0 3.297246697897549e-09
regulate O 0 2.7720265194375315e-08
its O 0 1.8472265495006468e-08
alternative O 0 3.665194583390985e-07
splicing O 0 4.7104367695283145e-06
. O 0 1.0588504437691881e-06

Splicing O 0 2.4399068934144452e-05
of O 0 5.077284868093557e-07
cTNT O 0 0.00015724662807770073
was O 0 6.179034244269133e-07
disrupted O 0 4.4404499931260943e-05
in O 0 1.6538094769202871e-06
DM B-Disease 1 0.9998507499694824
striated O 1 0.6246896982192993
muscle O 0 7.318356074392796e-05
and O 0 9.856746174818909e-08
in O 0 1.7860863010810135e-07
normal O 0 8.268419264823024e-07
cells O 0 5.934066962254292e-07
expressing O 0 1.478317415148922e-07
transcripts O 0 3.2459993803968246e-07
that O 0 2.7894602183664574e-08
contain O 0 7.321384600800229e-07
CUG O 0 0.0004741529992315918
repeats O 0 3.0850173061480746e-05
. O 0 2.284814399899915e-06

Altered O 0 0.00010318188287783414
expression O 0 3.1640927318221657e-06
of O 0 8.333620371558936e-08
genes O 0 5.21095103067637e-07
regulated O 0 2.891653991810017e-07
posttranscriptionally O 0 8.213991350203287e-06
by O 0 4.5189921138444333e-08
CUG O 0 0.0007073260494507849
- O 0 0.0008345858659595251
BP O 0 0.0002545041497796774
therefore O 0 7.081736441705289e-08
may O 0 4.0275171642178975e-08
contribute O 0 3.401453341211891e-08
to O 0 1.620908278709976e-07
DM B-Disease 1 0.9999028444290161
pathogenesis O 0 0.016127953305840492
. O 0 7.142903086787555e-07
. O 0 1.796881861082511e-06

Identification O 0 6.6010070440825075e-06
of O 0 5.8927867030433845e-08
a O 0 1.8066297968744038e-07
novel O 0 1.6422325188614195e-06
nonsense O 0 0.00011650978558463976
mutation O 0 1.772194764271262e-06
and O 0 7.293583070833165e-09
a O 0 1.006077710030695e-08
missense O 0 1.1479886552479002e-06
substitution O 0 1.3750796945544153e-08
in O 0 2.599744197695486e-09
the O 0 4.290343191826196e-09
vasopressin O 0 1.1551491070349584e-06
- O 0 1.6886560842976905e-05
neurophysin O 0 0.00013142569514457136
II O 0 5.418197815743042e-06
gene O 0 2.4620938177122298e-08
in O 0 3.013731708634282e-09
two O 0 6.477106850866221e-09
Spanish O 0 3.6246396462047414e-07
kindreds O 0 2.8118720365455374e-05
with O 0 1.270380266760185e-06
familial B-Disease 1 0.9578545689582825
neurohypophyseal I-Disease 1 0.9997959733009338
diabetes I-Disease 1 0.9984134435653687
insipidus I-Disease 1 0.8382343649864197
. O 0 3.641306102508679e-05

Familial B-Disease 1 0.9984727501869202
neurohypophyseal I-Disease 1 0.9998352527618408
diabetes I-Disease 1 0.9998181462287903
insipidus I-Disease 1 0.9982409477233887
( O 0 6.483522884082049e-05
FNDI B-Disease 1 0.9997273087501526
) O 0 1.8378909771854524e-07
is O 0 4.6293436639643915e-08
an O 0 2.9561596193161677e-07
autosomal B-Disease 1 0.9167276620864868
dominant I-Disease 1 0.9921985268592834
disease I-Disease 1 0.9832919239997864
caused O 0 0.0012293438194319606
by O 0 8.070216426858678e-05
deficiency O 1 0.9961452484130859
in O 0 1.0347627465989717e-07
the O 0 1.9676686235925445e-07
antidiuretic O 0 0.001132858102209866
hormone O 0 7.387076493614586e-06
arginine O 0 3.1565523386234418e-06
vasopressin O 0 3.8043683616706403e-06
( O 0 2.0960863267305285e-08
AVP O 0 4.311579857585457e-07
) O 0 2.0168546832621814e-09
encoded O 0 4.0578642668265275e-09
by O 0 1.3023505607279162e-09
the O 0 8.602928147638522e-09
AVP O 0 9.983769814425614e-06
- O 0 0.0004451547283679247
neurophysin O 0 0.00393022783100605
II O 0 2.0806844986509532e-05
( O 0 3.748005639181429e-08
AVP O 0 4.630152943718713e-06
- O 0 0.00010523270611884072
NPII O 0 0.0002787491830531508
) O 0 1.6844776240532155e-08
gene O 0 8.441718790663799e-08
on O 0 1.6026643834265997e-07
chromosome O 0 8.933647040976211e-05
20p13 O 0 0.00033385338610969484
. O 0 6.2519275161321275e-06

In O 0 1.1662193628581008e-06
this O 0 6.12611401606955e-08
study O 0 8.195129908017407e-08
, O 0 6.993117196429921e-09
we O 0 2.9336275630953423e-09
analyzed O 0 2.5515779711327014e-08
two O 0 1.1494124541044926e-09
families O 0 7.582303673814295e-09
with O 0 1.2033757990081995e-08
FNDI B-Disease 0 0.08761478215456009
using O 0 6.763743343185524e-09
direct O 0 4.4158237066938e-09
automated O 0 7.859260904297116e-07
fluorescent O 0 4.274489128874848e-06
, O 0 3.2890683510089502e-09
solid O 0 6.682103048660792e-08
phase O 0 6.693277043723356e-08
, O 0 1.5956976850972637e-09
single O 0 3.7238052641441755e-09
- O 0 5.921924071117246e-07
stranded O 0 3.7315714962460333e-08
DNA O 0 3.008507221125001e-08
sequencing O 0 2.5811775827833117e-08
of O 0 2.65649635622367e-09
PCR O 0 6.318016403383808e-07
- O 0 9.839952326728962e-06
amplified O 0 1.1506386726978235e-05
AVP O 0 1.694977436272893e-05
- O 0 0.00019701794371940196
NPII O 0 0.0006981827318668365
DNA O 0 1.7448463040636852e-05
. O 0 2.2262215679802466e-06

In O 0 6.40179507627181e-07
one O 0 2.144504840373429e-08
of O 0 4.0597303296863174e-09
the O 0 1.525701875948471e-08
families O 0 1.2554778550111223e-07
, O 0 1.039429093907529e-07
affected O 0 7.236357646434044e-08
individuals O 0 1.41631231187489e-08
presented O 0 1.59165637114711e-07
a O 0 3.594590580746626e-08
novel O 0 4.932518891109794e-07
nonsense O 0 2.2292182620731182e-05
mutation O 0 2.699634364944359e-07
in O 0 4.9144106561982426e-09
exon O 0 1.0036379762823344e-06
3 O 0 5.5544893129422235e-09
of O 0 5.099299871247354e-10
the O 0 4.774789452710593e-09
gene O 0 3.707124918150839e-08
, O 0 1.3018042199774982e-09
consisting O 0 4.098890116210896e-09
in O 0 6.3147678197594814e-09
a O 0 4.623651861379585e-08
G O 0 0.00034592399606481194
to O 0 2.092263784447823e-08
T O 0 8.845993579598144e-05
transition O 0 1.0457009125275363e-07
at O 0 1.4143146209733004e-08
nucleotide O 0 1.3445213653540122e-06
2101 O 0 1.986096140171867e-05
, O 0 5.868679764375884e-09
which O 0 2.142067412336246e-09
produces O 0 1.3387397856945427e-08
a O 0 2.3782538161043476e-09
stop O 0 1.0931687555171266e-08
signal O 0 3.9348499569769047e-08
in O 0 6.038663347140982e-09
codon O 0 2.261781020251874e-07
82 O 0 6.662567386683804e-08
( O 0 2.6359250782093113e-08
Glu O 0 0.00023734229034744203
) O 0 1.9292970776518814e-08
of O 0 5.149543724769501e-08
NPII O 0 0.005212410818785429
. O 0 6.055255653336644e-06

The O 0 5.917672297073295e-06
premature O 0 0.0001046836405294016
termination O 0 1.4579987691831775e-05
eliminates O 0 1.1322460977680748e-06
part O 0 1.2251832437470966e-08
of O 0 2.6192996660512335e-09
the O 0 1.3381832530967586e-08
C O 0 4.0315026694770495e-07
- O 0 3.001022150783683e-06
terminal O 0 3.478326959793776e-07
domain O 0 9.089033525810919e-09
of O 0 1.8075279051288362e-09
NPII O 0 3.8336991565302014e-05
, O 0 2.7949389469483776e-09
including O 0 2.3678796701176452e-09
a O 0 4.658740504481784e-09
cysteine O 0 5.933694424697933e-08
residue O 0 1.0278877482505777e-07
in O 0 3.130057768530037e-09
position O 0 1.557955364717145e-08
85 O 0 2.4386274333210167e-08
, O 0 4.344229420638612e-09
which O 0 3.106185086920732e-09
could O 0 8.042920995876557e-09
be O 0 7.447141792127354e-10
involved O 0 3.005041770975936e-09
in O 0 4.0065977202630165e-09
the O 0 1.2444343333584129e-08
correct O 0 8.554398505111749e-07
folding O 0 1.7557241562826675e-06
of O 0 2.4904226236799332e-08
the O 0 3.5279782650832203e-07
prohormone O 0 0.0027303278911858797
. O 0 5.084566055302275e-06

In O 0 6.203140401339624e-07
the O 0 3.1514694853740366e-08
second O 0 5.249887635727646e-08
family O 0 5.8782497092124686e-08
, O 0 4.258027264114617e-09
a O 0 3.600297837635935e-09
G279A O 0 2.4062990178208565e-07
substitution O 0 5.570254479891901e-09
at O 0 1.3544861898751037e-09
position O 0 2.6185955626090163e-09
- O 0 1.8904790977103403e-07
1 O 0 1.430657925460821e-09
of O 0 3.591441311012744e-10
the O 0 2.3400965609710056e-09
signal O 0 1.583740498745101e-07
peptide O 0 1.8812528423950425e-07
was O 0 7.832666959473045e-09
observed O 0 3.2243097081163796e-08
in O 0 4.752266136165417e-09
all O 0 5.924576385041291e-09
affected O 0 2.4178672219932196e-07
individuals O 0 3.9025391629365913e-07
. O 0 3.616512231019442e-06

This O 0 4.780159542860929e-06
missense O 0 0.0034378175623714924
mutation O 0 0.00013569043949246407
, O 0 9.646189624845647e-08
which O 0 4.078117754602317e-08
replaces O 0 8.957548743637744e-06
Ala O 0 2.15340951399412e-05
with O 0 9.619897411994316e-08
Thr O 0 0.0005444635753519833
, O 0 2.560831902087557e-08
is O 0 9.021123403840647e-09
frequent O 0 5.844888164574513e-07
among O 0 1.6223044667640352e-06
FNDI B-Disease 1 0.9999926090240479
patients O 0 1.4504362297884654e-05
and O 0 3.741662979450666e-08
is O 0 1.2555708472916649e-08
thought O 0 1.4110112189769097e-08
to O 0 1.8433539139550703e-09
reduce O 0 3.118343983032901e-08
the O 0 4.8891672932427355e-09
efficiency O 0 2.539230194997799e-07
of O 0 6.290820309118317e-09
cleavage O 0 7.793008262524381e-05
by O 0 6.220474091378492e-08
signal O 0 1.979414037123206e-06
peptidases O 0 1.6449739632662386e-05
. O 0 2.432588814826886e-07
. O 0 1.2983019814782892e-06

Genetic O 0 0.0007652412168681622
heterogeneity O 0 0.00019507166871335357
of O 0 1.4218984460967476e-06
Saethre B-Disease 1 0.8366797566413879
- I-Disease 1 0.9993994235992432
Chotzen I-Disease 1 0.9999339580535889
syndrome I-Disease 1 0.9999076128005981
, O 0 2.455847436522163e-07
due O 0 2.5842965101219306e-07
to O 0 2.7729889495731186e-08
TWIST O 0 1.7706435755826533e-05
and O 0 1.456389782106271e-06
FGFR O 0 0.34319719672203064
mutations O 0 6.875763210700825e-05
. O 0 3.891971573466435e-06

Thirty O 0 1.782945400918834e-05
- O 0 4.197630187263712e-05
two O 0 1.1450786985278683e-07
unrelated O 0 3.9302834920817986e-05
patients O 0 7.407792850244732e-07
with O 0 8.193672407230679e-09
features O 0 3.063290137106378e-07
of O 0 5.383125767366437e-08
Saethre B-Disease 1 0.9256293177604675
- I-Disease 1 0.9997673630714417
Chotzen I-Disease 1 0.9999713897705078
syndrome I-Disease 1 0.9998670816421509
, O 0 1.3377984942053445e-07
a O 0 8.83628729297925e-07
common O 0 9.105141361942515e-05
autosomal B-Disease 0 0.19080187380313873
dominant I-Disease 0 0.0008881581597961485
condition I-Disease 0 6.744403071934357e-05
of O 0 6.220628279152152e-07
craniosynostosis B-Disease 1 0.998711109161377
and O 0 0.00012132569099776447
limb B-Disease 1 0.998970627784729
anomalies I-Disease 0 0.23530486226081848
, O 0 4.686325638658673e-08
were O 0 9.052269156484272e-09
screened O 0 4.45369522594774e-07
for O 0 3.63748995368951e-08
mutations O 0 1.8463815649738535e-06
in O 0 3.246389113087389e-08
TWIST O 0 8.80066363606602e-06
, O 0 1.3990555203236e-07
FGFR2 O 0 0.0004311912052799016
, O 0 6.024860255138265e-08
and O 0 3.109619512997597e-07
FGFR3 O 0 0.0028238289523869753
. O 0 6.939763807167765e-06

Nine O 0 3.945765911339549e-06
novel O 0 1.098932330023672e-06
and O 0 5.6230437195381455e-08
three O 0 6.332523838636916e-08
recurrent O 0 0.0024490798823535442
TWIST O 0 0.005570397246629
mutations O 0 1.2819476978620514e-05
were O 0 1.5966117317134376e-08
found O 0 7.71743060568042e-08
in O 0 9.999848771258257e-08
12 O 0 6.403431598300813e-07
families O 0 2.010583330047666e-06
. O 0 7.235540124383988e-06

Seven O 0 2.878578470699722e-06
families O 0 4.386570822134672e-07
were O 0 2.3658538239601512e-08
found O 0 3.066487153091657e-08
to O 0 3.173623364105538e-09
have O 0 4.124865338184236e-09
the O 0 9.833926561952921e-09
FGFR3 O 0 0.0033059273846447468
P250R O 0 0.00033627566881477833
mutation O 0 2.2364761207427364e-06
, O 0 2.9012310331921753e-09
and O 0 1.127757109919969e-09
one O 0 2.0600177119689533e-09
individual O 0 9.263032119122272e-09
was O 0 1.792176895776265e-08
found O 0 1.5896777227908387e-08
to O 0 1.7094996529465334e-09
have O 0 2.7477946584753e-09
an O 0 7.53596474112328e-09
FGFR2 O 0 0.00020685215713456273
VV269 O 0 2.213225161540322e-05
- O 0 2.8699230824713595e-05
270 O 0 2.7165297069586813e-06
deletion O 0 6.394885713234544e-05
. O 0 4.604458354151575e-06

To O 0 4.759153569011687e-07
date O 0 8.09145262792299e-07
, O 0 2.2549917488845495e-08
our O 0 2.9230616149789057e-08
detection O 0 1.455531787541986e-06
rate O 0 2.1742286193671134e-08
for O 0 9.430386471720453e-10
TWIST O 0 5.462804892886197e-07
or O 0 4.7112859391518214e-08
FGFR O 0 0.001426848815754056
mutations O 0 5.228253598943411e-07
is O 0 2.915025776317748e-09
68 O 0 2.1691958451697246e-08
% O 0 6.141765762635032e-09
in O 0 1.2289888218219858e-08
our O 0 3.8631841903224995e-07
Saethre B-Disease 1 0.6674005389213562
- I-Disease 1 0.9998481273651123
Chotzen I-Disease 1 0.9999872446060181
syndrome I-Disease 1 0.9999905824661255
patients O 0 1.702159715932794e-05
, O 0 2.0180062065833226e-08
including O 0 1.678496275303587e-08
our O 0 1.2117703818148584e-07
five O 0 2.869170145913813e-07
patients O 0 4.539147539617261e-06
elsewhere O 0 3.250582949476666e-06
reported O 0 1.3065495068076416e-06
with O 0 2.1516261483611743e-07
TWIST O 0 0.0013482337817549706
mutations O 0 0.00012939557200297713
. O 0 6.0599404605454765e-06

More O 0 2.3224392009524308e-07
than O 0 5.173851391759854e-08
35 O 0 6.086120407644557e-08
different O 0 1.6190782048397523e-08
TWIST O 0 9.808481991058215e-06
mutations O 0 1.7934697780219722e-06
are O 0 2.8399982365812093e-09
now O 0 1.1590048920595564e-08
known O 0 1.5584072698970886e-08
in O 0 1.9371288573211132e-08
the O 0 1.1509535369214063e-07
literature O 0 3.53095720129204e-06
. O 0 3.192566509824246e-06

The O 0 7.05982017734641e-07
most O 0 1.0679192286033867e-07
common O 0 1.5326440916396677e-07
phenotypic O 0 1.8117488025382045e-06
features O 0 1.6541029026484466e-06
, O 0 3.750265520352514e-08
present O 0 1.2997555920435389e-08
in O 0 4.240269912969552e-09
more O 0 4.845892020988174e-10
than O 0 8.363724712801002e-10
a O 0 2.1087449564305416e-09
third O 0 7.578717209355545e-09
of O 0 2.4181583402338447e-09
our O 0 2.1177572762098862e-07
patients O 0 1.8440411508890975e-07
with O 0 3.036478446460933e-08
TWIST O 0 0.0006439568824134767
mutations O 0 6.452291017922107e-06
, O 0 7.323637696288188e-09
are O 0 2.7597910623455846e-09
coronal B-Disease 0 0.00022919509501662105
synostosis I-Disease 0 0.0025625936686992645
, O 0 8.116309402339539e-08
brachycephaly B-Disease 0 0.0001036215471685864
, O 0 1.0666245486845582e-07
low B-Disease 0 9.769552889338229e-06
frontal I-Disease 1 0.9819474220275879
hairline I-Disease 1 0.9999959468841553
, O 0 9.939962183125317e-05
facial B-Disease 1 0.9992021918296814
asymmetry I-Disease 0 0.39684659242630005
, O 0 1.0490192835277412e-05
ptosis B-Disease 1 0.9658827781677246
, O 0 1.483509208810574e-06
hypertelorism B-Disease 0 0.06927118450403214
, O 0 1.0598066779721194e-07
broad B-Disease 0 7.734730047559424e-07
great I-Disease 0 1.623341404410894e-06
toes I-Disease 0 4.031611024402082e-05
, O 0 6.29127896445425e-08
and O 0 2.3140400173815578e-07
clinodactyly B-Disease 0 0.001855465117841959
. O 0 8.019279448490124e-06

Significant O 0 7.884297701821197e-06
intra O 0 9.881818186840974e-06
- O 0 7.708778866799548e-05
and O 0 3.7519689044529514e-07
interfamilial O 0 0.0010686391033232212
phenotypic O 0 0.00022203345724847168
variability O 0 0.00042008841410279274
is O 0 2.135761256738533e-08
present O 0 1.7749904657193838e-08
for O 0 6.702344457210074e-09
either O 0 1.1548875988864893e-07
TWIST O 0 0.00021532292885240167
mutations O 0 1.3860140825272538e-05
or O 0 7.379679232144554e-07
FGFR O 0 0.030112288892269135
mutations O 0 6.740385288139805e-05
. O 0 3.3792134672694374e-06

The O 0 8.511968303537287e-07
overlap O 0 3.6639119116443908e-06
in O 0 2.850327405212738e-07
clinical O 0 5.213782060309313e-06
features O 0 6.805004773013934e-07
and O 0 1.6956535731083022e-08
the O 0 6.597452806289539e-09
presence O 0 9.248665833183622e-08
, O 0 3.907064893837742e-09
in O 0 1.182357323159522e-09
the O 0 7.100394716630376e-10
same O 0 4.00771371644737e-09
genes O 0 6.298336074905819e-09
, O 0 6.752615133720496e-10
of O 0 1.5505906558743732e-09
mutations O 0 1.3408575227913389e-07
for O 0 7.599384455048153e-10
more O 0 5.290088922471625e-10
than O 0 2.8570581456222044e-09
one O 0 2.6767761340806828e-08
craniosynostotic B-Disease 0 0.10744927823543549
condition I-Disease 0 1.3194808161642868e-05
- O 0 5.883571702725021e-06
such O 0 1.1054303250546127e-08
as O 0 8.3022513308606e-09
Saethre B-Disease 0 4.9930189561564475e-05
- I-Disease 0 6.284315895754844e-05
Chotzen I-Disease 0 0.0001363852061331272
, I-Disease 0 5.5750831506884424e-08
Crouzon I-Disease 0 1.3027177374169696e-05
, I-Disease 0 1.7110401984155033e-08
and I-Disease 0 9.941673084767899e-08
Pfeiffer I-Disease 0 0.23126330971717834
syndromes I-Disease 0 0.45040857791900635
- O 0 0.00010893014405155554
support O 0 5.6287955629841235e-08
the O 0 7.3743509076962255e-09
hypothesis O 0 1.1230036989218206e-07
that O 0 1.899526314019795e-09
TWIST O 0 2.568336014974193e-07
and O 0 9.023911395900086e-09
FGFRs O 0 5.386552857089555e-06
are O 0 7.310458904896677e-10
components O 0 9.734199224453732e-09
of O 0 6.479425884720058e-10
the O 0 4.168857259401193e-09
same O 0 5.530220548166653e-08
molecular O 0 3.224330794182606e-05
pathway O 0 1.0859496057946671e-07
involved O 0 5.899295274502947e-09
in O 0 3.003551629632284e-09
the O 0 7.59058060850748e-09
modulation O 0 8.426274007433676e-07
of O 0 5.290407045777101e-08
craniofacial O 1 0.9741486310958862
and O 0 3.635070243035443e-06
limb O 0 0.1276308298110962
development O 0 3.1495230246036954e-07
in O 0 1.416801893583397e-07
humans O 0 5.324491780811513e-07
. O 0 1.2484312605920422e-07
. O 0 1.4171898783388315e-06

Mutation O 0 0.0011654305271804333
analysis O 0 2.1356332581490278e-05
of O 0 6.113582458056044e-06
UBE3A O 1 0.9961810111999512
in O 1 0.7375090718269348
Angelman B-Disease 1 0.9999982118606567
syndrome I-Disease 1 0.9999992847442627
patients O 0 0.32291722297668457
. O 0 9.865005267784e-05

Angelman B-Disease 1 0.999998927116394
syndrome I-Disease 1 0.9999990463256836
( O 0 4.2977757402695715e-05
AS B-Disease 0 3.128644311800599e-05
) O 0 1.311515234192484e-07
is O 0 2.1785666604046128e-08
caused O 0 3.378680730747874e-07
by O 0 3.168272755260659e-08
chromosome O 0 1.3217377272667363e-05
15q11 O 0 2.093524562951643e-05
- O 0 1.7004984329105355e-05
q13 O 0 2.4805583507259144e-06
deletions O 0 5.578698960562178e-07
of O 0 8.87080187084166e-09
maternal O 0 3.2369342079618946e-05
origin O 0 1.0977951347967974e-07
, O 0 7.115718680950067e-09
by O 0 1.3909543739032415e-08
paternal O 0 0.0002146372862625867
uniparental B-Disease 1 0.6231760382652283
disomy I-Disease 0 0.3285824656486511
( O 0 5.562458795793646e-07
UPD B-Disease 1 0.9554733633995056
) O 0 1.4702563611024289e-08
15 O 0 7.208087904331251e-09
, O 0 6.381652983833419e-09
by O 0 8.623138825214482e-08
imprinting O 0 0.10579054057598114
defects O 0 0.3086673319339752
, O 0 2.9359016551211425e-08
and O 0 1.0795347726855198e-08
by O 0 4.1973752473722925e-08
mutations O 0 2.0450559077289654e-06
in O 0 4.619509041958736e-08
the O 0 3.820179870217544e-07
UBE3A O 0 0.011793454177677631
gene O 0 9.001478247228079e-06
. O 0 2.632253426781972e-06

UBE3A O 0 0.0031696800142526627
encodes O 0 1.593672641320154e-05
a O 0 5.98905614879186e-07
ubiquitin O 0 1.2058744687237777e-05
- O 0 6.31824805168435e-05
protein O 0 5.935170861448569e-07
ligase O 0 4.674988304032013e-06
and O 0 3.291386008186237e-08
shows O 0 8.243735578616906e-07
brain O 0 0.00013189713354222476
- O 0 8.520500705344602e-05
specific O 0 1.2529091009128024e-06
imprinting O 0 0.0003184668021276593
. O 0 4.464724042918533e-06

Here O 0 2.9617458494612947e-06
we O 0 1.504385380712847e-07
describe O 0 1.281252934859367e-06
UBE3A O 0 0.00022446557704824954
coding O 0 1.3703161130251829e-05
- O 0 6.976237636990845e-05
region O 0 3.272455387559603e-06
mutations O 0 8.21612229628954e-06
detected O 0 3.035256440853118e-06
by O 0 2.5303938500087497e-08
SSCP O 0 0.0002634190896060318
analysis O 0 8.597682921163141e-08
in O 0 1.7117713468906004e-08
13 O 0 1.0105900116741395e-07
AS B-Disease 0 1.0489565056559513e-06
individuals O 0 7.378519484291246e-08
or O 0 1.779394409595625e-07
families O 0 1.7770385056792293e-06
. O 0 5.99494660491473e-06

Two O 0 8.836918823362794e-07
identical O 0 3.2583109259576304e-06
de O 0 8.720906521375582e-07
novo O 0 1.1047326324842288e-06
5 O 0 9.584860549693985e-08
- O 0 2.944026846307679e-06
bp O 0 6.495879915746627e-06
duplications O 0 1.6057975926742074e-06
in O 0 6.372459182557577e-08
exon O 0 3.392098005861044e-05
16 O 0 1.3855162706022384e-07
were O 0 6.805582586366654e-08
found O 0 7.339168632825022e-07
. O 0 3.2463015031680698e-06

Among O 0 9.039623023454624e-07
the O 0 3.7901468630252566e-08
other O 0 7.738047536065551e-09
11 O 0 7.434404381001514e-08
unique O 0 7.397344461423927e-07
mutations O 0 5.023206995247165e-06
, O 0 1.0538236061563566e-08
8 O 0 5.512714729150048e-09
were O 0 1.17127807452988e-09
small O 0 5.7506039929933195e-09
deletions O 0 1.0972839845635463e-06
or O 0 1.9550942198520715e-08
insertions O 0 1.504067586211022e-05
predicted O 0 1.0627317351463716e-05
to O 0 1.1961720502995377e-08
cause O 0 8.154852366715204e-07
frameshifts O 0 0.0001066618351615034
, O 0 5.204769504274509e-09
1 O 0 2.1335329059013475e-09
was O 0 2.254762598852267e-09
a O 0 1.532859883468518e-08
mutation O 0 1.6862800578110182e-07
to O 0 5.23662113671719e-10
a O 0 1.67198344058761e-09
stop O 0 1.2939107563170182e-08
codon O 0 4.4680657396156676e-08
, O 0 6.261823282116552e-10
1 O 0 5.040324269067753e-10
was O 0 1.1729771598467664e-09
a O 0 1.3375402119208957e-08
missense O 0 0.0006207958213053644
mutation O 0 2.0723418856505305e-06
, O 0 1.8509499488672532e-09
and O 0 1.923919912272254e-09
1 O 0 7.082611386266535e-09
was O 0 2.9266429280028206e-08
predicted O 0 6.646922656727838e-07
to O 0 3.785441737846895e-09
cause O 0 9.407686718532204e-08
insertion O 0 8.392304806648099e-08
of O 0 2.5538990922058247e-09
an O 0 6.741654345887582e-09
isoleucine O 0 2.720156408031471e-05
in O 0 6.966039745037733e-09
the O 0 2.805840670916382e-09
hect O 0 3.879202267853543e-06
domain O 0 6.339821112533173e-09
of O 0 6.421906895148766e-10
the O 0 4.789419527639893e-09
UBE3A O 0 0.00032193277729675174
protein O 0 7.34159826265568e-08
, O 0 1.2966893114807476e-09
which O 0 8.347946778286541e-10
functions O 0 1.1045234726836384e-09
in O 0 4.704530542909424e-09
E2 O 0 8.573999821237521e-07
binding O 0 1.194908065826894e-07
and O 0 3.368590384411618e-08
ubiquitin O 0 4.575978437060257e-06
transfer O 0 1.3654691883857595e-06
. O 0 2.262862608404248e-06

Eight O 0 7.429541142300877e-07
of O 0 4.006829357194874e-08
the O 0 3.933731917982186e-08
cases O 0 1.3240725138530252e-07
were O 0 7.00711240142482e-08
familial O 0 0.008625222370028496
, O 0 2.318475793572361e-07
and O 0 4.8976914968079654e-08
five O 0 9.875583373286645e-08
were O 0 3.8606725638601347e-07
sporadic O 0 0.00011003793042618781
. O 0 1.2817568858736195e-05

In O 0 1.7908615745909628e-06
two O 0 2.721488101542491e-07
familial O 0 0.005223906133323908
cases O 0 4.630545845429879e-06
and O 0 1.2865751841673045e-07
one O 0 3.5512488949507315e-08
sporadic O 0 7.022175850579515e-06
case O 0 2.030901214311598e-06
, O 0 1.0822586204994877e-07
mosaicism O 0 6.437366391764954e-05
for O 0 9.410648260654852e-08
UBE3A O 0 0.12894107401371002
mutations O 0 5.836532636749325e-06
was O 0 4.5315942998058745e-08
detected O 0 5.322344236446952e-07
in O 0 4.718693435989962e-09
the O 0 3.274283955079227e-09
mother O 0 2.2264796939452935e-07
of O 0 1.1532664823121763e-09
three O 0 1.9934004669153182e-08
AS B-Disease 0 1.0177001968258992e-05
sons O 0 6.9002403506601695e-06
, O 0 9.36350197378033e-09
in O 0 2.371549845392451e-09
the O 0 4.828429212011542e-09
maternal O 0 1.738216269586701e-05
grandfather O 0 7.995331543497741e-07
of O 0 9.91729032229216e-10
two O 0 2.0705828163158913e-09
AS B-Disease 0 7.735232543382153e-08
first O 0 9.177755444511604e-09
cousins O 0 2.1057912817923352e-06
, O 0 6.486848835862702e-09
and O 0 3.133187487236455e-09
in O 0 2.617966066154054e-09
the O 0 9.864547401150503e-09
mother O 0 7.207526664387842e-07
of O 0 3.733449105425279e-09
an O 0 2.2281209766106258e-08
AS B-Disease 0 7.163564441725612e-05
daughter O 0 0.00605648523196578
. O 0 8.364532732230145e-06

The O 0 7.259484959831752e-07
frequencies O 0 6.673326993222872e-07
with O 0 1.7451535327950296e-08
which O 0 2.5672921566410878e-08
we O 0 2.3017317829499007e-08
detected O 0 4.117567641515052e-06
mutations O 0 9.624943686503684e-08
were O 0 2.547156707777276e-09
5 O 0 1.4197499176304973e-08
( O 0 3.1309712600346984e-09
14 O 0 7.194064455262605e-09
% O 0 1.866054422094976e-09
) O 0 3.159398576091377e-10
of O 0 3.0359598168772095e-10
35 O 0 6.544263353447377e-09
in O 0 8.057553735341116e-09
sporadic O 0 1.941247546710656e-06
cases O 0 1.2664777671034244e-07
and O 0 3.484049670987588e-08
8 O 0 5.0840291976328444e-08
( O 0 2.4330928383164974e-09
80 O 0 4.015717536276497e-09
% O 0 3.1939362266086846e-09
) O 0 5.873895259078665e-10
of O 0 8.027131181975733e-10
10 O 0 1.4507013368358912e-08
in O 0 2.2512492137138906e-07
familial O 0 0.07074704766273499
cases O 0 1.6126072296174243e-05
. O 0 1.5882068282735418e-06
. O 0 5.387041255744407e-06

The O 0 2.9709781301789917e-05
hemochromatosis B-Disease 1 0.9994171857833862
845 O 0 0.0008282007183879614
G O 0 0.0009546738583594561
- O 0 7.96200693002902e-05
- O 0 0.00013498928456101567
> O 0 2.631294591992628e-06
A O 0 1.3175672997078891e-08
and O 0 6.375788785817349e-09
187 O 0 8.845597676554462e-08
C O 0 4.817715080207563e-07
- O 0 2.5537199690006673e-05
- O 0 0.0034499720204621553
> O 0 0.00015967040963005275
G O 0 0.0071300785057246685
mutations O 0 3.597627028284478e-06
: O 0 1.0343463685558163e-07
prevalence O 0 4.8226979743049014e-06
in O 0 2.1735859334626184e-08
non O 0 4.751670417135756e-07
- O 0 0.027468888089060783
Caucasian O 0 0.002360106445848942
populations O 0 2.114085145876743e-05
. O 0 3.5611055864137597e-06

Hemochromatosis B-Disease 1 0.9984235763549805
, O 0 1.481861272623064e-05
the O 0 3.338835449540056e-05
inherited B-Disease 1 0.9999635219573975
disorder I-Disease 1 0.9973830580711365
of I-Disease 0 8.715577450857381e-07
iron I-Disease 1 0.9481468796730042
metabolism I-Disease 0 0.00034056062577292323
, O 0 3.5854014868164086e-08
leads O 0 3.707217501869309e-07
, O 0 4.627180771876738e-08
if O 0 2.4715706103961566e-07
untreated O 0 5.50367112737149e-05
, O 0 1.9622673264052537e-08
to O 0 1.5235963601867297e-08
progressive O 0 5.7684537750901654e-05
iron B-Disease 1 0.96861332654953
overload I-Disease 1 0.6795206665992737
and O 0 4.659912065108074e-06
premature B-Disease 0 0.0004319348372519016
death I-Disease 0 3.3523851016070694e-05
. O 0 5.886304279556498e-06

The O 0 3.35181612172164e-05
hemochromatosis B-Disease 1 0.9998089671134949
gene O 0 8.288196113426238e-05
, O 0 7.746571100142319e-07
HFE O 0 0.01350732147693634
, O 0 6.289671006243225e-08
recently O 0 1.1590140758244161e-07
has O 0 1.3120125430532426e-08
been O 0 1.1206346073322493e-08
identified O 0 1.1519924214553612e-07
, O 0 3.754142774425873e-09
and O 0 3.346788846059212e-09
characterization O 0 2.6994078439201985e-07
of O 0 8.547135221803615e-10
this O 0 2.912019514411668e-09
gene O 0 2.4558934441643032e-08
has O 0 2.9953135527449604e-09
shown O 0 1.1896101881347931e-08
that O 0 9.564325997857281e-10
it O 0 2.5823027050009273e-10
contains O 0 1.0493843571879324e-09
two O 0 3.2366993529819865e-09
mutations O 0 1.6225723697971262e-07
that O 0 3.5227711858709654e-09
result O 0 2.084830263981985e-08
in O 0 8.328722600481342e-09
amino O 0 2.029431556138661e-08
acid O 0 2.0895877028692666e-08
substitutions O 0 1.6746334097206272e-08
- O 0 1.9545636575912795e-07
cDNA O 0 9.905011211230885e-08
nucleotides O 0 9.122365440816793e-08
845 O 0 3.0520141081069596e-07
G O 0 2.9470099889294943e-06
- O 0 3.759393393920618e-06
- O 0 6.798800313845277e-05
> O 0 1.515194298917777e-06
A O 0 1.8825032199742964e-08
( O 0 4.917851903485371e-09
C282Y O 0 8.346950153281796e-07
) O 0 1.2565308793455188e-09
and O 0 1.5060578339998187e-09
187 O 0 3.6122681734696016e-08
C O 0 2.493569866146572e-07
- O 0 3.0218579922802746e-05
- O 0 0.00936023611575365
> O 0 0.0005106035969220102
G O 0 0.0007970609585754573
( O 0 9.613183493684119e-08
H63D O 0 0.00046072553959675133
) O 0 2.3259323711499746e-07
. O 0 1.0571069424258894e-06

Although O 0 0.0006752041517756879
hemochromatosis B-Disease 1 0.9997939467430115
is O 0 1.0306868034604122e-06
common O 0 2.5830351546574093e-07
in O 0 1.049815665510323e-07
Caucasians O 0 9.009121640701778e-06
, O 0 8.604867929307147e-08
affecting O 0 5.21755453064543e-07
> O 0 1.5217197869787924e-05
= O 0 6.13519296166487e-06
1 O 0 6.895580551002922e-09
/ O 0 1.768517989830798e-07
300 O 0 3.647965485242821e-09
individuals O 0 1.3578203006403555e-09
of O 0 6.9108768707693e-10
northern O 0 4.24658530562283e-08
European O 0 2.203969273750772e-08
origin O 0 6.652193462741707e-08
, O 0 8.829141862065626e-09
it O 0 1.0737433164820231e-09
has O 0 1.8748842478544248e-09
not O 0 9.334112371917058e-10
been O 0 4.3980037389701465e-09
recognized O 0 2.065814541651889e-08
in O 0 3.9964412223980617e-08
other O 0 9.835392944523846e-08
populations O 0 4.687060027208645e-06
. O 0 4.8546762627665885e-06

The O 0 6.609558909076441e-07
present O 0 2.2887040529440128e-07
study O 0 6.47160192102092e-08
used O 0 1.2102168156502557e-08
PCR O 0 2.292988341423552e-07
and O 0 3.2295706109408684e-09
restriction O 0 2.0984025184134225e-08
- O 0 7.57939972118038e-07
enzyme O 0 5.968905014697157e-08
digestion O 0 1.1602283933598301e-07
to O 0 8.892853675668277e-10
analyze O 0 3.311125595928388e-08
the O 0 1.56931156958251e-09
frequency O 0 1.1743792605045655e-08
of O 0 2.9920915745051957e-10
the O 0 2.2662054455224734e-09
845 O 0 1.6226371144512086e-06
G O 0 1.1643750440271106e-05
- O 0 5.495434379554354e-06
- O 0 3.064080374315381e-05
> O 0 6.873725624245708e-07
A O 0 4.645279716442019e-09
and O 0 2.590379244438168e-09
187 O 0 7.801121881811923e-08
C O 0 2.1422650320346293e-07
- O 0 9.828519978327677e-06
- O 0 0.000524441828019917
> O 0 8.449894812656567e-05
G O 0 0.00029639506828971207
mutations O 0 2.7014138481717964e-07
in O 0 5.379294787388744e-09
HLA O 0 8.42590907268459e-06
- O 0 2.867692273866851e-06
typed O 0 2.8482813263508433e-07
samples O 0 2.793101749887228e-08
from O 0 2.4885411509245614e-09
non O 0 3.484827360011877e-08
- O 0 6.593232683371753e-05
Caucasian O 0 2.3929120288812555e-05
populations O 0 1.137090137603991e-07
, O 0 1.8521717493058532e-09
comprising O 0 9.6708534513823e-09
Australian O 0 1.9299969267194683e-07
Aboriginal O 0 1.3373276885886298e-07
, O 0 4.152153287861893e-09
Chinese O 0 6.095295379537902e-09
, O 0 5.302497108061743e-09
and O 0 3.882092869389453e-08
Pacific O 0 4.154249381826958e-06
Islanders O 0 2.329330709471833e-05
. O 0 1.8016435205936432e-06

Results O 0 7.181335240602493e-05
showed O 0 3.6840447137365118e-06
that O 0 1.1448533676627903e-08
the O 0 8.413472585289128e-09
845 O 0 7.4857939580397215e-06
G O 0 0.00010134280455531552
- O 0 8.17359468783252e-05
- O 0 0.00021656343596987426
> O 0 6.808167199778836e-06
A O 0 1.098813271482868e-07
mutation O 0 8.322071494148986e-07
was O 0 6.5571077456638704e-09
present O 0 1.0598668609418382e-08
in O 0 7.76038167060733e-09
these O 0 3.770820544701792e-09
populations O 0 9.008093826423647e-08
( O 0 5.929143398475389e-09
allele O 0 8.278804841665988e-08
frequency O 0 1.862808396424498e-08
0 O 0 5.5146496258373645e-09
. O 0 1.1653282783186114e-09
32 O 0 1.3201280957275685e-08
% O 0 7.823275360863136e-09
) O 0 2.8127258300258973e-09
, O 0 3.5385629981732336e-09
and O 0 9.522954869112255e-09
, O 0 2.845096069847841e-08
furthermore O 0 1.2455082298856723e-07
, O 0 2.5539088621684414e-09
it O 0 8.100897730400902e-10
was O 0 3.648229940367287e-09
always O 0 8.418401087340044e-09
seen O 0 2.0105568765416137e-08
in O 0 2.646830976615888e-09
conjunction O 0 6.738751068269266e-08
with O 0 7.205629515283363e-08
HLA O 0 0.013563502579927444
haplotypes O 0 8.810080180410296e-05
common O 0 7.534430324085406e-08
in O 0 2.0839953762674668e-08
Caucasians O 0 7.473956316061958e-07
, O 0 8.72345040647815e-09
suggesting O 0 9.377929188758571e-08
that O 0 7.145926073093278e-09
845 O 0 4.960273599863285e-06
G O 0 0.00019177018839400262
- O 0 0.00020883508841507137
- O 0 0.005805663298815489
> O 0 2.4601500626886263e-05
A O 0 1.5172113876360527e-07
may O 0 6.43697219970818e-08
have O 0 1.1459253546064474e-09
been O 0 1.350325407045716e-09
introduced O 0 8.863039191453481e-09
into O 0 2.495813777869671e-09
these O 0 6.913253969287325e-09
populations O 0 1.221703200826596e-07
by O 0 1.5679651710343023e-07
Caucasian O 0 9.982040501199663e-05
admixture O 0 0.0005761689390055835
. O 0 1.44490850289003e-05

187 O 0 2.5031171389855444e-05
C O 0 1.2521777534857392e-05
- O 0 6.852387741673738e-05
- O 0 0.0011795761529356241
> O 0 6.928946095285937e-05
G O 0 2.4317581846844405e-05
was O 0 7.653544464858442e-09
present O 0 7.059818507570981e-09
at O 0 4.4719339342691455e-09
an O 0 3.068726606159089e-09
allele O 0 3.2588471299277444e-07
frequency O 0 4.314636115054782e-08
of O 0 8.39806535424259e-09
2 O 0 3.6891316312903655e-07
. O 0 1.593757019691111e-06

68 O 0 1.8687695046537556e-05
% O 0 3.974067794842995e-07
in O 0 1.7269945473685766e-08
the O 0 5.223735222159576e-09
two O 0 9.108210186070664e-09
populations O 0 4.312497026148776e-07
analyzed O 0 6.926731543899223e-07
( O 0 1.0674116701636649e-08
Australian O 0 1.2454012221496669e-07
Aboriginal O 0 3.147865470509714e-07
and O 0 2.6925423668444637e-08
Chinese O 0 1.9906957504645106e-07
) O 0 2.6669260932976613e-07
. O 0 1.1969192428296083e-06

In O 0 4.053457871577848e-07
the O 0 3.6764664201882624e-08
Australian O 0 2.8269650442780403e-07
Aboriginal O 0 4.822155119654781e-07
samples O 0 1.4357890165683784e-07
, O 0 5.5956941302781615e-09
187 O 0 4.383752028047638e-08
C O 0 1.0410798978455205e-07
- O 0 4.407799679029267e-06
- O 0 9.727889846544713e-05
> O 0 2.71462067757966e-05
G O 0 9.818558464758098e-05
was O 0 7.849252803282525e-09
found O 0 3.5176146440107914e-09
to O 0 1.2065606291855602e-09
be O 0 3.797917091930003e-09
associated O 0 6.391521623072549e-08
with O 0 5.2794295157809756e-08
HLA O 0 0.020025061443448067
haplotypes O 0 0.00023073365446180105
common O 0 1.135934653007098e-07
in O 0 3.9210721780591484e-08
Caucasians O 0 2.9144161999283824e-06
, O 0 3.190923791862588e-08
suggesting O 0 1.9104702175809507e-07
that O 0 2.7759299303653506e-09
it O 0 8.336109025286476e-10
was O 0 4.855886803767362e-09
introduced O 0 4.227198502348983e-08
by O 0 2.6103787575948445e-08
recent O 0 1.1988601045231917e-06
admixture O 0 8.967950998339802e-05
. O 0 5.08109042129945e-06

In O 0 4.7469418973378197e-07
the O 0 3.182529795253686e-08
Chinese O 0 2.7304873029265764e-08
samples O 0 9.831866520926269e-08
analyzed O 0 1.0849848308680521e-07
, O 0 3.4291955941512242e-09
187 O 0 3.326494990574247e-08
C O 0 2.0909438092076016e-07
- O 0 1.0935817954305094e-05
- O 0 0.0006793279899284244
> O 0 0.00015327974688261747
G O 0 0.0003658769419416785
was O 0 1.099689317385355e-08
present O 0 1.8575786242536196e-08
in O 0 2.5406368564517834e-08
association O 0 2.427318435138659e-08
with O 0 4.3618308964710195e-09
a O 0 1.4523569902280542e-08
wide O 0 7.354857700647699e-08
variety O 0 2.72192313133246e-08
of O 0 8.518381555688848e-09
HLA O 0 0.0016062709037214518
haplotypes O 0 3.687611751956865e-05
, O 0 1.8275731150652064e-08
showing O 0 5.464816013045493e-07
this O 0 1.3340191173938365e-08
mutation O 0 1.9997662548121298e-07
to O 0 1.1653239484488154e-09
be O 0 1.7792468609556522e-09
widespread O 0 1.272718037625964e-07
and O 0 3.7178455869479876e-08
likely O 0 1.0658435911636843e-07
to O 0 4.765836170150806e-09
predate O 0 1.784408709681884e-06
the O 0 2.9502256193580934e-09
more O 0 1.5273432518725372e-09
genetically O 0 2.328250836569623e-08
restricted O 0 1.1922770326577847e-08
845 O 0 2.1295961687428644e-06
G O 0 0.00010325068433303386
- O 0 7.710036152275279e-05
- O 0 0.0007156584761105478
> O 0 5.76035090489313e-05
A O 0 1.3020727465118398e-06
mutation O 0 4.1789051465457305e-05
. O 0 2.2093245206633583e-06

Genotype O 1 0.9856886863708496
- O 1 0.858412504196167
phenotype O 1 0.9006340503692627
correlations O 0 0.0061251758597791195
in O 0 0.00022226900910027325
attenuated B-Disease 1 0.9968109726905823
adenomatous I-Disease 1 0.99996018409729
polyposis I-Disease 1 0.9998799562454224
coli I-Disease 1 0.9990764856338501
. O 0 0.00024050753563642502

Germ O 0 0.2278967946767807
- O 0 0.0007964320247992873
line O 0 7.195478701760294e-06
mutations O 0 2.6644345325621543e-06
of O 0 2.5544364845586642e-08
the O 0 1.870945283144465e-07
tumor B-Disease 0 0.005237559787929058
suppressor O 0 0.000288495299173519
APC O 0 5.183599114388926e-06
are O 0 8.522025751744877e-08
implicated O 0 4.810869359062053e-05
in O 0 6.654141179751605e-05
attenuated B-Disease 1 0.9993754029273987
adenomatous I-Disease 1 0.9999889135360718
polyposis I-Disease 1 0.9999822378158569
coli I-Disease 1 0.9998365640640259
( O 0 0.00010023418872151524
AAPC B-Disease 1 0.9995563626289368
) O 0 2.3624185985227086e-07
, O 0 2.7156277226936254e-08
a O 0 1.5050656543280638e-07
variant O 0 0.00012019812857033685
of O 0 3.135056613245979e-05
familial B-Disease 1 0.9999946355819702
adenomatous I-Disease 1 0.9999924898147583
polyposis I-Disease 1 0.99998939037323
( O 0 8.656632417114452e-05
FAP B-Disease 0 0.008121762424707413
) O 0 1.9401111330807908e-06
. O 0 4.4355633690429386e-06

AAPC B-Disease 1 0.9986795783042908
is O 0 2.4586199742770987e-06
recognized O 0 2.3548000172013417e-07
by O 0 1.385986081459123e-08
the O 0 1.1997295601418045e-08
occurrence O 0 1.1118607972093741e-06
of O 0 2.3516328440109646e-08
< O 0 1.4108415598457213e-05
100 O 0 7.909490307156375e-08
colonic B-Disease 0 0.12013433128595352
adenomas I-Disease 0 0.001091289333999157
and O 0 2.1544344974699925e-08
a O 0 6.083195813744169e-08
later O 0 8.570345926273149e-07
onset O 0 0.04617684334516525
of O 0 0.012706737034022808
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
( O 0 3.637368990894174e-06
age O 0 1.092924958356889e-05
> O 0 3.0403081836993806e-05
40 O 0 9.204704554122145e-08
years O 0 4.818169827558449e-07
) O 0 4.1093275626735704e-07
. O 0 1.589473527019436e-06

The O 0 4.781189772984362e-07
aim O 0 6.949188104954374e-07
of O 0 2.1325698540408666e-08
this O 0 1.4135082437860547e-08
study O 0 6.169311461690086e-08
was O 0 1.6607140551627708e-08
to O 0 2.003356236457421e-08
assess O 0 4.4506847189040855e-05
genotype O 0 0.058768536895513535
- O 0 0.3138691484928131
phenotype O 0 0.16008295118808746
correlations O 0 0.00046131573617458344
in O 0 1.4727656889590435e-05
AAPC B-Disease 1 0.9981254935264587
families O 0 8.979838639788795e-06
. O 0 6.335197667795001e-06

By O 0 7.749304131721146e-07
protein O 0 1.132016109295364e-06
- O 0 8.875153071130626e-06
truncation O 0 5.9766457525256556e-06
test O 0 3.8826971149319434e-07
( O 0 1.0619875645545562e-08
PTT O 0 7.295087698366842e-07
) O 0 3.314650109942363e-09
assay O 0 2.044807132506321e-07
, O 0 1.1118962417455691e-09
the O 0 1.0181151477439698e-09
entire O 0 2.048819602862295e-08
coding O 0 3.81116649350588e-07
region O 0 1.137405192253027e-08
of O 0 7.90928766924992e-10
the O 0 7.223295739322566e-09
APC B-Disease 0 1.3298333669808926e-06
gene O 0 5.995661922497675e-08
was O 0 7.936189483359612e-09
screened O 0 3.751603969703865e-07
in O 0 3.88909668913584e-08
affected O 0 1.2258544757060008e-07
individuals O 0 3.777942225724473e-08
from O 0 1.121528896419477e-07
11 O 0 2.3299528038478456e-05
AAPC B-Disease 1 0.9997026324272156
kindreds O 0 0.0014395322650671005
, O 0 2.512790864273029e-08
and O 0 5.521280321829636e-09
their O 0 1.4846789575528874e-08
phenotypic O 0 4.401633304951247e-06
differences O 0 2.8905119506816845e-06
were O 0 7.394085628220637e-07
examined O 0 0.00010248409671476111
. O 0 1.2818498362321407e-05

Five O 0 1.755067728481663e-06
novel O 0 4.184260887996061e-06
germ O 0 0.0020181802101433277
- O 0 0.00019811317906714976
line O 0 5.955928827461321e-06
APC B-Disease 0 1.4308723621070385e-05
mutations O 0 1.228276119036309e-06
were O 0 1.9182195387656975e-08
identified O 0 2.2261738763518224e-07
in O 0 1.0537596750737066e-07
seven O 0 2.0226284505042713e-06
kindreds O 0 0.002667551627382636
. O 0 7.148012173274765e-06

Mutations O 0 0.0007600352400913835
were O 0 1.3425042766357365e-07
located O 0 6.151381626295915e-08
in O 0 7.330359874657688e-09
three O 0 2.8253452910576016e-09
different O 0 2.26910334966135e-09
regions O 0 1.2381791592019908e-08
of O 0 1.053967801922795e-09
the O 0 1.7336743596274573e-08
APC B-Disease 0 2.8540205221361248e-06
gene O 0 4.212999726860289e-08
( O 0 1.5084036242285492e-09
1 O 0 1.411042838128651e-09
) O 0 4.4486303529822635e-10
at O 0 4.78174999596348e-10
the O 0 6.658077422727615e-10
5 O 0 4.643508244583927e-09
end O 0 8.889856850657907e-09
spanning O 0 1.5547071541277546e-07
exons O 0 1.6572893457578175e-07
4 O 0 6.255929108078817e-09
and O 0 3.386717573050646e-09
5 O 0 8.386316530106797e-09
, O 0 1.565640173062377e-09
( O 0 6.744480529619068e-10
2 O 0 1.0703408159784544e-09
) O 0 4.0767295095278655e-10
within O 0 6.059635571098454e-10
exon O 0 3.0364867598109413e-06
9 O 0 5.458113605527615e-08
, O 0 2.8574069776965416e-09
and O 0 2.8077786762281676e-09
( O 0 1.7970775978426445e-09
3 O 0 1.958960549330868e-09
) O 0 3.677262383483537e-10
at O 0 6.95713986420543e-10
the O 0 9.972297432270238e-10
3 O 0 3.9878731428188985e-09
distal O 0 9.771910214340096e-08
end O 0 1.9511791293780334e-08
of O 0 3.911531543110414e-09
the O 0 1.1343249184392334e-07
gene O 0 3.83596579922596e-06
. O 0 1.2450668691599276e-06

Variability O 0 0.0034797133412212133
in O 0 3.8046769645916356e-07
the O 0 3.173534679490331e-08
number O 0 9.484854501806694e-08
of O 0 1.0764652870420832e-05
colorectal B-Disease 1 0.9999998807907104
adenomas I-Disease 1 0.9999852180480957
was O 0 1.1354812841091189e-06
most O 0 2.8139242047586777e-08
apparent O 0 7.246443601616193e-06
in O 0 1.721455475944822e-07
individuals O 0 1.7285170628156266e-08
with O 0 7.714766780964055e-08
mutations O 0 3.38962604473636e-06
in O 0 1.9730835632003618e-08
region O 0 8.137622842241399e-08
1 O 0 1.210701583431728e-08
, O 0 7.864297657533825e-09
and O 0 7.040389959911408e-08
upper O 0 0.0009037175332196057
- O 1 0.9953699707984924
gastrointestinal O 1 0.9981335997581482
manifestations O 0 0.011319910176098347
were O 0 5.3659860554944316e-08
more O 0 3.921146785046403e-08
severe O 0 0.00017008974100463092
in O 0 6.913103902661533e-07
them O 0 2.8606675073206134e-07
. O 0 5.707929631171282e-06

In O 0 3.5001669402845437e-06
individuals O 0 2.3748560806780006e-07
with O 0 1.6986665229978826e-07
mutations O 0 6.721942554577254e-06
in O 0 2.2457420811861084e-08
either O 0 1.7582303613039585e-08
region O 0 1.3518702246528846e-07
2 O 0 7.569356696990326e-09
or O 0 5.272845271520055e-09
region O 0 3.482083243966372e-08
3 O 0 3.505217671673222e-09
, O 0 8.494105974143906e-10
the O 0 7.856542638684516e-10
average O 0 2.034505008907672e-08
number O 0 2.028223144989738e-09
of O 0 2.9955877778320428e-09
adenomas B-Disease 0 0.00018658142653293908
tended O 0 1.2228012735704397e-07
to O 0 2.3396415915755142e-09
be O 0 2.718611558094608e-09
lower O 0 6.77889531175424e-08
than O 0 3.6110539003431086e-09
those O 0 4.100281891794566e-09
in O 0 1.0293470076305766e-08
individuals O 0 6.5710046293077085e-09
with O 0 6.846072864163943e-08
mutations O 0 3.0408307338802842e-06
in O 0 3.306140428094295e-08
region O 0 1.3068070359167905e-07
1 O 0 2.0806670164574825e-08
, O 0 2.0744774786862763e-08
although O 0 6.225815951665936e-08
age O 0 7.103184316292754e-07
at O 0 6.653696686953481e-07
diagnosis O 0 0.003775083227083087
was O 0 6.867651336506242e-07
similar O 0 4.9387836043024436e-06
. O 0 2.7329758722771658e-06

In O 0 6.917925475136144e-06
all O 0 1.1335672525092377e-06
AAPC B-Disease 1 0.9956913590431213
kindreds O 0 0.0007399697788059711
, O 0 1.1486180540032365e-07
a O 0 4.2101881092548865e-08
predominance O 0 5.0603930503712036e-06
of O 0 6.191638846075875e-08
right O 0 3.379144982318394e-05
- O 1 0.997435986995697
sided O 1 0.9998719692230225
colorectal B-Disease 1 0.9999997615814209
adenomas I-Disease 1 0.9999408721923828
and O 0 7.681475108256564e-05
rectal B-Disease 1 0.9971066117286682
polyp I-Disease 1 0.9561048746109009
sparing O 0 3.714112608577125e-05
was O 0 1.311579353568959e-06
observed O 0 1.055662869475782e-05
. O 0 2.234817429780378e-06

No O 0 5.5150663683889434e-05
desmoid B-Disease 1 0.9606006145477295
tumors I-Disease 1 0.9996534585952759
were O 0 1.551987196535265e-07
found O 0 1.531276723198971e-07
in O 0 8.637805848366042e-08
these O 0 1.8283895997228683e-07
kindreds O 0 0.0007996122003532946
. O 0 7.520591225329554e-06

Our O 0 3.2667553568899166e-06
data O 0 1.1021261343557853e-06
suggest O 0 3.761211928576813e-07
that O 0 1.1375310471350986e-08
, O 0 1.9148197694107694e-08
in O 0 1.0490530399920317e-07
AAPC B-Disease 1 0.9594513773918152
families O 0 5.539880376659312e-08
, O 0 3.703363615770172e-09
the O 0 1.8572022808527322e-09
location O 0 2.36854038604406e-08
of O 0 2.448053981751741e-09
the O 0 6.158812482226494e-08
APC B-Disease 0 9.603957005310804e-05
mutation O 0 3.6578512663254514e-05
may O 0 1.6643026583551546e-06
partially O 0 3.768877604670706e-06
predict O 0 3.173926870658761e-06
specific O 0 2.7674789748743933e-07
phenotypic O 0 1.988459553103894e-05
expression O 0 2.2129295757622458e-05
. O 0 5.1469160098349676e-06

This O 0 5.719829800909793e-07
should O 0 8.356270342346761e-08
help O 0 4.9458773077049045e-08
in O 0 5.965556493237045e-09
the O 0 4.4328616333189075e-09
design O 0 1.7307908706243325e-07
of O 0 1.2498673207517186e-08
tailored O 0 0.00011680345050990582
clinical O 0 0.0002746449608821422
- O 0 0.03241921588778496
management O 0 1.3770436453341972e-06
protocols O 0 2.2082578254867258e-07
in O 0 3.5849345714211722e-09
this O 0 2.5568136496900706e-09
subset O 0 1.0335536160255288e-07
of O 0 8.72072547508651e-08
FAP B-Disease 0 0.018726222217082977
patients O 0 1.2508314284787048e-05
. O 0 6.277308557400829e-07
. O 0 3.3124381388915936e-06

Wilms B-Disease 1 0.9938755631446838
' I-Disease 0 0.0005285030929371715
tumor I-Disease 0 0.00031767800101079047
1 O 0 6.641823091513288e-08
and O 0 2.9157169123550375e-08
Dax O 0 3.59049990947824e-05
- O 0 4.648930371331517e-06
1 O 0 1.49777399371942e-08
modulate O 0 7.302033964151633e-07
the O 0 1.1232110352921154e-08
orphan O 0 6.6945549406227656e-06
nuclear O 0 9.34233503357973e-06
receptor O 0 7.975066864673863e-07
SF O 0 0.00028599961660802364
- O 0 5.39201892024721e-07
1 O 0 3.5955900479223146e-09
in O 0 3.2476012989945957e-09
sex O 0 1.282755164311311e-07
- O 0 2.247644806629978e-05
specific O 0 2.7805953095594305e-07
gene O 0 1.3886767646908993e-06
expression O 0 3.5784169085673057e-06
. O 0 1.5329613916037488e-06

Products O 0 3.300361640867777e-06
of O 0 2.0061712291408185e-07
steroidogenic O 0 0.0011560384882614017
factor O 0 6.743019866917166e-07
1 O 0 6.487594106374672e-08
( O 0 3.245788704475672e-08
SF O 0 0.007362694945186377
- O 0 1.2441453691280913e-05
1 O 0 1.4877716836281252e-08
) O 0 6.229614157859942e-09
and O 0 1.6989093865049654e-07
Wilms B-Disease 1 0.9809978604316711
tumor I-Disease 0 0.003761970205232501
1 O 0 4.6186805491288396e-08
( O 0 2.0370714892692376e-08
WT1 O 0 9.50970861595124e-05
) O 0 6.6397811693263975e-09
genes O 0 1.3302257073632973e-08
are O 0 7.545309377299247e-10
essential O 0 4.5019730166018235e-09
for O 0 4.843602852133699e-09
mammalian O 0 2.4027040126384236e-06
gonadogenesis O 0 0.00017908395966514945
prior O 0 9.259256472660127e-08
to O 0 2.7725025830704908e-08
sexual O 0 1.944041287060827e-06
differentiation O 0 1.699383028608281e-05
. O 0 5.118236913403962e-06

In O 0 3.1584554562869016e-06
males O 0 3.824915438599419e-06
, O 0 1.7608792290957354e-07
SF O 0 0.006268604192882776
- O 0 1.5514870028709993e-05
1 O 0 1.6976406058688553e-08
participates O 0 4.525944774513846e-08
in O 0 5.701239924604806e-09
sexual O 0 3.268569770398244e-08
development O 0 2.461032799772056e-08
by O 0 8.589712940931804e-09
regulating O 0 7.414847402742453e-08
expression O 0 1.9747362856037398e-08
of O 0 1.5737537939486401e-09
the O 0 2.945369281803778e-08
polypeptide O 0 2.0855359252891503e-05
hormone O 0 7.72620114730671e-06
Mullerian O 0 0.00039143755566328764
inhibiting O 0 1.0312146514479537e-05
substance O 0 1.7888247384689748e-05
( O 0 5.248931529422407e-07
MIS O 0 0.0006957779405638576
) O 0 4.905806463284534e-07
. O 0 2.214961568824947e-06

Here O 0 3.4008903639914934e-06
, O 0 8.834823006509396e-08
we O 0 1.0171317121887569e-08
show O 0 5.70532208143959e-08
that O 0 2.0189993676922313e-08
WT1 O 0 0.000347829278325662
- O 0 0.00024334464978892356
KTS O 0 0.0013852621195837855
isoforms O 0 2.2959599732530478e-07
associate O 0 4.4675886101686046e-08
and O 0 9.49299572283735e-09
synergize O 0 3.1332514481619e-05
with O 0 1.297755716223037e-07
SF O 0 0.34956324100494385
- O 0 8.629128387838136e-06
1 O 0 7.47503747788869e-09
to O 0 5.858267648761739e-09
promote O 0 3.466557529918646e-07
MIS O 0 0.0009532737312838435
expression O 0 4.335261110099964e-06
. O 0 1.8877403817896266e-06

In O 0 5.555049483518815e-06
contrast O 0 3.991884659626521e-05
, O 0 1.0215508154942654e-06
WT1 O 0 0.0872875303030014
missense O 0 0.024625809863209724
mutations O 0 2.6956084184348583e-05
, O 0 7.64008518672199e-08
associated O 0 1.3220007133440959e-07
with O 0 5.712193384965758e-08
male B-Disease 0 7.787237700540572e-05
pseudohermaphroditism I-Disease 1 0.9993528723716736
in O 0 4.788477326655993e-06
Denys B-Disease 1 0.9933221936225891
- I-Disease 1 0.9998743534088135
Drash I-Disease 1 0.9999732971191406
syndrome I-Disease 1 0.9999150037765503
, O 0 3.925315468222834e-07
fail O 0 1.876604414974281e-06
to O 0 3.5401036768689664e-08
synergize O 0 0.00025647698203101754
with O 0 1.180244339593628e-06
SF O 1 0.971592903137207
- O 0 0.0008459193632006645
1 O 0 8.695543556314078e-07
. O 0 1.5617598592143622e-06

Additionally O 0 1.542640893603675e-05
, O 0 1.0393399207941911e-07
the O 0 2.0067140837909392e-08
X O 0 0.00011627382627921179
- O 0 0.0001380780740873888
linked O 0 1.9521601188898785e-06
, O 0 1.3722605274324451e-08
candidate O 0 2.821812188358308e-07
dosage O 0 4.44176112068817e-06
- O 0 7.75296393840108e-06
sensitive O 0 3.200292439942132e-07
sex O 0 3.478453152183647e-07
- O 0 8.204159530578181e-05
reversal O 0 1.2534094821603503e-05
gene O 0 1.4352508515003137e-07
, O 0 6.301292376775791e-09
Dax O 0 1.4217263924365398e-05
- O 0 2.426643959552166e-06
1 O 0 4.736384617842759e-09
, O 0 4.0689944746929996e-09
antagonizes O 0 4.5212684085527144e-07
synergy O 0 4.411709255691676e-07
between O 0 4.22611812211926e-08
SF O 0 0.03862888365983963
- O 0 7.067297701723874e-06
1 O 0 8.477697654996064e-09
and O 0 1.4609699228174122e-08
WT1 O 0 9.932969987858087e-05
, O 0 4.771566697314711e-09
most O 0 1.3934390308278921e-09
likely O 0 5.032488203937646e-09
through O 0 1.2353289502442522e-09
a O 0 3.0602513856337055e-09
direct O 0 8.025160980196233e-09
interaction O 0 6.473602098822084e-08
with O 0 2.5326301056338707e-07
SF O 1 0.9129027724266052
- O 0 0.00017640639271121472
1 O 0 6.430033181459294e-07
. O 0 1.0559764405115857e-06

We O 0 2.695366219995776e-06
propose O 0 5.677246008417569e-06
that O 0 1.7017617892634007e-07
WT1 O 0 3.376046151970513e-05
and O 0 5.858214535692241e-08
Dax O 0 0.00010087086411658674
- O 0 1.3552148629969452e-05
1 O 0 2.7055154561139716e-08
functionally O 0 1.1792818810363315e-07
oppose O 0 1.9350128610540196e-08
each O 0 1.1304231994913039e-09
other O 0 8.04535660314798e-10
in O 0 1.6666383828578546e-08
testis O 0 0.00020656816195696592
development O 0 7.126968171178305e-08
by O 0 9.400369549439347e-08
modulating O 0 0.00013988088176120073
SF O 0 0.08300869911909103
- O 0 2.0416580809978768e-05
1 O 0 5.053527019072135e-08
- O 0 5.342616532288957e-06
mediated O 0 1.3324712199391797e-05
transactivation O 0 0.00042150862282142043
. O 0 3.793517748817976e-07
. O 0 1.7697627754387213e-06

A O 0 1.0187965926888864e-05
mouse O 0 5.5963959312066436e-05
model O 0 6.942451364011504e-06
for O 0 3.396907231945079e-06
Prader B-Disease 1 0.9999918937683105
- I-Disease 1 0.9999933242797852
Willi I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999891519546509
imprinting O 0 0.20009362697601318
- O 0 0.12635397911071777
centre O 0 6.545995711348951e-05
mutations O 0 7.509845454478636e-05
. O 0 5.745422186009819e-06

Imprinting O 0 0.000569221971090883
in O 0 9.587563454260817e-07
the O 0 2.1784840953387175e-07
15q11 O 0 3.768227543332614e-05
- O 0 0.00012291896564420313
q13 O 0 3.069785816478543e-05
region O 0 2.0594066540979838e-07
involves O 0 9.45588141121334e-08
an O 0 1.3202841486759098e-08
imprinting O 0 3.916585774277337e-05
centre O 0 5.768743562839518e-07
( O 0 1.3842952562015398e-08
IC O 0 4.9297436817141715e-06
) O 0 4.57866411451846e-09
, O 0 1.7838444055229274e-09
mapping O 0 2.445248981075565e-07
in O 0 2.127267251239573e-09
part O 0 3.0955511487462672e-09
to O 0 1.711855324160183e-09
the O 0 3.820862737313746e-09
promoter O 0 1.5591199371556286e-06
and O 0 4.821352650452582e-09
first O 0 2.306570223709059e-08
exon O 0 1.3029799447394907e-05
of O 0 2.6579729706099897e-07
SNRPN O 0 0.0482417531311512
. O 0 4.321185315347975e-06

Deletion O 0 0.0002410079468972981
of O 0 4.505068034177384e-07
this O 0 2.5047384610843437e-07
IC O 0 6.278068030951545e-05
abolishes O 0 3.368324905750342e-05
local O 0 9.509671627938587e-08
paternally O 0 2.424233798592468e-06
derived O 0 6.768610916196849e-08
gene O 0 4.351745275243957e-08
expression O 0 4.146306409325007e-08
and O 0 2.2094157614560572e-08
results O 0 4.020857431896729e-06
in O 0 4.7572055336786434e-05
Prader B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999988079071045
Willi I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999947547912598
( O 0 0.0002708316606003791
PWS B-Disease 1 0.999713122844696
) O 0 2.4109031073749065e-06
. O 0 4.400415946292924e-06

We O 0 1.1511394859553548e-06
have O 0 6.279362452232817e-08
created O 0 5.7801656794254086e-08
two O 0 1.9988487309774428e-08
deletion O 0 0.00017521115660201758
mutations O 0 1.9003276975126937e-05
in O 0 2.9752024488516327e-07
mice O 0 1.709397474769503e-05
to O 0 5.313818363106293e-08
understand O 0 9.303667866333853e-06
PWS B-Disease 1 0.999054491519928
and O 0 2.0794292510117884e-08
the O 0 6.6392744635379586e-09
mechanism O 0 3.467489051445227e-08
of O 0 8.188064448688692e-09
this O 0 8.367913295614926e-08
IC O 0 0.000333749339915812
. O 0 3.5862815366272116e-06

Mice O 0 0.007740989793092012
harbouring O 0 0.003092898288741708
an O 0 3.950609084313328e-07
intragenic O 0 0.0008119726553559303
deletion O 0 0.00019721603894140571
in O 0 6.72098622089834e-07
Snrpn O 0 0.00038362096529453993
are O 0 4.3817877326546295e-08
phenotypically O 0 5.882220284547657e-05
normal O 0 2.4473135340485896e-07
, O 0 1.0524014548707328e-08
suggesting O 0 1.5933846952975728e-07
that O 0 1.2421435435783224e-08
mutations O 0 1.795716997321506e-07
of O 0 4.2819801038262995e-09
SNRPN O 0 0.00026933866320177913
are O 0 6.666671215072029e-09
not O 0 4.613220028204523e-09
sufficient O 0 1.5135161390844587e-07
to O 0 1.6078264764018968e-07
induce O 0 0.0003556272422429174
PWS B-Disease 1 0.9993595480918884
. O 0 1.6894551663426682e-05

Mice O 0 0.00028892498812638223
with O 0 1.2711339536508603e-07
a O 0 7.377519750662032e-08
larger O 0 1.8231102671961708e-07
deletion O 0 2.9903428639954654e-06
involving O 0 1.2299670970605803e-07
both O 0 1.5622999782749503e-08
Snrpn O 0 8.517250535078347e-05
and O 0 3.398230674633851e-08
the O 0 7.693372339190319e-08
putative O 0 0.009254379197955132
PWS O 1 0.9996803998947144
- O 0 0.001408408279530704
IC O 0 0.0001315707922913134
lack O 0 1.342835815876242e-07
expression O 0 3.0305766784977095e-08
of O 0 1.3545662369551792e-09
the O 0 2.0060635819163508e-08
imprinted O 0 9.569757094141096e-05
genes O 0 4.208887389722804e-07
Zfp127 O 0 1.557706309540663e-05
( O 0 1.369512325766209e-08
mouse O 0 2.0903416952933185e-07
homologue O 0 5.239154461378348e-07
of O 0 1.3161154832630473e-08
ZNF127 O 0 0.0004592395853251219
) O 0 2.0329570915578188e-08
, O 0 1.7168657606703164e-08
Ndn O 0 1.989164957194589e-05
and O 0 3.8812267177945614e-08
Ipw O 0 0.00013385199417825788
, O 0 3.6757789700914145e-08
and O 0 5.555032345228028e-08
manifest O 0 2.677568545550457e-06
several O 0 8.142016838519339e-08
phenotypes O 0 0.0005778755294159055
common O 0 2.193020463892026e-06
to O 0 7.533096322731581e-06
PWS B-Disease 1 0.9999608993530273
infants O 0 0.020923104137182236
. O 0 7.117253062460804e-06

These O 0 3.3058856274692516e-07
data O 0 3.193079578522884e-07
demonstrate O 0 1.528784565607566e-07
that O 0 1.8943089319378714e-09
both O 0 6.504364269410701e-10
the O 0 7.716525196599378e-10
position O 0 4.4363210882636395e-09
of O 0 7.882690611360488e-10
the O 0 5.544835257609293e-09
IC O 0 4.7997109504649416e-06
and O 0 4.598548652978707e-09
its O 0 1.3310752500217404e-09
role O 0 4.337291414913125e-09
in O 0 2.809332100284223e-09
the O 0 2.2210424610591417e-09
coordinate O 0 9.706467096748383e-08
expression O 0 1.8085669850620434e-08
of O 0 1.1789726972466497e-09
genes O 0 1.620882805752899e-08
is O 0 1.2248437819550873e-09
conserved O 0 1.721686260225397e-08
between O 0 4.182540536135093e-09
mouse O 0 4.6194384140108014e-07
and O 0 1.2750464684074814e-08
human O 0 3.6139770287491046e-08
, O 0 9.364002906409041e-09
and O 0 1.0765943692092605e-08
indicate O 0 1.691209945420269e-07
that O 0 1.7101975391398128e-09
the O 0 3.503733747578508e-09
mouse O 0 3.60821928779842e-07
is O 0 1.861855669638146e-09
a O 0 6.2077893936418604e-09
suitable O 0 1.6461699203773605e-07
model O 0 3.702744493239152e-07
system O 0 2.3148826855390325e-08
in O 0 3.0496929426249153e-09
which O 0 1.1278904477052265e-09
to O 0 6.506398753103326e-10
investigate O 0 4.9986542904889575e-08
the O 0 1.2576728103397272e-08
molecular O 0 8.454684575553983e-06
mechanisms O 0 4.849650991900489e-08
of O 0 2.1737840416591325e-09
imprinting O 0 3.825688963843277e-06
in O 0 1.2759465484180055e-08
this O 0 2.2454837989016596e-09
region O 0 1.5853718338121325e-08
of O 0 3.7499345850733334e-09
the O 0 4.5882305954592084e-08
genome O 0 1.0055128768726718e-05
. O 0 1.5893144222900446e-07
. O 0 7.860339792387094e-07

Mutations O 0 9.09160589799285e-05
of O 0 8.794858530336569e-08
the O 0 6.999979262900524e-08
ATM O 0 2.637884063005913e-05
gene O 0 1.3659719115821645e-06
detected O 0 2.219753469034913e-06
in O 0 5.1016108670864924e-08
Japanese O 0 5.596597839030437e-05
ataxia B-Disease 1 0.9999798536300659
- I-Disease 1 0.9999427795410156
telangiectasia I-Disease 1 0.9999973773956299
patients O 0 5.560000499826856e-05
: O 0 1.4148292848403798e-07
possible O 0 7.39875645194843e-08
preponderance O 0 6.636183115915628e-06
of O 0 3.02548119890389e-09
the O 0 4.956867361016748e-09
two O 0 1.6285058634935012e-08
founder O 0 1.761565545166377e-05
mutations O 0 1.6461541463286267e-06
4612del165 O 0 5.156786301085958e-06
and O 0 2.7289183890388813e-07
7883del5 O 0 9.380678966408595e-05
. O 0 3.0129920105537167e-06

The O 0 9.924165169650223e-07
ATM O 0 3.7864036130486056e-05
( O 0 1.8445020089075115e-07
A O 0 5.423274615168339e-06
- O 1 0.5371499061584473
T O 1 0.9986681938171387
, O 0 1.6088664267499553e-07
mutated O 0 1.8126301029042224e-06
) O 0 1.1192931026471342e-08
gene O 0 4.72175685217735e-08
on O 0 3.4394815884297714e-08
human O 0 8.572692422603723e-07
chromosome O 0 0.00023912990582175553
11q22 O 0 0.0009631747961975634
. O 0 4.582524979923619e-06

3 O 0 3.20226649819233e-06
has O 0 2.692399334591755e-07
recently O 0 3.362024756370374e-07
been O 0 1.1950819889250397e-08
identified O 0 5.2525216176491085e-08
as O 0 1.719460240856563e-09
the O 0 6.5224066148061866e-09
gene O 0 6.892506831945866e-08
responsible O 0 2.096046358701642e-08
for O 0 5.7601763359116376e-09
the O 0 4.229823957757617e-07
human O 0 0.004196975380182266
recessive B-Disease 1 0.9998393058776855
disease I-Disease 1 0.9998890161514282
ataxia B-Disease 1 0.9999972581863403
- I-Disease 1 0.999984622001648
telangiectasia I-Disease 1 0.9999949932098389
( O 0 3.145976734231226e-06
A B-Disease 0 0.0005521699204109609
- I-Disease 1 0.9994949102401733
T I-Disease 1 0.9998754262924194
) O 0 9.232562661054544e-07
. O 0 1.2614814295375254e-06

In O 0 1.4139028507997864e-06
order O 0 1.2555808837078075e-07
to O 0 1.4245321366956887e-08
define O 0 1.2062095322562527e-07
the O 0 9.962151104048189e-09
types O 0 1.0918063253484434e-07
of O 0 2.358101198751683e-07
disease O 0 0.007727139163762331
- O 0 0.019011545926332474
causing O 0 2.744103221630212e-05
ATM O 0 0.00031888086232356727
mutations O 0 1.139576511377527e-06
in O 0 1.0759702462337373e-08
Japanese O 0 3.647404298590118e-07
A B-Disease 0 0.00010855725122382864
- I-Disease 1 0.9997394680976868
T I-Disease 1 0.9999926090240479
patients O 0 1.4039208053873153e-06
as O 0 3.4632969825310056e-09
well O 0 2.7052662332494037e-09
as O 0 1.0242134917959334e-09
to O 0 1.0274987527481017e-09
look O 0 2.993755998659253e-08
for O 0 1.3348226968190602e-09
possible O 0 1.4755244137631962e-07
mutational O 0 0.0015087403589859605
hotspots O 0 1.1837809324788395e-05
, O 0 5.938356029133729e-09
reverse O 0 1.0179297049717206e-07
- O 0 3.4015093319794687e-07
transcribed O 0 2.8815993147190966e-08
RNA O 0 4.083782201291797e-09
derived O 0 1.5603158765031822e-09
from O 0 4.898937921993252e-10
ten O 0 8.061966205730187e-09
patients O 0 3.907625867327624e-08
belonging O 0 3.1625972951587755e-08
to O 0 2.2049313486149913e-09
eight O 0 1.9404755136065432e-08
unrelated O 0 1.168701032838726e-06
Japanese O 0 6.871005666653218e-07
A B-Disease 0 2.159126233891584e-05
- I-Disease 1 0.7471984028816223
T I-Disease 1 0.9956314563751221
families O 0 7.392775103198801e-08
was O 0 1.9515550064852505e-08
analyzed O 0 1.1778106312476666e-07
for O 0 6.823516862652923e-09
mutations O 0 1.5570530820241402e-07
by O 0 3.868513065441448e-09
the O 0 7.3224923902159844e-09
restriction O 0 1.287451567577591e-07
endonuclease O 0 4.2983251660189126e-06
fingerprinting O 0 3.9126375668274704e-06
method O 0 9.031919034896418e-07
. O 0 1.2671713420786546e-06

As O 0 6.400134680006886e-07
has O 0 1.2026190177039098e-07
been O 0 2.3706013152491323e-08
reported O 0 1.0658212090675079e-07
by O 0 9.87735049307048e-09
others O 0 2.7125528490046236e-08
, O 0 4.165394429378466e-08
mutations O 0 1.5644506845546857e-07
that O 0 1.9745660662096043e-09
lead O 0 1.5214590476375633e-08
to O 0 5.742099240535481e-09
exon O 0 9.095060704567004e-06
skipping O 0 6.219394776962872e-07
or O 0 6.149422659973425e-08
premature O 0 9.561595106788445e-07
protein O 0 3.859435082631535e-08
truncation O 0 1.8790025535508903e-07
were O 0 2.9272333446073162e-09
also O 0 7.147630487480683e-09
predominant O 0 3.176308496222191e-07
in O 0 5.40599884857329e-08
our O 0 5.780033234259463e-07
mutants O 0 0.00015984209312591702
. O 0 2.9553718832175946e-06

Six O 0 1.193801381305093e-06
different O 0 9.462502958967889e-08
mutations O 0 1.519758711765462e-06
were O 0 4.653048168989926e-09
identified O 0 5.36131068429313e-08
on O 0 5.2722120003068085e-09
12 O 0 7.563684789602121e-09
of O 0 1.9721193567079354e-09
the O 0 2.2203405336540527e-08
16 O 0 4.1762930891309225e-07
alleles O 0 3.513242745611933e-06
examined O 0 2.2127269403426908e-05
. O 0 3.6192309380567167e-06

Four O 0 4.260946298018098e-07
were O 0 4.607752401852849e-08
deletions O 0 1.7178668940687203e-06
involving O 0 3.5558721833695017e-07
a O 0 1.683805379570913e-07
loss O 0 3.908724920620443e-06
of O 0 3.0307485410219215e-09
a O 0 2.4012138055695686e-08
single O 0 1.1960538870425808e-07
exon O 0 7.463646034011617e-05
exon O 0 7.601999823236838e-05
7 O 0 8.868234147030307e-08
, O 0 6.698549270822696e-09
exon O 0 2.141461436622194e-06
16 O 0 2.9845026006114495e-08
, O 0 1.1742604222320097e-08
exon O 0 3.7866825550736394e-06
33 O 0 9.908016096460415e-08
or O 0 7.37566310249349e-08
exon O 0 4.287312913220376e-05
35 O 0 1.7733630102156894e-06
. O 0 2.0732375105581013e-06

The O 0 1.1882924582096166e-06
others O 0 2.498783260307391e-07
were O 0 9.619838259311564e-09
minute O 0 3.051859209790564e-08
deletions O 0 1.247280920324556e-06
, O 0 2.0888027307819357e-08
4649delA O 0 1.1309305136819603e-06
in O 0 2.0205172646114988e-08
exon O 0 6.131320787972072e-06
33 O 0 4.515252882697496e-08
and O 0 8.517504923588604e-09
7883del5 O 0 6.391537681338377e-06
in O 0 1.8782358779390051e-07
exon O 0 0.00022941174393054098
55 O 0 4.865976734436117e-06
. O 0 3.0186317871994106e-06

The O 0 2.996803686983185e-06
mutations O 0 2.425620550638996e-05
4612del165 O 0 8.323394467879552e-06
and O 0 2.920386599214453e-08
7883del5 O 0 4.963780156685971e-06
were O 0 6.379242911691563e-09
found O 0 1.933913296170431e-08
in O 0 4.9890314102185584e-09
more O 0 6.053235690473002e-10
than O 0 9.430171088453676e-10
two O 0 1.743871602677416e-09
unrelated O 0 6.526291826958186e-07
families O 0 3.2042255071473846e-08
; O 0 3.5476475090945314e-08
44 O 0 3.505205725673477e-08
% O 0 9.508235976340984e-09
( O 0 1.5281125254063e-09
7 O 0 3.264817527437458e-09
of O 0 7.921077682659927e-10
16 O 0 1.214925582360138e-08
) O 0 6.930148677142256e-10
of O 0 3.4762667744381304e-10
the O 0 5.256868718106489e-09
mutant O 0 1.0067074981634505e-05
alleles O 0 2.1267800320856622e-07
had O 0 4.189039337632039e-09
one O 0 1.2147487460367756e-09
of O 0 1.3650860442027124e-09
the O 0 1.7195006307701988e-08
two O 0 2.25276764354021e-07
mutations O 0 6.61485901218839e-05
. O 0 4.367129804450087e-06

The O 0 2.6183677164226538e-06
4612del165 O 0 0.00031735259108245373
mutations O 0 3.098538400081452e-06
in O 0 1.586460740554685e-08
three O 0 3.318610053426596e-09
different O 0 2.5203832354492306e-09
families O 0 6.589177647953193e-09
were O 0 1.607621036292528e-09
all O 0 7.561503645447942e-10
ascribed O 0 8.075512170080401e-08
to O 0 9.05352515179203e-10
the O 0 2.656901809672263e-09
same O 0 2.4489285266326988e-08
T O 0 8.062201231950894e-05
- O 0 5.723617505282164e-06
- O 0 1.4282341908256058e-05
> O 0 1.9991867361568438e-07
A O 0 2.390961650888812e-09
substitution O 0 4.91838658689403e-09
at O 0 2.320384995257996e-09
the O 0 2.2028840973575825e-09
splice O 0 1.0746812222350854e-06
donor O 0 1.2728251022053882e-06
site O 0 5.208079301155522e-07
in O 0 1.0531749694564496e-07
intron O 0 0.00028891864349134266
33 O 0 4.961858849128475e-06
. O 0 1.9698250071087386e-06

Microsatellite O 0 0.004073345568031073
genotyping O 0 0.0004356201970949769
around O 0 2.9512636956496863e-07
the O 0 4.996499924914133e-08
ATM O 0 8.206443453673273e-06
locus O 0 3.3432161217206158e-06
also O 0 6.67392541231493e-08
indicated O 0 3.5269351883471245e-07
that O 0 3.40421024702664e-09
a O 0 2.9574104942753365e-08
common O 0 1.2590369351528352e-06
haplotype O 0 0.0027226058300584555
was O 0 1.0376399295353167e-08
shared O 0 1.1690958423571374e-08
by O 0 5.22013943182742e-09
the O 0 1.7944890018384285e-08
mutant O 0 5.986417363601504e-06
alleles O 0 2.1828222429576272e-07
in O 0 3.663446790369562e-08
both O 0 1.752168401480958e-07
mutations O 0 4.535944026429206e-05
. O 0 4.516929948295001e-06

This O 0 1.8607862557473709e-06
suggests O 0 2.386692813161062e-06
that O 0 1.6418983506127915e-08
these O 0 3.4316232078168696e-09
two O 0 1.0243605075288542e-08
founder O 0 5.838850847794674e-05
mutations O 0 1.5677673218306154e-05
may O 0 1.681927557228846e-07
be O 0 6.153068721204136e-09
predominant O 0 1.5268058461970213e-07
among O 0 2.0765201114159026e-08
Japanese O 0 9.657968575993436e-07
ATM O 0 5.0886526878457516e-05
mutant O 0 0.00016562732344027609
alleles O 0 3.0737879569642246e-05
. O 0 3.858566742565017e-06

W474C O 0 0.00021587756054941565
amino O 0 2.689442681003129e-06
acid O 0 5.564708658312156e-07
substitution O 0 8.992746813873964e-08
affects O 0 6.215552161847882e-08
early O 0 5.936747538015652e-09
processing O 0 7.889327413579394e-09
of O 0 5.922246026912603e-10
the O 0 1.5989576329644706e-09
alpha O 0 1.6260974788906424e-08
- O 0 5.589030749320045e-08
subunit O 0 4.4780796848442606e-09
of O 0 7.544489477595562e-10
beta O 0 3.3760713336050685e-08
- O 0 7.939665010781027e-06
hexosaminidase O 0 1.605585202923976e-05
A O 0 2.5156682070814895e-08
and O 0 8.772037318749426e-09
is O 0 9.844492332433674e-09
associated O 0 3.7504594274651026e-07
with O 0 1.002801809590892e-06
subacute O 1 0.9998365640640259
G B-Disease 1 0.9104055762290955
( I-Disease 0 3.8963881365816633e-07
M2 I-Disease 0 0.002684116130694747
) I-Disease 0 5.027387146583351e-07
gangliosidosis I-Disease 0 0.00021992737310938537
. O 0 2.4134656086971518e-06

Mutations O 0 0.0010814957786351442
in O 0 1.0205604894508724e-06
the O 0 2.040011537474129e-07
HEXA O 0 0.009881171397864819
gene O 0 2.9777288546029013e-07
, O 0 6.512387518142759e-09
encoding O 0 1.1331005467241084e-08
the O 0 1.2693458506518596e-09
alpha O 0 2.3513816671538734e-08
- O 0 8.250792404851381e-08
subunit O 0 9.301894365876251e-09
of O 0 1.4658343427953469e-09
beta O 0 8.875527157670149e-08
- O 0 7.754746548016556e-06
hexosaminidase O 0 6.815820233896375e-05
A O 0 6.853663592210069e-08
( O 0 7.027977311224731e-09
Hex O 0 8.300796707771951e-07
A O 0 2.0447400217449285e-08
) O 0 2.131763654489305e-09
, O 0 1.1211878092609595e-09
that O 0 1.4367834699768878e-09
abolish O 0 2.7860554041581054e-07
Hex O 0 2.3244519979925826e-06
A O 0 5.069736275231662e-08
enzyme O 0 4.4563716983248014e-07
activity O 0 1.2254704415681772e-06
cause O 0 0.00020098731329198927
Tay B-Disease 1 0.9999948740005493
- I-Disease 1 0.9999818801879883
Sachs I-Disease 1 0.9999897480010986
disease I-Disease 0 0.06965189427137375
( O 0 2.1353382351207983e-07
TSD B-Disease 0 0.002016504993662238
) O 0 1.8042392468942126e-08
, O 0 6.9538268476776466e-09
the O 0 4.384437701787647e-08
fatal O 0 0.056345924735069275
infantile B-Disease 0 0.1338241845369339
form I-Disease 0 7.202510232673376e-07
of I-Disease 0 9.135059286791147e-08
G I-Disease 0 0.08825834840536118
( I-Disease 0 1.0802870065163006e-07
M2 I-Disease 0 0.00039687263779342175
) I-Disease 0 6.198965252224298e-08
gangliosidosis I-Disease 0 1.3911600944993552e-05
, I-Disease 0 3.6018310112240215e-08
Type I-Disease 0 9.469378596804745e-07
1 I-Disease 0 3.638177190623537e-07
. O 0 1.691675834081252e-06

Less O 0 7.851301779737696e-05
severe O 0 0.07160726934671402
, O 0 1.5896290278760716e-05
subacute O 1 0.9956009387969971
( O 0 4.332012395025231e-06
juvenile O 0 0.08722198009490967
- O 1 0.7345597743988037
onset O 1 0.5321428179740906
) O 0 7.411976525872888e-07
and O 0 6.4863588704611175e-06
chronic O 1 0.9780985116958618
( O 0 6.539511900882644e-07
adult O 0 6.185458005347755e-06
- O 0 0.20637404918670654
onset O 0 0.18724079430103302
) O 0 1.0062105104680086e-07
variants O 0 2.0780463216851786e-07
are O 0 7.204733698529253e-09
characterized O 0 1.6664738211602526e-07
by O 0 5.155437854398315e-09
a O 0 2.3943309557239445e-08
broad O 0 9.270703458241769e-07
spectrum O 0 2.3039513052935945e-06
of O 0 1.3047386460129928e-07
clinical O 0 0.0002552669611759484
manifestations O 0 0.0013152060564607382
and O 0 1.1010748579565188e-07
are O 0 8.79477113358007e-09
associated O 0 1.5444203427250613e-07
with O 0 6.191142887246315e-08
residual O 0 0.00015679416537750512
levels O 0 2.0297497371757345e-07
of O 0 4.005467069134738e-09
Hex O 0 3.762191226996947e-06
A O 0 2.0590766780514969e-07
enzyme O 0 1.264989577975939e-06
activity O 0 1.1153758805448888e-06
. O 0 8.308994665640057e-07

We O 0 1.18766706691531e-06
identified O 0 7.839124691599864e-07
a O 0 9.199456485475821e-08
1422 O 0 0.0001630509359529242
G O 0 8.440038072876632e-05
- O 0 9.073834371520206e-05
- O 0 0.0005984879680909216
> O 0 1.4435738194151781e-05
C O 0 3.0316203947222675e-07
( O 0 2.0746189210996135e-09
amino O 0 6.579156330843716e-09
acid O 0 8.905860937602483e-09
W474C O 0 5.174433681531809e-08
) O 0 1.9352693059193626e-10
substitution O 0 6.435849075892008e-10
in O 0 4.696817934579656e-10
the O 0 3.503250745051645e-10
first O 0 1.3012232402687118e-09
position O 0 3.460834063773177e-09
of O 0 1.1322185411444252e-09
exon O 0 7.38555490897852e-06
13 O 0 1.0735267785833003e-08
of O 0 2.1721011655984057e-09
HEXA O 0 0.0003062801552005112
of O 0 1.5340407832908909e-09
a O 0 1.1189281501344794e-08
non O 0 5.916426104590755e-08
- O 0 1.2325414900260512e-05
Jewish O 0 1.922962127309802e-07
proband O 0 0.00016980436339508742
who O 0 1.8366067422448396e-07
manifested O 0 2.531816562623135e-06
a O 0 2.5366767886225716e-07
subacute O 0 0.2152911275625229
variant O 0 1.4688326700706966e-05
of O 0 9.128545030989699e-08
G B-Disease 0 0.014640921726822853
( I-Disease 0 2.7321212314745935e-07
M2 I-Disease 0 0.0014886537101119757
) I-Disease 0 4.740232952826773e-07
gangliosidosis I-Disease 0 0.0004971691523678601
. O 0 2.8171436952106887e-06

On O 0 9.719674380903598e-07
the O 0 1.3151286282209185e-07
second O 0 3.34968717652373e-07
maternally O 0 0.00032634648960083723
inherited O 0 0.0017687180079519749
allele O 0 9.94078982330393e-06
, O 0 2.4521302322000338e-08
we O 0 7.130391388443513e-09
identified O 0 7.463942353069797e-08
the O 0 4.405058362522141e-08
common O 0 1.1415363587730099e-05
infantile O 1 0.9993651509284973
disease O 0 0.2902891933917999
- O 0 0.0026849843561649323
causing O 0 3.1604135983798187e-06
4 O 0 1.2680681038546027e-07
- O 0 2.8305330488365144e-05
bp O 0 1.7703634512145072e-05
insertion O 0 3.8911969113542e-07
, O 0 5.5488587946683765e-08
+ O 0 1.9324108961882303e-06
TATC O 0 8.85484623722732e-05
1278 O 0 4.516571789281443e-05
, O 0 2.1354516377414257e-08
in O 0 5.318290163813799e-08
exon O 0 0.00018061636365018785
11 O 0 6.12396343058208e-06
. O 0 2.767628984656767e-06

Pulse O 0 0.0002438523806631565
- O 0 3.2530882890569046e-05
chase O 0 1.55407417423703e-06
analysis O 0 4.144108700643301e-08
using O 0 1.7274953023616035e-08
proband O 0 1.2505153790698387e-05
fibroblasts O 0 1.5652296951884637e-06
revealed O 0 2.520991131405026e-07
that O 0 1.1799332622075553e-09
the O 0 1.1045909742435356e-09
W474C O 0 3.728021624738176e-07
- O 0 2.3016620787075226e-07
containing O 0 1.2160104922998016e-08
alpha O 0 2.281359634537239e-08
- O 0 1.7177164579607052e-07
subunit O 0 1.753581990726616e-08
precursor O 0 4.192110836243046e-08
was O 0 2.4454545055618837e-09
normally O 0 9.084423879812675e-09
synthesized O 0 9.181313487260923e-08
, O 0 1.2072282062902673e-09
but O 0 1.1863737769957083e-09
not O 0 1.1675175271008698e-09
phosphorylated O 0 6.969963095571075e-08
or O 0 2.493272921455514e-09
secreted O 0 2.2741609484455694e-08
, O 0 1.1070924177403185e-09
and O 0 1.507977964720908e-09
the O 0 9.387715493858195e-09
mature O 0 1.031463625622564e-06
lysosomal O 0 8.196065755328164e-05
alpha O 0 1.785440701951302e-07
- O 0 8.178263897207216e-07
subunit O 0 6.275698893887238e-08
was O 0 3.398217529593239e-08
not O 0 5.435092731431723e-08
detected O 0 1.1701904440997168e-05
. O 0 1.628859081392875e-06

When O 0 6.461143016167625e-07
the O 0 3.3830197310180665e-08
W474C O 0 1.2533416793303331e-06
- O 0 4.3571026253630407e-07
containing O 0 2.9497098097408525e-08
alpha O 0 7.137020219261103e-08
- O 0 1.8525550160575222e-07
subunit O 0 3.04434202291759e-08
was O 0 8.190047751099883e-09
transiently O 0 9.424710469829733e-07
co O 0 9.439876293981797e-07
- O 0 3.1224947178998264e-06
expressed O 0 1.2612882294149586e-08
with O 0 1.034801355714876e-09
the O 0 1.50949741595241e-09
beta O 0 1.4824124150436546e-08
- O 0 2.4574521262366034e-07
subunit O 0 8.424263064910065e-09
to O 0 1.1656484666389133e-09
produce O 0 1.576632868705019e-08
Hex O 0 1.3887284922020626e-06
A O 0 1.9988561916761682e-08
( O 0 5.513387524302971e-09
alphabeta O 0 3.035907866433263e-06
) O 0 3.2338791644548337e-09
in O 0 6.841735622487022e-09
COS O 0 0.00011682394688250497
- O 0 8.396513294428587e-05
7 O 0 2.604391511340509e-07
cells O 0 7.462362816568202e-08
, O 0 1.0992902144124628e-09
the O 0 1.1538010546985333e-09
mature O 0 3.375672008587571e-08
alpha O 0 1.2313117636608695e-08
- O 0 1.3003240439957153e-07
subunit O 0 1.0262202643218643e-08
was O 0 1.8505827981130096e-09
present O 0 3.542006465906411e-09
, O 0 1.194662035963745e-09
but O 0 6.739581115411397e-10
its O 0 9.757020746903322e-10
level O 0 6.3461245147777845e-09
was O 0 2.327201986673799e-09
much O 0 2.1708008723919647e-09
lower O 0 1.832410845281629e-08
than O 0 7.602342089185754e-10
that O 0 7.064138718426705e-10
from O 0 1.3641724416757484e-09
normal O 0 8.526834349709134e-09
alpha O 0 8.782885529967643e-09
- O 0 2.1116343873472943e-07
subunit O 0 1.851748976378076e-08
transfections O 0 1.9358121789991856e-06
, O 0 1.9348420643439113e-09
although O 0 2.2434374358226705e-09
higher O 0 5.772406996840118e-09
than O 0 1.5416965482017986e-09
in O 0 4.600408498589559e-09
those O 0 1.1440893565861643e-08
cells O 0 4.801024715561653e-07
transfected O 0 6.415402367565548e-06
with O 0 4.276772269662388e-09
an O 0 2.645836660875034e-09
alpha O 0 6.756305737098955e-08
- O 0 2.9447626275214134e-06
subunit O 0 2.953944431283162e-07
associated O 0 5.322603442436957e-07
with O 0 1.4773802377021639e-06
infantile O 1 0.959815502166748
TSD B-Disease 1 0.9427016377449036
. O 0 1.9381917809369043e-05

Furthermore O 0 1.3487912838172633e-05
, O 0 8.153905639574077e-08
the O 0 1.1528997312382216e-08
precursor O 0 1.1114561715430682e-07
level O 0 8.573574739045853e-09
of O 0 6.868706714513451e-10
the O 0 2.978240098983065e-09
W474C O 0 4.983832013749634e-07
alpha O 0 2.291302436674414e-08
- O 0 1.8209330221452547e-07
subunit O 0 2.0879065587564583e-08
was O 0 5.223197430126447e-09
found O 0 3.932822068009045e-09
to O 0 2.210654104217724e-09
accumulate O 0 1.597133376662896e-07
in O 0 3.972780771022144e-09
comparison O 0 2.2482277373114812e-08
to O 0 7.047853967101503e-10
the O 0 2.384176411851513e-09
normal O 0 1.9303682208260398e-08
alpha O 0 2.6855261126002006e-08
- O 0 3.8943710478633875e-07
subunit O 0 2.1233428526556963e-07
precursor O 0 1.6990567246466526e-06
levels O 0 1.407786271556688e-06
. O 0 8.13084113815421e-07

We O 0 9.401298370903532e-07
conclude O 0 9.404436696058838e-07
that O 0 1.4194439401649106e-08
the O 0 1.4019039262791466e-08
1422 O 0 9.573781426297501e-05
G O 0 5.355120083549991e-05
- O 0 4.137317955610342e-05
- O 0 0.004294153768569231
> O 0 0.0003206652181688696
C O 0 5.763185527030146e-06
mutation O 0 1.7665155382928788e-07
is O 0 1.3224106254483559e-09
the O 0 2.272888988130717e-09
cause O 0 8.415867824851375e-08
of O 0 9.959832958372772e-09
Hex B-Disease 0 0.0004446932871360332
A I-Disease 0 1.5162325325945858e-05
enzyme I-Disease 1 0.9798197150230408
deficiency I-Disease 1 0.9996335506439209
in O 0 1.6199840047192993e-07
the O 0 4.6850476564941346e-07
proband O 0 0.01866643689572811
. O 0 7.134629868232878e-06

The O 0 1.7808862367019174e-06
resulting O 0 2.7982639494439354e-06
W474C O 0 4.6906279749237e-06
substitution O 0 2.164435386475816e-07
clearly O 0 9.24512022493218e-08
interferes O 0 2.0314925563980069e-07
with O 0 4.6470614023519374e-09
alpha O 0 4.48889103665806e-08
- O 0 1.4826787264610175e-07
subunit O 0 1.3339785276400562e-08
processing O 0 1.1233567853707882e-08
, O 0 5.787971213422338e-10
but O 0 4.3803624616423065e-10
because O 0 2.0801850519891474e-10
the O 0 1.9148106711330826e-10
base O 0 5.5582618507799e-09
substitution O 0 1.1479561301541708e-08
falls O 0 2.2265092525231012e-07
at O 0 4.2503570107932376e-10
the O 0 2.561214851315441e-10
first O 0 7.455726036553756e-10
position O 0 2.2544057731721523e-09
of O 0 1.5268423192438263e-09
exon O 0 1.8948841898236424e-05
13 O 0 5.158312532671516e-08
, O 0 8.214922964100424e-09
aberrant O 0 1.5887370636846754e-06
splicing O 0 6.814187258896709e-07
may O 0 7.529990853072377e-08
also O 0 2.699400480921099e-09
contribute O 0 9.721730975797982e-09
to O 0 1.0496851388097639e-08
Hex B-Disease 0 0.00032088844454847276
A I-Disease 0 1.0869658581214026e-05
deficiency I-Disease 0 0.23145215213298798
in O 0 4.2974704683729215e-08
this O 0 3.7469906288833954e-08
proband O 0 0.0004182065895292908
. O 0 2.5199813080689637e-07
. O 0 1.4059334034755011e-06

Two O 0 5.561287707678275e-06
frequent O 0 0.00017541878332849592
missense O 1 0.5489658117294312
mutations O 0 0.01595969870686531
in O 0 0.0010060012573376298
Pendred B-Disease 1 0.9999879598617554
syndrome I-Disease 1 0.9999943971633911
. O 0 0.0002540781279094517

Pendred B-Disease 1 0.9999915361404419
syndrome I-Disease 1 0.9999984502792358
is O 0 0.00042452928028069437
an O 0 0.007991146296262741
autosomal B-Disease 1 0.9999986886978149
recessive I-Disease 1 0.9999996423721313
disorder I-Disease 1 0.9999995231628418
characterized O 0 0.05214165523648262
by O 0 1.1064638783864211e-05
early O 0 0.0035530864261090755
childhood O 1 0.9996753931045532
deafness B-Disease 1 0.9999966621398926
and O 0 0.22142402827739716
goiter B-Disease 1 0.9999946355819702
. O 0 0.0002877267252188176

A O 0 9.984017879105522e-07
century O 0 3.999888917860517e-07
after O 0 4.1693922980812204e-08
its O 0 7.537373392096924e-09
recognition O 0 6.411485031776465e-08
as O 0 1.7800353191432805e-08
a O 0 4.6816585381748155e-06
syndrome O 1 0.9585590362548828
by O 0 8.071031487588698e-08
Vaughan O 0 1.4269096027419437e-05
Pendred O 0 0.0004437147290445864
, O 0 3.75434510146988e-08
the O 0 3.380611417469481e-07
disease O 0 0.0002457370574120432
gene O 0 4.490903791065648e-07
( O 0 4.6608221282440354e-08
PDS O 0 1.5324996638810262e-05
) O 0 9.829276059747372e-09
was O 0 1.5516567586359997e-08
mapped O 0 3.0828575745545095e-06
to O 0 5.675096304003091e-08
chromosome O 0 9.02652318472974e-05
7q22 O 0 0.000221063251956366
- O 0 0.002498469315469265
q31 O 0 0.0006059064762666821
. O 0 4.397667908051517e-06

1 O 0 1.1051878345824662e-06
and O 0 4.5068212273235986e-08
, O 0 2.724203440607198e-08
recently O 0 1.9066932566147443e-07
, O 0 5.841564121311649e-09
found O 0 7.3448451765045775e-09
to O 0 3.6753147192314373e-09
encode O 0 1.5829401434075407e-07
a O 0 4.4445897628975217e-07
putative O 0 0.0012823205906897783
sulfate O 0 0.01371662225574255
transporter O 0 0.0013591294409707189
. O 0 5.014175258111209e-06

We O 0 1.348004502688127e-06
performed O 0 9.41727137160342e-07
mutation O 0 1.0245206567560672e-06
analysis O 0 1.7171309707464388e-08
of O 0 1.8477752661283375e-09
the O 0 2.474400062624227e-08
PDS B-Disease 0 0.00011233099940000102
gene O 0 2.8251537287360406e-07
in O 0 6.225138804438757e-08
patients O 0 1.1808462119233809e-07
from O 0 1.4737405962250705e-08
14 O 0 1.1557105494830466e-07
Pendred B-Disease 0 7.405703217955306e-05
families O 0 2.270152066330411e-08
originating O 0 3.332019460344782e-08
from O 0 2.6995448099143005e-09
seven O 0 4.8794226437109955e-09
countries O 0 2.3826851602848365e-09
and O 0 3.1053634330646673e-08
identified O 0 1.1234851626795717e-06
all O 0 1.0845585762808696e-07
mutations O 0 1.957473432412371e-05
. O 0 2.860494987544371e-06

The O 0 2.2446795355790528e-06
mutations O 0 6.973838480917038e-06
include O 0 5.2668070793515653e-08
three O 0 6.436748467564257e-09
single O 0 2.6975593314659818e-08
base O 0 8.986728516902076e-08
deletions O 0 9.097776683120173e-07
, O 0 5.623555843214945e-09
one O 0 2.7306474859045693e-09
splice O 0 2.2082713257987052e-06
site O 0 1.1817975291705807e-06
mutation O 0 1.630814381314849e-06
and O 0 4.353737637075028e-08
10 O 0 4.4005193444718316e-07
missense O 0 0.0005213646218180656
mutations O 0 8.922655251808465e-05
. O 0 7.674305379623547e-06

One O 0 8.112491741485428e-06
missense O 0 0.013537712395191193
mutation O 0 0.0003872062370646745
( O 0 3.1678320056016673e-07
L236P O 0 1.974511906155385e-05
) O 0 1.5518669016501008e-08
was O 0 6.542054453717583e-09
found O 0 1.1468465288544394e-08
in O 0 6.562813403832024e-09
a O 0 4.2161026669873536e-08
homozygous O 0 9.496531674813014e-06
state O 0 5.941667069464529e-08
in O 0 1.552799488990786e-08
two O 0 1.3404849674714114e-08
consanguineous O 0 0.0002843487309291959
families O 0 7.940825952346131e-08
and O 0 2.668696197360987e-08
in O 0 1.5444991063873204e-08
a O 0 5.265069802362632e-08
heterozygous O 0 5.752455081164953e-07
state O 0 2.776127061565603e-08
in O 0 1.4963633887532524e-08
five O 0 1.0464646926777732e-08
additional O 0 4.564575561971651e-08
non O 0 8.504925403940433e-07
- O 0 0.0013640760444104671
consanguineous O 0 0.009470224380493164
families O 0 6.614341600652551e-06
. O 0 4.95957328894292e-06

Another O 0 1.0013330211222637e-05
missense O 0 0.009507745504379272
mutation O 0 0.00022591272136196494
( O 0 3.468614409030124e-07
T416P O 0 3.8029193092370406e-05
) O 0 2.2401206223321424e-08
was O 0 9.580817028620459e-09
found O 0 1.5897503757855702e-08
in O 0 9.782796794866044e-09
a O 0 4.357110583441681e-08
homozygous O 0 1.5188809811661486e-05
state O 0 7.843209459679201e-08
in O 0 1.371182456466613e-08
one O 0 5.063007790795382e-09
family O 0 2.148082778319349e-08
and O 0 1.0159372898499441e-08
in O 0 1.4017327742976704e-08
a O 0 5.724234242165949e-08
heterozygous O 0 5.969713470221905e-07
state O 0 4.003124232099253e-08
in O 0 3.451198793413823e-08
four O 0 1.2761758227952669e-07
families O 0 1.3217628520578728e-06
. O 0 3.994363851234084e-06

Pendred B-Disease 1 0.7973771095275879
patients O 0 6.0503341956064105e-05
in O 0 1.754542893195321e-07
three O 0 4.466301817274143e-08
non O 0 2.4341065341104695e-07
- O 0 0.0003023431927431375
consanguineous O 0 0.0007187684532254934
families O 0 1.0055160259980767e-07
were O 0 7.09962666434194e-09
shown O 0 3.2777535352579434e-08
to O 0 2.6987827528301978e-09
be O 0 3.841366780221733e-09
compound O 0 2.1247203108032409e-07
heterozygotes O 0 6.401138307410292e-06
for O 0 4.5405748494431464e-08
L236P O 0 5.3008305258117616e-05
and O 0 8.909344728635915e-07
T416P O 0 0.0003083186747971922
. O 0 2.977804115289473e-06

In O 0 1.0548401405685581e-06
total O 0 1.9147857699408632e-07
, O 0 1.363369328544195e-08
one O 0 3.005511617359957e-09
or O 0 1.8851900041028102e-09
both O 0 5.238799394291505e-10
of O 0 1.6984106343542749e-09
these O 0 9.945614998230212e-09
mutations O 0 2.3202872512229078e-07
were O 0 3.5299883016648437e-09
found O 0 7.416329328435722e-09
in O 0 5.451940676692857e-09
nine O 0 7.613010666318587e-09
of O 0 2.4167103873651286e-09
the O 0 2.5281554627554215e-08
14 O 0 2.736875330811017e-07
families O 0 2.830828123023821e-07
analyzed O 0 1.5800436813151464e-05
. O 0 3.6657925193139818e-06

The O 0 9.250744028577174e-07
identification O 0 5.126552764522785e-07
of O 0 1.6838832550547522e-08
two O 0 4.0786623856092774e-08
frequent O 0 1.3940976714366116e-05
PDS B-Disease 0 0.13373896479606628
mutations O 0 7.353338332904968e-06
will O 0 1.9180951937869395e-08
facilitate O 0 5.2722647581049387e-08
the O 0 2.007560766514871e-07
molecular O 0 0.13502691686153412
diagnosis O 1 0.6219221353530884
of O 0 0.0003787419118452817
Pendred B-Disease 1 0.9999955892562866
syndrome I-Disease 1 0.9999959468841553
. O 0 0.00016343944298569113

Insertional O 0 0.014295258559286594
mutation O 0 7.751141674816608e-05
by O 0 1.5948761244999332e-07
transposable O 0 0.0002875610953196883
element O 0 1.1606915677475627e-06
, O 0 5.713108564009417e-08
L1 O 0 4.690347486757673e-05
, O 0 9.515582988228743e-09
in O 0 6.386889239706761e-09
the O 0 1.0672981431980588e-07
DMD B-Disease 1 0.9998006224632263
gene O 0 7.172857294790447e-07
results O 0 3.761398659207771e-07
in O 0 1.0079969570142566e-07
X B-Disease 0 0.08748801797628403
- I-Disease 1 0.7123255133628845
linked I-Disease 0 0.298235148191452
dilated I-Disease 1 0.9977446794509888
cardiomyopathy I-Disease 1 0.9999479055404663
. O 0 0.0001411737030139193

X B-Disease 1 0.5926529765129089
- I-Disease 1 0.8262001276016235
linked I-Disease 1 0.6457264423370361
dilated I-Disease 1 0.999592125415802
cardiomyopathy I-Disease 1 0.9999911785125732
( O 0 4.698139946412994e-06
XLDCM B-Disease 0 0.11853718012571335
) O 0 3.489609667894911e-08
is O 0 7.777762434102442e-09
a O 0 1.5127181995922e-07
clinical O 0 0.00015740699018351734
phenotype O 0 0.002441261662170291
of O 0 2.9328905526426752e-08
dystrophinopathy B-Disease 0 0.05200678110122681
which O 0 4.99997945269115e-08
is O 0 7.557872550023603e-09
characterized O 0 3.5426612043920613e-07
by O 0 8.27569408556883e-08
preferential O 0 1.6876772860996425e-05
myocardial B-Disease 1 0.9998058676719666
involvement I-Disease 0 2.2508471374749206e-05
without O 0 9.755094509955597e-08
any O 0 2.5688301263926405e-08
overt O 0 2.849945485650096e-05
clinical O 0 0.00028055315488018095
signs O 0 0.0003803614526987076
of O 0 2.6654548491933383e-05
skeletal B-Disease 1 0.9999825954437256
myopathy I-Disease 1 0.9999957084655762
. O 0 0.0005906096776016057

To O 0 6.237463594516157e-07
date O 0 1.3474506204147474e-06
, O 0 1.5699740174568433e-08
several O 0 8.106496807158692e-09
mutations O 0 1.3466026302921819e-06
in O 0 8.106530913210008e-08
the O 0 4.154297130298801e-06
Duchenne B-Disease 1 0.9999392032623291
muscular I-Disease 1 0.9998867511749268
dystrophy I-Disease 1 0.9997277855873108
gene O 0 1.786925167834852e-05
, O 0 1.2102649407097488e-06
DMD O 1 0.9997155070304871
, O 0 7.215669484139653e-08
have O 0 8.604438050952012e-09
been O 0 2.4433903789145006e-08
identified O 0 1.1717991128534777e-06
in O 0 5.560650038205495e-07
patients O 0 7.914355251159577e-07
with O 0 1.8212057284472394e-07
XLDCM B-Disease 1 0.5925261378288269
, O 0 8.523212358113597e-08
but O 0 1.1082042838950201e-08
a O 0 3.359178180062372e-08
pathogenic O 0 1.4764436855330132e-06
correlation O 0 3.522772829001042e-08
of O 0 1.8051231620574981e-09
these O 0 1.33596964602134e-08
cardiospecific O 0 0.015385699458420277
mutations O 0 1.0648763236531522e-05
in O 0 2.0677053669260204e-07
DMD O 1 0.9965445399284363
with O 0 6.40516617522735e-08
the O 0 2.45587301606065e-07
XLDCM B-Disease 1 0.9473784565925598
phenotype O 0 0.04145033285021782
has O 0 4.196278524659647e-08
remained O 0 4.4366700535647396e-08
to O 0 8.905146842153044e-09
be O 0 7.11581620294055e-08
elucidated O 0 0.00020562316058203578
. O 0 3.16953787660168e-06

We O 0 1.952666707438766e-06
report O 0 2.87455179659446e-07
here O 0 9.022259384039444e-09
the O 0 2.2131432242389337e-09
identification O 0 1.6234880106935634e-08
of O 0 1.3685533817309192e-09
a O 0 9.143247936549415e-09
unique O 0 5.7511666540221995e-08
de O 0 8.796468620175801e-08
novo O 0 1.93354708244442e-07
L1 O 0 6.039234904164914e-06
insertion O 0 1.4670327175281273e-07
in O 0 5.995751006793171e-09
the O 0 9.91612214562565e-09
muscle O 0 2.4212347398133716e-06
exon O 0 2.688573658815585e-05
1 O 0 7.611983221522678e-08
in O 0 2.9660401423825533e-07
DMD O 1 0.9988162517547607
in O 0 2.207108167340266e-07
three O 0 2.0422676527687145e-07
XLDCM B-Disease 1 0.6574546098709106
patients O 0 2.4923767796281027e-06
from O 0 1.8225117415227032e-08
two O 0 3.299852835425554e-08
unrelated O 0 9.203049557982013e-06
Japanese O 0 7.637383532710373e-06
families O 0 2.2832546164863743e-06
. O 0 5.548558419832261e-06

The O 0 5.43069290870335e-07
insertion O 0 2.632680207170779e-06
was O 0 3.654639257888448e-08
a O 0 1.0131198102669714e-08
5 O 0 7.454905137649348e-09
- O 0 1.5753095112813753e-06
truncated O 0 1.8964742309890426e-07
form O 0 4.2842756009520144e-09
of O 0 1.3825161016001175e-09
human O 0 4.295815259069968e-08
L1 O 0 9.504360059509054e-05
inversely O 0 1.7140736190413008e-06
integrated O 0 8.021384445555668e-08
in O 0 3.179458030189153e-09
the O 0 1.810806060653647e-09
5 O 0 9.704612224936682e-09
- O 0 1.4737996934854891e-05
untranslated O 0 0.00015166049706749618
region O 0 4.37056115742962e-08
in O 0 5.144259684897179e-09
the O 0 6.515815886842802e-09
muscle O 0 1.9470082861516858e-06
exon O 0 1.8287248167325743e-05
1 O 0 1.5840901923525053e-08
, O 0 1.9991641675431993e-09
which O 0 1.982063624339503e-09
affected O 0 3.151479743834784e-09
the O 0 1.053145903817665e-09
transcription O 0 8.116289862414305e-09
or O 0 1.085853296167727e-09
the O 0 9.935011702211227e-10
stability O 0 7.931619805390255e-09
of O 0 8.573962095859144e-10
the O 0 1.1527721888171527e-08
muscle O 0 6.172484177113802e-07
form O 0 1.8682952074300374e-08
of O 0 4.3680419281599825e-09
dystrophin O 0 5.020664684707299e-05
transcripts O 0 4.935492370350403e-07
but O 0 5.289465754287903e-09
not O 0 7.162748172362399e-10
that O 0 5.168785954801081e-10
of O 0 1.2127346904478031e-09
the O 0 1.207450281981437e-07
brain O 0 0.004172259010374546
or O 0 3.91280224221191e-07
Purkinje O 1 0.778275191783905
cell O 0 5.8823996369028464e-05
form O 0 2.1836424934917886e-07
, O 0 2.1181868703479267e-08
probably O 0 5.07197057686426e-08
due O 0 1.2131263105175094e-08
to O 0 1.7751250469544289e-09
its O 0 5.77246161981293e-09
unique O 0 5.2196543975924214e-08
site O 0 1.2976171603895637e-07
of O 0 2.6327294122552303e-08
integration O 0 2.4988121367641725e-06
. O 0 3.0135608994896756e-06

We O 0 1.2902285106974887e-06
speculate O 0 1.8159678347728914e-06
that O 0 1.0843017150818923e-08
this O 0 3.190051778290126e-09
insertion O 0 2.4659241759650286e-08
of O 0 1.4580711082956554e-09
an O 0 4.708444301115833e-09
L1 O 0 0.00020139149273745716
sequence O 0 7.373960215772968e-07
in O 0 4.6368285211428883e-07
DMD O 1 0.9998286962509155
is O 0 1.147564265835399e-08
responsible O 0 6.001403374256142e-09
for O 0 4.3951506323303136e-10
some O 0 2.0751046714284627e-10
of O 0 5.963209925852198e-10
the O 0 5.795375290773563e-09
population O 0 4.214532722812692e-09
of O 0 3.237989654181206e-09
Japanese O 0 2.674727966223145e-06
patients O 0 5.201478074923216e-07
with O 0 1.5040697576296225e-07
XLDCM B-Disease 0 0.07465328276157379
. O 0 7.611154728692782e-07
. O 0 2.4382798073929735e-06

Severe O 0 0.09007205069065094
early O 0 0.00010427962843095884
- O 1 0.9981920123100281
onset O 1 0.9998481273651123
obesity B-Disease 1 0.9999693632125854
, O 0 0.002556019462645054
adrenal B-Disease 1 0.9999853372573853
insufficiency I-Disease 1 0.9999831914901733
and O 0 3.041781747015193e-05
red O 0 0.05241168290376663
hair O 1 0.9230859279632568
pigmentation O 0 0.10771594941616058
caused O 0 6.860280791443074e-06
by O 0 8.059883498390263e-07
POMC O 1 0.7903520464897156
mutations O 0 2.659295205376111e-05
in O 0 8.937453799262585e-07
humans O 0 4.523081315710442e-06
. O 0 2.4213825327024097e-06

Sequential O 0 4.458832700038329e-05
cleavage O 0 0.00016615471395198256
of O 0 8.42338323536751e-08
the O 0 4.849373880233543e-08
precursor O 0 2.7762897047978186e-07
protein O 0 9.163188963157154e-08
pre O 0 1.2146020935688284e-06
- O 0 2.679540921235457e-05
pro O 0 9.340706697003043e-07
- O 0 0.00013577326899394393
opiomelanocortin O 0 0.0006939403829164803
( O 0 5.619881093821277e-08
POMC O 0 3.1746556487632915e-05
) O 0 4.169692591204921e-09
generates O 0 3.2186385112709104e-08
the O 0 1.1904500496484616e-08
melanocortin O 0 4.454794543562457e-05
peptides O 0 6.419258170353714e-06
adrenocorticotrophin O 0 0.0001045272292685695
( O 0 6.169217670048965e-08
ACTH O 0 1.4173077033774462e-05
) O 0 6.916207606622038e-09
, O 0 7.601852480831894e-09
melanocyte O 0 7.753160025458783e-05
- O 0 6.626785034313798e-05
stimulating O 0 9.375849913340062e-06
hormones O 0 7.914545676612761e-06
( O 0 2.921980168935079e-08
MSH O 0 3.20382860081736e-05
) O 0 2.7433120219910734e-09
alpha O 0 1.558924367373038e-08
, O 0 1.571168528613498e-09
beta O 0 5.162630767330256e-09
and O 0 2.098481388657092e-09
gamma O 0 2.9452243666128197e-07
as O 0 9.273616874416746e-10
well O 0 7.635940768579985e-10
as O 0 6.000770436109804e-10
the O 0 4.312379342508166e-09
opioid O 0 2.017582573898835e-06
- O 0 1.2054145372530911e-05
receptor O 0 9.31467752707249e-07
ligand O 0 5.523491381609347e-06
beta O 0 3.42924158758251e-06
- O 0 0.0009061265736818314
endorphin O 0 0.04161343723535538
. O 0 4.4426928980101366e-06

While O 0 1.0843594964171643e-06
a O 0 1.6776392897099868e-07
few O 0 9.446453930195275e-08
cases O 0 8.501974946284463e-08
of O 0 1.0838141406566137e-07
isolated O 0 0.00653482973575592
ACTH B-Disease 1 0.999902606010437
deficiency I-Disease 1 0.9997168183326721
have O 0 9.012665458385527e-08
been O 0 1.4376811918737076e-07
reported O 0 1.191989485960221e-05
( O 0 9.006150207824248e-07
OMIM O 1 0.8997394442558289
201400 O 0 9.797217353479937e-05
) O 0 1.3323967706924122e-08
, O 0 8.00218735719227e-09
an O 0 4.066932390855982e-08
inherited O 1 0.549750030040741
POMC O 1 0.9957484602928162
defect O 0 0.009837182238698006
has O 0 4.807048981092521e-08
not O 0 6.1987499577753624e-09
been O 0 1.0835242925111288e-08
described O 0 2.8070579105587967e-07
so O 0 3.9993238942770404e-08
far O 0 2.7970423843726167e-07
. O 0 2.29540000873385e-06

Recent O 0 2.8874846975668333e-05
studies O 0 1.7836567849371932e-06
in O 0 8.193410394596867e-08
animal O 0 4.624489804427867e-07
models O 0 7.523931913056003e-07
elucidated O 0 5.990300451230723e-06
a O 0 8.38580493933705e-09
central O 0 7.591391515404666e-09
role O 0 4.7448844853192895e-09
of O 0 2.257942943728608e-09
alpha O 0 3.9827676800996414e-07
- O 0 6.87817664584145e-05
MSH O 0 9.000626596389338e-05
in O 0 5.356636911812984e-09
the O 0 1.211599487405124e-09
regulation O 0 5.344227282932934e-09
of O 0 8.405304230407751e-10
food O 0 1.6438882255442877e-08
intake O 0 8.747196744707253e-08
by O 0 1.940393179467037e-09
activation O 0 2.694155476490323e-08
of O 0 1.6313652650978838e-09
the O 0 2.9770207632395795e-08
brain O 0 5.931020132265985e-05
melanocortin O 0 4.250065467203967e-05
- O 0 3.339679096825421e-06
4 O 0 2.6427210642054888e-08
- O 0 5.862713805981912e-06
receptor O 0 7.999136641956284e-07
( O 0 2.4311177071467682e-08
MC4 O 0 0.00035826413659378886
- O 0 5.136926847626455e-05
R O 0 8.268081728601828e-05
; O 0 1.8967902803979086e-08
refs O 0 2.444267295231839e-07
3 O 0 4.911805628893262e-09
- O 0 1.1292180488453596e-06
5 O 0 1.0058609944962882e-08
) O 0 6.481836734018032e-10
and O 0 4.967247724252388e-10
the O 0 1.2722058961855964e-09
linkage O 0 4.116929801512015e-07
of O 0 1.1093040264142928e-08
human O 0 1.0062285582534969e-05
obesity B-Disease 0 0.1104438379406929
to O 0 2.5949896453880683e-08
chromosome O 0 1.26416671264451e-05
2 O 0 1.5330995140061532e-08
in O 0 4.4359658168957594e-09
close O 0 1.313281927650678e-08
proximity O 0 6.047125111763307e-08
to O 0 4.528446950757825e-09
the O 0 2.5834680172920343e-08
POMC O 0 0.001894419896416366
locus O 0 7.015041774138808e-07
, O 0 3.129245973454431e-09
led O 0 6.087789383713016e-09
to O 0 7.346382391304473e-10
the O 0 1.1679675004927503e-09
proposal O 0 1.8889412700673347e-08
of O 0 8.436753518026308e-10
an O 0 2.6617963388986254e-09
association O 0 4.507921858021291e-08
of O 0 4.891511196092324e-08
POMC O 0 0.07508379220962524
with O 0 1.1863776308018714e-06
human O 0 0.00013107953418511897
obesity B-Disease 1 0.9484511017799377
. O 0 1.0858458153961692e-05

The O 0 7.841771321182023e-07
dual O 0 2.2548063043359434e-06
role O 0 9.602482009540836e-08
of O 0 1.3692120326425083e-08
alpha O 0 8.689790433891176e-07
- O 0 0.00013727582700084895
MSH O 0 0.00018109267693944275
in O 0 1.8607488883048973e-08
regulating O 0 8.20961716385682e-08
food O 0 4.706686951294614e-08
intake O 0 2.804328573802195e-07
and O 0 2.006270172216773e-08
influencing O 0 2.2605354388360865e-06
hair O 0 0.2671581506729126
pigmentation O 0 0.0377768911421299
predicts O 0 6.0768808907596394e-05
that O 0 1.1660247878353402e-08
the O 0 1.0702968467057872e-07
phenotype O 0 0.015748510137200356
associated O 0 2.220224502025303e-07
with O 0 3.2516503267743246e-08
a O 0 1.1578104022191837e-06
defect O 0 0.0019652824848890305
in O 0 1.1064523732784437e-06
POMC O 0 0.03281182050704956
function O 0 1.2298053775339213e-07
would O 0 4.022726329822035e-08
include O 0 2.348859197809361e-06
obesity B-Disease 1 0.7129802703857422
, O 0 3.464145095222193e-07
alteration O 0 0.00015962035104166716
in O 0 1.2544031960715074e-05
pigmentation O 1 0.6725379824638367
and O 0 0.00038354526623152196
ACTH B-Disease 1 0.999173104763031
deficiency I-Disease 1 0.9980588555335999
. O 0 1.5348749002441764e-05

The O 0 9.29792179249489e-07
observation O 0 4.016611001134152e-06
of O 0 6.414445863356377e-08
these O 0 3.2006832384468e-07
symptoms O 0 5.801785664516501e-05
in O 0 3.483770782963802e-08
two O 0 2.0014086388187025e-08
probands O 0 0.0001629046892048791
prompted O 0 3.7276521425155806e-07
us O 0 1.9568105358303e-08
to O 0 3.049815067157624e-09
search O 0 4.721577084865203e-08
for O 0 1.557961404330399e-08
mutations O 0 9.530714919492311e-07
within O 0 2.3772210866468413e-08
their O 0 4.09833404546589e-07
POMC O 0 0.07560186833143234
genes O 0 8.7413009168813e-06
. O 0 2.8313027087278897e-06

Patient O 0 0.0001326338096987456
1 O 0 3.6722829577229277e-07
was O 0 4.870071279583499e-08
found O 0 1.143639849487954e-08
to O 0 1.403040128522548e-09
be O 0 1.0416608686725226e-09
a O 0 5.762396337871678e-09
compound O 0 2.853817022696603e-07
heterozygote O 0 7.487514267268125e-06
for O 0 1.5146974785551492e-09
two O 0 5.454644735891634e-09
mutations O 0 4.5517955982177227e-07
in O 0 2.9004025847712e-08
exon O 0 2.4662291252752766e-05
3 O 0 5.0739444645842013e-08
( O 0 8.239057436298935e-09
G7013T O 0 1.9403851183597e-06
, O 0 1.0463608646205103e-08
C7133delta O 0 1.3056715943093877e-05
) O 0 2.2083783690618475e-09
which O 0 1.5117995744162727e-09
interfere O 0 7.88726683964569e-09
with O 0 2.229896933769737e-09
appropriate O 0 1.0488426127608363e-08
synthesis O 0 3.0397639960710876e-08
of O 0 6.46067199738809e-09
ACTH O 0 4.661136699724011e-05
and O 0 6.808634367416744e-08
alpha O 0 3.6525389077723958e-06
- O 0 0.0017149533377960324
MSH O 0 0.014500458724796772
. O 0 4.68954567622859e-06

Patient O 0 0.00022245579748414457
2 O 0 5.203760338190477e-07
was O 0 7.53969189304371e-08
homozygous O 0 1.2055672868882539e-06
for O 0 7.618792707830835e-09
a O 0 1.1543249200940409e-07
mutation O 0 2.3280347249965416e-06
in O 0 5.6745115273315605e-08
exon O 0 5.5479460570495576e-05
2 O 0 1.9842873655306903e-07
( O 0 4.893452043575053e-08
C3804A O 0 6.7813662099069916e-06
) O 0 3.266725201456211e-08
which O 0 6.494799720258015e-08
abolishes O 0 0.00016273655637633055
POMC O 0 0.00574162183329463
translation O 0 4.300202817830723e-06
. O 0 1.7253274791073636e-06

These O 0 1.4031766113475896e-06
findings O 0 1.4263830507843522e-06
represent O 0 4.022664867875392e-08
the O 0 4.138988263235888e-09
first O 0 3.4421048233923557e-09
examples O 0 3.4774373602886044e-08
of O 0 1.0460336596906927e-08
a O 0 9.507941285846755e-06
genetic B-Disease 1 0.9886687397956848
defect I-Disease 1 0.9532372355461121
within O 0 8.773781701165717e-08
the O 0 7.99599675360696e-08
POMC O 0 0.009072643704712391
gene O 0 1.0518139248461011e-07
and O 0 1.0188442089997807e-08
define O 0 2.646462178290676e-07
a O 0 2.1925445992110326e-07
new O 0 2.0523852072074078e-05
monogenic B-Disease 1 0.9997352957725525
endocrine I-Disease 1 0.9996848106384277
disorder I-Disease 0 0.09043635427951813
resulting O 0 2.1589157768175937e-06
in O 0 1.4124660197012417e-07
early O 0 3.961791207984788e-06
- O 1 0.9955228567123413
onset O 1 0.9997771382331848
obesity B-Disease 1 0.9999599456787109
, O 0 0.0011449693702161312
adrenal B-Disease 1 0.9999877214431763
insufficiency I-Disease 1 0.9999814033508301
and O 0 1.0824937817233149e-05
red O 0 0.021210186183452606
hair O 1 0.5994153618812561
pigmentation O 0 0.02372264303267002
. O 0 7.762262725918845e-07
. O 0 3.554648628778523e-06

A O 0 6.585884420928778e-06
European O 0 5.3675494200433604e-06
multicenter O 0 0.010975465178489685
study O 0 2.968722128571244e-06
of O 0 2.3681059246882796e-06
phenylalanine B-Disease 1 0.9999469518661499
hydroxylase I-Disease 1 0.9999899864196777
deficiency I-Disease 1 0.999992847442627
: O 0 1.512915901002998e-06
classification O 0 1.6989903315334232e-06
of O 0 6.488383608171944e-09
105 O 0 5.207627395975578e-07
mutations O 0 1.2021986321997247e-06
and O 0 4.264268937959059e-09
a O 0 1.207357769317241e-08
general O 0 4.681956511376484e-08
system O 0 7.13006755859169e-08
for O 0 1.6377073919215945e-08
genotype O 0 0.00020644885080400854
- O 0 6.846947508165613e-05
based O 0 4.4488177763923886e-07
prediction O 0 2.2181910026120022e-05
of O 0 2.446450082516094e-07
metabolic O 1 0.8680181503295898
phenotype O 0 0.2607819139957428
. O 0 7.504857876483584e-06

Phenylketonuria B-Disease 1 0.9962922930717468
( O 0 6.398282857844606e-05
PKU B-Disease 0 0.33134421706199646
) O 0 1.0895591913140379e-06
and O 0 1.664119963606936e-06
mild B-Disease 0 0.3646155297756195
hyperphenylalaninemia I-Disease 1 0.9999910593032837
( O 0 2.2090418497100472e-05
MHP B-Disease 1 0.9985692501068115
) O 0 8.432643028299935e-08
are O 0 1.8795904566104582e-07
allelic B-Disease 1 0.947599470615387
disorders I-Disease 1 0.9749290347099304
caused O 0 6.48950444883667e-05
by O 0 6.429033874155721e-07
mutations O 0 6.8202543843653984e-06
in O 0 4.2713942605132615e-08
the O 0 4.2770604835595805e-08
gene O 0 9.84111352408945e-07
encoding O 0 4.3818563426611945e-06
phenylalanine O 0 0.0010848607635125518
hydroxylase O 0 0.09568896144628525
( O 0 2.4858134111127583e-06
PAH O 1 0.9948105812072754
) O 0 7.195548619165493e-07
. O 0 1.687713393039303e-06

Previous O 0 1.2524071280495264e-05
studies O 0 1.2040001138302614e-06
have O 0 2.960791256612083e-08
suggested O 0 6.220165715831172e-08
that O 0 5.176108874849206e-09
the O 0 2.1762991408991184e-08
highly O 0 2.0828172182518756e-06
variable O 0 0.00010197454685112461
metabolic O 0 0.033280350267887115
phenotypes O 0 0.008206517435610294
of O 0 5.515913653653115e-05
PAH B-Disease 1 0.9999980926513672
deficiency I-Disease 1 0.9998044371604919
correlate O 0 0.0009745273855514824
with O 0 5.9404286730568856e-05
PAH O 1 0.9999067783355713
genotypes O 0 0.10695186257362366
. O 0 1.2059492291882634e-05

We O 0 1.7067495718947612e-06
identified O 0 1.0382793789176503e-06
both O 0 7.682169211875589e-08
causative O 0 9.592744027031586e-05
mutations O 0 6.782620857848087e-06
in O 0 1.1371324148967688e-07
686 O 0 0.0003652865707408637
patients O 0 5.083891664980911e-06
from O 0 9.36797164285963e-08
seven O 0 3.2549181128160853e-07
European O 0 1.3949962749393308e-06
centers O 0 6.389660029526567e-06
. O 0 4.620223535312107e-06

On O 0 3.2968964092106035e-07
the O 0 2.3387590530887792e-08
basis O 0 1.0664939154025888e-08
of O 0 3.791229552518871e-09
the O 0 9.399396816434091e-09
phenotypic O 0 3.542144668244873e-06
characteristics O 0 4.803474666914553e-07
of O 0 2.1467966959676232e-08
297 O 0 2.174668225052301e-05
functionally O 0 6.465920159826055e-05
hemizygous O 0 0.09565800428390503
patients O 0 5.311169388733106e-07
, O 0 4.1464791600276385e-09
105 O 0 7.77154962605664e-09
of O 0 2.2427657508927723e-09
the O 0 4.641748319045291e-08
mutations O 0 7.386290690192254e-07
were O 0 4.001206033166227e-09
assigned O 0 2.0628970531788582e-08
to O 0 7.996721618219738e-10
one O 0 1.651256464896278e-09
of O 0 2.0433121861174186e-09
four O 0 6.030860788541759e-08
arbitrary O 0 4.492789685173193e-06
phenotype O 0 0.004828406497836113
categories O 0 1.2084556146874093e-05
. O 0 3.4443444292264758e-06

We O 0 1.347271904705849e-06
proposed O 0 5.425299036687647e-07
and O 0 4.339693404631362e-08
tested O 0 2.636896283547685e-07
a O 0 1.0013854634394193e-08
simple O 0 4.5451326258216795e-08
model O 0 7.698480430917698e-08
for O 0 6.0837268556213075e-09
correlation O 0 6.978050350880949e-07
between O 0 1.365260544616831e-07
genotype O 0 0.00027561181923374534
and O 0 2.544223605127627e-07
phenotypic O 0 2.7790423700935207e-05
outcome O 0 5.180671359994449e-05
. O 0 7.38411836209707e-06

The O 0 2.843240736183361e-06
observed O 0 3.438483690842986e-05
phenotype O 0 0.002542149508371949
matched O 0 6.869885510241147e-06
the O 0 8.484592939339564e-08
predicted O 0 3.6537370760925114e-05
phenotype O 0 8.726184023544192e-05
in O 0 1.930500737046259e-08
79 O 0 7.101213839177944e-08
% O 0 3.737581355522934e-09
of O 0 1.0153711205163063e-09
the O 0 1.697342710826888e-08
cases O 0 5.759256538340196e-08
, O 0 4.940227338323666e-09
and O 0 2.8065791912723626e-09
in O 0 4.210683801630921e-09
only O 0 5.472597930378242e-10
5 O 0 2.0629549180029016e-09
of O 0 2.5360069599855706e-09
184 O 0 7.494894362025661e-06
patients O 0 1.1395917454137816e-06
was O 0 3.2084820134059555e-08
the O 0 4.158408373200473e-08
observed O 0 4.306703885958996e-06
phenotype O 0 4.148316656937823e-05
more O 0 9.459967253988566e-10
than O 0 2.095361661957895e-09
one O 0 4.087117311257771e-09
category O 0 1.7593147561001388e-07
away O 0 1.7886833347802167e-08
from O 0 1.556013273784629e-08
that O 0 4.693240285291722e-08
expected O 0 1.7284961586483405e-06
. O 0 2.2313929548545275e-06

Among O 0 1.5028440429887269e-06
the O 0 1.1163277946479866e-07
seven O 0 8.312443355862342e-08
contributing O 0 1.8272513102601806e-07
centers O 0 5.8017040061031366e-08
, O 0 2.5745681142552712e-09
the O 0 3.2781206638077265e-09
proportion O 0 1.269175129436917e-07
of O 0 9.658907451637333e-09
patients O 0 2.0183976801035897e-07
for O 0 8.99466456871778e-09
whom O 0 3.015085212609847e-07
the O 0 6.029366517168455e-08
observed O 0 1.1985802302660886e-05
phenotype O 0 0.00017009170551318675
did O 0 2.4868530346111584e-08
not O 0 1.2575882557541718e-09
match O 0 1.6742117026069536e-08
the O 0 1.3471336046677607e-08
predicted O 0 2.0221565137035213e-05
phenotype O 0 3.5463835956761613e-05
was O 0 5.077834153155436e-09
4 O 0 4.57182247615151e-09
% O 0 4.654405749704438e-09
- O 0 9.507251888862811e-06
23 O 0 1.6696043303454644e-07
% O 0 1.572566432628264e-08
( O 0 1.2173448027397171e-08
P O 0 5.475245779962279e-05
< O 0 1.7493011910119094e-06
. O 0 9.42478184384754e-09
0001 O 0 1.5859637869652943e-06
) O 0 1.2282383998751811e-09
, O 0 1.5067904701737689e-09
suggesting O 0 4.135084097356412e-08
that O 0 1.6796163349042104e-09
differences O 0 2.3056511366803534e-08
in O 0 8.418433061763153e-09
methods O 0 2.2195909110678258e-08
used O 0 7.645329702654635e-09
for O 0 1.9057837974401082e-08
mutation O 0 1.3764169125352055e-05
detection O 0 9.072986722458154e-05
or O 0 4.8642091314832214e-06
phenotype O 1 0.9046213626861572
classification O 0 0.0006466080085374415
may O 0 1.619656586626661e-07
account O 0 1.1874475625006653e-08
for O 0 9.291800107114057e-10
a O 0 1.406019745076037e-08
considerable O 0 2.2332463345264841e-07
proportion O 0 1.6843864614202175e-06
of O 0 1.900000796695167e-07
genotype O 0 0.42909035086631775
- O 1 0.848568320274353
phenotype O 0 0.3496464490890503
inconsistencies O 0 0.0004522763774730265
. O 0 9.083714758162387e-06

Our O 0 5.4375414038077e-06
data O 0 1.9695751234394265e-06
indicate O 0 9.86580857897934e-07
that O 0 2.216447647640507e-08
the O 0 1.7343597846775083e-07
PAH O 1 0.9996029734611511
- O 0 0.026752309873700142
mutation O 0 1.439199968444882e-05
genotype O 0 1.4257941984396894e-05
is O 0 1.830987916839888e-09
the O 0 1.5693654153992043e-09
main O 0 2.767087359245579e-08
determinant O 0 9.546670298732352e-07
of O 0 1.6885620368611853e-07
metabolic O 1 0.9498803615570068
phenotype O 0 0.07237731665372849
in O 0 4.209036035263125e-07
most O 0 8.778549158705573e-07
patients O 0 0.00023579003755003214
with O 0 0.032994743436574936
PAH B-Disease 1 0.9999972581863403
deficiency I-Disease 1 0.9997829794883728
. O 0 3.2749016099842265e-05

In O 0 7.188086215137446e-07
the O 0 9.326840455514684e-08
present O 0 1.7597275814296154e-07
study O 0 8.22700059188719e-08
, O 0 7.879056518333982e-09
the O 0 1.0563732999457898e-08
classification O 0 6.071720122236002e-07
of O 0 1.4025832051345333e-08
105 O 0 1.4898758308845572e-05
PAH O 1 0.9999682903289795
mutations O 0 1.9723462173715234e-05
may O 0 3.809207527183389e-08
allow O 0 2.0818013979351235e-09
the O 0 3.51886297877968e-09
prediction O 0 8.503976687279646e-07
of O 0 1.4965282346679487e-09
the O 0 4.6581558166280956e-08
biochemical O 0 0.02393968403339386
phenotype O 0 0.0006409842753782868
in O 0 2.5782549428754464e-08
> O 0 1.0347563375034952e-06
10 O 0 6.210110647941747e-09
, O 0 8.524168038093194e-09
000 O 0 1.1765622787152097e-07
genotypes O 0 2.0812560251215473e-05
, O 0 2.4356664241054204e-08
which O 0 1.743277167065571e-08
may O 0 8.633193715468224e-08
be O 0 1.4069847509290412e-09
useful O 0 4.4299794943469806e-09
for O 0 1.2420955375347376e-09
the O 0 1.7431940335654872e-08
management O 0 1.5453028368028754e-07
of O 0 4.500138217622407e-08
hyperphenylalaninemia B-Disease 1 0.9991958737373352
in O 0 2.8916620067320764e-05
newborns O 0 0.03205849602818489
. O 0 5.706797310267575e-06

Somatic O 0 0.0006774130742996931
instability O 0 0.0001348014920949936
of O 0 1.9594403966038954e-07
the O 0 2.1034459507518477e-07
CTG O 0 0.0010817662114277482
repeat O 0 1.553399852127768e-05
in O 0 1.980266404189024e-07
mice O 0 5.430239980341867e-06
transgenic O 0 1.0429178018966923e-06
for O 0 3.275509996569781e-08
the O 0 8.148778761096764e-06
myotonic B-Disease 1 0.9999990463256836
dystrophy I-Disease 1 0.9999972581863403
region O 0 3.561210542102344e-05
is O 0 1.148490937907809e-07
age O 0 3.4637818657756725e-07
dependent O 0 5.607653008610214e-08
but O 0 7.849986438657197e-09
not O 0 2.6476592029922585e-09
correlated O 0 1.2592286680046527e-07
to O 0 1.3164261902787189e-09
the O 0 6.313442213468079e-09
relative O 0 6.027929089214012e-07
intertissue O 0 1.778845580702182e-05
transcription O 0 2.3236754032041063e-07
levels O 0 6.355223831633339e-07
and O 0 3.599043623125908e-07
proliferative O 1 0.9037619233131409
capacities O 0 0.0001788179506547749
. O 0 3.802148512477288e-06

A O 0 1.0905335329880472e-05
( O 0 1.260816361536854e-06
CTG O 0 0.0001895538007374853
) O 0 3.1851044468567125e-08
nexpansion O 0 2.5766039470909163e-06
in O 0 5.9559153164912004e-09
the O 0 4.45648851155056e-09
3 O 0 2.111845276431268e-08
- O 0 8.337359759025276e-05
untranslated O 0 0.0009953276021406054
region O 0 5.43381702300394e-07
( O 0 2.2905682683926898e-08
UTR O 0 7.481753982574446e-06
) O 0 1.3659403608201615e-09
of O 0 6.7234678935435e-10
the O 0 2.007648092217096e-08
DM O 1 0.997175931930542
protein O 0 8.718977255739446e-07
kinase O 0 3.3435160275985254e-06
gene O 0 1.4928575353678752e-07
( O 0 1.2463084786418221e-08
DMPK O 0 0.00015857646940276027
) O 0 7.983405936329291e-09
is O 0 4.920028828792056e-09
responsible O 0 1.0841448983001101e-07
for O 0 7.546445885964204e-07
causing O 1 0.8803818225860596
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999985694885254
( O 0 0.0008763661608099937
DM B-Disease 1 0.9999107122421265
) O 0 3.6511803500616224e-06
. O 0 2.8160343390482012e-06

Major O 0 3.395457679289393e-05
instability O 0 7.315012771869078e-05
, O 0 5.999356744723627e-08
with O 0 9.634932851554368e-09
very O 0 3.6592966434767504e-09
large O 0 8.881772650681796e-09
expansions O 0 5.282487336444319e-07
between O 0 8.08420086428896e-09
generations O 0 5.9499235760540614e-08
and O 0 1.4775175749548453e-08
high O 0 2.572420214619342e-07
levels O 0 3.5909792472921254e-08
of O 0 2.232867668539029e-09
somatic O 0 2.8429474696167745e-05
mosaicism O 0 0.01815680041909218
, O 0 4.2193043725546886e-08
is O 0 2.0612489493032626e-08
observed O 0 4.534110189524654e-07
in O 0 1.1521148053361685e-06
patients O 0 2.706075792957563e-05
. O 0 1.4899127563694492e-05

There O 0 1.613795916455274e-06
is O 0 5.400032065949745e-08
a O 0 2.0715949844429815e-08
good O 0 2.3262533233037175e-08
correlation O 0 1.1723921744533072e-07
between O 0 2.036741264532793e-08
repeat O 0 8.490989785059355e-06
size O 0 1.037284732774424e-06
( O 0 4.611521831066057e-09
at O 0 2.1166914887515986e-09
least O 0 1.3285135214147203e-09
in O 0 1.5388827989681886e-08
leucocytes O 0 0.0008004569099284708
) O 0 2.4141595389437498e-08
, O 0 5.37930766597583e-08
clinical O 0 2.00574522750685e-05
severity O 0 0.0011768275871872902
and O 0 1.9948406304592936e-07
age O 0 8.782661211625964e-07
of O 0 2.2981461711424345e-07
onset O 0 0.07671122252941132
. O 0 2.2334614186547697e-05

The O 0 9.832757314143237e-06
trinucleotide O 0 0.019001731649041176
repeat O 0 0.0003395529056433588
instability O 0 5.603054887615144e-05
mechanisms O 0 1.9685030565597117e-06
involved O 0 2.3591269382450264e-07
in O 0 1.0974158612953033e-06
DM B-Disease 1 0.9998911619186401
and O 0 8.415577212872449e-07
other O 0 2.247182209202947e-07
human O 0 0.0023752294946461916
genetic B-Disease 1 0.9999786615371704
diseases I-Disease 1 0.9999804496765137
are O 0 1.197520873574831e-06
unknown O 0 3.861884033540264e-05
. O 0 4.832900231122039e-06

We O 0 1.864502451098815e-06
studied O 0 1.4833337900199695e-06
somatic O 0 1.1160483154526446e-05
instability O 0 5.836827767780051e-06
by O 0 5.922048273987457e-08
measuring O 0 9.030205546878278e-06
the O 0 4.085007176968247e-08
CTG O 0 0.00013202850823290646
repeat O 0 1.6502677908647456e-06
length O 0 8.726449607365794e-08
at O 0 4.436930378659554e-09
several O 0 3.0286277930002825e-09
ages O 0 1.3967425616101536e-07
in O 0 5.736877195516854e-09
various O 0 5.539328107317942e-09
tissues O 0 3.9602241486136336e-07
of O 0 6.889060433223904e-09
transgenic O 0 1.951361628016457e-05
mice O 0 4.231411821820075e-06
carrying O 0 4.53299442426669e-08
a O 0 3.1129420818842846e-08
( O 0 3.902553658008401e-08
CTG O 0 3.5747940273722634e-05
) O 0 5.668927105517696e-09
55expansion O 0 1.4722788819199195e-06
surrounded O 0 5.01523302887108e-08
by O 0 3.6067033803988124e-09
45 O 0 3.580151508586482e-09
kb O 0 1.0029567647507065e-06
of O 0 6.207363068000404e-09
the O 0 6.624097892427017e-08
human O 0 2.5131419079116313e-06
DM B-Disease 1 0.9993650317192078
region O 0 5.392034267970303e-07
, O 0 7.330541507144517e-09
using O 0 8.229759096423095e-09
small O 0 8.200743195629911e-08
- O 0 8.478337986161932e-05
pool O 0 2.524553747207392e-05
PCR O 0 2.5884211936499923e-05
. O 0 2.279306045238627e-06

These O 0 1.4831329053777154e-06
mice O 0 3.501597166177817e-05
have O 0 1.9909380810645416e-08
been O 0 7.3721859727982064e-09
shown O 0 2.704720714064024e-08
to O 0 5.6533671077829695e-09
reproduce O 0 6.638314289375558e-07
the O 0 3.0716253984763853e-09
intergenerational O 0 3.4130196127080126e-06
and O 0 2.8533291285270934e-08
somatic O 0 5.395823336584726e-06
instability O 0 6.200478424034372e-07
of O 0 1.8892503117484694e-09
the O 0 8.58211457455127e-09
55 O 0 1.801449371896524e-07
CTG O 0 0.00013836882135365158
repeat O 0 2.443897301418474e-06
suggesting O 0 1.6858155049703782e-07
that O 0 3.3051297254615974e-09
surrounding O 0 6.014113296259893e-08
sequences O 0 5.541899028571606e-08
and O 0 3.581647201045257e-09
the O 0 8.753250568815929e-09
chromatin O 0 3.728121555468533e-06
environment O 0 1.6813179399832734e-06
are O 0 4.42361303143457e-09
involved O 0 3.796304071101986e-08
in O 0 2.680409636468539e-07
instability O 0 2.6181474822806194e-05
mechanisms O 0 1.444468944100663e-05
. O 0 7.441563866450451e-06

As O 0 7.000546133895114e-07
observed O 0 5.603877752946573e-07
in O 0 1.1657958154387416e-08
some O 0 8.888512703641993e-10
of O 0 1.2788183845202639e-09
the O 0 1.5068055247979828e-08
tissues O 0 1.9878241801052354e-05
of O 0 5.184204496799794e-07
DM B-Disease 1 0.999995231628418
patients O 0 6.863087037345394e-05
, O 0 4.084267146708953e-08
there O 0 8.588959765631898e-09
is O 0 2.0979851189650844e-09
a O 0 8.796851247439008e-09
tendency O 0 1.1450612902308421e-07
for O 0 3.2742590860834753e-09
repeat O 0 1.7949156472241157e-06
length O 0 2.399662548668857e-07
and O 0 1.4943127624178487e-08
somatic O 0 4.068165253556799e-06
mosaicism O 0 9.12532486836426e-05
to O 0 4.489530969209454e-09
increase O 0 2.409982258200216e-08
with O 0 4.5956380922973494e-09
the O 0 1.5757850135855733e-08
age O 0 1.0026472097024453e-07
of O 0 6.19369178167517e-09
the O 0 1.8647321553544316e-07
mouse O 0 7.052484579617158e-05
. O 0 3.7756265101052122e-06

Furthermore O 0 4.34458015661221e-05
, O 0 1.9236921389165218e-07
we O 0 2.6389837870510746e-08
observed O 0 7.00371884931883e-08
no O 0 4.319294255594741e-09
correlation O 0 3.560248629241869e-08
between O 0 3.628486400231168e-09
the O 0 1.1250806508655842e-08
somatic O 0 1.7393769667251036e-05
mutation O 0 1.9340341168572195e-05
rate O 0 4.0027126146924275e-07
and O 0 1.6501687127856712e-07
tissue O 0 0.0013239525724202394
proliferation O 0 0.0011545446468517184
capacity O 0 1.3653045243700035e-05
. O 0 2.2683400402456755e-06

The O 0 1.0890812518482562e-06
somatic O 0 0.00018217629985883832
mutation O 0 0.000179953858605586
rates O 0 5.881041715838364e-07
in O 0 1.1989175874305147e-08
different O 0 8.634688519748579e-09
tissues O 0 1.8561497654445702e-06
were O 0 3.2038816044632767e-09
also O 0 5.363670840807799e-09
not O 0 2.389922260093158e-09
correlated O 0 1.2789098491339246e-07
to O 0 1.1418781475924789e-09
the O 0 2.118686781571455e-09
relative O 0 9.695845903934242e-08
inter O 0 1.3216262573223503e-07
- O 0 0.0009868447668850422
tissue O 0 3.9236700104083866e-05
difference O 0 1.2356586864825658e-07
in O 0 5.767146316060234e-09
transcriptional O 0 2.225834236924129e-07
levels O 0 3.594563224851299e-08
of O 0 5.661943136558989e-10
the O 0 1.981281139151747e-09
three O 0 5.080672327295588e-09
genes O 0 3.923039670894468e-08
( O 0 8.143535623617026e-09
DMAHP O 0 5.64641050004866e-05
, O 0 1.8023648351572774e-08
DMPK O 0 1.2799466276192106e-05
and O 0 1.3225323058918548e-08
59 O 0 7.022525494448928e-08
) O 0 3.958107175350278e-09
surrounding O 0 5.780860590220982e-08
the O 0 4.6795818775535736e-08
repeat O 0 3.265265695517883e-05
. O 0 3.6536567904477124e-07
. O 0 1.2622131180251017e-06

A O 0 7.365417332039215e-06
novel O 0 1.3982026757730637e-05
missense O 0 0.019971100613474846
mutation O 0 0.0002736987080425024
in O 0 6.392552336365043e-07
patients O 0 4.802402600034839e-07
from O 0 2.36572752498887e-08
a O 0 5.400715963332914e-07
retinoblastoma B-Disease 0 0.08787816017866135
pedigree O 0 0.0006475539994426072
showing O 0 4.1156868064717855e-06
only O 0 1.2277400429638874e-08
mild O 0 2.092363047268009e-06
expression O 0 8.212514757133249e-08
of O 0 1.546875338931386e-08
the O 0 2.3749403226247523e-06
tumor B-Disease 1 0.78322833776474
phenotype O 0 0.05997595563530922
. O 0 5.018188858230133e-06

We O 0 9.222187031809881e-07
have O 0 2.2209164285413863e-08
used O 0 1.0755312196408795e-08
single O 0 3.48207009892576e-08
strand O 0 2.8086801648896653e-06
conformation O 0 1.3834732271789107e-05
polymorphism O 0 6.079535523895174e-06
analysis O 0 4.196574820980459e-08
to O 0 1.771918167747799e-09
study O 0 6.091227522375675e-09
the O 0 3.3971272461741364e-09
27 O 0 9.947970625034941e-08
exons O 0 8.630180303725865e-08
of O 0 1.864289611575032e-09
the O 0 6.516676620549333e-08
RB1 O 0 0.0086680818349123
gene O 0 5.787744683516394e-08
in O 0 6.605612057342114e-09
individuals O 0 3.6811167447581283e-09
from O 0 4.0896592778949525e-09
a O 0 5.131463964858085e-08
family O 0 5.536879825740471e-07
showing O 0 5.212456380832009e-05
mild O 0 8.064362191362306e-05
expression O 0 1.9690332919708453e-07
of O 0 4.114118823395074e-08
the O 0 2.4408529952779645e-06
retinoblastoma B-Disease 1 0.7021387815475464
phenotype O 0 0.24682964384555817
. O 0 1.6706966562196612e-05

In O 0 1.8051055121759418e-06
this O 0 1.6528603907772776e-07
family O 0 6.421570333259297e-07
affected O 0 4.710530845386529e-07
individuals O 0 1.1278742562126354e-07
developed O 0 5.522395895241061e-06
unilateral B-Disease 0 0.04365585744380951
tumors I-Disease 1 0.9999896287918091
and O 0 3.6742869724548655e-07
, O 0 8.33598612359765e-09
as O 0 1.4978188689340755e-09
a O 0 8.01992694476894e-09
result O 0 4.022196975483894e-08
of O 0 4.046379675770595e-09
linkage O 0 1.1036459000024479e-05
analysis O 0 3.429482546835061e-07
, O 0 6.672194530210618e-08
unaffected O 0 3.79701959900558e-05
mutation O 0 2.721472128541791e-06
carriers O 0 1.1572083735700289e-07
were O 0 3.5784446517084234e-09
also O 0 1.7652769912501753e-08
identified O 0 2.1613826106658962e-07
within O 0 3.196180387021741e-08
the O 0 2.042628040044292e-07
pedigree O 0 0.0005852001486346126
. O 0 5.010814675188158e-06

A O 0 2.288962605234701e-06
single O 0 4.834029709854804e-07
band O 0 2.9922520639047434e-07
shift O 0 1.3790963748760987e-07
using O 0 2.6001966801914023e-08
SSCP O 0 2.1146093786228448e-05
was O 0 2.441843527378751e-08
identified O 0 4.379155882361374e-08
in O 0 9.06711328241272e-09
exon O 0 1.8888726117438637e-05
21 O 0 8.317820032743839e-08
which O 0 3.5884373250638646e-09
resulted O 0 5.120601187513785e-08
in O 0 1.150378103886851e-08
a O 0 1.028434866157113e-07
missense O 0 0.00011460047971922904
mutation O 0 6.988665859353205e-07
converting O 0 2.44493811862867e-08
a O 0 6.705160160436208e-08
cys O 0 0.004616922698915005
- O 0 6.924229819560423e-05
- O 0 0.00020514611969701946
> O 0 1.0245098565064836e-05
arg O 0 1.1023730621673167e-06
at O 0 9.770023901012337e-09
nucleotide O 0 1.6067779995410092e-07
position O 0 2.7380336220517165e-08
28 O 0 4.9293113590920257e-08
in O 0 1.5907451356156344e-08
the O 0 1.802129929728835e-07
exon O 0 0.0013366311322897673
. O 0 4.75852721137926e-06

The O 0 3.87329600926023e-06
mutation O 0 4.2259540350642055e-05
destroyed O 0 3.5037101042689756e-06
an O 0 1.1305331781841232e-07
NdeI O 0 0.00010316181578673422
restriction O 0 1.7142010619863868e-06
enzyme O 0 2.987845846291748e-06
site O 0 4.954108590027317e-06
. O 0 2.6617551611707313e-06

Analysis O 0 2.95480526801839e-06
of O 0 2.837389878607155e-08
all O 0 6.7226118005692115e-09
family O 0 3.732325737360043e-08
members O 0 8.978826571137688e-09
demonstrated O 0 2.6996266910828126e-07
that O 0 6.6304157719798695e-09
the O 0 2.4900332462607366e-08
missense O 0 0.0003118017630185932
mutation O 0 1.3504078197001945e-05
co O 0 5.4391643971030135e-06
- O 0 2.845225390046835e-05
segregated O 0 4.867290499532828e-07
with O 0 4.1057782595999015e-07
patients O 0 7.62625495553948e-06
with O 0 3.906451092916541e-05
tumors B-Disease 1 0.9999939203262329
or O 0 4.3127440108037263e-07
who O 0 1.3036341783845273e-07
, O 0 4.8725126156057286e-09
as O 0 9.104679232763147e-10
a O 0 7.25891480257701e-09
result O 0 3.4097418222245324e-08
of O 0 2.5601663011798337e-09
linkage O 0 6.3290622165368404e-06
analysis O 0 7.249080624660564e-08
had O 0 1.4715468843462531e-08
been O 0 1.4700824557678516e-08
predicted O 0 5.121905815030914e-07
to O 0 3.726590591668355e-09
carry O 0 1.1891683016074239e-07
the O 0 2.1737855604442302e-07
predisposing O 0 0.00018561682372819632
mutation O 0 5.6404802307952195e-05
. O 0 2.8498591291281627e-06

These O 0 4.580212760174618e-07
observations O 0 7.128924721655494e-07
point O 0 1.2193107856717234e-08
to O 0 1.468089538825268e-09
another O 0 2.8687328068599527e-09
region O 0 8.065841328175338e-09
of O 0 9.836810255237083e-10
the O 0 2.0744854722920536e-08
RB1 O 0 0.000298790808301419
gene O 0 4.9391744028071116e-08
where O 0 1.129828852697301e-08
mutations O 0 5.034103622847397e-08
only O 0 4.990609037136551e-10
modify O 0 1.5640143402606554e-08
the O 0 1.031541851936879e-09
function O 0 1.7358738890749237e-09
of O 0 2.399229148686288e-10
the O 0 2.6790425433631526e-09
gene O 0 2.23927472120522e-08
and O 0 4.705427603113321e-09
raise O 0 2.9445436311448248e-08
important O 0 2.846494817632106e-09
questions O 0 3.5221077610003704e-08
for O 0 1.2935874593722474e-08
genetic O 0 4.355766577646136e-06
counseling O 0 1.345564101029595e-06
in O 0 1.2083567924037197e-07
families O 0 5.554279880470858e-08
with O 0 6.51600515766404e-08
these O 0 9.560577041156648e-08
distinctive O 0 0.00013818120351061225
phenotypes O 0 0.002177916467189789
. O 0 5.868727157576359e-07
. O 0 2.6229065497318516e-06

Maternal B-Disease 0 0.027905773371458054
disomy I-Disease 0 0.0948028415441513
and O 0 0.00032680697040632367
Prader B-Disease 1 0.9999954700469971
- I-Disease 1 0.9999960660934448
Willi I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999852180480957
consistent O 0 5.6556195886514615e-06
with O 0 9.715209614569176e-08
gamete O 0 0.0005131933139637113
complementation O 0 0.0003621489158831537
in O 0 5.47092291469653e-08
a O 0 2.5545729087639302e-08
case O 0 5.291052929123907e-08
of O 0 1.3387040809220707e-08
familial O 0 0.008725276216864586
translocation O 0 0.39484918117523193
( O 0 1.2012321803922532e-07
3 O 0 5.768260535887748e-08
; O 0 9.752582741384686e-08
15 O 0 3.4766614476211544e-08
) O 0 1.1001970001700556e-08
( O 0 1.0853652199216413e-08
p25 O 0 2.353303216295899e-06
; O 0 5.0850474053731887e-08
q11 O 0 2.3492668788094306e-06
. O 0 1.4525121549979758e-08
2 O 0 4.8908674443737254e-08
) O 0 1.0724854604404754e-07
. O 0 5.589114948634233e-07

Maternal B-Disease 0 0.40291956067085266
uniparental I-Disease 1 0.982533872127533
disomy I-Disease 1 0.8877306580543518
( I-Disease 0 1.3537279301090166e-05
UPD I-Disease 1 0.9799053072929382
) I-Disease 0 2.7821593917565224e-08
for I-Disease 0 9.02212171638439e-09
chromosome I-Disease 0 9.448403034184594e-06
15 I-Disease 0 2.546458333085866e-08
is O 0 4.643251561020634e-09
responsible O 0 1.217472611614312e-08
for O 0 1.2831381512867779e-09
an O 0 3.088073352586207e-09
estimated O 0 9.176516613251806e-08
30 O 0 1.492902512723049e-08
% O 0 4.967211975070995e-09
of O 0 8.481611857291682e-09
cases O 0 7.141785545172752e-07
of O 0 3.597642353270203e-05
Prader B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999997615814209
Willi I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999972581863403
( O 0 0.0003587914980016649
PWS B-Disease 1 0.9998345375061035
) O 0 3.89003480449901e-06
. O 0 6.457825293182395e-06

We O 0 2.163305680369376e-06
report O 0 6.306428304014844e-07
on O 0 1.530928628312722e-08
an O 0 3.817569815822708e-09
unusual O 0 8.510136240147403e-08
case O 0 2.7043080663702312e-08
of O 0 4.545797516186667e-09
maternal B-Disease 0 8.721675840206444e-05
disomy I-Disease 0 0.003782662097364664
15 I-Disease 0 9.503307296654384e-08
in O 0 2.498783260307391e-07
PWS B-Disease 1 0.9996440410614014
that O 0 1.8014128855270428e-08
is O 0 2.0765271724343393e-09
most O 0 1.4846385232303305e-09
consistent O 0 2.169212542924015e-08
with O 0 4.862003688543837e-09
adjacent O 0 1.0578618514500704e-07
- O 0 5.4637812354485504e-06
1 O 0 5.584424034310587e-09
segregation O 0 1.4499213385477105e-08
of O 0 1.0417761098224787e-09
a O 0 4.377493922902431e-08
paternal O 0 0.00033052245271392167
t O 0 0.0012494296533986926
( O 0 4.804259656765453e-09
3 O 0 8.926642536266627e-09
; O 0 1.1111123576768023e-08
15 O 0 7.4023667195888265e-09
) O 0 2.8516411454404533e-09
( O 0 4.149675270070929e-09
p25 O 0 1.1412730600568466e-06
; O 0 2.699273338180319e-08
q11 O 0 7.997489319677697e-07
. O 0 1.6685364201407538e-09
2 O 0 2.9533111511881316e-09
) O 0 7.968006809910833e-10
with O 0 1.894229662013913e-09
simultaneous O 0 1.723921286611585e-06
maternal O 0 0.0005081509007140994
meiotic O 0 0.001973184524103999
nondisjunction O 0 0.00045705444063059986
for O 0 1.098092496931713e-07
chromosome O 0 7.335368718486279e-05
15 O 0 1.0170268751608091e-06
. O 0 3.6350288610265125e-06

The O 0 6.047545412002364e-06
patient O 0 5.707715172320604e-05
( O 0 3.956344016842195e-07
J O 0 0.0002867006987798959
. O 0 4.5946933369123144e-08
B O 0 3.801166315042792e-07
. O 0 3.555598482307687e-09
) O 0 7.571923643645562e-10
, O 0 8.088067993128334e-10
a O 0 3.2464495536288496e-09
17 O 0 2.264927445594367e-08
- O 0 6.832362942077452e-06
year O 0 2.6668448072086903e-07
- O 0 3.529938476276584e-05
old O 0 5.998881988489302e-06
white O 0 7.449985787388869e-06
male O 0 2.112118863806245e-06
with O 0 3.423616874442814e-07
PWS B-Disease 1 0.9997718930244446
, O 0 5.03528454487423e-08
was O 0 8.177825527866389e-09
found O 0 6.643847250131785e-09
to O 0 1.3609031679351347e-09
have O 0 3.0913147597289026e-09
47 O 0 6.12266859434385e-08
chromosomes O 0 2.8900549864374625e-07
with O 0 8.574833287866568e-09
a O 0 8.814406271540065e-08
supernumerary O 0 0.0003388181794434786
, O 0 6.633783300458163e-08
paternal O 0 1.738839637255296e-05
der O 0 0.00023492136097047478
( O 0 7.710041494135567e-09
15 O 0 2.983044034010618e-09
) O 0 3.8769906729463344e-10
consisting O 0 6.514171979610239e-10
of O 0 5.880890219245316e-10
the O 0 5.478908882139422e-09
short O 0 1.2255949854989012e-07
arm O 0 4.267941733360203e-07
and O 0 5.563629112970148e-09
the O 0 7.55432782995058e-09
proximal O 0 2.432607971059042e-06
long O 0 2.880517513403902e-07
arm O 0 6.247238388823462e-07
of O 0 1.188118048389697e-08
chromosome O 0 1.1081683624070138e-05
15 O 0 4.0486973773568025e-08
, O 0 1.5220367188817363e-08
and O 0 1.6605595476448798e-07
distal O 0 0.0012083185138180852
chromosome O 0 0.0674646869301796
arm O 0 0.00375266931951046
3p O 1 0.9291952848434448
. O 0 1.4944266695238184e-05

The O 0 3.81821655537351e-06
t O 0 0.00038711982779204845
( O 0 6.348948033974011e-08
3 O 0 1.8299903814522622e-08
; O 0 1.2809381111367202e-08
15 O 0 7.285088088337943e-09
) O 0 2.2050279380181337e-09
was O 0 3.951092786280697e-09
present O 0 6.624588433368217e-09
in O 0 4.4934460596834924e-09
the O 0 3.5382792251681394e-09
balanced O 0 2.291056091507926e-07
state O 0 2.5795779734494317e-08
in O 0 1.0965182539734997e-08
the O 0 5.68712401616267e-08
patients O 0 3.193797056155745e-06
father O 0 1.8584948975330917e-06
and O 0 1.4622794708429865e-07
a O 0 8.46262651066354e-07
sister O 0 0.00017367160762660205
. O 0 4.561547939374577e-06

Fluorescent O 0 0.0006308128358796239
in O 0 1.4107496326687397e-06
situ O 0 3.877412382280454e-05
hybridization O 0 3.903368451574352e-06
analysis O 0 6.849807618891646e-07
demonstrated O 0 6.700678909510316e-07
that O 0 1.6115423662199646e-08
the O 0 1.404996226028743e-07
PWS B-Disease 1 0.997383177280426
critical O 0 5.67068639156787e-07
region O 0 2.3773939972215885e-07
resided O 0 1.689862045850532e-07
on O 0 3.968251949260093e-09
the O 0 3.4226612655174904e-09
derivative O 0 2.3531590898073773e-07
chromosome O 0 2.285921482325648e-06
3 O 0 7.261379941780888e-09
and O 0 2.982270430607059e-09
that O 0 2.394777265379844e-09
there O 0 3.443759721832862e-09
was O 0 5.3424340507035595e-09
no O 0 3.688770844334499e-09
deletion O 0 3.748706944861624e-07
of O 0 3.169909001954352e-09
the O 0 1.808608800502043e-07
PWS B-Disease 1 0.9994640946388245
region O 0 1.6115383516535076e-07
on O 0 6.64623023283184e-09
the O 0 4.088505090038552e-09
normal O 0 3.231352607713234e-08
pair O 0 5.514378997872882e-08
of O 0 6.481469139174578e-09
15s O 0 1.2916891137138009e-05
present O 0 2.352120134219149e-07
in O 0 8.657868875161512e-07
J O 0 0.011158084496855736
. O 0 5.884132860956015e-06

B O 0 0.0014990053605288267
. O 0 7.343291508732364e-05

Methylation O 0 8.840814552968368e-05
analysis O 0 1.664756609898177e-06
at O 0 1.1594453042107489e-07
exon O 0 7.416243079205742e-06
alpha O 0 1.0977030484582428e-07
of O 0 3.656226654769057e-09
the O 0 8.012038144045164e-09
small O 0 8.116494853993572e-08
nuclear O 0 0.000534408784005791
ribonucleoprotein O 0 0.020256424322724342
- O 0 0.00010451576235936955
associated O 0 5.516871510735655e-07
polypeptide O 0 5.572505870077293e-06
N O 0 4.712499048764585e-06
( O 0 1.29442661034318e-08
SNRPN O 0 1.4559436749550514e-05
) O 0 6.454070611283669e-09
gene O 0 3.250751490213588e-08
showed O 0 1.0976025777154064e-07
a O 0 2.3488400557880595e-08
pattern O 0 2.00617614609655e-06
characteristic O 0 1.323524543295207e-07
of O 0 1.5844338063786267e-09
only O 0 2.707160495774019e-09
the O 0 3.7149817444515065e-08
maternal O 0 0.00039541724254377186
chromosome O 0 6.651558942394331e-05
15 O 0 1.9694427066951903e-07
in O 0 5.412296673057426e-07
J O 0 0.10505423694849014
. O 0 1.2936342500324827e-05

B O 0 0.001052616280503571
. O 0 5.7549150369595736e-05

Maternal B-Disease 0 0.014653841033577919
disomy I-Disease 0 0.002987113082781434
was O 0 4.33418449574674e-07
confirmed O 0 1.9736035028472543e-07
by O 0 9.54417522791573e-09
polymerase O 0 1.7778593530692888e-07
chain O 0 3.0049204724491574e-07
reaction O 0 5.792239576862812e-08
analysis O 0 8.572543563900581e-09
of O 0 1.935953397591561e-09
microsatellite O 0 1.0450939043948893e-05
repeats O 0 3.551808731572237e-07
at O 0 2.885866212665178e-09
the O 0 2.3520352332440098e-09
gamma O 0 6.53322842936177e-07
- O 0 1.0698315236368217e-05
aminobutyric O 0 4.5957865950185806e-05
acid O 0 1.876839235137595e-07
receptor O 0 2.786626396300562e-07
beta3 O 0 5.580829110840568e-06
subunit O 0 2.804906387154915e-07
( O 0 4.217904248093873e-08
GABRB3 O 0 5.3657422540709376e-05
) O 0 1.9547930207863828e-07
locus O 0 1.3634466085932218e-05
. O 0 2.880236934288405e-06

A O 0 7.820092832844239e-06
niece O 0 0.0015180381014943123
( O 0 1.7034211907684949e-07
B O 0 6.425356104955426e-07
. O 0 9.159970559835529e-09
B O 0 8.766755854594521e-08
. O 0 1.231881929797396e-09
) O 0 2.353676697985918e-10
with O 0 2.901561768631211e-10
45 O 0 2.6930648822087733e-09
chromosomes O 0 4.602113534701857e-08
and O 0 1.1872295369030894e-09
the O 0 1.4647051349570006e-09
derivative O 0 5.185271589880358e-08
3 O 0 6.210844727405629e-09
but O 0 1.3703165269163264e-09
without O 0 1.595113485741706e-09
the O 0 3.4836029616513997e-09
der O 0 4.10263346566353e-05
( O 0 5.3144444400743396e-09
15 O 0 4.626384164652109e-09
) O 0 1.5659538110668336e-09
demonstrated O 0 1.4079860477522743e-07
a O 0 1.0353983981303827e-07
phenotype O 0 0.0028872874099761248
consistent O 0 2.730662629346625e-07
with O 0 9.646811349739437e-09
that O 0 1.5321290902647888e-08
reported O 0 1.3653907160460221e-07
for O 0 6.510946448656796e-09
haploinsufficiency O 0 8.653577970108017e-05
of O 0 5.709361161621018e-08
distal O 0 3.8102232792880386e-05
3 O 0 5.712901383958524e-06
p O 0 0.0005995164392516017
. O 0 4.788701062352629e-06

Uniparental B-Disease 1 0.9994243383407593
disomy I-Disease 1 0.9978756904602051
associated O 0 4.274518505553715e-05
with O 0 3.085523303525406e-07
unbalanced O 0 2.9889122743043117e-05
segregation O 0 4.1228861391573446e-07
of O 0 1.0518034443407487e-08
non O 0 1.2315459230194392e-07
- O 0 0.000281925720628351
Robertsonian O 0 0.002088153036311269
translocations O 0 0.00012608515680767596
has O 0 5.081392018269071e-08
been O 0 1.6167916783160763e-08
reported O 0 3.698403645557846e-07
previously O 0 4.758717508934751e-08
but O 0 8.611629631616324e-09
has O 0 3.988162244894511e-09
not O 0 8.703137099885794e-10
, O 0 1.1832957946822376e-09
to O 0 5.380307865898715e-10
our O 0 3.8984375727579845e-09
knowledge O 0 1.4242332646574596e-08
, O 0 2.6882922554705146e-09
been O 0 4.797154229407852e-09
observed O 0 5.503304123521957e-08
in O 0 6.386145390280262e-09
a O 0 5.165519567640331e-08
case O 0 1.0880140735025634e-06
of O 0 2.506466216800618e-06
PWS B-Disease 1 0.9996922016143799
. O 0 2.532149119360838e-05

Furthermore O 0 5.686147414962761e-05
, O 0 4.1770820757847105e-07
our O 0 1.524550725662266e-07
findings O 0 2.605218867302028e-07
are O 0 3.209428944828119e-09
best O 0 8.233024928472332e-09
interpreted O 0 2.1209601186455984e-08
as O 0 2.8180688893542083e-09
true O 0 9.139660051005194e-08
gamete O 0 1.72103063960094e-05
complementation O 0 4.315880505600944e-05
resulting O 0 1.5917277096377802e-06
in O 0 1.2231353139213752e-06
maternal B-Disease 0 0.10964285582304001
UPD I-Disease 1 0.9993796348571777
15 I-Disease 0 1.0522015145397745e-05
and O 0 5.626920028589666e-05
PWS B-Disease 1 0.999261200428009

Schwartz B-Disease 0 0.09584537893533707
- I-Disease 1 0.9221032857894897
Jampel I-Disease 1 0.9990624785423279
syndrome I-Disease 1 0.9996254444122314
type I-Disease 0 6.985560503380839e-06
2 I-Disease 0 1.1695021839841502e-07
and O 0 1.9863701083977503e-07
Stuve B-Disease 1 0.8813818097114563
- I-Disease 1 0.999855637550354
Wiedemann I-Disease 1 0.9999920129776001
syndrome I-Disease 1 0.9998840093612671
: O 0 5.036259835833334e-07
a O 0 4.6678682252832004e-08
case O 0 9.950494472832361e-08
for O 0 1.0610724743287392e-08
" O 0 1.683537220742437e-07
lumping O 0 2.4697927074157633e-05
" O 0 9.405208629686967e-07
. O 0 1.5758022300360608e-06

Recent O 0 3.486353671178222e-05
studies O 0 2.256692823721096e-06
demonstrated O 0 1.0728143706728588e-06
the O 0 1.851194397772815e-08
existence O 0 5.2259803595688936e-08
of O 0 2.6264486141514e-09
a O 0 3.533425640966925e-08
genetically O 0 1.3466409143347846e-07
distinct O 0 3.165989426179294e-08
, O 0 1.0192368726791301e-08
usually O 0 1.7042589561810928e-08
lethal O 0 3.9982489852263825e-07
form O 0 1.2922805048276587e-08
of O 0 3.419750704836133e-09
the O 0 1.4868700759507192e-07
Schwartz B-Disease 0 0.006007638294249773
- I-Disease 1 0.9980810880661011
Jampel I-Disease 1 0.9999375343322754
syndrome I-Disease 1 0.9998999834060669
( O 0 1.2997527392144548e-06
SJS B-Disease 0 0.10081607848405838
) O 0 2.1049043397169953e-08
of O 0 9.515314758345994e-08
myotonia B-Disease 1 0.98569655418396
and O 0 6.74797993269749e-05
skeletal B-Disease 1 0.9998934268951416
dysplasia I-Disease 1 0.9974216222763062
, O 0 4.1566369191059493e-07
which O 0 3.073701648759197e-08
we O 0 2.241205976361016e-08
called O 0 1.8717927332545514e-06
SJS B-Disease 1 0.5483105778694153
type I-Disease 0 6.904815109010087e-06
2 I-Disease 0 1.367376967209566e-06
. O 0 2.5881292913254583e-06

This O 0 7.59843533160165e-05
disorder O 0 0.007196764927357435
is O 0 8.513870142223823e-08
reminiscent O 0 3.960767571697943e-06
of O 0 1.2161821771883297e-08
another O 0 2.3769497659031913e-07
rare O 0 3.1758001568960026e-05
condition O 0 2.7005251467926428e-05
, O 0 6.947572472881802e-08
the O 0 2.7709910455087083e-07
Stuve B-Disease 1 0.953403651714325
- I-Disease 1 0.9999492168426514
Wiedemann I-Disease 1 0.9999961853027344
syndrome I-Disease 1 0.9999736547470093
( O 0 1.7456416117056506e-06
SWS B-Disease 0 0.03519973158836365
) O 0 1.533503279915749e-08
, O 0 4.253538410381452e-09
which O 0 3.174150275953025e-09
comprises O 0 1.2222702849840061e-08
campomelia B-Disease 0 5.5121541663538665e-05
at O 0 1.0032479025312568e-07
birth O 0 8.73380031407578e-06
with O 0 3.7489039641513955e-06
skeletal B-Disease 1 0.9998007416725159
dysplasia I-Disease 1 0.9983903169631958
, O 0 3.5471341561787995e-06
contractures B-Disease 1 0.7820154428482056
, O 0 7.311707150847724e-08
and O 0 6.843957578439586e-08
early B-Disease 0 1.4090554714130121e-06
death I-Disease 0 4.7191868361551315e-05
. O 0 3.427665205890662e-06

To O 0 5.300537964103569e-07
test O 0 3.21041085271645e-07
for O 0 9.504971920648586e-09
possible O 0 1.7554266662500595e-07
nosologic O 0 0.00042288543772883713
identity O 0 2.2538215489475988e-06
between O 0 1.9433021236636705e-07
these O 0 5.842034624947701e-07
disorders O 0 0.010869113728404045
, O 0 3.9065824353201606e-08
we O 0 3.1397202615579545e-09
reviewed O 0 1.3536732623720127e-08
the O 0 1.6149939163767613e-09
literature O 0 1.4968314587804343e-08
and O 0 2.380168950821826e-09
obtained O 0 5.089352939080527e-09
a O 0 1.3663520315176925e-09
follow O 0 1.7393505524765374e-09
- O 0 1.1835576430030414e-07
up O 0 8.732268796940446e-10
of O 0 1.9863390099406075e-10
the O 0 6.046381728630479e-10
only O 0 3.032238626854422e-10
two O 0 2.607918991870406e-09
surviving O 0 3.250734516768716e-05
patients O 0 4.2743283756863093e-07
, O 0 4.488280858083726e-09
one O 0 2.2927348908297063e-09
with O 0 6.538551389212444e-08
SJS B-Disease 0 0.3884277939796448
type I-Disease 0 5.361413286664174e-07
2 I-Disease 0 8.667127460171287e-09
at O 0 9.705482639787988e-09
age O 0 4.0114553456760405e-08
10 O 0 2.4490860450754326e-09
years O 0 1.452994258244189e-08
and O 0 4.480309456766918e-09
another O 0 1.787554282373094e-08
with O 0 3.85304389283192e-07
SWS B-Disease 0 0.24873782694339752
at O 0 3.234060272916395e-07
age O 0 6.329607913357904e-07
7 O 0 4.6755314997426467e-07
years O 0 1.270215648219164e-06
. O 0 2.4399732865276746e-06

Patients O 0 0.0015391712076961994
reported O 0 1.5824187357793562e-05
as O 0 1.1535689026231921e-07
having O 0 3.542637614373234e-07
either O 0 4.1048647290153895e-06
neonatal O 1 0.9998704195022583
SJS B-Disease 1 0.9992578625679016
or O 0 3.609634632084635e-06
SWS B-Disease 0 0.05195501446723938
presented O 0 4.549243612927967e-07
a O 0 2.855670366841423e-08
combination O 0 4.652726488529879e-07
of O 0 1.4779883095172863e-08
a O 0 2.41489078689483e-06
severe O 0 0.09585053473711014
, O 0 4.02323785237968e-05
prenatal O 1 0.9998196959495544
- O 1 0.9999922513961792
onset O 1 0.999987006187439
neuromuscular B-Disease 1 0.9999985694885254
disorder I-Disease 1 0.9978785514831543
( O 0 4.051199994137278e-06
with O 0 0.00012783716374542564
congenital B-Disease 1 0.9999881982803345
joint I-Disease 1 0.9931507110595703
contractures I-Disease 1 0.9999973773956299
, O 0 0.0841204822063446
respiratory O 1 0.9964614510536194
and O 0 1.5581447314616526e-06
feeding O 0 2.23070692300098e-05
difficulties O 0 1.4304520846053492e-05
, O 0 9.048993376836734e-08
tendency O 0 3.235892904740467e-07
to O 0 6.139578090369469e-08
hyperthermia B-Disease 1 0.6912282705307007
, O 0 8.631202064179888e-08
and O 0 4.890577898208903e-08
frequent O 0 5.763949502579635e-06
death O 0 4.050551797263324e-05
in O 0 7.88785428085248e-07
infancy O 0 0.00029936936334706843
) O 0 3.040000251530728e-09
with O 0 4.022333133235634e-09
a O 0 6.716731348888061e-08
distinct O 0 8.560796800338721e-07
campomelic B-Disease 0 0.08620680868625641
- I-Disease 1 0.6846858859062195
metaphyseal I-Disease 1 0.9946137070655823
skeletal I-Disease 1 0.9972561001777649
dysplasia I-Disease 1 0.9634038805961609
. O 0 2.4087696147034876e-05

The O 0 7.173021003836766e-07
similarity O 0 2.4393125386268366e-06
of O 0 3.400363723926603e-08
the O 0 1.3169007218039042e-07
clinical O 0 2.8926604500156827e-05
and O 0 1.2473094557208242e-06
radiographic O 1 0.9603743553161621
findings O 0 5.654256165144034e-05
is O 0 1.5659367136322544e-08
so O 0 8.636567017106245e-09
extensive O 0 2.1815860407059517e-07
that O 0 9.799889255646121e-08
these O 0 4.197639782432816e-07
disorders O 0 0.003909875173121691
appear O 0 5.219898753239249e-07
to O 0 6.1097051862191165e-09
be O 0 6.777211680741857e-09
a O 0 4.531429809162546e-08
single O 0 1.407282752552419e-06
entity O 0 1.5762496332172304e-05
. O 0 3.959207788284402e-06

The O 0 3.7430910992952704e-07
follow O 0 1.6695072702077596e-07
- O 0 1.354637447548157e-06
up O 0 1.3361556305824251e-08
observation O 0 7.67893126862873e-08
of O 0 1.0424916485618496e-09
an O 0 2.460768699918958e-09
identical O 0 7.554524472652702e-07
and O 0 1.4747894461208944e-08
unique O 0 1.4928006919490144e-07
pattern O 0 1.7494013491159421e-06
of O 0 3.2514584802356694e-08
progressive O 0 0.0260162316262722
bone B-Disease 1 0.9819772243499756
dysplasia I-Disease 1 0.942756712436676
in O 0 1.6209591535698564e-07
the O 0 4.305001510829243e-08
two O 0 1.7018575704241812e-07
patients O 0 3.624643568400643e-06
( O 0 1.0453156562562071e-08
one O 0 7.633992993305583e-09
with O 0 7.152214038796956e-07
SJS B-Disease 1 0.9579597115516663
type I-Disease 0 1.7454734688726603e-06
2 I-Disease 0 1.753628708911492e-08
, O 0 4.056905034133251e-09
one O 0 4.017686627832973e-09
with O 0 1.0418248308496914e-07
SWS B-Disease 0 0.15664468705654144
) O 0 1.1649510689437648e-08
surviving O 0 5.422645017461036e-07
beyond O 0 2.2843298097541265e-07
infancy O 0 1.1928309504583012e-05
adds O 0 2.823042279942456e-07
to O 0 9.809417722550506e-10
the O 0 1.7145020958508894e-09
evidence O 0 2.4456097591496473e-08
in O 0 1.069215027627024e-08
favor O 0 2.8023228182405546e-08
of O 0 4.065815417675367e-08
identity O 0 7.436512987624155e-06
. O 0 3.0147623419907177e-06

The O 0 4.003478352387901e-06
hypothesis O 0 3.312410626676865e-05
that O 0 6.165748231978796e-07
SWS B-Disease 0 0.015044125728309155
and O 0 8.467067118544946e-07
SJS B-Disease 1 0.5038204789161682
type I-Disease 0 1.3825730320604634e-06
2 I-Disease 0 1.2987891651050631e-08
are O 0 1.016173256651598e-09
the O 0 9.282929980258814e-09
same O 0 1.4780581523154979e-06
disorder O 0 0.0001854708680184558
should O 0 2.1968599384081244e-08
be O 0 6.622162818104016e-09
testable O 0 2.117633130183094e-06
by O 0 4.305182343955494e-08
molecular O 0 1.7823434973252006e-05
methods O 0 4.5729413500339433e-07
. O 0 1.4123608593763493e-07
. O 0 9.95615891952184e-07

A O 0 7.659324182895944e-06
mouse O 0 6.679068610537797e-05
model O 0 1.2565307770273648e-05
of O 0 7.309361535590142e-06
severe O 1 0.9997344613075256
von B-Disease 1 0.9999994039535522
Willebrand I-Disease 1 0.9999974966049194
disease I-Disease 1 0.9999892711639404
: O 0 0.010178844444453716
defects O 1 0.9898234009742737
in O 0 4.577009895001538e-05
hemostasis O 1 0.9964466691017151
and O 0 0.0007842787890695035
thrombosis B-Disease 1 0.9998192191123962
. O 0 0.0002569679927546531

von B-Disease 1 0.9929191470146179
Willebrand I-Disease 1 0.9839584827423096
factor I-Disease 0 0.0001152371332864277
( I-Disease 0 1.2737547876895405e-05
vWf I-Disease 0 0.25920045375823975
) I-Disease 0 0.0016869667451828718
deficiency I-Disease 1 0.999893069267273
causes O 1 0.7409874200820923
severe O 1 0.9999042749404907
von B-Disease 1 0.9999997615814209
Willebrand I-Disease 1 0.9999983310699463
disease I-Disease 1 0.9999755620956421
in O 0 4.676822936744429e-05
humans O 0 3.957117223762907e-05
. O 0 5.651139417750528e-06

We O 0 7.837211342121009e-07
generated O 0 5.651709216181189e-07
a O 0 6.719204748151242e-08
mouse O 0 6.578719649041886e-07
model O 0 1.5424024013555027e-07
for O 0 5.4695852291786196e-09
this O 0 5.8646875800150156e-08
disease O 0 7.137522061384516e-06
by O 0 1.1056791038299707e-08
using O 0 1.26301955560848e-07
gene O 0 7.656342404516181e-07
targeting O 0 3.2638906759530073e-06
. O 0 1.9340407106938073e-06

vWf B-Disease 0 0.22589032351970673
- I-Disease 1 0.9014198780059814
deficient I-Disease 1 0.9865216016769409
mice O 0 0.00045195058919489384
appeared O 0 1.5761555687276996e-06
normal O 0 2.84979989828571e-07
at O 0 4.738040715324132e-08
birth O 0 2.2102792627265444e-06
; O 0 2.233128526540895e-08
they O 0 2.8320681355609167e-09
were O 0 7.07314784520463e-09
viable O 0 5.773691782451351e-07
and O 0 4.0654668964634766e-07
fertile O 0 0.00010586195276118815
. O 0 8.730427907721605e-06

Neither O 0 0.00036634603748098016
vWf O 0 0.008761453442275524
nor O 0 0.00010637641389621422
vWf O 0 0.00180605158675462
propolypeptide O 0 0.002534952014684677
( O 0 2.5914216621458763e-06
von B-Disease 0 0.17805011570453644
Willebrand I-Disease 0 0.3929768204689026
antigen O 0 0.001612187479622662
II O 0 3.888083665515296e-05
) O 0 1.552361261758506e-08
were O 0 7.190950501723137e-09
detectable O 0 6.270258381846361e-06
in O 0 1.5210993353775848e-08
plasma O 0 5.8744221860251855e-06
, O 0 3.181789409723024e-08
platelets O 0 2.3664192667638417e-06
, O 0 1.2110526803610355e-08
or O 0 2.0490308116904998e-08
endothelial O 0 5.680994036083575e-06
cells O 0 8.124285955091182e-08
of O 0 1.6190744300814686e-09
the O 0 3.735630471624063e-08
homozygous O 0 0.00011983419972239062
mutant O 0 0.0010013245046138763
mice O 0 0.0003788227622862905
. O 0 5.930768566031475e-06

The O 0 9.562877494317945e-06
mutant O 0 0.006995688192546368
mice O 0 0.0598745234310627
exhibited O 0 0.005740884225815535
defects O 0 0.3001839816570282
in O 0 8.637474024908443e-07
hemostasis O 0 0.01702466793358326
with O 0 1.2615979017027712e-07
a O 0 3.617560082602722e-07
highly O 0 3.995304723503068e-06
prolonged O 0 0.009041795507073402
bleeding O 0 0.019778911024332047
time O 0 6.251529782730358e-08
and O 0 7.076889119161933e-08
spontaneous O 0 1.674556733632926e-05
bleeding O 0 0.0005045689176768064
events O 0 6.564305721212804e-08
in O 0 1.4153292759999658e-08
approximately O 0 1.3056443037839927e-08
10 O 0 1.628381696150427e-08
% O 0 4.8530747420727494e-08
of O 0 3.8074756503192475e-07
neonates O 0 0.38741225004196167
. O 0 1.751914169290103e-05

As O 0 4.47868416131314e-07
in O 0 1.1626607943071576e-07
the O 0 2.08250014566147e-07
human O 0 1.199749021907337e-05
disease O 0 0.00028126421966589987
, O 0 1.5231432115569987e-08
the O 0 1.4865718434009523e-08
factor O 0 1.8167180826367257e-07
VIII O 0 0.00027347748982720077
level O 0 8.331316081466866e-08
in O 0 6.3948850659301115e-09
these O 0 5.8817684056577946e-09
mice O 0 5.482138476509135e-06
was O 0 1.7999497003984288e-08
reduced O 0 2.3916928881817512e-08
strongly O 0 9.732175954013655e-09
as O 0 5.743443498573697e-10
a O 0 3.5776803741782714e-09
result O 0 9.499063757800741e-09
of O 0 6.936628493825481e-10
the O 0 7.2709149812055784e-09
lack O 0 1.1227616170117471e-07
of O 0 1.1046083159271802e-08
protection O 0 1.686217046881211e-06
provided O 0 2.0071490780537715e-07
by O 0 4.4011699174006935e-07
vWf O 0 0.00019684030849020928
. O 0 2.732438815655769e-06

Defective O 1 0.898699164390564
thrombosis B-Disease 1 0.9991182684898376
in O 0 1.3443915122479666e-05
mutant O 0 0.005942474585026503
mice O 0 0.0001198728132294491
was O 0 5.8104419053961465e-08
also O 0 2.0602035633032756e-08
evident O 0 3.2625229096083785e-07
in O 0 4.828557997882399e-09
an O 0 1.9218515667773772e-09
in O 0 5.563865101976262e-08
vivo O 0 6.874110113130882e-05
model O 0 1.4686413578601787e-06
of O 0 8.770315389483585e-07
vascular B-Disease 1 0.9996631145477295
injury I-Disease 0 0.3665507733821869
. O 0 3.6087894841330126e-05

In O 0 1.4649009472122998e-06
this O 0 1.0906033054425279e-07
model O 0 2.1607499434139754e-07
, O 0 1.1666188015624357e-08
the O 0 1.9420898667021902e-08
exteriorized O 0 4.797387373400852e-05
mesentery O 0 3.3626536605879664e-05
was O 0 2.974063839644714e-08
superfused O 0 3.195911631337367e-06
with O 0 3.2302128971650745e-08
ferric O 0 5.4934142099227756e-05
chloride O 0 7.389849088212941e-07
and O 0 5.658804536068374e-09
the O 0 5.086228327400022e-09
accumulation O 0 2.75887771294947e-07
of O 0 4.056022628873279e-09
fluorescently O 0 0.00011354057642165571
labeled O 0 5.800735834782245e-06
platelets O 0 6.350046987790847e-06
was O 0 2.3472322752127184e-08
observed O 0 5.999825702929229e-08
by O 0 4.782557638804974e-08
intravital O 0 0.00029456731863319874
microscopy O 0 0.0005205944762565196
. O 0 2.9862676456104964e-06

We O 0 1.514697260063258e-06
conclude O 0 2.3412262635247316e-06
that O 0 2.7772552257943062e-08
these O 0 1.4469597076072205e-08
mice O 0 5.9757962844742e-06
very O 0 5.971114092062635e-08
closely O 0 3.874171397910686e-06
mimic O 0 0.15421411395072937
severe O 1 0.7962638735771179
human O 0 0.11852573603391647
von B-Disease 1 0.9999996423721313
Willebrand I-Disease 1 0.9999970197677612
disease I-Disease 1 0.9997990727424622
and O 0 2.743533968896372e-07
will O 0 4.63306264464336e-08
be O 0 2.4121884489858303e-09
very O 0 1.9717394383889086e-09
useful O 0 4.109536710927841e-09
for O 0 1.1263124877203268e-09
investigating O 0 7.336699070492614e-08
the O 0 4.471669701189285e-09
role O 0 8.920429728220824e-09
of O 0 5.218178333876722e-09
vWf O 0 1.1314157745800912e-05
in O 0 1.3098977547087998e-07
normal O 0 2.159731138817733e-06
physiology O 0 7.280107092810795e-05
and O 0 1.6392267809806071e-07
in O 0 7.685299351578578e-06
disease O 0 0.00042673046118579805
models O 0 3.1322981612902367e-06
. O 0 3.122808607258776e-07
. O 0 1.5127340020626434e-06

Oral O 0 0.0013755351537838578
contraceptives O 0 0.0014258933952078223
and O 0 5.133299509907374e-07
the O 0 3.8898352272553893e-07
risk O 0 1.2420756320352666e-05
of O 0 2.825319825205952e-05
hereditary B-Disease 1 0.9999792575836182
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999920129776001
. O 0 0.00023919716477394104

Hereditary B-Disease 1 0.9998698234558105
Ovarian I-Disease 1 0.9999914169311523
Cancer I-Disease 1 0.9998800754547119
Clinical O 0 0.4753342866897583
Study O 0 0.00015460039139725268
Group O 0 5.3433926950674504e-05
. O 0 1.55913603521185e-05

BACKGROUND O 0 0.0006074378616176546
Women O 0 5.242261067905929e-06
with O 0 3.50160519246856e-07
mutations O 0 2.892651764341281e-06
in O 0 2.9474207963176013e-08
either O 0 1.9537560902449513e-08
the O 0 5.334382535693294e-08
BRCA1 O 0 1.2539188901428133e-05
or O 0 1.6034663374853153e-08
the O 0 2.36206663117855e-08
BRCA2 O 0 1.644961412239354e-05
gene O 0 1.0838100195087463e-07
have O 0 6.767033600141303e-09
a O 0 4.5767979628408284e-08
high O 0 1.0432109775138088e-05
lifetime O 0 0.003876650473102927
risk O 0 0.00019547274860087782
of O 0 0.0010535316541790962
ovarian B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.999984860420227
. O 0 0.00030386957223527133

Oral O 0 0.004583979491144419
contraceptives O 0 0.0795801430940628
protect O 0 0.00044257924309931695
against O 1 0.5150865316390991
ovarian B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999595880508423
in O 0 4.535052653409366e-07
general O 0 1.6451012641027773e-07
, O 0 1.2538500904213379e-08
but O 0 4.137362008549417e-09
it O 0 8.204553147983518e-10
is O 0 1.2867727994247957e-09
not O 0 8.094982462125699e-10
known O 0 5.545977899146237e-09
whether O 0 6.170015609541224e-09
they O 0 2.7779054612153686e-09
also O 0 3.400271397779875e-09
protect O 0 3.929615033371192e-08
against O 0 3.137064652491972e-07
hereditary B-Disease 0 0.0015824128640815616
forms I-Disease 0 4.46513804490678e-05
of I-Disease 0 0.010055082850158215
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999831914901733
. O 0 9.02671308722347e-05

METHODS O 0 9.106855941354297e-06
We O 0 1.845709221015568e-07
enrolled O 0 4.6139044229676074e-07
207 O 0 1.0858952919079456e-06
women O 0 1.625744289412978e-06
with O 0 0.00021320441737771034
hereditary B-Disease 1 0.9999977350234985
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999920129776001
and O 0 2.3262428783255018e-07
161 O 0 1.0456251686719042e-07
of O 0 3.0399769368472107e-09
their O 0 2.1341161726695645e-08
sisters O 0 8.751482596380811e-07
as O 0 5.797121893635904e-09
controls O 0 2.8036595267622033e-08
in O 0 4.304720579995092e-09
a O 0 2.088834527569361e-08
case O 0 3.9298103615692526e-07
- O 0 0.0010355050908401608
control O 0 4.861204160988564e-06
study O 0 2.693791202545981e-06
. O 0 2.9109326078469167e-06

All O 0 3.266626151798846e-07
the O 0 2.5955148430512054e-07
patients O 0 9.70394694377319e-07
carried O 0 3.068436171815847e-07
a O 0 1.584562312473281e-07
pathogenic O 0 3.577204915927723e-05
mutation O 0 1.2969395584150334e-06
in O 0 2.108050267679573e-08
either O 0 7.350369202185902e-08
BRCA1 O 0 2.255181061627809e-05
( O 0 2.235101526082417e-08
179 O 0 4.067817371833371e-07
women O 0 4.766071128869953e-07
) O 0 3.976542828354468e-08
or O 0 1.1641275676765872e-07
BRCA2 O 0 6.112526170909405e-05
( O 0 9.583325066842008e-08
28 O 0 7.666841952413961e-07
women O 0 9.846914963418385e-07
) O 0 3.5064005032836576e-07
. O 0 2.647587734827539e-06

The O 0 6.677776696051296e-07
control O 0 8.448715789199923e-07
women O 0 1.4944515669412795e-07
were O 0 1.8154478809151442e-08
enrolled O 0 2.2397175314381457e-07
regardless O 0 5.5879432636629645e-08
of O 0 1.8098081921991138e-09
whether O 0 1.1669859745211397e-08
or O 0 6.0187472783468365e-09
not O 0 1.6257368784522441e-09
they O 0 2.512109187335909e-09
had O 0 3.2151348250408773e-08
either O 0 7.333753728744341e-07
mutation O 0 5.3152674809098244e-05
. O 0 2.9573652682302054e-06

Lifetime O 0 0.00020016953931190073
histories O 0 1.1233544682909269e-05
of O 0 1.3046962976659415e-07
oral O 0 9.621962817618623e-06
- O 0 0.000915747310500592
contraceptive O 0 0.0001675694657023996
use O 0 1.9582181209898408e-08
were O 0 2.6838196109935097e-09
obtained O 0 2.668370413516641e-08
by O 0 5.9680260733330215e-09
interview O 0 3.2270051519844856e-07
or O 0 3.232287992815941e-09
by O 0 1.7530793483544471e-09
written O 0 1.3716428881593856e-08
questionnaire O 0 6.393144076355384e-07
and O 0 3.6801690583843083e-09
were O 0 3.6773342149132304e-09
compared O 0 3.988560308698652e-07
between O 0 6.407927344298514e-08
patients O 0 1.3304332924235496e-06
and O 0 1.0139514472484734e-07
control O 0 1.71888632394257e-06
women O 0 5.39406073585269e-07
, O 0 1.1493056284450631e-08
after O 0 2.0086709184852225e-08
adjustment O 0 8.03872239885095e-08
for O 0 1.7520632722423102e-09
year O 0 3.27292433155435e-08
of O 0 9.945784640308375e-09
birth O 0 1.43480774568161e-05
and O 0 3.662235030787997e-07
parity O 0 2.002853034355212e-05
. O 0 3.8063717511249706e-06

RESULTS O 0 5.999184213578701e-05
The O 0 5.712105348720797e-07
adjusted O 0 4.5521854190155864e-05
odds O 0 0.0002590046206023544
ratio O 0 1.8679871573112905e-05
for O 0 0.00014674900739919394
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999993085861206
associated O 0 7.794748853484634e-06
with O 0 9.572360681886494e-09
any O 0 3.5616529725501778e-09
past O 0 1.269082616772721e-08
use O 0 6.449762945948123e-09
of O 0 1.4252115931867593e-08
oral O 0 0.000141947137308307
contraceptives O 0 0.006110597401857376
was O 0 7.986559467099141e-07
0 O 0 1.981748710022657e-06
. O 0 1.7797859754864476e-06

5 O 0 1.5853013337618904e-06
( O 0 7.990141881464297e-08
95 O 0 8.10438223197707e-08
percent O 0 1.248535852482746e-07
confidence O 0 3.4717521657512407e-07
interval O 0 1.1256413756655093e-07
, O 0 2.3637465318415707e-09
0 O 0 2.5077815379859203e-09
. O 0 3.0046731769317603e-10
3 O 0 6.009200359535782e-10
to O 0 6.301204558134543e-10
0 O 0 1.7881955471921174e-08
. O 0 6.856262668719637e-09
8 O 0 6.996869217346102e-08
) O 0 5.888955456612166e-08
. O 0 3.5552176314013195e-07

The O 0 5.4167144298844505e-06
risk O 0 4.2989642679458484e-05
decreased O 0 3.0658725336252246e-06
with O 0 1.5841537859273558e-08
increasing O 0 9.292623559531421e-08
duration O 0 1.5473364101126208e-07
of O 0 1.8880037533364202e-09
use O 0 1.4287880212293658e-08
( O 0 1.5734004321643624e-08
P O 0 7.272509719769005e-06
for O 0 2.09636907833044e-09
trend O 0 7.477094499108716e-08
, O 0 4.44162084889399e-09
< O 0 2.2118703668638773e-07
0 O 0 1.302977459261001e-08
. O 0 2.055194459060772e-09
001 O 0 2.2953840073114407e-07
) O 0 8.435401821493826e-10
; O 0 1.4058849640008475e-09
use O 0 4.883042303838181e-10
for O 0 3.86957355047457e-10
six O 0 3.863454445252046e-09
or O 0 4.4215382466461506e-09
more O 0 1.6369633426549512e-09
years O 0 6.860490486815252e-08
was O 0 3.907804924097036e-08
associated O 0 2.725643000189848e-08
with O 0 1.4780044965689854e-09
a O 0 3.190455188928354e-08
60 O 0 5.611997266896651e-08
percent O 0 5.864944796485361e-07
reduction O 0 6.170998858578969e-06
in O 0 1.564622266414517e-06
risk O 0 4.477255788515322e-05
. O 0 6.858527740405407e-06

Oral O 0 0.0002845711132977158
- O 0 0.0019087155815213919
contraceptive O 0 0.0009155562147498131
use O 0 9.863250625130604e-07
protected O 0 0.00018458538397680968
against O 0 0.09628354012966156
ovarian B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9998219609260559
both O 0 2.7322636597659766e-08
for O 0 8.169982912420437e-09
carriers O 0 8.148604280222571e-08
of O 0 3.4425644557245505e-09
the O 0 1.574673973436802e-07
BRCA1 O 0 0.012419118545949459
mutation O 0 1.21291905088583e-05
( O 0 1.5603971448285847e-08
odds O 0 2.997658384629176e-06
ratio O 0 1.159458520305634e-07
, O 0 2.3015154226868617e-09
0 O 0 6.001357188978318e-09
. O 0 5.746774722759085e-10
5 O 0 1.0915263137789566e-09
; O 0 2.754695138662555e-09
95 O 0 6.011186659549139e-09
percent O 0 2.4252219787967988e-08
confidence O 0 1.1366812913138347e-07
interval O 0 4.3278234329591214e-08
, O 0 1.4929187885925899e-09
0 O 0 2.1242587688874437e-09
. O 0 3.526904046591284e-10
3 O 0 4.4812215049816473e-10
to O 0 2.737811366504417e-10
0 O 0 5.867761831979124e-09
. O 0 2.415014854761921e-09
9 O 0 1.056494269846553e-08
) O 0 6.759702797509703e-10
and O 0 5.12168030208926e-10
for O 0 6.792129636501443e-10
carriers O 0 3.468124276650997e-08
of O 0 1.7641148541969187e-09
the O 0 3.5012610055673576e-07
BRCA2 O 0 0.014948406256735325
mutation O 0 1.4362397450895514e-05
( O 0 1.4733330111482701e-08
odds O 0 9.620531272958033e-06
ratio O 0 1.1384127418523349e-07
, O 0 2.0508557074805367e-09
0 O 0 3.9084961933610884e-09
. O 0 5.462231777997317e-10
4 O 0 2.0021100333167396e-09
; O 0 2.69063105129419e-09
95 O 0 7.224907339065112e-09
percent O 0 3.680900917402141e-08
confidence O 0 1.8702246507018572e-07
interval O 0 5.095523292197868e-08
, O 0 1.3502069462489885e-09
0 O 0 2.862829528993416e-09
. O 0 2.6953556053754824e-10
2 O 0 6.111217087934051e-10
to O 0 5.532346247782982e-10
1 O 0 2.9592090999841503e-09
. O 0 3.810724180652869e-09
1 O 0 2.169431745357997e-08
) O 0 6.705518273975031e-08
. O 0 1.1192438478246913e-06

CONCLUSIONS O 0 9.886534098768607e-05
Oral O 0 6.463318277383223e-05
- O 0 0.001252705347724259
contraceptive O 0 0.0008518772665411234
use O 0 2.2490260676022444e-07
may O 0 4.1091118418989936e-07
reduce O 0 3.014780247667659e-07
the O 0 9.579962068073655e-08
risk O 0 8.270349098893348e-06
of O 0 0.00017292749544139951
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999895095825195
in O 0 1.4732283943885705e-06
women O 0 1.149313106907357e-06
with O 0 1.6295348359562922e-06
pathogenic O 0 0.0023414830211549997
mutations O 0 1.6683420653862413e-06
in O 0 3.966695061308201e-08
the O 0 2.6446582523931284e-07
BRCA1 O 0 0.0003062486357521266
or O 0 7.1992330958892126e-06
BRCA2 O 0 0.00196424825116992
gene O 0 9.397216490469873e-05

A O 0 3.850285338558024e-06
Japanese O 0 3.701999503391562e-06
family O 0 6.902451445967017e-07
with O 0 7.882628096922417e-07
adrenoleukodystrophy B-Disease 1 0.9996935129165649
with O 0 7.300963034140295e-08
a O 0 5.780948697520216e-08
codon O 0 1.1198374068044359e-06
291 O 0 4.735077823170286e-07
deletion O 0 6.569655852217693e-06
: O 0 7.945552482624407e-08
a O 0 1.503050270912354e-07
clinical O 0 7.595233182655647e-05
, O 0 2.195282377215335e-06
biochemical O 0 0.03271888941526413
, O 0 6.541732773257536e-07
pathological O 0 0.0030216991435736418
, O 0 3.2087640988720523e-07
and O 0 1.0812316304509295e-06
genetic O 0 0.00016601472452748567
report O 0 2.3889266230980866e-05
. O 0 4.251344762451481e-06

We O 0 1.2894498695459333e-06
report O 0 3.6437779726838926e-07
a O 0 3.6906094180721993e-08
Japanese O 0 4.941610427522392e-07
family O 0 4.6169014922270435e-07
with O 0 4.820463345822645e-06
adrenoleukodystrophy B-Disease 1 0.9999964237213135
( O 0 2.528088225517422e-05
ALD B-Disease 1 0.9999074935913086
) O 0 8.480867563775973e-09
with O 0 1.9954193852811386e-09
a O 0 1.378267366902719e-08
three O 0 7.621103748078895e-09
base O 0 1.3315664659785398e-07
pair O 0 1.7868200075099594e-06
deletion O 0 8.188673746190034e-06
( O 0 1.5176681245065993e-08
delGAG O 0 1.0538021342654247e-05
291 O 0 8.227571584029647e-07
) O 0 1.5405390740852454e-08
in O 0 6.32613819107064e-08
the O 0 1.8418598983771517e-06
ALD B-Disease 1 0.9998182654380798
gene O 0 5.3994041081750765e-05
. O 0 4.450640062714228e-06

A O 0 2.188428197769099e-06
variety O 0 5.072812996331777e-07
of O 0 9.096216757598086e-08
phenotypes O 0 0.0011499931570142508
were O 0 8.160611031371445e-08
observed O 0 4.292993480703444e-07
within O 0 1.8921289424156384e-08
this O 0 3.161897410564052e-08
family O 0 1.1032755082851509e-06
. O 0 2.555967739681364e-06

While O 0 1.3963764331492712e-06
the O 0 1.9390553518405795e-07
proband O 0 0.0002667666703928262
( O 0 1.2598761145454773e-07
patient O 0 8.951024028647225e-07
1 O 0 2.009839761285548e-08
) O 0 4.065503045325158e-09
was O 0 7.671901336436804e-09
classified O 0 7.189526485262832e-08
as O 0 1.4519131452672696e-09
having O 0 1.1908201535959506e-08
a O 0 3.091882305739091e-08
rare O 0 2.9004581847402733e-06
intermediate O 0 1.5190805697784526e-06
type O 0 6.213620054040803e-07
of O 0 2.2318127790299513e-08
adult O 0 1.5272415112121962e-05
cerebral O 0 0.36353448033332825
and O 0 7.790354175085668e-07
cerebello O 1 0.840496838092804
- O 1 0.9638816714286804
brain O 0 0.11503960192203522
stem O 0 6.646601832471788e-06
forms O 0 1.1970249147452705e-07
, O 0 9.868499795118169e-09
his O 0 9.026084057950357e-08
younger O 0 3.597414206524263e-06
brother O 0 1.145353053289e-05
( O 0 5.287410687060401e-08
patient O 0 9.021210303217231e-07
2 O 0 3.2171101338462904e-08
) O 0 7.581030914138864e-09
and O 0 4.5074230570207874e-08
nephew O 0 0.0008402385283261538
( O 0 1.2708707686215348e-07
patient O 0 2.27480859393836e-06
3 O 0 3.6094579769496704e-08
) O 0 7.379922895012214e-09
had O 0 3.0075661072714865e-08
a O 0 3.507043174977298e-06
childhood O 1 0.9378597736358643
ALD B-Disease 1 0.9999830722808838
type O 0 0.0015054926043376327
. O 0 9.404165211890358e-06

Another O 0 1.1880649253726006e-05
nephew O 0 0.0008505698060616851
( O 0 5.978909598525206e-07
patient O 0 2.7011149086320074e-06
4 O 0 3.114409352633629e-08
) O 0 2.7322519802197576e-09
of O 0 3.9589833633613125e-09
patient O 0 2.286617018398829e-06
1 O 0 6.365632287952394e-08
was O 0 5.567400407358036e-08
classified O 0 5.074211344435753e-07
as O 0 7.786401745590865e-09
having O 0 2.7374175814998125e-08
an O 0 4.452624935424865e-08
adolescent O 0 0.0008994412492029369
form O 0 1.53909350046888e-05
. O 0 8.480129508825485e-06

The O 0 1.054764652508311e-06
tau O 0 6.176374427013798e-06
level O 0 1.8555961389665754e-07
in O 0 2.5530384917260562e-08
the O 0 3.867478994834528e-07
cerebrospinal O 1 0.9557136297225952
fluid O 0 0.03272468224167824
( O 0 3.675029631722282e-07
CSF O 0 0.0020389927085489035
) O 0 5.6751692234513484e-09
in O 0 9.139238699162888e-09
patient O 0 6.366440175042953e-07
1 O 0 1.636695579065872e-08
was O 0 9.384313770510744e-09
as O 0 4.212885151844148e-09
high O 0 3.75729634072286e-08
as O 0 1.2850485120452504e-09
that O 0 3.977693729950715e-09
of O 0 4.030483324868328e-08
patients O 0 3.208898124285042e-05
with O 0 0.0009558078600093722
Alzheimers B-Disease 1 0.9999961853027344
disease I-Disease 0 0.39839252829551697
( O 0 2.2808467292634305e-07
AD B-Disease 0 1.9683078789967112e-05
) O 0 2.3043064345529274e-07
. O 0 1.078367859008722e-06

His O 0 0.00011098497634520754
brain O 0 0.015007147565484047
magnetic O 0 0.0002741596836131066
resonance O 0 0.0019468311220407486
image O 0 0.0005802097730338573
( O 0 8.992786888484261e-07
MRI O 0 0.05908505618572235
) O 0 6.140269306342816e-07
showed O 0 0.000683260674122721
abnormalities B-Disease 0 0.033943697810173035
in I-Disease 0 2.6882627679469806e-08
the I-Disease 0 3.857153529907009e-08
bilateral I-Disease 0 4.510214785113931e-05
cerebellar I-Disease 1 0.9987762570381165
hemispheres I-Disease 0 0.11778183281421661
and O 0 8.707429515197873e-06
brain O 0 0.08947624266147614
stem O 0 3.8579815736738965e-05
, O 0 1.878887445627697e-08
but O 0 4.790680740995867e-09
not O 0 1.1702732116702919e-09
in O 0 6.348000347600191e-09
the O 0 1.6238044509009342e-07
cerebral O 1 0.8907665610313416
white O 0 2.3452788809663616e-05
matter O 0 1.9114123972485686e-07
, O 0 1.0663026905888273e-08
where O 0 1.3201280957275685e-08
marked O 0 2.1385254456163239e-07
reductions O 0 5.717631665902445e-07
of O 0 2.2232293783730483e-09
the O 0 1.5039995560073294e-07
cerebral O 1 0.7642974853515625
blood O 0 2.421007775410544e-05
flow O 0 5.963892135696369e-07
and O 0 6.854762091279554e-08
oxygen O 0 3.4726428566500545e-05
metabolism O 0 1.6498838704137597e-06
were O 0 4.901707040261272e-09
clearly O 0 4.347381477032286e-08
demonstrated O 0 1.1326666538025165e-07
by O 0 2.9300279535959817e-08
positron O 0 0.23775799572467804
emission O 0 0.0012378207175061107
tomography O 0 0.00210353615693748
( O 0 3.2330393651136546e-07
PET O 0 3.022595410584472e-05
) O 0 4.430488615980721e-07
. O 0 2.0912978015985573e-06

In O 0 7.00479313309188e-06
patients O 0 4.179068582743639e-06
2 O 0 8.000954920817094e-08
and O 0 2.9718465910377745e-08
3 O 0 3.8174697181148076e-08
, O 0 7.666328016853186e-09
the O 0 1.0822850171621212e-08
autopsy O 0 0.0002539645356591791
findings O 0 7.271268259501085e-06
showed O 0 3.071578248636797e-05
massive O 0 0.018529048189520836
demyelination B-Disease 1 0.9993302822113037
of I-Disease 0 7.518036682085949e-08
the I-Disease 0 6.556653602274309e-07
cerebral I-Disease 1 0.928713858127594
white I-Disease 0 1.2066958333889488e-05
matter I-Disease 0 3.744533216831769e-08
with O 0 2.5792323832263264e-09
sparing O 0 2.7901679189312745e-08
of O 0 1.2294852913541376e-09
the O 0 4.902885653024214e-09
U O 0 2.5413030016352423e-05
- O 0 0.0006207822007127106
fibers O 0 6.459312862716615e-05
, O 0 7.672500856870101e-09
compatible O 0 5.665662605736088e-09
with O 0 3.5913609863769125e-09
the O 0 1.919529779570439e-08
findings O 0 8.862888876137731e-07
of O 0 5.753661866947368e-07
childhood O 1 0.9259374141693115
ALD B-Disease 1 0.9999692440032959
. O 0 4.955832991981879e-05

Oleic O 0 0.004696234129369259
and O 0 4.681167411035858e-06
erucic O 0 0.07202877849340439
acids O 0 1.9708340914803557e-06
( O 0 3.735388176551169e-08
Lorenzos O 0 7.748647476546466e-06
Oil O 0 1.1177063186096348e-07
) O 0 9.97823379478291e-10
were O 0 1.0955664153655675e-09
administered O 0 2.619955630223103e-08
to O 0 1.3970324452827754e-08
patients O 0 1.1652838338704896e-07
1 O 0 5.923762813608846e-09
and O 0 6.00916916226879e-09
4 O 0 1.540330352156616e-08
, O 0 3.874405685166948e-09
but O 0 5.430064398126433e-09
sufficient O 0 7.339232155345599e-08
effectiveness O 0 1.9424943786816584e-07
was O 0 2.2988228209896988e-08
not O 0 1.8853276273489428e-08
obtained O 0 7.645259074706701e-07
. O 0 1.2946657079737633e-06

The O 0 3.947158802475315e-06
findings O 0 8.2720689533744e-06
in O 0 1.15416753487807e-07
this O 0 1.4234565526294318e-08
family O 0 1.0299719122031092e-07
suggest O 0 1.1841639491194655e-07
that O 0 5.992858653769417e-09
delGAG291 O 0 2.6348627670813585e-06
is O 0 1.8310962746070913e-09
part O 0 1.9977919318847626e-09
of O 0 9.818815760453958e-10
the O 0 1.7521642803330906e-08
cause O 0 2.0455911453609588e-07
of O 0 1.6899354804422728e-08
Japanese O 0 5.824614345328882e-05
ALD B-Disease 1 0.9982031583786011
with O 0 3.3086703865592426e-07
phenotypic O 0 8.366476686205715e-05
variations O 0 5.946061355643906e-05
. O 0 6.178713647386758e-06

Moreover O 0 4.560414527077228e-05
, O 0 7.978415794696048e-08
although O 0 1.3105444729433202e-08
the O 0 3.221707789435868e-09
scale O 0 6.359055646498746e-07
of O 0 2.514016994581425e-09
the O 0 1.5884136672639215e-08
study O 0 6.506901684133481e-08
is O 0 4.6397454767088675e-09
limited O 0 6.440297628529379e-09
, O 0 2.7965652016348486e-09
there O 0 1.134633276222985e-09
is O 0 6.509726091508128e-10
a O 0 4.81703255061916e-09
possibility O 0 1.1582793035813665e-07
that O 0 2.0064193861912827e-08
PET O 0 1.566706305311527e-05
can O 0 6.333539204206318e-08
detect O 0 1.7404820027877577e-05
an O 0 4.8042075206922163e-08
insidious B-Disease 0 0.26442840695381165
lesion I-Disease 0 0.4720920920372009
which O 0 6.233229754570857e-08
is O 0 2.6243368367318e-08
undetectable O 0 1.6832913161124452e-06
by O 0 5.1841713144540336e-09
computed O 0 3.7226927815936506e-06
tomogram O 0 0.0007867751410230994
( O 0 7.566688964288915e-08
CT O 0 0.05059928447008133
) O 0 7.531625101364625e-09
or O 0 7.592173112414002e-09
MRI O 0 0.00016812962712720037
analysis O 0 6.200218649610179e-08
, O 0 1.8655881284246334e-09
and O 0 9.481373464126364e-10
that O 0 5.01616581605191e-10
the O 0 1.2361538459515486e-09
higher O 0 2.748991079215557e-08
level O 0 7.985903494045488e-09
of O 0 1.542711292046306e-09
tau O 0 1.7510025429601228e-07
reflects O 0 3.6063749320192073e-08
the O 0 2.2987558523368534e-09
process O 0 6.1098681669591315e-09
of O 0 3.204848653126646e-08
neuronal B-Disease 0 0.01116362027823925
degeneration I-Disease 0 0.17145872116088867
in O 0 8.100956620182842e-05
ALD B-Disease 1 0.9998936653137207
. O 0 2.7570062229642645e-05

Lorenzos O 0 0.0010885761585086584
Oil O 0 4.7416660891030915e-06
should O 0 4.213433513200471e-08
be O 0 2.790507158678679e-09
given O 0 1.4903241973840409e-09
in O 0 2.263458087625736e-09
the O 0 3.936597270381981e-09
early O 0 5.406339198543719e-08
stage O 0 1.8254499991599005e-06
. O 0 1.64321349416241e-07
. O 0 1.2901865602543694e-06

Nonsense O 0 0.002202131086960435
mutation O 0 9.748635056894273e-05
in O 0 3.549224913967919e-07
exon O 0 1.7585609384696e-05
4 O 0 3.4750769373204093e-08
of O 0 3.3781306640889852e-09
human O 0 5.7644108153454e-08
complement O 0 1.6528681499039521e-06
C9 O 0 0.050716862082481384
gene O 0 1.6578869121985917e-07
is O 0 2.091520512337297e-09
the O 0 2.335726723146081e-09
major O 0 5.899872235204384e-08
cause O 0 1.5713543177753309e-07
of O 0 4.199986136654843e-08
Japanese O 0 5.7647248468128964e-05
complement B-Disease 0 0.0029150929767638445
C9 I-Disease 1 0.9996238946914673
deficiency I-Disease 1 0.9972909092903137
. O 0 9.325769497081637e-06

Deficiency B-Disease 1 0.9917072653770447
of I-Disease 0 2.0476035444971785e-07
the I-Disease 0 1.0038719011618014e-07
ninth I-Disease 0 1.15508964881883e-06
component I-Disease 0 1.1459788851198027e-07
of I-Disease 0 4.3137040606211485e-09
human I-Disease 0 1.0570247610530714e-07
complement I-Disease 0 9.168763313027739e-07
( O 0 1.0817942808216685e-07
C9 O 0 0.002816809806972742
) O 0 8.616969360275561e-09
is O 0 1.5133372333053785e-09
the O 0 3.0621138957798166e-09
most O 0 1.714349373571622e-08
common O 0 1.2007151781290304e-05
complement B-Disease 1 0.9993894100189209
deficiency I-Disease 1 0.9999924898147583
in O 0 3.802395269758563e-07
Japan O 0 1.0134947387996363e-06
but O 0 3.923907954117567e-08
is O 0 1.160320994841868e-08
rare O 0 3.314474952276214e-07
in O 0 3.9478177171758944e-08
other O 0 2.5243970469546184e-08
countries O 0 2.358305835059582e-07
. O 0 2.4680496153450804e-06

We O 0 1.2791675771950395e-06
studied O 0 3.4182534136562026e-07
the O 0 3.23715170225114e-08
molecular O 0 3.0952303404774284e-06
basis O 0 1.743117472585709e-08
of O 0 2.6008967779489467e-07
C9 B-Disease 1 0.9999061822891235
deficiency I-Disease 1 0.9531052112579346
in O 0 3.7762205806757265e-08
four O 0 3.270640291930249e-08
Japanese O 0 3.4444428820279427e-06
C9 B-Disease 1 0.9872226715087891
- I-Disease 1 0.9732306599617004
deficient I-Disease 1 0.9562285542488098
patients O 0 5.07718641529209e-06
who O 0 7.312522711799829e-07
had O 0 1.1678648661472835e-05
suffered O 1 0.5252310037612915
from O 0 0.002076151082292199
meningococcal B-Disease 1 0.9999825954437256
meningitis I-Disease 1 0.9998753070831299
. O 0 7.189817551989108e-05

Direct O 0 1.3014197293159668e-06
sequencing O 0 2.7224846235185396e-06
of O 0 8.718381394601238e-08
amplified O 0 1.0537860362092033e-05
C9 O 0 0.0001444113877369091
cDNA O 0 8.336058954228065e-07
and O 0 3.119516023275537e-08
DNA O 0 5.914361054237816e-07
revealed O 0 5.151047162144096e-07
a O 0 1.7001161367602435e-08
nonsense O 0 4.764484913266642e-07
substitution O 0 2.800260467950011e-08
( O 0 3.3988771797055506e-09
CGA O 0 2.7188210083295417e-07
- O 0 5.871912435395643e-06
- O 0 4.870472912443802e-05
> O 0 1.111409073928371e-05
TGA O 0 4.360019738669507e-05
) O 0 3.4408054183643344e-09
at O 0 2.287999567585075e-09
codon O 0 2.6924190876798093e-08
95 O 0 2.6185802415312764e-09
in O 0 2.1729631427547247e-09
exon O 0 1.0405583452666178e-06
4 O 0 8.325212519366687e-09
in O 0 3.1452584980939946e-09
the O 0 1.5018189358784184e-08
four O 0 7.21909714229696e-07
C9 B-Disease 1 0.9781146049499512
- I-Disease 1 0.7723157405853271
deficient I-Disease 0 0.17511403560638428
individuals O 0 1.9909170987375546e-06
. O 0 5.522306310012937e-06

An O 0 5.339360313882935e-07
allele O 0 6.5205322243855335e-06
- O 0 3.7998793231963646e-06
specific O 0 3.3888579054064394e-08
polymerase O 0 3.141477691315231e-07
chain O 0 1.2169684850960039e-06
reaction O 0 4.679894516357308e-07
system O 0 3.983078400437989e-08
designed O 0 1.6317666506893147e-07
to O 0 5.399081626222824e-09
detect O 0 1.4652321169705829e-06
exclusively O 0 4.564939093398834e-09
only O 0 3.307852602940642e-10
one O 0 4.922879881519293e-10
of O 0 3.813710736100262e-10
the O 0 4.150846777406514e-09
normal O 0 3.315619068189335e-08
and O 0 8.565842257723943e-09
mutant O 0 2.662717406565207e-06
alleles O 0 1.0801139183058694e-07
indicated O 0 4.617429638642534e-08
that O 0 5.819164594633719e-10
all O 0 1.7257908990764292e-10
the O 0 2.0972690251142012e-09
four O 0 2.1481074696794167e-08
patients O 0 2.0377366638513195e-07
were O 0 7.833637738485777e-09
homozygous O 0 7.485691071451583e-07
for O 0 4.090361827024935e-09
the O 0 3.444011298370242e-08
mutation O 0 5.851296691616881e-07
in O 0 1.1564301516386877e-08
exon O 0 4.854606686421903e-06
4 O 0 2.2509480501753387e-08
and O 0 3.1905267317000607e-09
that O 0 1.476992861348947e-09
the O 0 4.6220098859350855e-09
parents O 0 2.0519602017543548e-08
of O 0 5.86155346482542e-09
patient O 0 2.715835535127553e-06
2 O 0 7.831400949953604e-08
were O 0 2.2320176640278078e-07
heterozygous O 0 2.264953036501538e-05
. O 0 4.168313807895174e-06

The O 0 2.85051692117122e-06
common O 0 1.9872502434736816e-06
mutation O 0 3.6237554468243616e-06
at O 0 3.845407903213527e-08
codon O 0 5.656702342093922e-07
95 O 0 1.916921021916096e-08
in O 0 1.2636744983751669e-08
exon O 0 9.427187251276337e-06
4 O 0 8.202088253028705e-08
might O 0 2.067935511718133e-08
be O 0 2.1403070427084003e-09
responsible O 0 1.3771795259742703e-08
for O 0 6.006659614143928e-09
most O 0 8.39709244360165e-08
Japanese O 0 0.0009497774299234152
C9 B-Disease 1 0.99988853931427
deficiency I-Disease 1 0.9990929365158081
. O 0 7.107215651558363e-07
. O 0 2.723783154578996e-06

BRCA1 O 0 0.001364838914014399
required O 0 1.222963874170091e-06
for O 0 6.0905442467174e-08
transcription O 0 6.091003683650342e-07
- O 0 7.586156425531954e-05
coupled O 0 3.660353468148969e-05
repair O 0 2.604605288070161e-05
of O 0 1.6915518585847167e-07
oxidative O 0 0.4291284680366516
DNA O 0 0.004087986424565315
damage O 0 0.013259205967187881
. O 0 9.280308404413518e-06

The O 0 4.291997174732387e-05
breast B-Disease 1 0.9724944829940796
and I-Disease 1 0.7363922595977783
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999949932098389
susceptibility O 1 0.9268743991851807
gene O 0 1.1459059351182077e-05
BRCA1 O 0 2.1456404283526354e-05
encodes O 0 2.246507335712522e-07
a O 0 1.2346350786174298e-07
zinc O 0 0.0005150118377059698
finger O 0 5.248192792350892e-06
protein O 0 1.9371276493984624e-07
of O 0 4.0694850156342e-08
unknown O 0 3.7460588373505743e-06
function O 0 1.1666041928037885e-06
. O 0 1.980698016268434e-06

Association O 0 4.330864157964243e-06
of O 0 6.747342240487342e-08
the O 0 1.0370349201593854e-07
BRCA1 O 0 2.9982820706209168e-05
protein O 0 1.0100254854705781e-07
with O 0 7.974989557624212e-09
the O 0 1.2407204152964368e-08
DNA O 0 2.332737494725734e-06
repair O 0 0.00013289916387293488
protein O 0 9.698654821477248e-07
Rad51 O 0 5.713521022698842e-05
and O 0 1.0566172825576814e-08
changes O 0 1.2741566024487838e-08
in O 0 1.5468569758425588e-09
the O 0 7.748766073234492e-10
phosphorylation O 0 1.8240244870071365e-08
and O 0 4.192564517779829e-09
cellular O 0 5.587777422988438e-07
localization O 0 5.412261216974912e-08
of O 0 5.026806193519917e-10
the O 0 2.747432947813877e-09
protein O 0 3.317890318044192e-08
after O 0 1.988801301422427e-08
exposure O 0 1.4907989225321217e-06
to O 0 7.868814044798e-09
DNA O 0 2.7651044547383208e-06
- O 0 0.0010352017125114799
damaging O 0 1.5172913663263898e-05
agents O 0 2.29180784572236e-07
are O 0 2.937289300675161e-09
consistent O 0 2.1422971840934224e-08
with O 0 1.8425736492133638e-09
a O 0 1.0169046937846815e-08
role O 0 5.214878129322642e-08
for O 0 6.437475974507834e-08
BRCA1 O 0 0.00010559698421275243
in O 0 4.575035177367681e-07
DNA O 0 0.00012397153477650136
repair O 0 0.005134376231580973
. O 0 1.2600575246324297e-05

Here O 0 2.99328462460835e-06
, O 0 6.774138938681062e-08
it O 0 5.694588800508882e-09
is O 0 3.9386476302638584e-09
shown O 0 2.556205735970707e-08
that O 0 8.999915479535048e-09
mouse O 0 4.830292255064705e-06
embryonic O 0 5.596651681116782e-05
stem O 0 0.00022285874001681805
cells O 0 4.562171670841053e-05
deficient B-Disease 0 0.00048058206448331475
in I-Disease 0 1.4016249849646556e-07
BRCA1 I-Disease 0 3.140913031529635e-05
are O 0 8.70896954552336e-09
defective O 0 5.750277409788396e-07
in O 0 1.0479647372108047e-08
the O 0 7.826931991417041e-09
ability O 0 5.815819292820379e-08
to O 0 1.2464147491897393e-09
carry O 0 7.715484251491489e-09
out O 0 1.945644756418119e-09
transcription O 0 1.6736498409386513e-08
- O 0 2.4120552097883774e-06
coupled O 0 2.870486014217022e-06
repair O 0 6.057635346223833e-06
of O 0 2.0620904095380865e-08
oxidative O 0 0.1802217960357666
DNA O 0 0.004008459392935038
damage O 0 0.002752570668235421
, O 0 2.8933577311818226e-08
and O 0 1.171949026712582e-08
are O 0 1.0360460045433229e-08
hypersensitive O 0 0.00019905687076970935
to O 0 6.426330401154701e-07
ionizing O 1 0.9933739900588989
radiation O 1 0.955947756767273
and O 0 1.443139012735628e-06
hydrogen O 0 0.0004885473172180355
peroxide O 0 0.07522554695606232
. O 0 4.4150401663500816e-06

These O 0 1.1943639037781395e-06
results O 0 1.9337621779413894e-06
suggest O 0 4.0462202832713956e-07
that O 0 2.0046330817535818e-08
BRCA1 O 0 5.110208348924061e-06
participates O 0 2.6551103360361594e-07
, O 0 7.394661327708718e-09
directly O 0 6.028789023559966e-09
or O 0 6.636628580025672e-09
indirectly O 0 6.523080031684003e-08
, O 0 2.4057189573767346e-09
in O 0 2.748114402706392e-09
transcription O 0 1.661430104604733e-08
- O 0 1.0999116966559086e-05
coupled O 0 9.624954145692755e-06
repair O 0 1.0055061466118786e-05
of O 0 7.533309798191112e-08
oxidative O 0 0.34606996178627014
DNA O 0 0.0011327465763315558
damage O 0 0.0012016607215628028
. O 0 1.2325897387199802e-06
. O 0 2.449116436764598e-06

Truncation O 0 0.0021962225437164307
mutations O 0 0.00029969491879455745
in O 0 4.340190287166479e-07
the O 0 9.602335637737269e-08
transactivation O 0 7.368312071776018e-05
region O 0 3.418302298996423e-07
of O 0 3.6753586840632124e-08
PAX6 O 0 0.008547117933630943
result O 0 6.141042376839323e-07
in O 0 1.105747102769783e-07
dominant O 0 2.2315098249237053e-06
- O 0 0.00013425221550278366
negative O 0 8.87528858584119e-06
mutants O 0 0.0002110522036673501
. O 0 2.9895559237047564e-06

PAX6 O 0 0.024244971573352814
is O 0 5.352227958610456e-07
a O 0 5.558095139690522e-08
transcription O 0 7.219400544045129e-08
factor O 0 1.0663474547811802e-08
with O 0 1.159395579541922e-09
two O 0 5.0837356546651336e-09
DNA O 0 1.3571072940976592e-06
- O 0 8.218669245252386e-05
binding O 0 4.2205121530969336e-07
domains O 0 1.5885780157987028e-07
( O 0 6.393860996212197e-09
paired O 0 1.5517785811880458e-07
box O 0 8.035715381993214e-07
and O 0 3.576058560383899e-08
homeobox O 0 5.747488103224896e-06
) O 0 3.698267247997933e-09
and O 0 2.500769369362388e-09
a O 0 1.3699173351255922e-08
proline O 0 6.742968707840191e-06
- O 0 1.6412604963988997e-05
serine O 0 2.7406861136114458e-06
- O 0 0.00013845486682839692
threonine O 0 6.315713108051568e-06
( O 0 3.601405040853933e-08
PST O 0 1.2000579772575293e-05
) O 0 1.832333929030483e-08
- O 0 7.985836418811232e-06
rich O 0 3.1025035696075065e-06
transactivation O 0 8.316506864503026e-05
domain O 0 4.7012285904202145e-06
. O 0 2.749589611994452e-06

PAX6 O 0 0.3001450002193451
regulates O 0 0.00047068734420463443
eye O 0 0.0008636316051706672
development O 0 1.7910801943799015e-06
in O 0 1.411822125874096e-07
animals O 0 2.5096710487559903e-07
ranging O 0 3.831088974948216e-07
from O 0 2.9531435075114132e-08
jellyfish O 0 2.3967220386111876e-06
to O 0 7.668755408474226e-09
Drosophila O 0 1.369733695355535e-07
to O 0 6.095891080803995e-08
humans O 0 2.1566440864262404e-06
. O 0 2.2785345663578482e-06

Heterozygous O 0 0.002408144995570183
mutations O 0 0.00014261626347433776
in O 0 3.030334312370542e-07
the O 0 1.4511668666727928e-07
human O 0 1.293698005611077e-06
PAX6 O 0 0.009861903265118599
gene O 0 1.3159658465156099e-06
result O 0 1.7873335877993668e-07
in O 0 2.38918520523157e-08
various O 0 2.229085893645788e-08
phenotypes O 0 0.0003894139372278005
, O 0 1.1978505654042237e-07
including O 0 2.4626469894428737e-06
aniridia B-Disease 1 0.9999752044677734
, O 0 8.002524555195123e-05
Peters B-Disease 1 0.999241828918457
anomaly I-Disease 1 0.9998615980148315
, O 0 2.457812115608249e-05
autosomal B-Disease 0 0.04372679442167282
dominant I-Disease 0 0.001547589898109436
keratitis I-Disease 1 0.9361894726753235
, O 0 1.726278810565418e-06
and O 0 5.12139104102971e-06
familial B-Disease 1 0.9807615876197815
foveal I-Disease 1 0.999723494052887
dysplasia I-Disease 1 0.9993835687637329
. O 0 0.0001314999390160665

It O 0 5.47317654309154e-07
is O 0 6.134193597517879e-08
believed O 0 4.2781536535585474e-08
that O 0 2.61180144178752e-09
the O 0 6.194944113246947e-09
mutated O 0 2.100734718624153e-06
allele O 0 1.7819655795392464e-07
of O 0 1.0056979249384312e-08
PAX6 O 0 0.00010708936315495521
produces O 0 1.0133116035149214e-07
an O 0 3.3375644470368115e-09
inactive O 0 2.249714725621743e-07
protein O 0 1.264427282876568e-07
and O 0 7.252081957176415e-08
aniridia B-Disease 1 0.9980471134185791
is O 0 2.2449225411946827e-07
caused O 0 1.0293823606843944e-06
due O 0 2.4693699174349604e-07
to O 0 2.2933666343760706e-07
genetic O 0 0.0001382028276566416
haploinsufficiency O 0 0.07253915071487427
. O 0 8.976474418886937e-06

However O 0 2.798205287035671e-06
, O 0 8.589798738967147e-08
several O 0 1.7218175329958285e-08
truncation O 0 2.0002837118227035e-05
mutations O 0 9.278246579924598e-06
have O 0 8.643058713175833e-09
been O 0 7.302213056448181e-09
found O 0 1.495798329642639e-08
to O 0 1.0234758818228329e-08
occur O 0 2.138829273690135e-07
in O 0 4.7892734222898525e-09
the O 0 1.8393370382341345e-08
C O 0 3.1243087050825125e-06
- O 0 1.3693050277652219e-05
terminal O 0 5.44135161817394e-07
half O 0 3.817206106759841e-09
of O 0 4.462084923773091e-09
PAX6 O 0 0.00025290451594628394
in O 0 3.201086258286523e-07
patients O 0 3.3616979067119246e-07
with O 0 2.0920927568113257e-07
Aniridia B-Disease 1 0.9992190599441528
resulting O 0 1.4189980674927938e-06
in O 0 3.990644614759731e-08
mutant O 0 1.4814365840720711e-06
proteins O 0 9.936815814626243e-09
that O 0 1.271041827344277e-09
retain O 0 2.2860378479094834e-08
the O 0 4.798710317999166e-09
DNA O 0 2.999151433868974e-07
- O 0 7.330835160246352e-06
binding O 0 1.0397284455621048e-07
domains O 0 7.691831171996455e-08
but O 0 2.6417319443083898e-09
have O 0 1.2780770886067216e-09
lost O 0 2.6958927534792565e-08
most O 0 6.797118978774108e-10
of O 0 2.127879872304561e-09
the O 0 9.663425970529715e-08
transactivation O 0 0.0001256834075320512
domain O 0 3.392361804799293e-06
. O 0 3.37141727868584e-06

It O 0 4.704936884536437e-07
is O 0 5.511876111086167e-08
not O 0 5.622879939437553e-09
clear O 0 1.0162124475243672e-08
whether O 0 8.26587864821704e-09
such O 0 9.895339658783087e-09
mutants O 0 7.269077741511865e-06
really O 0 6.827647069940213e-08
behave O 0 9.942981193944433e-08
as O 0 3.279096327801767e-09
loss O 0 2.912341301453125e-07
- O 0 8.654781709083181e-07
of O 0 5.452242213266345e-09
- O 0 0.000285863847238943
function O 0 1.9012405516605213e-07
mutants O 0 3.4562888231448596e-06
as O 0 9.114101473528535e-09
predicted O 0 7.517692210967652e-07
by O 0 1.8034330651062191e-07
haploinsufficiency O 0 0.0017746303929015994
. O 0 3.7722759316238808e-06

Contrary O 0 5.758126008004183e-06
to O 0 4.29776569887963e-08
this O 0 1.2186225362142977e-08
theory O 0 5.10491098282273e-08
, O 0 2.9813604918160763e-09
our O 0 4.291357935670703e-09
data O 0 2.871361814982265e-08
showed O 0 8.820259012054521e-08
that O 0 1.313286257520474e-09
these O 0 1.647921354930304e-09
mutants O 0 5.207841127230495e-07
are O 0 1.8611454599692934e-09
dominant O 0 4.631631256302171e-08
- O 0 3.861375262204092e-06
negative O 0 6.79623042287858e-08
in O 0 2.3446819596983914e-08
transient O 0 9.615834642318077e-06
transfection O 0 0.0003446168848313391
assays O 0 6.768650109734153e-06
when O 0 2.6207953141010876e-08
they O 0 1.8489456632408974e-09
are O 0 1.5595006397362e-09
coexpressed O 0 6.802942607464502e-06
with O 0 4.212654047819342e-08
wild O 0 5.649038030242082e-06
- O 0 0.0014858843060210347
type O 0 0.00017282151384279132
PAX6 O 0 0.02658502385020256
. O 0 9.795544428925496e-06

We O 0 1.011523181659868e-06
found O 0 9.273289691691389e-08
that O 0 7.434571180908733e-09
the O 0 8.821264607661305e-09
dominant O 0 2.615789469473384e-07
- O 0 2.0572133507812396e-05
negative O 0 3.956683372052794e-07
effects O 0 1.1533119277373771e-06
result O 0 3.706941242853645e-08
from O 0 1.9978452225899446e-09
the O 0 2.7883044761978226e-09
enhanced O 0 7.213549793050333e-07
DNA O 0 9.632269666326465e-07
binding O 0 1.5405487374664517e-07
ability O 0 4.024583688533312e-08
of O 0 6.036060540282051e-09
these O 0 8.652398264530348e-08
mutants O 0 5.022283221478574e-05
. O 0 2.7462010621093214e-06

Kinetic O 0 0.00021358043886721134
studies O 0 1.0821579508046852e-06
of O 0 3.1688649926309154e-08
binding O 0 1.0032198360931943e-06
and O 0 1.1312211967151597e-07
dissociation O 0 0.000198417910723947
revealed O 0 3.852900590572972e-06
that O 0 1.7746171199206628e-09
various O 0 1.4888098531784522e-09
truncation O 0 1.959554083441617e-06
mutants O 0 1.3963725677967886e-06
have O 0 1.6936293478764242e-09
3 O 0 2.2626120976809716e-09
- O 0 6.529852498715627e-07
5 O 0 8.74412364737509e-09
- O 0 1.0554820164543344e-06
fold O 0 2.6117439233530604e-07
higher O 0 1.3357198902497203e-08
affinity O 0 1.8068808671500847e-08
to O 0 4.0296413428286826e-10
various O 0 1.0871672451173708e-09
DNA O 0 2.1030147934197885e-07
- O 0 4.118996912438888e-06
binding O 0 4.605344727792726e-08
sites O 0 2.2843117619686382e-08
when O 0 4.096748718040999e-09
compared O 0 2.324483716620307e-08
with O 0 1.353182121910379e-09
the O 0 9.150645574607097e-09
wild O 0 1.350217530671216e-06
- O 0 0.0005585781764239073
type O 0 7.70165934227407e-05
PAX6 O 0 0.013837615959346294
. O 0 6.603323981835274e-06

These O 0 8.187229809664132e-07
results O 0 1.885940832835331e-06
provide O 0 4.025351429959301e-08
a O 0 1.2650442471340284e-08
new O 0 3.4716585162186675e-08
insight O 0 1.7976704214106576e-07
into O 0 1.968673002394894e-09
the O 0 2.345440952566946e-09
role O 0 1.2059860665658562e-08
of O 0 1.0627778657124054e-08
mutant O 0 7.489442214136943e-05
PAX6 O 0 0.0013172526378184557
in O 0 7.781481485835684e-07
causing O 0 4.162836921750568e-05
aniridia B-Disease 1 0.9741148948669434
. O 0 1.1380647038095049e-06
. O 0 2.474504981364589e-06

Reversal O 0 0.009327362291514874
of O 0 0.000135526861413382
severe O 1 0.9996738433837891
hypertrophic B-Disease 1 0.9999877214431763
cardiomyopathy I-Disease 1 0.9999942779541016
and O 0 2.199246773670893e-05
excellent O 0 4.410520341480151e-05
neuropsychologic O 0 0.008324249647557735
outcome O 0 1.006880324894155e-06
in O 0 1.505857483152795e-08
very B-Disease 0 7.1090981990096225e-09
- I-Disease 0 7.141580226743827e-06
long I-Disease 0 4.887165232503321e-07
- I-Disease 0 3.1332514481619e-05
chain I-Disease 0 3.5925045267504174e-06
acyl I-Disease 0 5.256197709968546e-06
- I-Disease 0 8.249079110100865e-05
coenzyme I-Disease 0 3.9960170397534966e-05
A I-Disease 0 7.215646292024758e-06
dehydrogenase I-Disease 0 0.02678794600069523
deficiency I-Disease 1 0.9401407241821289
. O 0 1.0272551662637852e-05

Very B-Disease 0 2.7901362500415416e-06
- I-Disease 0 2.6797299142344855e-05
long I-Disease 0 7.986864147824235e-07
- I-Disease 0 1.569776577525772e-05
chain I-Disease 0 1.8092417803927674e-06
acyl I-Disease 0 2.481126102793496e-06
- I-Disease 0 1.3226329429016914e-05
coenzyme I-Disease 0 3.1831846172281075e-06
A I-Disease 0 1.1645861519582468e-07
dehydrogenase I-Disease 0 8.684473868925124e-06
( I-Disease 0 2.406053738468472e-07
VLCAD I-Disease 0 0.24109886586666107
) I-Disease 0 6.8192530306987464e-06
deficiency I-Disease 0 0.39382311701774597
is O 0 1.842433938747945e-08
a O 0 3.782737678648118e-07
disorder O 0 0.00010167480650125071
of O 0 6.15459683217523e-08
fatty O 0 2.1992216716171242e-05
acid O 0 8.794160066827317e-07
beta O 0 5.994164098410693e-08
oxidation O 0 2.6048834911307495e-07
that O 0 5.85450354861905e-09
reportedly O 0 1.9330916245507979e-07
has O 0 2.9242997356959677e-08
high O 0 3.8707148064531793e-07
rates O 0 1.55990974803899e-07
of O 0 6.014733600068212e-08
morbidity O 1 0.9111390709877014
and O 0 2.4815692086122e-05
mortality O 0 0.06307315826416016
. O 0 1.579316085553728e-05

We O 0 8.833085303194821e-07
describe O 0 4.986960107089544e-07
the O 0 1.7748821079521804e-08
outcome O 0 2.8742714874852027e-08
of O 0 1.5849114243238205e-09
a O 0 8.182896138464457e-09
5 O 0 1.2827252149349988e-08
- O 0 6.00258999838843e-06
year O 0 1.5856356583299203e-07
- O 0 4.874804290011525e-05
old O 0 1.685518873273395e-05
girl O 0 0.00017214591207448393
with O 0 1.7747162928571925e-05
VLCAD B-Disease 1 0.9999986886978149
deficiency I-Disease 1 0.9999918937683105
who O 0 1.5743647452381992e-07
was O 0 1.3188595993085528e-08
first O 0 4.9360826537281355e-09
seen O 0 9.766338848749001e-08
at O 0 1.2240223945525486e-08
5 O 0 1.022669859906955e-08
months O 0 2.6299037614307963e-08
of O 0 1.2415750205718723e-08
age O 0 2.7017797037842683e-05
with O 0 0.00041346246143803
severe O 1 0.9999613761901855
hypertrophic B-Disease 1 0.9999988079071045
cardiomyopathy I-Disease 1 0.9999995231628418
, O 0 0.07482033222913742
hepatomegaly B-Disease 1 0.9999957084655762
, O 0 0.001380064175464213
encephalopathy B-Disease 1 0.9377422332763672
, O 0 7.031867994555796e-07
and O 0 3.013026571352384e-06
hypotonia B-Disease 0 0.40535011887550354
. O 0 1.2202226571389474e-05

Biochemical O 1 0.8463484644889832
studies O 0 0.0033463304862380028
indicated O 1 0.9452419281005859
VLCAD B-Disease 1 0.9999973773956299
deficiency I-Disease 1 0.9999970197677612
caused O 0 4.4901607907377183e-05
by O 0 9.823431668110061e-08
a O 0 3.870541434025654e-07
stable O 0 4.952568815497216e-06
yet O 0 1.8090139519699733e-06
inactive O 0 5.440944278234383e-06
enzyme O 0 2.8173881219117902e-06
. O 0 1.6610172224318376e-06

Molecular O 0 0.08695876598358154
genetic O 0 0.0003071214014198631
analysis O 0 1.942349399541854e-06
of O 0 6.939175989373325e-08
her O 0 3.159557536491775e-06
VLCAD O 0 0.12751854956150055
gene O 0 3.259333652749774e-06
revealed O 0 1.909615548356669e-06
a O 0 6.585863587815766e-08
T1372C O 0 5.984779272694141e-05
( O 0 4.9602274287963155e-08
F458L O 0 7.702966286160517e-06
) O 0 4.144567355979234e-08
missense O 0 5.2006049372721463e-05
mutation O 0 2.8321453555690823e-06
and O 0 2.629226614203617e-08
a O 0 8.290203368233051e-07
1668 O 0 0.19895167648792267
ACAG O 0 0.0700593888759613
1669 O 0 0.0010871099075302482
splice O 0 0.00015770160825923085
site O 0 2.6629701096680947e-05
mutation O 0 8.58513594721444e-05
. O 0 8.299424735014327e-06

After O 0 3.0237520149967168e-06
initial O 0 3.225809678042424e-06
treatment O 0 8.293405926451669e-07
with O 0 5.307862593895152e-08
intravenous O 0 1.3855092220182996e-05
glucose O 0 3.909918177669169e-06
and O 0 1.836377236941189e-07
carnitine O 0 0.0038101912941783667
, O 0 1.4743394949334743e-08
the O 0 6.615951786415053e-09
patient O 0 4.397176098791533e-07
has O 0 9.40111810621147e-09
thrived O 0 1.7485960768226505e-07
on O 0 2.6250213114309418e-09
a O 0 6.031664501193745e-09
low O 0 1.010023495950918e-07
- O 0 7.255371201608796e-06
fat O 0 2.907554232933762e-07
diet O 0 2.5284688121018917e-08
supplemented O 0 1.3993179948101897e-08
with O 0 1.5381776963252491e-09
medium O 0 3.984362351161508e-08
- O 0 2.7113972009829013e-06
chain O 0 5.510519827112148e-07
triglyceride O 0 9.858227940640063e-07
oil O 0 6.392229323637366e-08
and O 0 1.4349464727558825e-08
carnitine O 0 4.475186506169848e-05
and O 0 2.9367249965162046e-08
avoidance O 0 6.323668003460625e-06
of O 0 8.025607911577026e-08
fasting O 0 3.312732951599173e-05
. O 0 3.808019755524583e-06

Her O 0 0.00022721878485754132
ventricular O 0 0.06327668577432632
hypertrophy O 0 0.28680047392845154
resolved O 0 1.6604881238890812e-05
significantly O 0 1.1248274631725508e-06
over O 0 2.168376944666761e-08
1 O 0 2.3138319704685273e-08
year O 0 8.514162885830956e-08
, O 0 1.498162660595881e-08
and O 0 1.1959546952766686e-07
cognitively O 0 0.0010594219202175736
, O 0 2.4500732109800083e-08
she O 0 4.2080529283339274e-08
is O 0 2.52368792530433e-09
in O 0 5.545618186886259e-09
the O 0 9.170074477538037e-09
superior O 0 1.274078499591269e-06
range O 0 1.363667792020351e-07
for O 0 9.133246692272223e-08
age O 0 3.4859692732425174e-06
. O 0 1.8110439441443305e-06

Clinical O 0 0.0006504401098936796
recognition O 0 3.349944017827511e-05
of O 0 5.278635580907576e-05
VLCAD B-Disease 1 0.9999984502792358
deficiency I-Disease 1 0.9999970197677612
is O 0 1.2516856884303706e-07
important O 0 1.0312276366164497e-08
because O 0 9.074171636314077e-09
it O 0 8.312562860268713e-10
is O 0 4.925960750412628e-10
one O 0 3.680904192560064e-10
of O 0 4.725932423177426e-10
the O 0 5.4468061172485704e-09
few O 0 7.101417054400372e-08
directly O 0 3.091404323640745e-06
treatable O 1 0.9961974620819092
causes O 0 1.4012620340508875e-05
of O 0 6.746428766746249e-07
cardiomyopathy B-Disease 1 0.999943733215332
in O 0 3.499545982776908e-06
children O 0 2.760609277174808e-06
. O 0 7.446607810379646e-07
. O 0 3.4048205179715296e-06

Cloning O 0 2.8994076274102554e-05
of O 0 8.533883288919242e-08
a O 0 7.040886629283705e-08
novel O 0 1.2347528866030189e-07
member O 0 8.74400640782369e-09
of O 0 1.242171254745017e-09
the O 0 1.2854683539842426e-08
low O 0 6.858239771645458e-07
- O 0 9.855622192844748e-05
density O 0 5.136476374900667e-06
lipoprotein O 0 0.011321693658828735
receptor O 0 1.206483011628734e-05
family O 0 2.5437823296670103e-06
. O 0 2.0244424376869574e-06

A O 0 1.8601440388010815e-06
gene O 0 5.642779683512344e-07
encoding O 0 1.1033748137379007e-07
a O 0 2.6814621634230207e-08
novel O 0 1.5876450731866498e-07
transmembrane O 0 1.8632921637617983e-05
protein O 0 4.9775330523971206e-08
was O 0 3.909964796378063e-09
identified O 0 9.86959047821756e-09
by O 0 1.38350808587262e-09
DNA O 0 4.7039137029969424e-08
sequence O 0 1.335877897190585e-08
analysis O 0 4.2004644207338515e-09
within O 0 9.304640391505359e-10
the O 0 7.68275221219028e-09
insulin B-Disease 0 2.7125817723572254e-05
- I-Disease 1 0.8149679899215698
dependent I-Disease 0 0.08478082716464996
diabetes I-Disease 1 0.999943733215332
mellitus I-Disease 1 0.9992951154708862
( O 0 2.5511751573503716e-06
IDDM B-Disease 0 0.003865085309371352
) O 0 1.0571901043476828e-07
locus O 0 3.847664174827514e-06
IDDM4 O 0 0.00019033272110391408
on O 0 7.519125801991322e-07
chromosome O 0 0.0001905077660921961
11q13 O 0 0.0002333266456844285
. O 0 4.3638201532303356e-06

Based O 0 1.7989701746046194e-06
on O 0 6.897398918681574e-08
its O 0 6.398364860160655e-08
chromosomal O 0 0.0007068624836392701
position O 0 5.961373403806647e-07
, O 0 1.8616610475419293e-08
this O 0 4.81190864931591e-09
gene O 0 3.5713416224325556e-08
is O 0 2.2525874499024212e-09
a O 0 6.970478860779394e-09
candidate O 0 1.8535340018388524e-07
for O 0 1.9470673962018736e-08
conferring O 0 0.00027071419754065573
susceptibility O 0 0.3253401815891266
to O 0 1.688577322056517e-05
diabetes B-Disease 0 0.2740861177444458
. O 0 3.715678758453578e-05

The O 0 1.7499452269476024e-06
gene O 0 2.499798938515596e-06
, O 0 8.924602923343627e-08
termed O 0 1.0445372709000367e-06
low O 0 5.993763920741912e-07
- O 0 3.253764589317143e-05
density O 0 2.822581109285238e-06
lipoprotein O 0 0.0021756202913820744
receptor O 0 3.2242103316093562e-06
related O 0 4.580186612201942e-07
protein O 0 1.4126517555723694e-07
5 O 0 1.252377757055001e-08
( O 0 6.682291608939295e-09
LRP5 O 0 1.94427884707693e-05
) O 0 2.4529336339895735e-09
, O 0 7.238725729941109e-10
encodes O 0 3.343451737691794e-09
a O 0 1.893496248683846e-09
protein O 0 4.4802241916386265e-09
of O 0 1.2082740363794642e-09
1615 O 0 1.1077383533120155e-05
amino O 0 2.2847912006795923e-08
acids O 0 5.5947553256885385e-09
that O 0 5.87909554372601e-10
contains O 0 1.718909348191744e-09
conserved O 0 3.46261188610697e-08
modules O 0 6.515085715363966e-08
which O 0 1.784664527271218e-09
are O 0 3.5750521987232275e-10
characteristic O 0 1.4181613217090216e-08
of O 0 1.5546122167364729e-09
the O 0 2.196893333916705e-08
low O 0 1.439114839740796e-06
- O 0 0.0008336352766491473
density O 0 2.585564106993843e-05
lipoprotein O 1 0.5005070567131042
( O 0 6.378953685270972e-07
LDL O 0 0.0002779209753498435
) O 0 8.716435218047991e-08
receptor O 0 2.1665182430297136e-06
family O 0 1.6243943719018716e-06
. O 0 1.6468261492263991e-06

These O 0 4.4213803107595595e-07
modules O 0 1.1817536460512201e-06
include O 0 5.965217297898562e-08
a O 0 2.060883375065714e-08
putative O 0 4.432747118698899e-06
signal O 0 2.6489797733120213e-07
peptide O 0 5.063368035962412e-08
for O 0 6.12330519622617e-10
protein O 0 7.420120962109422e-09
export O 0 8.452510691370207e-09
, O 0 2.4981761104214684e-09
four O 0 1.7097745441674306e-08
epidermal O 0 0.0001148819865193218
growth O 0 1.9519256966304965e-06
factor O 0 8.777379889579606e-08
( O 0 2.9634920295507072e-08
EGF O 0 8.2313372331555e-06
) O 0 6.686128983801609e-09
repeats O 0 9.404278955571499e-08
with O 0 5.155693205693979e-09
associated O 0 9.789781785229934e-08
spacer O 0 4.468945462576812e-06
domains O 0 5.64713502626546e-07
, O 0 1.3964783107667245e-08
three O 0 1.5775652784100203e-08
LDL O 0 9.978462912840769e-05
- O 0 0.00011144417658215389
receptor O 0 2.8398155791364843e-06
( O 0 3.588753827443725e-08
LDLR O 0 8.304096991196275e-05
) O 0 6.491206239189751e-09
repeats O 0 7.510110577868545e-08
, O 0 1.3367438267408716e-09
a O 0 2.2324928572459157e-09
single O 0 6.331389101887908e-08
transmembrane O 0 2.219244561274536e-05
spanning O 0 6.693283012282336e-07
domain O 0 6.06166423722243e-08
, O 0 4.368425177148083e-09
and O 0 6.462274271257229e-09
a O 0 9.903121878096499e-08
cytoplasmic O 0 2.0738680177601054e-05
domain O 0 3.084645641138195e-06
. O 0 2.5871670459309826e-06

The O 0 8.985157364804763e-07
encoded O 0 9.590810350346146e-07
protein O 0 7.118401299521793e-07
has O 0 2.7561629423189515e-08
a O 0 1.4452219865290772e-08
unique O 0 8.560080999586717e-08
organization O 0 1.270557614674317e-08
of O 0 3.937002279741364e-09
EGF O 0 2.8965307137696072e-05
and O 0 5.275030900975253e-08
LDLR O 0 0.001335888635367155
repeats O 0 3.7331024032027926e-06
; O 0 4.1777589387947955e-08
therefore O 0 6.057975010520522e-09
, O 0 4.791978369667049e-09
LRP5 O 0 7.296655530808493e-05
likely O 0 5.8460255303316444e-08
represents O 0 1.1712965708454703e-08
a O 0 7.087841868980149e-09
new O 0 1.6035642147471663e-08
category O 0 1.0883258738658697e-07
of O 0 4.571726552882183e-09
the O 0 1.0765166535975368e-07
LDLR O 0 0.01603434607386589
family O 0 3.7878994589846116e-06
. O 0 3.289125515948399e-06

Both O 0 7.975781386448944e-07
human O 0 7.389926395262592e-07
and O 0 6.97502997581978e-08
mouse O 0 1.0669387847883627e-05
LRP5 O 0 0.0024704295210540295
cDNAs O 0 4.304469985072501e-05
have O 0 1.533737226111498e-08
been O 0 6.216830161775988e-09
isolated O 0 2.6443750300586544e-08
and O 0 2.2958683842944083e-09
the O 0 1.9170993681427717e-09
encoded O 0 3.1913621967305517e-08
mature O 0 8.039366150569549e-08
proteins O 0 2.571088675296096e-09
are O 0 4.735930536625688e-10
95 O 0 6.306606348260857e-09
% O 0 1.4987627139362303e-08
identical O 0 1.8264338450535433e-06
, O 0 2.934188714220909e-08
indicating O 0 7.405193400700227e-07
a O 0 4.128377995016308e-08
high O 0 8.050012638705084e-07
degree O 0 5.40050507424894e-07
of O 0 3.636539247509063e-08
evolutionary O 0 2.0383313312777318e-05
conservation O 0 2.252487320220098e-06
. O 0 1.7703760590848105e-07
. O 0 1.4471964959739125e-06

The O 0 1.5210579249469447e-06
APC B-Disease 0 7.435590759996558e-06
variants O 0 1.3129108538123546e-06
I1307K O 0 6.882895831950009e-06
and O 0 5.7833528188666605e-08
E1317Q O 0 1.5418670955114067e-05
are O 0 4.1147934837226785e-08
associated O 0 2.806254633469507e-05
with O 1 0.796367347240448
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.1099655188882025e-06
but O 0 2.664098630589251e-08
not O 0 3.7023251131529378e-09
always O 0 1.082093081805624e-08
with O 0 4.128611674758531e-09
a O 0 8.340092705338975e-08
family O 0 6.2413135992756e-07
history O 0 3.4981646876985906e-06
. O 0 3.3458445614087395e-06

Classical O 0 0.22890602052211761
familial B-Disease 1 0.9999182224273682
adenomatous I-Disease 1 0.9999526739120483
polyposis I-Disease 1 0.9999716281890869
( O 0 8.849520236253738e-05
FAP B-Disease 0 0.0038364867214113474
) O 0 1.5413907306083274e-07
is O 0 1.827343076854504e-08
a O 0 5.364962518683569e-08
high O 0 3.3421674743294716e-05
- O 1 0.9943267703056335
penetrance O 1 0.9997351765632629
autosomal B-Disease 1 0.9557620882987976
dominant I-Disease 0 0.06090841442346573
disease I-Disease 0 0.003915876150131226
that O 0 7.602276497209459e-08
predisposes O 0 1.2684272405749653e-05
to O 0 7.419413527998131e-09
hundreds O 0 1.6291396676137992e-08
or O 0 1.6064417351913107e-08
thousands O 0 3.0614677370977006e-07
of O 0 4.052472286275588e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999982118606567
and I-Disease 0 0.15918785333633423
carcinoma I-Disease 1 0.9999991655349731
and O 0 3.5065741599282774e-07
that O 0 3.116274882586367e-08
results O 0 4.042860837216722e-07
from O 0 2.8543635011146762e-08
truncating O 0 0.00012260150106158108
mutations O 0 1.8126387431038893e-06
in O 0 1.9272924589586182e-08
the O 0 5.836555416749434e-08
APC B-Disease 0 3.056110654142685e-05
gene O 0 5.702928774553584e-06
. O 0 2.806393695209408e-06

A O 0 9.633173249312676e-06
variant O 0 3.703519905684516e-05
of O 0 8.933303661251557e-07
FAP B-Disease 0 0.01682019792497158
is O 0 1.6327550838468596e-05
attenuated B-Disease 1 0.9671472907066345
adenomatous I-Disease 1 0.9999692440032959
polyposis I-Disease 1 0.999943733215332
coli I-Disease 1 0.960602343082428
, O 0 2.1726104648678302e-07
which O 0 1.581620701074371e-08
results O 0 9.514425158840822e-08
from O 0 2.5473619658100688e-08
germ O 0 0.029077284038066864
- O 0 0.0003084327036049217
line O 0 2.5709093733894406e-06
mutations O 0 1.2649277891796373e-07
in O 0 1.5518274443238056e-09
the O 0 1.386672998648919e-09
5 O 0 4.861243407816573e-09
and O 0 1.955783313078996e-09
3 O 0 1.0540929906710517e-08
regions O 0 1.7182612666033492e-08
of O 0 3.180331331620323e-09
the O 0 7.644705846132638e-08
APC B-Disease 0 4.9250964366365224e-05
gene O 0 5.524270818568766e-06
. O 0 1.714855216050637e-06

Attenuated B-Disease 1 0.9979739785194397
adenomatous I-Disease 1 0.9999172687530518
polyposis I-Disease 1 0.9999613761901855
coli I-Disease 1 0.999908447265625
patients O 0 0.023974251002073288
have O 0 1.7426642671125592e-06
" O 0 8.370793125322962e-07
multiple O 0 9.077676077140495e-05
" O 0 0.03817112743854523
colorectal B-Disease 1 0.9999997615814209
adenomas I-Disease 1 0.9999692440032959
( O 0 3.3851250691441237e-07
typically O 0 6.585913325807269e-08
fewer O 0 1.5228236449615906e-08
than O 0 2.684725775026209e-09
100 O 0 5.086373544571643e-09
) O 0 3.0201710021771078e-09
without O 0 5.201226560558325e-09
the O 0 2.3284329131456616e-08
florid O 0 0.08982399106025696
phenotype O 0 0.0005152752855792642
of O 0 6.78300793310882e-08
classical O 0 1.3547134585678577e-05
FAP B-Disease 0 0.0009652231819927692
. O 0 4.1490229705232196e-06

Another O 0 3.636279870988801e-06
group O 0 7.237661066028522e-07
of O 0 5.458103302657946e-08
patients O 0 8.774514981269022e-07
with O 0 1.0274956707689853e-07
multiple O 0 8.842888928484172e-05
adenomas B-Disease 1 0.7443745732307434
has O 0 3.428616253131622e-07
no O 0 1.739992541160973e-07
mutations O 0 6.305135684669949e-07
in O 0 8.605241852421841e-09
the O 0 1.0155304153158795e-08
APC B-Disease 0 4.364240339782555e-06
gene O 0 1.1856249670927355e-07
, O 0 5.979111872278509e-09
and O 0 7.36029903691815e-09
their O 0 5.046533857466784e-08
phenotype O 0 0.007709452882409096
probably O 0 3.76242809352334e-07
results O 0 7.29710620817059e-08
from O 0 2.5863111652313364e-09
variation O 0 8.222922076583927e-08
at O 0 8.884788016416678e-09
a O 0 3.084943145381658e-08
locus O 0 4.091217761015287e-06
, O 0 1.8596702844320134e-08
or O 0 8.364462900090075e-09
loci O 0 1.9945059648307506e-07
, O 0 1.497751078716192e-08
elsewhere O 0 1.3048382641045464e-07
in O 0 1.7179990763338537e-08
the O 0 8.801084305787299e-08
genome O 0 2.638679143274203e-05
. O 0 1.7726242731441744e-06

Recently O 0 4.4596061343327165e-05
, O 0 1.5937798991672025e-07
however O 0 3.5204958948042986e-08
, O 0 6.993304157987268e-09
a O 0 2.5474541587300337e-08
missense O 0 6.434537499444559e-05
variant O 0 2.6196166800218634e-06
of O 0 9.843365234019075e-09
APC B-Disease 0 9.520935236650985e-06
( O 0 1.6260260693456985e-08
I1307K O 0 3.2144041597348405e-06
) O 0 2.089989292741734e-09
was O 0 5.396312285910199e-09
described O 0 1.3969703616112383e-07
that O 0 4.740849490758592e-09
confers O 0 1.2824361874663737e-06
an O 0 8.294211539805474e-09
increased O 0 4.300202817830723e-06
risk O 0 7.64199867262505e-05
of O 0 0.022748379036784172
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 5.8004479797091335e-06
including O 0 5.218619207880693e-07
multiple O 0 6.831438804510981e-05
adenomas B-Disease 0 0.23683711886405945
, O 0 4.316908359669469e-07
in O 0 7.830846016076976e-07
Ashkenazim O 0 0.00032142948475666344
. O 0 5.893927209399408e-06

We O 0 7.429612196574453e-07
have O 0 3.99062969336228e-08
studied O 0 3.8606717822631254e-08
a O 0 5.5559938871851955e-09
set O 0 7.796179701813344e-09
of O 0 7.1650472222017925e-09
164 O 0 1.8582983102533035e-05
patients O 0 4.802008788828971e-06
with O 0 7.029875632724725e-06
multiple O 1 0.9973621964454651
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999922513961792
and I-Disease 0 0.00011060758697567508
/ I-Disease 0 0.2058558464050293
or I-Disease 0 7.498438935726881e-05
carcinoma I-Disease 1 0.9999972581863403
and O 0 9.60399916039023e-07
analyzed O 0 4.004417860414833e-06
codons O 0 2.3613245048181852e-06
1263 O 0 5.165536276763305e-05
- O 0 0.00016824895283207297
1377 O 0 0.00021745481353718787
( O 0 3.179908603101467e-08
exon O 0 1.694717320788186e-05
15G O 0 1.2505642189353239e-05
) O 0 1.6657255574870078e-09
of O 0 4.737863990023072e-10
the O 0 2.6604816127928643e-09
APC B-Disease 0 3.2114061809807026e-07
gene O 0 2.6995307322863482e-08
for O 0 1.7732645574142225e-08
germ O 0 0.017098335549235344
- O 0 0.00053584692068398
line O 0 6.615211987082148e-06
variants O 0 4.40842177340528e-06
. O 0 1.8957576912725926e-06

Three O 0 2.857626441254979e-06
patients O 0 1.9074914234806783e-06
with O 0 2.3494539647117563e-08
the O 0 3.105251167312417e-08
I1307K O 0 3.25505570799578e-05
allele O 0 1.5849840337978094e-06
were O 0 1.533307170120679e-08
detected O 0 6.010891411278863e-07
, O 0 2.464827231207778e-09
each O 0 2.766684881194692e-09
of O 0 5.7323742197468164e-08
Ashkenazi O 0 5.03063274663873e-05
descent O 0 0.00011494544014567509
. O 0 4.205519871902652e-06

Four O 0 9.918063369696029e-06
patients O 0 1.1617664313234854e-05
had O 0 1.2451222630716074e-07
a O 0 2.3279049798929918e-07
germ O 0 0.028513558208942413
- O 0 0.00015087523206602782
line O 0 1.0210433174506761e-06
E1317Q O 0 9.8395103123039e-06
missense O 0 6.237384695850778e-06
variant O 0 2.631768722949346e-07
of O 0 4.500299244369899e-09
APC O 0 1.029463760460203e-06
that O 0 6.2569673886514465e-09
was O 0 6.892871606822837e-09
not O 0 1.0155454255311724e-09
present O 0 5.779259293348105e-09
in O 0 5.735980135312957e-09
controls O 0 7.039477623038692e-08
; O 0 1.0581056031355729e-08
one O 0 5.397524649453089e-10
of O 0 1.1092590179728745e-09
these O 0 5.5409978827469786e-09
individuals O 0 1.2288857043074586e-08
had O 0 1.2432813001339582e-08
an O 0 3.3433753543476996e-09
unusually O 0 1.7237913425560691e-06
large O 0 3.429276063116049e-08
number O 0 6.09787642602555e-09
of O 0 1.0783987924867233e-08
metaplastic B-Disease 0 0.003631551517173648
polyps I-Disease 0 4.6116969315335155e-05
of I-Disease 0 3.257970249137543e-08
the I-Disease 0 4.0906260778683645e-07
colorectum I-Disease 0 0.0022379381116479635
. O 0 5.242720817477675e-06

There O 0 9.85869860414823e-07
is O 0 5.4227498935688345e-08
increasing O 0 6.825836607049496e-08
evidence O 0 5.464822194767294e-08
that O 0 6.716370126724769e-09
there O 0 6.126228857539218e-09
exist O 0 5.471737196671711e-08
germ O 0 0.00012648435949813575
- O 0 1.146636077464791e-05
line O 0 5.687059001502348e-08
variants O 0 8.447610611028722e-09
of O 0 5.814105308310502e-10
the O 0 5.170346817351401e-09
APC B-Disease 0 7.872703804423509e-07
gene O 0 3.700371919990175e-08
that O 0 3.1085678475761824e-09
predispose O 0 1.3894010919557331e-07
to O 0 1.918214920237915e-09
the O 0 4.281016430240925e-09
development O 0 3.902903245034395e-08
of O 0 4.131695163778204e-07
multiple O 1 0.9968750476837158
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.999998927116394
and I-Disease 0 0.445656418800354
carcinoma I-Disease 1 0.9999996423721313
, O 0 9.43372072015336e-07
but O 0 1.6491169319010623e-08
without O 0 6.5897056700237044e-09
the O 0 1.3757565753280687e-08
florid O 0 0.03491586819291115
phenotype O 0 0.00014474130875896662
of O 0 3.4263842874082684e-09
classical O 0 7.834580628696131e-07
FAP B-Disease 0 2.7384719942347147e-05
, O 0 1.2955430506167431e-08
and O 0 9.546797130610685e-09
possibly O 0 5.030158689578457e-08
with O 0 2.332095228041453e-08
importance O 0 5.459104158944683e-06
for O 0 0.0833006426692009
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
risk O 0 0.0001949344587046653
in O 0 3.9868481849225645e-08
the O 0 1.3753892247336807e-08
general O 0 1.0808125239236688e-07
population O 0 7.487884090551233e-08
. O 0 1.585086693012272e-07
. O 0 1.2392148391882074e-06

Genomic O 0 0.0004834263236261904
structure O 0 9.125198630499654e-06
of O 0 9.892946195577679e-08
the O 0 1.835983198361646e-06
human O 0 0.005881090648472309
congenital B-Disease 1 0.9999947547912598
chloride I-Disease 1 0.9999071359634399
diarrhea I-Disease 1 0.9999963045120239
( O 0 9.278441575588658e-05
CLD B-Disease 1 0.965339720249176
) O 0 1.5314183201553533e-06
gene O 0 6.677441433566855e-06
. O 0 4.38817914982792e-06

Congenital B-Disease 1 0.9999854564666748
chloride I-Disease 1 0.9998247027397156
diarrhea I-Disease 1 0.999990701675415
( O 0 8.628199429949746e-05
CLD B-Disease 1 0.981964647769928
) O 0 1.6188921847515303e-07
is O 0 4.3299287710851786e-08
caused O 0 6.548748956447525e-07
by O 0 9.15903015652475e-08
mutations O 0 2.7950368348683696e-06
in O 0 1.0600811783945119e-08
a O 0 2.2500982410633696e-08
gene O 0 5.5429769219017544e-08
which O 0 7.761195242039776e-09
encodes O 0 1.5457509050520457e-07
an O 0 4.6295556899167423e-07
intestinal O 1 0.9950451850891113
anion O 1 0.5974056720733643
transporter O 0 0.004475634079426527
. O 0 4.668652763939463e-06

We O 0 1.1442571121733636e-06
report O 0 3.6347299214867235e-07
here O 0 1.1032417646106296e-08
the O 0 4.3242156522182995e-09
complete O 0 9.882630536139914e-08
genomic O 0 2.2269073269853834e-06
organization O 0 1.3178110158662548e-08
of O 0 1.5682343201817162e-09
the O 0 1.4442465889885625e-08
human O 0 6.626435151702026e-07
CLD B-Disease 0 0.021575164049863815
gene O 0 1.6210735509503138e-07
which O 0 9.984350235470174e-09
spans O 0 2.1571304387180135e-07
approximately O 0 1.3882879734694598e-08
39kb O 0 2.0309251340222545e-05
, O 0 1.4337509846029661e-08
and O 0 1.4225717492877266e-08
comprises O 0 1.4934755654394394e-07
21 O 0 4.940097824146505e-07
exons O 0 1.1947344319196418e-05
. O 0 3.572095465642633e-06

All O 0 6.341661560327339e-07
exon O 0 0.00019255162624176592
/ O 0 2.855979801097419e-05
intron O 0 2.7883015718543902e-05
boundaries O 0 1.2637063662168657e-07
conform O 0 2.273864225799116e-07
to O 0 7.75671082919871e-09
the O 0 4.211127802022929e-08
GT O 0 0.00023585835879202932
/ O 0 0.0007735975668765604
AG O 1 0.6164055466651917
rule O 0 2.9129851100151427e-06
. O 0 2.785951437545009e-06

An O 0 2.780913632705051e-07
analysis O 0 1.2971581497822626e-07
of O 0 8.081302738105478e-09
the O 0 3.8174846395122586e-08
putative O 0 4.4073920435039327e-05
promoter O 0 2.034967292274814e-05
region O 0 1.6906244582060026e-07
sequence O 0 6.044496103640995e-08
shows O 0 1.96731892998514e-08
a O 0 2.1236603586771707e-08
putative O 0 1.8445178284309804e-05
TATA O 0 0.0007103016832843423
box O 0 3.510245278448565e-06
and O 0 7.744045404933786e-08
predicts O 0 2.0665200281655416e-05
multiple O 0 2.5250719204450434e-07
transcription O 0 2.0103330200527125e-07
factor O 0 1.5611925618941314e-07
binding O 0 4.847311174671631e-07
sites O 0 2.2515894215757726e-06
. O 0 1.7877287064038683e-06

The O 0 2.118362090186565e-06
genomic O 0 0.00010253814980387688
structure O 0 6.427565040212357e-06
was O 0 6.271821462178195e-08
determined O 0 6.52101590503662e-08
using O 0 7.2592749589261985e-09
DNA O 0 8.67992042685728e-08
from O 0 1.881174327422741e-09
several O 0 1.4892103106234345e-09
sources O 0 6.639413463460642e-09
including O 0 3.814963900339308e-09
multiple O 0 3.703817341715876e-08
large O 0 8.857617928015316e-08
- O 0 3.684500916278921e-05
insert O 0 2.4312491859745933e-06
libaries O 0 1.4209727851266507e-05
and O 0 1.1623477291777817e-08
genomic O 0 7.599448395012587e-07
DNA O 0 9.565187610860448e-07
from O 0 1.722386571145762e-07
Finnish O 0 0.07822155207395554
CLD B-Disease 1 0.9978916049003601
patients O 0 2.741568641795311e-05
and O 0 1.1997213960057707e-06
controls O 0 2.867222974600736e-05
. O 0 9.282317478209734e-06

Exon O 0 0.000382595753762871
- O 0 3.463157918304205e-05
specific O 0 2.1830179264270555e-07
primers O 0 7.807313522789627e-06
developed O 0 2.1120915505434823e-07
in O 0 1.5520415175274138e-08
this O 0 8.336686008192373e-09
study O 0 2.476354765690303e-08
will O 0 6.039285516123982e-09
facilitate O 0 7.052674533269965e-08
mutation O 0 1.9388755845284322e-06
screening O 0 3.680704878661345e-07
studies O 0 5.0459753708764765e-08
of O 0 1.3523416164673563e-08
patients O 0 1.5896069953669212e-06
with O 0 3.105233474798297e-07
the O 0 3.0078419513301924e-05
disease O 0 0.10504403710365295
. O 0 1.3744808711635415e-05

Genomic O 0 0.00010418688907520846
sequencing O 0 7.578996701340657e-06
of O 0 1.500668531662086e-07
a O 0 5.206778155297798e-07
BAC O 0 8.012543548829854e-05
clone O 0 0.000159736824571155
H O 1 0.9912057518959045
_ O 0 9.313354780715599e-07
RG364P16 O 0 7.698061381233856e-06
revealed O 0 4.336743870680948e-07
the O 0 2.3735364784727153e-09
presence O 0 1.1125989907156963e-08
of O 0 8.515680938181447e-10
another O 0 1.0052817245309598e-08
, O 0 2.8919715511221966e-09
highly O 0 1.3150139643869352e-08
homologous O 0 1.787971228850438e-07
gene O 0 3.274822901744301e-08
3 O 0 2.010559496667952e-09
of O 0 1.00625963117551e-09
the O 0 8.752888192020691e-08
CLD B-Disease 0 0.1890752911567688
gene O 0 2.789551274418045e-07
, O 0 2.3234363322188756e-09
with O 0 1.6091394883233079e-09
a O 0 2.561725942484827e-08
similar O 0 4.80914422951173e-07
genomic O 0 4.7567562432959676e-05
structure O 0 4.527146302280016e-06
, O 0 1.274117789051843e-08
recently O 0 1.7978160826714884e-07
identified O 0 1.5933787267385924e-07
as O 0 2.9213616414835997e-08
the O 0 6.9427364906005096e-06
Pendred B-Disease 1 0.9999983310699463
syndrome I-Disease 1 0.9999988079071045
gene O 0 2.5975579774240032e-05
( O 0 2.8070257940271404e-07
PDS B-Disease 0 0.00013703934382647276
) O 0 1.1154359924603341e-07
. O 0 2.2472123362149432e-07
. O 0 1.7155568912130548e-06

The O 0 5.984339622955304e-06
APCI1307K O 0 0.026514653116464615
allele O 0 0.0005784006789326668
and O 0 1.8179507605964318e-05
cancer B-Disease 1 0.6018410325050354
risk O 0 1.4953020581742749e-05
in O 0 5.8851714612728756e-08
a O 0 3.741905629794928e-08
community O 0 5.484996989935098e-08
- O 0 9.772463090484962e-05
based O 0 2.2117416165201575e-07
study O 0 6.26783887014426e-08
of O 0 2.2272754307550713e-08
Ashkenazi O 0 1.0197431947744917e-05
Jews O 0 2.3419386252498953e-06
. O 0 3.6753874610440107e-06

Mutations O 0 0.0036256725434213877
in O 0 6.096255674492568e-06
APC O 0 0.00013658119132742286
are O 0 6.734067596880777e-07
classically O 0 0.21014444530010223
associated O 0 5.5221975344466045e-05
with O 0 0.00010528228449402377
familial B-Disease 1 0.9999953508377075
adenomatous I-Disease 1 0.9999955892562866
polyposis I-Disease 1 0.9999969005584717
( O 0 8.166329280356877e-06
FAP B-Disease 0 0.0004382629704196006
) O 0 6.959083975743852e-08
, O 0 1.5509110440348195e-08
a O 0 3.615121784150688e-07
highly O 0 0.0037838537245988846
penetrant O 1 0.9999725818634033
autosomal B-Disease 1 0.9999839067459106
dominant I-Disease 1 0.9896262884140015
disorder I-Disease 1 0.9997021555900574
characterized O 0 0.0004081962106283754
by O 0 4.893129698757548e-06
multiple O 0 0.09921970218420029
intestinal O 1 0.999983549118042
polyps B-Disease 0 0.24472008645534515
and O 0 1.9301478459965438e-07
, O 0 2.9287427594226756e-08
without O 0 3.569856943386185e-08
surgical O 0 2.7605390641838312e-05
intervention O 0 4.0640404108671646e-07
, O 0 1.2510217750616448e-08
the O 0 1.0488906632133421e-08
development O 0 9.327709449280519e-07
of O 0 0.004270981065928936
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
( O 0 6.083416155888699e-05
CRC B-Disease 0 0.03648075833916664
) O 0 1.2480828672778443e-06
. O 0 2.2764795630791923e-06

APC B-Disease 0 0.0003341536794323474
is O 0 9.358718102703278e-07
a O 0 2.122335672538611e-06
tumour O 1 0.9994801878929138
- O 0 0.0021670679561793804
suppressor O 0 9.49593450059183e-05
gene O 0 1.7286924958170857e-07
, O 0 4.497390015956171e-09
and O 0 2.1858172161159928e-08
somatic O 0 3.709666998474859e-05
loss O 0 0.00046893759281374514
occurs O 0 1.895988498290535e-05
in O 0 1.171555049950257e-05
tumours B-Disease 1 0.9996620416641235
. O 0 2.363753992540296e-05

The O 0 4.988871296518482e-06
germline O 0 0.005863842088729143
T O 0 0.0004503767122514546
- O 0 4.8821807467902545e-06
to O 0 9.34783539463524e-09
- O 0 2.3637219328520587e-06
A O 0 6.860281587250938e-08
transversion O 0 2.4057531845755875e-05
responsible O 0 1.3058087944273211e-08
for O 0 7.540389423965621e-10
the O 0 5.367907895958979e-09
APC O 0 9.115319130614807e-07
I1307K O 0 1.5865174418649985e-06
allele O 0 6.232528448890662e-08
converts O 0 8.782634175474868e-09
the O 0 2.9557227776422224e-09
wild O 0 7.568132787127979e-08
- O 0 5.009677352063591e-06
type O 0 1.6120502266403491e-07
sequence O 0 3.172995732825257e-08
to O 0 1.80970116669954e-09
a O 0 7.761864395661178e-08
homopolymer O 0 0.3106493353843689
tract O 0 0.002658188110217452
( O 0 5.2427530761178787e-08
A8 O 0 0.00022827716020401567
) O 0 6.50471498886418e-09
that O 0 4.9742752139536606e-09
is O 0 1.7032579791020908e-08
genetically O 0 7.147236829041503e-07
unstable O 0 4.6237804781412706e-05
and O 0 3.285562684141041e-07
prone O 0 0.00016640395915601403
to O 0 1.9682090623973636e-07
somatic O 0 0.0008239319431595504
mutation O 0 0.0002585910842753947
. O 0 7.310030468943296e-06

The O 0 2.345125722058583e-06
I1307K O 0 9.747297008289024e-05
allele O 0 1.1037195690732915e-05
was O 0 1.660521462554243e-07
found O 0 1.0745002754219968e-07
in O 0 1.3750093330600066e-07
6 O 0 1.975157829292584e-06
. O 0 3.2588952763035195e-06

1 O 0 1.903028760352754e-06
% O 0 2.408716852642101e-07
of O 0 6.252281536944793e-08
unselected O 0 0.000970709603279829
Ashkenazi O 0 5.565898845816264e-06
Jews O 0 7.260523915419981e-08
and O 0 2.4683476596010223e-08
higher O 0 1.12845533806194e-07
proportions O 0 1.3791451465294813e-06
of O 0 3.495310263446072e-09
Ashkenazim O 0 9.770062661118573e-07
with O 0 2.3442435548304275e-08
family O 0 8.337547541259482e-08
or O 0 2.0786997012578468e-08
personal O 0 7.89586238170159e-07
histories O 0 2.758182745310478e-06
of O 0 8.414808405632357e-08
CRC B-Disease 0 0.004504153039306402
( O 0 2.1730249954998726e-07
ref O 0 0.0034104783553630114
. O 0 2.0361470731700138e-08
2 O 0 8.889979596915509e-08
) O 0 1.129844449110351e-07
. O 0 1.08762503714388e-06

To O 0 6.321542400655744e-07
evaluate O 0 1.713037477202306e-06
the O 0 1.1190603999011728e-08
role O 0 1.4458396258021367e-08
of O 0 7.796030487838834e-09
I1307K O 0 0.00011169142089784145
in O 0 2.870992375392234e-06
cancer B-Disease 0 0.0010121539235115051
, O 0 2.2302979019173108e-08
we O 0 1.4588424690487045e-08
genotyped O 0 1.4873771760903765e-05
5 O 0 4.415531051904509e-08
, O 0 2.641088414634396e-08
081 O 0 0.00018906823243014514
Ashkenazi O 0 2.4818525616865372e-06
volunteers O 0 1.5012753351584252e-07
in O 0 1.849556952038256e-08
a O 0 8.352525782129305e-08
community O 0 2.731490837959427e-07
survey O 0 3.4248434531036764e-05
. O 0 2.6258396701450692e-06

Risk O 0 0.00018804737192112952
of O 0 1.9184192296961555e-06
developing O 0 0.006048743613064289
colorectal B-Disease 1 0.9999908208847046
, I-Disease 0 3.4058284654747695e-05
breast I-Disease 0 0.0033595594577491283
and I-Disease 0 5.401731186793768e-07
other I-Disease 0 2.736697695127077e-07
cancers I-Disease 0 0.0863327607512474
were O 0 5.036350714249238e-08
compared O 0 1.5866504554651328e-06
between O 0 4.924284269236523e-08
genotyped O 0 0.003697392763569951
I1307K O 0 5.0835606089094654e-05
carriers O 0 1.7092925475026277e-07
and O 0 6.601481139512089e-09
non O 0 3.594055542066599e-08
- O 0 1.0912740435742307e-05
carriers O 0 2.1082598777866224e-07
and O 0 6.77403289017775e-09
their O 0 4.748596182935216e-09
first O 0 3.7674865893677634e-08
- O 0 0.00021123462647665292
degree O 0 1.5310828530346043e-05
relatives O 0 4.278017513570376e-05
. O 0 9.956310350389685e-06

Sperm O 0 0.0004948099376633763
DNA O 0 7.0928581408225e-05
analysis O 0 3.3915241601789603e-06
in O 0 3.634452809819777e-07
a O 0 3.11525832330517e-06
Friedreich B-Disease 1 0.9910305738449097
ataxia I-Disease 1 0.982239842414856
premutation O 0 0.22187232971191406
carrier O 0 8.103738218778744e-05
suggests O 0 2.3542700944290118e-07
both O 0 4.85281326234599e-09
meiotic O 0 7.68829067965271e-06
and O 0 3.3248966246901546e-08
mitotic O 0 1.0258101610816084e-05
expansion O 0 3.502119341192156e-07
in O 0 2.8753241565482313e-08
the O 0 7.739836860309879e-08
FRDA B-Disease 0 0.0012278050417080522
gene O 0 7.832190931367222e-06
. O 0 1.8986073655469227e-06

Friedreich B-Disease 1 0.9989756345748901
ataxia I-Disease 1 0.9982962012290955
is O 0 6.678052614006447e-06
usually O 0 1.1049824024667032e-06
caused O 0 9.602745194570161e-07
by O 0 4.887442006662468e-09
an O 0 2.1500368152516103e-09
expansion O 0 6.565720411799703e-08
of O 0 3.0825475505480426e-09
a O 0 1.008612429131972e-07
GAA O 0 2.5693339921417646e-05
trinucleotide O 0 9.033153764903545e-05
repeat O 0 4.6942159315221943e-07
in O 0 1.1138665989562924e-08
intron O 0 3.5988896343042143e-06
1 O 0 5.705983685544425e-09
of O 0 3.042981866485661e-09
the O 0 1.0076356460331226e-07
FRDA B-Disease 0 0.0038782120682299137
gene O 0 5.956133009021869e-06
. O 0 1.5899253185125417e-06

Occasionally O 0 1.4705819921800867e-05
, O 0 1.8874203533414402e-07
a O 0 4.272958875617405e-08
fully O 0 8.825576003346214e-08
expanded O 0 1.3724284997351788e-07
allele O 0 4.965528432876454e-07
has O 0 6.829454335388618e-09
been O 0 4.766254502186484e-09
found O 0 1.601400079209725e-08
to O 0 8.894571301709675e-09
arise O 0 3.707479550030257e-07
from O 0 2.8404802954185016e-09
a O 0 1.9154008157329372e-08
premutation O 0 1.3767871678282972e-05
of O 0 3.9458356582144916e-09
100 O 0 1.26192354343857e-08
or O 0 3.3989305592285746e-08
less O 0 2.7276539071863226e-07
triplet O 0 0.07050345838069916
repeats O 0 0.00010396439029136673
. O 0 2.3527263692812994e-06

We O 0 9.649065759731457e-07
have O 0 5.515557077728772e-08
examined O 0 2.460130019699136e-07
the O 0 1.017154982463353e-08
sperm O 0 5.476131832438114e-07
DNA O 0 2.0418431745383714e-07
of O 0 1.1512912401201447e-08
a O 0 4.1734185174391314e-07
premutation O 0 0.009485713206231594
carrier O 0 0.00018593212007544935
. O 0 2.7425239750300534e-06

This O 0 7.809210842424363e-07
mans O 0 1.0086399925057776e-05
leucocyte O 0 0.00022001672186888754
DNA O 0 5.403449904406443e-06
showed O 0 9.162173455479206e-07
one O 0 1.937919691386014e-08
normal O 0 6.195478619019923e-08
allele O 0 1.4891406863171142e-07
and O 0 3.946505788832155e-09
one O 0 5.547946102524293e-09
allele O 0 1.3319728964233946e-07
of O 0 4.741383285988832e-09
approximately O 0 3.9729037837332726e-08
100 O 0 1.1633218122142353e-07
repeats O 0 1.303125281992834e-05
. O 0 2.467374315529014e-06

His O 0 4.652394181903219e-06
sperm O 0 3.842150545096956e-05
showed O 0 1.6315361790475436e-06
an O 0 7.384879818772561e-09
expanded O 0 8.294784237250497e-08
allele O 0 4.06005028708023e-07
in O 0 7.250362976662927e-09
a O 0 1.0652781767817032e-08
tight O 0 4.350450808487949e-07
range O 0 2.8620773306897718e-08
centering O 0 3.533425640966925e-08
on O 0 3.884720545244136e-09
a O 0 6.0214913055745e-09
size O 0 7.970385240696487e-08
of O 0 7.82340947580451e-09
approximately O 0 2.5559626237736666e-07
320 O 0 6.421431862690952e-06
trinucleotide O 0 0.0021687813568860292
repeats O 0 7.02559482306242e-05
. O 0 4.693889877671609e-06

His O 0 1.1226434253330808e-05
affected O 0 6.086397661420051e-06
son O 0 5.410596713772975e-06
has O 0 4.701572819953981e-08
repeat O 0 1.2960666708750068e-06
sizes O 0 7.218931727948075e-07
of O 0 2.919562369640971e-08
1040 O 0 6.439048593165353e-05
and O 0 3.2698986274226627e-07
540 O 0 2.1588750314549543e-05
. O 0 2.2662943592877127e-06

These O 0 5.567797529693053e-07
data O 0 5.470124619932903e-07
suggest O 0 1.0372090031296466e-07
that O 0 4.759250771257939e-09
expansion O 0 1.2390880499424384e-07
occurs O 0 2.8677822783151896e-08
in O 0 1.7911336858134064e-09
two O 0 1.4927878932979866e-09
stages O 0 3.828480998890882e-07
, O 0 2.700399681643262e-09
the O 0 5.249321533007389e-10
first O 0 1.99431982039755e-09
during O 0 2.1869766442250693e-08
meiosis O 0 3.271679815952666e-07
followed O 0 9.386641686148778e-09
by O 0 2.0139601097923787e-09
a O 0 1.7250521011646924e-08
second O 0 1.354851661972134e-07
mitotic O 0 0.00015985110076144338
expansion O 0 1.5431911378982477e-05
. O 0 1.6234528175118612e-06

We O 0 6.185618985909969e-07
also O 0 3.849319440973886e-08
show O 0 2.4809404308712146e-08
that O 0 2.1948189932174955e-09
in O 0 1.4358109146073161e-09
all O 0 5.007944059443048e-10
informative O 0 9.754238305959007e-08
carrier O 0 1.3353426311368821e-06
father O 0 9.989172866653462e-08
to O 0 6.104707850340674e-09
affected O 0 8.491230829577034e-08
child O 0 2.227816594313481e-06
transmissions O 0 7.4883209890685976e-06
, O 0 3.182686114655553e-09
with O 0 1.3053995662204443e-09
the O 0 1.8103364363142305e-09
notable O 0 2.185396219545055e-08
exception O 0 1.1616074324649617e-08
of O 0 7.957405845360199e-10
the O 0 5.93547966332153e-09
premutation O 0 0.00011495507351355627
carrier O 0 1.0284422842232743e-06
, O 0 2.7443483041622585e-09
the O 0 2.0630885888550665e-09
expansion O 0 1.7802193497118424e-07
size O 0 2.704293137867353e-06
decreases O 0 7.826403816579841e-06
. O 0 1.372530675780581e-07
. O 0 9.607820175006054e-07

The O 0 3.572313516997383e-06
R496H O 0 0.00013607836444862187
mutation O 0 7.207455837487942e-06
of O 0 6.433768362512637e-08
arylsulfatase O 0 0.00012173803406767547
A O 0 5.135777314535517e-07
does O 0 4.4782740360460593e-07
not O 0 3.3795058129726385e-07
cause O 0 0.00026700535090640187
metachromatic B-Disease 1 0.9997542500495911
leukodystrophy I-Disease 1 0.9998196959495544
. O 0 6.813234358560294e-05

Deficiency B-Disease 1 0.9957507848739624
of I-Disease 0 2.158409188268706e-06
arylsulfatase I-Disease 0 0.001520163263194263
A I-Disease 0 1.6724328588679782e-06
( O 0 2.9389590849859815e-07
ARSA O 0 0.002547699026763439
) O 0 9.790883837013098e-08
enzyme O 0 1.12908230676112e-06
activity O 0 2.5678807560325367e-06
causes O 0 0.0003572596760932356
metachromatic B-Disease 1 0.9999321699142456
leukodystrophy I-Disease 1 0.9999687671661377
( O 0 0.00016088449046947062
MLD B-Disease 1 0.9995724558830261
) O 0 2.6003117454820313e-06
. O 0 2.2775436718802666e-06

A O 0 1.3220326309237862e-06
number O 0 9.684978152790791e-08
of O 0 7.376619493015824e-08
ARSA O 0 0.17772774398326874
gene O 0 9.486277122050524e-06
mutations O 0 3.481507064861944e-06
responsible O 0 1.422305047071859e-07
for O 0 1.6619409848317446e-07
MLD B-Disease 1 0.9998987913131714
have O 0 2.0059991356902174e-07
been O 0 1.8914745680831402e-07
identified O 0 5.323889126884751e-06
. O 0 2.5400659069418907e-06

Recently O 0 1.856427661550697e-05
, O 0 1.9493997172048694e-07
the O 0 4.360203220699077e-08
R496H O 0 1.2595744919963181e-05
mutation O 0 9.30461908410507e-07
of O 0 2.2242824471163658e-08
ARSA O 0 0.005082242656499147
was O 0 5.3333856442350225e-08
proposed O 0 3.0935574102386454e-08
to O 0 2.274884280950573e-09
be O 0 2.922424524598455e-09
a O 0 3.337687104476572e-08
cause O 0 1.6308842987200478e-06
of O 0 3.7858089285691676e-07
MLD B-Disease 1 0.9999849796295166
( O 0 3.5391528285799723e-07
Draghia O 0 0.0012278551002964377
et O 0 3.449630457907915e-05
al O 0 7.2261127570527606e-06
. O 0 1.2779779012817016e-08
, O 0 2.097018025892794e-08
1997 O 0 5.999969516778947e-07
) O 0 1.328923957544248e-07
. O 0 6.693148861813825e-07

We O 0 9.508245284450823e-07
have O 0 5.705180683435174e-08
investigated O 0 2.980543456487794e-07
the O 0 1.758723477962576e-08
R496H O 0 4.202896889182739e-05
mutation O 0 8.681838039592549e-07
and O 0 6.57938192816232e-09
found O 0 1.581617681267744e-08
this O 0 8.388364669542625e-09
mutation O 0 2.7644401257020945e-07
at O 0 5.2164672581511695e-09
a O 0 2.1359934265774427e-08
relatively O 0 1.9197921119484818e-07
high O 0 1.408255911883316e-07
frequency O 0 4.4520895414734696e-08
in O 0 8.351402902562199e-10
an O 0 5.684385739890274e-10
African O 0 3.9208085667041814e-09
American O 0 7.755438957701699e-09
population O 0 5.9456999323970194e-09
( O 0 5.034811678683582e-09
f O 0 1.988196345337201e-06
= O 0 9.351705330118421e-07
0 O 0 1.0358483848449396e-08
. O 0 1.8770418552804813e-09
09 O 0 9.218883434414238e-08
, O 0 4.167807876598317e-09
n O 0 2.2400922716769855e-06
= O 0 1.441808581148507e-05
61 O 0 3.5558588251660694e-07
subjects O 0 1.0671307109078043e-06
) O 0 2.9384011668298626e-07
. O 0 9.014863735501422e-07

The O 0 4.096972133993404e-06
ARSA O 0 0.003896390087902546
enzyme O 0 3.2794096114230342e-06
activity O 0 1.8756867348201922e-07
in O 0 1.8835951465234757e-08
subjects O 0 1.1064960858675477e-07
with O 0 9.540171319599722e-09
and O 0 1.1638118913026574e-08
without O 0 5.333413266583875e-09
the O 0 7.350534403371967e-09
R496H O 0 2.4297853087773547e-05
mutation O 0 9.54210122472432e-07
was O 0 7.327409790036654e-09
determined O 0 3.0273067608277415e-08
and O 0 7.751135733258252e-09
found O 0 1.8616434616092192e-08
to O 0 7.628898401890183e-09
be O 0 3.1609086903472416e-08
normal O 0 1.4960643284211983e-06
. O 0 1.2174955372756813e-06

It O 0 7.462319331352774e-07
is O 0 1.0679477213670907e-07
therefore O 0 6.287199738608251e-08
concluded O 0 8.289106290249038e-08
that O 0 2.594285231083404e-09
the O 0 5.572422079325179e-09
R496H O 0 1.1903172890015412e-05
mutation O 0 3.939138366604311e-07
of O 0 9.263914968471454e-09
ARSA O 0 0.0060036866925656796
does O 0 2.976027246859303e-08
not O 0 1.2590497533437883e-09
negatively O 0 1.5771773220762952e-08
influence O 0 4.506027995176964e-09
the O 0 3.435545847807475e-09
activity O 0 1.3109445085035532e-08
of O 0 6.686128983801609e-09
ARSA O 0 0.0021042439620941877
and O 0 3.16379811238221e-08
is O 0 7.284684855335399e-09
not O 0 4.858073499036664e-09
a O 0 1.7200950708229357e-07
cause O 0 1.7738042515702546e-05
of O 0 9.405097443959676e-06
MLD B-Disease 1 0.9997065663337708

Down O 0 1.1921247278223746e-05
- O 0 1.6077856344054453e-05
regulation O 0 5.685615747097472e-07
of O 0 8.457739397726982e-08
transmembrane O 0 0.0009879461722448468
carbonic O 0 0.0008904557907953858
anhydrases O 0 0.0063626994378864765
in O 0 2.0007493731100112e-05
renal B-Disease 1 0.9998133778572083
cell I-Disease 1 0.9997732043266296
carcinoma I-Disease 1 0.9999990463256836
cell O 0 0.0017843812238425016
lines O 0 1.6213022036026814e-06
by O 0 2.7427953241954128e-08
wild O 0 1.21842720091081e-06
- O 0 0.00043318362440913916
type O 0 0.00021617046149913222
von B-Disease 1 0.9539661407470703
Hippel I-Disease 1 0.9849522709846497
- I-Disease 0 0.20914842188358307
Lindau I-Disease 0 0.4979468882083893
transgenes O 0 0.0033085772302001715
. O 0 1.1063362762797624e-05

To O 0 2.624650505822501e-06
discover O 0 2.29969882639125e-05
genes O 0 9.805092986425734e-07
involved O 0 2.292415359761435e-07
in O 0 7.536132784480287e-07
von B-Disease 1 0.941320538520813
Hippel I-Disease 1 0.9973260164260864
- I-Disease 1 0.9155152440071106
Lindau I-Disease 1 0.9942966103553772
( O 0 9.05026695363631e-07
VHL B-Disease 0 0.0029242823366075754
) O 0 1.498345447714655e-08
- O 0 6.354232937155757e-06
mediated O 0 2.281992055941373e-05
carcinogenesis O 0 0.01313426811248064
, O 0 8.71831389304134e-08
we O 0 4.410438592117316e-08
used O 0 7.794563316565473e-06
renal B-Disease 1 0.9999139308929443
cell I-Disease 1 0.999875545501709
carcinoma I-Disease 1 0.9999992847442627
cell O 0 0.011612314730882645
lines O 0 1.395377330482006e-05
stably O 0 2.0130442862864584e-05
transfected O 0 2.428953484923113e-05
with O 0 3.438366391605996e-08
wild O 0 1.9003373381565325e-06
- O 0 0.0005248481757007539
type O 0 9.702543320599943e-05
VHL O 0 0.04781573638319969
- O 0 0.00021447976178023964
expressing O 0 2.5003162591019645e-05
transgenes O 0 0.0006580448243767023
. O 0 5.3067001317685936e-06

Large O 0 3.6678695778391557e-06
- O 0 1.2621165296877734e-05
scale O 0 4.283879661670653e-06
RNA O 0 2.3350224864771008e-07
differential O 0 4.262628863216378e-07
display O 0 9.914894008034025e-07
technology O 0 6.789311441934842e-07
applied O 0 8.162880149598095e-09
to O 0 1.1965136659242148e-09
these O 0 2.6475732717301526e-09
cell O 0 1.1463913551779115e-06
lines O 0 3.716343144333223e-07
identified O 0 2.219764638766719e-08
several O 0 1.6650838485787745e-09
differentially O 0 2.76576912483506e-07
expressed O 0 3.357685685045908e-08
genes O 0 1.6591309659474973e-08
, O 0 1.961143913931096e-09
including O 0 4.128344333054201e-09
an O 0 8.278690621921214e-09
alpha O 0 3.199296315870015e-06
carbonic O 0 6.930624658707529e-05
anhydrase O 0 8.314049773616716e-05
gene O 0 3.7195343338680686e-07
, O 0 6.209828740111334e-08
termed O 0 5.513481937668985e-06
CA12 O 0 0.002736673690378666
. O 0 4.477083621168276e-06

The O 0 6.698589345432993e-07
deduced O 0 3.7809954847034533e-06
protein O 0 3.469521061560954e-07
sequence O 0 1.2012482386580814e-07
was O 0 1.3857060388033915e-08
classified O 0 3.638447054754579e-08
as O 0 1.257818516009479e-09
a O 0 5.7207603099129756e-09
one O 0 9.605024331449385e-09
- O 0 0.00010536926129134372
pass O 0 2.0995169052184792e-06
transmembrane O 0 0.00809908751398325
CA O 0 2.5762253699213034e-06
possessing O 0 1.6519322798558278e-07
an O 0 3.99574595633112e-09
apparently O 0 4.833223101741169e-07
intact O 0 7.019237955319113e-07
catalytic O 0 1.8867346796014317e-07
domain O 0 3.749779153849886e-08
in O 0 1.3963903811031741e-08
the O 0 5.210414144585229e-08
extracellular O 0 2.7953090466326103e-05
CA O 0 6.341996049741283e-05
module O 0 0.00023160094860941172
. O 0 3.602237711675116e-06

Reintroduced O 0 0.00011541265121195465
wild O 0 1.1750840712920763e-05
- O 0 0.00024753311299718916
type O 0 2.4471961296512745e-05
VHL B-Disease 0 0.002930322429165244
strongly O 0 3.4481033139854844e-07
inhibited O 0 1.606868380576998e-07
the O 0 8.346868085595816e-09
overexpression O 0 1.4852643914764485e-07
of O 0 1.8903316689744543e-09
the O 0 1.3422860156708794e-08
CA12 O 0 0.00020906499412376434
gene O 0 1.0338769129702996e-07
in O 0 2.118760633607053e-08
the O 0 4.514702141023008e-07
parental O 1 0.5328662395477295
renal B-Disease 1 0.9999850988388062
cell I-Disease 1 0.999936580657959
carcinoma I-Disease 1 0.9999992847442627
cell O 0 0.26041123270988464
lines O 0 0.00018980374443344772
. O 0 7.677871508349199e-06

Similar O 0 1.1756714229704812e-05
results O 0 2.7648802642943338e-06
were O 0 2.014625799517944e-08
obtained O 0 1.2505832103215653e-07
with O 0 1.0376522396882137e-07
CA9 O 0 0.042937248945236206
, O 0 1.3939103205018455e-08
encoding O 0 3.739558351867345e-08
another O 0 4.3265522720048466e-08
transmembrane O 0 0.00016536492330487818
CA O 0 6.63568755499e-07
with O 0 5.316735496307956e-09
an O 0 1.344789701818172e-08
intact O 0 2.4892176497814944e-06
catalytic O 0 2.766164470813237e-06
domain O 0 2.7262829007668188e-06
. O 0 1.8212592749478063e-06

Although O 0 1.29524369185674e-06
both O 0 3.8419404546630176e-08
domains O 0 1.1770391949994519e-07
of O 0 6.157859111510788e-09
the O 0 6.060762558490751e-08
VHL B-Disease 0 0.005032447166740894
protein O 0 7.37961656227526e-08
contribute O 0 1.0590020416145762e-08
to O 0 1.2789598269336011e-09
regulation O 0 7.475437158177556e-09
of O 0 2.2018926681965922e-09
CA12 O 0 0.00022678071400150657
expression O 0 8.302128406967313e-08
, O 0 2.8490587666851752e-09
the O 0 3.104917434271215e-09
elongin O 0 1.0175226634601131e-05
binding O 0 1.3502351237093535e-07
domain O 0 7.675139102047979e-08
alone O 0 1.7492281756403827e-07
could O 0 7.820459302365634e-08
effectively O 0 5.590356977336342e-07
regulate O 0 1.0994775038852822e-05
CA9 O 0 0.012835223227739334
expression O 0 1.4638195352745242e-05
. O 0 2.609635203043581e-06

We O 0 4.711115252575837e-06
mapped O 0 0.00016142446838784963
CA12 O 0 0.001144440728239715
and O 0 7.539762805208738e-07
CA9 O 0 0.0031176896300166845
loci O 0 2.1649980226357e-06
to O 0 9.032076775383757e-08
chromosome O 0 2.4988095901790075e-05
bands O 0 3.683258000819478e-06
15q22 O 0 4.219640322844498e-05
and O 0 5.539763492379279e-07
17q21 O 0 0.00019831709505524486
. O 0 4.380360678624129e-06

2 O 0 2.2509495920530753e-06
respectively O 0 1.944651330632041e-06
, O 0 1.21527364171925e-07
regions O 0 7.981922180988477e-07
prone O 0 1.9450393665465526e-05
to O 0 1.6128522517533384e-08
amplification O 0 2.4812113679217873e-06
in O 0 4.206736647915932e-08
some O 0 3.175950524791915e-08
human O 0 1.649306432227604e-05
cancers B-Disease 0 0.26265349984169006
. O 0 2.7189838874619454e-05

Additional O 0 1.1211069477212732e-06
experiments O 0 4.732644811156206e-06
are O 0 9.369111708679156e-09
needed O 0 1.4363841671638511e-08
to O 0 1.9063064460311807e-09
define O 0 2.4482094573841096e-08
the O 0 1.985972719609208e-09
role O 0 1.1642092623276312e-08
of O 0 1.4031370731970583e-08
CA O 0 1.2889217032352462e-05
IX O 0 2.1586525690509006e-05
and O 0 6.575683642040531e-08
CA O 0 4.598551640810911e-06
XII O 0 1.722547494864557e-05
enzymes O 0 4.824206811804288e-08
in O 0 2.2621977624481815e-09
the O 0 1.1962101309492823e-09
regulation O 0 1.878618682837896e-08
of O 0 5.0320370093004385e-09
pH O 0 1.1790331882366445e-05
in O 0 8.154213304578661e-09
the O 0 6.010556052871152e-09
extracellular O 0 1.9033045646210667e-06
microenvironment O 0 5.853653055964969e-05
and O 0 1.1361303009493895e-08
its O 0 1.2836919971448424e-08
potential O 0 4.4219029859959846e-07
impact O 0 2.063144847852527e-06
on O 0 6.576607574970694e-06
cancer B-Disease 0 0.09422300010919571
cell O 0 0.0005821973318234086
growth O 0 2.2490425180876628e-05
. O 0 4.77831827083719e-06

A O 0 2.9876462122047087e-06
gene O 0 2.2516387616633438e-06
encoding O 0 4.4153293288218265e-07
a O 0 1.1329984062058429e-07
transmembrane O 0 7.55171276978217e-05
protein O 0 2.3188781028693484e-07
is O 0 1.4847241658344501e-08
mutated O 0 2.7088358365290333e-06
in O 0 3.7836289834558556e-07
patients O 0 2.2683729184791446e-05
with O 0 0.010293478146195412
diabetes B-Disease 1 0.999996542930603
mellitus I-Disease 1 0.999976396560669
and O 0 0.21987782418727875
optic B-Disease 1 0.9999984502792358
atrophy I-Disease 1 0.9999817609786987
( O 0 0.3523293733596802
Wolfram B-Disease 1 0.9999945163726807
syndrome I-Disease 1 0.9999977350234985
) O 0 1.2776771654898766e-05
. O 0 8.547616744181141e-06

Wolfram B-Disease 1 0.9999638795852661
syndrome I-Disease 1 0.9999961853027344
( O 0 0.0002789935388136655
WFS B-Disease 1 0.9949122667312622
; O 0 0.00013846662477590144
OMIM O 1 0.9820928573608398
222300 O 0 0.0008726140949875116
) O 0 7.901498833007281e-08
is O 0 5.7493569016742185e-08
an O 0 2.031784561040695e-06
autosomal B-Disease 1 0.9995608925819397
recessive I-Disease 1 0.9999655485153198
neurodegenerative I-Disease 1 0.9999967813491821
disorder I-Disease 1 0.9475427269935608
defined O 0 2.3215231976791983e-06
by O 0 9.308233472893335e-08
young O 0 9.329399972557439e-07
- O 0 0.009298861026763916
onset O 0 0.0013689518673345447
non O 0 2.6677146252040984e-06
- O 0 0.09838642925024033
immune O 0 0.011428046971559525
insulin B-Disease 0 0.0001503668026998639
- I-Disease 1 0.7550567984580994
dependent I-Disease 0 0.04227227717638016
diabetes I-Disease 1 0.9998934268951416
mellitus I-Disease 1 0.9923123717308044
and O 0 3.621113864937797e-05
progressive O 1 0.8870022296905518
optic B-Disease 1 0.9999815225601196
atrophy I-Disease 1 0.9987086057662964
. O 0 5.0085800467059016e-05

Linkage O 0 0.0002722015487961471
to O 0 3.5389939512242563e-07
markers O 0 6.756312814104604e-06
on O 0 7.194423119472049e-07
chromosome O 0 0.003312806598842144
4p O 1 0.9873570203781128
was O 0 4.6063905756454915e-07
confirmed O 0 8.734623406780884e-07
in O 0 5.266355174171622e-08
five O 0 2.2117733067261724e-07
families O 0 2.324899469385855e-06
. O 0 6.128538188931998e-06

On O 0 5.67862514344597e-07
the O 0 4.047338819646029e-08
basis O 0 1.3906704232624634e-08
of O 0 1.852992426165656e-08
meiotic O 0 0.001171135576441884
recombinants O 1 0.6317334771156311
and O 0 2.4838016543071717e-05
disease O 0 0.0051107583567500114
- O 0 0.024624979123473167
associated O 0 2.134456553903874e-05
haplotypes O 0 0.00011175491090398282
, O 0 2.146509991973744e-08
the O 0 2.8899107107349664e-08
WFS B-Disease 0 0.0029972156044095755
gene O 0 2.410506851902028e-07
was O 0 1.855362086189416e-08
localized O 0 2.2981701874869032e-07
to O 0 8.42498693032212e-09
a O 0 1.3721027869451063e-07
BAC O 0 5.3412935812957585e-05
/ O 0 9.355931979371235e-06
P1 O 0 0.0002998120617121458
contig O 0 8.990207788883708e-06
of O 0 5.4736757348905485e-09
less O 0 3.0973183129390236e-08
than O 0 2.552692812685109e-08
250 O 0 3.8567202409467427e-07
kb O 0 0.0008086894522421062
. O 0 3.833325081359362e-06

Mutations O 0 0.0009736226056702435
in O 0 4.6395311414926255e-07
a O 0 1.0709952391607658e-07
novel O 0 7.572405706923746e-07
gene O 0 5.50703134649666e-07
( O 0 1.562475837602051e-08
WFS1 O 0 9.022828635352198e-06
) O 0 1.2265901627728226e-09
encoding O 0 6.869194990599681e-09
a O 0 5.8528728530404805e-09
putative O 0 4.229358637530822e-06
transmembrane O 0 5.4761232604505494e-05
protein O 0 7.886036712534406e-08
were O 0 2.9249227484484663e-09
found O 0 7.137916036015213e-09
in O 0 3.986701635483314e-09
all O 0 2.2488613193871743e-09
affected O 0 1.5236959427511465e-07
individuals O 0 1.6034631400430044e-08
in O 0 5.068720909662261e-08
six O 0 8.42891040520044e-07
WFS B-Disease 0 0.3403298854827881
families O 0 1.1289869661368357e-07
, O 0 1.2888661693466474e-08
and O 0 7.965138770771318e-09
these O 0 1.683093309168271e-08
mutations O 0 6.886933761052205e-07
were O 0 1.576266051017683e-08
associated O 0 2.2848657010854367e-07
with O 0 2.3887938027655764e-07
the O 0 4.2039995605591685e-05
disease O 1 0.8650908470153809
phenotype O 1 0.5110447406768799
. O 0 1.909166712721344e-05

WFS1 O 0 0.008296050131320953
appears O 0 7.6056207944930065e-06
to O 0 4.1361804647976896e-08
function O 0 6.790308759718755e-08
in O 0 4.8896826143618455e-08
survival O 0 2.8713948267977685e-06
of O 0 6.393190421505324e-09
islet O 0 7.677043868170585e-06
beta O 0 6.558723271155031e-07
- O 0 0.0001681028661550954
cells O 0 2.731704398684087e-06
and O 0 1.6402182723140868e-07
neurons O 0 2.486979792593047e-05
. O 0 2.882694047912082e-07
. O 0 1.3357500847632764e-06

Stable O 0 3.1101379136089236e-05
interaction O 0 7.867502063163556e-07
between O 0 4.406671649803684e-08
the O 0 8.489558389612739e-09
products O 0 1.5495448479896368e-08
of O 0 2.7074342767718917e-09
the O 0 3.8587725015304386e-08
BRCA1 O 0 5.93192562519107e-05
and O 0 8.61047283251537e-07
BRCA2 O 0 0.002340033184736967
tumor B-Disease 0 0.0013099599163979292
suppressor O 0 3.4230310120619833e-05
genes O 0 1.748701237147543e-07
in O 0 5.248696055559776e-08
mitotic O 0 4.1436309402342886e-05
and O 0 1.5504990642511984e-06
meiotic O 0 0.049747563898563385
cells O 0 0.00016764937026891857
. O 0 5.5057685131032486e-06

BRCA1 O 0 0.017797496169805527
and O 0 3.5070097510470077e-06
BRCA2 O 0 0.00012058522406732664
account O 0 3.1628027841179573e-07
for O 0 1.2810112970385035e-08
most O 0 1.0257291016557701e-08
cases O 0 2.1258163229731508e-08
of O 0 1.1536586796978554e-08
familial O 0 0.01584431901574135
, O 0 2.1173887034819927e-06
early O 0 2.0266586943762377e-05
onset O 1 0.9023445248603821
breast B-Disease 0 0.24692659080028534
and I-Disease 0 1.1578928933886345e-05
/ I-Disease 1 0.7494387030601501
or I-Disease 0 0.31467416882514954
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999538660049438
and O 0 1.1994040960416896e-07
encode O 0 1.7027456067353341e-07
products O 0 2.6490699411851892e-08
that O 0 2.2574651037388094e-09
each O 0 5.44722178474899e-09
interact O 0 8.559101871696839e-08
with O 0 2.5997411512435065e-07
hRAD51 O 0 0.001549618085846305
. O 0 6.662759915343486e-06

Results O 0 3.977194501203485e-05
presented O 0 2.9953234843560494e-06
here O 0 1.34111843408391e-07
show O 0 1.1176040004556853e-07
that O 0 3.6664523861418274e-08
BRCA1 O 0 3.211849616491236e-05
and O 0 3.833870323433075e-07
BRCA2 O 0 0.00013882198254577816
coexist O 0 1.1223532965232152e-05
in O 0 5.251609991319128e-08
a O 0 2.337923490358662e-07
biochemical O 0 0.0036223705392330885
complex O 0 6.58896055938385e-07
and O 0 3.200780440693052e-08
colocalize O 0 0.00013279453560244292
in O 0 6.620145143187983e-08
subnuclear O 0 6.629370182054117e-05
foci O 0 6.833926818217151e-06
in O 0 3.5063564496340405e-08
somatic O 0 9.39769233809784e-06
cells O 0 9.071412705452531e-07
and O 0 3.947311366658823e-09
on O 0 3.49186524140066e-09
the O 0 4.644039375278908e-09
axial O 0 1.546731482449104e-06
elements O 0 6.045072353799696e-08
of O 0 2.6017596965743905e-08
developing O 0 3.944434411096154e-06
synaptonemal O 0 0.0016099234344437718
complexes O 0 0.00015141571930143982
. O 0 3.2020770959206857e-06

Like O 0 2.191266139561776e-05
BRCA1 O 0 0.0005471521872095764
and O 0 2.045830342467525e-06
RAD51 O 0 0.010266819037497044
, O 0 4.4917860009263677e-07
BRCA2 O 0 1.9987259292975068e-05
relocates O 0 2.7192616016691318e-06
to O 0 5.929666357928909e-08
PCNA O 0 0.0001325458288192749
+ O 0 4.1442797282797983e-07
replication O 0 9.486176111295208e-08
sites O 0 4.8553520315408605e-08
following O 0 3.60328087367634e-08
exposure O 0 6.762564339624078e-07
of O 0 1.483948519620526e-08
S O 0 0.0004642462299671024
phase O 0 4.162315690336982e-06
cells O 0 4.41928506234035e-07
to O 0 3.16146362422387e-08
hydroxyurea O 0 3.4934226277982816e-05
or O 0 1.1248789633100387e-06
UV O 0 0.04646889120340347
irradiation O 0 0.0002975976385641843
. O 0 2.9196517061791383e-06

Thus O 0 1.1840654224215541e-05
, O 0 6.953543447707489e-07
BRCA1 O 0 2.0117968233535066e-05
and O 0 1.3045222146956803e-07
BRCA2 O 0 2.8448183002183214e-05
participate O 0 7.919106081999416e-08
, O 0 7.914874977643649e-09
together O 0 5.485151000073074e-09
, O 0 5.782831991041348e-09
in O 0 5.054912488589025e-09
a O 0 2.6613307113620976e-08
pathway O 0 7.027764468148234e-07
( O 0 2.343282545780312e-08
s O 0 4.564269329421222e-05
) O 0 6.546959863129587e-09
associated O 0 1.2290966466821374e-08
with O 0 8.143562491014222e-10
the O 0 2.6413591314167206e-09
activation O 0 5.500523059254192e-08
of O 0 2.0259922628440563e-09
double O 0 1.9860774500557454e-06
- O 0 8.308786345878616e-05
strand O 0 6.882003162900219e-06
break O 0 7.466838951586396e-07
repair O 0 2.1218083929852583e-05
and O 0 1.5965758848324185e-07
/ O 0 7.579936664114939e-06
or O 0 9.362577202409739e-08
homologous O 0 3.0256442187237553e-06
recombination O 0 2.8647689759964123e-05
. O 0 3.879350060742581e-06

Dysfunction O 0 0.00293295131996274
of O 0 6.390218345586618e-07
this O 0 3.0419974450524023e-07
pathway O 0 6.771607331756968e-06
may O 0 2.6678648623601475e-07
be O 0 1.3854277725044994e-09
a O 0 3.651543289961978e-09
general O 0 3.111297885993736e-08
phenomenon O 0 2.443898949877621e-07
in O 0 1.7503730687096208e-09
the O 0 1.2499191681669686e-09
majority O 0 5.832568206187716e-09
of O 0 1.7637885596499814e-09
cases O 0 4.0099713771724055e-08
of O 0 1.0100755076791756e-07
hereditary B-Disease 1 0.8636618256568909
breast I-Disease 1 0.9117029309272766
and I-Disease 0 0.0001904563541756943
/ I-Disease 1 0.9945089221000671
or I-Disease 1 0.8423066735267639
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.999988317489624
. O 0 1.765775596140884e-05
. O 0 7.799299964972306e-06

A O 0 5.044502358941827e-06
novel O 0 9.165273695543874e-06
Arg362Ser O 0 0.0018084610346704721
mutation O 0 1.3556412341131363e-05
in O 0 4.9263977786040414e-08
the O 0 3.833346795545367e-08
sterol O 0 0.002267183968797326
27 O 0 1.9509616322466172e-06
- O 0 0.0003713680780492723
hydroxylase O 0 0.00038586161099374294
gene O 0 1.4684212601423496e-07
( O 0 6.260751028719369e-09
CYP27 O 0 9.851952199824154e-06
) O 0 2.5241067014292184e-09
: O 0 2.2801143195749773e-09
its O 0 1.210654687611168e-09
effects O 0 2.3199481447022663e-08
on O 0 4.609244097508736e-09
pre O 0 1.0605007219055551e-06
- O 0 2.9029929464741144e-06
mRNA O 0 4.972731559860222e-08
splicing O 0 5.186053186889694e-08
and O 0 7.55870921409496e-09
enzyme O 0 1.2134195515045576e-07
activity O 0 2.939449359473656e-07
. O 0 3.868976534704416e-07

A O 0 3.2960147109406535e-06
novel O 0 2.198907168349251e-06
C O 0 1.8190339687862433e-06
to O 0 1.4741454279487698e-08
A O 0 9.610727147446596e-08
mutation O 0 1.6534482938368456e-06
in O 0 8.839387000136867e-09
the O 0 1.4635190836997936e-08
sterol O 0 0.0014294267166405916
27 O 0 9.978421076084487e-07
- O 0 0.00017252661928068846
hydroxylase O 0 0.000802038237452507
gene O 0 7.85637013223095e-08
( O 0 4.714447499054586e-09
CYP27 O 0 1.2761391189997084e-05
) O 0 2.219928463276233e-09
was O 0 2.768764773009025e-09
identified O 0 1.3813729715650425e-08
by O 0 2.4171900037117666e-09
sequencing O 0 1.5809607134542603e-07
amplified O 0 1.5674658015996101e-06
CYP27 O 0 3.179845953127369e-05
gene O 0 5.11709608019828e-08
products O 0 8.449995370085617e-09
from O 0 1.7838206467502005e-09
a O 0 3.805576298532287e-08
patient O 0 6.8354265749803744e-06
with O 0 4.287402589397971e-06
cerebrotendinous B-Disease 1 0.9999700784683228
xanthomatosis I-Disease 1 0.9999067783355713
( O 0 9.108845006267074e-06
CTX B-Disease 1 0.6123781204223633
) O 0 8.754053624215885e-07
. O 0 1.7238390910279122e-06

The O 0 2.6094062377524097e-06
mutation O 0 1.3641983969137073e-05
changed O 0 2.7879767117156007e-07
the O 0 2.575910151847438e-08
adrenodoxin O 0 4.074723165103933e-06
cofactor O 0 3.724219652667671e-07
binding O 0 1.5294290278689004e-07
residue O 0 4.957465762345237e-07
362Arg O 0 1.9033664102607872e-06
to O 0 1.2613146971318656e-08
362Ser O 0 1.1971398635068908e-05
( O 0 2.3404103544066857e-08
CGT O 0 1.1118437214463484e-05
362Arg O 0 2.3273132683243603e-06
to O 0 1.2620269274066231e-08
AGT O 0 0.00011217322753509507
362Ser O 0 8.547551260562614e-06
) O 0 3.906043932744296e-09
, O 0 1.8498981235737233e-09
and O 0 3.0243156867726384e-09
was O 0 2.319027991859457e-08
responsible O 0 2.539077570418158e-07
for O 0 8.078868631855585e-07
deficiency O 1 0.8141099810600281
in O 0 2.962977596610017e-08
the O 0 4.444606105380444e-08
sterol O 0 0.0144133809953928
27 O 0 1.4267857295635622e-06
- O 0 0.0003365256416145712
hydroxylase O 0 0.0007461701170541346
activity O 0 4.41023679798036e-08
, O 0 1.1899000673665228e-09
as O 0 1.2808103466710463e-09
confirmed O 0 1.4041544815768248e-08
by O 0 1.0422570584367463e-09
expression O 0 5.255615498356292e-09
of O 0 8.076028734649299e-10
mutant O 0 1.051599269885628e-07
cDNA O 0 7.882727715013971e-08
into O 0 1.7033391586096513e-08
COS O 0 1.838476600823924e-05
- O 0 1.664700721448753e-05
1 O 0 2.444192546136037e-07
cells O 0 5.578540822170908e-06
. O 0 1.4833141221970436e-06

Quantitative O 0 2.493857937224675e-05
analysis O 0 2.6239597445965046e-06
showed O 0 1.3217980949775665e-06
that O 0 4.515836593554923e-09
the O 0 3.2249476422663292e-09
expression O 0 1.911615932215227e-08
of O 0 3.4760299083558266e-09
CYP27 O 0 1.1453377737780102e-05
gene O 0 2.8712742405900826e-08
mRNA O 0 1.6122555734909838e-08
in O 0 2.167523938112481e-09
the O 0 8.873390022756666e-09
patient O 0 9.348308367407299e-07
represented O 0 7.234810937006841e-07
52 O 0 3.38087693307898e-06
. O 0 3.453534191066865e-06

5 O 0 2.287613824591972e-06
% O 0 1.9048721355829912e-07
of O 0 1.7685223951957596e-08
the O 0 1.0536330563581942e-07
normal O 0 1.095840843845508e-06
level O 0 2.7733706247090595e-06
. O 0 1.6098898640848347e-06

As O 0 4.904188131149567e-07
the O 0 1.7296589760462666e-07
mutation O 0 5.81597441851045e-06
occurred O 0 3.186113701758586e-07
at O 0 3.923606328726237e-09
the O 0 2.013218924901139e-09
penultimate O 0 2.597325021724828e-07
nucleotide O 0 1.2714684771708562e-07
of O 0 2.9543252288988242e-09
exon O 0 6.3333554862765595e-06
6 O 0 2.7499876154024605e-08
( O 0 1.5044040457823371e-09
- O 0 1.9105777937511448e-07
2 O 0 4.517008100890507e-09
position O 0 1.7929794315918457e-09
of O 0 1.4868489772723592e-09
exon O 0 3.2155753615370486e-06
6 O 0 3.964017381008489e-08
- O 0 3.4902204788522795e-06
intron O 0 7.711566468060482e-06
6 O 0 2.07374952765349e-08
splice O 0 3.7809957120771287e-07
site O 0 2.736394222324634e-08
) O 0 3.9451417133129496e-10
of O 0 2.364520523823188e-10
the O 0 2.5627704403063944e-09
gene O 0 3.232610268355529e-08
, O 0 2.976326518577821e-09
we O 0 2.2370281183015095e-09
hypothesized O 0 1.0156973928587831e-07
that O 0 1.660763970789958e-09
the O 0 1.4568015238580756e-08
mutation O 0 1.7470172679168172e-05
may O 0 3.3505531860100746e-07
partially O 0 1.4572455597772205e-07
affect O 0 1.1665431287610772e-08
the O 0 1.6079031439630853e-09
normal O 0 1.8538267809731224e-08
splicing O 0 8.508870052992279e-08
efficiency O 0 1.5438195077877026e-07
in O 0 8.124049877267225e-09
exon O 0 5.6147932809835766e-06
6 O 0 3.5726564817650797e-08
and O 0 8.392396999568064e-09
cause O 0 1.0006373685200742e-07
alternative O 0 2.6893088644897034e-08
splicing O 0 4.196822942503786e-07
elsewhere O 0 9.97717748418836e-08
, O 0 2.8905653426392064e-09
which O 0 2.7752786735391055e-09
resulted O 0 3.518193381069068e-08
in O 0 3.466814746388991e-08
decreased O 0 2.5003901100717485e-06
transcript O 0 4.2220199247822165e-06
in O 0 5.221944832101144e-08
the O 0 1.3280813959681836e-07
patient O 0 2.9137187084415928e-05
. O 0 3.878096322296187e-06

Transfection O 0 0.0019075614400207996
of O 0 4.2460874283278827e-07
constructed O 0 1.228464680025354e-05
minigenes O 0 0.00034854825935326517
, O 0 1.4568404260728585e-08
with O 0 3.7059921798032747e-09
or O 0 4.987889656860034e-09
without O 0 2.699534373817869e-09
the O 0 3.9591343536926615e-09
mutation O 0 1.6058818630426686e-07
, O 0 1.500858881620104e-09
into O 0 2.6060045232867424e-09
COS O 0 3.2119751267600805e-05
- O 0 4.986550266039558e-06
1 O 0 2.7201171093338417e-08
cells O 0 1.5478455850370665e-07
confirmed O 0 1.6036315386713795e-08
that O 0 9.136200684878304e-10
the O 0 2.7695201687549797e-09
mutant O 0 6.459481937781675e-06
minigene O 0 5.832440365338698e-05
was O 0 1.6186151086117206e-08
responsible O 0 6.8915042561457085e-09
for O 0 6.794707574364622e-10
a O 0 1.008939065627601e-08
mRNA O 0 2.074468312684985e-07
species O 0 1.4628101396851889e-08
alternatively O 0 2.856176806176336e-08
spliced O 0 2.576117310582049e-07
at O 0 8.823014319148115e-09
an O 0 6.551144515754004e-09
activated O 0 1.4661317436548416e-05
cryptic O 0 1.016599253489403e-05
5 O 0 7.64158247790192e-09
splice O 0 5.552950597120798e-07
site O 0 8.918834737414727e-08
88 O 0 6.070700209193092e-08
bp O 0 1.1032775546482299e-06
upstream O 0 2.0459808069972496e-08
from O 0 1.1071896732772757e-09
the O 0 1.5740240222328339e-09
3 O 0 4.8887289771926135e-09
end O 0 7.618676356457854e-09
of O 0 1.0798354210805883e-08
exon O 0 8.255697321146727e-05
6 O 0 2.5282793103542645e-06
. O 0 7.973302444952424e-07

Our O 0 3.4470260743546532e-06
data O 0 1.0425120535728638e-06
suggest O 0 2.1786648574106948e-07
that O 0 6.3109144576856124e-09
the O 0 4.617145776819598e-09
C O 0 1.3048718017216743e-07
to O 0 1.3474181770334326e-09
A O 0 4.599252889647687e-08
mutation O 0 3.6468338748818496e-07
at O 0 1.7637649118995569e-09
the O 0 1.0570803121723316e-09
penultimate O 0 1.0480491141606763e-07
nucleotide O 0 3.576413121209043e-08
of O 0 1.4117750302133913e-09
exon O 0 1.788470399333164e-06
6 O 0 5.497342581151088e-09
of O 0 5.726696339358739e-10
the O 0 7.683601310759514e-09
CYP27 O 0 0.00021062382438685745
gene O 0 4.5191132613808804e-08
not O 0 8.726640521317108e-10
only O 0 2.0277126644430155e-09
causes O 0 9.201428383676102e-07
the O 0 1.7096884903367027e-06
deficiency B-Disease 1 0.6549582481384277
in I-Disease 0 2.4737110138062235e-08
the I-Disease 0 2.0958346169663855e-08
sterol I-Disease 0 0.0030171044636517763
27 I-Disease 0 7.285465244422085e-07
- I-Disease 0 0.0001270664215553552
hydroxylase I-Disease 0 0.00017187675985042006
activity I-Disease 0 3.353109789827613e-08
, O 0 2.153127010018352e-09
but O 0 2.4635957718288637e-09
also O 0 4.5984962504519444e-09
partially O 0 1.1339679417687876e-07
leads O 0 1.7355338499669415e-08
to O 0 8.188856259749855e-10
alternative O 0 1.057827070383155e-08
pre O 0 4.002189655238908e-07
- O 0 4.2045147097269364e-07
mRNA O 0 3.762316325151005e-08
splicing O 0 3.0871326828219026e-08
of O 0 5.8361178112420475e-09
the O 0 7.875725316353055e-08
gene O 0 2.1548839868046343e-06
. O 0 1.580633693265554e-06

To O 0 4.6331641101460264e-07
our O 0 2.0146974577528454e-07
knowledge O 0 1.9511313098519167e-07
, O 0 9.60000612337808e-09
this O 0 1.2536581772693012e-09
is O 0 8.345208968307816e-10
the O 0 1.1982447256642104e-09
first O 0 1.3738318926925785e-08
report O 0 7.746246666329171e-08
regarding O 0 1.479088229672243e-08
effects O 0 7.847893357393332e-08
on O 0 4.698360811516977e-09
pre O 0 5.144689225744514e-07
- O 0 1.4622029311794904e-06
mRNA O 0 1.333505217360198e-08
splicing O 0 9.269059297878357e-09
of O 0 3.510367552195248e-10
a O 0 8.193266509692876e-09
mutation O 0 1.96469642332886e-07
at O 0 1.8320394090665104e-09
the O 0 1.8009549407338454e-09
- O 0 2.0844365735683823e-06
2 O 0 6.877454161724472e-09
position O 0 2.815463417960018e-09
of O 0 1.0979701592361835e-09
a O 0 1.9477731427741674e-08
5 O 0 8.01260782168356e-08
splice O 0 1.196170887851622e-05
site O 0 4.303755758883199e-06
. O 0 1.9841465928038815e-06

ATM O 0 0.011781527660787106
germline O 1 0.9097358584403992
mutations O 0 0.0024189245887100697
in O 0 8.633499419374857e-06
classical O 0 0.001362898270599544
ataxia B-Disease 1 0.9999860525131226
- I-Disease 1 0.9999655485153198
telangiectasia I-Disease 1 0.9999924898147583
patients O 0 8.46253169584088e-05
in O 0 1.095160087061231e-07
the O 0 1.0049408416534789e-07
Dutch O 0 1.4278842172643635e-05
population O 0 8.498892611896736e-07
. O 0 1.8707113440541434e-06

Germline O 1 0.9525045156478882
mutations O 0 0.0004773282853420824
in O 0 2.8086057568543765e-07
the O 0 5.0789406458306985e-08
ATM O 0 2.72188462986378e-05
gene O 0 2.6123916541109793e-07
are O 0 4.718198720610189e-09
responsible O 0 4.33277911326968e-08
for O 0 2.1144172990261723e-07
the O 0 0.04597212374210358
autosomal B-Disease 1 0.9999994039535522
recessive I-Disease 1 0.9999998807907104
disorder I-Disease 1 1.0
ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999970197677612
telangiectasia I-Disease 1 0.9999980926513672
( O 0 3.462933818809688e-06
A B-Disease 0 0.0018233800074085593
- I-Disease 1 0.9985135197639465
T I-Disease 1 0.9998807907104492
) O 0 1.5352613900176948e-06
. O 0 2.2707943116984097e-06

In O 0 1.646936084398476e-06
our O 0 2.713068454340828e-07
study O 0 1.0080392343070343e-07
, O 0 7.541112623243862e-09
we O 0 1.7544241615041756e-09
have O 0 1.626803802778909e-09
determined O 0 8.153233643781732e-09
the O 0 2.9836020321027945e-09
ATM O 0 8.182466444850434e-06
mutation O 0 1.1085223832196789e-06
spectrum O 0 8.438032494950676e-08
in O 0 8.75872885330864e-09
19 O 0 4.581811552384352e-08
classical O 0 2.3081707922756323e-07
A B-Disease 0 0.00023783292272128165
- I-Disease 1 0.999659538269043
T I-Disease 1 0.999993085861206
patients O 0 5.949275418970501e-06
, O 0 8.150559338560015e-09
including O 0 3.935643366759223e-09
some O 0 2.4022890343644576e-09
immigrant O 0 5.2073564802412875e-06
populations O 0 2.1234076541531977e-07
, O 0 4.604209902225875e-09
as O 0 6.61042331984163e-10
well O 0 9.902547670748163e-10
as O 0 6.873621116731954e-10
12 O 0 2.004027832569477e-09
of O 0 2.132959142642221e-09
Dutch O 0 1.4903738474458805e-06
ethnic O 0 2.6023258214991074e-07
origin O 0 2.2837380129203666e-06
. O 0 1.174856151919812e-06

Both O 0 4.246042806244077e-07
the O 0 1.8962843739700475e-07
protein O 0 4.68701387035253e-07
truncation O 0 3.9183769331430085e-06
test O 0 4.204057404422201e-07
( O 0 1.5882804405009665e-08
PTT O 0 1.043659949573339e-06
) O 0 2.5006454684728396e-09
and O 0 1.0162605201813335e-09
the O 0 2.4555735222975272e-09
restriction O 0 4.053194402331428e-08
endonuclease O 0 1.7866598227556096e-06
fingerprinting O 0 1.643858922761865e-06
( O 0 1.6744545305868996e-08
REF O 0 0.00021262869995553046
) O 0 1.1307142999683606e-09
method O 0 1.2021204032208743e-09
were O 0 3.023898631493438e-10
used O 0 1.6380251599557027e-09
and O 0 4.461531588617618e-09
compared O 0 5.046880247050467e-08
for O 0 8.055259792527636e-10
their O 0 5.4617661504607895e-09
detection O 0 4.100607839063741e-06
efficiency O 0 5.096777044855116e-07
, O 0 2.0152282065311056e-09
identifying O 0 2.574215862694018e-08
76 O 0 2.9281618907361917e-08
% O 0 2.4407897925016186e-09
and O 0 2.2501054353085692e-09
60 O 0 8.525371519851888e-09
% O 0 3.6784004731060804e-09
of O 0 2.562330347899433e-09
the O 0 1.2793367432095692e-07
mutations O 0 1.4480315257969778e-05
, O 0 2.428490688544116e-07
respectively O 0 1.1996117791568395e-05
. O 0 3.272102958362666e-06

Most O 0 7.700220521655865e-06
patients O 0 8.91928266355535e-06
were O 0 6.442634514769452e-08
found O 0 1.1838805136221708e-07
to O 0 4.242594187076065e-08
be O 0 6.484265924200372e-08
compound O 0 1.918917587317992e-05
heterozygote O 0 0.0014771332498639822
. O 0 9.421345566806849e-06

Seventeen O 0 7.681446004426107e-05
mutations O 0 5.148588752490468e-05
were O 0 2.8111022842836064e-08
distinct O 0 6.879569269813146e-08
, O 0 4.116785135011014e-09
of O 0 6.676109665093577e-10
which O 0 5.7728470892470796e-09
10 O 0 5.833213911898838e-09
were O 0 4.884963100693085e-09
not O 0 3.001720827455756e-08
reported O 0 5.789472652395489e-06
previously O 0 5.329909072315786e-06
. O 0 4.147456365899416e-06

Mutations O 0 0.0007966604316607118
are O 0 1.5710605794083676e-07
small O 0 1.4235358491987427e-07
deletions O 0 6.1371592892101035e-06
or O 0 1.3997242831464973e-07
point O 0 1.5864689828504197e-07
mutations O 0 2.2490141873277025e-06
frequently O 0 4.1796479877120873e-07
affecting O 0 8.876202173269121e-07
splice O 0 4.4250213250052184e-05
sites O 0 6.5765825638663955e-06
. O 0 4.796882876689779e-06

Moreover O 0 0.00010687175381463021
, O 0 1.0576655995464534e-06
a O 0 7.809233579791908e-07
16 O 0 2.2566844108951045e-06
. O 0 4.187690137769096e-06

7 O 0 5.398777830123436e-06
- O 0 2.1330157323973253e-05
kb O 0 8.78077553352341e-05
genomic O 0 9.067909559234977e-06
deletion O 0 3.543999582689139e-06
of O 0 5.49926149062685e-09
the O 0 5.07154229723028e-09
3 O 0 4.4572194823899736e-09
end O 0 2.7790394430127208e-09
of O 0 5.042333772742325e-10
the O 0 2.9532942757981573e-09
gene O 0 4.390731334069642e-08
, O 0 3.2050673226535764e-09
most O 0 9.726957017619497e-10
likely O 0 1.1935716415223396e-08
a O 0 5.240760714286807e-09
result O 0 2.2368928043192682e-08
of O 0 1.3144140220688882e-09
recombination O 0 2.7261012292001396e-07
between O 0 7.349258979161277e-09
two O 0 4.4782928476649886e-09
LINE O 0 4.719730952729151e-07
elements O 0 1.0948676276711922e-07
, O 0 1.6201223473899518e-08
was O 0 6.280104969391687e-08
identified O 0 2.0682334707089467e-06
. O 0 1.419711452399497e-06

The O 0 7.769416470182477e-07
most O 0 4.283534238425091e-08
frequently O 0 2.1131332061941066e-07
found O 0 8.453495752291929e-07
mutation O 0 8.371412150154356e-06
, O 0 2.462572901151816e-08
identified O 0 7.583058447835356e-08
in O 0 8.260646389146586e-09
three O 0 8.460752098926605e-09
unrelated O 0 2.041402240138268e-06
Turkish O 0 2.2591000288230134e-06
A B-Disease 0 0.00036726711550727487
- I-Disease 1 0.9973118305206299
T I-Disease 1 0.9996644258499146
individuals O 0 8.260649764224581e-08
, O 0 2.0804369782467802e-08
was O 0 1.8098608833838625e-08
previously O 0 6.667131202675591e-08
described O 0 1.666677178491227e-07
to O 0 1.5490653204608407e-09
be O 0 1.3641282547993683e-09
a O 0 1.0394980876071713e-08
Turkish O 0 4.444331125341705e-07
A B-Disease 0 4.127741340198554e-05
- I-Disease 1 0.9832422733306885
T I-Disease 1 0.9997876286506653
founder O 0 0.00023332131968345493
mutation O 0 2.5604991606087424e-05
. O 0 1.8091070614900673e-06

The O 0 1.140293989010388e-06
presence O 0 2.982241085192072e-07
of O 0 1.4606884590762093e-08
a O 0 7.332754137223674e-08
founder O 0 3.5628003388410434e-05
mutation O 0 2.6304039693059167e-06
among O 0 6.058864965297062e-09
relatively O 0 9.633573938572226e-09
small O 0 2.167912738215705e-09
ethnic O 0 9.42747835352975e-09
population O 0 8.40452329953223e-09
groups O 0 2.896658468642954e-09
in O 0 1.0128667682351988e-08
Western O 0 4.255674923570041e-08
Europe O 0 7.017237635409401e-08
could O 0 3.6130533231926165e-08
indicate O 0 1.1089934304209237e-07
a O 0 1.9738138234970393e-08
high O 0 5.128650855112937e-07
carrier O 0 6.596589628315996e-06
frequency O 0 3.23124226042637e-07
in O 0 1.6566044536148183e-08
such O 0 6.234133564930744e-08
communities O 0 1.2117189953642082e-06
. O 0 2.1166335955058457e-06

In O 0 9.863186278380454e-06
patients O 0 1.4490635749098146e-06
of O 0 2.314635416666988e-08
Dutch O 0 9.507220966042951e-07
ethnic O 0 3.7377255068804516e-08
origin O 0 1.7422442510905967e-07
, O 0 2.3808784277434825e-08
however O 0 1.1361736440562709e-08
, O 0 4.5110244428769875e-09
no O 0 1.2618247779982994e-08
significant O 0 2.9258226064143855e-08
founder O 0 1.297559265367454e-06
effect O 0 1.9671225004458393e-07
could O 0 3.2639160707503834e-08
be O 0 2.8801158791225134e-08
identified O 0 2.8984177333768457e-06
. O 0 2.6454174530954333e-06

The O 0 5.228650024946546e-06
observed O 0 1.7134774680016562e-05
genetic O 0 2.188018879678566e-05
heterogeneity O 0 5.371972656575963e-05
including O 0 5.538010228178791e-08
the O 0 4.3842874219990335e-08
relative O 0 2.0387174117786344e-06
high O 0 3.017092922164011e-07
percentage O 0 7.97908583649587e-08
of O 0 4.14940615200976e-09
splice O 0 1.0844177268154453e-05
- O 0 0.0010151746682822704
site O 0 6.557305823662318e-06
mutations O 0 1.4160497130433214e-06
had O 0 1.1243256103909971e-08
no O 0 1.6331966889993055e-08
reflection O 0 2.0523775390302035e-07
on O 0 5.5693543998813766e-08
the O 0 4.894525886811607e-07
phenotype O 0 0.010748098604381084
. O 0 3.893096618412528e-06

All O 0 5.802556188427843e-06
patients O 0 2.9242686650832184e-05
manifested O 0 2.198672154918313e-05
classical O 0 2.801177060973714e-06
A B-Disease 0 5.789510760223493e-05
- I-Disease 1 0.8796513676643372
T I-Disease 1 0.9426301717758179
and O 0 4.451801061122751e-08
increased O 0 3.155867034365656e-07
cellular O 0 2.324730303371325e-05
radioresistant O 0 0.00013978168135508895
DNA O 0 3.800259719355381e-06
synthesis O 0 2.2052872736821882e-06
. O 0 1.0746739462774713e-06

Determination O 0 1.8785071006277576e-05
of O 0 7.552026204393769e-08
the O 0 3.909198653673229e-08
genomic O 0 3.27570887748152e-06
structure O 0 2.1961166396522458e-07
of O 0 4.076785575790609e-09
the O 0 3.409299509371522e-08
COL4A4 O 0 0.000606561719905585
gene O 0 1.2685337935636198e-07
and O 0 5.321311391526251e-09
of O 0 1.3093802486707773e-08
novel O 0 2.4869277694961056e-05
mutations O 0 0.009558262303471565
causing O 0 0.02550194039940834
autosomal B-Disease 1 0.9980921149253845
recessive I-Disease 1 0.9997836947441101
Alport I-Disease 1 0.9999847412109375
syndrome I-Disease 1 0.9999518394470215
. O 0 0.00019471414270810783

Autosomal B-Disease 1 0.9998379945755005
recessive I-Disease 1 0.9999232292175293
Alport I-Disease 1 0.999994158744812
syndrome I-Disease 1 0.9999850988388062
is O 0 4.108526354684727e-06
a O 0 5.0704506975307595e-06
progressive O 0 0.027794895693659782
hematuric B-Disease 1 0.9996962547302246
glomerulonephritis I-Disease 1 0.9999828338623047
characterized O 0 0.0003776404191739857
by O 0 1.7414447484043194e-06
glomerular B-Disease 1 0.9986013770103455
basement I-Disease 1 0.993055522441864
membrane I-Disease 1 0.5522096753120422
abnormalities I-Disease 1 0.874110996723175
and O 0 2.788179074286745e-07
associated O 0 6.292772809501912e-07
with O 0 1.8363405729360238e-07
mutations O 0 1.923343234011554e-06
in O 0 1.0299990194084785e-08
either O 0 5.657692536686909e-09
the O 0 1.0574760622716894e-08
COL4A3 O 0 6.990103429416195e-05
or O 0 5.3778070885357465e-09
the O 0 7.146566893823092e-09
COL4A4 O 0 8.000677917152643e-05
gene O 0 3.399112102897561e-08
, O 0 7.313276095821664e-10
which O 0 4.967380395903831e-10
encode O 0 7.865692985831174e-09
the O 0 3.63569152561638e-09
alpha3 O 0 6.76333365845494e-06
and O 0 2.6996904267662103e-08
alpha4 O 0 0.00022750752395950258
type O 0 1.3894867151975632e-05
IV O 0 0.00079280388308689
collagen O 0 0.00010963311797240749
chains O 0 7.97331813373603e-06
, O 0 1.7006698271870846e-07
respectively O 0 7.3920373324654065e-06
. O 0 3.4225174658786273e-06

To O 0 8.951502081799845e-07
date O 0 1.6851689679242554e-06
, O 0 1.0656566473699058e-07
mutation O 0 7.514975095546106e-07
screening O 0 1.1716745973444631e-07
in O 0 5.095024846468732e-09
the O 0 2.0760992924806487e-09
two O 0 4.727197744358591e-09
genes O 0 6.073457115007841e-08
has O 0 9.013813695446515e-09
been O 0 1.9507250925698827e-08
hampered O 0 3.0786120532866335e-06
by O 0 1.1154015489012181e-08
the O 0 1.5384808094154323e-08
lack O 0 1.383145189493007e-07
of O 0 2.8127221440854555e-08
genomic O 0 5.888443411095068e-05
structure O 0 1.072335089702392e-05
information O 0 1.2897758097096812e-06
. O 0 2.979701775984722e-06

We O 0 1.4982874745328445e-06
report O 0 5.910695790589671e-07
here O 0 1.6270124802986174e-08
the O 0 3.7087357629417284e-09
complete O 0 2.100148144279501e-08
characterization O 0 1.7241170269244321e-07
of O 0 8.779330595842794e-10
the O 0 2.9537055024064784e-09
48 O 0 2.0298845271327082e-08
exons O 0 6.19419040503999e-08
of O 0 1.2055254572373997e-09
the O 0 1.0898667746062074e-08
COL4A4 O 0 0.00031044709612615407
gene O 0 1.3226488704276562e-07
, O 0 2.8967523935108375e-09
a O 0 4.844822321103948e-09
comprehensive O 0 3.222588702556095e-07
gene O 0 9.607391859844938e-08
screen O 0 7.543164883827558e-07
, O 0 4.941056452878456e-09
and O 0 1.4138339388125587e-09
the O 0 1.957343398473199e-09
subsequent O 0 4.6197556002880447e-08
detection O 0 2.767510522971861e-07
of O 0 1.8446271177197104e-09
10 O 0 7.207042518331264e-09
novel O 0 1.7787361628052167e-07
mutations O 0 9.868349479802419e-07
in O 0 7.601246920785343e-08
eight O 0 1.4438698599406052e-05
patients O 0 0.07345839589834213
diagnosed O 1 0.9977947473526001
with O 0 0.06719937175512314
autosomal B-Disease 1 0.9998791217803955
recessive I-Disease 1 0.999911904335022
Alport I-Disease 1 0.9999939203262329
syndrome I-Disease 1 0.9999610185623169
. O 0 0.0002626517089083791

Furthermore O 0 3.0025739761185832e-05
, O 0 2.055746932683178e-07
we O 0 2.3135759974479697e-08
identified O 0 3.9138541296779294e-08
a O 0 6.365229232585534e-09
glycine O 0 3.7606523051181284e-07
to O 0 1.8735257789614934e-09
alanine O 0 1.2632412449420372e-07
substitution O 0 7.916656663553567e-09
in O 0 2.0899373343041816e-09
the O 0 7.620245767725464e-09
collagenous O 0 0.0005894418573006988
domain O 0 1.082335003843582e-07
that O 0 6.024788667957637e-09
is O 0 2.7002553526500606e-09
apparently O 0 4.4183870784308965e-08
silent O 0 1.5933846952975728e-07
in O 0 6.795463303177485e-09
the O 0 1.1018728152123458e-08
heterozygous O 0 4.5895873768131423e-07
carriers O 0 3.2707845321056084e-07
, O 0 1.1977153491216086e-08
in O 0 7.213949260176378e-08
11 O 0 2.00053068510897e-06
. O 0 3.674136451081722e-06

5 O 0 1.6924439023568993e-06
% O 0 6.436027177869619e-08
of O 0 5.503217437308194e-09
all O 0 4.18121670620053e-09
control O 0 1.7912442729084432e-07
individuals O 0 2.300726542614484e-08
, O 0 1.76824919151386e-08
and O 0 7.522035438967123e-09
in O 0 7.599373574862511e-09
one O 0 6.478218406158476e-09
control O 0 5.7216254845116055e-08
individual O 0 2.1612912348700775e-08
homozygous O 0 9.924430059982114e-07
for O 0 4.0984677873723285e-09
this O 0 1.9203573842219157e-08
glycine O 0 1.2086618880857714e-05
substitution O 0 3.2114996884047287e-06
. O 0 1.9546080238797003e-06

There O 0 8.109607279038755e-07
has O 0 7.883915742468162e-08
been O 0 9.138157786026113e-09
no O 0 6.144484032688524e-09
previous O 0 9.2572038923322e-09
finding O 0 4.153507315862726e-09
of O 0 6.17763118437864e-10
a O 0 3.960765937449651e-09
glycine O 0 2.740160880421172e-07
substitution O 0 1.681206818204828e-08
that O 0 2.0828936353467498e-09
is O 0 2.0728707639250388e-09
not O 0 2.3543782479151787e-09
associated O 0 1.5136901510004463e-08
with O 0 8.431866760361117e-09
any O 0 2.4369953166569758e-08
obvious O 0 2.3332855562330224e-05
phenotype O 0 0.006076439283788204
in O 0 4.040270482619235e-07
homozygous O 0 0.00023671897361055017
individuals O 0 2.502207962606917e-06
. O 0 8.772165529080667e-06

Founder O 0 0.0013148466823622584
BRCA1 O 0 0.00339742423966527
and O 0 5.998733286105562e-06
BRCA2 O 0 0.0027690702117979527
mutations O 0 2.62589910562383e-05
in O 0 2.0072371853530058e-07
French O 0 1.3218675121606793e-05
Canadian O 0 0.0009631141438148916
breast B-Disease 1 0.9856584668159485
and I-Disease 1 0.8061955571174622
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999829530715942
families O 0 0.00020289892563596368
. O 0 4.760713636642322e-05

We O 0 7.558884931313514e-07
have O 0 8.899090175873425e-08
identified O 0 1.8071139606945508e-07
four O 0 2.6689912502320112e-08
mutations O 0 3.933571406378178e-07
in O 0 3.7198653046743857e-09
each O 0 8.329020806385756e-10
of O 0 4.3965613372165535e-09
the O 0 3.3356620861013653e-06
breast B-Disease 1 0.9975060820579529
cancer I-Disease 1 0.9660409688949585
- O 1 0.8475258350372314
susceptibility O 0 0.09704945236444473
genes O 0 5.992683895783557e-07
, O 0 6.354908776984303e-08
BRCA1 O 0 2.036244586633984e-05
and O 0 2.2743502370303759e-07
BRCA2 O 0 3.228921559639275e-05
, O 0 1.7390130224725908e-08
in O 0 3.544563043078597e-08
French O 0 1.006381990009686e-05
Canadian O 0 0.015301418490707874
breast B-Disease 1 0.9991063475608826
cancer I-Disease 1 0.976348876953125
and O 0 0.003787137335166335
breast B-Disease 1 0.9999717473983765
/ I-Disease 1 0.9999977350234985
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999856948852539
families O 0 8.25071765575558e-06
from O 0 4.826489202969242e-06
Quebec O 0 0.0009629118721932173
. O 0 1.660540328884963e-05

To O 0 1.243349856849818e-06
identify O 0 5.5949672059796285e-06
founder O 0 3.1832194508751854e-05
effects O 0 1.533084287075326e-05
, O 0 8.006068696886359e-08
we O 0 1.4832467698511209e-08
examined O 0 4.866181484430854e-07
independently O 0 7.216509345653321e-08
ascertained O 0 1.3447649962472497e-06
French O 0 1.2269368880879483e-06
Canadian O 0 3.152288991259411e-05
cancer B-Disease 0 4.241983333486132e-05
families O 0 1.6914993850036808e-08
for O 0 1.522305947965208e-09
the O 0 4.311647483490333e-09
distribution O 0 6.822514997395501e-09
of O 0 2.7211328745835317e-09
these O 0 1.4467665288009357e-08
eight O 0 6.629911695199553e-07
mutations O 0 2.593676617834717e-05
. O 0 3.350260612933198e-06

Mutations O 0 0.0005927051533944905
were O 0 2.109156866936246e-07
found O 0 7.779249955319756e-08
in O 0 2.762309847526012e-08
41 O 0 1.0430296271124462e-07
of O 0 2.0631212294119905e-08
97 O 0 1.5904819292700267e-06
families O 0 1.525095854049141e-06
. O 0 4.702197202277603e-06

Six O 0 5.584980726780486e-07
of O 0 4.993927760210681e-08
eight O 0 2.695019531984144e-07
mutations O 0 1.7452987322030822e-06
were O 0 2.804643628451231e-08
observed O 0 2.420038072159514e-07
at O 0 5.500470834363114e-08
least O 0 1.192871081912017e-07
twice O 0 2.4186406335502397e-06
. O 0 3.4922979921248043e-06

The O 0 5.858627901034197e-06
BRCA1 O 0 0.00104862404987216
C4446T O 0 0.001535029150545597
mutation O 0 1.5339208403020166e-05
was O 0 3.2411239914154066e-08
the O 0 7.314312266970546e-09
most O 0 6.005056008007159e-09
common O 0 4.994579967387835e-07
mutation O 0 1.0128154826816171e-05
found O 0 4.4445044977692305e-08
, O 0 5.989521767446604e-09
followed O 0 1.133113602946878e-08
by O 0 6.2299703174062415e-09
the O 0 1.8481681252069393e-07
BRCA2 O 0 0.0008507075835950673
8765delAG O 0 0.0006142693455331028
mutation O 0 5.190522279008292e-05
. O 0 1.7811936459111166e-06

Together O 0 1.6420601696154336e-06
, O 0 1.424841116204334e-07
these O 0 1.6563927118795618e-08
mutations O 0 1.9310812149342382e-07
were O 0 2.723978376195646e-09
found O 0 8.979203158787641e-09
in O 0 6.793441365005037e-09
28 O 0 1.8363573772717245e-08
of O 0 1.9547690133236983e-09
41 O 0 2.1990150855799584e-07
families O 0 6.029262777929034e-08
identified O 0 3.272353694683261e-07
to O 0 1.3943889598522219e-08
have O 0 3.619371469198995e-08
a O 0 5.602894361800281e-07
mutation O 0 0.000105466773675289
. O 0 3.14025123770989e-06

The O 0 1.8484338397684041e-06
odds O 0 1.012316261039814e-05
of O 0 2.1733663757572685e-08
detection O 0 1.877030399555224e-06
of O 0 2.2868913429618942e-09
any O 0 3.057468278555575e-09
of O 0 1.4400043379936278e-09
the O 0 1.4752564503339727e-08
four O 0 2.376233538825545e-07
BRCA1 O 0 0.0011276390869170427
mutations O 0 5.59284399059834e-06
was O 0 2.9820051850038e-07
18 O 0 1.0241103609587299e-06
. O 0 2.2484350665763486e-06

7x O 0 0.03843037784099579
greater O 0 2.6848865672945976e-06
if O 0 1.308746391259774e-07
one O 0 8.265972795129528e-09
or O 0 3.1450486659423404e-09
more O 0 2.961354494956936e-09
cases O 0 2.8863362899755884e-07
of O 0 0.0005912833148613572
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999958276748657
were O 0 2.160473684398312e-07
also O 0 4.7777255929304374e-08
present O 0 8.840267895493525e-08
in O 0 5.301983563299473e-08
the O 0 1.8039749249965098e-07
family O 0 2.4526736979169073e-06
. O 0 5.176238573767478e-06

The O 0 9.30651822272921e-07
odds O 0 7.949704922793899e-06
of O 0 1.5319946200520462e-08
detection O 0 1.3554360975831514e-06
of O 0 1.631107027222356e-09
any O 0 1.3648621122186455e-09
of O 0 1.2617688005533978e-09
the O 0 1.648261793718575e-08
four O 0 4.6346002591235447e-07
BRCA2 O 0 0.001254096976481378
mutations O 0 6.0060374380555e-06
was O 0 2.6599889224598883e-07
5 O 0 7.655459057787084e-07
. O 0 2.0164670786471106e-06

3x O 0 0.002090055961161852
greater O 0 4.044984052598011e-06
if O 0 1.595469427684293e-07
there O 0 4.3574237551524675e-09
were O 0 1.210881062085889e-09
at O 0 2.2409059052819202e-09
least O 0 1.4032166539834634e-09
five O 0 4.755974725156875e-09
cases O 0 6.197452506739864e-08
of O 0 1.853623643910396e-06
breast B-Disease 1 0.999647855758667
cancer I-Disease 1 0.7794150710105896
in O 0 4.6180952040231205e-07
the O 0 5.381328378462058e-07
family O 0 6.899161235196516e-06
. O 0 6.520184342662105e-06

Interestingly O 0 9.220096399076283e-05
, O 0 7.072584651268699e-08
the O 0 1.1275942846111775e-08
presence O 0 2.3766814294390315e-08
of O 0 6.73179867405338e-09
a O 0 2.716141125347349e-06
breast B-Disease 1 0.9542326927185059
cancer I-Disease 0 0.14181526005268097
case O 0 5.998350616209791e-07
< O 0 2.7561397928366205e-06
36 O 0 2.828258338638534e-08
years O 0 1.1469952987397392e-08
of O 0 3.627863787158958e-09
age O 0 4.321430822074035e-07
was O 0 2.08366550680239e-08
strongly O 0 4.946981135844908e-08
predictive O 0 9.517020771454554e-08
of O 0 9.457946648083748e-10
the O 0 1.5714022305601816e-09
presence O 0 4.688120114337835e-09
of O 0 4.083889337813673e-10
any O 0 7.346620534143256e-10
of O 0 1.1878388272990037e-09
the O 0 1.3904504214679037e-08
eight O 0 8.709553185326513e-07
mutations O 0 2.1047808331786655e-05
screened O 0 1.8537455616751686e-05
. O 0 4.748916126118274e-06

Carriers O 0 7.27330734662246e-06
of O 0 3.000753423521019e-08
the O 0 1.913695335531429e-08
same O 0 1.096872139783045e-07
mutation O 0 1.7317067886324367e-06
, O 0 3.847526297562354e-09
from O 0 9.991908411777217e-10
different O 0 1.6422421200701365e-09
families O 0 1.986378883600537e-08
, O 0 1.0063982536223648e-08
shared O 0 4.742679138303174e-08
similar O 0 3.174261280491919e-07
haplotypes O 0 3.851229485007934e-05
, O 0 2.343474569954651e-08
indicating O 0 1.524158079746485e-07
that O 0 1.026335350040597e-09
the O 0 1.8342701801898897e-09
mutant O 0 2.171679625462275e-06
alleles O 0 5.738686326139941e-08
were O 0 3.428005435068826e-09
likely O 0 1.8389126665852018e-08
to O 0 1.4619726540487932e-09
be O 0 2.936818788157325e-09
identical O 0 3.54492215137725e-07
by O 0 8.395759643065048e-09
descent O 0 4.1260094008066517e-07
for O 0 4.018736454725058e-09
a O 0 1.0339420697391688e-07
mutation O 0 2.280647549923742e-06
in O 0 1.6655452128588877e-08
the O 0 5.4045553810055935e-08
founder O 0 1.4236095012165606e-05
population O 0 5.419435069597967e-07
. O 0 1.4394923937288695e-06

The O 0 6.890297186146199e-07
identification O 0 7.408937676700589e-07
of O 0 5.371884626015344e-08
common O 0 1.1852366696984973e-06
BRCA1 O 0 0.0003743541019503027
and O 0 2.599181016194052e-06
BRCA2 O 0 0.005366866011172533
mutations O 0 5.754113317379961e-06
will O 0 2.331147896939001e-08
facilitate O 0 6.397791452172896e-08
carrier O 0 1.0383158951299265e-05
detection O 0 3.529738478391664e-06
in O 0 6.288675535870425e-08
French O 0 1.2671771401073784e-05
Canadian O 0 0.005959375761449337
breast B-Disease 1 0.9965699911117554
cancer I-Disease 1 0.9253609776496887
and O 0 0.0022092987783253193
breast B-Disease 1 0.9999445676803589
/ I-Disease 1 0.9999908208847046
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999717473983765
families O 0 0.00014394217578228563
. O 0 3.4317283279960975e-05

Are O 0 1.8962261947308434e-06
Dp71 O 0 0.0002159238647436723
and O 0 1.0758614052974735e-06
Dp140 O 0 0.0014278106391429901
brain O 0 0.0036837237421423197
dystrophin O 0 0.0002908022725023329
isoforms O 0 2.0675665837188717e-06
related O 0 8.566775591134501e-07
to O 0 2.884932825963915e-07
cognitive B-Disease 0 0.006827940233051777
impairment I-Disease 1 0.9701074957847595
in O 0 0.004183078184723854
Duchenne B-Disease 1 0.9999368190765381
muscular I-Disease 1 0.9999492168426514
dystrophy I-Disease 1 0.9997958540916443
? O 0 0.005701007321476936

Molecular O 0 0.10372374951839447
study O 0 1.1539673323568422e-05
and O 0 8.197379202101729e-07
neuropsychological O 0 0.00094793108291924
analysis O 0 4.645995659302571e-07
were O 0 7.940428758956841e-09
performed O 0 3.573617490815195e-08
concurrently O 0 1.416374484364269e-08
on O 0 2.843088786619319e-08
49 O 0 1.9806186628557043e-06
patients O 0 5.364586286304984e-06
with O 0 0.00019565472030080855
Duchenne B-Disease 1 0.9999953508377075
muscular I-Disease 1 0.9999960660934448
dystrophy I-Disease 1 0.999974250793457
( O 0 7.854620344005525e-05
DMD B-Disease 1 0.9999457597732544
) O 0 4.210734161347318e-08
in O 0 1.1240811836898956e-08
order O 0 5.475158548762238e-09
to O 0 3.3943421406945617e-09
find O 0 3.835775075344827e-08
a O 0 9.098246778194152e-08
molecular O 0 5.451717515825294e-05
explanation O 0 1.6639995692457887e-07
for O 0 4.849741053192247e-09
the O 0 8.035502929715221e-08
cognitive B-Disease 0 0.0010875541483983397
impairment I-Disease 0 0.24149775505065918
observed O 0 5.702379894501064e-06
in O 0 9.65195567914634e-07
most O 0 8.10710116638802e-06
DMD B-Disease 1 0.9999713897705078
patients O 0 0.0008124230662360787
. O 0 2.3819493435439654e-05

Complete O 0 6.649797342106467e-06
analysis O 0 5.152177209311049e-07
of O 0 1.9733130685040123e-08
the O 0 5.247754941706262e-08
dystrophin O 0 0.00010434996511321515
gene O 0 4.38496471133476e-07
was O 0 1.5174190792777154e-08
performed O 0 1.7570938481981102e-08
to O 0 1.3768215456622102e-09
define O 0 2.8794017836730745e-08
the O 0 5.230205601947091e-09
localization O 0 2.6569136934995186e-07
of O 0 2.1816508599670215e-09
deletions O 0 1.4794402432016796e-06
and O 0 2.8195543677611568e-08
duplications O 0 5.282943220663583e-06
in O 0 1.9225014469270718e-08
relation O 0 1.5734971725578362e-07
to O 0 9.141051471317496e-09
the O 0 7.889947539752029e-08
different O 0 1.84930127034022e-06
DMD B-Disease 1 0.9996477365493774
promoters O 0 0.00034142128424718976
. O 0 6.4283740357495844e-06

Qualitative O 0 2.2554260795004666e-05
analysis O 0 1.259768396266736e-06
of O 0 3.019129835024614e-08
the O 0 3.558877281761852e-08
Dp71 O 0 8.483481360599399e-05
transcript O 0 3.932662821171107e-06
and O 0 8.184410482670046e-09
testing O 0 1.3857800240657525e-08
for O 0 4.47924780599962e-10
the O 0 1.0376156600599984e-09
specific O 0 2.8622562098234994e-09
first O 0 3.1329845384675536e-09
exon O 0 8.385974865632306e-07
of O 0 3.902454803750288e-09
Dp140 O 0 3.260120138293132e-06
were O 0 4.442231027468324e-09
also O 0 8.801364970167924e-09
carried O 0 1.0644438219742369e-07
out O 0 1.6303481231716432e-07
. O 0 1.8021365804088418e-06

Neuropsychological O 0 0.008661855943500996
analysis O 0 2.2058757167542353e-05
assessed O 0 6.8055705924052745e-06
verbal O 0 1.4553634173353203e-05
and O 0 9.517971193417907e-07
visuospatial O 0 0.008915175683796406
intelligence O 0 1.0963646673189942e-05
, O 0 2.549588273836889e-08
verbal O 0 3.310767624498112e-06
memory O 0 0.00015217122563626617
, O 0 5.1409468682095394e-08
and O 0 3.125030545447771e-08
reading O 0 2.0646566554205492e-06
skills O 0 4.3408381316112354e-06
. O 0 1.680253490121686e-06

Comparison O 0 1.2008777957817074e-05
of O 0 4.217253035676549e-07
molecular O 0 0.00036873636418022215
and O 0 3.389757239347091e-07
psychometric O 0 0.011220194399356842
findings O 0 2.1069639842608012e-05
demonstrated O 0 1.5639390085198102e-06
that O 0 4.869409320207296e-09
deletions O 0 5.525707251763379e-07
and O 0 1.3959403410979121e-08
duplications O 0 1.5162639783738996e-06
that O 0 5.612443843006076e-09
were O 0 2.6160293931098977e-09
localized O 0 4.5038137841402204e-07
in O 0 1.2026506901463563e-08
the O 0 5.747500697594887e-09
distal O 0 5.165012453289819e-07
part O 0 9.387751020994983e-09
of O 0 1.6797028212778287e-09
the O 0 9.349350627019248e-09
gene O 0 8.738825840737263e-08
seemed O 0 3.5463617820141735e-08
to O 0 2.7232565091850347e-09
be O 0 8.691992903209211e-09
preferentially O 0 1.9267727111582644e-06
associated O 0 6.873279971841839e-07
with O 0 8.403034144066623e-07
cognitive B-Disease 0 0.013863411732017994
impairment I-Disease 1 0.8384720087051392
. O 0 3.2458370696986094e-05

Two O 0 1.3576418496086262e-06
altered O 0 7.91209276940208e-06
Dp71 O 0 2.4000015400815755e-05
transcripts O 0 5.484509983944008e-07
and O 0 5.773574063283604e-09
two O 0 1.8575316840241385e-09
deleted O 0 7.425872894373242e-08
Dp140 O 0 1.0468647815287113e-06
DNA O 0 9.494248587316179e-08
sequences O 0 4.1516564408539125e-08
were O 0 1.760833812092244e-09
found O 0 1.0861667121275786e-08
in O 0 2.1441449504777665e-08
four O 0 5.170221584194223e-07
patients O 0 3.374115112819709e-05
with O 0 0.00015333997725974768
severe O 1 0.9998942613601685
cerebral B-Disease 1 0.9999878406524658
dysfunction I-Disease 1 0.9994490742683411
. O 0 0.00034644940751604736

These O 0 1.7111059378294158e-06
findings O 0 3.925565579265822e-06
suggest O 0 4.066839665028965e-07
that O 0 5.919403189835748e-09
some O 0 8.381723093364712e-10
sequences O 0 1.9587112376484583e-08
located O 0 9.879196127826617e-09
in O 0 3.782403279473101e-09
the O 0 2.7845787897717855e-09
distal O 0 1.7883988334688183e-07
part O 0 5.753917342588011e-09
of O 0 1.599476218139273e-09
the O 0 9.817396673383882e-09
gene O 0 9.756285379580731e-08
and O 0 7.814401570271912e-09
, O 0 6.16066708758467e-09
in O 0 4.974588296846605e-09
particular O 0 1.921760706125042e-08
, O 0 1.2368856161515396e-08
some O 0 8.602764722809297e-09
DMD B-Disease 1 0.9642462730407715
isoforms O 0 2.511555408091226e-07
expressed O 0 4.144393273008973e-08
in O 0 2.7276401581843857e-08
the O 0 3.17589041287647e-07
brain O 0 0.031455107033252716
may O 0 5.014931616642571e-07
be O 0 7.218709185963235e-09
related O 0 5.408030645526196e-08
to O 0 1.235791469156311e-08
the O 0 8.404732625422184e-07
cognitive B-Disease 0 0.19751466810703278
impairment I-Disease 1 0.9887440204620361
associated O 0 4.91467108076904e-05
with O 0 2.97790775221074e-05
DMD B-Disease 1 0.9999638795852661
. O 0 4.8013494051701855e-06
. O 0 5.2191198847140186e-06

I1307K O 0 0.0008219111477956176
APC O 0 5.03219744132366e-05
and O 0 4.522338201695675e-07
hMLH1 O 0 0.00021237482724245638
mutations O 0 4.507561698119389e-06
in O 0 1.6558052706727722e-08
a O 0 2.6789571450080985e-08
non O 0 1.1067176330925577e-07
- O 0 3.105608993791975e-05
Jewish O 0 1.37133866928707e-07
family O 0 6.441847943960965e-08
with O 0 2.0990475491089455e-07
hereditary B-Disease 0 0.18706242740154266
non I-Disease 0 0.09419529139995575
- I-Disease 1 0.9999948740005493
polyposis I-Disease 1 0.9999984502792358
colorectal I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999886751174927
. O 0 0.0002147171035176143

We O 0 1.0118550335391774e-06
describe O 0 1.1240541653023683e-06
a O 0 1.1095117713466607e-07
French O 0 2.548835709603736e-06
Canadian O 0 2.156265873054508e-05
hereditary B-Disease 0 0.04513588920235634
non I-Disease 0 0.0318882092833519
- I-Disease 1 0.9999983310699463
polyposis I-Disease 1 0.9999996423721313
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
( O 0 0.0002021608524955809
HNPCC B-Disease 1 0.9934147596359253
) O 0 2.314602909336827e-07
kindred O 0 0.0001105335759348236
which O 0 4.0806696688378e-08
carries O 0 1.4909893764070148e-07
a O 0 6.290654397389517e-08
novel O 0 1.0389330782345496e-06
truncating O 0 0.00014836012269370258
mutation O 0 6.148687589302426e-06
in O 0 3.6979309925300186e-07
hMLH1 O 0 0.00015241112851072103
. O 0 2.1432388166431338e-06

Interestingly O 0 0.00010439822654007003
, O 0 2.0071031769930414e-07
the O 0 7.456301887032168e-08
I1307K O 0 3.989175093010999e-05
APC O 0 1.3253880752017722e-05
polymorphism O 0 4.6559474867535755e-05
, O 0 4.092704841696104e-08
associated O 0 4.92110068250895e-08
with O 0 8.196298750817732e-09
an O 0 1.626581358493695e-08
increased O 0 1.8561357137514278e-05
risk O 0 0.00044629687909036875
of O 0 0.056117944419384
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
, O 0 2.4290843612106983e-06
is O 0 3.5888497507130523e-08
also O 0 1.1641870578671387e-08
present O 0 2.9163119918962366e-08
in O 0 4.448006762913792e-08
this O 0 5.7811138987062805e-08
family O 0 1.1125373475806555e-06
. O 0 3.186495177942561e-06

The O 0 2.062316752926563e-06
I1307K O 0 0.0001552949397591874
polymorphism O 0 0.00013321763253770769
has O 0 1.1024282287053211e-07
previously O 0 5.005828995763295e-08
only O 0 2.595562431650933e-09
been O 0 9.461921912645721e-09
identified O 0 2.0424508306859934e-07
in O 0 2.6353317750249516e-08
individuals O 0 9.826352176389719e-09
of O 0 9.201155393157023e-09
self O 0 3.950277823605575e-05
- O 0 0.12519584596157074
reported O 0 4.052085932926275e-05
Ashkenazi O 0 9.26108805288095e-06
Jewish O 0 1.9311767118779244e-06
origins O 0 1.6849226085469127e-05
. O 0 3.642874844445032e-06

In O 0 2.1318780909496127e-06
addition O 0 3.2447306352878513e-07
, O 0 1.8278624835943447e-08
in O 0 7.359639120352313e-09
this O 0 5.386738166635041e-09
family O 0 5.6233872669508855e-08
, O 0 9.502542752670706e-09
there O 0 5.403078873200684e-09
appears O 0 6.637871763359726e-08
to O 0 1.8780696997566793e-09
be O 0 2.3274193683420208e-09
no O 0 9.14959841225027e-09
relationship O 0 5.8825115445415577e-08
between O 0 8.494741798870109e-09
the O 0 1.5110593665212946e-08
I1307K O 0 5.9822625189553946e-05
polymorphism O 0 8.334872291015927e-06
and O 0 4.720385859968701e-09
the O 0 4.884013193873216e-09
presence O 0 4.783907670002918e-08
or O 0 1.324314524708825e-08
absence O 0 2.618597534365108e-07
of O 0 3.113251523245708e-07
cancer B-Disease 0 0.046514905989170074
. O 0 1.6278186194540467e-06
. O 0 4.352975793153746e-06

Identification O 0 6.839188699814258e-06
of O 0 6.464298252240042e-08
a O 0 1.266505478270119e-07
novel O 0 5.348819627215562e-07
mutation O 0 3.7451550838341063e-07
of O 0 1.5587273693995485e-09
the O 0 7.196959916910828e-09
CPO O 0 6.876302450109506e-06
gene O 0 5.2895092750304684e-08
in O 0 7.986268535375984e-09
a O 0 3.78867994754728e-08
Japanese O 0 1.042980238707969e-05
hereditary B-Disease 0 0.003810690715909004
coproporphyria I-Disease 0 0.19708934426307678
family O 0 1.3866209883417469e-05
. O 0 6.5673943936417345e-06

Hereditary B-Disease 1 0.9897043108940125
coproporphyria I-Disease 1 0.9872045516967773
( O 0 3.684887269628234e-05
HCP B-Disease 1 0.7708612680435181
) O 0 1.0700110664174645e-07
is O 0 2.374076579769735e-08
an O 0 2.0499852837474464e-07
autosomal B-Disease 1 0.9523243308067322
dominant I-Disease 1 0.9741443395614624
disease I-Disease 1 0.7556174993515015
characterized O 0 3.254913099226542e-05
by O 0 5.1204943929406e-07
a O 0 6.689235306112096e-05
deficiency B-Disease 1 0.6481439471244812
of I-Disease 0 4.8195346380452975e-08
coproporphyrinogen I-Disease 0 0.06217425689101219
oxidase I-Disease 0 1.3382733413891401e-05
( O 0 4.7147736381703e-08
CPO O 0 7.79416222940199e-06
) O 0 8.927476535802725e-09
caused O 0 5.41476019577658e-08
by O 0 3.4528560011182208e-09
a O 0 6.392960472112463e-08
mutation O 0 6.478647378571623e-07
in O 0 2.7047002859603708e-08
the O 0 1.366370270261541e-07
CPO O 0 0.0002102869184454903
gene O 0 3.198497097400832e-06
. O 0 1.7496448663223418e-06

Only O 0 4.2235558339598356e-07
11 O 0 4.308419363496796e-07
mutations O 0 3.331861364586075e-07
of O 0 2.996582315617502e-09
the O 0 1.4925268132515157e-08
gene O 0 1.9690652663939545e-07
have O 0 2.404142307455004e-08
been O 0 5.907686784212274e-08
reported O 0 7.503576853196137e-06
in O 0 8.036457984417211e-06
HCP B-Disease 1 0.9994426369667053
patients O 0 0.00013740992289967835
. O 0 1.0125421795237344e-05

We O 0 1.8178251366407494e-06
report O 0 6.391680926753907e-07
another O 0 9.452887894667583e-08
mutation O 0 9.297744441028044e-07
in O 0 1.3689456679344403e-08
a O 0 5.288499949074321e-08
Japanese O 0 3.3437488582421793e-06
family O 0 3.6200387967255665e-06
. O 0 4.3600512071861885e-06

Polymerase O 0 8.03828879725188e-05
chain O 0 2.1601703338092193e-05
reaction O 0 1.9008484741789289e-06
- O 0 7.557770459243329e-06
single O 0 1.588297635635172e-07
strand O 0 7.547492259618593e-06
conformational O 0 3.350282668179716e-06
polymorphism O 0 1.7361780919600278e-06
and O 0 3.519970315224441e-09
direct O 0 6.805139118881698e-09
sequence O 0 8.481454472075711e-08
analyses O 0 3.5375734341869247e-07
demonstrated O 0 2.1989647791542666e-07
a O 0 2.0711958370611683e-08
C O 0 3.0232624226300686e-07
to O 0 2.185457592673856e-09
T O 0 1.0533282193136984e-06
substitution O 0 4.348208459958869e-09
in O 0 1.2899599166615872e-09
exon O 0 2.675056975931511e-07
1 O 0 1.0761790347757483e-09
of O 0 2.610425764437707e-10
the O 0 3.320458796807202e-09
CPO O 0 2.352147475903621e-06
gene O 0 1.3466454618082935e-08
at O 0 1.255955783818763e-09
nucleotide O 0 7.445131444683284e-08
position O 0 8.578873611497784e-09
85 O 0 1.0528792948605314e-08
, O 0 2.2959951717638205e-09
which O 0 2.74278888490187e-09
lies O 0 2.9961153558133446e-08
in O 0 5.026502325478077e-09
the O 0 8.242860616292091e-09
putative O 0 1.0785225640574936e-05
presequence O 0 1.7893484255182557e-05
for O 0 5.670570235594141e-09
targeting O 0 1.5489901272758289e-07
to O 0 7.817357072781306e-08
mitochondria O 0 7.216235098894686e-05
. O 0 3.855800514429575e-06

This O 0 2.173121174564585e-06
mutation O 0 1.2551810868899338e-05
changes O 0 1.4251426705413905e-07
the O 0 1.1238024733017937e-08
codon O 0 1.328332217553907e-07
for O 0 2.9657747369071785e-09
glutamine O 0 1.207092310551161e-07
to O 0 3.2023785845325392e-09
a O 0 1.6986705375643396e-08
termination O 0 2.2025465113983955e-06
codon O 0 2.708314355004404e-07
at O 0 1.987477915577074e-08
amino O 0 6.752235037765786e-08
acid O 0 2.9978704674249457e-07
position O 0 2.395590286141669e-07
29 O 0 1.959116616490064e-06
. O 0 1.348698788206093e-06

MaeI O 0 0.000981922959908843
restriction O 0 4.313963017921196e-06
analysis O 0 7.532381687269663e-07
showed O 0 3.106430028765317e-07
two O 0 6.578440903126648e-09
other O 0 5.241680423040407e-09
carriers O 0 2.8614397251658374e-07
in O 0 2.7761059229192142e-08
the O 0 8.342256307969365e-08
family O 0 3.891960659530014e-06
. O 0 4.474215529626235e-06

The O 0 4.544683179119602e-06
C O 0 0.00010096844198415056
- O 0 0.06512684375047684
T O 0 0.35980916023254395
mutation O 0 4.350411472842097e-06
is O 0 6.453184209220808e-09
located O 0 9.512153731350281e-09
within O 0 2.563704137870104e-09
a O 0 1.731800480797574e-08
recently O 0 3.022806822627899e-07
proposed O 0 8.313045896102267e-08
putative O 0 1.0448710554555873e-06
alternative O 0 1.793818427131555e-08
translation O 0 1.009759298398194e-08
initiation O 0 1.732114363051096e-08
codon O 0 1.5537865749593038e-07
( O 0 4.457712421412907e-09
TIC O 0 8.013071237655822e-06
- O 0 6.894340003782418e-06
1 O 0 8.659724493043086e-09
) O 0 1.1236047647855685e-09
, O 0 5.888522447428102e-10
supporting O 0 1.0291841157084036e-08
that O 0 3.2490883317137786e-09
TIC O 0 3.621407086029649e-05
- O 0 6.706005933665438e-06
1 O 0 8.230670367481707e-09
is O 0 9.740732664909046e-10
the O 0 1.920048786629991e-09
real O 0 2.0881400075722922e-07
TIC O 0 0.00014029029989615083
rather O 0 1.845434027814008e-08
than O 0 1.6732668584040766e-08
TIC O 0 0.00010666009620763361
- O 0 1.9604100089054555e-05
2 O 0 1.2254477610440517e-07
. O 0 1.0397047134347304e-07
. O 0 1.1729754305633833e-06

Human B-Disease 0 5.071644045528956e-05
complement I-Disease 0 0.0001435594749636948
factor I-Disease 0 0.0003587528190109879
H I-Disease 1 0.9999823570251465
deficiency I-Disease 1 0.9997825026512146
associated O 0 0.0018084360053762794
with O 0 0.19029109179973602
hemolytic B-Disease 1 0.9999966621398926
uremic I-Disease 1 0.9999979734420776
syndrome I-Disease 1 0.9999872446060181
. O 0 0.0007124765543267131

This O 0 1.0416483746666927e-06
study O 0 2.475878488894523e-07
reports O 0 7.010240210547636e-08
on O 0 1.3563507650360407e-08
six O 0 2.7380545830624214e-08
cases O 0 1.1565077784325695e-07
of O 0 1.037560764416412e-06
deficiency B-Disease 1 0.9892104864120483
in I-Disease 0 3.4617006150483576e-08
the I-Disease 0 1.0663108618302886e-08
human I-Disease 0 6.012702868929409e-08
complement I-Disease 0 2.725726915286941e-07
regulatory I-Disease 0 1.8400304497845354e-06
protein I-Disease 0 4.383748262171139e-07
Factor I-Disease 0 1.0263811844879456e-07
H I-Disease 1 0.7663196921348572
( O 0 7.198692486554137e-08
FH O 0 5.469421739690006e-05
) O 0 2.2797708165711583e-09
in O 0 1.1375261843582507e-09
the O 0 2.2339923244629745e-09
context O 0 3.1754840534858886e-08
of O 0 5.583308748668969e-08
an O 0 0.00010540262883296236
acute B-Disease 1 0.9999932050704956
renal I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999935626983643
. O 0 0.0006165080703794956

Five O 0 2.8816771191486623e-07
of O 0 2.239736218712096e-08
the O 0 4.337723780167835e-08
cases O 0 7.774562504891946e-08
were O 0 3.2593810317393945e-08
observed O 0 8.921869607547706e-07
in O 0 8.5158347928882e-08
children O 0 9.939092251443071e-07
presenting O 0 9.668932761996984e-05
with O 0 0.33587580919265747
idiopathic O 1 0.999998927116394
hemolytic B-Disease 1 0.9999998807907104
uremic I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999984502792358
( O 0 0.001575091970153153
HUS B-Disease 1 0.9997653365135193
) O 0 1.6528174455743283e-05
. O 0 1.8901628209277987e-05

Two O 0 2.739371893767384e-07
of O 0 6.534138208280638e-08
the O 0 7.069401419812493e-08
children O 0 4.1389907323718944e-07
exhibited O 0 2.8547900001285598e-05
a O 0 8.475521099171601e-06
homozygous O 1 0.9969931840896606
deficiency O 1 0.9993709921836853
characterized O 0 8.101923413050827e-06
by O 0 1.1624186058156738e-08
the O 0 5.988756601738032e-09
absence O 0 2.7947644198889066e-08
of O 0 7.161531923038922e-10
the O 0 1.093503843030419e-09
150 O 0 4.9162385273859854e-09
- O 0 8.349963536602445e-06
kD O 0 4.92278159072157e-05
form O 0 7.905279986175628e-09
of O 0 1.797338167186524e-09
Factor O 0 4.9478586561235716e-08
H O 0 0.07582659274339676
and O 0 5.025495575239347e-09
the O 0 2.7820521442123436e-09
presence O 0 1.8924898981254046e-08
, O 0 1.5417670473638623e-09
upon O 0 1.7380936689903592e-09
immunoblotting O 0 1.6340603679054766e-06
, O 0 7.580304717258457e-10
of O 0 2.0792211008480166e-10
the O 0 9.416618595992077e-10
42 O 0 3.1053811966330613e-08
- O 0 2.9218546842457727e-05
kD O 0 0.0021063166204839945
Factor O 0 6.309544886562435e-08
H O 0 0.0050621903501451015
- O 0 1.621923956918181e-06
like O 0 1.5890408988639138e-08
protein O 0 1.8181891547897067e-08
1 O 0 3.3506144525574655e-09
( O 0 3.883639188018151e-09
FHL O 0 6.9025836637592874e-06
- O 0 9.779216725291917e-07
1 O 0 4.2048893256207975e-09
) O 0 6.923714379603041e-10
and O 0 1.5880432524539856e-09
other O 0 5.43795186658258e-09
FH O 0 0.0007797929574735463
- O 0 0.00018397987878415734
related O 0 3.2316725082637277e-06
protein O 0 5.677786134583584e-07
( O 0 3.878384902122889e-08
FHR O 0 0.00021299821673892438
) O 0 1.1165258939627165e-07
bands O 0 4.527232704276685e-06
. O 0 1.9816975509456825e-06

Southern O 0 1.662083377595991e-05
blot O 0 0.00016634477651678026
and O 0 9.698806024971418e-08
PCR O 0 8.57418001487531e-07
analysis O 0 2.5256637670167947e-08
of O 0 2.389466402519247e-09
DNA O 0 2.2586037573546491e-07
of O 0 2.6424675780845064e-09
one O 0 2.7538087365996944e-08
patient O 0 2.5937631562555907e-06
with O 0 2.2420329059968935e-06
homozygous O 1 0.9975903034210205
deficiency O 1 0.9970665574073792
ruled O 0 1.2591902986969217e-07
out O 0 3.4702996032365263e-09
the O 0 3.2910452141265978e-09
presence O 0 9.329612637998252e-09
of O 0 5.051093432406617e-10
a O 0 5.6619890997922084e-09
large O 0 1.74887215820263e-08
deletion O 0 6.030856525285344e-07
of O 0 3.22278315145752e-09
the O 0 9.076321560996803e-08
FH O 0 0.002279038541018963
gene O 0 9.656756105869135e-08
as O 0 4.169143696941546e-09
the O 0 4.2571361547061315e-08
underlying O 0 0.00012660937500186265
defect O 0 0.0002389630681136623
for O 0 3.0320427413244033e-07
the O 0 3.9292117435252294e-05
deficiency O 1 0.9978471994400024
. O 0 1.4129783266980667e-05

The O 0 6.477220608758216e-07
other O 0 5.359020960327143e-08
four O 0 5.597351915298532e-08
children O 0 8.982033250504173e-08
presented O 0 7.894402074271056e-07
with O 0 3.688558535941411e-06
heterozygous O 0 0.18982894718647003
deficiency O 1 0.9910687208175659
and O 0 2.0059761141055787e-07
exhibited O 0 4.228402303851908e-06
a O 0 9.635414244257845e-08
normal O 0 5.826366873407096e-07
immunoblotting O 0 5.72183562326245e-05
pattern O 0 1.945033858419265e-07
of O 0 1.4423958694109729e-09
proteins O 0 7.890426090284564e-09
of O 0 3.2300448982169883e-09
the O 0 2.0186978133551747e-07
FH O 0 0.015102650038897991
family O 0 1.9166379843227332e-06
. O 0 2.5836852728389204e-06

Factor B-Disease 0 0.009803641587495804
H I-Disease 1 0.99997878074646
deficiency I-Disease 1 0.9977458119392395
is O 0 9.065144723763296e-08
the O 0 4.466378555889605e-08
only O 0 1.904850392975277e-07
complement B-Disease 1 0.9962177872657776
deficiency I-Disease 1 0.9999922513961792
associated O 0 3.363173163961619e-05
with O 0 1.182293999590911e-05
HUS B-Disease 1 0.9998095631599426
. O 0 4.980112862540409e-05

These O 0 1.4964396086725174e-06
observations O 0 5.512035841093166e-06
suggest O 0 4.970076474819507e-07
a O 0 2.523939635068473e-08
role O 0 4.4540602317511e-08
for O 0 2.1794061666469133e-08
FH O 0 0.0017395878676325083
and O 0 1.9515890414822934e-07
/ O 0 2.0641386072384194e-05
or O 0 1.9201711154437362e-07
FH O 0 0.0017856165068224072
receptors O 0 9.099138651436078e-07
in O 0 1.6588113993520892e-08
the O 0 9.093510300317575e-08
pathogenesis O 0 0.0003920735325664282
of O 0 1.16405033168121e-06
idiopathic O 1 0.9998887777328491
HUS B-Disease 1 0.9999532699584961
. O 0 2.277467865496874e-05
. O 0 7.465539511031238e-06

Further O 0 1.1152568504257943e-06
evidence O 0 4.3859728293682565e-07
for O 0 9.60773594016473e-09
a O 0 2.7190745655047976e-08
major O 0 3.1354616680800973e-07
ancient O 0 2.6190615244559012e-05
mutation O 0 0.0867389589548111
underlying O 1 0.7927262783050537
myotonic B-Disease 1 0.9999958276748657
dystrophy I-Disease 1 0.9999624490737915
from O 0 6.892860255902633e-07
linkage O 0 0.000808886019513011
disequilibrium O 0 0.006652332842350006
studies O 0 2.562508427672583e-07
in O 0 1.9124946959436784e-08
the O 0 3.389943969978049e-08
Japanese O 0 2.945138930954272e-06
population O 0 8.85642464254488e-07
. O 0 2.8226700123923365e-06

The O 0 0.006122323218733072
myotonic B-Disease 1 0.9999873638153076
dystrophy I-Disease 1 0.999993085861206
( O 0 0.0006493524415418506
DM B-Disease 1 0.9999309778213501
) O 0 1.9076824173680507e-06
mutation O 0 1.2576182598422747e-05
is O 0 2.6600670111065483e-08
an O 0 3.521060065736492e-08
unstable O 0 0.0026252635288983583
( O 0 2.293169814038265e-07
CTG O 0 0.0002895760990213603
) O 0 8.726378730727902e-09
n O 0 8.846556625030644e-07
repeat O 0 9.91398565020063e-07
, O 0 5.107089418032729e-09
present O 0 3.753154675933956e-09
at O 0 1.0703429254022012e-09
a O 0 2.5465249908762644e-09
copy O 0 3.884381882812704e-08
number O 0 8.606501622487883e-10
of O 0 5.374973799376903e-10
5 O 0 7.415622338413641e-09
- O 0 1.6600290564383613e-06
37 O 0 3.163948747442191e-08
repeats O 0 9.942868217649448e-08
on O 0 4.534791209209743e-09
normal O 0 2.2290052470452792e-08
chromosomes O 0 4.598516056830704e-08
but O 0 1.4825163319187595e-09
amplified O 0 6.945081310050227e-08
to O 0 9.501668341016511e-10
50 O 0 3.352851996041295e-09
- O 0 8.013918773031037e-07
3000 O 0 3.34716133920665e-07
copies O 0 6.79150105042936e-08
on O 0 3.5946735010838893e-07
DM B-Disease 1 0.9954931735992432
chromosomes O 0 9.324456914328039e-05
. O 0 3.744287369045196e-06

Previous O 0 2.1382846171036363e-05
findings O 0 8.704938409209717e-06
in O 0 3.3250526598749275e-07
Caucasian O 0 4.5832864998374134e-05
populations O 0 2.7251212486589793e-07
of O 0 9.660768185426605e-09
a O 0 3.185213245160412e-06
DM B-Disease 1 0.9999653100967407
founder O 0 0.00010521875810809433
chromosome O 0 3.141994238831103e-05
raise O 0 9.743119022687097e-08
a O 0 7.498843324071913e-09
question O 0 1.495946655438729e-08
about O 0 1.626822565548025e-09
the O 0 7.693382819695671e-09
molecular O 0 8.898646228772122e-06
events O 0 5.209976450260001e-08
involved O 0 1.824389883609001e-08
in O 0 1.5920411655656608e-08
the O 0 4.127220165628387e-08
expansion O 0 9.20218099054182e-06
mutation O 0 3.1681345717515796e-05
. O 0 1.699747144812136e-06

To O 0 9.177459787679254e-07
investigate O 0 3.276340294178226e-06
whether O 0 1.7234809490673797e-07
a O 0 9.553485824653762e-08
founder O 0 3.0994162898423383e-06
chromosome O 0 1.9876806618412957e-06
for O 0 6.939596008948001e-09
the O 0 2.5331544861728617e-07
DM B-Disease 1 0.9999909400939941
mutation O 0 0.00011408724094508216
exists O 0 5.6322104313721866e-08
in O 0 1.8075416718943416e-09
the O 0 1.8240757793108742e-09
Japanese O 0 5.9829815768353e-08
population O 0 1.069280397558714e-08
, O 0 4.4653885034051655e-09
we O 0 3.3940703580981335e-09
genotyped O 0 3.171131083945511e-06
families O 0 1.3910313789722295e-08
using O 0 1.7660346074421795e-08
polymorphic O 0 5.600861186394468e-06
markers O 0 1.670473920967197e-06
near O 0 1.1497731833287617e-07
the O 0 2.0594725924638624e-08
( O 0 3.3510701769046136e-08
CTG O 0 3.117942105745897e-05
) O 0 1.0421065788079886e-08
n O 0 7.112789717211854e-07
repeat O 0 1.777974262040516e-06
region O 0 3.796130556565913e-07
and O 0 1.7479625569194468e-07
constructed O 0 6.602204666705802e-05
haplotypes O 0 0.0011146925389766693
. O 0 6.630609732383164e-06

Six O 0 2.1940641090623103e-06
different O 0 1.81822429112799e-07
haplotypes O 0 3.2120089599629864e-05
were O 0 5.487686038918582e-08
found O 0 1.7585264799890865e-07
and O 0 7.384051059489138e-07
DM B-Disease 1 0.9998650550842285
alleles O 0 3.108640157734044e-06
were O 0 6.26959675287253e-08
always O 0 7.416204539367754e-07
haplotype O 0 0.0002645963686518371
A O 0 2.7955727546213893e-06
. O 0 6.70235476718517e-06

To O 0 2.550965518821613e-07
find O 0 8.551317876026587e-08
an O 0 2.957296407757326e-09
origin O 0 1.6084898746271392e-08
of O 0 2.055688286262125e-09
the O 0 1.1918086961770769e-08
( O 0 2.5381131862900475e-08
CTG O 0 2.2347736376104876e-05
) O 0 3.1156552893207845e-09
n O 0 7.158792527661717e-07
repeat O 0 1.6818695485198987e-06
mutation O 0 1.9960566532972734e-07
and O 0 1.3026189016329681e-09
to O 0 1.0795631055771082e-09
investigate O 0 3.6106836631688566e-08
the O 0 2.0189601102060806e-09
mechanism O 0 5.808765912718172e-09
of O 0 3.6697439531607756e-10
the O 0 2.6308506484440386e-09
expansion O 0 2.1515357673251856e-07
mutation O 0 8.330013656632218e-08
in O 0 1.3041056012852437e-09
the O 0 1.3923232566881438e-09
Japanese O 0 4.25787547442269e-08
population O 0 4.196028413616659e-09
we O 0 1.1932546062354277e-09
have O 0 1.1576013481118252e-09
studied O 0 1.8382111832693226e-08
90 O 0 7.142642033386437e-09
Japanese O 0 3.446045582222723e-07
DM B-Disease 1 0.823350191116333
families O 0 4.849947288221301e-08
comprising O 0 2.7151514814249822e-08
190 O 0 5.7128254127292166e-08
affected O 0 4.725883329115277e-08
and O 0 2.4206148196981303e-08
130 O 0 3.7505949990190857e-07
unaffected O 0 2.5162733436445706e-05
members O 0 7.908643624432443e-07
. O 0 2.7893488550034817e-06

The O 0 2.1455700789374532e-06
results O 0 6.8363192440301646e-06
suggest O 0 6.962302450119751e-07
that O 0 9.345518137138242e-09
a O 0 1.040005770391872e-08
few O 0 1.2093399170964858e-08
common O 0 7.477822094870135e-08
ancestral O 0 3.760469553526491e-05
mutations O 0 7.394917815872759e-07
in O 0 4.850249535337525e-09
both O 0 6.468748647847633e-09
Caucasian O 0 4.205459845252335e-06
and O 0 2.453936076562968e-08
Japanese O 0 3.7439266975525243e-07
populations O 0 6.949586150994946e-08
have O 0 3.194192244038163e-09
originated O 0 6.1044866939141684e-09
by O 0 6.024877818866514e-10
expansion O 0 1.1160953050648459e-08
of O 0 6.787156392462634e-10
an O 0 1.6469599017909786e-09
ancestral O 0 3.813456942225457e-06
n O 0 1.0193182788498234e-05
= O 0 1.7670002989689237e-06
5 O 0 5.230155863955588e-09
repeat O 0 7.79213991108918e-08
to O 0 2.669519494347128e-09
n O 0 2.185122639275505e-06
= O 0 2.5990868834924186e-06
19 O 0 2.5095914679695852e-08
- O 0 1.8422392713546287e-06
37 O 0 2.1620299150981737e-07
copies O 0 5.900918154111423e-07
. O 0 1.1378704130038386e-06

These O 0 9.311569328929181e-07
data O 0 4.053086968269781e-07
support O 0 4.034452061318916e-08
multistep O 0 1.316115231020376e-06
models O 0 7.79246676074763e-08
of O 0 6.069725611013155e-09
triplet O 0 0.0012283194810152054
repeat O 0 3.419581389607629e-06
expansion O 0 2.1790825144307746e-07
that O 0 4.389012264738312e-09
have O 0 1.9679597951238748e-09
been O 0 2.860471637333717e-09
proposed O 0 8.68044569557469e-09
for O 0 5.819322801414728e-09
both O 0 1.6961040216756373e-07
DM B-Disease 1 0.9999140501022339
and O 0 1.5533791156485677e-05
Friedreichs B-Disease 1 0.8292845487594604
ataxia I-Disease 1 0.6029658317565918
. O 0 1.2277960195206106e-06
. O 0 3.155005288135726e-06

The O 0 2.996583589265356e-06
molecular O 0 8.140155841829255e-05
basis O 0 3.1300240266318724e-07
of O 0 6.1644227571378e-06
C6 B-Disease 1 0.999997615814209
deficiency I-Disease 1 0.9999837875366211
in O 0 8.120861849647554e-08
the O 0 2.2205691507792835e-08
western O 0 1.3172775936709513e-07
Cape O 0 2.2487911337520927e-06
, O 0 2.743177240915884e-08
South O 0 2.410872355085303e-07
Africa O 0 6.090980946282798e-07
. O 0 1.6385062053814181e-06

Deficiency B-Disease 1 0.9551453590393066
of I-Disease 0 1.0939492511852222e-07
the I-Disease 0 3.204799980949247e-08
sixth I-Disease 0 2.3145389604906086e-07
component I-Disease 0 1.0502562730607679e-07
of I-Disease 0 3.8732088647464025e-09
human I-Disease 0 8.231348402887306e-08
complement I-Disease 0 5.3281848977349e-07
( O 0 5.664087510126592e-08
C6 O 0 0.00035943000693805516
) O 0 4.632176420216183e-09
has O 0 2.124716624862799e-09
been O 0 3.816004845447196e-09
reported O 0 1.219682275177547e-07
in O 0 3.4333711429468394e-09
a O 0 5.715699469277524e-09
number O 0 3.5542695453472106e-09
of O 0 1.2653115222249767e-09
families O 0 1.1100744323755407e-08
from O 0 5.04755170993576e-09
the O 0 1.2277423522277786e-08
western O 0 1.5138293463223818e-07
Cape O 0 1.6373564903915394e-06
, O 0 4.869727732170759e-08
South O 0 3.0774330639360414e-07
Africa O 0 1.2425391560100252e-06
. O 0 2.679933913896093e-06

Meningococcal B-Disease 1 0.9998095631599426
disease I-Disease 1 0.9970993995666504
is O 0 3.998136890004389e-06
endemic O 0 4.833098500967026e-05
in O 0 5.0328459622051014e-08
the O 0 2.5215001642209245e-08
Cape O 0 1.1856018318212591e-06
and O 0 6.935943819286194e-09
almost O 0 2.773728136062914e-09
all O 0 5.19664256071195e-10
pedigrees O 0 1.0967860362143256e-06
of O 0 1.8083495589849008e-08
total O 0 0.0009740316891111434
C6 B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.999996542930603
( O 0 2.842910760136874e-07
C6Q0 O 0 0.003358979942277074
) O 0 9.18232601065938e-09
have O 0 5.2681810025489995e-09
been O 0 1.7438292587712567e-08
ascertained O 0 1.1901811376446858e-05
because O 0 8.793768557779913e-08
of O 0 1.1404985116314492e-06
recurrent O 1 0.999671220779419
disease O 1 0.9836732149124146
. O 0 5.711309495382011e-05

We O 0 8.844970693644427e-07
have O 0 4.8721251033612134e-08
sequenced O 0 7.662755479032057e-07
the O 0 1.3271997723052209e-08
expressed O 0 2.9392747791234797e-08
exons O 0 1.4432420414323133e-07
of O 0 1.6465891983230563e-09
the O 0 1.0951513473855812e-08
C6 O 0 4.9260306695941836e-05
gene O 0 3.226296740876933e-08
from O 0 4.013481547104902e-09
selected O 0 1.936415827685778e-08
cases O 0 1.197299681621189e-08
and O 0 1.1466540605908904e-08
have O 0 1.779841696247786e-08
found O 0 7.582740835232471e-08
three O 0 2.0564783653753693e-07
molecular O 1 0.5215392112731934
defects O 0 0.3399735391139984
leading O 0 3.310444185444794e-07
to O 0 6.318480672007354e-08
total O 0 0.00013628251326736063
deficiency O 1 0.9993083477020264
879delG O 0 0.0029051308520138264
, O 0 4.181082857712681e-08
which O 0 5.50311263225467e-09
is O 0 3.072035292817077e-09
the O 0 1.0295020835826563e-08
common O 0 4.1008556195265555e-07
defect O 0 3.0366629289346747e-05
in O 0 1.7907485272417034e-08
the O 0 2.540656041105649e-08
Cape O 0 2.283346248077578e-06
and O 0 4.6735433301137164e-08
hitherto O 0 5.328928637027275e-06
unreported O 0 6.522591320390347e-06
, O 0 1.6369202882060563e-08
and O 0 1.0343044642979748e-08
1195delC O 0 7.826210094208363e-06
and O 0 2.4395530928700282e-08
1936delG O 0 2.840356683009304e-05
, O 0 6.414357489603617e-09
which O 0 2.1412749351412685e-09
have O 0 2.1815345085940407e-09
been O 0 1.058081355864715e-08
previously O 0 8.773446324994438e-08
reported O 0 1.4329341979646415e-07
in O 0 1.8698496973001966e-08
African O 0 9.356667618476422e-08
- O 0 0.0003934157721232623
Americans O 0 6.224109711183701e-06
. O 0 4.384682142699603e-06

We O 0 1.0627251185724162e-06
also O 0 7.528009149382342e-08
show O 0 7.025754911182958e-08
that O 0 3.453376473672165e-09
the O 0 7.24013737851692e-09
879delG O 0 9.381734344060533e-06
and O 0 2.093519668733279e-07
1195delC O 0 0.0266555268317461
defects O 0 0.02388324774801731
are O 0 2.3876362220676128e-08
associated O 0 2.4287709265991e-07
with O 0 1.282040784644778e-07
characteristic O 0 0.0011469944147393107
C6 O 1 0.712411105632782
/ O 0 0.00011178133718203753
C7 O 0 0.0009350645705126226
region O 0 6.118571036495268e-07
DNA O 0 1.179207060886256e-06
marker O 0 1.1582341358007398e-05
haplotypes O 0 8.139938290696591e-05
, O 0 3.0668264372479825e-08
although O 0 1.3213423244451405e-08
small O 0 1.4283465077369328e-08
variations O 0 4.719456399016053e-07
were O 0 1.438938852516003e-07
observed O 0 4.42812051915098e-06
. O 0 2.635131750139408e-06

The O 0 5.655430868500844e-06
1936delG O 0 0.003078585024923086
defect O 0 0.0008696105796843767
was O 0 1.3724704217565886e-07
observed O 0 1.167053298445353e-07
only O 0 1.4200687292742487e-09
once O 0 1.0110542625341168e-08
in O 0 3.0750253454669974e-09
the O 0 7.361843579190008e-09
Cape O 0 1.8213113435194828e-06
, O 0 6.510151973060374e-09
but O 0 3.6912901624219785e-09
its O 0 2.148668798440667e-08
associated O 0 1.181667926175578e-06
haplotype O 0 0.000298575236229226
could O 0 9.984144355712488e-08
be O 0 4.577950463158231e-08
deduced O 0 6.437693173211301e-06
. O 0 1.1975255347351776e-06

The O 0 8.675150979797763e-07
data O 0 4.905984383185569e-07
from O 0 1.5994647384331984e-08
the O 0 2.3404906457358265e-08
haplotypes O 0 1.3403080629359465e-05
indicate O 0 3.386820139894553e-07
that O 0 2.5918815982350907e-09
these O 0 1.929836956904296e-09
three O 0 2.2817165046262744e-08
molecular O 0 0.023666273802518845
defects O 0 0.006700729485601187
account O 0 7.26678663909297e-08
for O 0 6.201328339727752e-09
the O 0 1.7400024887592735e-07
defects O 0 0.0035278021823614836
in O 0 1.0568812491840163e-08
all O 0 9.5924057585961e-10
the O 0 6.245794992310039e-09
38 O 0 1.111015279775529e-07
unrelated O 0 4.957090823154431e-06
C6Q0 O 0 0.010602357797324657
individuals O 0 2.7108770339623334e-08
we O 0 6.481976289052227e-09
have O 0 6.430772359067305e-09
studied O 0 5.480155351733629e-08
from O 0 1.266082261253132e-08
the O 0 1.5873438030666875e-07
Cape O 0 5.812690142192878e-05
. O 0 3.169039246131433e-06

We O 0 5.764531465501932e-07
have O 0 2.912987717706983e-08
also O 0 1.1160102175722386e-08
observed O 0 4.904496719859708e-08
the O 0 9.036226877867648e-09
879delG O 0 5.576694820774719e-05
defect O 0 1.3987253623781726e-05
in O 0 2.1653432824564334e-08
two O 0 3.729337194613436e-08
Dutch O 0 0.002454145811498165
C6 B-Disease 1 0.9998793601989746
- I-Disease 1 0.9971005320549011
deficient I-Disease 1 0.9994422793388367
kindreds O 0 0.00011237298895139247
, O 0 1.2228579038264797e-08
but O 0 5.243600220694589e-09
the O 0 1.3168386381323671e-08
879delG O 0 6.318483792711049e-05
defect O 0 2.3965820219018497e-05
in O 0 1.5585380097604684e-08
the O 0 2.1053180532248916e-08
Cape O 0 6.977503744565183e-06
probably O 0 1.3435403900530218e-07
did O 0 7.49571160696405e-09
not O 0 9.43704447919913e-10
come O 0 2.0773351927516615e-09
from O 0 1.190358589475693e-09
The O 0 8.233873138863146e-09
Netherlands O 0 1.6168368119906518e-06
. O 0 9.129624345405318e-08
. O 0 1.0714156815083697e-06

Complement B-Disease 1 0.9368658661842346
C7 I-Disease 1 0.9999812841415405
deficiency I-Disease 1 0.9999762773513794
: O 0 2.007690000027651e-06
seven O 0 1.2283975081572862e-07
further O 0 2.121561664125693e-07
molecular O 0 0.1861623227596283
defects O 0 0.2162298858165741
and O 0 1.3714029023503826e-07
their O 0 1.2443564401110052e-07
associated O 0 3.6182473195367493e-06
marker O 0 0.00013785217015538365
haplotypes O 0 0.002754648681730032
. O 0 6.032637884345604e-06

Seven O 0 3.2568570986768464e-06
further O 0 8.45538181692973e-07
molecular O 0 5.570906796492636e-05
bases O 0 4.54600058219512e-06
of O 0 1.5964700651238672e-05
C7 B-Disease 1 0.9999960660934448
deficiency I-Disease 1 0.9999946355819702
are O 0 1.3520728998628329e-06
described O 0 4.086553235538304e-05
. O 0 1.2565272299980279e-05

All O 0 3.2880356570785807e-07
these O 0 6.419353582032272e-08
new O 0 1.1944185871470836e-06
molecular O 0 0.010780437849462032
defects O 0 0.004225913435220718
involve O 0 1.327761083302903e-07
single O 0 5.766368360582419e-08
- O 0 1.7123029465437867e-05
nucleotide O 0 7.530306334047054e-07
events O 0 1.8026810266746907e-08
, O 0 1.7397718821143826e-09
deletions O 0 5.829068072671362e-08
and O 0 2.8136757368457666e-09
substitutions O 0 2.433544210589389e-08
, O 0 1.5326895308476196e-09
some O 0 2.0545623535817015e-10
of O 0 1.8433117254801346e-09
which O 0 2.469732152121651e-08
alter O 0 2.340487299079541e-06
splice O 0 2.4160658540495206e-06
sites O 0 1.6192426244288072e-07
, O 0 1.7670320318075028e-08
and O 0 6.811595198996656e-08
others O 0 4.7036670025590865e-07
codons O 0 1.3257775208330713e-05
. O 0 2.032026714005042e-06

They O 0 5.638702305077459e-07
are O 0 1.8021310665972123e-08
distributed O 0 1.771598157063181e-08
along O 0 8.717296218208048e-09
the O 0 1.552692907580422e-08
C7 O 0 0.00015623554645571858
gene O 0 1.3171418800084211e-07
, O 0 3.2978251240933787e-09
but O 0 1.094319745931216e-09
predominantly O 0 2.0654944421494292e-09
towards O 0 3.4870397680464293e-09
the O 0 6.900106708229714e-09
3 O 0 9.467395045703597e-08
end O 0 4.714058832178125e-07
. O 0 1.8594204220789834e-06

All O 0 3.2206838795900694e-07
were O 0 6.712774336392613e-08
found O 0 1.148324528799094e-07
in O 0 7.26177091792124e-08
compound O 0 6.780311650800286e-06
heterozygous O 0 2.3014628823148087e-05
individuals O 0 1.8125574570149183e-06
. O 0 8.207116479752585e-06

The O 0 2.1946958440821618e-05
C6 O 0 0.053635112941265106
/ O 0 0.0002782465307973325
C7 O 0 0.0013918171171098948
marker O 0 5.316925307852216e-05
haplotypes O 0 0.0005714959115721285
associated O 0 1.2231377013449674e-06
with O 0 8.3662854422073e-08
most O 0 7.298887680917687e-07
C7 B-Disease 1 0.9991775155067444
defects I-Disease 1 0.9478013515472412
are O 0 2.4189074565583724e-07
tabulated O 0 0.001530717476271093
. O 0 9.423128517482837e-07
. O 0 3.1661420507589355e-06

A O 0 5.9681588027160615e-06
genome O 0 1.8853812434826978e-05
- O 0 2.409346416243352e-05
wide O 0 7.691859309488791e-07
search O 0 6.853584295640758e-07
for O 0 6.189017653923656e-08
chromosomal O 0 0.011972104199230671
loci O 0 7.041503704385832e-05
linked O 0 0.0005949158221483231
to O 0 9.494304322288372e-06
mental O 1 0.9888166189193726
health O 0 0.0323641262948513
wellness O 0 0.0039574760012328625
in O 0 6.29849523647863e-07
relatives O 0 1.257971871382324e-05
at O 0 2.5642050331953214e-06
high O 0 0.00035406838287599385
risk O 0 0.0001400135224685073
for O 0 1.3062793186691124e-05
bipolar B-Disease 1 0.9999831914901733
affective I-Disease 1 0.9999724626541138
disorder I-Disease 1 0.6102718114852905
among O 0 1.539544030038087e-07
the O 0 6.496559024071757e-08
Old O 0 7.723327144049108e-06
Order O 0 6.689849669783143e-07
Amish O 0 0.000125174832646735
. O 0 7.162068868638016e-06

Bipolar B-Disease 1 0.9999021291732788
affective I-Disease 1 0.9999011754989624
disorder I-Disease 1 0.9995939135551453
( O 0 0.00011672774417093024
BPAD B-Disease 1 0.999966025352478
; O 0 0.013920582830905914
manic B-Disease 1 0.9999641180038452
- I-Disease 1 0.999993085861206
depressive I-Disease 1 0.9999988079071045
illness I-Disease 1 0.9980151653289795
) O 0 1.3719980529458553e-07
is O 0 2.7753648268458164e-08
characterized O 0 4.4725081238539133e-07
by O 0 2.142387067749496e-08
episodes O 0 1.229288244530835e-07
of O 0 7.662778500616696e-08
mania B-Disease 0 0.08309763669967651
and O 0 5.423638071988535e-07
/ O 0 6.174349982757121e-05
or O 0 3.1974309422366787e-07
hypomania B-Disease 0 0.004702376201748848
interspersed O 0 5.923318440181902e-06
with O 0 9.237223963509678e-08
periods O 0 3.891162577929208e-06
of O 0 8.330376886078739e-07
depression B-Disease 0 0.014857737347483635
. O 0 1.5279656508937478e-05

Compelling O 0 2.606990710773971e-05
evidence O 0 3.2741786526457872e-06
supports O 0 1.5566283764201216e-06
a O 0 1.5568807043564448e-07
significant O 0 2.195708361796278e-07
genetic O 0 1.5567783293590765e-06
component O 0 1.544953676102523e-07
in O 0 2.3358705192322304e-08
the O 0 7.154807235565386e-08
susceptibility O 0 0.0002648300724104047
to O 0 4.2209785533486865e-07
develop O 0 8.40101347421296e-05
BPAD B-Disease 1 0.9991365075111389
. O 0 1.387609063385753e-05

To O 0 8.073400294961175e-07
date O 0 2.1069424747111043e-06
, O 0 2.6208253345316734e-08
however O 0 1.0434630048905547e-08
, O 0 1.0585133658480572e-08
linkage O 0 2.085389041894814e-06
studies O 0 3.327777164940926e-08
have O 0 1.970532625961141e-09
attempted O 0 3.144696592016771e-08
only O 0 5.920969825545797e-10
to O 0 2.9715616634007347e-09
identify O 0 4.4567588020072435e-07
chromosomal O 0 0.00261500827036798
loci O 0 5.005045295547461e-06
that O 0 1.234208895084521e-07
cause O 0 1.887466623884393e-06
or O 0 3.930619385528189e-08
increase O 0 5.089462433716108e-07
the O 0 1.1761976281832176e-07
risk O 0 1.6895298813324189e-06
of O 0 1.3020115829931456e-07
developing O 0 0.00020909692102577537
BPAD B-Disease 1 0.99964439868927
. O 0 1.7329495676676743e-05

To O 0 6.391625788637612e-07
determine O 0 9.925348649630905e-07
whether O 0 6.615171344037662e-08
there O 0 1.2442350261210322e-08
could O 0 2.3550711603093077e-08
be O 0 5.1888600083316305e-09
protective O 0 1.0228687642666046e-05
alleles O 0 5.348477998268208e-07
that O 0 1.0572280828569092e-08
prevent O 0 1.5728460311947856e-07
or O 0 3.566535511367874e-08
reduce O 0 2.1357209334382787e-07
the O 0 2.2488666928666134e-08
risk O 0 9.89402195727962e-08
of O 0 7.87752441056e-09
developing O 0 1.0347383977205027e-05
BPAD B-Disease 1 0.9997596144676208
, O 0 3.893059741244542e-08
similar O 0 1.5508280881704195e-08
to O 0 2.3155439787814203e-09
what O 0 1.0284894713663562e-08
is O 0 5.834081218125675e-09
observed O 0 9.886042562357034e-08
in O 0 5.3209991079938845e-08
other O 0 4.923405867884867e-06
genetic B-Disease 1 0.9999849796295166
disorders I-Disease 1 0.999991774559021
, O 0 2.074439862553845e-06
we O 0 4.01806460104126e-07
used O 0 1.497212542744819e-05
mental O 1 0.9769617915153503
health O 0 0.22391308844089508
wellness O 0 0.08450068533420563
( O 0 2.3971713858372823e-07
absence O 0 5.560718818742316e-07
of O 0 4.5704123152745524e-08
any O 0 7.4799422691285145e-06
psychiatric B-Disease 1 0.9985783100128174
disorder I-Disease 1 0.6063752174377441
) O 0 4.415219478914878e-08
as O 0 7.206768071199576e-09
the O 0 1.1111424669252301e-07
phenotype O 0 0.00041766680078580976
in O 0 1.971759289176589e-08
our O 0 3.5454554847547115e-08
genome O 0 4.65192357523847e-07
- O 0 3.250694362577633e-06
wide O 0 2.3078736433035374e-07
linkage O 0 4.126931798964506e-06
scan O 0 6.536546152347e-06
of O 0 3.134837500695653e-09
several O 0 2.2783579467500203e-09
large O 0 5.4113531433586104e-08
multigeneration O 0 5.540289930650033e-05
Old O 0 4.142694933761959e-07
Order O 0 2.4339387394434198e-08
Amish O 0 4.030540367239155e-06
pedigrees O 0 3.903267497662455e-05
exhibiting O 0 8.754279861022951e-07
an O 0 1.0962088126120761e-08
extremely O 0 6.601017048524227e-07
high O 0 1.4546806596626993e-05
incidence O 0 0.005473340395838022
of O 0 1.5257768382070935e-06
BPAD B-Disease 1 0.9997164607048035
. O 0 2.2288993932306767e-05

We O 0 1.8719462104854756e-06
have O 0 1.1870142913039672e-07
found O 0 6.115513428994745e-08
strong O 0 1.0660490090685926e-07
evidence O 0 4.8669328123196465e-08
for O 0 1.910911429092721e-09
a O 0 1.7388073203505883e-08
locus O 0 2.7280905214865925e-06
on O 0 3.479654253624176e-07
chromosome O 0 0.0007986812852323055
4p O 1 0.5547307133674622
at O 0 5.5329213211052775e-08
D4S2949 O 0 3.1613328701496357e-06
( O 0 4.924516350257591e-09
maximum O 0 2.543259647325158e-08
GENEHUNTER O 0 1.901072755572386e-05
- O 0 3.440775572016719e-06
PLUS O 0 9.74904921235975e-08
nonparametric O 0 1.2062043879268458e-06
linkage O 0 3.7805881447638967e-07
score O 0 1.7754441472561666e-08
= O 0 2.915122934155079e-07
4 O 0 4.051615931643937e-09
. O 0 1.4757397526210525e-09
05 O 0 1.5246247357936227e-06
, O 0 7.902475118726215e-09
P O 0 9.951129868568387e-06
= O 0 9.312759061685938e-07
5 O 0 1.553711159729687e-09
. O 0 7.263619705710767e-10
22 O 0 4.542079601321802e-09
x O 0 6.332203952297277e-07
10 O 0 2.1105193148684975e-09
( O 0 2.3588282438424812e-09
- O 0 1.3613317833005567e-06
4 O 0 1.2871784527135333e-08
) O 0 1.2784281411271081e-09
; O 0 5.103330646960558e-09
SIBPAL O 0 2.608667273307219e-06
Pempirical O 0 1.0915955499513075e-06
value O 0 4.906646200453224e-09
< O 0 8.366636450318765e-08
3 O 0 3.727778086215494e-09
x O 0 5.093035611025698e-07
10 O 0 4.042291390504715e-09
( O 0 3.029494433093305e-09
- O 0 3.980245764978463e-06
5 O 0 1.6085266452137148e-08
) O 0 1.3918453056760427e-09
) O 0 7.920518685367028e-10
and O 0 3.91983645542382e-09
suggestive O 0 2.8688000384136103e-06
evidence O 0 6.735204749475088e-08
for O 0 2.9208528928847954e-09
a O 0 2.6742602798890402e-08
locus O 0 3.19300193041272e-06
on O 0 1.7291108633799013e-06
chromosome O 0 0.06855254620313644
4q O 1 0.9994114637374878
at O 0 1.5351544391251082e-07
D4S397 O 0 1.7668167856754735e-05
( O 0 1.3921009234252324e-08
maximum O 0 7.570847060378583e-08
GENEHUNTER O 0 0.00010107209527632222
- O 0 7.54139091441175e-06
PLUS O 0 1.7673396257578133e-07
nonparametric O 0 1.982171852432657e-06
linkage O 0 4.8924255224847e-07
score O 0 1.709950581130215e-08
= O 0 3.2419714557363477e-07
3 O 0 3.3578055891325675e-09
. O 0 9.988211369105215e-10
29 O 0 1.1229347229857467e-08
, O 0 4.284675725330089e-09
P O 0 7.437512522301404e-06
= O 0 4.7310783202192397e-07
2 O 0 1.3339573889936673e-09
. O 0 7.060016460336271e-10
57 O 0 1.5823207633047787e-08
x O 0 1.5365385479526594e-06
10 O 0 4.134845354997196e-09
( O 0 2.8087534520437885e-09
- O 0 7.898098601799575e-07
3 O 0 7.92529863957725e-09
) O 0 1.1650395093099064e-09
; O 0 5.330870411768274e-09
SIBPAL O 0 3.985255716543179e-06
Pempirical O 0 2.306004489582847e-06
value O 0 6.4807399446920044e-09
< O 0 1.6247123824086884e-07
1 O 0 3.1147697754363435e-09
x O 0 5.209594178268162e-07
10 O 0 4.828364819076114e-09
( O 0 2.7292987869742547e-09
- O 0 2.6196141789114336e-06
3 O 0 2.091761075462273e-08
) O 0 1.3619392280617149e-09
) O 0 9.218013574674444e-10
that O 0 1.242723590699768e-09
are O 0 7.733562235046065e-09
linked O 0 1.4277345144364517e-05
to O 0 3.2309758353221696e-06
mental O 1 0.9846628904342651
health O 0 0.49837416410446167
wellness O 1 0.5276174545288086
. O 0 6.2988416175358e-05

These O 0 2.1820842448505573e-06
findings O 0 4.797554993274389e-06
are O 0 1.264233873143894e-08
consistent O 0 5.0681119745377146e-08
with O 0 4.146795351545052e-09
the O 0 1.3679120058895933e-08
hypothesis O 0 3.1048190862748015e-07
that O 0 1.8498628184815402e-09
certain O 0 3.7132941166362343e-09
alleles O 0 1.6617887865777448e-07
could O 0 4.001895348437756e-08
prevent O 0 1.3241673002539756e-07
or O 0 2.4351367144959113e-08
modify O 0 2.4162537215488555e-07
the O 0 4.901382411048871e-08
clinical O 0 1.0644113899616059e-05
manifestations O 0 4.049748167744838e-05
of O 0 1.5263749730820564e-07
BPAD B-Disease 1 0.9998441934585571
and O 0 6.368814524648769e-07
perhaps O 0 6.835549015704601e-07
other O 0 1.401284208668585e-07
related O 0 0.0013086606049910188
affective B-Disease 1 0.9994984865188599
disorders I-Disease 1 0.9988827109336853
. O 0 0.0001308513747062534

Segregation O 0 0.0016060315538197756
distortion O 0 0.03652915731072426
in O 0 0.0021350341849029064
myotonic B-Disease 1 0.99993896484375
dystrophy I-Disease 1 0.9999395608901978
. O 0 0.0008550806087441742

Myotonic B-Disease 1 0.999982476234436
dystrophy I-Disease 1 0.9999849796295166
( O 0 0.002208106918260455
DM B-Disease 1 0.9999016523361206
) O 0 4.982577479495376e-07
is O 0 5.2912650261305316e-08
an O 0 1.8301358295502723e-07
autosomal B-Disease 1 0.924140989780426
dominant I-Disease 1 0.7266805768013
disease I-Disease 0 0.05318370461463928
which O 0 7.438744376031536e-08
, O 0 1.4510141532753096e-08
in O 0 9.54139078856997e-09
the O 0 1.7033098487218012e-08
typical O 0 5.185566806176212e-06
pedigree O 0 8.780750067671761e-05
, O 0 7.997213558041949e-09
shows O 0 1.7347661085409527e-08
a O 0 9.84811698856447e-09
three O 0 3.519810931607026e-08
generation O 0 5.748836429120274e-06
anticipation O 0 2.4500610379618593e-05
cascade O 0 0.000659955374430865
. O 0 1.96362111637427e-06

This O 0 2.6311488454666687e-06
results O 0 2.2848404114483856e-05
in O 0 2.3850792786106467e-05
infertility B-Disease 1 0.9990938901901245
and O 1 0.9567901492118835
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999994039535522
( O 0 1.3102793673169799e-05
CDM B-Disease 0 0.005390006583184004
) O 0 1.6164277027996832e-08
with O 0 3.6158436245159464e-09
the O 0 1.652668935037127e-08
disappearance O 0 5.326921382220462e-06
of O 0 1.5914712037101708e-07
DM B-Disease 1 0.9998838901519775
in O 0 3.0400195782931405e-07
that O 0 2.714654954161233e-07
pedigree O 0 0.0008171218796633184
. O 0 5.766962658526609e-06

The O 0 6.797979494876927e-07
concept O 0 3.408026145734766e-07
of O 0 2.1019754825601922e-08
segregation O 0 1.2202435755170882e-06
distortion O 0 3.168343391735107e-05
, O 0 2.29544916408031e-08
where O 0 1.1523128229384838e-08
there O 0 3.4433722539972678e-09
is O 0 1.4781454948931128e-09
preferential O 0 3.7963111765293434e-08
transmission O 0 2.3686132522016123e-07
of O 0 9.765492858804237e-10
the O 0 4.261715869091631e-09
larger O 0 7.353455089287309e-08
allele O 0 1.895528640716293e-07
at O 0 1.1718507941793632e-08
the O 0 7.166717352902197e-08
DM B-Disease 1 0.9994164705276489
locus O 0 9.038468306243885e-06
, O 0 1.837345564581483e-08
has O 0 4.4994492576222456e-09
been O 0 1.5652341645022716e-09
put O 0 2.8644679961331576e-09
forward O 0 8.199675605169432e-09
to O 0 2.152519273934672e-09
explain O 0 1.3043430158177216e-07
partially O 0 1.4622459332258586e-07
the O 0 6.798107854422142e-09
maintenance O 0 3.59220251766601e-07
of O 0 1.776846580980873e-08
DM B-Disease 1 0.9977239966392517
in O 0 7.547547653530273e-08
the O 0 9.580638504758099e-08
population O 0 3.997295721092087e-07
. O 0 2.176616135329823e-06

In O 0 1.1410392062316532e-06
a O 0 1.7614534897347767e-07
survey O 0 2.42480700762826e-06
of O 0 5.466406705068039e-08
DM B-Disease 1 0.998656153678894
in O 0 1.2371468471883418e-07
Northern O 0 1.85099381155851e-07
Ireland O 0 1.7308387612047227e-07
, O 0 2.636216756002341e-08
59 O 0 2.680910426988703e-07
pedigrees O 0 1.630715087230783e-05
were O 0 2.883326715164003e-07
ascertained O 0 0.00012146901281084865
. O 0 3.929686045012204e-06

Sibships O 0 0.0012450945796445012
where O 0 4.788143428413605e-07
the O 0 1.6940825631195366e-08
status O 0 1.2302177943013248e-08
of O 0 6.367690819075733e-10
all O 0 3.337919385337784e-10
the O 0 1.0338326861258906e-09
members O 0 1.4553676042083907e-09
had O 0 1.0897275082299984e-08
been O 0 7.593389916848992e-09
identified O 0 5.819680737317867e-08
were O 0 3.6716643059264698e-09
examined O 0 2.5979986162383284e-07
to O 0 3.3304679014634075e-09
determine O 0 4.582370749517395e-08
the O 0 4.99533481246317e-09
transmission O 0 3.824076486580452e-07
of O 0 1.7034326171838643e-09
the O 0 7.267950508094145e-08
DM B-Disease 1 0.9805020689964294
expansion O 0 4.183691828529845e-07
from O 0 1.3452925884394062e-08
affected O 0 5.3687909229438446e-08
parents O 0 2.66824820016609e-08
to O 0 7.955801351045011e-09
their O 0 1.019132227497721e-07
offspring O 0 2.0296994989621453e-05
. O 0 4.453786004887661e-06

Where O 0 3.6561004890245385e-06
the O 0 6.490502642009233e-07
transmitting O 0 0.00029566153534688056
parent O 0 2.1765040401078295e-06
was O 0 7.977533300618234e-08
male O 0 1.5129994608287234e-06
, O 0 3.070198317800532e-07
58 O 0 2.395782530584256e-06
. O 0 2.7973194391961442e-06

3 O 0 9.299712928623194e-07
% O 0 7.895126685752984e-08
of O 0 7.063750917524203e-09
the O 0 2.1660454763150483e-08
offspring O 0 1.700731331766292e-06
were O 0 2.9905027787435756e-08
affected O 0 8.943722917820196e-08
, O 0 5.64960522808633e-09
and O 0 6.19603124363266e-09
in O 0 4.435255274159999e-09
the O 0 4.518300844580381e-09
case O 0 2.7390260726178894e-08
of O 0 3.5776122064845595e-09
a O 0 1.3251627706267755e-07
female O 0 9.924524783855304e-05
transmitting O 0 0.007908895611763
parent O 0 3.0373819299711613e-06
, O 0 1.7353227121930104e-07
68 O 0 2.0642960407712962e-06
. O 0 2.4607006707810797e-06

7 O 0 1.2262536074558739e-05
% O 0 1.3182267366573797e-06
were O 0 4.439667122824176e-07
affected O 0 5.0843332246586215e-06
. O 0 5.830596819578204e-06

Studies O 0 9.774668797035702e-06
on O 0 3.66210912261522e-07
meiotic O 0 7.374201959464699e-05
drive O 0 2.178428985644132e-06
in O 0 4.92355638925801e-07
DM B-Disease 1 0.9970991611480713
have O 0 1.0273213035816298e-07
shown O 0 1.609788853329519e-07
increased O 0 1.709941557237471e-07
transmission O 0 3.428799288940354e-07
of O 0 1.0744890532876639e-09
the O 0 3.742004039963831e-09
larger O 0 4.750102533535028e-08
allele O 0 1.9366380854535237e-07
at O 0 8.718360255954849e-09
the O 0 5.024251947816083e-08
DM B-Disease 1 0.9969658255577087
locus O 0 7.1077561187848914e-06
in O 0 1.0379571335761284e-07
non O 0 1.911938852572348e-06
- O 0 0.1414256989955902
DM O 1 0.999727189540863
heterozygotes O 0 0.00044709077337756753
for O 0 5.765828632320336e-07
CTGn O 0 0.0016143465181812644
. O 0 5.977728960715467e-06

This O 0 9.711872053230763e-07
study O 0 4.115445619845559e-07
provides O 0 6.135714158972405e-08
further O 0 8.135183193758166e-09
evidence O 0 3.431029327316537e-08
that O 0 5.7122777619156295e-09
the O 0 3.908579770950382e-08
DM B-Disease 1 0.927889883518219
expansion O 0 7.845347340662556e-07
tends O 0 9.101197662175764e-08
to O 0 6.424409892957783e-09
be O 0 3.3614728778275094e-08
transmitted O 0 4.05119590141112e-06
preferentially O 0 1.159964085672982e-05
. O 0 2.5662427560746437e-06

Diagnosis O 1 0.970538854598999
of O 0 0.0003980263718403876
hemochromatosis B-Disease 1 0.9998546838760376
. O 0 0.0004403572529554367

If O 0 0.00029539165552705526
untreated O 1 0.5263569355010986
, O 0 0.0002522768918424845
hemochromatosis B-Disease 1 0.9999936819076538
can O 0 0.00025566009571775794
cause O 0 0.012318532913923264
serious O 0 0.04063764959573746
illness O 0 0.2917754054069519
and O 0 9.901731345962617e-07
early B-Disease 0 5.7824922805593815e-06
death I-Disease 0 3.107060547336005e-05
, O 0 3.101474632671852e-08
but O 0 2.9659233291567944e-08
the O 0 3.4088452594005503e-07
disease O 0 7.855616422602907e-05
is O 0 1.2225570777957273e-08
still O 0 8.534502171642089e-08
substantially O 0 1.1963588804064784e-06
under O 0 8.674538207742444e-07
- O 1 0.9322826266288757
diagnosed O 1 0.9227254986763
. O 0 2.386376218055375e-05

The O 0 5.940074743193691e-07
cornerstone O 0 2.9290051770658465e-06
of O 0 2.9312463567521263e-08
screening O 0 6.741026936651906e-07
and O 0 5.001018976713567e-08
case O 0 2.6937195229947974e-07
detection O 0 3.0957824037614046e-06
is O 0 5.076942866111267e-09
the O 0 2.789565245464587e-09
measurement O 0 7.882096753064616e-08
of O 0 8.979545995657645e-09
serum O 0 0.0003956049622502178
transferrin O 0 0.00016625612624920905
saturation O 0 1.2187944093966507e-06
and O 0 1.2577880070807623e-08
the O 0 4.321669777596071e-08
serum O 0 0.000653937750030309
ferritin O 0 0.005278266035020351
level O 0 4.0539166548114736e-06
. O 0 3.859556727547897e-06

Once O 0 1.2159766811237205e-05
the O 0 9.278318771066552e-07
diagnosis O 0 0.0017487661680206656
is O 0 6.411583086674e-08
suspected O 0 2.1111059140821453e-06
, O 0 6.97287489970222e-08
physicians O 0 8.473240598050324e-08
must O 0 1.8075771990311296e-08
use O 0 7.926178113848437e-08
serum O 0 0.14007730782032013
ferritin O 1 0.5948945879936218
levels O 0 1.6016115296224598e-06
and O 0 3.8045893546723164e-08
hepatic O 0 5.471774784382433e-05
iron O 0 4.566681673168205e-05
stores O 0 1.8241102850424795e-07
on O 0 4.933116315442021e-07
liver O 0 0.0010527350241318345
biopsy O 0 0.14893099665641785
specimens O 0 0.00010449394176248461
to O 0 3.418696081780581e-08
assess O 0 3.1446503271581605e-05
patients O 0 3.280856617493555e-07
for O 0 3.303024964651513e-09
the O 0 9.005822754204473e-09
presence O 0 2.0605166639597883e-07
of O 0 1.0527251248504399e-07
iron B-Disease 1 0.8076070547103882
overload I-Disease 1 0.6455676555633545
. O 0 8.743084435991477e-06

Liver O 1 0.9480133652687073
biopsy O 1 0.6369444727897644
is O 0 4.457192233076057e-07
also O 0 1.3743952642641943e-08
used O 0 4.264773423301449e-09
to O 0 1.839834395944706e-09
establish O 0 1.2894662226869968e-08
the O 0 3.2921125825424724e-09
presence O 0 6.244248851317025e-08
or O 0 1.6821434911662436e-08
absence O 0 1.0835826458333031e-07
of O 0 4.5910319101949426e-08
cirrhosis B-Disease 0 0.04327542707324028
, O 0 5.37633297881257e-08
which O 0 2.4094489958770282e-08
can O 0 2.253990345479906e-07
affect O 0 1.8547852960182354e-05
prognosis O 1 0.840854287147522
and O 0 2.9033362807240337e-06
management O 0 2.8839758670073934e-05
. O 0 4.397365955810528e-06

A O 0 3.869873125950107e-06
DNA O 0 2.0636878616642207e-05
- O 0 0.00011389493738533929
based O 0 1.758058658651862e-07
test O 0 4.255301533362399e-08
for O 0 1.5003521758316651e-09
the O 0 2.0382296739285266e-08
HFE O 0 0.0027110232040286064
gene O 0 1.0734043343063604e-07
is O 0 1.8396870693493383e-09
commercially O 0 6.45030473478414e-09
available O 0 2.0883115237069205e-09
, O 0 1.4025155481434126e-09
but O 0 6.645821670758778e-10
its O 0 5.938534108906879e-10
place O 0 2.182807934403286e-09
in O 0 5.5547855204451935e-09
the O 0 4.1531610150968845e-08
diagnosis O 0 0.001324554206803441
of O 0 2.071421249638661e-06
hemochromatosis B-Disease 1 0.9999967813491821
is O 0 6.028118946233008e-07
still O 0 2.0917495646699535e-07
being O 0 2.982283717756218e-07
evaluated O 0 1.3260063497000374e-05
. O 0 4.2072124415426515e-06

Currently O 0 2.0712968762381934e-06
, O 0 4.3516124037523696e-08
the O 0 5.548696613288939e-09
most O 0 1.755147027715509e-09
useful O 0 3.5463669778579288e-09
role O 0 3.826886807445362e-09
for O 0 9.606851980592523e-10
this O 0 2.942700749741789e-09
test O 0 5.437052053025582e-08
is O 0 1.6891064102964037e-09
in O 0 2.248299324492109e-09
the O 0 7.514177724488036e-09
detection O 0 9.803245120565407e-06
of O 0 2.460282360061683e-07
hemochromatosis B-Disease 1 0.9999794960021973
in O 0 8.90922819962725e-08
the O 0 8.873239032425317e-09
family O 0 2.9913415744431404e-08
members O 0 1.992091824831732e-09
of O 0 7.51860707026708e-09
patients O 0 2.4316889835063193e-07
with O 0 2.080262362369467e-08
a O 0 1.4828374332864769e-06
proven O 0 7.21686810720712e-05
case O 0 1.3900518069931422e-07
of O 0 2.319169567499557e-08
the O 0 1.0287080840498675e-05
disease O 0 0.02584768459200859
. O 0 6.5189778979402035e-06

It O 0 1.128851977227896e-06
is O 0 2.4646362817293266e-07
crucial O 0 8.601370495853189e-07
to O 0 7.34361810827977e-06
diagnose O 1 0.9998635053634644
hemochromatosis B-Disease 1 0.999996542930603
before O 0 0.011539282277226448
hepatic B-Disease 1 0.9995408058166504
cirrhosis I-Disease 1 0.9988170862197876
develops O 0 0.0026407658588141203
because O 0 3.4675933875405462e-06
phlebotomy O 1 0.5009723901748657
therapy O 0 0.0003721814719028771
can O 0 3.3167625588248484e-06
avert O 1 0.8783026337623596
serious O 1 0.9992204904556274
chronic O 1 0.9999980926513672
disease O 1 0.9726153612136841
and O 0 9.50603293858876e-07
can O 0 1.3980886137687776e-07
even O 0 5.507399691850878e-08
lead O 0 9.272404355442632e-08
to O 0 1.5024463451140946e-08
normal O 0 7.637468684151827e-07
life O 0 3.119640268778312e-06
expectancy O 0 3.2085339626064524e-05
. O 0 1.8586015926302935e-07
. O 0 1.5783228946020245e-06

Prevalence O 0 0.0006301218527369201
of O 0 1.3931347098150582e-07
the O 0 1.2925286796416913e-07
I1307K O 0 5.6684653827687725e-05
APC B-Disease 0 6.9247371357050724e-06
gene O 0 2.3822940420359373e-07
variant O 0 3.1323799021265586e-07
in O 0 7.321654393876997e-09
Israeli O 0 4.99274648291248e-08
Jews O 0 8.956231312140517e-09
of O 0 1.874033150883747e-09
differing O 0 7.644020882935365e-08
ethnic O 0 4.372045125933255e-08
origin O 0 4.881822519564594e-07
and O 0 8.854879069986055e-07
risk O 0 7.097600609995425e-05
for O 0 0.0014583505690097809
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999911785125732
. O 0 0.000216825443203561

BACKGROUND O 0 0.0012718380894511938
& O 0 3.159098923788406e-05
AIMS O 0 1.3448508298097295e-06
Israeli O 0 1.8585184591302095e-07
Jews O 0 1.7126794205069018e-08
of O 0 3.031072282055902e-09
European O 0 7.376999633379455e-08
birth O 0 1.151341507465986e-06
, O 0 1.1444865499754542e-08
i O 0 2.1066073330189283e-08
. O 0 2.3688644379404877e-09
e O 0 4.425505295557741e-08
. O 0 1.7715227063064276e-09
, O 0 2.3753254918545963e-09
Ashkenazim O 0 1.0498636981992604e-07
, O 0 2.9596491923911117e-09
have O 0 5.5828692779869016e-09
the O 0 1.0433266197651392e-06
highest O 1 0.9998915195465088
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
incidence O 0 0.31161272525787354
of O 0 2.7022199589055163e-08
any O 0 2.3042311170229368e-08
Israeli O 0 1.6311130366375437e-06
ethnic O 0 1.0621515684761107e-06
group O 0 7.968787031131797e-06
. O 0 3.9026162994559854e-06

The O 0 6.329375992208952e-06
I1307K O 0 0.0001254764647455886
APC B-Disease 0 4.02328405471053e-05
gene O 0 3.471308900770964e-06
variant O 0 6.110644790169317e-06
was O 0 6.326898471797904e-08
found O 0 8.864513745265867e-08
in O 0 1.698972624808448e-07
6 O 0 2.442853428874514e-06
. O 0 2.6258296657033497e-06

1 O 0 4.187236299912911e-07
% O 0 3.08994856368372e-08
of O 0 1.9140375950854605e-09
American O 0 8.691081632150599e-09
Jews O 0 1.4812394866225986e-08
, O 0 7.965867965253892e-09
28 O 0 1.6922738765856593e-08
% O 0 2.984501312752741e-09
of O 0 6.5409686555994995e-09
their O 0 0.0002311696152901277
familial O 1 0.9999990463256836
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
cases O 0 2.9527509468607605e-05
, O 0 1.1669575883388461e-07
but O 0 1.39827474043841e-08
not O 0 2.8724118639189555e-09
in O 0 9.46704847848423e-09
non O 0 1.333468873099264e-07
- O 0 0.0001738084392854944
Jews O 0 2.5428389562875964e-06
. O 0 3.3376222745573614e-06

We O 0 1.7989840443988214e-06
assessed O 0 2.1809880763612455e-06
the O 0 1.2800251170119736e-07
I1307K O 0 0.00011405210534576327
prevalence O 0 2.086401218548417e-05
in O 0 1.3260181397356519e-08
Israeli O 0 3.958381000757072e-08
Jews O 0 8.711578125542019e-09
of O 0 2.2301691604553753e-09
differing O 0 6.967530907786568e-08
ethnic O 0 3.137046178380842e-08
origin O 0 1.8702264981129701e-07
and O 0 9.305709909313009e-07
risk O 0 0.0001425519585609436
for O 0 0.0012956002028658986
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999938011169434
. O 0 0.0002933317155111581

METHODS O 0 8.96867823030334e-06
DNA O 0 6.5816652750072535e-06
samples O 0 4.968873099642224e-07
from O 0 1.1916358566566032e-08
500 O 0 9.940778866734945e-09
unrelated O 0 5.8502756417055934e-08
Jews O 0 7.20844539614518e-09
of O 0 1.7806048857593737e-09
European O 0 1.4783548607510966e-08
or O 0 7.905369692196018e-09
non O 0 2.5976042650199815e-08
- O 0 5.409539426182164e-06
European O 0 4.019122101794892e-08
origin O 0 4.786792118238736e-08
, O 0 2.4182504887448886e-09
with O 0 2.5833384320606e-09
or O 0 7.691079773053389e-09
without O 0 4.4679269173286684e-09
a O 0 6.565968657668009e-09
personal O 0 4.670887676638813e-07
and O 0 1.0270959904801202e-07
/ O 0 1.2883305316790938e-05
or O 0 1.9848867438554407e-08
family O 0 2.7615723041662932e-08
history O 0 3.600354503419112e-08
of O 0 2.847625957258515e-08
neoplasia B-Disease 1 0.5995000600814819
, O 0 2.8847395583397883e-08
were O 0 6.179932565686386e-09
examined O 0 2.891874544275197e-07
for O 0 2.9554296787637213e-09
the O 0 1.72712635304606e-08
I1307K O 0 1.822712511057034e-05
variant O 0 3.7346478620747803e-07
by O 0 3.347854882207457e-09
the O 0 7.259939316384134e-09
allele O 0 3.9813852481529466e-07
- O 0 1.0958251550619025e-06
specific O 0 5.6913016521775717e-08
oligonucleotide O 0 9.250224684365094e-05
( O 0 1.117118060278699e-07
ASO O 0 7.563452527392656e-05
) O 0 6.495679372164886e-08
method O 0 2.904572227180324e-07
. O 0 9.00505085610348e-07

RESULTS O 0 7.209370232885703e-05
In O 0 2.650430133144255e-07
persons O 0 1.2164900908828713e-07
at O 0 1.4530724001815543e-07
average O 0 2.7678068363456987e-05
risk O 0 0.00020995951490476727
for O 0 0.019628679379820824
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999973773956299
, O 0 6.496882633655332e-06
I1307K O 0 0.00021926822955720127
was O 0 1.1686525880350018e-07
found O 0 6.173726063707363e-08
in O 0 1.253080768037762e-07
5 O 0 8.767346457716485e-07
. O 0 2.0763457087014103e-06

0 O 0 3.7277482078934554e-06
% O 0 1.1645239794688678e-07
of O 0 7.284893577264029e-09
120 O 0 2.6124407526140203e-08
European O 0 6.578745370688921e-08
and O 0 6.784082273725289e-08
1 O 0 5.889123713131994e-07
. O 0 2.194181433878839e-06

6 O 0 2.011651758948574e-06
% O 0 8.175723564818327e-08
of O 0 5.202536179638173e-09
188 O 0 1.217517251461686e-07
non O 0 6.163454457919215e-08
- O 0 6.826579465268878e-06
European O 0 7.427727410913576e-08
Jews O 0 5.6617544430537237e-08
( O 0 2.8301469612301844e-08
P O 0 2.5309371267212555e-05
= O 0 1.0343438816562411e-06
0 O 0 3.1548612611231874e-08
. O 0 1.1839173197358832e-08
08 O 0 8.173382752829639e-07
) O 0 5.422345950023555e-08
. O 0 6.292845000643865e-07

It O 0 2.181133595513529e-06
occurred O 0 9.475708793615922e-06
in O 0 8.357304750461481e-07
15 O 0 2.698035814319155e-06
. O 0 4.065481334691867e-06

4 O 0 1.905789417833148e-06
% O 0 1.0798832761338417e-07
of O 0 2.1025369889571266e-08
52 O 0 5.82457232667366e-07
Ashkenazi O 0 4.876183083979413e-06
Israelis O 0 6.161833425721852e-07
with O 0 1.7009843986670603e-06
familial O 1 0.9966727495193481
cancer B-Disease 1 0.9112169146537781
( O 0 1.6368508681807725e-07
P O 0 0.0007632377673871815
= O 0 5.522874744201545e-06
0 O 0 2.5498753331021362e-08
. O 0 5.215571530214902e-09
02 O 0 1.2809559848392382e-06
) O 0 8.486527036666303e-10
and O 0 1.3827718969849911e-09
was O 0 7.851364003386152e-09
not O 0 4.913651263649399e-09
detected O 0 3.534370023317024e-07
in O 0 5.808367120607727e-09
51 O 0 2.8501471405206757e-08
non O 0 1.920906989028026e-08
- O 0 2.0959239463991253e-06
European O 0 3.634327327972642e-08
Jews O 0 4.848189760764399e-08
at O 0 1.9864741318542656e-07
increased O 0 2.5517942049191333e-05
cancer B-Disease 0 0.1767490655183792
risk O 0 9.640070493333042e-05
. O 0 6.121949354565004e-06

Colorectal B-Disease 1 0.9993056058883667
neoplasia I-Disease 1 0.9981451034545898
occurred O 0 0.0005842859391123056
personally O 0 4.890582204097882e-06
or O 0 6.50257163670176e-08
in O 0 1.1316232395586212e-08
the O 0 4.713107681908468e-09
families O 0 5.7579137013874515e-09
of O 0 1.3831598089097952e-09
13 O 0 5.334185981809014e-09
of O 0 1.0258205396240783e-09
20 O 0 2.9197574136219373e-08
Ashkenazi O 0 1.2570561693792115e-06
I1307K O 0 9.24691357795382e-06
carriers O 0 1.6542465175461984e-07
, O 0 3.121603642242121e-09
8 O 0 3.6255811686203288e-09
of O 0 1.5817949172713952e-09
whom O 0 2.9607727469738165e-07
also O 0 2.79667347058421e-08
had O 0 1.5320591018053165e-08
a O 0 2.5991207408537775e-08
personal O 0 3.204731910955161e-06
or O 0 1.1600580762660684e-07
family O 0 2.0565764202729042e-07
history O 0 4.2957663026754744e-07
of O 0 8.469845056424674e-07
noncolonic O 1 0.9253311157226562
neoplasia B-Disease 1 0.9951406717300415
. O 0 1.5322744729928672e-05

CONCLUSIONS O 0 5.575211253017187e-05
The O 0 7.617900905643182e-07
I1307K O 0 0.00010528730490477756
APC O 0 3.2976004149531946e-05
variant O 0 2.3362070351140574e-05
may O 0 1.3085568184578733e-07
represent O 0 2.145138822129411e-08
a O 0 7.549534331019458e-08
susceptibility O 0 0.0017019954975694418
gene O 0 1.4786164683755487e-06
for O 0 1.227852180818445e-06
colorectal B-Disease 1 0.9999918937683105
, I-Disease 0 5.981538606647518e-07
or I-Disease 0 2.3020961137376617e-08
other I-Disease 0 7.929381595772611e-09
, I-Disease 0 6.942246386643092e-07
cancers I-Disease 0 0.002313113771378994
in O 0 1.0496034263951515e-07
Ashkenazi O 0 2.820619783960865e-06
Jews O 0 2.9031257398060006e-08
, O 0 7.45362527254656e-09
and O 0 1.0819135809470026e-08
partially O 0 6.713823381687689e-07
explains O 0 2.3767094603499572e-07
the O 0 1.543350691690648e-08
higher O 0 3.1293154734157724e-06
incidence O 0 0.013427282683551311
of O 0 0.002768320729956031
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999885559082031
in O 0 5.128869361215038e-06
European O 0 3.896037924278062e-06
Israelis O 0 9.537284313410055e-06
. O 0 5.195649464440066e-06

Systematic O 0 2.617243808344938e-05
analysis O 0 4.3492332224559505e-06
of O 0 2.170388313516014e-07
coproporphyrinogen O 0 0.0035026578698307276
oxidase O 0 0.0001661859278101474
gene O 0 4.7065488615771756e-05
defects O 0 0.008235063403844833
in O 0 1.285360099245736e-06
hereditary B-Disease 0 0.014159686863422394
coproporphyria I-Disease 0 0.47173479199409485
and O 0 9.330973625765182e-06
mutation O 0 0.00028439186280593276
update O 0 0.0001401632762281224
. O 0 2.8095107609260594e-06

Hereditary B-Disease 1 0.940980076789856
coproporphyria I-Disease 1 0.7372186779975891
( O 0 1.9177337890141644e-05
HC B-Disease 1 0.904689371585846
) O 0 6.01088004259509e-07
is O 0 1.5764501881676551e-07
an O 0 9.057900456355128e-07
acute O 1 0.9995840191841125
hepatic B-Disease 1 0.9999539852142334
porphyria I-Disease 1 0.9999253749847412
with O 0 0.0008731870912015438
autosomal O 1 0.8066924214363098
dominant O 0 0.0002495785302016884
inheritance O 0 0.0017666226485744119
caused O 0 5.219315062277019e-05
by O 0 8.73131682510575e-07
deficient B-Disease 0 0.006616868544369936
activity I-Disease 0 1.879206905641695e-07
of I-Disease 0 5.658451129875175e-08
coproporphyrinogen I-Disease 0 0.06899342685937881
III I-Disease 0 0.0015532005345448852
oxidase I-Disease 0 9.909279469866306e-06
( O 0 1.6707672045868094e-07
CPO O 0 9.937946742866188e-06
) O 0 2.551116153881594e-07
. O 0 6.770198410777084e-07

Clinical O 0 0.011227354407310486
manifestations O 0 0.0007307877531275153
of O 0 7.722767350060167e-07
the O 0 2.5880261091515422e-05
disease O 0 0.05209920182824135
are O 0 1.1202504168750238e-07
characterized O 0 2.7326652343617752e-05
by O 0 2.6082293516083155e-06
acute O 0 0.4245389401912689
attacks O 0 0.0014814042951911688
of O 0 5.296364179230295e-05
neurological B-Disease 1 0.9999487400054932
dysfunction I-Disease 1 0.8343168497085571
often O 0 1.232251293004083e-06
precipitated O 0 5.416660133050755e-05
by O 0 5.407607872598419e-08
drugs O 0 2.772333971279295e-07
, O 0 3.0358009439623856e-08
fasting O 0 3.634241352301615e-07
, O 0 1.0495513436126203e-07
cyclical O 0 0.00029752697446383536
hormonal O 0 0.0022700778208673
changes O 0 6.111164907451894e-07
, O 0 6.750714760528354e-07
or O 0 4.6814944653306156e-05
infectious B-Disease 1 0.9976129531860352
diseases I-Disease 1 0.6641870737075806
. O 0 1.3744782336289063e-05

Skin O 1 0.9990993738174438
photosensitivity O 1 0.9989213943481445
may O 0 6.689853762509301e-05
also O 0 2.329530843780958e-07
be O 0 8.088893110880235e-08
present O 0 1.868953063421941e-06
. O 0 4.304293724999297e-06

The O 0 9.270526675209112e-07
seven O 0 2.758072525921307e-07
exons O 0 1.8030151522907545e-06
, O 0 1.500994173397885e-08
the O 0 1.0337522837744473e-08
exon O 0 1.1304601684969384e-05
/ O 0 2.732115717662964e-06
intron O 0 4.758590876008384e-06
boundaries O 0 6.3299734343047476e-09
and O 0 1.2812818583896046e-09
part O 0 1.565998553054726e-09
of O 0 1.3662531106461984e-09
3 O 0 7.859934036957839e-09
noncoding O 0 1.1428654715928133e-06
sequence O 0 8.357924130564243e-09
of O 0 3.582225904796843e-10
the O 0 2.274606503149812e-09
CPO O 0 1.8880932657339144e-06
gene O 0 2.015594446902469e-08
were O 0 1.1153243884010067e-09
systematically O 0 3.5355423477767545e-08
analyzed O 0 4.9355580955534606e-08
by O 0 1.0581352460903304e-09
an O 0 1.6681324099820927e-09
exon O 0 3.947994173358893e-06
- O 0 2.438542651361786e-06
by O 0 1.5406302011911066e-08
- O 0 2.010580647038296e-05
exon O 0 7.243729487527162e-05
denaturing O 0 0.00013202511763665825
gradient O 0 3.584881415008567e-05
gel O 0 0.0001532248134026304
electrophoresis O 0 4.180531686870381e-05
( O 0 2.8650212868797098e-08
DGGE O 0 1.1057001756853424e-05
) O 0 2.473860671869943e-09
strategy O 0 9.20954779104477e-09
followed O 0 1.7231538418371883e-09
by O 0 5.53348589171776e-10
direct O 0 1.7228185544837515e-09
sequencing O 0 6.29972021215508e-08
in O 0 6.3654117532507826e-09
seven O 0 2.940766385961524e-08
unrelated O 0 2.109251727233641e-05
heterozygous O 0 0.0002657015866134316
HC B-Disease 1 0.9949354529380798
patients O 0 6.690419013466453e-06
from O 0 8.249156735473662e-08
France O 0 6.221083367563551e-06
, O 0 9.017806945621487e-08
Holland O 0 9.991857041313779e-06
, O 0 2.1492096990982645e-08
and O 0 3.943505433312566e-08
Czech O 0 6.149752880446613e-05
Republic O 0 7.0103064899740275e-06
. O 0 3.2220525554294e-06

Seven O 0 3.3943297239602543e-06
novel O 0 3.68481073564908e-06
mutations O 0 5.000188593839994e-06
and O 0 2.054776082616172e-08
two O 0 2.0169672154679574e-08
new O 0 6.371901122292911e-07
polymorphisms O 0 6.609196861973032e-05
were O 0 6.998016033321619e-07
detected O 0 0.00014310693950392306
. O 0 2.4374148779315874e-06

Among O 0 4.600679403665708e-06
these O 0 2.9342120910769154e-07
mutations O 0 1.695118953648489e-06
two O 0 9.880175788623546e-09
are O 0 1.6369140709571184e-08
missense O 0 6.016732731950469e-05
( O 0 4.2580133197134273e-08
G197W O 0 7.221986834338168e-06
, O 0 3.4852060792900375e-08
W427R O 0 8.186377272068057e-06
) O 0 3.1257263444217642e-09
, O 0 9.860893213087252e-10
two O 0 8.224451120142362e-10
are O 0 4.141665232992864e-09
nonsense O 0 6.858278993604472e-06
( O 0 1.030954255298866e-08
Q306X O 0 2.609667490105494e-06
, O 0 1.2231635260206986e-08
Q385X O 0 1.47229582125874e-06
) O 0 2.0572417103181806e-09
, O 0 3.3270122767881105e-10
two O 0 4.676712905826719e-10
are O 0 6.556029052973145e-10
small O 0 8.481482183242406e-09
deletions O 0 3.9035171539580915e-06
( O 0 2.827503386981789e-08
662de14bp O 0 4.734084541269112e-06
; O 0 3.7353025561515096e-08
1168del3bp O 0 2.9280279250087915e-06
removing O 0 2.572223145591579e-08
a O 0 6.892924009349599e-09
glycine O 0 5.50155107248429e-07
at O 0 4.059776959053352e-09
position O 0 1.1416130263341984e-08
390 O 0 4.628654792782072e-08
) O 0 2.8917177541387673e-09
, O 0 1.205359922984428e-09
and O 0 1.4782131074753124e-09
one O 0 2.2440622693409296e-09
is O 0 1.2348529976335954e-09
a O 0 1.1062339488887574e-08
splicing O 0 4.451097993296571e-06
mutation O 0 1.6535350368940271e-06
( O 0 1.1218535433954457e-08
IVS1 O 0 1.3900102203479037e-05
- O 0 1.8495220501790754e-05
15c O 0 8.054058525885921e-06
- O 0 7.937325790408067e-06
- O 0 8.759190677665174e-05
> O 0 1.3711579413211439e-05
g O 0 1.114185306505533e-05
) O 0 2.1381854065083417e-09
which O 0 1.8396099088491269e-09
creates O 0 3.330113429456105e-08
a O 0 1.010464334427752e-08
new O 0 9.180578786072147e-08
acceptor O 0 2.4427602056675823e-06
splice O 0 1.532721762487199e-05
site O 0 4.854722192249028e-06
. O 0 1.1655043863356696e-06

The O 0 2.2295805592875695e-06
pathological O 0 6.204942474141717e-05
significance O 0 6.058075996406842e-07
of O 0 7.749184405270171e-09
the O 0 1.1409469813372652e-08
point O 0 5.272767467090489e-08
mutations O 0 1.037874426401686e-06
G197W O 0 3.3212415928574046e-06
, O 0 1.0374064274287775e-08
W427R O 0 2.055871618722449e-06
, O 0 3.135519177632773e-09
and O 0 1.6729596596931628e-09
the O 0 1.6583963091676424e-09
in O 0 7.644586297317346e-09
- O 0 9.355566362501122e-06
frame O 0 4.31063563155476e-05
deletion O 0 3.6237703170627356e-05
390delGly O 0 1.585533573233988e-05
were O 0 5.3457362980680045e-09
assessed O 0 1.767733159852014e-08
by O 0 1.3822419875353376e-09
their O 0 1.946420358223122e-09
respective O 0 1.861075382691979e-08
expression O 0 2.5522789215415287e-08
in O 0 2.8611371050146772e-09
a O 0 8.605849366460916e-09
prokaryotic O 0 4.633380683571886e-07
system O 0 2.5118229274312398e-08
using O 0 1.172159258544525e-08
site O 0 2.414523692095827e-07
- O 0 6.280563411564799e-06
directed O 0 2.0086840777366888e-06
mutagenesis O 0 0.00022375531261786819
. O 0 3.4966435578098753e-06

These O 0 2.8587169254024047e-06
mutations O 0 3.3627948141656816e-05
resulted O 0 4.780259246217611e-07
in O 0 2.3220465550366498e-08
the O 0 1.538383820332001e-08
absence O 0 2.1312162346021069e-07
or O 0 1.304713315164463e-08
a O 0 2.924076447641255e-08
dramatic O 0 8.86791167431511e-06
decrease O 0 8.86116595211206e-06
of O 0 6.645446859465665e-08
CPO O 0 0.00017366099928040057
activity O 0 2.2418917069444433e-06
. O 0 1.8299557495993213e-06

The O 0 5.521350772141886e-07
two O 0 6.824664922078227e-08
polymorphisms O 0 6.229804512258852e-06
were O 0 2.053138459245929e-08
localized O 0 1.6371019455618807e-06
in O 0 4.247209162144827e-08
noncoding O 0 6.812992978666443e-06
part O 0 9.108262588597427e-09
of O 0 1.2302923124707377e-09
the O 0 4.091968985875383e-09
gene O 0 2.5168105821649078e-08
1 O 0 4.395463104600594e-09
) O 0 1.3324266134873142e-09
a O 0 1.5148627241501345e-08
C O 0 4.351228199084289e-06
/ O 0 1.5925954357953742e-05
G O 0 0.00012083914771210402
polymorphism O 0 5.059717750555137e-06
in O 0 1.1919927267456387e-08
the O 0 1.8525401657143448e-08
promotor O 0 0.0017926711589097977
region O 0 1.9560553710107342e-07
, O 0 5.8163713845260645e-09
142 O 0 6.238725092089226e-08
bp O 0 3.1982531254470814e-06
upstream O 0 2.5397014269401552e-08
from O 0 5.503529298955812e-10
the O 0 8.894346925636398e-10
transcriptional O 0 2.7194841933919633e-08
initiation O 0 1.8463987672134863e-08
site O 0 4.279132781448425e-08
( O 0 3.1633133890096587e-09
- O 0 2.6660663934308104e-06
142C O 0 4.791077662957832e-05
/ O 0 2.8658647352131084e-05
G O 0 5.087691897642799e-05
) O 0 1.6331335173092043e-09
, O 0 4.3849518460703507e-10
and O 0 1.4242950152620892e-09
2 O 0 2.6497861682628354e-09
) O 0 8.187232558576341e-10
a O 0 3.946889925998676e-09
6 O 0 1.0463693200790658e-07
bp O 0 2.1792915504192933e-05
deletion O 0 3.696101202876889e-06
polymorphism O 0 6.152394689706853e-06
in O 0 8.93021923076276e-09
the O 0 3.339162724103062e-09
3 O 0 1.7448606115522125e-08
noncoding O 0 1.3239857707958436e-06
part O 0 4.007958409601997e-09
of O 0 1.0802592154135482e-09
the O 0 6.9093255561369915e-09
CPO O 0 3.6798589917452773e-06
gene O 0 3.2429547047740925e-08
, O 0 3.4047036301387834e-09
574 O 0 4.793946573045105e-07
bp O 0 1.3526546354114544e-06
downstream O 0 1.6064539920535026e-08
of O 0 3.609839926976832e-10
the O 0 1.7623728032489794e-09
last O 0 1.7839745680703345e-08
base O 0 8.771534609763876e-09
of O 0 1.1068265193259208e-09
the O 0 9.491638586212048e-09
normal O 0 2.846909694653732e-07
termination O 0 2.821050202328479e-06
codon O 0 7.044956760182686e-07
( O 0 2.076409266749124e-08
+ O 0 4.721914592664689e-07
574 O 0 3.488496531645069e-06
delATTCTT O 0 3.068557271035388e-05
) O 0 2.9259464895403653e-07
. O 0 1.1127145853606635e-06

Five O 0 2.9711693514400395e-06
intragenic O 0 0.0009056514245457947
dimorphisms O 0 0.0006533670239150524
are O 0 2.4070970994216623e-08
now O 0 1.710244212915768e-08
well O 0 1.0803834271655433e-08
characterized O 0 4.318546871218132e-07
and O 0 1.999004872743626e-08
the O 0 2.1506901148882207e-08
high O 0 5.363760919863125e-07
degree O 0 1.3153807287835662e-07
of O 0 8.84245565657693e-09
allelic O 0 0.00023664426407776773
heterogeneity O 0 0.00030199435423128307
in O 0 9.990236549128895e-07
HC B-Disease 0 0.3499014675617218
is O 0 5.896125898630089e-08
demonstrated O 0 2.4545806809328496e-07
with O 0 6.105732808237008e-09
seven O 0 9.799904887586308e-09
new O 0 1.7961738763005997e-08
different O 0 5.264243707614469e-09
mutations O 0 7.17977002295811e-08
making O 0 9.241462595177552e-10
a O 0 1.8839785287383393e-09
total O 0 2.539705334925202e-09
of O 0 4.123834607128174e-09
nineteen O 0 2.657820914464537e-06
CPO O 0 0.0008045335416682065
gene B-Disease 0 1.5137937225517817e-05
defects I-Disease 0 0.009455171413719654
reported O 0 2.032699285337003e-06
so O 0 4.128991903940005e-08
far O 0 1.2027727791519283e-07
. O 0 2.6585587420413503e-07
. O 0 1.3621031484944979e-06

Coincidence O 0 3.4527009120211005e-05
of O 0 1.9284350116777205e-07
two O 0 4.808937958955539e-08
novel O 0 4.855486395172193e-07
arylsulfatase O 0 5.436702849692665e-05
A O 0 1.0733347011182559e-07
alleles O 0 4.910506277155946e-07
and O 0 8.465357126397066e-08
mutation O 0 1.9609224182204343e-06
459 O 0 4.519088633969659e-06
+ O 0 8.747404535824899e-06
1G O 0 0.002623053267598152
> O 0 3.595273938117316e-06
A O 0 1.6588019846608404e-08
within O 0 3.4388500935733646e-09
a O 0 5.926229462716037e-08
family O 0 3.550559029008582e-07
with O 0 1.891791725938674e-06
metachromatic B-Disease 1 0.9999676942825317
leukodystrophy I-Disease 1 0.9999516010284424
: O 0 2.268733851451543e-06
molecular O 0 4.96458005727618e-06
basis O 0 3.489769184739089e-08
of O 0 8.792343209051978e-08
phenotypic O 0 0.0002262873895233497
heterogeneity O 0 0.014512920752167702
. O 0 2.6168994736508466e-05

In O 0 1.0153115681532654e-06
a O 0 1.5642477535493526e-07
family O 0 1.1348204509431525e-07
with O 0 1.871012678122952e-08
three O 0 3.630461620218739e-08
siblings O 0 7.716377695032861e-06
, O 0 2.4998550784971485e-08
one O 0 5.034571426421053e-09
developed O 0 9.906484876864852e-08
classical O 0 1.2599557521753013e-06
late O 0 4.600267857313156e-05
infantile O 1 0.9932657480239868
metachromatic B-Disease 1 0.9999871253967285
leukodystrophy I-Disease 1 0.9999819993972778
( O 0 1.0901768291660119e-05
MLD B-Disease 1 0.99977046251297
) O 0 5.990049345427906e-08
, O 0 4.245459450658018e-08
fatal O 0 9.52014306676574e-05
at O 0 3.040495073491911e-07
age O 0 8.106559903353627e-07
5 O 0 5.476508846413708e-08
years O 0 1.0549441498142187e-07
, O 0 1.9150975916204516e-08
with O 0 2.2135606059237034e-07
deficient O 0 0.4037337601184845
arylsulfatase O 0 0.0065006990917027
A O 0 6.592310342057317e-07
( O 0 8.441139698334155e-08
ARSA O 0 0.00023507508740294725
) O 0 1.0500476044228435e-08
activity O 0 1.8984698257895616e-08
and O 0 1.0109193482321643e-08
increased O 0 3.6944692283213953e-07
galactosylsulfatide O 0 0.001427518087439239
( O 0 6.837009323135135e-07
GS O 1 0.9890900254249573
) O 0 2.5557091021255474e-07
excretion O 0 1.275620797969168e-05
. O 0 2.0458890048757894e-06

The O 0 5.496432322615874e-07
two O 0 3.0293975328277156e-08
other O 0 2.363990958542672e-08
siblings O 0 2.4515161385352258e-06
, O 0 5.364164223919943e-08
apparently O 0 3.7499225413739623e-07
healthy O 0 1.3516768149202107e-07
at O 0 6.460696422294632e-09
12 O 0 7.50619832956545e-09
( O 0 1.7802923579779417e-09
1 O 0 3.0727680400133295e-09
/ O 0 2.069609195132216e-07
2 O 0 2.2091239948451857e-09
) O 0 5.562501570466338e-10
and O 0 8.370299453552832e-10
15 O 0 4.520041674282993e-09
years O 0 3.135556525535321e-08
, O 0 4.631628858220438e-09
respectively O 0 6.790412498958176e-08
, O 0 2.582880131996035e-09
and O 0 2.435297963288008e-09
their O 0 3.976419193918446e-09
father O 0 1.1310039553791285e-06
, O 0 2.4468789661113988e-08
apparently O 0 1.8539759594204952e-07
healthy O 0 6.219786286010276e-08
as O 0 1.2836521845471793e-09
well O 0 3.4096165890673547e-09
, O 0 5.770689703865628e-09
presented O 0 3.956079694944492e-07
ARSA O 0 0.0009459849097765982
and O 0 6.689830911454919e-08
GS O 1 0.6866267323493958
values O 0 3.2027099194920083e-08
within O 0 2.270254872982491e-09
the O 0 6.880458869318318e-09
range O 0 3.681020643853117e-07
of O 0 1.8401884744889685e-06
MLD B-Disease 1 0.999915599822998
patients O 0 0.00016359769506379962
. O 0 8.88287559064338e-06

Mutation O 0 0.00036395314964465797
screening O 0 4.657130830310052e-06
and O 0 8.243147675557339e-08
sequence O 0 3.255744047692133e-07
analysis O 0 1.3938550580405717e-07
disclosed O 0 1.1978200973317144e-06
the O 0 3.9575942523129015e-09
involvement O 0 5.106946332489315e-08
of O 0 1.61512325735913e-09
three O 0 8.67807870008619e-09
different O 0 3.980959561999953e-08
ARSA O 0 0.12291676551103592
mutations O 0 1.2538713463072781e-06
being O 0 3.973068540830127e-09
the O 0 5.23500620630557e-09
molecular O 0 1.5370691244243062e-06
basis O 0 7.705835969318287e-09
of O 0 5.817261694573972e-08
intrafamilial O 0 0.002999590476974845
phenotypic O 0 0.0001395850849803537
heterogeneity O 0 0.0017860184889286757
. O 0 1.3323580787982792e-05

The O 0 3.1253459837898845e-06
late O 0 4.301589433453046e-05
infantile O 1 0.8822288513183594
patient O 0 0.0016397543950006366
inherited O 0 0.0006511899991892278
from O 0 5.949299008989328e-08
his O 0 1.0531568506166877e-07
mother O 0 1.2472618209358188e-06
the O 0 7.479787456077247e-09
frequent O 0 2.1530240701395087e-07
0 O 0 7.007727731433988e-08
- O 0 4.2646082874853164e-05
type O 0 9.572065209795255e-06
mutation O 0 2.6548166260909056e-06
459 O 0 3.5978223422716837e-06
+ O 0 3.300824346297304e-06
1G O 0 0.00044063269160687923
> O 0 3.0480018722300883e-06
A O 0 1.140944760891216e-08
, O 0 2.4310331525612128e-09
and O 0 1.2466668808386316e-09
from O 0 2.042579660965771e-09
his O 0 3.203345499969146e-08
father O 0 3.806324571087316e-07
a O 0 1.560355222807175e-08
novel O 0 4.5369908718839724e-08
, O 0 2.2400170607284053e-09
single O 0 9.651413002131903e-09
basepair O 0 4.3212680793658365e-06
microdeletion O 0 1.2985658486286411e-06
of O 0 2.0076931228629746e-09
guanine O 0 3.162012660595792e-07
at O 0 4.7130805924666674e-09
nucleotide O 0 1.1409625955138836e-07
7 O 0 1.830405871316998e-08
in O 0 1.1434086566453061e-08
exon O 0 1.1026150787074585e-05
1 O 0 1.1753655826396425e-07
( O 0 7.005428415141068e-08
7delG O 0 2.5034607460838743e-05
) O 0 4.7386464530063677e-07
. O 0 1.813968538044719e-06

The O 0 1.512948983872775e-06
two O 0 3.1310298709286144e-07
clinically O 0 3.658238347270526e-05
unaffected O 0 5.1532217185012996e-05
siblings O 0 2.657367303982028e-06
carried O 0 1.3197383452734357e-07
the O 0 4.868947556246894e-08
maternal O 0 9.04861226445064e-05
mutation O 0 3.2597595236438792e-06
459 O 0 5.840998710482381e-06
+ O 0 5.092675564810634e-06
1G O 0 0.0006976935546845198
> O 0 2.063589590761694e-06
A O 0 1.3139183074883931e-08
and O 0 5.984885476095769e-09
, O 0 1.4005347992451789e-09
on O 0 1.5968668609644965e-09
their O 0 6.994557821826675e-09
paternal O 0 1.1988510777882766e-05
allele O 0 6.046641374268802e-07
, O 0 2.0026944547169023e-09
a O 0 3.895033628964484e-09
novel O 0 9.113113463854461e-08
cytosine O 0 6.624047159675683e-07
to O 0 5.008347958579407e-09
thymidine O 0 5.1258962230349425e-06
transition O 0 8.090775338587264e-08
at O 0 8.465901757404026e-09
nucleotide O 0 2.549455189182481e-07
2435 O 0 3.851548626698786e-06
in O 0 8.905826298644115e-09
exon O 0 5.531419446924701e-06
8 O 0 4.1805165551522805e-08
, O 0 3.0950493279391367e-09
resulting O 0 1.0404541228581365e-08
in O 0 1.7731893731109949e-09
substitution O 0 6.259353924065181e-09
of O 0 4.550282373116943e-09
alanine O 0 5.98065980739193e-06
464 O 0 3.179337454639608e-06
by O 0 2.0671691913776158e-07
valine O 0 0.00023738980235066265
( O 0 1.5782582352130703e-07
A464V O 0 3.2948348234640434e-05
) O 0 2.778509156087239e-07
. O 0 1.4700315205118386e-06

The O 0 3.4008580769295804e-06
fathers O 0 1.7349519112030976e-05
genotype O 0 0.0006529269739985466
thus O 0 9.19866465665109e-07
was O 0 4.74495493563154e-07
7delG O 0 0.00016709064948372543
/ O 0 0.00011953244393225759
A464V O 0 0.00018949196964967996
. O 0 3.844103048322722e-06

Mutation O 0 0.0027841045521199703
A464V O 0 0.0002686846419237554
was O 0 4.990637876289838e-07
not O 0 2.4638602269533294e-08
found O 0 5.08859834269515e-08
in O 0 8.73819132607423e-08
18 O 0 1.173911982732534e-06
unrelated O 0 0.00635033892467618
MLD B-Disease 1 0.9999850988388062
patients O 0 1.6280222553177737e-05
and O 0 2.297136063589278e-07
50 O 0 4.69077917841787e-07
controls O 0 4.345974502939498e-06
. O 0 6.190285148477415e-06

A464V O 0 0.0007042854558676481
, O 0 3.694109977914195e-07
although O 0 1.2366101032057486e-07
clearly O 0 3.098453476013674e-07
modifying O 0 2.124137836290174e-06
ARSA O 0 0.000719964038580656
and O 0 8.206914117181441e-07
GS O 1 0.9998937845230103
levels O 0 5.799563496111659e-06
, O 0 3.436464979245102e-08
apparently O 0 2.4492118200214463e-07
bears O 0 5.445110105029016e-07
little O 0 1.2468173160584684e-08
significance O 0 4.6605823200707164e-08
for O 0 9.914666421195761e-09
clinical O 0 4.495549546845723e-06
manifestation O 0 0.00015582969353999943
of O 0 7.409241220557305e-07
MLD B-Disease 1 0.9999572038650513
, O 0 2.2486594275505922e-07
mimicking O 0 1.553762922412716e-05
the O 0 1.1647405528947274e-07
frequent O 0 2.0506007786025293e-05
ARSA O 0 0.11629338562488556
pseudodeficiency O 0 0.005224510096013546
allele O 0 0.00010511656728340313
. O 0 4.475589321373263e-06

Our O 0 7.153917977120727e-06
results O 0 5.434466856968356e-06
demonstrate O 0 1.6456629055028316e-06
that O 0 2.1693862706229083e-08
in O 0 2.8056762246819744e-08
certain O 0 8.603588241840043e-08
genetic O 0 0.0001308689679717645
conditions O 0 0.0004040394560433924
MLD B-Disease 1 0.9996077418327332
- O 0 8.832641469780356e-05
like O 0 5.155371809451026e-07
ARSA O 0 0.000929317669942975
and O 0 1.1890299589367714e-07
GS O 1 0.9193880558013916
values O 0 5.99688618763139e-08
need O 0 8.674271967379354e-09
not O 0 1.389792059214301e-09
be O 0 2.048127223375218e-09
paralleled O 0 1.770460016814468e-06
by O 0 1.8864229787141085e-06
clinical O 1 0.7736806869506836
disease O 0 0.11428028345108032
, O 0 9.950210255738057e-08
a O 0 8.392288464165176e-08
finding O 0 3.400889738713886e-07
with O 0 4.7183721108012833e-07
serious O 0 0.00019542372319847345
diagnostic O 0 0.0016908885445445776
and O 0 4.814812200493179e-06
prognostic O 0 0.043222036212682724
implications O 0 0.00048707553651183844
. O 0 1.0394413038739003e-05

Moreover O 0 0.00010306947660865262
, O 0 6.359018698276486e-07
further O 0 3.297572845895047e-07
ARSA O 0 0.005148806143552065
alleles O 0 5.33621596332523e-06
functionally O 0 1.9575070382416015e-06
similar O 0 4.498825134646722e-08
to O 0 1.3390870634566454e-08
A464V O 0 5.0215359806315973e-05
might O 0 2.3330169085511443e-07
exist O 0 1.822995088218704e-08
which O 0 1.9946089224731622e-09
, O 0 1.0267641181727072e-09
together O 0 1.4565006978273232e-09
with O 0 3.6147955739807003e-09
0 O 0 1.778588654133273e-07
- O 0 0.0035953407641500235
type O 0 0.0005224525812081993
mutations O 0 2.08027759072138e-05
, O 0 5.3266656863115713e-08
may O 0 1.1162549071741523e-06
cause O 0 3.2605742035229923e-06
pathological O 0 0.0032637740951031446
ARSA O 1 0.79908686876297
and O 0 6.32065393801895e-06
GS O 1 0.9999788999557495
levels O 0 3.2823254514369182e-06
, O 0 5.187692497798935e-09
but O 0 5.130022628918596e-09
not O 0 1.3814994481720078e-08
clinical O 0 4.048376467835624e-06
outbreak O 0 5.9564913499343675e-06
of O 0 4.3291443319048994e-08
the O 0 1.3678381037607323e-05
disease O 0 0.02936788648366928
. O 0 5.099961981613887e-07
. O 0 3.195094905095175e-06

Human O 0 0.051633719354867935
MLH1 O 1 0.9992732405662537
deficiency O 1 0.9996223449707031
predisposes O 0 0.024314289912581444
to O 0 2.206639328505844e-05
hematological B-Disease 1 0.9992139339447021
malignancy I-Disease 1 0.9995692372322083
and O 0 0.00016176390636246651
neurofibromatosis B-Disease 1 0.9992175102233887
type I-Disease 0 0.00016004782810341567
1 I-Disease 0 2.745028268691385e-06
. O 0 4.822155460715294e-06

Heterozygous O 0 0.0005837779608555138
germ O 0 0.041007086634635925
- O 0 0.0009652987355366349
line O 0 1.4233353795134462e-05
mutations O 0 3.4057170523738023e-06
in O 0 1.468541110938304e-08
the O 0 3.963548778074255e-08
DNA O 0 2.1547097276197746e-05
mismatch O 0 0.17988784611225128
repair O 0 0.0009320443496108055
genes O 0 6.557159508702171e-07
lead O 0 5.804736815662181e-07
to O 0 1.359879888696014e-06
hereditary B-Disease 1 0.9984171390533447
nonpolyposis I-Disease 1 0.9999915361404419
colorectal I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999852180480957
. O 0 0.00032295455457642674

The O 0 0.0003168767725583166
disease O 1 0.634316086769104
susceptibility O 0 0.004560267552733421
of O 0 1.7095111104481475e-07
individuals O 0 3.838439681658201e-07
who O 0 4.3896176293856115e-07
constitutionally O 0 8.278842074105341e-07
lack O 0 1.148876549450506e-07
both O 0 1.568959184794494e-08
wild O 0 1.1405919622120564e-06
- O 0 0.00014586186443921179
type O 0 7.611628461745568e-06
alleles O 0 2.0437437342479825e-06
is O 0 9.644386267382288e-08
unknown O 0 4.34871481047594e-06
. O 0 1.4843130884401035e-06

We O 0 9.072788316188962e-07
have O 0 4.036083467440221e-08
identified O 0 1.3773087914614734e-07
three O 0 1.4072967680078818e-08
offspring O 0 6.723357728333212e-07
in O 0 6.626802928622055e-08
a O 0 1.6990039512165822e-05
hereditary B-Disease 1 0.9999505281448364
nonpolyposis I-Disease 1 0.9999996423721313
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999980926513672
family O 0 5.647078432957642e-05
who O 0 1.6612942999927327e-05
developed O 0 0.0005342939402908087
hematological B-Disease 1 0.9997476935386658
malignancy I-Disease 1 0.9674586057662964
at O 0 8.416188990167939e-08
a O 0 2.5939998593571545e-08
very O 0 1.1528030086083163e-08
early O 0 7.718224992459e-08
age O 0 2.1089918789130024e-07
, O 0 5.014580306550442e-09
and O 0 2.33583352660105e-09
at O 0 2.8273292596026067e-09
least O 0 9.231244657570414e-10
two O 0 3.821414573668136e-10
of O 0 7.295443693600134e-10
them O 0 1.726091380938044e-09
displayed O 0 1.3988343425808125e-06
signs O 0 2.6069585601362633e-06
of O 0 8.060801093279224e-08
neurofibromatosis B-Disease 1 0.9792200326919556
type I-Disease 0 1.06375173345441e-05
1 I-Disease 0 2.0974306380594498e-07
( O 0 3.678269706597348e-07
NF1 B-Disease 0 0.001370309037156403
) O 0 3.3725126513672876e-07
. O 0 1.2787198784280918e-06

DNA O 0 5.583879101322964e-05
sequence O 0 4.497775535128312e-06
analysis O 0 4.175488754754042e-07
and O 0 3.088251432359357e-08
allele O 0 6.82035761201405e-07
- O 0 2.1851519704796374e-06
specific O 0 2.611822935705277e-08
amplification O 0 1.2046845085933455e-06
in O 0 1.1259651877537635e-08
two O 0 8.395631745372611e-09
siblings O 0 6.5153294599440414e-06
revealed O 0 6.669511094514746e-06
a O 0 6.609622005271376e-07
homozygous O 0 0.002389304107055068
MLH1 O 1 0.858452558517456
mutation O 0 1.478087233408587e-05
( O 0 2.3293212692010457e-08
C676T O 0 4.1329581108584534e-06
- O 0 9.095977293327451e-05
- O 0 0.004600959829986095
> O 0 0.00025328987976536155
Arg226Stop O 0 0.00034382371813990176
) O 0 1.5140055609208503e-07
. O 0 8.725847919777152e-07

Thus O 0 6.507244506792631e-06
, O 0 1.1592208437605223e-07
a O 0 1.7949021469121362e-07
homozygous O 0 5.5675129260635003e-05
germ O 0 0.11686280369758606
- O 0 0.0007593629416078329
line O 0 4.0742648707237095e-05
MLH1 O 0 0.09090156853199005
mutation O 0 9.23318657441996e-06
and O 0 3.8102069765955093e-07
consequent O 0 0.2384987622499466
mismatch O 1 0.9998795986175537
repair O 1 0.9999003410339355
deficiency O 1 0.9999308586120605
results O 0 1.8422551875119098e-05
in O 0 1.7930149454059574e-07
a O 0 6.0708271121256985e-06
mutator O 1 0.9996501207351685
phenotype O 1 0.9499118328094482
characterized O 0 0.0001340798771707341
by O 0 1.1462458132882603e-05
leukemia B-Disease 1 0.9995133876800537
and O 0 2.9597993489005603e-05
/ O 1 0.6026424169540405
or O 0 0.02023293264210224
lymphoma B-Disease 1 0.9999996423721313
associated O 0 0.00011376220936654136
with O 0 9.221350410371087e-06
neurofibromatosis B-Disease 1 0.9995146989822388
type I-Disease 0 1.4662770809081849e-05
1 I-Disease 0 1.836808110056154e-07
. O 0 1.866690979568375e-07
. O 0 1.1571116829145467e-06

Missense O 0 0.43637627363204956
mutations O 0 0.0006452546222135425
in O 0 2.5024891670000216e-07
the O 0 2.129740650502754e-08
most O 0 6.5380749703081165e-09
ancient O 0 3.0415328922117624e-08
residues O 0 4.079883808572049e-08
of O 0 3.98372224097443e-09
the O 0 2.1085490686800767e-08
PAX6 O 0 0.00024199621111620218
paired O 0 2.8128242774982937e-06
domain O 0 4.897817689197836e-07
underlie O 0 7.525118689954979e-06
a O 0 1.0407404005263743e-07
spectrum O 0 4.031282060168451e-06
of O 0 7.309656666620867e-07
human O 0 0.011600833386182785
congenital B-Disease 1 0.9999847412109375
eye I-Disease 1 0.99973064661026
malformations I-Disease 1 0.9998679161071777
. O 0 0.000160209383466281

Mutations O 0 0.00017999624833464622
of O 0 2.7224299969930144e-07
the O 0 2.7552567871680367e-07
human O 0 3.892458153131884e-06
PAX6 O 1 0.5040239095687866
gene O 0 0.0004324504698161036
underlie O 1 0.7500331997871399
aniridia B-Disease 1 0.9999738931655884
( O 0 8.605725452071056e-05
congenital B-Disease 1 0.9974495768547058
absence I-Disease 0 2.825702495101723e-06
of I-Disease 0 1.8958244751843267e-08
the I-Disease 0 5.6051288765957e-07
iris I-Disease 1 0.5186880230903625
) O 0 7.437297711021529e-08
, O 0 1.3871021664613181e-08
a O 0 7.657300216123986e-08
rare O 0 2.4592540285084397e-05
dominant O 0 0.00012880933354608715
malformation B-Disease 0 0.4452603757381439
of I-Disease 0 1.093771828664103e-07
the I-Disease 0 3.5525540624803398e-06
eye I-Disease 0 0.0351065956056118
. O 0 2.237379339931067e-05

The O 0 1.6315439097525086e-06
spectrum O 0 6.651287549175322e-06
of O 0 3.4877737675742537e-07
PAX6 O 1 0.6001985669136047
mutations O 0 0.00018866336904466152
in O 0 2.773759206320392e-06
aniridia B-Disease 1 0.9999285936355591
patients O 0 7.687462129979394e-06
is O 0 1.4708172457744695e-08
highly O 0 2.7577247152521522e-08
biased O 0 2.3532212622967563e-08
, O 0 1.8164584281166185e-09
with O 0 1.7267038909807297e-09
92 O 0 4.640810402634088e-08
% O 0 2.7798134905054894e-09
of O 0 8.796947614797546e-10
all O 0 5.151122639546202e-09
reported O 0 4.2444498831173405e-06
mutations O 0 1.0099867040480603e-06
leading O 0 3.523996028320653e-08
to O 0 8.42874747775113e-09
premature O 0 2.0631664483516943e-06
truncation O 0 1.7356802572976449e-07
of O 0 6.125080442842545e-10
the O 0 5.798935998058141e-09
protein O 0 1.404185780984335e-07
( O 0 4.3877235178513274e-09
nonsense O 0 2.9302327675395645e-07
, O 0 1.7943718733093306e-09
splicing O 0 2.7000714553082616e-08
, O 0 1.6142793768381125e-09
insertions O 0 3.3510195862618275e-07
and O 0 4.530952057990589e-09
deletions O 0 3.5023163036385085e-07
) O 0 1.445701003355282e-09
and O 0 7.45143280411753e-10
just O 0 9.56151713360498e-10
2 O 0 1.8245212007883538e-09
% O 0 9.94938575971105e-10
leading O 0 2.08477368701665e-09
to O 0 3.3380659347770347e-10
substitution O 0 1.4994366859255592e-09
of O 0 4.670553388486098e-10
one O 0 2.7861515317084695e-09
amino O 0 2.0210338291803964e-08
acid O 0 2.5316973406575016e-08
by O 0 2.6157598309595187e-09
another O 0 2.508653373922698e-08
( O 0 1.1570582358899628e-07
missense O 0 0.00011899656965397298
) O 0 3.116923323887022e-07
. O 0 1.134149101744697e-06

The O 0 1.2492998848756542e-06
extraordinary O 0 5.345032604964217e-06
conservation O 0 3.401188166662905e-07
of O 0 6.626648119123502e-09
the O 0 1.5880198489526265e-08
PAX6 O 0 5.835466436110437e-05
protein O 0 9.257736621748336e-08
at O 0 5.206387321265993e-09
the O 0 3.535877812765875e-09
amino O 0 3.7789874340887764e-08
acid O 0 1.1381706599422614e-07
level O 0 3.328678488401238e-08
amongst O 0 4.7688576643167835e-08
vertebrates O 0 4.0377112782152835e-06
predicts O 0 3.7517187593039125e-05
that O 0 5.6032590123322734e-08
pathological O 0 0.0007959582726471126
missense O 0 0.031033318489789963
mutations O 0 8.772960427450016e-06
should O 0 1.0221142154875906e-08
in O 0 6.769783400528695e-09
fact O 0 2.624837236453459e-08
be O 0 7.333002205456296e-09
common O 0 3.2208738787176117e-08
even O 0 3.5554169386387e-08
though O 0 1.6570815830618812e-08
they O 0 2.1512305270476872e-09
are O 0 2.1269630501308256e-09
hardly O 0 1.402744373990572e-07
ever O 0 1.8613245345022733e-07
seen O 0 8.479947837258806e-07
in O 0 8.862634786055423e-07
aniridia B-Disease 1 0.9998213648796082
patients O 0 0.00020150115597061813
. O 0 8.100215382000897e-06

This O 0 2.0430188669706695e-06
indicates O 0 4.3638242459564935e-06
that O 0 2.7335147478879662e-08
there O 0 4.656927732327176e-09
is O 0 3.3112250719113945e-09
a O 0 1.340421018625193e-08
heavy O 0 1.2604180483322125e-05
ascertainment O 0 0.000629073882009834
bias O 0 3.518240987432364e-07
in O 0 3.4934040105127906e-09
the O 0 8.094472314645884e-10
selection O 0 5.0119792760483506e-09
of O 0 7.121855549740985e-09
patients O 0 2.2220886819468433e-07
for O 0 3.051702179845961e-08
PAX6 O 0 0.4721843898296356
mutation O 0 1.2696482372120954e-05
analysis O 0 4.157528010750866e-08
and O 0 5.171391759262178e-09
that O 0 6.596169388473072e-09
the O 0 5.0785050831336775e-08
missing O 0 2.0571917048073374e-05
PAX6 O 0 0.4371725618839264
missense O 0 0.12023372948169708
mutations O 0 5.147675619809888e-05
frequently O 0 2.2346873720380245e-06
may O 0 1.2343858543317765e-05
underlie O 0 0.002019048435613513
phenotypes O 0 0.0008458178490400314
distinct O 0 1.3717681213165633e-06
from O 0 7.274524023159756e-07
textbook O 0 0.0008070770418271422
aniridia B-Disease 1 0.9977594614028931
. O 0 2.40953013417311e-05

Here O 0 2.1203875348874135e-06
we O 0 8.450144406424442e-08
present O 0 2.5312917983910665e-08
four O 0 2.0258193345057407e-08
novel O 0 7.08912125446659e-07
PAX6 O 0 0.04492024704813957
missense O 0 0.020414503291249275
mutations O 0 9.976298315450549e-06
, O 0 9.08678021716014e-09
two O 0 5.507921674308136e-09
in O 0 8.869299961133947e-08
association O 0 1.4630117561864608e-07
with O 0 2.275710500043715e-07
atypical O 0 0.021072763949632645
phenotypes O 0 0.055620741099119186
ectopia B-Disease 0 0.05431973189115524
pupillae I-Disease 0 0.006982477381825447
( O 0 6.117310391573483e-08
displaced B-Disease 0 5.121309527567064e-07
pupils I-Disease 0 5.2272412176535e-07
) O 0 8.947305474293898e-08
and O 0 1.614438406249974e-05
congenital B-Disease 1 0.9999514818191528
nystagmus I-Disease 0 0.11414463818073273
( O 0 7.929550349672354e-08
searching B-Disease 0 5.50155107248429e-07
gaze I-Disease 0 2.9095979698468e-05
) O 0 6.9707715155686856e-09
, O 0 1.5105601214315811e-09
and O 0 1.4700199946204862e-09
two O 0 2.636758367202674e-09
in O 0 5.9420301568025025e-08
association O 0 6.384077977372726e-08
with O 0 1.6779905465114098e-08
more O 0 7.776549892923867e-08
recognizable O 0 0.0007286563632078469
aniridia B-Disease 1 0.9993723034858704
phenotypes O 0 0.03619173914194107
. O 0 6.610387117689243e-06

Strikingly O 0 0.0006582362111657858
, O 0 2.2257960097249452e-07
all O 0 1.0798930638600268e-08
four O 0 6.896004123291277e-08
mutations O 0 1.2027284128635074e-06
are O 0 2.457297920699375e-09
located O 0 9.005668211159445e-09
within O 0 2.356480788279214e-09
the O 0 1.0128261784814185e-08
PAX6 O 0 0.0001636743254493922
paired O 0 7.016166136963875e-07
domain O 0 5.3618631312701837e-08
and O 0 8.692755848471734e-09
affect O 0 2.897162509896134e-08
amino O 0 2.1516173731583876e-08
acids O 0 8.011045160571939e-09
which O 0 1.2360500400987462e-09
are O 0 9.155267099991704e-10
highly O 0 9.614189444562271e-09
conserved O 0 3.9243271743316654e-08
in O 0 2.3072908028609618e-09
all O 0 9.021514646434525e-10
known O 0 3.39652643788213e-08
paired O 0 7.135931241464277e-07
domain O 0 2.699150343232759e-07
proteins O 0 4.156942452482326e-07
. O 0 7.506809538426751e-07

Our O 0 1.7632380604482023e-06
results O 0 6.765170610378846e-07
support O 0 3.82873608373302e-08
the O 0 1.0665468508364029e-08
hypothesis O 0 1.3394848963343975e-07
that O 0 9.391633026822888e-10
the O 0 5.908233347007297e-10
under O 0 3.841711393448577e-09
- O 0 6.649611350439955e-07
representation O 0 5.3427623214474806e-08
of O 0 3.177247265284677e-08
missense O 0 0.005438805092126131
mutations O 0 9.849537491390947e-06
is O 0 1.3322265068893557e-08
caused O 0 1.486542657858081e-07
by O 0 3.060305431290544e-08
ascertainment O 0 0.0015036800177767873
bias O 0 1.5330549558711937e-06
and O 0 3.785320856763974e-08
suggest O 0 1.4339073572955385e-07
that O 0 2.377763985705883e-09
a O 0 1.8157942704988272e-08
substantial O 0 6.30036936399847e-07
burden O 0 5.851737569173565e-06
of O 0 8.228758474615461e-08
PAX6 B-Disease 1 0.7826999425888062
- I-Disease 1 0.8825939297676086
related I-Disease 0 0.013372587971389294
disease I-Disease 0 0.005465478636324406
remains O 0 1.8551997982285684e-07
to O 0 6.418273468256075e-09
be O 0 3.1826814961277705e-08
uncovered O 0 5.252454138826579e-05
. O 0 5.120713808537403e-07
. O 0 2.1421496967377607e-06

The O 0 1.9767539924941957e-06
chromosomal O 0 0.000731971173081547
order O 0 2.9247800625853415e-07
of O 0 4.871557734986709e-08
genes O 0 5.406827767728828e-07
controlling O 0 8.632409276287945e-07
the O 0 4.070781400855594e-08
major O 0 1.4495004734271788e-06
histocompatibility O 0 0.3489428162574768
complex O 0 4.246628122928087e-06
, O 0 4.404352438314163e-08
properdin O 0 2.6741214242065325e-05
factor O 0 6.84213006252321e-08
B O 0 3.1288331570067385e-07
, O 0 1.4118620050851405e-08
and O 0 1.9891965052920568e-07
deficiency B-Disease 0 0.0016655782237648964
of I-Disease 0 1.3523512309987495e-09
the I-Disease 0 5.221981957959088e-09
second I-Disease 0 3.095794909313554e-08
component I-Disease 0 1.3318776836968027e-07
of I-Disease 0 3.23465805251999e-08
complement I-Disease 0 8.321831046487205e-06
. O 0 2.8488918815128272e-06

The O 0 7.670096238143742e-07
relationship O 0 6.500401923403842e-07
of O 0 1.2262446169586383e-08
the O 0 2.1634360081179693e-08
genes O 0 1.0440786013532488e-07
coding O 0 2.0404552003583376e-07
for O 0 3.084400290731537e-09
HLA O 0 5.36041352461325e-06
to O 0 2.323799819237138e-09
those O 0 3.49605677740783e-09
coding O 0 1.8353776454205217e-07
for O 0 2.4147706056965035e-09
properdin O 0 3.123948772554286e-05
Factor O 0 5.967117289173984e-08
B O 0 1.6695439342129248e-07
allotypes O 0 4.025815087516094e-06
and O 0 9.205630924213892e-09
for O 0 6.950222797286187e-08
deficiency B-Disease 0 0.0018744475673884153
of I-Disease 0 9.929631561433894e-10
the I-Disease 0 2.192471981743438e-09
second I-Disease 0 1.2091553536208721e-08
component I-Disease 0 2.2477646410834495e-08
of I-Disease 0 1.610257149842198e-09
complement I-Disease 0 2.7864379603670386e-07
( O 0 2.8223414716421757e-08
C2 O 0 7.325728074647486e-05
) O 0 3.700666217909543e-09
was O 0 5.552391435514892e-09
studied O 0 3.104445411850065e-08
in O 0 1.101078694887292e-08
families O 0 3.447468444051083e-08
of O 0 9.32337229642144e-08
patients O 0 1.8137721781386063e-05
with O 0 8.561606955481693e-05
connective O 1 0.9999287128448486
tissue O 1 0.9999397993087769
disorders O 1 0.999041736125946
. O 0 7.825544889783487e-05

Patients O 0 7.38684248062782e-05
were O 0 1.3810020504934073e-07
selected O 0 1.1100303254352184e-07
because O 0 3.2282049033938165e-08
they O 0 1.1971534874533063e-08
were O 0 1.1278351585986002e-08
heterozygous O 0 8.414542094214994e-07
or O 0 2.0566234582020115e-07
homozygous O 0 0.00029679745784960687
for O 0 9.794760262593627e-05
C2 B-Disease 1 0.9999899864196777
deficiency I-Disease 1 0.9999823570251465
. O 0 5.9446669183671474e-05

12 O 0 3.911633939424064e-06
families O 0 3.2908278058130236e-07
with O 0 6.735397306556479e-08
15 O 0 2.72276253099335e-07
matings O 0 0.00013259639672469348
informative O 0 1.4299597751232795e-05
for O 0 7.567969441879541e-05
C2 B-Disease 1 0.9999978542327881
deficiency I-Disease 1 0.9999880790710449
were O 0 1.976260136871133e-06
found O 0 5.931220584898256e-06
. O 0 3.6568503674061503e-06

Of O 0 5.042156772105955e-07
57 O 0 1.1248263263041736e-06
informative O 0 9.16757471713936e-07
meioses O 0 9.939658775692806e-05
, O 0 1.4131713577114624e-08
two O 0 1.8909267485156533e-09
crossovers O 0 1.1674985245235803e-07
were O 0 3.5205143245065074e-09
noted O 0 3.1590463578368144e-08
between O 0 2.3664812331958274e-08
the O 0 1.6171055904123932e-05
C2 B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999853372573853
gene O 0 1.6831134530548297e-07
and O 0 4.0791894306835275e-09
the O 0 6.343546576914605e-09
HLA O 0 0.00011605050531215966
- O 0 0.00048355976468883455
B O 0 1.4707464970342699e-06
gene O 0 2.6689098930887667e-08
, O 0 6.747774561333131e-10
with O 0 6.946028752174982e-10
a O 0 7.362854326231627e-09
recombinant O 0 4.870327074968372e-07
fraction O 0 1.6866596297404612e-07
of O 0 2.8726272915946538e-08
0 O 0 1.3330903811947792e-06
. O 0 1.530079771328019e-06

035 O 0 0.47024786472320557
. O 0 0.0008159197750501335

A O 0 3.201396111762733e-06
lod O 0 0.00018555346468929201
score O 0 1.2139196314819856e-07
of O 0 6.8713044143464685e-09
13 O 0 3.4134966853116566e-08
was O 0 1.1239268182805517e-08
calculated O 0 8.203763002256892e-08
for O 0 7.789045852746312e-09
linkage O 0 0.00012729149602819234
between O 0 0.0003335009387228638
C2 B-Disease 1 0.9999986886978149
deficiency I-Disease 1 0.9999847412109375
and O 0 2.7684896508617385e-07
HLA O 0 0.0007697840337641537
- O 0 0.000245598639594391
B O 0 1.816525809772429e-07
at O 0 1.940126725941127e-09
a O 0 1.7957549891534086e-09
maximum O 0 1.672099081417855e-08
likelihood O 0 5.143359871340181e-08
value O 0 1.6878375364015596e-09
of O 0 3.1102267983307286e-10
the O 0 1.7603435376045695e-09
recombinant O 0 7.12873529096214e-08
fraction O 0 6.931661999942662e-08
of O 0 1.0766969538167359e-08
0 O 0 1.9585954760259483e-06
. O 0 1.6570617162869894e-06

04 O 0 0.045618027448654175
. O 0 0.0002471824118401855

18 O 0 4.607959908753401e-06
families O 0 3.244674928737368e-07
with O 0 4.9355019626773355e-08
21 O 0 9.977100745572898e-08
informative O 0 2.842211301867792e-07
matings O 0 1.3197274711274076e-05
for O 0 7.844927374378585e-09
both O 0 1.4718668062130291e-08
properdin O 0 0.00017430800653528422
Factor O 0 1.8743172347512882e-07
B O 0 2.3762650869230129e-07
allotype O 0 4.818197339773178e-06
and O 0 2.6992578838758163e-08
HLA O 0 3.1413528631674126e-05
- O 0 0.00010219552495982498
B O 0 4.911620976599806e-07
were O 0 2.9915813826164595e-08
found O 0 4.82372342958115e-07
. O 0 1.6765288819442503e-06

Of O 0 8.951681707003445e-07
72 O 0 1.7603229025553446e-06
informative O 0 1.798088646864926e-06
meioses O 0 0.00010198543895967305
, O 0 1.9053768340882016e-08
three O 0 7.022282755286824e-09
recombinants O 0 1.6034031432354823e-05
were O 0 9.923576627102193e-09
found O 0 8.835038478594015e-09
, O 0 1.5359790106472815e-09
giving O 0 1.6998332741380295e-09
a O 0 7.394492129719765e-09
recombinant O 0 1.895555783448799e-07
fraction O 0 5.4491572143433586e-08
of O 0 1.960654749666446e-08
0 O 0 1.1856899391204934e-06
. O 0 9.583194469087175e-07

042 O 0 0.01983252353966236
. O 0 0.0002979448181577027

A O 0 6.054516688891454e-06
lod O 0 0.0003367960744071752
score O 0 9.451932925230722e-08
of O 0 6.657369766571719e-09
16 O 0 1.2097320478687834e-08
between O 0 8.432189169127469e-09
HLA O 0 2.33935297728749e-05
- O 0 2.0058101654285565e-05
B O 0 2.2184318027029803e-07
and O 0 4.931998809354354e-09
Factor O 0 1.8255978062597933e-08
B O 0 1.0059092403480463e-07
allotypes O 0 3.7994880131009268e-06
was O 0 4.89107954138035e-09
calculated O 0 9.953338597767925e-09
at O 0 1.209406019775372e-09
a O 0 3.165939288507502e-09
maximum O 0 2.374017427086983e-08
likelihood O 0 7.193408180228289e-08
value O 0 1.4075859366968757e-09
of O 0 3.112458069054469e-10
the O 0 2.764110940134401e-09
recombinant O 0 1.5067918468503194e-07
fraction O 0 6.240284022851483e-08
of O 0 1.9358102676392264e-08
0 O 0 7.620407700414944e-07
. O 0 1.596641482137784e-06

04 O 0 0.03025154210627079
. O 0 0.00023071120085660368

A O 0 1.766257355484413e-06
crossover O 0 2.4259568363049766e-06
was O 0 1.0941578665324414e-07
shown O 0 5.652604428973973e-08
to O 0 3.4640701418453546e-09
have O 0 7.774099586299599e-09
occurred O 0 8.198131240533257e-08
between O 0 3.496643641298647e-09
genes O 0 1.0170249531427089e-08
for O 0 7.153136416526706e-10
Factor O 0 8.028758102796019e-09
B O 0 4.549989540691968e-08
and O 0 8.286400010604211e-09
HLA O 0 8.279173925984651e-05
- O 0 0.013446916826069355
D O 0 0.06832845509052277
, O 0 7.6929422831995e-09
in O 0 3.609924359437855e-09
which O 0 1.92549229893757e-08
HLA O 0 0.00026339147007092834
- O 0 0.0022402573376893997
D O 0 0.017265304923057556
segregared O 0 1.82763506018091e-05
with O 0 2.2200186577947534e-08
HLA O 0 4.500440263655037e-05
- O 0 1.5530236851191148e-05
A O 0 1.2771570823133516e-07
and O 0 2.317792535677654e-07
B O 0 7.508580893045291e-06
. O 0 1.5510286175413057e-06

These O 0 7.63184800689487e-07
studies O 0 5.265271170173946e-07
suggest O 0 1.1996249327239639e-07
that O 0 4.353378546539943e-09
the O 0 3.3958120759791655e-09
genes O 0 1.461287535420297e-08
for O 0 2.1155612817125302e-09
Factor O 0 5.659724777729025e-08
B O 0 5.18932620252599e-06
and O 0 0.0002272107667522505
C2 B-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9999934434890747
are O 0 1.0057305210864342e-08
located O 0 1.4465927122842004e-08
outside O 0 6.13436634822051e-09
those O 0 2.7903848121013652e-09
for O 0 5.37216848783828e-09
HLA O 0 8.538345718989149e-05
, O 0 7.512428901179646e-09
that O 0 4.6212314530613696e-10
the O 0 5.396906810339885e-10
order O 0 1.1706526859001087e-09
of O 0 9.213637075511372e-10
genese O 0 1.85858898475999e-05
is O 0 1.0035345887615676e-08
HLA O 0 3.6645828913606238e-06
- O 0 1.9937463093810948e-06
A O 0 1.7379386818561215e-08
, O 0 6.231420712765612e-09
- O 0 8.661751962790731e-06
B O 0 2.859480900951894e-07
, O 0 5.775369071869818e-09
- O 0 1.857945608207956e-05
D O 0 0.00023304852948058397
, O 0 6.044240219438279e-09
Factor O 0 1.0769907632379727e-08
B O 0 6.179687943586032e-07
allotype O 0 0.0036781663075089455
, O 0 0.00010532324813539162
C2 B-Disease 1 0.999996542930603
deficiency I-Disease 1 0.9999743700027466
, O 0 2.0136768696943363e-08
that O 0 1.5758203630866774e-09
the O 0 6.165428168003473e-09
genes O 0 1.2564589724206598e-07
coding O 0 4.313988029025495e-06
for O 0 2.029228426181362e-06
C2 B-Disease 1 0.9999977350234985
deficiency I-Disease 1 0.999968409538269
and O 0 1.0475255152186946e-07
Factor O 0 9.62219104394535e-08
B O 0 2.0076181783679203e-07
allotypes O 0 2.5958320293284487e-06
are O 0 7.535300161620739e-10
approximately O 0 1.271148408754641e-09
3 O 0 2.3886916888926635e-09
- O 0 5.402689566835761e-07
- O 0 3.7841950870642904e-06
5 O 0 6.7461050079486995e-09
centimorgans O 0 6.128872769295413e-07
from O 0 6.554040643536041e-10
the O 0 1.4526471137088492e-09
HLA O 0 6.271968686633045e-06
- O 0 1.306974468207045e-06
A O 0 1.0125093652391115e-08
and O 0 1.4594101926945768e-08
HLA O 0 3.230788206565194e-05
- O 0 3.138419197057374e-05
B O 0 2.7747040576286963e-07
loci O 0 4.755705163006496e-08
, O 0 1.8930521594739957e-09
and O 0 8.423054476125458e-10
that O 0 8.910308046949922e-10
the O 0 4.439165035563519e-09
apparent O 0 2.4447153919027187e-06
lack O 0 5.053257012832546e-08
of O 0 5.089575871863872e-09
recombinants O 0 1.725735819491092e-05
between O 0 5.269758851511597e-09
the O 0 6.072446545601906e-09
Factor O 0 3.556468186616257e-08
B O 0 3.6043331874680007e-07
gene O 0 3.364773704106483e-07
and O 0 1.9444345525698736e-05
C2 B-Disease 1 0.9999977350234985
deficiency I-Disease 1 0.9999911785125732
gene O 0 9.738898825162323e-07
suggests O 0 1.0805590022755496e-07
that O 0 1.2813821115287283e-09
these O 0 3.113597990545003e-10
two O 0 1.5561668620378555e-09
genes O 0 4.2220737128673136e-08
lie O 0 1.7573673858350958e-06
in O 0 2.049175407137227e-08
close O 0 4.328739677816884e-08
proximity O 0 1.3403308685155935e-07
to O 0 1.3637283302614378e-08
one O 0 3.728142417003255e-08
another O 0 5.065527375336387e-07
. O 0 3.824565283139236e-06

Distribution O 0 2.381501872150693e-06
of O 0 2.319696648100944e-07
emerin O 0 0.0002753192966338247
and O 0 5.719256819247676e-07
lamins O 0 0.009288911707699299
in O 0 1.592549097040319e-07
the O 0 1.4382062829554343e-07
heart O 0 0.00010340872540837154
and O 0 1.5452778256985766e-07
implications O 0 1.8899595488619525e-06
for O 0 1.2217778078138508e-07
Emery B-Disease 0 0.0008860314846970141
- I-Disease 1 0.9822894930839539
Dreifuss I-Disease 1 0.9994572997093201
muscular I-Disease 1 0.9995688796043396
dystrophy I-Disease 1 0.9990112781524658
. O 0 6.914128607604653e-05

Emerin O 0 0.0016063273651525378
is O 0 2.895572492889187e-07
a O 0 7.558309533806096e-08
nuclear O 0 1.161846194008831e-05
membrane O 0 2.0633394797187066e-06
protein O 0 1.0549301521223242e-07
which O 0 4.967723565840743e-09
is O 0 3.687194993773346e-09
missing O 0 1.0453279486455358e-07
or O 0 5.0256897310418935e-08
defective O 0 8.037700354179833e-06
in O 0 5.911440439376747e-07
Emery B-Disease 0 0.0035249809734523296
- I-Disease 1 0.9992712140083313
Dreifuss I-Disease 1 0.9999572038650513
muscular I-Disease 1 0.9999616146087646
dystrophy I-Disease 1 0.9999001026153564
( O 0 2.255929575767368e-05
EDMD B-Disease 1 0.999386191368103
) O 0 2.2397289285436273e-06
. O 0 3.3813410027505597e-06

It O 0 2.72945186452489e-07
is O 0 2.9814870572408836e-08
one O 0 3.913725343807073e-09
member O 0 4.926263397209141e-09
of O 0 1.3222012373859116e-09
a O 0 1.2667537241384252e-08
family O 0 2.8762677573013207e-08
of O 0 2.9270841750417276e-08
lamina O 0 0.2740171551704407
- O 0 0.0005199477891437709
associated O 0 3.5213022897551127e-07
proteins O 0 1.0853403509258897e-08
which O 0 2.86269852267651e-09
includes O 0 2.8840078769576394e-08
LAP1 O 0 8.293120481539518e-05
, O 0 7.660630529926493e-08
LAP2 O 0 0.00014221988385543227
and O 0 2.154361027351115e-07
lamin O 0 0.0028886632062494755
B O 0 2.3486451027565636e-05
receptor O 0 1.8584825738798827e-05
( O 0 1.1822676242445596e-06
LBR O 0 0.18395733833312988
) O 0 9.356718919661944e-07
. O 0 1.530434246888035e-06

A O 0 3.504478854665649e-06
panel O 0 1.9729045561689418e-06
of O 0 5.962066751408202e-08
16 O 0 2.651451325164089e-07
monoclonal O 0 2.8519516490632668e-05
antibodies O 0 1.2458480341592804e-05
( O 0 8.417954688866303e-08
mAbs O 0 1.024630091706058e-05
) O 0 4.755448479443203e-09
has O 0 2.7547317760223677e-09
been O 0 2.5369455425305887e-09
mapped O 0 4.165514440046536e-07
to O 0 1.152498985135253e-09
six O 0 2.186933523162793e-09
specific O 0 2.90893309440321e-09
sites O 0 1.0772804870384789e-08
throughout O 0 2.6528810259662805e-09
the O 0 3.1509868048118506e-09
emerin O 0 3.6829487726208754e-06
molecule O 0 5.807472547303405e-08
using O 0 5.49090817258957e-09
phage O 0 2.9120332101228996e-07
- O 0 6.55409678529395e-07
displayed O 0 2.612645744193287e-07
peptide O 0 2.2454428005858063e-07
libraries O 0 1.607980770756967e-08
and O 0 3.390964398164442e-09
has O 0 2.39215225406042e-09
been O 0 9.241021836636776e-10
used O 0 4.0034198178773295e-09
to O 0 3.9363192705366146e-09
localize O 0 1.0925862625299487e-05
emerin O 0 0.00067994772689417
in O 0 6.296344423617484e-08
human O 0 1.8629084763688297e-07
and O 0 2.964736722788075e-07
rabbit O 0 0.0018923950847238302
heart O 0 0.0020984583534300327
. O 0 5.425187737273518e-06

Several O 0 1.4729923805134604e-06
mAbs O 0 6.282854155870155e-05
against O 0 3.4684757110881037e-07
different O 0 1.1813158096174448e-07
emerin O 0 0.00042839095112867653
epitopes O 0 0.003586211707442999
did O 0 9.917791032876266e-08
not O 0 7.845555316521313e-09
recognize O 0 1.0779303494246051e-07
intercalated O 0 3.115042272838764e-05
discs O 0 8.415641445935762e-07
in O 0 1.9612008017588778e-08
the O 0 4.613310267131965e-08
heart O 0 0.00010327078052796423
, O 0 2.3365922530160788e-08
though O 0 1.1974686131566159e-08
they O 0 2.2244339703547666e-09
recognized O 0 1.549793182675785e-08
cardiomyocyte O 0 1.8653669030754827e-05
nuclei O 0 2.757951506282552e-06
strongly O 0 3.473320830948978e-08
, O 0 1.1743919170470463e-09
both O 0 6.560344489869863e-10
at O 0 2.4189379388417365e-09
the O 0 3.662466774301265e-09
rim O 0 2.504614258214133e-07
and O 0 9.404651279965037e-09
in O 0 3.558171357553874e-08
intranuclear O 0 8.125900785671547e-05
spots O 0 1.5853105423957459e-06
or O 0 1.257440658264386e-07
channels O 0 1.4567453945346642e-06
. O 0 1.9030942439712817e-06

A O 0 5.549161869566888e-06
polyclonal O 0 0.0004335608100518584
rabbit O 0 0.00010161576938116923
antiserum O 0 0.00019725647871382535
against O 0 7.011677780610626e-07
emerin O 0 0.00027327786665409803
did O 0 1.3522982555969065e-07
recognize O 0 1.215795322195845e-07
both O 0 7.910860411186604e-09
nuclear O 0 6.162453701108461e-06
membrane O 0 4.784081397701812e-07
and O 0 1.4635106460048064e-08
intercalated O 0 2.2566868210560642e-05
discs O 0 1.0651521051840973e-06
but O 0 5.93293281170304e-09
, O 0 1.3951784172405723e-09
after O 0 4.2825187840378476e-09
affinity O 0 5.362425525845538e-08
purification O 0 9.629755481910252e-08
against O 0 5.197815067248257e-09
a O 0 4.40030323289875e-09
pure O 0 7.097503385011805e-08
- O 0 4.0433002141071483e-05
emerin O 0 2.59131829807302e-05
band O 0 1.933504023554633e-08
on O 0 1.060679322151259e-09
a O 0 1.956372841505072e-09
western O 0 2.549204047852527e-08
blot O 0 1.525212519482011e-05
, O 0 7.8556627869375e-09
it O 0 2.8613227343043945e-09
stained O 0 4.736247774417279e-06
only O 0 4.6049737356668174e-09
the O 0 2.2996998083613107e-08
nuclear O 0 9.890842920867726e-05
membrane O 0 1.9907021851395257e-05
. O 0 2.1860605556867085e-06

These O 0 5.301422447701043e-07
results O 0 1.3276423942443216e-06
would O 0 2.648327246390636e-08
not O 0 3.6870333453009607e-09
be O 0 1.635530710863975e-09
expected O 0 1.9951881924384907e-08
if O 0 7.992089656738699e-09
immunostaining O 0 5.594524282059865e-06
at O 0 1.7590423340152483e-08
intercalated O 0 2.5314680897281505e-05
discs O 0 6.898364972585114e-07
were O 0 4.604780556860533e-09
due O 0 1.5215055881867556e-08
to O 0 1.2057669307452556e-09
a O 0 5.307738248916394e-09
product O 0 1.4547634208383897e-08
of O 0 8.473167723010988e-10
the O 0 9.825789071271629e-09
emerin O 0 0.00037207079003565013
gene O 0 7.155844627959596e-08
and O 0 6.765794591245822e-09
, O 0 6.178612732554711e-09
therefore O 0 4.725556390638985e-09
, O 0 1.1286866996584877e-09
cast O 0 6.734483193326923e-09
some O 0 4.18423018455627e-10
doubt O 0 1.2568454721417766e-08
upon O 0 2.9695785830341492e-09
the O 0 9.918618815163427e-09
hypothesis O 0 1.7369847000736627e-06
that O 0 3.042635796646209e-07
cardiac B-Disease 1 0.9781339764595032
defects I-Disease 1 0.8472171425819397
in O 0 6.959932761674281e-06
EDMD B-Disease 1 0.9999165534973145
are O 0 1.1766161378545803e-07
caused O 0 1.3950507309345994e-06
by O 0 2.3367169532662047e-08
absence O 0 2.2154760870307655e-07
of O 0 3.447770424713781e-08
emerin O 0 0.0012143099447712302
from O 0 4.468381575861713e-07
intercalated O 0 0.0068301553837955
discs O 0 0.00021820252004545182
. O 0 6.119538284110604e-06

Although O 0 5.746770057157846e-06
emerin O 0 6.567980744875968e-05
was O 0 7.645450494919714e-08
abundant O 0 2.5365338274241367e-07
in O 0 6.241864802802866e-09
the O 0 2.655888398095385e-09
membranes O 0 1.7694037524051964e-07
of O 0 2.996993764270428e-09
cardiomyocyte O 0 0.0005808646674267948
nuclei O 0 3.863906385959126e-05
, O 0 8.897880654501478e-09
it O 0 1.0496025160122713e-09
was O 0 3.128840075916628e-09
absent O 0 3.275066262631299e-08
from O 0 2.0569670411418883e-09
many O 0 1.26261379129744e-09
non O 0 7.222582354415863e-08
- O 0 0.001674402505159378
myocyte O 0 0.18482866883277893
cells O 0 2.261251211166382e-06
in O 0 5.268706360084252e-08
the O 0 1.7818398134750169e-07
heart O 0 0.0003880056319758296
. O 0 6.742042842233786e-06

This O 0 2.8208947355778946e-07
distribution O 0 5.645794587394448e-08
of O 0 9.328065431191135e-09
emerin O 0 9.288010915042832e-05
was O 0 1.6827724991230752e-08
similar O 0 8.015966557195497e-09
to O 0 9.707681325465956e-10
that O 0 8.80569339667403e-10
of O 0 2.970201640195569e-09
lamin O 0 0.00020071880135219544
A O 0 1.160916838216508e-07
, O 0 8.586567901147646e-09
a O 0 8.238397519733098e-09
candidate O 0 4.2062393390551733e-07
gene O 0 7.331062334969829e-08
for O 0 2.6605022629411224e-09
an O 0 3.097696676945816e-08
autosomal O 0 8.93729375093244e-05
form O 0 1.8193480855188682e-06
of O 0 2.524920546420617e-06
EDMD B-Disease 1 0.9998822212219238
. O 0 2.8355554604786448e-05

In O 0 3.6211713450029492e-06
contrast O 0 2.1358553567552008e-05
, O 0 8.98185078312963e-07
lamin O 0 0.004356301389634609
B1 O 0 0.013707304373383522
was O 0 8.414230734388184e-08
absent O 0 2.4429994027741486e-07
from O 0 1.3657638575637066e-08
cardiomyocyte O 0 3.925882265320979e-05
nuclei O 0 7.392672159767244e-06
, O 0 1.1804899280321024e-08
showing O 0 2.7357063459021447e-07
that O 0 3.446048424393666e-08
lamin O 0 0.0036480017006397247
B1 O 0 0.10284356772899628
is O 0 7.900757381662515e-09
not O 0 1.2773776481012078e-09
essential O 0 1.2570918750398619e-09
for O 0 1.017237849509911e-09
localization O 0 1.3854527480816614e-07
of O 0 2.67793920372128e-09
emerin O 0 2.589680480014067e-05
to O 0 1.7908748262129848e-08
the O 0 1.2864303755577566e-07
nuclear O 0 0.004233641549944878
lamina O 0 0.22583357989788055
. O 0 4.706490472017322e-06

Lamin O 1 0.8151069283485413
B1 O 1 0.5987647175788879
is O 0 5.493267281053704e-07
also O 0 7.269711232993359e-08
almost O 0 5.426370819350268e-08
completely O 0 1.828598783504276e-07
absent O 0 1.2964869711140636e-06
from O 0 3.933379844056617e-07
skeletal O 0 0.005468939896672964
muscle O 0 0.0007406961522065103
nuclei O 0 0.00793534331023693
. O 0 1.3965754988021217e-05

In O 0 2.6884405087912455e-05
EDMD B-Disease 1 0.9240705370903015
, O 0 9.026754810292914e-08
the O 0 5.893604715367928e-09
additional O 0 6.167768074050173e-09
absence O 0 8.930511796734208e-08
of O 0 2.9763167930241252e-08
lamin O 0 0.03964555636048317
B1 O 0 0.21502964198589325
from O 0 2.1136531813681358e-07
heart O 0 5.7130087952828035e-05
and O 0 1.2432431049091974e-06
skeletal O 0 0.23132267594337463
muscle O 0 8.223968325182796e-05
nuclei O 0 0.0001037618494592607
which O 0 5.108027423261774e-08
already O 0 1.500415152122514e-07
lack O 0 1.1313005643387442e-06
emerin O 0 0.037479013204574585
may O 0 1.9825640151793777e-07
offer O 0 1.0899666058605817e-08
an O 0 1.0689493734616917e-09
alternative O 0 1.9362532910349728e-08
explanation O 0 2.755237815676992e-08
of O 0 1.2715413166830558e-09
why O 0 4.6781273965734727e-08
these O 0 4.4378105634734766e-09
tissues O 0 1.4860920600767713e-06
are O 0 8.485754321441163e-09
particularly O 0 1.9599674772052822e-07
affected O 0 3.3737481430762273e-07
. O 0 2.525972888633987e-07
. O 0 2.3050192794471513e-06

Genetic O 0 0.00023809338745195419
mapping O 0 1.273836096515879e-05
of O 0 9.792826460852666e-08
the O 0 3.873809646393056e-07
copper B-Disease 0 0.41452983021736145
toxicosis I-Disease 1 0.760981023311615
locus O 0 1.0252047104586381e-05
in O 0 1.2838810903303965e-07
Bedlington O 0 0.0001251583598786965
terriers O 0 1.1565971362870187e-05
to O 0 1.534451143925253e-08
dog O 0 1.6412681361543946e-05
chromosome O 0 2.3123900973587297e-05
10 O 0 1.3675521159939308e-08
, O 0 5.263259605925441e-09
in O 0 5.649669621021758e-09
a O 0 4.6601378755894984e-08
region O 0 1.2272107596800197e-06
syntenic O 0 0.0001443104847567156
to O 0 2.0574544734586198e-08
human O 0 3.8893566056685813e-07
chromosome O 0 3.651442239060998e-05
region O 0 3.0908736334822606e-06
2p13 O 0 0.00020635794498957694
- O 0 0.0035574245266616344
p16 O 0 0.00021521969756577164
. O 0 1.6237811450992012e-06

Abnormal O 1 0.9809437394142151
hepatic B-Disease 1 0.9976304769515991
copper I-Disease 1 0.9137921929359436
accumulation I-Disease 0 0.01026031281799078
is O 0 1.745775222161683e-07
recognized O 0 1.6955669934759499e-07
as O 0 3.7276016939813417e-08
an O 0 2.141326604032656e-06
inherited B-Disease 1 0.9999943971633911
disorder I-Disease 1 0.9999288320541382
in O 0 2.5667152385722147e-06
man O 0 5.8057492424268275e-05
, O 0 2.445880795676203e-07
mouse O 0 7.342575372604188e-06
, O 0 1.6767978650022997e-07
rat O 0 0.00011401947267586365
and O 0 4.5880031507294916e-07
dog O 0 0.00015318056102842093
. O 0 6.4956752794387285e-06

The O 0 1.5695046613473096e-06
major O 0 1.7142583601525985e-06
cause O 0 5.333931767381728e-06
of O 0 3.8304568761304836e-07
hepatic B-Disease 1 0.9576138257980347
copper I-Disease 1 0.971493661403656
accumulation I-Disease 0 0.0001973857288248837
in O 0 1.1572900149303678e-07
man O 0 2.325618197573931e-06
is O 0 1.1173562519672942e-08
a O 0 1.0708767916867146e-07
dysfunctional O 0 0.00025778854615055025
ATP7B O 0 0.07159382104873657
gene O 0 5.017767762183212e-06
, O 0 7.076092174429505e-07
causing O 0 0.0001475931057939306
Wilson B-Disease 0 0.35397011041641235
disease I-Disease 0 0.041859570890665054
( O 0 5.094569587527076e-06
WD B-Disease 1 0.9987861514091492
) O 0 6.027588824508712e-06
. O 0 3.7561540011665784e-06

Mutations O 0 0.0004931681323796511
in O 0 3.925005103155854e-07
the O 0 7.112505073791908e-08
ATP7B O 0 0.0008155513205565512
genes O 0 2.1984656939366687e-07
have O 0 5.088091281635343e-09
also O 0 3.6983094364728686e-09
been O 0 5.0106794269311195e-09
demonstrated O 0 6.776722898393928e-07
in O 0 1.208224347237774e-07
mouse O 0 2.402360041742213e-05
and O 0 1.0998791140082176e-06
rat O 0 0.007999179884791374
. O 0 4.479821654967964e-06

The O 0 1.2043514061588212e-06
ATP7B O 0 0.0003126763040199876
gene O 0 8.68085351157788e-07
has O 0 2.7339945418702882e-08
been O 0 4.141696763326763e-09
excluded O 0 2.55074112942566e-08
in O 0 8.777426785400166e-09
the O 0 7.052321837619502e-09
much O 0 6.183046963315064e-08
rarer O 0 0.0006766922888346016
human O 0 2.47494663199177e-05
copper B-Disease 1 0.9955583810806274
overload I-Disease 1 0.9974290728569031
disease O 0 0.0004307734197936952
non B-Disease 0 2.581985825145239e-07
- I-Disease 0 0.0016816228162497282
Indian I-Disease 0 3.233574898331426e-05
childhood I-Disease 0 0.40705567598342896
cirrhosis I-Disease 1 0.7117802500724792
, O 0 1.202077214657038e-06
indicating O 0 5.4045402066549286e-05
genetic O 0 0.00014822125376667827
heterogeneity O 0 0.0016068543773144484
. O 0 1.9006902221008204e-05

By O 0 2.343314918107353e-06
investigating O 0 1.0066335562441964e-05
the O 0 8.481015356665011e-07
common O 0 2.966682950500399e-05
autosomal O 1 0.5387452840805054
recessive O 1 0.8359279632568359
copper B-Disease 1 0.9997747540473938
toxicosis I-Disease 1 0.9998303651809692
( O 0 1.5399800759041682e-06
CT B-Disease 0 0.24354104697704315
) O 0 2.0765835273550692e-08
in O 0 3.5619944327436315e-08
Bedlington O 0 0.0005841999081894755
terriers O 0 0.00010323827882530168
, O 0 2.183500491526047e-08
we O 0 3.995311192994677e-09
have O 0 2.838286938811052e-09
identified O 0 4.2964870772266295e-08
a O 0 1.1655889586847934e-08
new O 0 9.414616641834073e-08
locus O 0 2.8872775601485046e-06
involved O 0 2.425992988719372e-07
in O 0 9.850364222074859e-06
progressive O 1 0.9979477524757385
liver B-Disease 1 0.9999970197677612
disease I-Disease 1 0.9999083280563354
. O 0 9.172767749987543e-05

We O 0 1.6414981018897379e-06
examined O 0 4.243114290147787e-06
whether O 0 1.5537169417711993e-07
the O 0 1.2991438325116178e-07
WD B-Disease 1 0.7479243874549866
gene O 0 9.107750997827679e-07
ATP7B O 0 8.075720688793808e-05
was O 0 2.5186450258729565e-08
also O 0 7.528695000758034e-09
causative O 0 1.2412315300025512e-06
for O 0 2.104037299943684e-08
CT B-Disease 0 0.032795730978250504
by O 0 2.573656132653923e-08
investigating O 0 5.647161742672324e-07
the O 0 6.823558607038649e-08
chromosomal O 0 0.0015347338048741221
co O 0 2.3666791094001383e-05
- O 0 3.491004463285208e-05
localization O 0 6.650892601101077e-07
of O 0 3.784878632728805e-09
ATP7B O 0 0.0001374086132273078
and O 0 1.5462973124158452e-08
C04107 O 0 1.626685616429313e-06
, O 0 2.458118375514573e-09
using O 0 4.198606351479839e-09
fluorescence O 0 2.7249730010225903e-06
in O 0 2.7249100753579114e-08
situ O 0 1.0880350600928068e-05
hybridization O 0 1.2515047274064273e-06
( O 0 2.316729030837905e-08
FISH O 0 1.0700600228119583e-07
) O 0 1.0885169388075155e-07
. O 0 6.915946073604573e-07

C04107 O 0 0.000941765436436981
is O 0 5.524248081201222e-07
an O 0 9.270795686688871e-08
anonymous O 0 1.7251185226996313e-06
microsatellite O 0 0.00034840122680179775
marker O 0 6.444724567700177e-05
closely O 0 2.3016848444967763e-06
linked O 0 1.0245567864330951e-05
to O 0 7.873236427258234e-07
CT B-Disease 1 0.9034826755523682
. O 0 2.888707422243897e-05

However O 0 4.142491889069788e-06
, O 0 2.0595204830442526e-07
BAC O 0 9.307430445915088e-06
clones O 0 7.72131613757665e-07
containing O 0 1.4232642797651351e-07
ATP7B O 0 4.454025474842638e-05
and O 0 2.582379288185166e-08
C04107 O 0 4.304310095903929e-06
mapped O 0 1.5966475075401831e-06
to O 0 2.3206638832817816e-09
the O 0 7.108583055526196e-09
canine O 0 0.000247325049713254
chromosome O 0 0.00033931067446246743
regions O 0 7.088871143423603e-07
CFA22q11 O 0 7.57073430577293e-05
and O 0 8.064229461979266e-08
CFA10q26 O 0 0.00030814966885372996
, O 0 1.8413800262351288e-08
respectively O 0 1.0786460791223362e-07
, O 0 5.636441535727954e-09
demonstrating O 0 7.624130660133233e-08
that O 0 4.1612409518165805e-08
WD B-Disease 1 0.9112712144851685
cannot O 0 1.7263381835164182e-07
be O 0 5.016378423761125e-09
homologous O 0 5.636588866764214e-07
to O 0 4.5324412667469005e-07
CT B-Disease 1 0.8565049767494202
. O 0 1.2623211659956723e-05

The O 0 3.6823271329922136e-06
copper O 0 0.0003364927542861551
transport O 0 2.8090712476114277e-06
genes O 0 5.731689611820912e-07
CTR1 O 0 1.5281215382856317e-05
and O 0 3.3503862795214445e-08
CTR2 O 0 4.503698801272549e-05
were O 0 7.2781296545088026e-09
also O 0 3.5861451586072235e-09
excluded O 0 1.721896403239498e-08
as O 0 2.090172701585402e-09
candidate O 0 1.1056711457513302e-07
genes O 0 2.677649213467248e-08
for O 0 5.197557051417334e-09
CT B-Disease 0 0.3144557774066925
since O 0 2.269594148174292e-07
they O 0 3.4864147124835654e-09
both O 0 6.099144744808882e-09
mapped O 0 7.97216944192769e-06
to O 0 5.958656856819289e-08
canine O 0 0.004153259098529816
chromosome O 0 0.0011517505627125502
region O 0 1.4169617315928917e-05
CFA11q22 O 0 0.005493078380823135
. O 0 1.2639835404115729e-05

2 O 0 1.3714928172703367e-05
- O 0 0.00022377853747457266
22 O 0 8.530782906746026e-06
. O 0 6.825544460298261e-06

5 O 0 0.0001575670758029446
. O 0 4.8636458814144135e-05

A O 0 1.181794118565449e-06
transcribed O 0 1.9212734514439944e-06
sequence O 0 3.7780509387630445e-07
identified O 0 8.501375248215481e-08
from O 0 4.9834394388881265e-09
the O 0 4.4150492151118215e-09
C04107 O 0 1.995243337660213e-06
- O 0 2.3609957224834943e-06
containing O 0 1.79050644533163e-07
BAC O 0 2.598435003164923e-06
was O 0 6.209068370566229e-09
found O 0 3.612142140951846e-09
to O 0 9.840639414449015e-10
be O 0 1.5761569827077437e-09
homologous O 0 8.315028310335038e-08
to O 0 2.136493648663418e-09
a O 0 9.84888703925435e-09
gene O 0 3.2209044320552493e-08
expressed O 0 1.7315494815761667e-08
from O 0 6.010969055836313e-09
human O 0 1.0931315586049095e-07
chromosome O 0 1.4832298802502919e-05
2p13 O 0 3.904956975020468e-05
- O 0 0.0005796009209007025
p16 O 0 2.0929694073856808e-05
, O 0 7.297604742717567e-09
a O 0 8.957991681768362e-09
region O 0 8.41712051169452e-08
devoid O 0 2.4585514779573714e-07
of O 0 2.7742730335234e-09
any O 0 8.887228730714014e-09
positional O 0 3.0630437777290354e-06
candidate O 0 7.179514796007425e-06
genes O 0 2.8390086299623363e-06
. O 0 1.5379517890323768e-06

Molecular O 0 0.0009011616348288953
analysis O 0 1.3096170050630462e-06
of O 0 3.484435140421738e-08
the O 0 3.429445882829896e-08
APC B-Disease 0 2.0303064047766384e-06
gene O 0 5.4593940035374544e-08
in O 0 7.137548774238667e-09
205 O 0 5.4977018493218566e-08
families O 0 2.840162061090723e-08
: O 0 6.895281501329009e-08
extended O 0 4.0096509223985777e-07
genotype O 0 0.011265117675065994
- O 0 0.06429743766784668
phenotype O 0 0.011806081049144268
correlations O 0 1.8184380678576417e-05
in O 0 8.916946825365812e-08
FAP B-Disease 0 1.795921525626909e-05
and O 0 1.9684975427480822e-08
evidence O 0 3.202795895163035e-08
for O 0 8.101052051401325e-10
the O 0 7.814592306587542e-10
role O 0 5.4746887023782165e-09
of O 0 4.8900719029632e-09
APC B-Disease 0 6.127825145085808e-06
amino O 0 3.0123374017421156e-07
acid O 0 1.1488669997561374e-06
changes O 0 1.8423693290969823e-06
in O 0 0.003003620309755206
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999953508377075
predisposition O 1 0.9864126443862915
. O 0 0.00011446494318079203

BACKGROUND O 0 0.0008405828848481178
/ O 0 0.00011100932897534221
AIMS O 0 2.4289663542731432e-06
The O 0 5.425739857400913e-08
development O 0 3.149967540139187e-07
of O 0 0.00038188157486729324
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.999996542930603
and O 0 4.5195699271971534e-07
a O 0 1.9802172346317093e-07
variable O 0 2.166123522329144e-06
range O 0 3.4393178083291787e-08
of O 0 2.033980983640049e-08
extracolonic O 0 0.13292013108730316
manifestations O 0 0.10471061617136002
in O 0 0.0004441504133865237
familial B-Disease 1 0.9999918937683105
adenomatous I-Disease 1 0.999987006187439
polyposis I-Disease 1 0.9999955892562866
( O 0 5.595057700702455e-06
FAP B-Disease 0 0.00019190188322681934
) O 0 2.0792864319219007e-08
is O 0 2.745510485624436e-09
the O 0 3.5809302190159542e-09
result O 0 2.556717504376138e-08
of O 0 2.55705256968497e-09
the O 0 4.6638636064244565e-08
dominant O 0 1.1187230484210886e-05
inheritance O 0 7.185142749221995e-05
of O 0 5.8472203818382695e-05
adenomatous B-Disease 1 0.999994158744812
polyposis I-Disease 1 0.9999855756759644
coli I-Disease 1 0.9994491934776306
( O 0 2.7294022402202245e-06
APC B-Disease 0 4.0195565816247836e-05
) O 0 4.585282340485719e-07
gene O 0 5.588333351624897e-06
mutations O 0 2.4906303224270232e-05
. O 0 4.402044396556448e-06

In O 0 1.8692204548642621e-06
this O 0 1.361519679221601e-07
study O 0 1.549270791656454e-07
, O 0 7.626163700535926e-09
direct O 0 2.206972915530514e-08
mutation O 0 1.0547023521212395e-06
analysis O 0 1.1868451998964247e-08
of O 0 4.650463902855506e-10
the O 0 3.375181023557161e-09
APC B-Disease 0 1.5189472151178052e-06
gene O 0 4.097586625562144e-08
was O 0 3.0163427311435953e-09
performed O 0 9.432820746724246e-09
to O 0 3.2574527519813046e-09
determine O 0 2.1090775135235162e-06
genotype O 0 0.08491809666156769
- O 0 0.2405232936143875
phenotype O 0 0.0028352835215628147
correlations O 0 1.8770231235976098e-06
for O 0 6.140383312924769e-09
nine O 0 9.574737447337611e-08
extracolonic O 0 0.0014978438848629594
manifestations O 0 2.2504222215502523e-05
and O 0 1.3789615671555566e-08
to O 0 4.893636162961457e-09
investigate O 0 3.807954840340244e-07
the O 0 1.1022263635140916e-07
incidence O 0 0.00020870170556008816
of O 0 4.88298184109226e-08
APC B-Disease 0 0.0001515904878033325
mutations O 0 3.4286492791579803e-06
in O 0 2.752932459770818e-07
non O 0 2.769776801869739e-05
- O 1 0.9997468590736389
FAP O 1 0.9998401403427124
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999682903289795
. O 0 0.0001410847471561283

METHODS O 0 7.53512222217978e-06
The O 0 2.3435019613771146e-07
APC B-Disease 0 4.436722520040348e-06
gene O 0 4.508179642925825e-07
was O 0 2.6775113681765106e-08
analysed O 0 2.425197180855321e-07
in O 0 1.3122478215166211e-08
190 O 0 1.1315989212334898e-07
unrelated O 0 1.8914994370788918e-06
FAP B-Disease 0 1.6301974028465338e-05
and O 0 4.7193619678864707e-08
15 O 0 1.106797853367425e-07
non O 0 8.010656529222615e-06
- O 1 0.9998063445091248
FAP O 1 0.9999749660491943
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999949932098389
patients O 0 2.0300227333791554e-05
using O 0 4.2496321839280427e-07
denaturing O 0 0.0014396000187844038
gradient O 0 0.000216572530916892
gel O 0 0.00035254296381026506
electrophoresis O 0 1.280468040931737e-05
, O 0 5.146203019279483e-09
the O 0 2.192706016757029e-09
protein O 0 2.8929550310863306e-08
truncation O 0 4.769440238305833e-07
test O 0 1.0612954781663575e-07
, O 0 5.819333903644974e-09
and O 0 8.408579610375e-09
direct O 0 1.331801371406982e-07
sequencing O 0 5.401620910561178e-06
. O 0 1.2200899845993263e-06

RESULTS O 0 0.0002407158463029191
Chain O 0 2.4724935428821482e-05
terminating O 0 5.2819154916505795e-06
signals O 0 9.453065104025882e-07
were O 0 9.660215738449551e-09
only O 0 4.398196917776431e-09
identified O 0 1.7416311948181828e-07
in O 0 1.2499870649662626e-07
patients O 0 4.648198341783427e-07
belonging O 0 1.8033522053428896e-07
to O 0 7.4489920898201945e-09
the O 0 7.565549253740755e-08
FAP B-Disease 0 0.0004741149896290153
group O 0 6.587998768736725e-07
( O 0 5.827322624440967e-08
105 O 0 8.25784354674397e-07
patients O 0 2.5423685201531043e-06
) O 0 4.138335896186618e-07
. O 0 3.613368107835413e-06

Amino O 0 4.872907811659388e-05
acid O 0 1.2972269360034261e-05
changes O 0 1.8211206054274953e-07
were O 0 1.5896079119670503e-08
identified O 0 9.931419242548145e-08
in O 0 2.4576037205292778e-08
four O 0 7.766885090632059e-08
patients O 0 4.814968406208209e-07
, O 0 6.142843567147338e-09
three O 0 1.6493584276133788e-09
of O 0 3.0658307004216567e-09
whom O 0 2.6103370487362554e-07
belonged O 0 1.0913648651467156e-07
to O 0 1.8238253129965187e-09
the O 0 5.291544535879211e-09
non O 0 1.5696498678607895e-07
- O 0 0.0007489488925784826
FAP O 0 0.00028906328952871263
group O 0 1.112435529648792e-05
of O 0 0.0004855722072534263
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999996542930603
patients O 0 0.018791673704981804
. O 0 0.00010007430682890117

Genotype O 1 0.9954291582107544
- O 1 0.9714321494102478
phenotype O 1 0.9465416669845581
correlations O 0 0.0012881780276075006
identified O 0 9.048110769072082e-06
significant O 0 4.4876884430777864e-07
differences O 0 5.044397539677448e-07
in O 0 5.645234679718669e-08
the O 0 2.4510969254265547e-08
nature O 0 2.2633733465227124e-07
of O 0 3.860198827254635e-09
certain O 0 3.490188760224555e-08
extracolonic O 0 0.001846464117988944
manifestations O 0 0.00020826519175898284
in O 0 1.0638689218467334e-06
FAP B-Disease 0 0.0168372243642807
patients O 0 6.402053713827627e-06
belonging O 0 8.862060667524929e-07
to O 0 3.898803768720427e-08
three O 0 5.167244125914294e-07
mutation O 0 7.761629967717454e-05
subgroups O 0 0.00015426406753249466
. O 0 7.788700713717844e-06

CONCLUSIONS O 0 7.047752296784893e-05
Extended O 0 1.1101315976702608e-05
genotype O 0 0.08319701999425888
- O 0 0.24920520186424255
phenotype O 0 0.050857361406087875
correlations O 0 1.3565478184318636e-05
made O 0 1.3005566401602664e-08
in O 0 2.2095337115501934e-08
this O 0 1.7319953471428562e-08
study O 0 2.7172373506800795e-07
may O 0 1.4873991460717662e-07
have O 0 2.728429482345973e-09
the O 0 2.013061495276247e-09
potential O 0 3.818766103336202e-08
to O 0 1.9118775451687497e-09
determine O 0 2.7513831213354933e-08
the O 0 2.8569711041370738e-09
most O 0 1.2560468221067822e-09
appropriate O 0 4.988174762132758e-09
surveillance O 0 3.982304406235926e-07
and O 0 6.973327515424899e-08
prophylactic O 0 0.0006047615315765142
treatment O 0 3.104517236351967e-05
regimens O 0 0.00011197893036296591
for O 0 4.229747219142155e-08
those O 0 5.242353040557646e-07
patients O 0 2.180703177145915e-06
with O 0 9.566684866513242e-07
mutations O 0 9.946295904228464e-05
associated O 0 1.8575468629933312e-06
with O 0 3.906236827333487e-07
life O 0 0.00011809203715529293
threatening O 0 0.021646713837981224
conditions O 0 0.00026848589186556637
. O 0 1.3461042726703454e-05

This O 0 1.7498267652626964e-06
study O 0 5.987548661323672e-07
also O 0 2.134926191388331e-08
provided O 0 2.081302241663252e-08
evidence O 0 4.1445037624043835e-08
for O 0 2.020107858768938e-09
the O 0 2.152996714244182e-08
pathological O 0 5.7328794355271384e-05
nature O 0 4.6277986598397547e-07
of O 0 6.580160416547187e-09
amino O 0 6.816742370574502e-08
acid O 0 9.653368238105031e-08
changes O 0 9.366253550524561e-09
in O 0 2.0122140398370902e-08
APC O 0 1.1493382316984935e-06
associated O 0 3.1238567288482955e-08
with O 0 4.2335304151208675e-09
both O 0 2.202746429702529e-08
FAP B-Disease 0 3.62431637768168e-05
and O 0 4.5817941440873255e-07
non O 0 3.489546725177206e-05
- O 1 0.9999208450317383
FAP O 1 0.9999798536300659
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
patients O 0 0.004872002173215151
. O 0 5.98472752244561e-06
. O 0 6.165104878164129e-06

Inherited B-Disease 1 0.9998424053192139
colorectal I-Disease 1 0.9999921321868896
polyposis I-Disease 1 0.9999244213104248
and O 0 0.18150661885738373
cancer B-Disease 1 0.9984862804412842
risk O 0 2.5002040274557658e-05
of O 0 6.860137347075579e-08
the O 0 3.864828101995954e-07
APC O 0 0.00014955547521822155
I1307K O 0 0.0010511315194889903
polymorphism O 0 0.0005300770862959325
. O 0 5.8327545957581606e-06

Germ O 0 0.0165325328707695
- O 0 6.876209226902574e-05
line O 0 7.897202749518328e-07
and O 0 3.1604205474877745e-08
somatic O 0 2.5659883249318227e-06
truncating O 0 4.8894416977418587e-05
mutations O 0 7.537749979746877e-07
of O 0 2.444330515771753e-09
the O 0 1.4094565514710666e-08
APC B-Disease 0 2.7676157969835913e-06
gene O 0 9.354776864256564e-08
are O 0 2.6125588359349194e-09
thought O 0 1.9329213785113097e-08
to O 0 6.253330298022775e-08
initiate O 0 0.014798826538026333
colorectal B-Disease 1 0.999998927116394
tumor I-Disease 1 0.9998822212219238
formation O 0 0.11824173480272293
in O 0 0.004715105053037405
familial B-Disease 1 0.9999971389770508
adenomatous I-Disease 1 0.9999983310699463
polyposis I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999916553497314
and O 0 0.0001820748730096966
sporadic O 1 0.9623699188232422
colorectal O 1 0.9999977350234985
carcinogenesis O 1 0.9992544054985046
, O 0 1.2742504623020068e-05
respectively O 0 6.01104402448982e-05
. O 0 7.1158142418426e-06

Recently O 0 1.928203164425213e-05
, O 0 1.3623508721138933e-07
an O 0 2.9345692098559084e-08
isoleucine O 0 6.022163506713696e-05
- O 0 0.0002790688013192266
- O 0 0.001407406758517027
> O 0 1.4381145774677861e-05
lysine O 0 8.154066790666548e-07
polymorphism O 0 1.4221031960914843e-06
at O 0 1.7463587909105627e-08
codon O 0 4.637616086711205e-07
1307 O 0 6.307261628535343e-06
( O 0 6.593175783109473e-09
I1307K O 0 3.3976286317738413e-07
) O 0 4.867197200830731e-10
of O 0 1.9634108228139269e-10
the O 0 4.591020896782538e-09
APC B-Disease 0 1.5327186702052131e-06
gene O 0 4.123074148765227e-08
has O 0 3.1274678402581912e-09
been O 0 1.6675882896777239e-09
identified O 0 2.0906123054942327e-08
in O 0 4.390393826270156e-09
6 O 0 2.968821277704592e-08
% O 0 7.35627114778481e-09
- O 0 5.056485861132387e-06
7 O 0 5.576859152256475e-08
% O 0 4.787382934523521e-09
of O 0 1.5555732257865884e-09
the O 0 5.687080673055789e-08
Ashkenazi O 0 1.748299109749496e-05
Jewish O 0 1.5209027424134547e-06
population O 0 1.2693509461314534e-06
. O 0 2.957125389002613e-06

To O 0 1.9208596313546877e-06
assess O 0 1.2184493243694305e-05
the O 0 1.3200669002344512e-07
risk O 0 2.707250530420424e-07
of O 0 6.925831463888699e-09
this O 0 2.2930423781986065e-08
common O 0 1.8877209129186667e-07
APC B-Disease 0 1.0399112397863064e-05
allelic O 0 0.0001682519941823557
variant O 0 0.00010894583829212934
in O 0 5.721273919334635e-05
colorectal O 1 0.9999939203262329
carcinogenesis O 1 0.9843201637268066
, O 0 1.978818460202092e-07
we O 0 6.84257139837996e-09
have O 0 2.8015889608212774e-09
analyzed O 0 6.128124141469016e-08
a O 0 9.683496671186731e-09
large O 0 4.60803377677621e-08
cohort O 0 1.205080025101779e-05
of O 0 3.257255443145368e-08
unselected O 0 0.004903825465589762
Ashkenazi O 0 3.964932147937361e-06
Jewish O 0 1.7353988823742839e-07
subjects O 0 3.924791656118032e-07
with O 0 5.826366873407096e-07
adenomatous B-Disease 1 0.817226231098175
polyps I-Disease 0 0.004781017545610666
and O 0 9.66252855505445e-07
. O 0 4.541191174212145e-06
or O 0 0.031214209273457527
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999912977218628
, I-Disease 0 1.7015931064179313e-07
for O 0 1.5507394479641334e-08
the O 0 1.671639040523587e-07
APC O 0 0.00014375550381373614
I1307K O 0 0.00037158443592488766
polymorphism O 0 0.00034494558349251747
. O 0 1.1093695320596453e-05

The O 0 2.8035206014465075e-06
APC O 0 2.2323454686556943e-05
I1307K O 0 4.862199057242833e-05
allele O 0 6.236664830794325e-06
was O 0 4.114848195513332e-08
identified O 0 9.301808745476592e-08
in O 0 1.1271104050081249e-08
48 O 0 3.7149110454492984e-08
( O 0 4.087093774529649e-09
10 O 0 3.117700098087539e-09
. O 0 1.0607198452916577e-09
1 O 0 2.2285830958423958e-09
% O 0 4.83806283924082e-09
) O 0 2.101854246205903e-09
of O 0 1.3798771902884255e-08
476 O 0 0.00044268809142522514
patients O 0 8.016287756618112e-05
. O 0 8.95030825631693e-06

Compared O 0 8.827511010167655e-06
with O 0 4.4818587952022426e-08
the O 0 1.4448334972883004e-08
frequency O 0 8.895796810293177e-08
in O 0 2.25930008035391e-09
two O 0 1.0204695977122924e-09
separate O 0 2.3239518753825905e-08
population O 0 1.9712516063918883e-08
control O 0 2.33741239696883e-08
groups O 0 6.291564158544816e-09
, O 0 2.1503567815273072e-09
the O 0 3.0134330586406577e-09
APC O 0 9.922441677190363e-07
I1307K O 0 1.3661080629390199e-05
allele O 0 6.695090064567921e-07
is O 0 4.4912096264226875e-09
associated O 0 1.7088678916366007e-08
with O 0 2.4397475151261006e-09
an O 0 8.495178782652602e-09
estimated O 0 5.454896836454282e-07
relative O 0 7.801441824994981e-06
risk O 0 1.5743167978143902e-06
of O 0 4.21733332700569e-08
1 O 0 1.0665650052033016e-06
. O 0 2.8832794214395108e-06

5 O 0 1.8844248188543133e-05
- O 0 9.673755994299427e-05
1 O 0 3.7496047298191115e-06
. O 0 4.16189914176357e-06

7 O 0 3.778245081775822e-05
for O 0 2.7276530090603046e-05
colorectal B-Disease 1 0.9999798536300659
neoplasia I-Disease 1 0.9988013505935669
( O 0 3.6880695120089513e-07
both O 0 1.440733683466533e-07
P O 0 0.018797433003783226
= O 0 8.593588427174836e-05
. O 0 8.420507668915889e-08
01 O 0 2.264994145662058e-05
) O 0 1.1006297739868387e-07
. O 0 6.696276955153735e-07

Furthermore O 0 3.559539982234128e-05
, O 0 2.961012626201409e-07
compared O 0 3.120084670626966e-07
with O 0 2.8523281514480914e-08
noncarriers O 0 0.0002757088514044881
, O 0 5.54978996092359e-08
APC O 0 7.68819234053808e-07
I1307K O 0 2.163565568480408e-06
carriers O 0 8.076251134525592e-08
had O 0 9.78722081157457e-09
increased O 0 1.3168262036344913e-08
numbers O 0 1.4776952106387853e-08
of O 0 9.455354721410458e-09
adenomas B-Disease 0 0.06495623290538788
and O 0 0.01133808121085167
colorectal B-Disease 1 0.9999996423721313
cancers I-Disease 1 0.9987145662307739
per O 0 4.062888365297113e-06
patient O 0 2.309271803824231e-05
( O 0 7.818012903726412e-08
P O 0 0.0011488402960821986
= O 0 1.9179478840669617e-05
. O 0 1.0059684640850719e-08
03 O 0 8.583322596678045e-06
) O 0 2.230815754344917e-09
, O 0 9.926336419496806e-10
as O 0 4.653356311390411e-10
well O 0 9.255998745238969e-10
as O 0 2.189817882580769e-09
a O 0 1.0690625629194983e-07
younger O 0 9.432925253349822e-06
age O 0 3.765708697756054e-06
at O 0 3.261864776504808e-06
diagnosis O 0 0.042955610901117325
. O 0 1.7196411135955714e-05

We O 0 1.2658379091590177e-06
conclude O 0 1.1269372635069885e-06
that O 0 1.8279042279800706e-08
the O 0 1.8401021151248642e-08
APC O 0 2.751738065853715e-06
I1307K O 0 6.586531071661739e-06
variant O 0 1.2030003517793375e-06
leads O 0 1.7010559361096966e-07
to O 0 1.8739520157851075e-08
increased O 0 5.877537660126109e-06
adenoma B-Disease 1 0.9997332692146301
formation O 0 4.814798558072653e-06
and O 0 8.349049451794599e-09
directly O 0 3.0585534105398438e-09
contributes O 0 1.2457832099244115e-08
to O 0 6.44022057905147e-10
3 O 0 2.5826241145665563e-09
% O 0 2.1050516885168236e-09
- O 0 9.75556645244069e-07
4 O 0 1.974759022971284e-08
% O 0 5.103311551124534e-09
of O 0 4.31520996713175e-09
all O 0 1.1352231155115078e-07
Ashkenazi O 0 0.0014836410991847515
Jewish O 0 0.1561814397573471
colorectal B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999637603759766
. O 0 0.0001445374364266172

The O 0 1.5081503761393833e-06
estimated O 0 3.023535555257695e-06
relative O 0 1.7010515875881538e-05
risk O 0 2.5729182198119815e-06
for O 0 2.829045975261124e-08
carriers O 0 3.5258697153039975e-06
may O 0 5.547789214688237e-07
justify O 0 8.553525958632235e-07
specific O 0 8.577797672160159e-08
clinical O 0 9.347407399218355e-07
screening O 0 8.668818196611028e-08
for O 0 1.4482124388592865e-09
the O 0 2.673198329361526e-09
360 O 0 1.5339361780775107e-08
, O 0 2.696673107038805e-09
000 O 0 1.9122284200534523e-08
Americans O 0 1.0398867544836321e-08
expected O 0 2.073583438289006e-08
to O 0 2.5222586241824274e-09
harbor O 0 3.915522938768845e-06
this O 0 1.7158638954128946e-08
allele O 0 7.870894478401169e-07
, O 0 4.8976231958874905e-09
and O 0 2.2375671093755045e-08
genetic O 0 9.706149057819857e-07
testing O 0 7.712589678021686e-08
in O 0 3.796729153293654e-09
the O 0 1.5307146661314164e-09
setting O 0 1.5817533949302742e-08
of O 0 1.9768495729266533e-09
long O 0 1.261304305444355e-07
- O 0 2.5943074433598667e-05
term O 0 6.706400768052845e-07
- O 0 4.1423787479288876e-05
outcome O 0 1.084990572053357e-06
studies O 0 1.674496701298267e-07
may O 0 1.619398517505033e-07
impact O 0 2.2064461973059224e-06
significantly O 0 3.946373180951923e-05
on O 0 0.22586572170257568
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
prevention O 0 0.12025982141494751
in O 0 4.913345037493855e-07
this O 0 1.9696136632774142e-07
population O 0 8.666790449751716e-07
. O 0 3.1722686344437534e-06

Localization O 0 4.843664646614343e-05
of O 0 1.3989755132115533e-07
human O 0 1.5544729876637575e-06
BRCA1 O 0 4.199848626740277e-05
and O 0 2.8454000045030625e-08
its O 0 4.85721400877992e-08
loss O 0 1.196633093059063e-05
in O 0 7.609632035610048e-08
high O 0 1.36497317271278e-06
- O 0 0.0007014377624727786
grade O 0 6.722038506268291e-06
, O 0 8.001916285138577e-08
non B-Disease 0 1.7552770259499084e-06
- I-Disease 1 0.874809980392456
inherited I-Disease 1 0.9927807450294495
breast I-Disease 1 0.9979666471481323
carcinomas I-Disease 1 0.9999421834945679
. O 0 0.00015759306552354246

Although O 0 2.0148850126133766e-06
the O 0 7.572479177042624e-08
link O 0 9.63125899033912e-07
between O 0 3.64197454416626e-08
the O 0 3.027844286407344e-07
BRCA1 O 0 0.015098487958312035
tumour B-Disease 1 0.9996436834335327
- O 0 0.00578678771853447
suppressor O 0 0.00020270863024052233
gene O 0 6.827906418038765e-07
and O 0 2.716027438509627e-07
hereditary B-Disease 1 0.9151689410209656
breast I-Disease 1 0.9997686743736267
and I-Disease 1 0.9978312849998474
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999971389770508
is O 0 3.8911375099814904e-07
established O 0 4.3751651190859775e-08
, O 0 3.567214079680525e-09
the O 0 1.0797421845509803e-09
role O 0 1.6225344623421734e-08
, O 0 5.606259900758914e-09
if O 0 1.5841860045995304e-09
any O 0 5.177626660746171e-10
, O 0 1.5146656151543425e-09
of O 0 2.6738511405000054e-09
BRCA1 O 0 9.15400596568361e-06
in O 0 9.541120959966065e-08
non B-Disease 0 6.093239335314138e-06
- I-Disease 1 0.9791101217269897
familial I-Disease 1 0.9997561573982239
cancers I-Disease 1 0.9982919096946716
is O 0 2.0749662326124962e-06
unclear O 0 1.2001976756437216e-05
. O 0 3.3651888315944234e-06

BRCA1 O 1 0.9586641788482666
mutations O 0 0.0015648931730538607
are O 0 1.456224225648839e-07
rare O 0 2.543568825785769e-06
in O 0 4.2538655975477013e-07
sporadic B-Disease 0 0.004707731306552887
cancers I-Disease 1 0.960211455821991
, O 0 1.8751002528460958e-07
but O 0 6.501616667264898e-08
loss O 0 2.533123279135907e-06
of O 0 1.8632242415606015e-08
BRCA1 O 0 9.920020966092125e-05
resulting O 0 4.35981661439655e-07
from O 0 1.905660163004086e-08
reduced O 0 8.365439896351745e-08
expression O 0 8.991134592406524e-08
or O 0 1.376869551705795e-08
incorrect O 0 1.318782238968197e-07
subcellular O 0 2.0895393390674144e-05
localization O 0 1.7553942370795994e-06
is O 0 4.094896866035924e-09
postulated O 0 1.4096305278599175e-07
to O 0 1.2809520111289885e-09
be O 0 9.551764934556672e-10
important O 0 1.457439946506156e-09
in O 0 1.6830611571094778e-08
non B-Disease 0 6.718435088259866e-07
- I-Disease 1 0.5460073351860046
familial I-Disease 1 0.9990718364715576
breast I-Disease 1 0.9998378753662109
and I-Disease 1 0.9962373971939087
ovarian I-Disease 1 0.9999995231628418
cancers I-Disease 1 0.9999895095825195
. O 0 0.00020588624465744942

Epigenetic O 0 0.04607820883393288
loss O 0 0.018883494660258293
, O 0 6.542705932588433e-07
however O 0 8.2936139733647e-08
, O 0 8.323434386170447e-09
has O 0 4.79422723742573e-09
not O 0 9.382340460106775e-10
received O 0 4.897370953216296e-09
general O 0 1.1996061033414662e-08
acceptance O 0 1.8742456120435236e-07
due O 0 4.665340824772102e-08
to O 0 2.1466481925358494e-09
controversy O 0 3.254151081932832e-08
regarding O 0 8.264302131522072e-09
the O 0 2.0947383827518706e-09
subcellular O 0 1.1479788781798561e-06
localization O 0 2.1666451743840298e-07
of O 0 4.561874877850869e-09
BRCA1 O 0 8.480954420519993e-06
proteins O 0 3.193158093495185e-08
, O 0 3.204419396496405e-09
reports O 0 8.329596568046327e-09
of O 0 7.335265173047389e-10
which O 0 3.1256073285135244e-09
have O 0 2.986630942558577e-09
ranged O 0 2.9878921736781194e-07
from O 0 2.515177621731368e-09
exclusively O 0 1.4177609308774208e-08
nuclear O 0 6.898562787682749e-06
, O 0 2.5505644263290606e-09
to O 0 1.3504386497942278e-09
conditionally O 0 6.219679562491365e-07
nuclear O 0 3.4545291782706045e-06
, O 0 9.98935489882058e-10
to O 0 8.251225258604222e-10
the O 0 1.0152128027129947e-08
ER O 0 0.0003375614178366959
/ O 0 2.1061201550764963e-05
golgi O 0 0.0007125457632355392
, O 0 6.043433753433192e-09
to O 0 1.932621840339266e-09
cytoplasmic O 0 3.8923548117963946e-07
invaginations O 0 2.286379185534315e-06
into O 0 1.922978221102767e-08
the O 0 6.276021480289273e-08
nucleus O 0 6.239532012841664e-06
. O 0 1.194048422803462e-06

In O 0 7.923848670543521e-07
an O 0 1.7187137046903445e-08
attempt O 0 1.0842648379139064e-07
to O 0 1.130453952669086e-08
resolve O 0 3.7230975635793584e-07
this O 0 1.2879545430166672e-08
issue O 0 2.6788139706468428e-08
, O 0 3.771726486689886e-09
we O 0 2.4955995048259183e-09
have O 0 5.050960982799779e-09
comprehensively O 0 8.029349373828154e-06
characterized O 0 1.707752630863979e-06
19 O 0 3.909527492851339e-07
anti O 0 3.981683767051436e-05
- O 0 0.28287023305892944
BRCA1 O 0 0.005061695352196693
antibodies O 0 6.147800013422966e-05
. O 0 3.1398501505464083e-06

These O 0 1.6664785107423086e-06
reagents O 0 2.9315115170902573e-05
detect O 0 1.6434498320450075e-05
a O 0 6.026606769182763e-08
220 O 0 1.1025501578387775e-07
- O 0 4.4758991862181574e-05
kD O 0 0.0017429455183446407
protein O 0 1.688331821014799e-07
localized O 0 2.1526564353280264e-07
in O 0 1.8263500933812793e-08
discrete O 0 5.693619300473074e-07
nuclear O 0 9.96460803435184e-05
foci O 0 1.5322088074753992e-05
in O 0 2.0702955794149602e-08
all O 0 7.332316975805497e-09
epithelial O 0 0.001069151796400547
cell O 0 0.0001367779914289713
lines O 0 9.907313369694748e-07
, O 0 4.024305333416578e-09
including O 0 4.349452353835659e-09
those O 0 1.6458553631082395e-08
derived O 0 2.3051130426665623e-07
from O 0 1.1147931218147278e-06
breast B-Disease 0 0.10375232994556427
malignancies I-Disease 1 0.9247263669967651
. O 0 3.478907092357986e-05

Immunohistochemical O 0 0.06389772146940231
staining O 0 0.0008349104318767786
of O 0 1.2270445495232707e-06
human O 0 2.760552342806477e-05
breast O 0 0.12041333317756653
specimens O 0 0.0006907033384777606
also O 0 8.172463026312471e-07
revealed O 0 0.0003415743412915617
BRCA1 O 0 0.0017769411206245422
nuclear O 0 0.0010796331334859133
foci O 0 0.0007314399117603898
in O 0 4.124106908420799e-06
benign O 1 0.5562357902526855
breast O 1 0.8257224559783936
, O 0 0.00015892251394689083
invasive B-Disease 1 0.979137659072876
lobular I-Disease 1 0.9999775886535645
cancers I-Disease 1 0.9942317605018616
and O 0 6.8452832238108385e-06
low B-Disease 0 0.0002443905104883015
- I-Disease 1 0.7011661529541016
grade I-Disease 0 0.48223862051963806
ductal I-Disease 1 0.9993278980255127
carcinomas I-Disease 1 0.9999305009841919
. O 0 0.00012533714470919222

Conversely O 0 0.00016556165064685047
, O 0 7.883109560680168e-07
BRCA1 O 0 2.0314964785939083e-05
expression O 0 7.167250259954017e-07
was O 0 3.984697016790051e-08
reduced O 0 9.01376608908322e-08
or O 0 1.995408993593628e-08
undetectable O 0 4.773535692947917e-06
in O 0 2.795882636519309e-09
the O 0 1.4446204232854143e-09
majority O 0 6.939556485008325e-09
of O 0 3.490979505471614e-09
high O 0 1.474642431276152e-06
- O 0 0.002716664457693696
grade O 0 4.5709952246397734e-05
, O 0 1.6473933328597923e-06
ductal B-Disease 1 0.9956308603286743
carcinomas I-Disease 1 0.9999804496765137
, O 0 2.803991776545445e-07
suggesting O 0 2.760862400918995e-07
that O 0 3.470981280173646e-09
absence O 0 6.414946795985088e-08
of O 0 1.7275283425988164e-08
BRCA1 O 0 0.002885157708078623
may O 0 6.811399657635775e-07
contribute O 0 2.9666987089171926e-08
to O 0 2.6860984547738553e-09
the O 0 1.568665908280309e-08
pathogenesis O 0 7.720315807091538e-06
of O 0 2.327827708370478e-09
a O 0 1.587126696733776e-08
significant O 0 8.158121289625342e-08
percentage O 0 3.07297824519992e-07
of O 0 4.28280699793504e-08
sporadic B-Disease 0 0.023072242736816406
breast I-Disease 1 0.9997546076774597
cancers I-Disease 1 0.9935237169265747
. O 0 4.541442649497185e-06
. O 0 6.280683464865433e-06

